

Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelssystem.org.

Overview for Request: cder_mpl1r_wp236

Request ID: cder_mpl1r_wp236_nsdv_v01

Request Description: In this report, we characterized dispensing and administration patterns of 23 New Molecular Entities (NMEs) approved from January 1, 2017 to June 30, 2017, stratified by age and sex in the Sentinel Distributed Database (SDD).

Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis module, version 11.0.0

Data Source: We distributed this request to 14 Sentinel Data Partners on March 22, 2023. The study period included available data from January 1, 2017 to most recent available data. Please see Appendix A for a list of dates of available data for each Data Partner.

Study Design: We identified individuals initiating any of the 23 NME drugs. We described demographic and clinical characteristics for individuals initiating each NME based on history recorded in the six months prior to initiation of treatment with the NME. The analyses characterized dispensing patterns by examining cumulative exposure episode durations, first exposure episode durations, all exposure episode durations, days supplied per dispensing, and lengths of gaps between episodes, overall and stratified by age and sex. This was a Type 5 analysis in the Query Request Package (QRP) documentation.

Exposures of Interest: Our exposures of interest were NMEs approved between January 1, 2017, and June 30, 2017, administered or dispensed in any care setting. These were defined using Healthcare Common Procedure Coding System (HCPCS) procedure codes and National Drug Codes (NDCs). Please see Appendix B for a list of non-proprietary and proprietary names of medical products, and Appendix C for a list of procedure codes used to define exposures in this request. All valid exposure episodes were included.

Cohort Eligibility Criteria: We defined index exposure as the first qualifying administration or dispensing of a given NME to an individual during the query period. We required individuals to be enrolled in health plans with both medical and drug coverage for at least 183 days prior to their index exposure, during which gaps in coverage of up to 45 days were allowed. The following age groups were included: 0-17, 18-24, 25-40, 41-64, 65+ years.

Baseline Characteristics: We described demographic characteristics such as sex, age, and calendar year on the day of each index NME exposure. We also described 31 clinical characteristics based on history recorded in the six months prior to the index exposure. The set of clinical characteristics included 24 chronic conditions and 7 lifestyle-related conditions. Chronic conditions were defined using Centers for Medicare and Medicaid Services' (CMS) Chronic Conditions Data Warehouse¹ (CCW) algorithms and included: acute myocardial infarction, Alzheimer's disease and related conditions, atrial fibrillation, diabetes, heart failure, hyperlipidemia, hypertension, depression, ischemic heart disease, rheumatoid arthritis/osteoarthritis, stroke/transient ischemic attack (TIA), breast cancer, colorectal cancer, prostate cancer, lung cancer, endometrial cancer, acquired hypothyroidism, anemia, asthma, benign prostatic hyperplasia, chronic kidney disease, chronic obstructive pulmonary disease (COPD) and bronchiectasis, glaucoma, and osteoporosis. Lifestyle-related conditions included: obesity, overweight, smoking, alcohol abuse or dependence, drug abuse or dependence, history of cardiac arrest, and history of coronary angioplasty or bypass. International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS) procedure codes, HCPCS procedure codes, Current Procedural Terminology, Fourth Edition (CPT-4) procedure codes, and NDCs were used to define the clinical characteristics. Please see Appendix D for a list of diagnosis and procedure codes used to define baseline characteristics in this request, and Appendix E for a list of non-proprietary and proprietary names of medical products used to define baseline characteristics in this request.

Overview for Request: cder_mpl1r_wp236

Please refer to Appendices F, G, and H for the specifications of parameters used in this request, baseline characteristics used in this request, and a design diagram.

Limitations: Algorithms used to define exposures and inclusion criteria are imperfect; thus, it is possible that there may be misclassification. Therefore, data should be interpreted with this limitation in mind.

Notes: Please contact the Sentinel Operations Center (info@sentinel-system.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (<https://dev.sentinel-system.org/projects/SENTINEL/repos/sentinel-routine-querying-tool-documentation/browse>).

¹Chronic Conditions Data Warehouse. Condition Categories - Chronic Conditions Data Warehouse. <https://www.ccwdata.org/web/guest/condition-categories>

Table of Contents

| | |
|------------------------|--|
| <u>Glossary</u> | List of Terms to Define the Cohort Identification and Descriptive Analysis (CIDA) Found in this Report |
| <u>Table 1a</u> | Aggregated Baseline Table for Abaloparatide in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Table 1b</u> | Aggregated Baseline Table for Avelumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Table 1c</u> | Aggregated Baseline Table for Betrixaban in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Table 1d</u> | Aggregated Baseline Table for Brigatinib in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Table 1e</u> | Aggregated Baseline Table for Brodalumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Table 1f</u> | Aggregated Baseline Table for Cerliponase Alfa in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Table 1g</u> | Aggregated Baseline Table for Deflazacort in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Table 1h</u> | Aggregated Baseline Table for Delafloxacin in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Table 1i</u> | Aggregated Baseline Table for Deutetrabenazine in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Table 1j</u> | Aggregated Baseline Table for Dupilumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Table 1k</u> | Aggregated Baseline Table for Durvalumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Table 1l</u> | Aggregated Baseline Table for Edaravone in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Table 1m</u> | Aggregated Baseline Table for Etelcalcetide in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Table 1n</u> | Aggregated Baseline Table for Midostaurin in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Table 1o</u> | Aggregated Baseline Table for Naldemedine in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Table 1p</u> | Aggregated Baseline Table for Niraparib in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Table 1q</u> | Aggregated Baseline Table for Ocrelizumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Table 1r</u> | Aggregated Baseline Table of Plecanatide in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Table 1s</u> | Aggregated Baseline Table for Ribociclib in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Table 1t</u> | Aggregated Baseline Table for Safinamide in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Table 1u</u> | Aggregated Baseline Table for Sarilumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Table 1v</u> | Aggregated Baseline Table for Telotristat ethyl in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Table 1w</u> | Aggregated Baseline Table for Valbenazine in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |

Table of Contents

| | |
|------------------------|--|
| <u>Table 2a</u> | Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Table 2b</u> | Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Table 2c</u> | Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Sex |
| <u>Table 2d</u> | Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Sex |
| <u>Table 2e</u> | Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group |
| <u>Table 2f</u> | Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group |
| <u>Table 3a</u> | Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Table 3b</u> | Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Table 3c</u> | Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Sex |
| <u>Table 3d</u> | Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Sex |
| <u>Table 3e</u> | Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group |
| <u>Table 3f</u> | Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group |
| <u>Table 4a</u> | Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Table 4b</u> | Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Table 4c</u> | Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Sex |
| <u>Table 4d</u> | Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Sex |
| <u>Table 4e</u> | Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group |
| <u>Table 4f</u> | Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group |
| <u>Table 5a</u> | Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Table 5b</u> | Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Table 5c</u> | Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Sex |
| <u>Table 5d</u> | Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Sex |
| <u>Table 5e</u> | Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group |
| <u>Table 5f</u> | Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group |

Table of Contents

| | |
|-------------------------|--|
| <u>Table 6a</u> | Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Table 6b</u> | Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Table 6c</u> | Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Sex |
| <u>Table 6d</u> | Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Sex |
| <u>Table 6e</u> | Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group |
| <u>Table 6f</u> | Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group |
| <u>Table 7a</u> | Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Table 7b</u> | Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Sex |
| <u>Table 7c</u> | Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group |
| <u>Table 8a</u> | Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Table 8b</u> | Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Sex |
| <u>Table 8c</u> | Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group |
| <u>Table 9</u> | Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 ¹ |
| <u>Table 10</u> | Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Figure 1a</u> | Patient Entry into Study by Month for Abaloparatide in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Figure 1b</u> | Patient Entry into Study by Month for Avelumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Figure 1c</u> | Patient Entry into Study by Month for betrixaban in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Figure 1d</u> | Patient Entry into Study by Month for Brigatinib in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Figure 1e</u> | Patient Entry into Study by Month for Brodalumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Figure 1f</u> | Patient Entry into Study by Month for Cerliponase Alfa in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Figure 1g</u> | Patient Entry into Study by Month for Deflazacort in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Figure 1h</u> | Patient Entry into Study by Month for Delafloxacin in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Figure 1i</u> | Patient Entry into Study by Month for Deutetrabenazine in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Figure 1j</u> | Patient Entry into Study by Month for Dupilumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |

Table of Contents

| | |
|--------------------------|--|
| <u>Figure 1k</u> | Patient Entry into Study by Month for Durvalumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Figure 1l</u> | Patient Entry into Study by Month for Edaravone in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Figure 1m</u> | Patient Entry into Study by Month for Etecalcetide in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Figure 1n</u> | Patient Entry into Study by Month for Midostaurin in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Figure 1o</u> | Patient Entry into Study by Month for Naldemedine in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Figure 1p</u> | Patient Entry into Study by Month for Niraparib in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Figure 1q</u> | Patient Entry into Study by Month for Ocrelizumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Figure 1r</u> | Patient Entry into Study by Month for Plecanatide in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Figure 1s</u> | Patient Entry into Study by Month for Ribociclib in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Figure 1t</u> | Patient Entry into Study by Month for Safinamide in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Figure 1u</u> | Patient Entry into Study by Month for Sarilumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Figure 1v</u> | Patient Entry into Study by Month for Telotristat Ethyl in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Figure 1w</u> | Patient Entry into Study by Month for Valbenazine in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022 |
| <u>Appendix A</u> | Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (March 22, 2023) |
| <u>Appendix B</u> | List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposures in this Request |
| <u>Appendix C</u> | List of Healthcare Common Procedure Coding System, Level II (HCPCS) and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exposures in this Request |
| <u>Appendix D</u> | List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this request. |
| <u>Appendix E</u> | List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request |
| <u>Appendix F</u> | Specifications Defining Parameters for this Request |
| <u>Appendix G</u> | Specifications Defining Parameters for Baseline Characteristics in this Request |
| <u>Appendix H</u> | Diagram Detailing the Design of this Request |

**Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module***

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing.

Blackout Period - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Charlson/Elixhauser Combined Comorbidity Score - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).

Code Days - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.

Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.

Computed Start Marketing Date - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.

Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.

Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" sequence.

Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

Event Deduplication - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."

Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.

Lookback Period - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

Maximum Episode Duration - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Member-Years - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.

Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.

Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Monitoring Period - used to define time periods of interest for both sequential analysis and simple cohort characterization requests.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.

Query Period - period in which the modular program looks for exposures and outcomes of interest.

Switch Evaluation Step Value - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).

Switch Gap Inclusion Indicator - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.

Switch Pattern Cohort Inclusion Date - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.

Switch Pattern Cohort Inclusion Strategy - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.

Treatment Episode Truncation Indicator - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.

Washout Period (drug/exposure) - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

Washout Period (event/outcome) - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report

Table 1a. Aggregated Baseline Table for Abaloparatide in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Characteristics | Number | |
|--|---------------|---------------------------|
| Number of unique patients | 23,148 | |
| Demographic Characteristics | Mean | Standard Deviation |
| Age (years) | 69.9 | 8.8 |
| Age | Number | Percent |
| 0-17 years | ***** | ***** |
| 18-24 years | ***** | ***** |
| 25-40 years | 146 | 0.6% |
| 41-64 years | 6,307 | 27.2% |
| ≥ 65 years | 16,681 | 72.1% |
| Sex | | |
| Female | 22,565 | 97.5% |
| Male | 583 | 2.5% |
| Race¹ | | |
| American Indian or Alaska Native | 53 | 0.2% |
| Asian | 894 | 3.9% |
| Black or African American | 409 | 1.8% |
| Native Hawaiian or Other Pacific Islander | 20 | 0.1% |
| Unknown | 6,495 | 28.1% |
| White | 15,277 | 66.0% |
| Hispanic origin | | |
| Yes | 625 | 2.7% |
| No | 15,581 | 67.3% |
| Unknown | 6,942 | 30.0% |
| Year | | |
| 2017 | 987 | 4.3% |
| 2018 | 4,767 | 20.6% |
| 2019 | 5,473 | 23.6% |
| 2020 | 4,577 | 19.8% |
| 2021 | 5,250 | 22.7% |
| 2022 | 2,094 | 9.0% |
| Health Characteristics | | |
| Acute Myocardial Infarction | 96 | 0.4% |
| Alzheimer's Disease and related conditions | 1,133 | 4.9% |
| Atrial Fibrillation | 1,684 | 7.3% |
| Diabetes Mellitus | 3,387 | 14.6% |
| Heart Failure | 1,877 | 8.1% |
| Hyperlipidemia | 8,444 | 36.5% |
| Hypertension | 10,115 | 43.7% |
| Depression | 6,167 | 26.6% |
| Ischemic Heart Disease | 3,649 | 15.8% |

Table 1a. Aggregated Baseline Table for Abaloparatide in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Health Characteristics | Number | Percent |
|--|---------------|---------------------------|
| Rheumatoid Arthritis/Osteoarthritis | 9,725 | 42.0% |
| Stroke/Transient Ischemic Attack | 582 | 2.5% |
| Breast Cancer | 740 | 3.2% |
| Colorectal Cancer | 180 | 0.8% |
| Prostate Cancer | 28 | 0.1% |
| Lung Cancer | 144 | 0.6% |
| Endometrial Cancer | 65 | 0.3% |
| Acquired Hypothyroidism | 4,875 | 21.1% |
| Anemia | 6,121 | 26.4% |
| Asthma | 1,606 | 6.9% |
| Benign Prostatic Hyperplasia | 129 | 0.6% |
| Chronic Kidney Disease | 2,509 | 10.8% |
| Chronic Obstructive Pulmonary Disease and Bronchiectasis | 2,818 | 12.2% |
| Glaucoma | 998 | 4.3% |
| Osteoporosis | 17,970 | 77.6% |
| Obesity: diagnosed or identified by weight management procedures | 2,809 | 12.1% |
| Obesity: identified by weight management-related prescriptions | 157 | 0.7% |
| Overweight | 2,077 | 9.0% |
| Smoking: diagnosed or identified by smoking cessation procedures | 4,831 | 20.9% |
| Smoking: identified by smoking-related prescriptions | 243 | 1.0% |
| Alcohol Abuse or Dependence | 448 | 1.9% |
| Drug Abuse or Dependence | 1,179 | 5.1% |
| History of Cardiac Arrest | 32 | 0.1% |
| History of Coronary Angioplasty or Bypass | 754 | 3.3% |
| Health Service Utilization Intensity Metrics | Mean | Standard Deviation |
| Mean number of ambulatory encounters | 18.5 | 13.4 |
| Mean number of emergency room encounters | 0.4 | 1.1 |
| Mean number of inpatient hospital encounters | 0.2 | 0.6 |
| Mean number of non-acute institutional encounters | 0.1 | 0.4 |
| Mean number of other ambulatory encounters | 5.8 | 10.9 |
| Mean number of filled prescriptions | 24.5 | 203.3 |
| Mean number of generics dispensed | 9.4 | 7.5 |
| Mean number of unique drug classes dispensed | 8.7 | 5.8 |

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 1b. Aggregated Baseline Table for Avelumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Characteristics | Number | |
|--|---------------|---------------------------|
| Number of unique patients | 2,803 | |
| Demographic Characteristics | Mean | Standard Deviation |
| Age (years) | 73.9 | 8.7 |
| | Number | Percent |
| Age | | |
| 0-17 years | ***** | ***** |
| 18-24 years | ***** | ***** |
| 25-40 years | ***** | ***** |
| 41-64 years | 293 | 10.5% |
| ≥ 65 years | 2,492 | 88.9% |
| Sex | | |
| Female | 739 | 26.4% |
| Male | 2,064 | 73.6% |
| Race ¹ | | |
| American Indian or Alaska Native | ***** | ***** |
| Asian | ***** | ***** |
| Black or African American | 91 | 3.2% |
| Native Hawaiian or Other Pacific Islander | ***** | ***** |
| Unknown | 481 | 17.2% |
| White | 2,191 | 78.2% |
| Hispanic origin | | |
| Yes | 37 | 1.3% |
| No | 2,198 | 78.4% |
| Unknown | 568 | 20.3% |
| Year | | |
| 2017 | 18 | 0.6% |
| 2018 | 501 | 17.9% |
| 2019 | 273 | 9.7% |
| 2020 | 525 | 18.7% |
| 2021 | 987 | 35.2% |
| 2022 | 499 | 17.8% |
| Health Characteristics | | |
| Acute Myocardial Infarction | 36 | 1.3% |
| Alzheimer's Disease and related conditions | 109 | 3.9% |
| Atrial Fibrillation | 437 | 15.6% |
| Diabetes Mellitus | 776 | 27.7% |
| Heart Failure | 406 | 14.5% |
| Hyperlipidemia | 1,442 | 51.4% |
| Hypertension | 1,937 | 69.1% |
| Depression | 441 | 15.7% |
| Ischemic Heart Disease | 991 | 35.4% |

Table 1b. Aggregated Baseline Table for Avelumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Health Characteristics | Number | Percent |
|--|---------------|---------------------------|
| Rheumatoid Arthritis/Osteoarthritis | 486 | 17.3% |
| Stroke/Transient Ischemic Attack | 112 | 4.0% |
| Breast Cancer | 99 | 3.5% |
| Colorectal Cancer | 76 | 2.7% |
| Prostate Cancer | 383 | 13.7% |
| Lung Cancer | 188 | 6.7% |
| Endometrial Cancer | 22 | 0.8% |
| Acquired Hypothyroidism | 467 | 16.7% |
| Anemia | 1,610 | 57.4% |
| Asthma | 145 | 5.2% |
| Chronic Kidney Disease | 1,610 | 57.4% |
| Chronic Obstructive Pulmonary Disease and Bronchiectasis | 423 | 15.1% |
| Glaucoma | 80 | 2.9% |
| Osteoporosis | 84 | 3.0% |
| Obesity Diagnosis/Procedure | 578 | 20.6% |
| Obesity: diagnosed or identified by weight management procedures | 16 | 0.6% |
| Obesity: identified by weight management-related prescriptions | 339 | 12.1% |
| Smoking Diagnosis/Procedure | 1,397 | 49.8% |
| Smoking: diagnosed or identified by smoking cessation procedures | 12 | 0.4% |
| Smoking: identified by smoking-related prescriptions | 74 | 2.6% |
| Drug Abuse or Dependence | 66 | 2.4% |
| History of Cardiac Arrest | ***** | ***** |
| History of Coronary Angioplasty or Bypass | 385 | 13.7% |
| Health Service Utilization Intensity Metrics | Mean | Standard Deviation |
| Mean number of ambulatory encounters | 34.1 | 16.2 |
| Mean number of emergency room encounters | 0.6 | 1.3 |
| Mean number of inpatient hospital encounters | 0.5 | 0.9 |
| Mean number of non-acute institutional encounters | 0.0 | 0.2 |
| Mean number of other ambulatory encounters | 8.9 | 10.4 |
| Mean number of filled prescriptions | 21.0 | 15.8 |
| Mean number of generics dispensed | 10.1 | 5.4 |
| Mean number of unique drug classes dispensed | 9.4 | 4.8 |

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 1c. Aggregated Baseline Table for Betrixaban in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Characteristics | Number | |
|--|---------------|---------------------------|
| Number of unique patients | 21 | |
| Demographic Characteristics | Mean | Standard Deviation |
| Age (years) | 70.0 | 9.3 |
| | Number | Percent |
| Age | | |
| 0-17 years | 0 | 0.0% |
| 18-24 years | 0 | 0.0% |
| 25-40 years | 0 | 0.0% |
| 41-64 years | ***** | ***** |
| ≥ 65 years | ***** | ***** |
| Sex | | |
| Female | ***** | ***** |
| Male | ***** | ***** |
| Race ¹ | | |
| American Indian or Alaska Native | 0 | 0.0% |
| Asian | ***** | ***** |
| Black or African American | ***** | ***** |
| Native Hawaiian or Other Pacific Islander | 0 | 0.0% |
| Unknown | ***** | ***** |
| White | ***** | ***** |
| Hispanic origin | | |
| Yes | ***** | ***** |
| No | ***** | ***** |
| Unknown | ***** | ***** |
| Year | | |
| 2017 | 0 | 0.0% |
| 2018 | ***** | ***** |
| 2019 | ***** | ***** |
| 2020 | ***** | ***** |
| 2021 | ***** | ***** |
| 2022 | 0 | 0.0% |
| Health Characteristics | | |
| Acute Myocardial Infarction | ***** | ***** |
| Alzheimer's Disease and related conditions | ***** | ***** |
| Atrial Fibrillation | ***** | ***** |
| Diabetes Mellitus | 11 | 52.4% |
| Heart Failure | ***** | ***** |
| Hyperlipidemia | ***** | ***** |
| Hypertension | 15 | 71.4% |
| Depression | ***** | ***** |
| Ischemic Heart Disease | ***** | ***** |

Table 1c. Aggregated Baseline Table for Betrixaban in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Health Characteristics | Number | Percent |
|--|---------------|---------------------------|
| Rheumatoid Arthritis/Osteoarthritis | ***** | ***** |
| Stroke/Transient Ischemic Attack | ***** | ***** |
| Breast Cancer | ***** | ***** |
| Colorectal Cancer | 0 | 0.0% |
| Prostate Cancer | ***** | ***** |
| Lung Cancer | 0 | 0.0% |
| Endometrial Cancer | ***** | ***** |
| Acquired Hypothyroidism | ***** | ***** |
| Anemia | ***** | ***** |
| Asthma | ***** | ***** |
| Chronic Kidney Disease | ***** | ***** |
| Chronic Obstructive Pulmonary Disease and Bronchiectasis | ***** | ***** |
| Glaucoma | 0 | 0.0% |
| Osteoporosis | ***** | ***** |
| Obesity Diagnosis/Procedure | ***** | ***** |
| Obesity: diagnosed or identified by weight management procedures | ***** | ***** |
| Obesity: identified by weight management-related prescriptions | ***** | ***** |
| Smoking Diagnosis/Procedure | ***** | ***** |
| Smoking: diagnosed or identified by smoking cessation procedures | 0 | 0.0% |
| Smoking: identified by smoking-related prescriptions | ***** | ***** |
| Drug Abuse or Dependence | ***** | ***** |
| History of Cardiac Arrest | 0 | 0.0% |
| History of Coronary Angioplasty or Bypass | 0 | 0.0% |
| Health Service Utilization Intensity Metrics | Mean | Standard Deviation |
| Mean number of ambulatory encounters | 11.8 | 10.1 |
| Mean number of emergency room encounters | 1.1 | 0.7 |
| Mean number of inpatient hospital encounters | 1.2 | 1.1 |
| Mean number of non-acute institutional encounters | 0.5 | 0.8 |
| Mean number of other ambulatory encounters | 21.1 | 23.2 |
| Mean number of filled prescriptions | 41.8 | 30.5 |
| Mean number of generics dispensed | 14.2 | 6.3 |
| Mean number of unique drug classes dispensed | 13.0 | 5.8 |

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 1d. Aggregated Baseline Table for Brigatinib in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Characteristics | Number | |
|--|---------------|---------------------------|
| Number of unique patients | 502 | |
| Demographic Characteristics | Mean | Standard Deviation |
| Age (years) | 61.5 | 12.5 |
| Age | Number | Percent |
| 0-17 years | ***** | ***** |
| 18-24 years | ***** | ***** |
| 25-40 years | ***** | ***** |
| 41-64 years | 229 | 45.6% |
| ≥ 65 years | 228 | 45.4% |
| Sex | | |
| Female | 292 | 58.2% |
| Male | 210 | 41.8% |
| Race¹ | | |
| American Indian or Alaska Native | 0 | 0.0% |
| Asian | 29 | 5.8% |
| Black or African American | ***** | ***** |
| Native Hawaiian or Other Pacific Islander | ***** | ***** |
| Unknown | 212 | 42.2% |
| White | 234 | 46.6% |
| Hispanic origin | | |
| Yes | 25 | 5.0% |
| No | 277 | 55.2% |
| Unknown | 200 | 39.8% |
| Year | | |
| 2017 | 104 | 20.7% |
| 2018 | 126 | 25.1% |
| 2019 | 89 | 17.7% |
| 2020 | 66 | 13.1% |
| 2021 | 83 | 16.5% |
| 2022 | 34 | 6.8% |
| Health Characteristics | | |
| Acute Myocardial Infarction | ***** | ***** |
| Alzheimer's Disease and related conditions | 14 | 2.8% |
| Atrial Fibrillation | 39 | 7.8% |
| Diabetes Mellitus | 76 | 15.1% |
| Heart Failure | 47 | 9.4% |
| Hyperlipidemia | 141 | 28.1% |
| Hypertension | 182 | 36.3% |
| Depression | 91 | 18.1% |
| Ischemic Heart Disease | 79 | 15.7% |

Table 1d. Aggregated Baseline Table for Brigatinib in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Health Characteristics | Number | Percent |
|--|---------------|---------------------------|
| Rheumatoid Arthritis/Osteoarthritis | 44 | 8.8% |
| Stroke/Transient Ischemic Attack | 26 | 5.2% |
| Breast Cancer | 30 | 6.0% |
| Colorectal Cancer | ***** | ***** |
| Prostate Cancer | 15 | 3.0% |
| Lung Cancer | 472 | 94.0% |
| Endometrial Cancer | ***** | ***** |
| Acquired Hypothyroidism | 64 | 12.7% |
| Anemia | 185 | 36.9% |
| Asthma | 36 | 7.2% |
| Chronic Kidney Disease | 90 | 17.9% |
| Chronic Obstructive Pulmonary Disease and Bronchiectasis | 61 | 12.2% |
| Glaucoma | ***** | ***** |
| Osteoporosis | 21 | 4.2% |
| Obesity Diagnosis/Procedure | 61 | 12.2% |
| Obesity: diagnosed or identified by weight management procedures | ***** | ***** |
| Obesity: identified by weight management-related prescriptions | 37 | 7.4% |
| Smoking Diagnosis/Procedure | 131 | 26.1% |
| Smoking: diagnosed or identified by smoking cessation procedures | 0 | 0.0% |
| Smoking: identified by smoking-related prescriptions | ***** | ***** |
| Drug Abuse or Dependence | 19 | 3.8% |
| History of Cardiac Arrest | 0 | 0.0% |
| History of Coronary Angioplasty or Bypass | 20 | 4.0% |
| Health Service Utilization Intensity Metrics | Mean | Standard Deviation |
| Mean number of ambulatory encounters | 22.9 | 13.3 |
| Mean number of emergency room encounters | 0.6 | 1.1 |
| Mean number of inpatient hospital encounters | 0.5 | 1.0 |
| Mean number of non-acute institutional encounters | 0.1 | 0.3 |
| Mean number of other ambulatory encounters | 9.4 | 14.8 |
| Mean number of filled prescriptions | 22.9 | 17.4 |
| Mean number of generics dispensed | 9.2 | 5.6 |
| Mean number of unique drug classes dispensed | 8.5 | 5.0 |

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 1e. Aggregated Baseline Table for Brodalumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Characteristics | Number | |
|--|---------------|---------------------------|
| Number of unique patients | 841 | |
| Demographic Characteristics | Mean | Standard Deviation |
| Age (years) | 54.1 | 12.3 |
| | Number | Percent |
| Age | | |
| 0-17 years | 0 | 0.0% |
| 18-24 years | 18 | 2.1% |
| 25-40 years | 140 | 16.6% |
| 41-64 years | 466 | 55.4% |
| ≥ 65 years | 217 | 25.8% |
| Sex | | |
| Female | 397 | 47.2% |
| Male | 444 | 52.8% |
| Race ¹ | | |
| American Indian or Alaska Native | ***** | ***** |
| Asian | ***** | ***** |
| Black or African American | 29 | 3.4% |
| Native Hawaiian or Other Pacific Islander | ***** | ***** |
| Unknown | 447 | 53.2% |
| White | 334 | 39.7% |
| Hispanic origin | | |
| Yes | 30 | 3.6% |
| No | 339 | 40.3% |
| Unknown | 472 | 56.1% |
| Year | | |
| 2017 | 24 | 2.9% |
| 2018 | 301 | 35.8% |
| 2019 | 264 | 31.4% |
| 2020 | 128 | 15.2% |
| 2021 | 89 | 10.6% |
| 2022 | 35 | 4.2% |
| Health Characteristics | | |
| Acute Myocardial Infarction | ***** | ***** |
| Alzheimer's Disease and related conditions | ***** | ***** |
| Atrial Fibrillation | 31 | 3.7% |
| Diabetes Mellitus | 194 | 23.1% |
| Heart Failure | 46 | 5.5% |
| Hyperlipidemia | 218 | 25.9% |
| Hypertension | 273 | 32.5% |
| Depression | 149 | 17.7% |
| Ischemic Heart Disease | 90 | 10.7% |

Table 1e. Aggregated Baseline Table for Brodalumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Health Characteristics | Number | Percent |
|--|---------------|---------------------------|
| Rheumatoid Arthritis/Osteoarthritis | 262 | 31.2% |
| Stroke/Transient Ischemic Attack | ***** | ***** |
| Breast Cancer | 11 | 1.3% |
| Colorectal Cancer | ***** | ***** |
| Prostate Cancer | ***** | ***** |
| Lung Cancer | ***** | ***** |
| Endometrial Cancer | ***** | ***** |
| Acquired Hypothyroidism | 64 | 7.6% |
| Anemia | 112 | 13.3% |
| Asthma | 27 | 3.2% |
| Chronic Kidney Disease | 60 | 7.1% |
| Chronic Obstructive Pulmonary Disease and Bronchiectasis | 63 | 7.5% |
| Glaucoma | 26 | 3.1% |
| Osteoporosis | 16 | 1.9% |
| Obesity Diagnosis/Procedure | 231 | 27.5% |
| Obesity: diagnosed or identified by weight management procedures | 23 | 2.7% |
| Obesity: identified by weight management-related prescriptions | 58 | 6.9% |
| Smoking Diagnosis/Procedure | 143 | 17.0% |
| Smoking: diagnosed or identified by smoking cessation procedures | 13 | 1.5% |
| Smoking: identified by smoking-related prescriptions | 18 | 2.1% |
| Drug Abuse or Dependence | 26 | 3.1% |
| History of Cardiac Arrest | 0 | 0.0% |
| History of Coronary Angioplasty or Bypass | 20 | 2.4% |
| Health Service Utilization Intensity Metrics | Mean | Standard Deviation |
| Mean number of ambulatory encounters | 12.2 | 13.7 |
| Mean number of emergency room encounters | 0.3 | 0.9 |
| Mean number of inpatient hospital encounters | 0.1 | 0.3 |
| Mean number of non-acute institutional encounters | 0.0 | 0.1 |
| Mean number of other ambulatory encounters | 2.7 | 4.6 |
| Mean number of filled prescriptions | 24.5 | 19.9 |
| Mean number of generics dispensed | 9.2 | 5.6 |
| Mean number of unique drug classes dispensed | 8.4 | 5.0 |

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 1f. Aggregated Baseline Table for Cerliponase Alfa in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Characteristics | Number | |
|--|--------|--------------------|
| Number of unique patients | 18 | |
| Demographic Characteristics | Mean | Standard Deviation |
| Age (years) | 7.0 | 3.5 |
| Age | Number | Percent |
| 0-17 years | 18 | 100.0% |
| 18-24 years | 0 | 0.0% |
| 25-40 years | 0 | 0.0% |
| 41-64 years | 0 | 0.0% |
| ≥ 65 years | 0 | 0.0% |
| Sex | | |
| Female | ***** | ***** |
| Male | ***** | ***** |
| Race ¹ | | |
| American Indian or Alaska Native | 0 | 0.0% |
| Asian | 0 | 0.0% |
| Black or African American | 0 | 0.0% |
| Native Hawaiian or Other Pacific Islander | 0 | 0.0% |
| Unknown | ***** | ***** |
| White | ***** | ***** |
| Hispanic origin | | |
| Yes | ***** | ***** |
| No | ***** | ***** |
| Unknown | ***** | ***** |
| Year | | |
| 2017 | ***** | ***** |
| 2018 | ***** | ***** |
| 2019 | ***** | ***** |
| 2020 | ***** | ***** |
| 2021 | ***** | ***** |
| 2022 | ***** | ***** |
| Health Characteristics | | |
| Acute Myocardial Infarction | 0 | 0.0% |
| Alzheimer's Disease and related conditions | 0 | 0.0% |
| Atrial Fibrillation | 0 | 0.0% |
| Diabetes Mellitus | 0 | 0.0% |
| Heart Failure | 0 | 0.0% |
| Hyperlipidemia | 0 | 0.0% |
| Hypertension | 0 | 0.0% |
| Depression | 0 | 0.0% |
| Ischemic Heart Disease | 0 | 0.0% |

Table 1f. Aggregated Baseline Table for Cerliponase Alfa in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Health Characteristics | Number | Percent |
|--|---------------|---------------------------|
| Rheumatoid Arthritis/Osteoarthritis | 0 | 0.0% |
| Stroke/Transient Ischemic Attack | 0 | 0.0% |
| Breast Cancer | 0 | 0.0% |
| Colorectal Cancer | 0 | 0.0% |
| Prostate Cancer | 0 | 0.0% |
| Lung Cancer | 0 | 0.0% |
| Endometrial Cancer | 0 | 0.0% |
| Acquired Hypothyroidism | 0 | 0.0% |
| Anemia | 0 | 0.0% |
| Asthma | 0 | 0.0% |
| Chronic Kidney Disease | 0 | 0.0% |
| Chronic Obstructive Pulmonary Disease and Bronchiectasis | 0 | 0.0% |
| Glaucoma | 0 | 0.0% |
| Osteoporosis | 0 | 0.0% |
| Obesity Diagnosis/Procedure | 0 | 0.0% |
| Obesity: diagnosed or identified by weight management procedures | 0 | 0.0% |
| Obesity: identified by weight management-related prescriptions | 0 | 0.0% |
| Smoking Diagnosis/Procedure | 0 | 0.0% |
| Smoking: diagnosed or identified by smoking cessation procedures | 0 | 0.0% |
| Smoking: identified by smoking-related prescriptions | 0 | 0.0% |
| Drug Abuse or Dependence | 0 | 0.0% |
| History of Cardiac Arrest | 0 | 0.0% |
| History of Coronary Angioplasty or Bypass | 0 | 0.0% |
| Health Service Utilization Intensity Metrics | Mean | Standard Deviation |
| Mean number of ambulatory encounters | 33.4 | 15.3 |
| Mean number of emergency room encounters | 0.3 | 0.4 |
| Mean number of inpatient hospital encounters | 0.6 | 0.6 |
| Mean number of non-acute institutional encounters | 0.0 | NaN |
| Mean number of other ambulatory encounters | 7.1 | 10.5 |
| Mean number of filled prescriptions | 10.8 | 9.5 |
| Mean number of generics dispensed | 3.4 | 2.5 |
| Mean number of unique drug classes dispensed | 3.1 | 2.4 |

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 1g. Aggregated Baseline Table for Deflazacort in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Characteristics | Number | |
|--|--------|--------------------|
| Number of unique patients | 1,129 | |
| Demographic Characteristics | Mean | Standard Deviation |
| Age (years) | 14.2 | 6.2 |
| Age | Number | Percent |
| 0-17 years | 868 | 76.9% |
| 18-24 years | 179 | 15.9% |
| 25-40 years | ***** | ***** |
| 41-64 years | ***** | ***** |
| ≥ 65 years | ***** | ***** |
| Sex | | |
| Female | ***** | ***** |
| Male | ***** | ***** |
| Race ¹ | | |
| American Indian or Alaska Native | ***** | ***** |
| Asian | ***** | ***** |
| Black or African American | 38 | 3.4% |
| Native Hawaiian or Other Pacific Islander | ***** | ***** |
| Unknown | 619 | 54.8% |
| White | 441 | 39.1% |
| Hispanic origin | | |
| Yes | 180 | 15.9% |
| No | 493 | 43.7% |
| Unknown | 456 | 40.4% |
| Year | | |
| 2017 | 536 | 47.5% |
| 2018 | 394 | 34.9% |
| 2019 | 60 | 5.3% |
| 2020 | 61 | 5.4% |
| 2021 | 54 | 4.8% |
| 2022 | 24 | 2.1% |
| Health Characteristics | | |
| Acute Myocardial Infarction | 0 | 0.0% |
| Alzheimer's Disease and related conditions | ***** | ***** |
| Atrial Fibrillation | ***** | ***** |
| Diabetes Mellitus | ***** | ***** |
| Heart Failure | 115 | 10.2% |
| Hyperlipidemia | ***** | ***** |
| Hypertension | 24 | 2.1% |
| Depression | 57 | 5.0% |
| Ischemic Heart Disease | ***** | ***** |

Table 1g. Aggregated Baseline Table for Deflazacort in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Health Characteristics | Number | Percent |
|--|---------------|----------------|
| Rheumatoid Arthritis/Osteoarthritis | ***** | ***** |
| Stroke/Transient Ischemic Attack | ***** | ***** |
| Breast Cancer | 0 | 0.0% |
| Colorectal Cancer | 0 | 0.0% |
| Prostate Cancer | 0 | 0.0% |
| Lung Cancer | 0 | 0.0% |
| Endometrial Cancer | 0 | 0.0% |
| Acquired Hypothyroidism | ***** | ***** |
| Anemia | 17 | 1.5% |
| Asthma | 18 | 1.6% |
| Chronic Kidney Disease | ***** | ***** |
| Chronic Obstructive Pulmonary Disease and Bronchiectasis | ***** | ***** |
| Glaucoma | ***** | ***** |
| Osteoporosis | 40 | 3.5% |
| Obesity Diagnosis/Procedure | 90 | 8.0% |
| Obesity: diagnosed or identified by weight management procedures | 0 | 0.0% |
| Obesity: identified by weight management-related prescriptions | 20 | 1.8% |
| Smoking Diagnosis/Procedure | ***** | ***** |
| Smoking: diagnosed or identified by smoking cessation procedures | ***** | ***** |
| Smoking: identified by smoking-related prescriptions | ***** | ***** |
| Drug Abuse or Dependence | ***** | ***** |
| History of Cardiac Arrest | 0 | 0.0% |
| History of Coronary Angioplasty or Bypass | 0 | 0.0% |
| Health Service Utilization Intensity Metrics | | |
| Mean number of ambulatory encounters | 14.2 | 19.5 |
| Mean number of emergency room encounters | 0.2 | 0.7 |
| Mean number of inpatient hospital encounters | 0.0 | 0.3 |
| Mean number of non-acute institutional encounters | 0.0 | 0.1 |
| Mean number of other ambulatory encounters | 24.5 | 42.3 |
| Mean number of filled prescriptions | 11.5 | 12.7 |
| Mean number of generics dispensed | 3.6 | 3.2 |
| Mean number of unique drug classes dispensed | 3.5 | 3.1 |

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 1h. Aggregated Baseline Table for Delafloxacin in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Characteristics | Number | |
|--|---------------|---------------------------|
| Number of unique patients | 2,996 | |
| Demographic Characteristics | Mean | Standard Deviation |
| Age (years) | 61.5 | 13.7 |
| Age | Number | Percent |
| 0-17 years | 15 | 0.5% |
| 18-24 years | 41 | 1.4% |
| 25-40 years | 268 | 8.9% |
| 41-64 years | 1,342 | 44.8% |
| ≥ 65 years | 1,330 | 44.4% |
| Sex | | |
| Female | 1,374 | 45.9% |
| Male | 1,622 | 54.1% |
| Race¹ | | |
| American Indian or Alaska Native | ***** | ***** |
| Asian | ***** | ***** |
| Black or African American | 227 | 7.6% |
| Native Hawaiian or Other Pacific Islander | ***** | ***** |
| Unknown | 1,129 | 37.7% |
| White | 1,610 | 53.7% |
| Hispanic origin | | |
| Yes | 87 | 2.9% |
| No | 1,746 | 58.3% |
| Unknown | 1,163 | 38.8% |
| Year | | |
| 2017 | 0 | 0.0% |
| 2018 | 874 | 29.2% |
| 2019 | 1,410 | 47.1% |
| 2020 | 423 | 14.1% |
| 2021 | 190 | 6.3% |
| 2022 | 99 | 3.3% |
| Health Characteristics | | |
| Acute Myocardial Infarction | 32 | 1.1% |
| Alzheimer's Disease and related conditions | 221 | 7.4% |
| Atrial Fibrillation | 453 | 15.1% |
| Diabetes Mellitus | 1,583 | 52.8% |
| Heart Failure | 700 | 23.4% |
| Hyperlipidemia | 1,439 | 48.0% |
| Hypertension | 1,986 | 66.3% |
| Depression | 787 | 26.3% |
| Ischemic Heart Disease | 895 | 29.9% |

Table 1h. Aggregated Baseline Table for Delafloxacin in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Health Characteristics | Number | Percent |
|--|---------------|---------------------------|
| Rheumatoid Arthritis/Osteoarthritis | 792 | 26.4% |
| Stroke/Transient Ischemic Attack | 142 | 4.7% |
| Breast Cancer | 83 | 2.8% |
| Colorectal Cancer | 28 | 0.9% |
| Prostate Cancer | 52 | 1.7% |
| Lung Cancer | 37 | 1.2% |
| Endometrial Cancer | 16 | 0.5% |
| Acquired Hypothyroidism | 491 | 16.4% |
| Anemia | 1,135 | 37.9% |
| Asthma | 230 | 7.7% |
| Benign Prostatic Hyperplasia | 207 | 6.9% |
| Chronic Kidney Disease | 985 | 32.9% |
| Chronic Obstructive Pulmonary Disease and Bronchiectasis | 527 | 17.6% |
| Glaucoma | 89 | 3.0% |
| Osteoporosis | 145 | 4.8% |
| Obesity: diagnosed or identified by weight management procedures | 1,159 | 38.7% |
| Obesity: identified by weight management-related prescriptions | 81 | 2.7% |
| Overweight | 261 | 8.7% |
| Smoking: diagnosed or identified by smoking cessation procedures | 969 | 32.3% |
| Smoking: identified by smoking-related prescriptions | 39 | 1.3% |
| Alcohol Abuse or Dependence | 96 | 3.2% |
| Drug Abuse or Dependence | 229 | 7.6% |
| History of Cardiac Arrest | ***** | ***** |
| History of Coronary Angioplasty or Bypass | 322 | 10.7% |
| Health Service Utilization Intensity Metrics | Mean | Standard Deviation |
| Mean number of ambulatory encounters | 24.5 | 21.0 |
| Mean number of emergency room encounters | 0.8 | 1.7 |
| Mean number of inpatient hospital encounters | 0.7 | 1.1 |
| Mean number of non-acute institutional encounters | 0.2 | 0.5 |
| Mean number of other ambulatory encounters | 13.7 | 20.1 |
| Mean number of filled prescriptions | 33.1 | 25.7 |
| Mean number of generics dispensed | 13.0 | 6.8 |
| Mean number of unique drug classes dispensed | 11.8 | 5.9 |

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 1i. Aggregated Baseline Table for Deutetrabenazine in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Characteristics | Number | |
|--|---------------|---------------------------|
| Number of unique patients | 16,357 | |
| Demographic Characteristics | Mean | Standard Deviation |
| Age (years) | 59.5 | 13.1 |
| | Number | Percent |
| Age | | |
| 0-17 years | 24 | 0.1% |
| 18-24 years | 160 | 1.0% |
| 25-40 years | 1,500 | 9.2% |
| 41-64 years | 8,412 | 51.4% |
| ≥ 65 years | 6,261 | 38.3% |
| Sex | | |
| Female | 10,101 | 61.8% |
| Male | 6,256 | 38.2% |
| Race ¹ | | |
| American Indian or Alaska Native | 112 | 0.7% |
| Asian | 190 | 1.2% |
| Black or African American | 2,165 | 13.2% |
| Native Hawaiian or Other Pacific Islander | 20 | 0.1% |
| Unknown | 2,282 | 14.0% |
| White | 11,588 | 70.8% |
| Hispanic origin | | |
| Yes | 533 | 3.3% |
| No | 13,540 | 82.8% |
| Unknown | 2,284 | 14.0% |
| Year | | |
| 2017 | 697 | 4.3% |
| 2018 | 3,189 | 19.5% |
| 2019 | 3,876 | 23.7% |
| 2020 | 3,323 | 20.3% |
| 2021 | 3,382 | 20.7% |
| 2022 | 1,890 | 11.6% |
| Health Characteristics | | |
| Acute Myocardial Infarction | 52 | 0.3% |
| Alzheimer's Disease and related conditions | 2,338 | 14.3% |
| Atrial Fibrillation | 515 | 3.1% |
| Diabetes Mellitus | 4,123 | 25.2% |
| Heart Failure | 1,005 | 6.1% |
| Hyperlipidemia | 5,406 | 33.1% |
| Hypertension | 6,968 | 42.6% |
| Depression | 10,306 | 63.0% |
| Ischemic Heart Disease | 2,115 | 12.9% |

Table 1i. Aggregated Baseline Table for Deutetrabenazine in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Health Characteristics | Number | Percent |
|--|---------------|---------------------------|
| Rheumatoid Arthritis/Osteoarthritis | 2,950 | 18.0% |
| Stroke/Transient Ischemic Attack | 603 | 3.7% |
| Breast Cancer | 301 | 1.8% |
| Colorectal Cancer | 79 | 0.5% |
| Prostate Cancer | 101 | 0.6% |
| Lung Cancer | 75 | 0.5% |
| Endometrial Cancer | 23 | 0.1% |
| Acquired Hypothyroidism | 2,667 | 16.3% |
| Anemia | 3,275 | 20.0% |
| Asthma | 1,036 | 6.3% |
| Chronic Kidney Disease | 1,967 | 12.0% |
| Chronic Obstructive Pulmonary Disease and Bronchiectasis | 2,276 | 13.9% |
| Glaucoma | 423 | 2.6% |
| Osteoporosis | 588 | 3.6% |
| Obesity Diagnosis/Procedure | 3,789 | 23.2% |
| Obesity: diagnosed or identified by weight management procedures | 180 | 1.1% |
| Obesity: identified by weight management-related prescriptions | 1,409 | 8.6% |
| Smoking Diagnosis/Procedure | 4,546 | 27.8% |
| Smoking: diagnosed or identified by smoking cessation procedures | 273 | 1.7% |
| Smoking: identified by smoking-related prescriptions | 1,016 | 6.2% |
| Drug Abuse or Dependence | 1,676 | 10.2% |
| History of Cardiac Arrest | 16 | 0.1% |
| History of Coronary Angioplasty or Bypass | 384 | 2.3% |
| Health Service Utilization Intensity Metrics | Mean | Standard Deviation |
| Mean number of ambulatory encounters | 16.0 | 17.0 |
| Mean number of emergency room encounters | 0.7 | 1.9 |
| Mean number of inpatient hospital encounters | 0.2 | 0.6 |
| Mean number of non-acute institutional encounters | 0.2 | 0.6 |
| Mean number of other ambulatory encounters | 10.4 | 19.9 |
| Mean number of filled prescriptions | 43.0 | 84.5 |
| Mean number of generics dispensed | 11.7 | 7.6 |
| Mean number of unique drug classes dispensed | 10.9 | 6.2 |

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 1j. Aggregated Baseline Table for Dupilumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Characteristics | Number | |
|--|---------------|---------------------------|
| Number of unique patients | 83,061 | |
| Demographic Characteristics | Mean | Standard Deviation |
| Age (years) | 48.0 | 16.9 |
| | Number | Percent |
| Age | | |
| 0-17 years | 7,038 | 8.5% |
| 18-24 years | 7,843 | 9.4% |
| 25-40 years | 16,043 | 19.3% |
| 41-64 years | 32,163 | 38.7% |
| ≥ 65 years | 19,974 | 24.0% |
| Sex | | |
| Female | 45,942 | 55.3% |
| Male | 37,119 | 44.7% |
| Race ¹ | | |
| American Indian or Alaska Native | 165 | 0.2% |
| Asian | 2,117 | 2.5% |
| Black or African American | 5,596 | 6.7% |
| Native Hawaiian or Other Pacific Islander | 140 | 0.2% |
| Unknown | 52,305 | 63.0% |
| White | 22,738 | 27.4% |
| Hispanic origin | | |
| Yes | 1,212 | 1.5% |
| No | 25,358 | 30.5% |
| Unknown | 56,491 | 68.0% |
| Year | | |
| 2017 | 5,334 | 6.4% |
| 2018 | 9,230 | 11.1% |
| 2019 | 15,195 | 18.3% |
| 2020 | 18,924 | 22.8% |
| 2021 | 23,194 | 27.9% |
| 2022 | 11,184 | 13.5% |
| Health Characteristics | | |
| Acute Myocardial Infarction | 179 | 0.2% |
| Alzheimer's Disease and related conditions | 1,026 | 1.2% |
| Atrial Fibrillation | 2,572 | 3.1% |
| Diabetes Mellitus | 9,228 | 11.1% |
| Heart Failure | 3,492 | 4.2% |
| Hyperlipidemia | 14,079 | 17.0% |
| Hypertension | 19,296 | 23.2% |
| Depression | 13,393 | 16.1% |
| Ischemic Heart Disease | 6,547 | 7.9% |

Table 1j. Aggregated Baseline Table for Dupilumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Health Characteristics | Number | Percent |
|--|---------------|---------------------------|
| Rheumatoid Arthritis/Osteoarthritis | 7,716 | 9.3% |
| Stroke/Transient Ischemic Attack | 738 | 0.9% |
| Breast Cancer | 861 | 1.0% |
| Colorectal Cancer | 217 | 0.3% |
| Prostate Cancer | 759 | 0.9% |
| Lung Cancer | 245 | 0.3% |
| Endometrial Cancer | 53 | 0.1% |
| Acquired Hypothyroidism | 5,129 | 6.2% |
| Anemia | 8,310 | 10.0% |
| Asthma | 19,884 | 23.9% |
| Chronic Kidney Disease | 4,519 | 5.4% |
| Chronic Obstructive Pulmonary Disease and Bronchiectasis | 6,885 | 8.3% |
| Glaucoma | 1,619 | 1.9% |
| Osteoporosis | 1,750 | 2.1% |
| Obesity Diagnosis/Procedure | 13,530 | 16.3% |
| Obesity: diagnosed or identified by weight management procedures | 745 | 0.9% |
| Obesity: identified by weight management-related prescriptions | 5,238 | 6.3% |
| Smoking Diagnosis/Procedure | 10,421 | 12.5% |
| Smoking: diagnosed or identified by smoking cessation procedures | 626 | 0.8% |
| Smoking: identified by smoking-related prescriptions | 1,442 | 1.7% |
| Drug Abuse or Dependence | 1,881 | 2.3% |
| History of Cardiac Arrest | 61 | 0.1% |
| History of Coronary Angioplasty or Bypass | 1,570 | 1.9% |
| Health Service Utilization Intensity Metrics | Mean | Standard Deviation |
| Mean number of ambulatory encounters | 12.3 | 11.8 |
| Mean number of emergency room encounters | 0.3 | 1.0 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 |
| Mean number of non-acute institutional encounters | 0.0 | 0.1 |
| Mean number of other ambulatory encounters | 2.8 | 7.1 |
| Mean number of filled prescriptions | 19.9 | 18.2 |
| Mean number of generics dispensed | 8.7 | 5.8 |
| Mean number of unique drug classes dispensed | 7.8 | 5.1 |

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 1k. Aggregated Baseline Table for Durvalumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Characteristics | Number | |
|--|---------------|---------------------------|
| Number of unique patients | 26,005 | |
| Demographic Characteristics | Mean | Standard Deviation |
| Age (years) | 71.0 | 7.5 |
| Age | Number | Percent |
| 0-17 years | ***** | ***** |
| 18-24 years | ***** | ***** |
| 25-40 years | ***** | ***** |
| 41-64 years | 4,635 | 17.8% |
| ≥ 65 years | 21,303 | 81.9% |
| Sex | | |
| Female | 12,431 | 47.8% |
| Male | 13,574 | 52.2% |
| Race¹ | | |
| American Indian or Alaska Native | 94 | 0.4% |
| Asian | 299 | 1.1% |
| Black or African American | 2,057 | 7.9% |
| Native Hawaiian or Other Pacific Islander | 39 | 0.1% |
| Unknown | 4,132 | 15.9% |
| White | 19,384 | 74.5% |
| Hispanic origin | | |
| Yes | 158 | 0.6% |
| No | 20,502 | 78.8% |
| Unknown | 5,345 | 20.6% |
| Year | | |
| 2017 | 48 | 0.2% |
| 2018 | 602 | 2.3% |
| 2019 | 8,726 | 33.6% |
| 2020 | 6,467 | 24.9% |
| 2021 | 6,625 | 25.5% |
| 2022 | 3,537 | 13.6% |
| Health Characteristics | | |
| Acute Myocardial Infarction | 385 | 1.5% |
| Alzheimer's Disease and related conditions | 949 | 3.6% |
| Atrial Fibrillation | 3,934 | 15.1% |
| Diabetes Mellitus | 6,754 | 26.0% |
| Heart Failure | 4,039 | 15.5% |
| Hyperlipidemia | 13,976 | 53.7% |
| Hypertension | 17,713 | 68.1% |
| Depression | 6,299 | 24.2% |
| Ischemic Heart Disease | 10,346 | 39.8% |

Table 1k. Aggregated Baesline Table for Durvalumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Health Characteristics | Number | Percent |
|--|---------------|---------------------------|
| Rheumatoid Arthritis/Osteoarthritis | 5,289 | 20.3% |
| Stroke/Transient Ischemic Attack | 1,148 | 4.4% |
| Breast Cancer | 1,440 | 5.5% |
| Colorectal Cancer | 651 | 2.5% |
| Prostate Cancer | 1,271 | 4.9% |
| Lung Cancer | 24,932 | 95.9% |
| Endometrial Cancer | 172 | 0.7% |
| Acquired Hypothyroidism | 4,208 | 16.2% |
| Anemia | 12,555 | 48.3% |
| Asthma | 1,434 | 5.5% |
| Chronic Kidney Disease | 5,127 | 19.7% |
| Chronic Obstructive Pulmonary Disease and Bronchiectasis | 16,179 | 62.2% |
| Glaucoma | 646 | 2.5% |
| Osteoporosis | 1,459 | 5.6% |
| Obesity Diagnosis/Procedure | 5,354 | 20.6% |
| Obesity: diagnosed or identified by weight management procedures | 107 | 0.4% |
| Obesity: identified by weight management-related prescriptions | 3,451 | 13.3% |
| Smoking Diagnosis/Procedure | 22,526 | 86.6% |
| Smoking: diagnosed or identified by smoking cessation procedures | 1,058 | 4.1% |
| Smoking: identified by smoking-related prescriptions | 1,372 | 5.3% |
| Drug Abuse or Dependence | 1,290 | 5.0% |
| History of Cardiac Arrest | 75 | 0.3% |
| History of Coronary Angioplasty or Bypass | 3,851 | 14.8% |
| Health Service Utilization Intensity Metrics | Mean | Standard Deviation |
| Mean number of ambulatory encounters | 47.8 | 16.0 |
| Mean number of emergency room encounters | 0.7 | 1.4 |
| Mean number of inpatient hospital encounters | 0.5 | 0.9 |
| Mean number of non-acute institutional encounters | 0.0 | 0.2 |
| Mean number of other ambulatory encounters | 9.4 | 11.5 |
| Mean number of filled prescriptions | 24.9 | 17.1 |
| Mean number of generics dispensed | 12.0 | 5.9 |
| Mean number of unique drug classes dispensed | 11.1 | 5.2 |

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 11. Aggregated Baseline Table for Edaravone in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Characteristics | Number | |
|--|---------------|---------------------------|
| Number of unique patients | 2,163 | |
| Demographic Characteristics | Mean | Standard Deviation |
| Age (years) | 64.3 | 10.7 |
| Age | Number | Percent |
| 0-17 years | ***** | ***** |
| 18-24 years | ***** | ***** |
| 25-40 years | ***** | ***** |
| 41-64 years | 829 | 38.3% |
| ≥ 65 years | 1,249 | 57.7% |
| Sex | | |
| Female | 977 | 45.2% |
| Male | 1,186 | 54.8% |
| Race¹ | | |
| American Indian or Alaska Native | ***** | ***** |
| Asian | ***** | ***** |
| Black or African American | 88 | 4.1% |
| Native Hawaiian or Other Pacific Islander | ***** | ***** |
| Unknown | 549 | 25.4% |
| White | 1,473 | 68.1% |
| Hispanic origin | | |
| Yes | 77 | 3.6% |
| No | 1,538 | 71.1% |
| Unknown | 548 | 25.3% |
| Year | | |
| 2017 | 249 | 11.5% |
| 2018 | 434 | 20.1% |
| 2019 | 645 | 29.8% |
| 2020 | 338 | 15.6% |
| 2021 | 318 | 14.7% |
| 2022 | 179 | 8.3% |
| Health Characteristics | | |
| Acute Myocardial Infarction | ***** | ***** |
| Alzheimer's Disease and related conditions | 79 | 3.7% |
| Atrial Fibrillation | 79 | 3.7% |
| Diabetes Mellitus | 271 | 12.5% |
| Heart Failure | 80 | 3.7% |
| Hyperlipidemia | 582 | 26.9% |
| Hypertension | 821 | 38.0% |
| Depression | 546 | 25.2% |
| Ischemic Heart Disease | 250 | 11.6% |

Table 11. Aggregated Baseline Table for Edaravone in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Health Characteristics | Number | Percent |
|--|---------------|---------------------------|
| Rheumatoid Arthritis/Osteoarthritis | 372 | 17.2% |
| Stroke/Transient Ischemic Attack | 74 | 3.4% |
| Breast Cancer | 31 | 1.4% |
| Colorectal Cancer | ***** | ***** |
| Prostate Cancer | 43 | 2.0% |
| Lung Cancer | ***** | ***** |
| Endometrial Cancer | ***** | ***** |
| Acquired Hypothyroidism | 216 | 10.0% |
| Anemia | 283 | 13.1% |
| Asthma | 86 | 4.0% |
| Chronic Kidney Disease | 101 | 4.7% |
| Chronic Obstructive Pulmonary Disease and Bronchiectasis | 150 | 6.9% |
| Glaucoma | 39 | 1.8% |
| Osteoporosis | 71 | 3.3% |
| Obesity Diagnosis/Procedure | 194 | 9.0% |
| Obesity: diagnosed or identified by weight management procedures | ***** | ***** |
| Obesity: identified by weight management-related prescriptions | 192 | 8.9% |
| Smoking Diagnosis/Procedure | 415 | 19.2% |
| Smoking: diagnosed or identified by smoking cessation procedures | ***** | ***** |
| Smoking: identified by smoking-related prescriptions | 48 | 2.2% |
| Drug Abuse or Dependence | 35 | 1.6% |
| History of Cardiac Arrest | ***** | ***** |
| History of Coronary Angioplasty or Bypass | 66 | 3.1% |
| Health Service Utilization Intensity Metrics | Mean | Standard Deviation |
| Mean number of ambulatory encounters | 26.9 | 21.9 |
| Mean number of emergency room encounters | 0.4 | 0.9 |
| Mean number of inpatient hospital encounters | 0.2 | 0.5 |
| Mean number of non-acute institutional encounters | 0.0 | 0.3 |
| Mean number of other ambulatory encounters | 7.4 | 14.7 |
| Mean number of filled prescriptions | 18.5 | 16.3 |
| Mean number of generics dispensed | 7.5 | 4.7 |
| Mean number of unique drug classes dispensed | 7.0 | 4.3 |

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 1m. Aggregated Baseline Table for Etelcalcetide in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Characteristics | Number | |
|--|---------------|---------------------------|
| Number of unique patients | 53,102 | |
| Demographic Characteristics | Mean | Standard Deviation |
| Age (years) | 59.3 | 14.3 |
| | Number | Percent |
| Age | | |
| 0-17 years | 17 | 0.0% |
| 18-24 years | 455 | 0.9% |
| 25-40 years | 5,735 | 10.8% |
| 41-64 years | 26,938 | 50.7% |
| ≥ 65 years | 19,957 | 37.6% |
| Sex | | |
| Female | 24,800 | 46.7% |
| Male | 28,302 | 53.3% |
| Race ¹ | | |
| American Indian or Alaska Native | 609 | 1.1% |
| Asian | 2,003 | 3.8% |
| Black or African American | 24,712 | 46.5% |
| Native Hawaiian or Other Pacific Islander | 49 | 0.1% |
| Unknown | 8,630 | 16.3% |
| White | 17,099 | 32.2% |
| Hispanic origin | | |
| Yes | 4,594 | 8.7% |
| No | 43,795 | 82.5% |
| Unknown | 4,713 | 8.9% |
| Year | | |
| 2017 | ***** | ***** |
| 2018 | 22,932 | 43.2% |
| 2019 | 17,269 | 32.5% |
| 2020 | 9,237 | 17.4% |
| 2021 | 2,589 | 4.9% |
| 2022 | ***** | ***** |
| Health Characteristics | | |
| Acute Myocardial Infarction | 1,932 | 3.6% |
| Alzheimer's Disease and related conditions | 3,522 | 6.6% |
| Atrial Fibrillation | 7,502 | 14.1% |
| Diabetes Mellitus | 30,952 | 58.3% |
| Heart Failure | 20,872 | 39.3% |
| Hyperlipidemia | 26,026 | 49.0% |
| Hypertension | 42,078 | 79.2% |
| Depression | 11,225 | 21.1% |
| Ischemic Heart Disease | 20,899 | 39.4% |

Table 1m. Aggregated Baseline Table for Etelcalcetide in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Health Characteristics | Number | Percent |
|--|---------------|---------------------------|
| Rheumatoid Arthritis/Osteoarthritis | 7,342 | 13.8% |
| Stroke/Transient Ischemic Attack | 3,567 | 6.7% |
| Breast Cancer | 760 | 1.4% |
| Colorectal Cancer | 499 | 0.9% |
| Prostate Cancer | 834 | 1.6% |
| Lung Cancer | 214 | 0.4% |
| Endometrial Cancer | 124 | 0.2% |
| Acquired Hypothyroidism | 6,046 | 11.4% |
| Anemia | 51,919 | 97.8% |
| Asthma | 3,291 | 6.2% |
| Benign Prostatic Hyperplasia | 1,829 | 3.4% |
| Chronic Kidney Disease | 53,031 | 99.9% |
| Chronic Obstructive Pulmonary Disease and Bronchiectasis | 7,485 | 14.1% |
| Glaucoma | 2,205 | 4.2% |
| Osteoporosis | 1,216 | 2.3% |
| Obesity: diagnosed or identified by weight management procedures | 14,053 | 26.5% |
| Obesity: identified by weight management-related prescriptions | 178 | 0.3% |
| Overweight | 4,180 | 7.9% |
| Smoking: diagnosed or identified by smoking cessation procedures | 17,014 | 32.0% |
| Smoking: identified by smoking-related prescriptions | 227 | 0.4% |
| Alcohol Abuse or Dependence | 1,022 | 1.9% |
| Drug Abuse or Dependence | 3,016 | 5.7% |
| History of Cardiac Arrest | 523 | 1.0% |
| History of Coronary Angioplasty or Bypass | 7,223 | 13.6% |
| Health Service Utilization Intensity Metrics | Mean | Standard Deviation |
| Mean number of ambulatory encounters | 80.7 | 16.8 |
| Mean number of emergency room encounters | 1.0 | 2.4 |
| Mean number of inpatient hospital encounters | 0.7 | 1.3 |
| Mean number of non-acute institutional encounters | 0.2 | 0.6 |
| Mean number of other ambulatory encounters | 18.7 | 20.7 |
| Mean number of filled prescriptions | 23.3 | 21.3 |
| Mean number of generics dispensed | 8.9 | 5.5 |
| Mean number of unique drug classes dispensed | 8.3 | 4.9 |

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 1n. Aggregated Baseline Table for Midostaurin in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Characteristics | Number | |
|--|---------------|---------------------------|
| Number of unique patients | 1,841 | |
| Demographic Characteristics | Mean | Standard Deviation |
| Age (years) | 59.7 | 12.3 |
| | Number | Percent |
| Age | | |
| 0-17 years | 18 | 1.0% |
| 18-24 years | 45 | 2.4% |
| 25-40 years | 178 | 9.7% |
| 41-64 years | 739 | 40.1% |
| ≥ 65 years | 861 | 46.8% |
| Sex | | |
| Female | 948 | 51.5% |
| Male | 893 | 48.5% |
| Race ¹ | | |
| American Indian or Alaska Native | ***** | ***** |
| Asian | ***** | ***** |
| Black or African American | 108 | 5.9% |
| Native Hawaiian or Other Pacific Islander | ***** | ***** |
| Unknown | 658 | 35.7% |
| White | 1,025 | 55.7% |
| Hispanic origin | | |
| Yes | 57 | 3.1% |
| No | 1,106 | 60.1% |
| Unknown | 678 | 36.8% |
| Year | | |
| 2017 | 395 | 21.5% |
| 2018 | 515 | 28.0% |
| 2019 | 288 | 15.6% |
| 2020 | 275 | 14.9% |
| 2021 | 267 | 14.5% |
| 2022 | 101 | 5.5% |
| Health Characteristics | | |
| Acute Myocardial Infarction | 54 | 2.9% |
| Alzheimer's Disease and related conditions | 48 | 2.6% |
| Atrial Fibrillation | 193 | 10.5% |
| Diabetes Mellitus | 394 | 21.4% |
| Heart Failure | 293 | 15.9% |
| Hyperlipidemia | 674 | 36.6% |
| Hypertension | 966 | 52.5% |
| Depression | 472 | 25.6% |
| Ischemic Heart Disease | 405 | 22.0% |

Table 1n. Aggregated Baseline Table for Midostaurin in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Health Characteristics | Number | Percent |
|--|---------------|---------------------------|
| Rheumatoid Arthritis/Osteoarthritis | 272 | 14.8% |
| Stroke/Transient Ischemic Attack | 123 | 6.7% |
| Breast Cancer | 68 | 3.7% |
| Colorectal Cancer | 17 | 0.9% |
| Prostate Cancer | 54 | 2.9% |
| Lung Cancer | 16 | 0.9% |
| Endometrial Cancer | 12 | 0.7% |
| Acquired Hypothyroidism | 262 | 14.2% |
| Anemia | 1,666 | 90.5% |
| Asthma | 140 | 7.6% |
| Chronic Kidney Disease | 579 | 31.5% |
| Chronic Obstructive Pulmonary Disease and Bronchiectasis | 256 | 13.9% |
| Glaucoma | 41 | 2.2% |
| Osteoporosis | 74 | 4.0% |
| Obesity Diagnosis/Procedure | 474 | 25.7% |
| Obesity: diagnosed or identified by weight management procedures | ***** | ***** |
| Obesity: identified by weight management-related prescriptions | 172 | 9.3% |
| Smoking Diagnosis/Procedure | 703 | 38.2% |
| Smoking: diagnosed or identified by smoking cessation procedures | 35 | 1.9% |
| Smoking: identified by smoking-related prescriptions | 48 | 2.6% |
| Drug Abuse or Dependence | 90 | 4.9% |
| History of Cardiac Arrest | ***** | ***** |
| History of Coronary Angioplasty or Bypass | 108 | 5.9% |
| Health Service Utilization Intensity Metrics | Mean | Standard Deviation |
| Mean number of ambulatory encounters | 19.8 | 17.5 |
| Mean number of emergency room encounters | 0.9 | 1.6 |
| Mean number of inpatient hospital encounters | 1.5 | 1.3 |
| Mean number of non-acute institutional encounters | 0.0 | 0.2 |
| Mean number of other ambulatory encounters | 18.2 | 18.8 |
| Mean number of filled prescriptions | 19.7 | 17.4 |
| Mean number of generics dispensed | 9.9 | 6.3 |
| Mean number of unique drug classes dispensed | 9.2 | 5.6 |

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 1o. Aggregated Baseline Table for Naldemedine in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Characteristics | Number | |
|--|---------------|---------------------------|
| Number of unique patients | 13,921 | |
| Demographic Characteristics | Mean | Standard Deviation |
| Age (years) | 61.4 | 12.3 |
| Age | Number | Percent |
| 0-17 years | ***** | ***** |
| 18-24 years | ***** | ***** |
| 25-40 years | 957 | 6.9% |
| 41-64 years | 7,235 | 52.0% |
| ≥ 65 years | 5,677 | 40.8% |
| Sex | | |
| Female | 9,168 | 65.9% |
| Male | 4,753 | 34.1% |
| Race¹ | | |
| American Indian or Alaska Native | ***** | ***** |
| Asian | 92 | 0.7% |
| Black or African American | 1,322 | 9.5% |
| Native Hawaiian or Other Pacific Islander | ***** | ***** |
| Unknown | 4,281 | 30.8% |
| White | 8,156 | 58.6% |
| Hispanic origin | | |
| Yes | 284 | 2.0% |
| No | 9,074 | 65.2% |
| Unknown | 4,563 | 32.8% |
| Year | | |
| 2017 | 348 | 2.5% |
| 2018 | 3,799 | 27.3% |
| 2019 | 4,100 | 29.5% |
| 2020 | 2,288 | 16.4% |
| 2021 | 2,445 | 17.6% |
| 2022 | 941 | 6.8% |
| Health Characteristics | | |
| Acute Myocardial Infarction | 77 | 0.6% |
| Alzheimer's Disease and related conditions | 561 | 4.0% |
| Atrial Fibrillation | 906 | 6.5% |
| Diabetes Mellitus | 3,605 | 25.9% |
| Heart Failure | 1,494 | 10.7% |
| Hyperlipidemia | 4,656 | 33.4% |
| Hypertension | 6,888 | 49.5% |
| Depression | 5,836 | 41.9% |
| Ischemic Heart Disease | 2,721 | 19.5% |

Table 10. Aggregated Baseline Table for Naldemedine in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Health Characteristics | Number | Percent |
|--|---------------|---------------------------|
| Rheumatoid Arthritis/Osteoarthritis | 7,636 | 54.9% |
| Stroke/Transient Ischemic Attack | 411 | 3.0% |
| Breast Cancer | 361 | 2.6% |
| Colorectal Cancer | 137 | 1.0% |
| Prostate Cancer | 223 | 1.6% |
| Lung Cancer | 181 | 1.3% |
| Endometrial Cancer | 30 | 0.2% |
| Acquired Hypothyroidism | 2,138 | 15.4% |
| Anemia | 3,287 | 23.6% |
| Asthma | 1,112 | 8.0% |
| Benign Prostatic Hyperplasia | 648 | 4.7% |
| Chronic Kidney Disease | 1,995 | 14.3% |
| Chronic Obstructive Pulmonary Disease and Bronchiectasis | 2,205 | 15.8% |
| Glaucoma | 357 | 2.6% |
| Osteoporosis | 792 | 5.7% |
| Obesity: diagnosed or identified by weight management procedures | 3,937 | 28.3% |
| Obesity: identified by weight management-related prescriptions | 298 | 2.1% |
| Overweight | 1,344 | 9.7% |
| Smoking: diagnosed or identified by smoking cessation procedures | 4,396 | 31.6% |
| Smoking: identified by smoking-related prescriptions | 403 | 2.9% |
| Alcohol Abuse or Dependence | 358 | 2.6% |
| Drug Abuse or Dependence | 3,163 | 22.7% |
| History of Cardiac Arrest | 13 | 0.1% |
| History of Coronary Angioplasty or Bypass | 810 | 5.8% |
| Health Service Utilization Intensity Metrics | Mean | Standard Deviation |
| Mean number of ambulatory encounters | 19.6 | 15.0 |
| Mean number of emergency room encounters | 0.7 | 1.7 |
| Mean number of inpatient hospital encounters | 0.3 | 0.7 |
| Mean number of non-acute institutional encounters | 0.1 | 0.3 |
| Mean number of other ambulatory encounters | 6.6 | 13.8 |
| Mean number of filled prescriptions | 45.8 | 140.3 |
| Mean number of generics dispensed | 14.5 | 8.3 |
| Mean number of unique drug classes dispensed | 13.0 | 6.4 |

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 1p. Aggregated Baseline Table for Niraparib in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Characteristics | Number | |
|--|---------------|---------------------------|
| Number of unique patients | 6,415 | |
| Demographic Characteristics | Mean | Standard Deviation |
| Age (years) | 68.6 | 8.9 |
| Age | Number | Percent |
| 0-17 years | ***** | ***** |
| 18-24 years | ***** | ***** |
| 25-40 years | ***** | ***** |
| 41-64 years | 1,887 | 29.4% |
| ≥ 65 years | 4,454 | 69.4% |
| Sex | | |
| Female | 6,382 | 99.5% |
| Male | 33 | 0.5% |
| Race¹ | | |
| American Indian or Alaska Native | ***** | ***** |
| Asian | 166 | 2.6% |
| Black or African American | 328 | 5.1% |
| Native Hawaiian or Other Pacific Islander | ***** | ***** |
| Unknown | 1,720 | 26.8% |
| White | 4,165 | 64.9% |
| Hispanic origin | | |
| Yes | 169 | 2.6% |
| No | 4,459 | 69.5% |
| Unknown | 1,787 | 27.9% |
| Year | | |
| 2017 | 1,105 | 17.2% |
| 2018 | 1,031 | 16.1% |
| 2019 | 937 | 14.6% |
| 2020 | 1,599 | 24.9% |
| 2021 | 1,244 | 19.4% |
| 2022 | 499 | 7.8% |
| Health Characteristics | | |
| Acute Myocardial Infarction | 29 | 0.5% |
| Alzheimer's Disease and related conditions | 161 | 2.5% |
| Atrial Fibrillation | 414 | 6.5% |
| Diabetes Mellitus | 969 | 15.1% |
| Heart Failure | 492 | 7.7% |
| Hyperlipidemia | 2,092 | 32.6% |
| Hypertension | 3,073 | 47.9% |
| Depression | 1,354 | 21.1% |
| Ischemic Heart Disease | 847 | 13.2% |

Table 1p. Aggregated Baseline Table for Niraparib in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Health Characteristics | Number | Percent |
|--|---------------|----------------|
| Rheumatoid Arthritis/Osteoarthritis | 778 | 12.1% |
| Stroke/Transient Ischemic Attack | 128 | 2.0% |
| Breast Cancer | 691 | 10.8% |
| Colorectal Cancer | 278 | 4.3% |
| Prostate Cancer | 16 | 0.2% |
| Lung Cancer | 109 | 1.7% |
| Endometrial Cancer | 429 | 6.7% |
| Acquired Hypothyroidism | 1,096 | 17.1% |
| Anemia | 3,336 | 52.0% |
| Asthma | 339 | 5.3% |
| Benign Prostatic Hyperplasia | ***** | ***** |
| Chronic Kidney Disease | 1,211 | 18.9% |
| Chronic Obstructive Pulmonary Disease and Bronchiectasis | 448 | 7.0% |
| Glaucoma | 183 | 2.9% |
| Osteoporosis | 470 | 7.3% |
| Obesity: diagnosed or identified by weight management procedures | 1,179 | 18.4% |
| Obesity: identified by weight management-related prescriptions | 13 | 0.2% |
| Overweight | 560 | 8.7% |
| Smoking: diagnosed or identified by smoking cessation procedures | 1,533 | 23.9% |
| Smoking: identified by smoking-related prescriptions | 15 | 0.2% |
| Alcohol Abuse or Dependence | 76 | 1.2% |
| Drug Abuse or Dependence | 112 | 1.7% |
| History of Cardiac Arrest | ***** | ***** |
| History of Coronary Angioplasty or Bypass | 163 | 2.5% |
| Health Service Utilization Intensity Metrics | | |
| Mean number of ambulatory encounters | 27.2 | 13.2 |
| Mean number of emergency room encounters | 0.5 | 1.0 |
| Mean number of inpatient hospital encounters | 0.5 | 0.9 |
| Mean number of non-acute institutional encounters | 0.0 | 0.3 |
| Mean number of other ambulatory encounters | 8.4 | 11.0 |
| Mean number of filled prescriptions | 19.9 | 15.1 |
| Mean number of generics dispensed | 9.1 | 5.1 |
| Mean number of unique drug classes dispensed | 8.5 | 4.6 |

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 1q. Aggregated Baseline Table for Ocrelizumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Characteristics | Number | |
|--|---------------|---------------------------|
| Number of unique patients | 43,156 | |
| Demographic Characteristics | Mean | Standard Deviation |
| Age (years) | 50.4 | 12.0 |
| | Number | Percent |
| Age | | |
| 0-17 years | 55 | 0.1% |
| 18-24 years | 784 | 1.8% |
| 25-40 years | 10,500 | 24.3% |
| 41-64 years | 24,374 | 56.5% |
| ≥ 65 years | 7,443 | 17.2% |
| Sex | | |
| Female | 29,326 | 68.0% |
| Male | 13,830 | 32.0% |
| Race ¹ | | |
| American Indian or Alaska Native | 93 | 0.2% |
| Asian | 167 | 0.4% |
| Black or African American | 3,951 | 9.2% |
| Native Hawaiian or Other Pacific Islander | 36 | 0.1% |
| Unknown | 18,521 | 42.9% |
| White | 20,388 | 47.2% |
| Hispanic origin | | |
| Yes | 1,016 | 2.4% |
| No | 22,092 | 51.2% |
| Unknown | 20,048 | 46.5% |
| Year | | |
| 2017 | 2,063 | 4.8% |
| 2018 | 14,667 | 34.0% |
| 2019 | 8,475 | 19.6% |
| 2020 | 7,720 | 17.9% |
| 2021 | 7,333 | 17.0% |
| 2022 | 2,898 | 6.7% |
| Health Characteristics | | |
| Acute Myocardial Infarction | 65 | 0.2% |
| Alzheimer's Disease and related conditions | 915 | 2.1% |
| Atrial Fibrillation | 544 | 1.3% |
| Diabetes Mellitus Mellitus | 3,401 | 7.9% |
| Heart Failure | 727 | 1.7% |
| Hyperlipidemia | 6,137 | 14.2% |
| Hypertension | 8,568 | 19.9% |
| Depression | 13,171 | 30.5% |
| Ischemic Heart Disease | 1,937 | 4.5% |

Table 1q. Aggregated Baseline Table for Ocrelizumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Health Characteristics | Number | Percent |
|--|---------------|---------------------------|
| Rheumatoid Arthritis/Osteoarthritis | 4,597 | 10.7% |
| Stroke/Transient Ischemic Attack | 694 | 1.6% |
| Breast Cancer | 300 | 0.7% |
| Colorectal Cancer | 75 | 0.2% |
| Prostate Cancer | 181 | 0.4% |
| Lung Cancer | 49 | 0.1% |
| Endometrial Cancer | 36 | 0.1% |
| Acquired Hypothyroidism | 2,929 | 6.8% |
| Anemia | 4,773 | 11.1% |
| Asthma | 1,363 | 3.2% |
| Benign Prostatic Hyperplasia | 762 | 1.8% |
| Chronic Kidney Disease | 1,474 | 3.4% |
| Chronic Obstructive Pulmonary Disease and Bronchiectasis | 1,065 | 2.5% |
| Glaucoma | 798 | 1.8% |
| Osteoporosis | 1,258 | 2.9% |
| Obesity: diagnosed or identified by weight management procedures | 6,776 | 15.7% |
| Obesity: identified by weight management-related prescriptions | 205 | 0.5% |
| Overweight | 2,765 | 6.4% |
| Smoking: diagnosed or identified by smoking cessation procedures | 7,460 | 17.3% |
| Smoking: identified by smoking-related prescriptions | 536 | 1.2% |
| Alcohol Abuse or Dependence | 636 | 1.5% |
| Drug Abuse or Dependence | 1,626 | 3.8% |
| History of Cardiac Arrest | 19 | 0.0% |
| History of Coronary Angioplasty or Bypass | 417 | 1.0% |
| Health Service Utilization Intensity Metrics | Mean | Standard Deviation |
| Mean number of ambulatory encounters | 13.0 | 11.2 |
| Mean number of emergency room encounters | 0.4 | 1.0 |
| Mean number of inpatient hospital encounters | 0.1 | 0.5 |
| Mean number of non-acute institutional encounters | 0.0 | 0.3 |
| Mean number of other ambulatory encounters | 4.7 | 11.9 |
| Mean number of filled prescriptions | 17.8 | 18.2 |
| Mean number of generics dispensed | 6.8 | 5.2 |
| Mean number of unique drug classes dispensed | 6.4 | 4.8 |

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 1r. Aggregated Baseline Table of Plecanatide in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Characteristics | Number | |
|--|---------------|---------------------------|
| Number of unique patients | 66,616 | |
| Demographic Characteristics | Mean | Standard Deviation |
| Age (years) | 58.9 | 14.3 |
| | Number | Percent |
| Age | | |
| 0-17 years | 135 | 0.2% |
| 18-24 years | 2,505 | 3.8% |
| 25-40 years | 8,810 | 13.2% |
| 41-64 years | 27,632 | 41.5% |
| ≥ 65 years | 27,534 | 41.3% |
| Sex | | |
| Female | 51,852 | 77.8% |
| Male | 14,764 | 22.2% |
| Race ¹ | | |
| American Indian or Alaska Native | 141 | 0.2% |
| Asian | 1,510 | 2.3% |
| Black or African American | 5,364 | 8.1% |
| Native Hawaiian or Other Pacific Islander | 43 | 0.1% |
| Unknown | 27,951 | 42.0% |
| White | 31,607 | 47.4% |
| Hispanic origin | | |
| Yes | 2,419 | 3.6% |
| No | 35,616 | 53.5% |
| Unknown | 28,581 | 42.9% |
| Year | | |
| 2017 | 6,682 | 10.0% |
| 2018 | 14,688 | 22.0% |
| 2019 | 10,835 | 16.3% |
| 2020 | 12,742 | 19.1% |
| 2021 | 15,075 | 22.6% |
| 2022 | 6,594 | 9.9% |
| Health Characteristics | | |
| Acute Myocardial Infarction | 236 | 0.4% |
| Alzheimer's Disease and related conditions | 2,788 | 4.2% |
| Atrial Fibrillation | 3,704 | 5.6% |
| Diabetes Mellitus | 14,512 | 21.8% |
| Heart Failure | 5,159 | 7.7% |
| Hyperlipidemia | 22,155 | 33.3% |
| Hypertension | 27,596 | 41.4% |
| Depression | 21,742 | 32.6% |
| Ischemic Heart Disease | 11,167 | 16.8% |

Table 1r. Aggregated Baseline Table of Plecanatide in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Health Characteristics | Number | Percent |
|--|---------------|---------------------------|
| Rheumatoid Arthritis/Osteoarthritis | 15,546 | 23.3% |
| Stroke/Transient Ischemic Attack | 1,601 | 2.4% |
| Breast Cancer | 1,598 | 2.4% |
| Colorectal Cancer | 472 | 0.7% |
| Prostate Cancer | 825 | 1.2% |
| Lung Cancer | 392 | 0.6% |
| Endometrial Cancer | 142 | 0.2% |
| Acquired Hypothyroidism | 10,158 | 15.2% |
| Anemia | 15,570 | 23.4% |
| Asthma | 4,998 | 7.5% |
| Benign Prostatic Hyperplasia | 2,910 | 4.4% |
| Chronic Kidney Disease | 7,008 | 10.5% |
| Chronic Obstructive Pulmonary Disease and Bronchiectasis | 6,239 | 9.4% |
| Glaucoma | 2,477 | 3.7% |
| Osteoporosis | 3,821 | 5.7% |
| Obesity: diagnosed or identified by weight management procedures | 14,536 | 21.8% |
| Obesity: identified by weight management-related prescriptions | 1,250 | 1.9% |
| Overweight | 7,088 | 10.6% |
| Smoking: diagnosed or identified by smoking cessation procedures | 12,220 | 18.3% |
| Smoking: identified by smoking-related prescriptions | 902 | 1.4% |
| Alcohol Abuse or Dependence | 1,163 | 1.7% |
| Drug Abuse or Dependence | 3,417 | 5.1% |
| History of Cardiac Arrest | 71 | 0.1% |
| History of Coronary Angioplasty or Bypass | 2,757 | 4.1% |
| Health Service Utilization Intensity Metrics | Mean | Standard Deviation |
| Mean number of ambulatory encounters | 17.2 | 15.1 |
| Mean number of emergency room encounters | 0.6 | 1.6 |
| Mean number of inpatient hospital encounters | 0.2 | 0.5 |
| Mean number of non-acute institutional encounters | 0.0 | 0.2 |
| Mean number of other ambulatory encounters | 5.0 | 11.5 |
| Mean number of filled prescriptions | 31.7 | 53.4 |
| Mean number of generics dispensed | 11.7 | 7.2 |
| Mean number of unique drug classes dispensed | 10.9 | 6.2 |

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 1s. Aggregated Baseline Table for Ribociclib in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Characteristics | Number | |
|--|---------------|---------------------------|
| Number of unique patients | 4,213 | |
| Demographic Characteristics | Mean | Standard Deviation |
| Age (years) | 66.5 | 10.9 |
| | Number | Percent |
| Age | | |
| 0-17 years | ***** | ***** |
| 18-24 years | ***** | ***** |
| 25-40 years | 166 | 3.9% |
| 41-64 years | 1,358 | 32.2% |
| ≥ 65 years | 2,675 | 63.5% |
| Sex | | |
| Female | 4,135 | 98.1% |
| Male | 78 | 1.9% |
| Race ¹ | | |
| American Indian or Alaska Native | ***** | ***** |
| Asian | 89 | 2.1% |
| Black or African American | 360 | 8.5% |
| Native Hawaiian or Other Pacific Islander | ***** | ***** |
| Unknown | 1,171 | 27.8% |
| White | 2,570 | 61.0% |
| Hispanic origin | | |
| Yes | 121 | 2.9% |
| No | 2,893 | 68.7% |
| Unknown | 1,199 | 28.5% |
| Year | | |
| 2017 | 741 | 17.6% |
| 2018 | 928 | 22.0% |
| 2019 | 875 | 20.8% |
| 2020 | 733 | 17.4% |
| 2021 | 551 | 13.1% |
| 2022 | 385 | 9.1% |
| Health Characteristics | | |
| Acute Myocardial Infarction | 18 | 0.4% |
| Alzheimer's Disease and related conditions | 136 | 3.2% |
| Atrial Fibrillation | 230 | 5.5% |
| Diabetes Mellitus | 839 | 19.9% |
| Heart Failure | 366 | 8.7% |
| Hyperlipidemia | 1,128 | 26.8% |
| Hypertension | 1,872 | 44.4% |
| Depression | 882 | 20.9% |
| Ischemic Heart Disease | 561 | 13.3% |

Table 1s. Aggregated Baseline Table for Ribociclib in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Health Characteristics | Number | Percent |
|--|---------------|---------------------------|
| Rheumatoid Arthritis/Osteoarthritis | 703 | 16.7% |
| Stroke/Transient Ischemic Attack | 92 | 2.2% |
| Breast Cancer | 4,151 | 98.5% |
| Colorectal Cancer | 57 | 1.4% |
| Prostate Cancer | ***** | ***** |
| Lung Cancer | 139 | 3.3% |
| Endometrial Cancer | 32 | 0.8% |
| Acquired Hypothyroidism | 613 | 14.6% |
| Anemia | 1,403 | 33.3% |
| Asthma | 208 | 4.9% |
| Benign Prostatic Hyperplasia | 11 | 0.3% |
| Chronic Kidney Disease | 613 | 14.6% |
| Chronic Obstructive Pulmonary Disease and Bronchiectasis | 393 | 9.3% |
| Glaucoma | 128 | 3.0% |
| Osteoporosis | 332 | 7.9% |
| Obesity: diagnosed or identified by weight management procedures | 830 | 19.7% |
| Obesity: identified by weight management-related prescriptions | 24 | 0.6% |
| Overweight | 346 | 8.2% |
| Smoking: diagnosed or identified by smoking cessation procedures | 947 | 22.5% |
| Smoking: identified by smoking-related prescriptions | 28 | 0.7% |
| Alcohol Abuse or Dependence | 58 | 1.4% |
| Drug Abuse or Dependence | 128 | 3.0% |
| History of Cardiac Arrest | ***** | ***** |
| History of Coronary Angioplasty or Bypass | 105 | 2.5% |
| Health Service Utilization Intensity Metrics | Mean | Standard Deviation |
| Mean number of ambulatory encounters | 22.3 | 13.2 |
| Mean number of emergency room encounters | 0.5 | 1.3 |
| Mean number of inpatient hospital encounters | 0.3 | 0.7 |
| Mean number of non-acute institutional encounters | 0.1 | 0.3 |
| Mean number of other ambulatory encounters | 7.0 | 11.0 |
| Mean number of filled prescriptions | 24.0 | 188.7 |
| Mean number of generics dispensed | 9.3 | 9.8 |
| Mean number of unique drug classes dispensed | 8.5 | 6.1 |

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 1t. Aggregated Baseline Table for Safinamide in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Characteristics | Number | |
|--|---------------|---------------------------|
| Number of unique patients | 2,319 | |
| Demographic Characteristics | Mean | Standard Deviation |
| Age (years) | 72.5 | 8.5 |
| | Number | Percent |
| Age | | |
| 0-17 years | 0 | 0.0% |
| 18-24 years | 0 | 0.0% |
| 25-40 years | ***** | ***** |
| 41-64 years | ***** | ***** |
| ≥ 65 years | 1,956 | 84.3% |
| Sex | | |
| Female | 968 | 41.7% |
| Male | 1,351 | 58.3% |
| Race ¹ | | |
| American Indian or Alaska Native | ***** | ***** |
| Asian | 104 | 4.5% |
| Black or African American | ***** | ***** |
| Native Hawaiian or Other Pacific Islander | ***** | ***** |
| Unknown | 492 | 21.2% |
| White | 1,671 | 72.1% |
| Hispanic origin | | |
| Yes | 45 | 1.9% |
| No | 1,737 | 74.9% |
| Unknown | 537 | 23.2% |
| Year | | |
| 2017 | 537 | 23.2% |
| 2018 | 712 | 30.7% |
| 2019 | 451 | 19.4% |
| 2020 | 330 | 14.2% |
| 2021 | 222 | 9.6% |
| 2022 | 67 | 2.9% |
| Health Characteristics | | |
| Acute Myocardial Infarction | ***** | ***** |
| Alzheimer's Disease and related conditions | 330 | 14.2% |
| Atrial Fibrillation | 150 | 6.5% |
| Diabetes Mellitus | 304 | 13.1% |
| Heart Failure | 142 | 6.1% |
| Hyperlipidemia | 740 | 31.9% |
| Hypertension | 872 | 37.6% |
| Depression | 599 | 25.8% |
| Ischemic Heart Disease | 399 | 17.2% |

Table 1t. Aggregated Baseline Table for Safinamide in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Health Characteristics | Number | Percent |
|--|---------------|---------------------------|
| Rheumatoid Arthritis/Osteoarthritis | 451 | 19.4% |
| Stroke/Transient Ischemic Attack | 71 | 3.1% |
| Breast Cancer | 39 | 1.7% |
| Colorectal Cancer | 12 | 0.5% |
| Prostate Cancer | 84 | 3.6% |
| Lung Cancer | ***** | ***** |
| Endometrial Cancer | 0 | 0.0% |
| Acquired Hypothyroidism | 243 | 10.5% |
| Anemia | 453 | 19.5% |
| Asthma | 84 | 3.6% |
| Chronic Kidney Disease | 185 | 8.0% |
| Chronic Obstructive Pulmonary Disease and Bronchiectasis | 102 | 4.4% |
| Glaucoma | 117 | 5.0% |
| Osteoporosis | 144 | 6.2% |
| Obesity Diagnosis/Procedure | 201 | 8.7% |
| Obesity: diagnosed or identified by weight management procedures | ***** | ***** |
| Obesity: identified by weight management-related prescriptions | 188 | 8.1% |
| Smoking Diagnosis/Procedure | 275 | 11.9% |
| Smoking: diagnosed or identified by smoking cessation procedures | ***** | ***** |
| Smoking: identified by smoking-related prescriptions | 11 | 0.5% |
| Drug Abuse or Dependence | 45 | 1.9% |
| History of Cardiac Arrest | ***** | ***** |
| History of Coronary Angioplasty or Bypass | 111 | 4.8% |
| Health Service Utilization Intensity Metrics | Mean | Standard Deviation |
| Mean number of ambulatory encounters | 16.9 | 13.5 |
| Mean number of emergency room encounters | 0.4 | 1.1 |
| Mean number of inpatient hospital encounters | 0.1 | 0.4 |
| Mean number of non-acute institutional encounters | 0.1 | 0.3 |
| Mean number of other ambulatory encounters | 5.9 | 12.4 |
| Mean number of filled prescriptions | 25.7 | 19.0 |
| Mean number of generics dispensed | 9.0 | 4.9 |
| Mean number of unique drug classes dispensed | 8.5 | 4.5 |

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 1u. Aggregated Baseline Table for Sarilumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Characteristics | Number | |
|--|---------------|---------------------------|
| Number of unique patients | 8,534 | |
| Demographic Characteristics | Mean | Standard Deviation |
| Age (years) | 60.5 | 12.7 |
| Age | Number | Percent |
| 0-17 years | ***** | ***** |
| 18-24 years | ***** | ***** |
| 25-40 years | 671 | 7.9% |
| 41-64 years | 4,468 | 52.4% |
| ≥ 65 years | 3,322 | 38.9% |
| Sex | | |
| Female | 6,345 | 74.3% |
| Male | 2,189 | 25.7% |
| Race¹ | | |
| American Indian or Alaska Native | 34 | 0.4% |
| Asian | 115 | 1.3% |
| Black or African American | 835 | 9.8% |
| Native Hawaiian or Other Pacific Islander | 18 | 0.2% |
| Unknown | 3,162 | 37.1% |
| White | 4,370 | 51.2% |
| Hispanic origin | | |
| Yes | 438 | 5.1% |
| No | 4,782 | 56.0% |
| Unknown | 3,314 | 38.8% |
| Year | | |
| 2017 | 366 | 4.3% |
| 2018 | 1,366 | 16.0% |
| 2019 | 1,710 | 20.0% |
| 2020 | 1,059 | 12.4% |
| 2021 | 2,857 | 33.5% |
| 2022 | 1,176 | 13.8% |
| Health Characteristics | | |
| Acute Myocardial Infarction | 48 | 0.6% |
| Alzheimer's Disease and related conditions | 202 | 2.4% |
| Atrial Fibrillation | 438 | 5.1% |
| Diabetes Mellitus | 2,016 | 23.6% |
| Heart Failure | 788 | 9.2% |
| Hyperlipidemia | 2,606 | 30.5% |
| Hypertension | 3,627 | 42.5% |
| Depression | 2,144 | 25.1% |
| Ischemic Heart Disease | 1,341 | 15.7% |

Table 1u. Aggregated Baseline Table for Sarilumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Health Characteristics | Number | Percent |
|--|---------------|---------------------------|
| Rheumatoid Arthritis/Osteoarthritis | 6,400 | 75.0% |
| Stroke/Transient Ischemic Attack | 157 | 1.8% |
| Breast Cancer | 130 | 1.5% |
| Colorectal Cancer | 33 | 0.4% |
| Prostate Cancer | 70 | 0.8% |
| Lung Cancer | 56 | 0.7% |
| Endometrial Cancer | ***** | ***** |
| Acquired Hypothyroidism | 1,130 | 13.2% |
| Anemia | 1,864 | 21.8% |
| Asthma | 534 | 6.3% |
| Benign Prostatic Hyperplasia | 206 | 2.4% |
| Chronic Kidney Disease | 1,063 | 12.5% |
| Chronic Obstructive Pulmonary Disease and Bronchiectasis | 967 | 11.3% |
| Glaucoma | 223 | 2.6% |
| Osteoporosis | 790 | 9.3% |
| Obesity: diagnosed or identified by weight management procedures | 2,572 | 30.1% |
| Obesity: identified by weight management-related prescriptions | 139 | 1.6% |
| Overweight | 817 | 9.6% |
| Smoking: diagnosed or identified by smoking cessation procedures | 1,857 | 21.8% |
| Smoking: identified by smoking-related prescriptions | 106 | 1.2% |
| Alcohol Abuse or Dependence | 110 | 1.3% |
| Drug Abuse or Dependence | 465 | 5.4% |
| History of Cardiac Arrest | ***** | ***** |
| History of Coronary Angioplasty or Bypass | 370 | 4.3% |
| Health Service Utilization Intensity Metrics | Mean | Standard Deviation |
| Mean number of ambulatory encounters | 14.2 | 13.4 |
| Mean number of emergency room encounters | 0.5 | 1.4 |
| Mean number of inpatient hospital encounters | 0.2 | 0.5 |
| Mean number of non-acute institutional encounters | 0.0 | 0.3 |
| Mean number of other ambulatory encounters | 4.1 | 9.3 |
| Mean number of filled prescriptions | 30.6 | 103.5 |
| Mean number of generics dispensed | 11.2 | 8.4 |
| Mean number of unique drug classes dispensed | 10.3 | 6.4 |

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 1v. Aggregated Baseline Table for Telotristat ethyl in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Characteristics | Number | |
|--|---------------|---------------------------|
| Number of unique patients | 1,061 | |
| Demographic Characteristics | Mean | Standard Deviation |
| Age (years) | 66.5 | 10.5 |
| Age | Number | Percent |
| 0-17 years | ***** | ***** |
| 18-24 years | ***** | ***** |
| 25-40 years | ***** | ***** |
| 41-64 years | 376 | 35.4% |
| ≥ 65 years | 651 | 61.4% |
| Sex | | |
| Female | 610 | 57.5% |
| Male | 451 | 42.5% |
| Race¹ | | |
| American Indian or Alaska Native | ***** | ***** |
| Asian | ***** | ***** |
| Black or African American | ***** | ***** |
| Native Hawaiian or Other Pacific Islander | ***** | ***** |
| Unknown | 315 | 29.7% |
| White | 655 | 61.7% |
| Hispanic origin | | |
| Yes | 14 | 1.3% |
| No | 701 | 66.1% |
| Unknown | 346 | 32.6% |
| Year | | |
| 2017 | 351 | 33.1% |
| 2018 | 250 | 23.6% |
| 2019 | 144 | 13.6% |
| 2020 | 145 | 13.7% |
| 2021 | 141 | 13.3% |
| 2022 | 30 | 2.8% |
| Health Characteristics | | |
| Acute Myocardial Infarction | ***** | ***** |
| Alzheimer's Disease and related conditions | 40 | 3.8% |
| Atrial Fibrillation | 89 | 8.4% |
| Diabetes Mellitus | 295 | 27.8% |
| Heart Failure | 144 | 13.6% |
| Hyperlipidemia | 306 | 28.8% |
| Hypertension | 586 | 55.2% |
| Depression | 259 | 24.4% |
| Ischemic Heart Disease | 210 | 19.8% |

Table 1v. Aggregated Baseline Table for Telotristat ethyl in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Health Characteristics | Number | Percent |
|--|---------------|---------------------------|
| Rheumatoid Arthritis/Osteoarthritis | 157 | 14.8% |
| Stroke/Transient Ischemic Attack | 27 | 2.5% |
| Breast Cancer | 52 | 4.9% |
| Colorectal Cancer | 85 | 8.0% |
| Prostate Cancer | 32 | 3.0% |
| Lung Cancer | 36 | 3.4% |
| Endometrial Cancer | ***** | ***** |
| Acquired Hypothyroidism | 169 | 15.9% |
| Anemia | 432 | 40.7% |
| Asthma | 49 | 4.6% |
| Benign Prostatic Hyperplasia | 71 | 6.7% |
| Chronic Kidney Disease | 252 | 23.8% |
| Chronic Obstructive Pulmonary Disease and Bronchiectasis | 79 | 7.4% |
| Glaucoma | 31 | 2.9% |
| Osteoporosis | 54 | 5.1% |
| Obesity: diagnosed or identified by weight management procedures | 168 | 15.8% |
| Obesity: identified by weight management-related prescriptions | 11 | 1.0% |
| Overweight | 92 | 8.7% |
| Smoking: diagnosed or identified by smoking cessation procedures | 284 | 26.8% |
| Smoking: identified by smoking-related prescriptions | ***** | ***** |
| Alcohol Abuse or Dependence | 12 | 1.1% |
| Drug Abuse or Dependence | 40 | 3.8% |
| History of Cardiac Arrest | ***** | ***** |
| History of Coronary Angioplasty or Bypass | 70 | 6.6% |
| Health Service Utilization Intensity Metrics | Mean | Standard Deviation |
| Mean number of ambulatory encounters | 23.4 | 15.9 |
| Mean number of emergency room encounters | 0.6 | 1.3 |
| Mean number of inpatient hospital encounters | 0.4 | 0.9 |
| Mean number of non-acute institutional encounters | 0.0 | 0.2 |
| Mean number of other ambulatory encounters | 7.0 | 11.6 |
| Mean number of filled prescriptions | 25.2 | 19.2 |
| Mean number of generics dispensed | 10.3 | 5.9 |
| Mean number of unique drug classes dispensed | 9.6 | 5.3 |

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 1w. Aggregated Baseline Table for Valbenazine in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Characteristics | Number | |
|--|---------------|---------------------------|
| Number of unique patients | 26,601 | |
| Demographic Characteristics | Mean | Standard Deviation |
| Age (years) | 58.8 | 12.7 |
| | Number | Percent |
| Age | | |
| 0-17 years | 25 | 0.1% |
| 18-24 years | 292 | 1.1% |
| 25-40 years | 2,528 | 9.5% |
| 41-64 years | 14,581 | 54.8% |
| ≥ 65 years | 9,175 | 34.5% |
| Sex | | |
| Female | 15,837 | 59.5% |
| Male | 10,764 | 40.5% |
| Race ¹ | | |
| American Indian or Alaska Native | 197 | 0.7% |
| Asian | 381 | 1.4% |
| Black or African American | 4,218 | 15.9% |
| Native Hawaiian or Other Pacific Islander | 19 | 0.1% |
| Unknown | 3,657 | 13.7% |
| White | 18,129 | 68.2% |
| Hispanic origin | | |
| Yes | 911 | 3.4% |
| No | 22,341 | 84.0% |
| Unknown | 3,349 | 12.6% |
| Year | | |
| 2017 | 3,261 | 12.3% |
| 2018 | 6,134 | 23.1% |
| 2019 | 5,557 | 20.9% |
| 2020 | 4,133 | 15.5% |
| 2021 | 4,722 | 17.8% |
| 2022 | 2,794 | 10.5% |
| Health Characteristics | | |
| Acute Myocardial Infarction | 85 | 0.3% |
| Alzheimer's Disease and related conditions | 3,179 | 12.0% |
| Atrial Fibrillation | 773 | 2.9% |
| Diabetes Mellitus | 7,125 | 26.8% |
| Heart Failure | 1,531 | 5.8% |
| Hyperlipidemia | 8,602 | 32.3% |
| Hypertension | 11,348 | 42.7% |
| Depression | 16,618 | 62.5% |
| Ischemic Heart Disease | 3,150 | 11.8% |

Table 1w. Aggregated Baseline Table for Valbenazine in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Health Characteristics | Number | Percent |
|--|---------------|---------------------------|
| Rheumatoid Arthritis/Osteoarthritis | 4,430 | 16.7% |
| Stroke/Transient Ischemic Attack | 837 | 3.1% |
| Breast Cancer | 457 | 1.7% |
| Colorectal Cancer | 118 | 0.4% |
| Prostate Cancer | 188 | 0.7% |
| Lung Cancer | 101 | 0.4% |
| Endometrial Cancer | 34 | 0.1% |
| Acquired Hypothyroidism | 4,303 | 16.2% |
| Anemia | 5,217 | 19.6% |
| Asthma | 1,728 | 6.5% |
| Benign Prostatic Hyperplasia | 993 | 3.7% |
| Chronic Kidney Disease | 3,135 | 11.8% |
| Chronic Obstructive Pulmonary Disease and Bronchiectasis | 3,873 | 14.6% |
| Glaucoma | 631 | 2.4% |
| Osteoporosis | 900 | 3.4% |
| Obesity: diagnosed or identified by weight management procedures | 6,273 | 23.6% |
| Obesity: identified by weight management-related prescriptions | 282 | 1.1% |
| Overweight | 2,039 | 7.7% |
| Smoking: diagnosed or identified by smoking cessation procedures | 8,112 | 30.5% |
| Smoking: identified by smoking-related prescriptions | 589 | 2.2% |
| Alcohol Abuse or Dependence | 1,978 | 7.4% |
| Drug Abuse or Dependence | 3,133 | 11.8% |
| History of Cardiac Arrest | 30 | 0.1% |
| History of Coronary Angioplasty or Bypass | 578 | 2.2% |
| Health Service Utilization Intensity Metrics | Mean | Standard Deviation |
| Mean number of ambulatory encounters | 17.0 | 17.9 |
| Mean number of emergency room encounters | 0.8 | 2.0 |
| Mean number of inpatient hospital encounters | 0.2 | 0.6 |
| Mean number of non-acute institutional encounters | 0.2 | 0.6 |
| Mean number of other ambulatory encounters | 10.5 | 19.7 |
| Mean number of filled prescriptions | 44.1 | 29.9 |
| Mean number of generics dispensed | 11.7 | 6.3 |
| Mean number of unique drug classes dispensed | 11.0 | 5.6 |

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 2a. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| | Number of Dispensings by Days Supplied | | | | | | | | |
|-------------------|--|-----------------------|------------------------------|-----------------------|------------------------------|-----------------------|------------------------------|-----------------------|------------------------------|
| | Total Number of Dispensings | 1-30 Days | | 31-60 Days | | 61-90 Days | | 91+ Days | |
| | | Number of Dispensings | Percent of Total Dispensings | Number of Dispensings | Percent of Total Dispensings | Number of Dispensings | Percent of Total Dispensings | Number of Dispensings | Percent of Total Dispensings |
| Abaloparatide | 172,918 | 164,422 | 95.1% | 1,725 | 1.0% | 6,751 | 3.9% | 20 | 0.0% |
| Avelumab | 36,767 | 36,767 | 100.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Betrixaban | 46 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% |
| Brigatinib | 4,006 | 3,881 | 96.9% | ***** | ***** | ***** | ***** | 0 | 0.0% |
| Brodalumab | 9,896 | 9,632 | 97.3% | ***** | ***** | 148 | 1.5% | ***** | ***** |
| Cerliponase Alfa | 543 | 543 | 100.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Deflazacort | 14,118 | 12,506 | 88.6% | 1,580 | 11.2% | ***** | ***** | ***** | ***** |
| Delafloxacin | 4,712 | 4,654 | 98.8% | 26 | 0.6% | 32 | 0.7% | 0 | 0.0% |
| Deutetrabenazine | 197,975 | 186,179 | 94.0% | 10,110 | 5.1% | 1,598 | 0.8% | 88 | 0.0% |
| Dupilumab | 983,993 | 961,171 | 97.7% | 9,048 | 0.9% | 13,709 | 1.4% | 65 | 0.0% |
| Durvalumab | 287,585 | 287,246 | 99.9% | ***** | ***** | 0 | 0.0% | ***** | ***** |
| Edaravone | 110,774 | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| Etelcalcetide | 8,584,539 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% |
| Midostaurin | 8,713 | 8,587 | 98.6% | 109 | 1.3% | ***** | ***** | ***** | ***** |
| Naldemedine | 79,010 | 74,460 | 94.2% | ***** | ***** | 4,074 | 5.2% | ***** | ***** |
| Niraparib | 35,806 | 35,655 | 99.6% | 82 | 0.2% | ***** | ***** | ***** | ***** |
| Ocrelizumab | 168,499 | 162,887 | 96.7% | 308 | 0.2% | 1,216 | 0.7% | 4,088 | 2.4% |
| Plecanatide | 314,069 | 264,870 | 84.3% | 4,205 | 1.3% | 44,874 | 14.3% | 120 | 0.0% |
| Ribociclib | 36,942 | 36,621 | 99.1% | 219 | 0.6% | ***** | ***** | ***** | ***** |
| Safinamide | 24,987 | 19,994 | 80.0% | ***** | ***** | 4,475 | 17.9% | ***** | ***** |
| Sarilumab | 54,789 | 53,271 | 97.2% | ***** | ***** | 1,248 | 2.3% | ***** | ***** |
| Telotristat Ethyl | 8,345 | 8,238 | 98.7% | ***** | ***** | ***** | ***** | 0 | 0.0% |
| Valbenazine | 290,546 | 285,155 | 98.1% | 3,168 | 1.1% | 2,204 | 0.8% | 19 | 0.0% |

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 2b. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Distribution of Days Supplied by Dispensing | | | | | | | | | |
|---|-----------------------------|---------|----|--------|----|---------|------|--------------------|--|
| | Total Number of Dispensings | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation | |
| Abaloparatide | 172,918 | 1 | 30 | 30 | 30 | 360 | 31.8 | 12.2 | |
| Avelumab | 36,767 | 1 | 1 | 1 | 1 | 30 | 1.1 | 1.4 | |
| Betrixaban | 46 | 3 | 14 | 23 | 30 | 90 | 26.3 | 19.8 | |
| Brigatinib | 4,006 | 1 | 30 | 30 | 30 | 90 | 29.4 | 6.7 | |
| Brodalumab | 9,896 | 1 | 28 | 28 | 28 | 174 | 27.9 | 8.4 | |
| Cerliponase Alfa | 543 | 1 | 1 | 1 | 1 | 14 | 1.2 | 1.7 | |
| Deflazacort | 14,118 | 1 | 30 | 30 | 30 | 120 | 31.4 | 10.8 | |
| Delafloxacin | 4,712 | 1 | 10 | 10 | 14 | 90 | 12.9 | 9.0 | |
| Deutetrabenazine | 197,975 | 1 | 30 | 30 | 30 | 270 | 28.5 | 11.4 | |
| Dupilumab | 983,993 | 1 | 28 | 28 | 28 | 360 | 27.2 | 9.0 | |
| Durvalumab | 287,585 | 1 | 1 | 1 | 1 | 168 | 1.2 | 2.5 | |
| Edaravone | 110,774 | 1 | 1 | 1 | 1 | 56 | 4.1 | 8.2 | |
| Etelcalcetide | 8,584,539 | 1 | 1 | 1 | 1 | 90 | 1.0 | 0.1 | |
| Midostaurin | 8,713 | 1 | 21 | 28 | 28 | 198 | 25.1 | 7.4 | |
| Naldemedine | 79,010 | 1 | 30 | 30 | 30 | 180 | 31.7 | 14.5 | |
| Niraparib | 35,806 | 1 | 30 | 30 | 30 | 114 | 29.1 | 5.2 | |
| Ocrelizumab | 168,499 | 1 | 1 | 1 | 1 | 360 | 6.2 | 27.5 | |
| Plecanatide | 314,069 | 1 | 30 | 30 | 30 | 250 | 38.0 | 21.6 | |
| Ribociclib | 36,942 | 1 | 28 | 28 | 28 | 91 | 27.1 | 4.8 | |
| Safinamide | 24,987 | 1 | 30 | 30 | 30 | 175 | 39.5 | 24.3 | |
| Sarilumab | 54,789 | 1 | 28 | 28 | 28 | 118 | 27.8 | 10.7 | |
| Telotristat Ethyl | 8,345 | 1 | 28 | 28 | 28 | 84 | 27.5 | 3.6 | |
| Valbenazine | 290,546 | 1 | 30 | 30 | 30 | 180 | 29.2 | 7.4 | |

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Databases (SDD) from January 1, 2017 to November 30, 2022, by Sex

| | Number of Dispensings by Days Supplied | | | | | | | | |
|-------------------------|--|-----------------------|------------------------------|-----------------------|------------------------------|-----------------------|------------------------------|-----------------------|------------------------------|
| | Total Number of Dispensings | 1-30 Days | | 31-60 Days | | 61-90 Days | | 91+ Days | |
| | | Number of Dispensings | Percent of Total Dispensings | Number of Dispensings | Percent of Total Dispensings | Number of Dispensings | Percent of Total Dispensings | Number of Dispensings | Percent of Total Dispensings |
| Abaloparatide | 172,918 | 164,422 | 100.0% | 1,725 | 100.0% | 6,751 | 100.0% | 20 | 100.0% |
| Female | 168,841 | 160,535 | 97.6% | 1,654 | 95.9% | 6,632 | 98.2% | 20 | 100.0% |
| Male | 4,077 | 3,887 | 2.4% | 71 | 4.1% | 119 | 1.8% | 0 | 0.0% |
| Avelumab | 36,767 | 36,767 | 100.0% | 0 | NaN | 0 | NaN | 0 | NaN |
| Female | 8,749 | 8,749 | 23.8% | 0 | NaN | 0 | NaN | 0 | NaN |
| Male | 28,018 | 28,018 | 76.2% | 0 | NaN | 0 | NaN | 0 | NaN |
| Betrixaban | 46 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | NaN |
| Female | 27 | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | NaN |
| Male | 19 | ***** | ***** | 0 | 0.0% | ***** | ***** | 0 | NaN |
| Brigatinib | 4,006 | 3,881 | 100.0% | ***** | ***** | ***** | ***** | 0 | NaN |
| Female | 2,353 | 2,313 | 59.6% | ***** | ***** | ***** | ***** | 0 | NaN |
| Male | 1,653 | 1,568 | 40.4% | ***** | ***** | ***** | ***** | 0 | NaN |
| Brodalumab | 9,896 | 9,632 | 100.0% | ***** | ***** | 148 | 100.0% | ***** | ***** |
| Female | 4,672 | 4,549 | 47.2% | ***** | ***** | 61 | 41.2% | ***** | ***** |
| Male | 5,224 | 5,083 | 52.8% | ***** | ***** | 87 | 58.8% | 0 | 0.0% |
| Cerliponase Alfa | 543 | 543 | 100.0% | 0 | NaN | 0 | NaN | 0 | NaN |
| Female | 316 | 316 | 58.2% | 0 | NaN | 0 | NaN | 0 | NaN |
| Male | 227 | 227 | 41.8% | 0 | NaN | 0 | NaN | 0 | NaN |
| Deflazacort | 14,118 | 12,506 | 100.0% | 1,580 | 100.0% | ***** | ***** | ***** | ***** |
| Female | 176 | 164 | 1.3% | 12 | 0.8% | 0 | 0.0% | 0 | 0.0% |
| Male | 13,942 | 12,342 | 98.7% | 1,568 | 99.2% | ***** | ***** | ***** | ***** |
| Delafloxacin | 4,712 | 4,654 | 100.0% | 26 | 100.0% | 32 | 100.0% | 0 | NaN |
| Female | 2,117 | 2,093 | 45.0% | 12 | 46.2% | 12 | 37.5% | 0 | NaN |
| Male | 2,595 | 2,561 | 55.0% | 14 | 53.8% | 20 | 62.5% | 0 | NaN |

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Databases (SDD) from January 1, 2017 to November 30, 2022, by Sex

| | Number of Dispensings by Days Supplied | | | | | | | | |
|-------------------------|--|-----------------------|------------------------------|-----------------------|------------------------------|-----------------------|------------------------------|-----------------------|------------------------------|
| | Total Number of Dispensings | 1-30 Days | | 31-60 Days | | 61-90 Days | | 91+ Days | |
| | | Number of Dispensings | Percent of Total Dispensings | Number of Dispensings | Percent of Total Dispensings | Number of Dispensings | Percent of Total Dispensings | Number of Dispensings | Percent of Total Dispensings |
| Deutetrabenazine | 197,975 | 186,179 | 100.0% | 10,110 | 100.0% | 1,598 | 100.0% | 88 | 100.0% |
| Female | 120,383 | 113,052 | 60.7% | 6,239 | 61.7% | 1,020 | 63.8% | 72 | 81.8% |
| Male | 77,592 | 73,127 | 39.3% | 3,871 | 38.3% | 578 | 36.2% | 16 | 18.2% |
| Dupilumab | 983,993 | 961,171 | 100.0% | 9,048 | 100.0% | 13,709 | 100.0% | 65 | 100.0% |
| Female | 535,082 | 523,030 | 54.4% | 4,919 | 54.4% | 7,095 | 51.8% | 38 | 58.5% |
| Male | 448,911 | 438,141 | 45.6% | 4,129 | 45.6% | 6,614 | 48.2% | 27 | 41.5% |
| Durvalumab | 287,585 | 287,246 | 100.0% | **** | **** | 0 | NaN | **** | **** |
| Female | 138,589 | 138,440 | 48.2% | **** | **** | 0 | NaN | **** | **** |
| Male | 148,996 | 148,806 | 51.8% | 190 | 56.2% | 0 | NaN | 0 | 0.0% |
| Edaravone | 110,774 | **** | **** | **** | **** | 0 | NaN | 0 | NaN |
| Female | 51,052 | **** | **** | **** | **** | 0 | NaN | 0 | NaN |
| Male | 59,722 | **** | **** | **** | **** | 0 | NaN | 0 | NaN |
| Etelcalcetide | 8,584,539 | **** | **** | **** | **** | **** | **** | 0 | NaN |
| Female | 3,946,974 | **** | **** | **** | **** | 0 | 0.0% | 0 | NaN |
| Male | 4,637,565 | **** | **** | 0 | 0.0% | **** | **** | 0 | NaN |
| Midostaurin | 8,713 | 8,587 | 100.0% | 109 | 100.0% | **** | **** | **** | **** |
| Female | 4,666 | 4,612 | 53.7% | **** | **** | **** | **** | **** | **** |
| Male | 4,047 | 3,975 | 46.3% | **** | **** | **** | **** | 0 | 0.0% |
| Naldemedine | 79,010 | 74,460 | 100.0% | **** | **** | 4,074 | 100.0% | **** | **** |
| Female | 52,108 | 49,180 | 66.0% | **** | **** | 2,624 | 64.4% | **** | **** |
| Male | 26,902 | 25,280 | 34.0% | **** | **** | 1,450 | 35.6% | **** | **** |
| Niraparib | 35,806 | 35,655 | 100.0% | 82 | 100.0% | **** | **** | **** | **** |
| Female | 35,683 | 35,532 | 99.7% | 82 | 100.0% | **** | **** | **** | **** |
| Male | 123 | 123 | 0.3% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Databases (SDD) from January 1, 2017 to November 30, 2022, by Sex

| | Number of Dispensings by Days Supplied | | | | | | | | |
|--------------------------|--|-----------------------|------------------------------|-----------------------|------------------------------|-----------------------|------------------------------|-----------------------|------------------------------|
| | Total Number of Dispensings | 1-30 Days | | 31-60 Days | | 61-90 Days | | 91+ Days | |
| | | Number of Dispensings | Percent of Total Dispensings | Number of Dispensings | Percent of Total Dispensings | Number of Dispensings | Percent of Total Dispensings | Number of Dispensings | Percent of Total Dispensings |
| Ocrelizumab | 168,499 | 162,887 | 100.0% | 308 | 100.0% | 1,216 | 100.0% | 4,088 | 100.0% |
| Female | 113,827 | 109,963 | 67.5% | 213 | 69.2% | 828 | 68.1% | 2,823 | 69.1% |
| Male | 54,672 | 52,924 | 32.5% | 95 | 30.8% | 388 | 31.9% | 1,265 | 30.9% |
| Plecanatide | 314,069 | 264,870 | 100.0% | 4,205 | 100.0% | 44,874 | 100.0% | 120 | 100.0% |
| Female | 242,794 | 204,012 | 77.0% | 3,212 | 76.4% | 35,475 | 79.1% | 95 | 79.2% |
| Male | 71,275 | 60,858 | 23.0% | 993 | 23.6% | 9,399 | 20.9% | 25 | 20.8% |
| Ribociclib | 36,942 | 36,621 | 100.0% | 219 | 100.0% | ***** | ***** | ***** | ***** |
| Female | 36,216 | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** |
| Male | 726 | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| Safinamide | 24,987 | 19,994 | 100.0% | ***** | ***** | 4,475 | 100.0% | ***** | ***** |
| Female | 11,217 | 9,115 | 45.6% | ***** | ***** | 1,878 | 42.0% | ***** | ***** |
| Male | 13,770 | 10,879 | 54.4% | ***** | ***** | 2,597 | 58.0% | ***** | ***** |
| Sarilumab | 54,789 | 53,271 | 100.0% | ***** | ***** | 1,248 | 100.0% | ***** | 100.0% |
| Female | 45,141 | 43,873 | 82.4% | ***** | ***** | 1,045 | 83.7% | ***** | ***** |
| Male | 9,648 | 9,398 | 17.6% | ***** | ***** | 203 | 16.3% | 0 | 0.0% |
| Telotristat Ethyl | 8,345 | 8,238 | 100.0% | ***** | ***** | ***** | ***** | 0 | NaN |
| Female | 4,696 | 4,659 | 56.6% | ***** | ***** | ***** | ***** | 0 | NaN |
| Male | 3,649 | 3,579 | 43.4% | ***** | ***** | ***** | ***** | 0 | NaN |
| Valbenazine | 290,546 | 285,155 | 100.0% | 3,168 | 100.0% | 2,204 | 100.0% | 19 | 100.0% |
| Female | 171,150 | 168,024 | 58.9% | 1,703 | 53.8% | ***** | ***** | ***** | ***** |
| Male | 119,396 | 117,131 | 41.1% | 1,465 | 46.2% | ***** | ***** | ***** | ***** |

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Sex

| Distribution of Days Supplied by Dispensing | | | | | | | | |
|---|-----------------------------|----------|-----------|-----------|-----------|------------|-------------|--------------------|
| | Total Number of Dispensings | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Abaloparatide | 172,918 | 1 | 30 | 30 | 30 | 360 | 31.8 | 12.2 |
| Female | 168,841 | 1 | 30 | 30 | 30 | 360 | 31.8 | 12.2 |
| Male | 4,077 | 1 | 30 | 30 | 30 | 90 | 31.3 | 10.6 |
| Avelumab | 36,767 | 1 | 1 | 1 | 1 | 30 | 1.1 | 1.4 |
| Female | 8,749 | 1 | 1 | 1 | 1 | 28 | 1.1 | 1.6 |
| Male | 28,018 | 1 | 1 | 1 | 1 | 30 | 1.1 | 1.3 |
| Betrixaban | 46 | 3 | 14 | 23 | 30 | 90 | 26.3 | 19.8 |
| Female | 27 | 3 | 14 | 14 | 17 | 60 | 18.6 | 11.0 |
| Male | 19 | 7 | 30 | 30 | 30 | 90 | 37.4 | 24.2 |
| Brigatinib | 4,006 | 1 | 30 | 30 | 30 | 90 | 29.4 | 6.7 |
| Female | 2,353 | 1 | 30 | 30 | 30 | 67 | 29.0 | 5.9 |
| Male | 1,653 | 1 | 30 | 30 | 30 | 90 | 29.9 | 7.7 |
| Brodalumab | 9,896 | 1 | 28 | 28 | 28 | 174 | 27.9 | 8.4 |
| Female | 4,672 | 1 | 28 | 28 | 28 | 174 | 27.8 | 8.1 |
| Male | 5,224 | 1 | 28 | 28 | 28 | 84 | 27.9 | 8.7 |
| Cerliponase Alfa | 543 | 1 | 1 | 1 | 1 | 14 | 1.2 | 1.7 |
| Female | 316 | 1 | 1 | 1 | 1 | 1 | 1.0 | 0.0 |
| Male | 227 | 1 | 1 | 1 | 1 | 14 | 1.5 | 2.5 |
| Deflazacort | 14,118 | 1 | 30 | 30 | 30 | 120 | 31.4 | 10.8 |
| Female | 176 | 7 | 28 | 30 | 30 | 60 | 30.9 | 7.7 |
| Male | 13,942 | 1 | 30 | 30 | 30 | 120 | 31.5 | 10.8 |
| Delafloxacin | 4,712 | 1 | 10 | 10 | 14 | 90 | 12.9 | 9.0 |
| Female | 2,117 | 1 | 10 | 10 | 14 | 90 | 12.6 | 8.5 |
| Male | 2,595 | 1 | 10 | 10 | 14 | 90 | 13.1 | 9.4 |

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Sex

| Distribution of Days Supplied by Dispensing | | | | | | | | |
|---|-----------------------------|----------|-----------|-----------|-----------|------------|-------------|--------------------|
| | Total Number of Dispensings | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Deutetrabenazine | 197,975 | 1 | 30 | 30 | 30 | 270 | 28.5 | 11.4 |
| Female | 120,383 | 1 | 30 | 30 | 30 | 270 | 28.6 | 11.6 |
| Male | 77,592 | 1 | 30 | 30 | 30 | 180 | 28.5 | 11.0 |
| Dupilumab | 983,993 | 1 | 28 | 28 | 28 | 360 | 27.2 | 9.0 |
| Female | 535,082 | 1 | 28 | 28 | 28 | 280 | 27.1 | 8.9 |
| Male | 448,911 | 1 | 28 | 28 | 28 | 360 | 27.3 | 9.1 |
| Durvalumab | 287,585 | 1 | 1 | 1 | 1 | 168 | 1.2 | 2.5 |
| Female | 138,589 | 1 | 1 | 1 | 1 | 168 | 1.1 | 2.3 |
| Male | 148,996 | 1 | 1 | 1 | 1 | 58 | 1.2 | 2.7 |
| Edaravone | 110,774 | 1 | 1 | 1 | 1 | 56 | 4.1 | 8.2 |
| Female | 51,052 | 1 | 1 | 1 | 1 | 34 | 4.0 | 8.1 |
| Male | 59,722 | 1 | 1 | 1 | 1 | 56 | 4.1 | 8.3 |
| Etelcalcetide | 8,584,539 | 1 | 1 | 1 | 1 | 90 | 1.0 | 0.1 |
| Female | 3,946,974 | 1 | 1 | 1 | 1 | 56 | 1.0 | 0.1 |
| Male | 4,637,565 | 1 | 1 | 1 | 1 | 90 | 1.0 | 0.1 |
| Midostaurin | 8,713 | 1 | 21 | 28 | 28 | 198 | 25.1 | 7.4 |
| Female | 4,666 | 1 | 21 | 28 | 28 | 198 | 25.3 | 7.7 |
| Male | 4,047 | 1 | 21 | 28 | 28 | 84 | 24.8 | 7.1 |
| Naldemedine | 79,010 | 1 | 30 | 30 | 30 | 180 | 31.7 | 14.5 |
| Female | 52,108 | 1 | 30 | 30 | 30 | 180 | 31.6 | 14.4 |
| Male | 26,902 | 1 | 30 | 30 | 30 | 120 | 32.0 | 14.7 |
| Niraparib | 35,806 | 1 | 30 | 30 | 30 | 114 | 29.1 | 5.2 |
| Female | 35,683 | 1 | 30 | 30 | 30 | 114 | 29.1 | 5.2 |
| Male | 123 | 3 | 30 | 30 | 30 | 30 | 28.9 | 3.9 |

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Sex

| Distribution of Days Supplied by Dispensing | | | | | | | | |
|---|-----------------------------|----------|-----------|-----------|-----------|------------|-------------|--------------------|
| | Total Number of Dispensings | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Ocrelizumab | 168,499 | 1 | 1 | 1 | 1 | 360 | 6.2 | 27.5 |
| Female | 113,827 | 1 | 1 | 1 | 1 | 360 | 6.3 | 27.7 |
| Male | 54,672 | 1 | 1 | 1 | 1 | 195 | 6.0 | 26.9 |
| Plecanatide | 314,069 | 1 | 30 | 30 | 30 | 250 | 38.0 | 21.6 |
| Female | 242,794 | 1 | 30 | 30 | 30 | 250 | 38.2 | 21.8 |
| Male | 71,275 | 1 | 30 | 30 | 30 | 180 | 37.4 | 21.0 |
| Ribociclib | 36,942 | 1 | 28 | 28 | 28 | 91 | 27.1 | 4.8 |
| Female | 36,216 | 1 | 28 | 28 | 28 | 91 | 27.1 | 4.9 |
| Male | 726 | 2 | 28 | 28 | 28 | 56 | 27.0 | 3.8 |
| Safinamide | 24,987 | 1 | 30 | 30 | 30 | 175 | 39.5 | 24.3 |
| Female | 11,217 | 1 | 30 | 30 | 30 | 175 | 38.5 | 23.9 |
| Male | 13,770 | 1 | 30 | 30 | 30 | 120 | 40.3 | 24.5 |
| Sarilumab | 54,789 | 1 | 28 | 28 | 28 | 118 | 27.8 | 10.7 |
| Female | 45,141 | 1 | 28 | 28 | 28 | 118 | 28.3 | 10.1 |
| Male | 9,648 | 1 | 28 | 28 | 28 | 90 | 25.3 | 12.8 |
| Telotristat Ethyl | 8,345 | 1 | 28 | 28 | 28 | 84 | 27.5 | 3.6 |
| Female | 4,696 | 2 | 28 | 28 | 28 | 84 | 27.3 | 3.6 |
| Male | 3,649 | 1 | 28 | 28 | 28 | 84 | 27.8 | 3.6 |
| Valbenazine | 290,546 | 1 | 30 | 30 | 30 | 180 | 29.2 | 7.4 |
| Female | 171,150 | 1 | 30 | 30 | 30 | 120 | 29.4 | 7.4 |
| Male | 119,396 | 1 | 30 | 30 | 30 | 180 | 29.0 | 7.3 |

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| | Number of Dispensings by Days Supplied | | | | | | | | |
|----------------------|--|-----------------------|------------------------------|-----------------------|------------------------------|-----------------------|------------------------------|-----------------------|------------------------------|
| | 1-30 Days | | 31-60 Days | | 61-90 Days | | 91+ Days | | |
| | Total Number of Dispensings | Number of Dispensings | Percent of Total Dispensings | Number of Dispensings | Percent of Total Dispensings | Number of Dispensings | Percent of Total Dispensings | Number of Dispensings | Percent of Total Dispensings |
| Abaloparatide | 172,918 | 164,422 | 100.0% | 1,725 | 100.0% | 6,751 | 100.0% | 20 | 100.0% |
| 0-17 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | 1,046 | 1,012 | 0.6% | 15 | 0.9% | 19 | 0.3% | 0 | 0.0% |
| 41-64 years | 48,619 | 46,901 | 28.5% | ***** | ***** | 1,376 | 20.4% | ***** | ***** |
| ≥ 65 years | 123,203 | 116,459 | 70.8% | ***** | ***** | 5,356 | 79.3% | ***** | ***** |
| Avelumab | 36,767 | 36,767 | 100.0% | 0 | NaN | 0 | NaN | 0 | NaN |
| 0-17 years | ***** | ***** | ***** | 0 | NaN | 0 | NaN | 0 | NaN |
| 18-24 years | ***** | ***** | ***** | 0 | NaN | 0 | NaN | 0 | NaN |
| 25-40 years | 89 | 89 | 0.2% | 0 | NaN | 0 | NaN | 0 | NaN |
| 41-64 years | 3,271 | 3,271 | 8.9% | 0 | NaN | 0 | NaN | 0 | NaN |
| ≥ 65 years | 33,375 | 33,375 | 90.8% | 0 | NaN | 0 | NaN | 0 | NaN |
| Betrixaban | 46 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | NaN |
| 0-17 years | 0 | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | NaN |
| 18-24 years | 0 | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | NaN |
| 25-40 years | 0 | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | NaN |
| 41-64 years | 14 | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | NaN |
| ≥ 65 years | 32 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | NaN |
| Brigatinib | 4,006 | 3,881 | 100.0% | ***** | ***** | ***** | ***** | 0 | NaN |
| 0-17 years | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | NaN |
| 18-24 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | NaN |
| 25-40 years | 303 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | NaN |
| 41-64 years | 1,909 | 1,838 | 47.4% | ***** | ***** | ***** | ***** | 0 | NaN |
| ≥ 65 years | 1,766 | 1,720 | 44.3% | ***** | ***** | ***** | ***** | 0 | NaN |

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| | Number of Dispensings by Days Supplied | | | | | | | | |
|-------------------------|--|-----------------------|------------------------------|-----------------------|------------------------------|-----------------------|------------------------------|-----------------------|------------------------------|
| | 1-30 Days | | 31-60 Days | | 61-90 Days | | 91+ Days | | |
| | Total Number of Dispensings | Number of Dispensings | Percent of Total Dispensings | Number of Dispensings | Percent of Total Dispensings | Number of Dispensings | Percent of Total Dispensings | Number of Dispensings | Percent of Total Dispensings |
| Brodalumab | 9,896 | 9,632 | 100.0% | ***** | ***** | 148 | 100.0% | ***** | ***** |
| 0-17 years | 0 | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | 132 | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | 1,317 | ***** | ***** | ***** | ***** | 14 | 9.5% | ***** | ***** |
| 41-64 years | 5,395 | 5,277 | 54.8% | 65 | 56.5% | 53 | 35.8% | 0 | 0.0% |
| ≥ 65 years | 3,052 | 2,933 | 30.5% | 38 | 33.0% | 81 | 54.7% | 0 | 0.0% |
| Cerliponase Alfa | 543 | 543 | 100.0% | 0 | NaN | 0 | NaN | 0 | NaN |
| 0-17 years | 543 | 543 | 100.0% | 0 | NaN | 0 | NaN | 0 | NaN |
| 18-24 years | 0 | 0 | 0.0% | 0 | NaN | 0 | NaN | 0 | NaN |
| 25-40 years | 0 | 0 | 0.0% | 0 | NaN | 0 | NaN | 0 | NaN |
| 41-64 years | 0 | 0 | 0.0% | 0 | NaN | 0 | NaN | 0 | NaN |
| ≥ 65 years | 0 | 0 | 0.0% | 0 | NaN | 0 | NaN | 0 | NaN |
| Deflazacort | 14,118 | 12,506 | 100.0% | 1,580 | 100.0% | ***** | ***** | ***** | ***** |
| 0-17 years | 10,396 | 9,042 | 72.3% | 1,330 | 84.2% | ***** | ***** | ***** | ***** |
| 18-24 years | 2,179 | 2,019 | 16.1% | ***** | 9.8% | ***** | ***** | 0 | 0.0% |
| 25-40 years | 1,465 | 1,379 | 11.0% | ***** | ***** | ***** | ***** | 0 | 0.0% |
| 41-64 years | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| ≥ 65 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Delafloxacin | 4,712 | 4,654 | 100.0% | 26 | 100.0% | 32 | 100.0% | 0 | NaN |
| 0-17 years | 24 | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | NaN |
| 18-24 years | 60 | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | NaN |
| 25-40 years | 427 | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | NaN |
| 41-64 years | 2,106 | 2,084 | 44.8% | ***** | ***** | ***** | ***** | 0 | NaN |
| ≥ 65 years | 2,095 | 2,062 | 44.3% | ***** | ***** | ***** | ***** | 0 | NaN |

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| | Number of Dispensings by Days Supplied | | | | | | | | |
|-------------------------|--|-----------------------|------------------------------|-----------------------|------------------------------|-----------------------|------------------------------|-----------------------|------------------------------|
| | Total Number of Dispensings | 1-30 Days | | 31-60 Days | | 61-90 Days | | 91+ Days | |
| | | Number of Dispensings | Percent of Total Dispensings | Number of Dispensings | Percent of Total Dispensings | Number of Dispensings | Percent of Total Dispensings | Number of Dispensings | Percent of Total Dispensings |
| Deutetrabenazine | 197,975 | 186,179 | 100.0% | 10,110 | 100.0% | 1,598 | 100.0% | 88 | 100.0% |
| 0-17 years | 116 | 103 | 0.1% | ***** | ***** | ***** | ***** | 0 | 0.0% |
| 18-24 years | 1,496 | 1,400 | 0.8% | ***** | ***** | ***** | ***** | 0 | 0.0% |
| 25-40 years | 16,967 | 15,986 | 8.6% | 866 | 8.6% | ***** | ***** | ***** | ***** |
| 41-64 years | 99,605 | 93,973 | 50.5% | 4,910 | 48.6% | ***** | ***** | ***** | ***** |
| ≥ 65 years | 79,791 | 74,717 | 40.1% | 4,232 | 41.9% | 798 | 49.9% | 44 | 50.0% |
| Dupilumab | 983,993 | 961,171 | 100.0% | 9,048 | 100.0% | 13,709 | 100.0% | 65 | 100.0% |
| 0-17 years | 78,000 | 75,709 | 7.9% | 1,506 | 16.6% | ***** | ***** | ***** | ***** |
| 18-24 years | 85,304 | 83,892 | 8.7% | ***** | ***** | ***** | ***** | ***** | ***** |
| 25-40 years | 180,644 | 178,123 | 18.5% | ***** | ***** | 1,674 | 12.2% | ***** | ***** |
| 41-64 years | 412,162 | 404,332 | 42.1% | 2,451 | 27.1% | 5,359 | 39.1% | 20 | 30.8% |
| ≥ 65 years | 227,883 | 219,115 | 22.8% | 3,892 | 43.0% | 4,848 | 35.4% | 28 | 43.1% |
| Durvalumab | 287,585 | 287,246 | 100.0% | ***** | ***** | 0 | NaN | ***** | ***** |
| 0-17 years | ***** | ***** | ***** | 0 | 0.0% | 0 | NaN | 0 | 0.0% |
| 18-24 years | ***** | ***** | ***** | 0 | 0.0% | 0 | NaN | 0 | 0.0% |
| 25-40 years | 265 | ***** | 0.1% | 0 | 0.0% | 0 | NaN | 0 | 0.0% |
| 41-64 years | 49,922 | ***** | ***** | ***** | ***** | 0 | NaN | ***** | ***** |
| ≥ 65 years | 237,386 | 237,130 | ***** | ***** | ***** | 0 | NaN | 0 | 0.0% |
| Edaravone | 110,774 | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN |
| 0-17 years | ***** | ***** | ***** | 0 | 0.0% | 0 | NaN | 0 | NaN |
| 18-24 years | ***** | ***** | ***** | 0 | 0.0% | 0 | NaN | 0 | NaN |
| 25-40 years | 3,006 | 3,006 | 2.7% | 0 | 0.0% | 0 | NaN | 0 | NaN |
| 41-64 years | 37,503 | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN |
| ≥ 65 years | 70,239 | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN |

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| | Total Number of Dispensings | Number of Dispensings by Days Supplied | | | | | | | |
|----------------------|-----------------------------|--|------------------------------|-----------------------|------------------------------|-----------------------|------------------------------|-----------------------|------------------------------|
| | | 1-30 Days | | 31-60 Days | | 61-90 Days | | 91+ Days | |
| | | Number of Dispensings | Percent of Total Dispensings | Number of Dispensings | Percent of Total Dispensings | Number of Dispensings | Percent of Total Dispensings | Number of Dispensings | Percent of Total Dispensings |
| Etelcalcetide | 8,584,539 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | NaN |
| 0-17 years | 1,558 | 1,558 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | NaN |
| 18-24 years | 64,553 | 64,553 | 0.8% | 0 | 0.0% | 0 | 0.0% | 0 | NaN |
| 25-40 years | 955,022 | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | NaN |
| 41-64 years | 4,517,373 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | NaN |
| ≥ 65 years | 3,046,033 | 3,046,033 | 35.5% | 0 | 0.0% | 0 | 0.0% | 0 | NaN |
| Midostaurin | 8,713 | 8,587 | 100.0% | 109 | 100.0% | ***** | ***** | ***** | ***** |
| 0-17 years | 76 | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | 165 | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | 829 | ***** | 9.5% | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| 41-64 years | 3,488 | 3,418 | 39.8% | 59 | 54.1% | ***** | ***** | ***** | ***** |
| ≥ 65 years | 4,155 | 4,118 | 48.0% | ***** | ***** | ***** | ***** | 0 | 0.0% |
| Naldemedine | 79,010 | 74,460 | 100.0% | ***** | ***** | 4,074 | 100.0% | ***** | ***** |
| 0-17 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | ***** | ***** | ***** | 0 | 0.0% | ***** | ***** | 0 | 0.0% |
| 25-40 years | 4,921 | 4,761 | 6.4% | ***** | ***** | ***** | ***** | ***** | ***** |
| 41-64 years | 42,942 | 40,646 | 54.6% | ***** | ***** | 2,047 | 50.2% | ***** | ***** |
| ≥ 65 years | 30,975 | 28,884 | 38.8% | ***** | ***** | 1,893 | 46.5% | ***** | ***** |
| Niraparib | 35,806 | 35,655 | 100.0% | 82 | 100.0% | ***** | ***** | ***** | ***** |
| 0-17 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | 439 | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| 41-64 years | 12,756 | 12,711 | 35.6% | ***** | ***** | ***** | ***** | ***** | ***** |
| ≥ 65 years | 22,599 | 22,494 | 63.1% | 53 | 64.6% | 52 | 76.5% | 0 | 0.0% |

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| | Number of Dispensings by Days Supplied | | | | | | | | |
|--------------------|--|-----------------------|------------------------------|-----------------------|------------------------------|-----------------------|------------------------------|-----------------------|------------------------------|
| | 1-30 Days | | 31-60 Days | | 61-90 Days | | 91+ Days | | |
| | Total Number of Dispensings | Number of Dispensings | Percent of Total Dispensings | Number of Dispensings | Percent of Total Dispensings | Number of Dispensings | Percent of Total Dispensings | Number of Dispensings | Percent of Total Dispensings |
| Ocrelizumab | 168,499 | 162,887 | 100.0% | 308 | 100.0% | 1,216 | 100.0% | 4,088 | 100.0% |
| 0-17 years | 163 | 163 | 0.1% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | 2,435 | 2,385 | 1.5% | ***** | ***** | ***** | ***** | 26 | 0.6% |
| 25-40 years | 38,247 | 37,026 | 22.7% | ***** | ***** | ***** | ***** | 901 | 22.0% |
| 41-64 years | 94,752 | 91,144 | 56.0% | 196 | 63.6% | 809 | 66.5% | 2,603 | 63.7% |
| ≥ 65 years | 32,902 | 32,169 | 19.7% | 22 | 7.1% | 153 | 12.6% | 558 | 13.6% |
| Plecanatide | 314,069 | 264,870 | 100.0% | 4,205 | 100.0% | 44,874 | 100.0% | 120 | 100.0% |
| 0-17 years | 574 | 519 | 0.2% | ***** | ***** | 45 | 0.1% | ***** | ***** |
| 18-24 years | 9,551 | 8,315 | 3.1% | ***** | ***** | 1,142 | 2.5% | ***** | ***** |
| 25-40 years | 37,406 | 32,612 | 12.3% | ***** | ***** | 4,317 | 9.6% | ***** | ***** |
| 41-64 years | 134,938 | 113,119 | 42.7% | 1,799 | 42.8% | 19,951 | 44.5% | 69 | 57.5% |
| ≥ 65 years | 131,600 | 110,305 | 41.6% | 1,848 | 43.9% | 19,419 | 43.3% | 28 | 23.3% |
| Ribociclib | 36,942 | 36,621 | 100.0% | 219 | 100.0% | ***** | 100.0% | ***** | 100.0% |
| 0-17 years | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | 1,268 | ***** | 3.4% | ***** | ***** | ***** | ***** | 0 | 0.0% |
| 41-64 years | 11,418 | 11,366 | 31.0% | ***** | ***** | ***** | ***** | 0 | 0.0% |
| ≥ 65 years | 24,165 | 23,903 | 65.3% | 167 | 76.3% | ***** | ***** | ***** | ***** |
| Safinamide | 24,987 | 19,994 | 100.0% | ***** | ***** | 4,475 | 100.0% | ***** | ***** |
| 0-17 years | 0 | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | 0 | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | 132 | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| 41-64 years | 3,375 | ***** | ***** | ***** | ***** | 554 | 12.4% | ***** | ***** |
| ≥ 65 years | 21,480 | 17,110 | 85.6% | ***** | ***** | 3,921 | 87.6% | ***** | ***** |

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| | Number of Dispensings by Days Supplied | | | | | | | | |
|--------------------------|--|-----------------------|------------------------------|-----------------------|------------------------------|-----------------------|------------------------------|-----------------------|------------------------------|
| | 1-30 Days | | 31-60 Days | | 61-90 Days | | 91+ Days | | |
| | Total Number of Dispensings | Number of Dispensings | Percent of Total Dispensings | Number of Dispensings | Percent of Total Dispensings | Number of Dispensings | Percent of Total Dispensings | Number of Dispensings | Percent of Total Dispensings |
| Sarilumab | 54,789 | 53,271 | 100.0% | ***** | ***** | 1,248 | 100.0% | ***** | ***** |
| 0-17 years | 12 | 12 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | 377 | 364 | 0.7% | 0 | 0.0% | 13 | 1.0% | 0 | 0.0% |
| 25-40 years | 4,908 | 4,755 | 8.9% | 34 | 12.8% | 119 | 9.5% | 0 | 0.0% |
| 41-64 years | 33,199 | 32,347 | 60.7% | ***** | ***** | 670 | 53.7% | ***** | ***** |
| ≥ 65 years | 16,293 | 15,793 | 29.6% | 54 | 20.3% | 446 | 35.7% | 0 | 0.0% |
| Telotristat Ethyl | 8,345 | 8,238 | 100.0% | ***** | ***** | ***** | ***** | 0 | NaN |
| 0-17 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | NaN |
| 18-24 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | NaN |
| 25-40 years | 271 | 271 | 3.3% | 0 | 0.0% | 0 | 0.0% | 0 | NaN |
| 41-64 years | 3,134 | 3,119 | 37.9% | ***** | ***** | ***** | ***** | 0 | NaN |
| ≥ 65 years | 4,911 | 4,819 | 58.5% | ***** | ***** | ***** | ***** | 0 | NaN |
| Valbenazine | 290,546 | 285,155 | 100.0% | 3,168 | 100.0% | 2,204 | 100.0% | 19 | 100.0% |
| 0-17 years | 100 | 100 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | 2,083 | 2,065 | 0.7% | ***** | ***** | ***** | ***** | 0 | 0.0% |
| 25-40 years | 23,287 | 22,834 | 8.0% | ***** | ***** | ***** | ***** | ***** | ***** |
| 41-64 years | 160,345 | 157,443 | 55.2% | 1,835 | 57.9% | ***** | ***** | ***** | ***** |
| ≥ 65 years | 104,731 | 102,713 | 36.0% | 973 | 30.7% | ***** | ***** | ***** | ***** |

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| Distribution of Days Supplied by Dispensing | | | | | | | | |
|---|-----------------------------|----------|-----------|-----------|-----------|------------|-------------|--------------------|
| | Total Number of Dispensings | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Abaloparatide | 172,918 | 1 | 30 | 30 | 30 | 360 | 31.8 | 12.2 |
| 0-17 years | ***** | 18 | 18 | 24 | 30 | 30 | 24.0 | 8.5 |
| 18-24 years | ***** | 5 | 30 | 30 | 30 | 30 | 29.1 | 4.5 |
| 25-40 years | 1,046 | 1 | 30 | 30 | 30 | 90 | 30.4 | 9.2 |
| 41-64 years | 48,619 | 1 | 30 | 30 | 30 | 360 | 31.0 | 10.8 |
| ≥ 65 years | 123,203 | 1 | 30 | 30 | 30 | 150 | 32.1 | 12.7 |
| Avelumab | 36,767 | 1 | 1 | 1 | 1 | 30 | 1.1 | 1.4 |
| 0-17 years | ***** | 1 | 1 | 1 | 1 | 1 | 1.0 | 0.0 |
| 18-24 years | ***** | 1 | 1 | 1 | 1 | 1 | 1.0 | 0.0 |
| 25-40 years | 89 | 1 | 1 | 1 | 1 | 1 | 1.0 | 0.0 |
| 41-64 years | 3,271 | 1 | 1 | 1 | 1 | 28 | 1.1 | 1.3 |
| ≥ 65 years | 33,375 | 1 | 1 | 1 | 1 | 30 | 1.1 | 1.4 |
| Betrixaban | 46 | 3 | 14 | 23 | 30 | 90 | 26.3 | 19.8 |
| 0-17 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 18-24 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 25-40 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 41-64 years | 14 | 17 | 30 | 30 | 30 | 35 | 29.4 | 3.8 |
| ≥ 65 years | 32 | 3 | 14 | 14 | 30 | 90 | 25.0 | 23.6 |
| Brigatinib | 4,006 | 1 | 30 | 30 | 30 | 90 | 29.4 | 6.7 |
| 0-17 years | ***** | 1 | 12 | 30 | 30 | 58 | 25.2 | 12.6 |
| 18-24 years | ***** | 30 | 30 | 30 | 30 | 30 | 30.0 | 0.0 |
| 25-40 years | 303 | 2 | 30 | 30 | 30 | 90 | 28.9 | 7.1 |
| 41-64 years | 1,909 | 1 | 30 | 30 | 30 | 90 | 29.3 | 7.2 |
| ≥ 65 years | 1,766 | 1 | 30 | 30 | 30 | 67 | 29.7 | 5.9 |

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| Distribution of Days Supplied by Dispensing | | | | | | | | |
|---|-----------------------------|----------|-----------|-----------|-----------|------------|-------------|--------------------|
| | Total Number of Dispensings | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Brodalumab | 9,896 | 1 | 28 | 28 | 28 | 174 | 27.9 | 8.4 |
| 0-17 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 18-24 years | 132 | 1 | 28 | 28 | 28 | 42 | 26.1 | 5.7 |
| 25-40 years | 1,317 | 1 | 28 | 28 | 28 | 174 | 27.3 | 8.7 |
| 41-64 years | 5,395 | 1 | 28 | 28 | 28 | 84 | 27.5 | 7.4 |
| ≥ 65 years | 3,052 | 1 | 28 | 28 | 28 | 84 | 28.8 | 9.9 |
| Cerliponase Alfa | 543 | 1 | 1 | 1 | 1 | 14 | 1.2 | 1.7 |
| 0-17 years | 543 | 1 | 1 | 1 | 1 | 14 | 1.2 | 1.7 |
| 18-24 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 25-40 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 41-64 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| ≥ 65 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| Deflazacort | 14,118 | 1 | 30 | 30 | 30 | 120 | 31.4 | 10.8 |
| 0-17 years | 10,396 | 1 | 30 | 30 | 30 | 120 | 31.6 | 11.5 |
| 18-24 years | 2,179 | 1 | 30 | 30 | 30 | 90 | 31.2 | 9.1 |
| 25-40 years | 1,465 | 2 | 30 | 30 | 30 | 90 | 30.4 | 7.8 |
| 41-64 years | 22 | 30 | 30 | 53 | 60 | 60 | 45.7 | 15.0 |
| ≥ 65 years | 56 | 23 | 28 | 28 | 28 | 30 | 28.1 | 1.1 |
| Delafloxacin | 4,712 | 1 | 10 | 10 | 14 | 90 | 12.9 | 9.0 |
| 0-17 years | 24 | 4 | 10 | 10 | 14 | 30 | 11.5 | 5.0 |
| 18-24 years | 60 | 4 | 10 | 10 | 14 | 60 | 13.7 | 10.4 |
| 25-40 years | 427 | 1 | 10 | 10 | 14 | 42 | 12.6 | 6.5 |
| 41-64 years | 2,106 | 1 | 10 | 10 | 14 | 90 | 12.8 | 8.2 |
| ≥ 65 years | 2,095 | 1 | 10 | 10 | 14 | 90 | 13.0 | 10.1 |

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| Distribution of Days Supplied by Dispensing | | | | | | | | |
|---|-----------------------------|----------|-----------|-----------|-----------|------------|-------------|--------------------|
| | Total Number of Dispensings | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Deutetrabenazine | 197,975 | 1 | 30 | 30 | 30 | 270 | 28.5 | 11.4 |
| 0-17 years | 116 | 1 | 30 | 30 | 30 | 86 | 30.4 | 12.6 |
| 18-24 years | 1,496 | 1 | 30 | 30 | 30 | 90 | 30.2 | 9.4 |
| 25-40 years | 16,967 | 1 | 30 | 30 | 30 | 180 | 29.1 | 10.4 |
| 41-64 years | 99,605 | 1 | 30 | 30 | 30 | 270 | 28.8 | 10.8 |
| ≥ 65 years | 79,791 | 1 | 28 | 30 | 30 | 180 | 28.1 | 12.2 |
| Dupilumab | 983,993 | 1 | 28 | 28 | 28 | 360 | 27.2 | 9.0 |
| 0-17 years | 78,000 | 1 | 28 | 28 | 28 | 112 | 26.7 | 8.9 |
| 18-24 years | 85,304 | 1 | 28 | 28 | 28 | 280 | 26.8 | 8.6 |
| 25-40 years | 180,644 | 1 | 28 | 28 | 28 | 191 | 26.8 | 7.9 |
| 41-64 years | 412,162 | 1 | 28 | 28 | 28 | 360 | 27.1 | 8.7 |
| ≥ 65 years | 227,883 | 1 | 28 | 28 | 28 | 168 | 28.0 | 10.3 |
| Durvalumab | 287,585 | 1 | 1 | 1 | 1 | 168 | 1.2 | 2.5 |
| 0-17 years | ***** | 1 | 1 | 1 | 1 | 1 | 1.0 | NaN |
| 18-24 years | ***** | 1 | 1 | 1 | 1 | 1 | 1.0 | 0.0 |
| 25-40 years | 265 | 1 | 1 | 1 | 1 | 14 | 1.0 | 0.8 |
| 41-64 years | 49,922 | 1 | 1 | 1 | 1 | 168 | 1.3 | 3.1 |
| ≥ 65 years | 237,386 | 1 | 1 | 1 | 1 | 58 | 1.2 | 2.4 |
| Edaravone | 110,774 | 1 | 1 | 1 | 1 | 56 | 4.1 | 8.2 |
| 0-17 years | ***** | 28 | 28 | 28 | 28 | 28 | 28.0 | NaN |
| 18-24 years | ***** | 1 | 1 | 1 | 1 | 14 | 1.5 | 2.6 |
| 25-40 years | 3,006 | 1 | 1 | 1 | 14 | 30 | 7.9 | 11.2 |
| 41-64 years | 37,503 | 1 | 1 | 1 | 1 | 56 | 4.4 | 8.6 |
| ≥ 65 years | 70,239 | 1 | 1 | 1 | 1 | 34 | 3.7 | 7.8 |

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| Distribution of Days Supplied by Dispensing | | | | | | | | |
|---|-----------------------------|----------|-----------|-----------|-----------|------------|-------------|--------------------|
| | Total Number of Dispensings | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Etelcalcetide | 8,584,539 | 1 | 1 | 1 | 1 | 90 | 1.0 | 0.1 |
| 0-17 years | 1,558 | 1 | 1 | 1 | 1 | 1 | 1.0 | 0.0 |
| 18-24 years | 64,553 | 1 | 1 | 1 | 1 | 1 | 1.0 | 0.0 |
| 25-40 years | 955,022 | 1 | 1 | 1 | 1 | 56 | 1.0 | 0.1 |
| 41-64 years | 4,517,373 | 1 | 1 | 1 | 1 | 90 | 1.0 | 0.1 |
| ≥ 65 years | 3,046,033 | 1 | 1 | 1 | 1 | 30 | 1.0 | 0.0 |
| Midostaurin | 8,713 | 1 | 21 | 28 | 28 | 198 | 25.1 | 7.4 |
| 0-17 years | 76 | 7 | 15 | 28 | 28 | 56 | 24.8 | 10.8 |
| 18-24 years | 165 | 2 | 14 | 28 | 28 | 56 | 23.7 | 8.6 |
| 25-40 years | 829 | 1 | 28 | 28 | 28 | 56 | 25.6 | 6.2 |
| 41-64 years | 3,488 | 1 | 21 | 28 | 28 | 198 | 24.9 | 8.1 |
| ≥ 65 years | 4,155 | 1 | 24 | 28 | 28 | 90 | 25.2 | 6.8 |
| Naldemedine | 79,010 | 1 | 30 | 30 | 30 | 180 | 31.7 | 14.5 |
| 0-17 years | 15 | 15 | 30 | 30 | 30 | 30 | 28.0 | 5.3 |
| 18-24 years | 157 | 2 | 30 | 30 | 30 | 90 | 29.7 | 9.9 |
| 25-40 years | 4,921 | 1 | 30 | 30 | 30 | 120 | 30.5 | 11.0 |
| 41-64 years | 42,942 | 1 | 30 | 30 | 30 | 120 | 31.8 | 13.8 |
| ≥ 65 years | 30,975 | 1 | 30 | 30 | 30 | 180 | 31.9 | 15.9 |
| Niraparib | 35,806 | 1 | 30 | 30 | 30 | 114 | 29.1 | 5.2 |
| 0-17 years | ***** | 28 | 28 | 28 | 28 | 28 | 28.0 | 0.0 |
| 18-24 years | ***** | 28 | 30 | 30 | 30 | 30 | 29.8 | 0.6 |
| 25-40 years | 439 | 3 | 30 | 30 | 30 | 60 | 28.5 | 5.1 |
| 41-64 years | 12,756 | 1 | 30 | 30 | 30 | 114 | 29.0 | 5.1 |
| ≥ 65 years | 22,599 | 1 | 30 | 30 | 30 | 90 | 29.1 | 5.3 |

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| Distribution of Days Supplied by Dispensing | | | | | | | | |
|---|-----------------------------|----------|-----------|-----------|-----------|------------|-------------|--------------------|
| | Total Number of Dispensings | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Ocrelizumab | 168,499 | 1 | 1 | 1 | 1 | 360 | 6.2 | 27.5 |
| 0-17 years | 163 | 1 | 1 | 1 | 1 | 15 | 1.1 | 1.1 |
| 18-24 years | 2,435 | 1 | 1 | 1 | 1 | 180 | 3.9 | 18.8 |
| 25-40 years | 38,247 | 1 | 1 | 1 | 1 | 336 | 6.0 | 26.8 |
| 41-64 years | 94,752 | 1 | 1 | 1 | 1 | 360 | 6.9 | 29.2 |
| ≥ 65 years | 32,902 | 1 | 1 | 1 | 1 | 297 | 4.6 | 23.2 |
| Plecanatide | 314,069 | 1 | 30 | 30 | 30 | 250 | 38.0 | 21.6 |
| 0-17 years | 574 | 2 | 30 | 30 | 30 | 120 | 34.4 | 17.2 |
| 18-24 years | 9,551 | 1 | 30 | 30 | 30 | 180 | 36.6 | 20.2 |
| 25-40 years | 37,406 | 1 | 30 | 30 | 30 | 180 | 36.3 | 19.9 |
| 41-64 years | 134,938 | 1 | 30 | 30 | 30 | 180 | 38.3 | 22.0 |
| ≥ 65 years | 131,600 | 1 | 30 | 30 | 30 | 250 | 38.4 | 21.9 |
| Ribociclib | 36,942 | 1 | 28 | 28 | 28 | 91 | 27.1 | 4.8 |
| 0-17 years | 68 | 5 | 25 | 28 | 28 | 56 | 25.7 | 6.5 |
| 18-24 years | 23 | 4 | 21 | 28 | 28 | 28 | 23.4 | 7.0 |
| 25-40 years | 1,268 | 1 | 28 | 28 | 28 | 84 | 27.1 | 4.5 |
| 41-64 years | 11,418 | 1 | 28 | 28 | 28 | 84 | 26.9 | 4.4 |
| ≥ 65 years | 24,165 | 1 | 28 | 28 | 28 | 91 | 27.1 | 5.0 |
| Safinamide | 24,987 | 1 | 30 | 30 | 30 | 175 | 39.5 | 24.3 |
| 0-17 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 18-24 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 25-40 years | 132 | 2 | 30 | 30 | 30 | 37 | 26.9 | 6.6 |
| 41-64 years | 3,375 | 1 | 30 | 30 | 30 | 175 | 38.8 | 23.4 |
| ≥ 65 years | 21,480 | 1 | 30 | 30 | 30 | 120 | 39.7 | 24.4 |

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| Distribution of Days Supplied by Dispensing | | | | | | | | |
|---|-----------------------------|----------|-----------|-----------|-----------|------------|-------------|--------------------|
| | Total Number of Dispensings | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Sarilumab | 54,789 | 1 | 28 | 28 | 28 | 118 | 27.8 | 10.7 |
| 0-17 years | 12 | 1 | 1 | 1 | 28 | 28 | 11.5 | 13.2 |
| 18-24 years | 377 | 1 | 28 | 28 | 28 | 84 | 28.9 | 11.2 |
| 25-40 years | 4,908 | 1 | 28 | 28 | 28 | 84 | 28.5 | 10.1 |
| 41-64 years | 33,199 | 1 | 28 | 28 | 28 | 118 | 28.2 | 9.5 |
| ≥ 65 years | 16,293 | 1 | 28 | 28 | 28 | 90 | 26.6 | 12.8 |
| Telotristat Ethyl | 8,345 | 1 | 28 | 28 | 28 | 84 | 27.5 | 3.6 |
| 0-17 years | ***** | 21 | 21 | 28 | 28 | 28 | 25.8 | 3.3 |
| 18-24 years | ***** | 28 | 28 | 28 | 28 | 28 | 28.0 | 0.0 |
| 25-40 years | 271 | 6 | 28 | 28 | 28 | 30 | 26.8 | 3.2 |
| 41-64 years | 3,134 | 2 | 28 | 28 | 28 | 84 | 27.4 | 3.5 |
| ≥ 65 years | 4,911 | 1 | 28 | 28 | 28 | 84 | 27.7 | 3.7 |
| Valbenazine | 290,546 | 1 | 30 | 30 | 30 | 180 | 29.2 | 7.4 |
| 0-17 years | 100 | 1 | 30 | 30 | 30 | 30 | 28.5 | 5.5 |
| 18-24 years | 2,083 | 1 | 30 | 30 | 30 | 90 | 28.9 | 5.5 |
| 25-40 years | 23,287 | 1 | 30 | 30 | 30 | 180 | 28.9 | 6.9 |
| 41-64 years | 160,345 | 1 | 30 | 30 | 30 | 120 | 29.2 | 7.0 |
| ≥ 65 years | 104,731 | 1 | 30 | 30 | 30 | 122 | 29.3 | 8.0 |

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 3a. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| | Number of Patients by Cumulative Treatment Episode Duration | | | | | | | | | | |
|-------------------|---|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|
| | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | | |
| | Total Number of Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients |
| Abaloparatide | 23,148 | 4,520 | 19.5% | 4,426 | 19.1% | 8,376 | 36.2% | 5,377 | 23.2% | 449 | 1.9% |
| Avelumab | 2,803 | 2,475 | 88.3% | 298 | 10.6% | ***** | ***** | ***** | ***** | 0 | 0.0% |
| Betrixaban | 21 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| Brigatinib | 502 | 93 | 18.5% | 124 | 24.7% | 193 | 38.4% | 56 | 11.2% | 36 | 7.2% |
| Brodalumab | 841 | 61 | 7.3% | 148 | 17.6% | 366 | 43.5% | 160 | 19.0% | 106 | 12.6% |
| Cerliponase Alfa | 18 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| Deflazacort | 1,129 | 97 | 8.6% | 131 | 11.6% | 474 | 42.0% | 275 | 24.4% | 152 | 13.5% |
| Delafloxacin | 2,996 | 2,680 | 89.5% | 258 | 8.6% | ***** | 1.7% | ***** | ***** | ***** | ***** |
| Deutetrabenazine | 16,357 | 2,495 | 15.3% | 2,996 | 18.3% | 5,410 | 33.1% | 2,838 | 17.4% | 2,618 | 16.0% |
| Dupilumab | 83,061 | 10,733 | 12.9% | 12,961 | 15.6% | 32,885 | 39.6% | 16,331 | 19.7% | 10,151 | 12.2% |
| Durvalumab | 26,005 | 25,525 | 98.2% | 308 | 1.2% | 134 | 0.5% | ***** | ***** | ***** | ***** |
| Edaravone | 2,163 | 574 | 26.5% | 430 | 19.9% | 792 | 36.6% | 233 | 10.8% | 134 | 6.2% |
| Etelcalcetide | 53,102 | 9,409 | 17.7% | 11,793 | 22.2% | 26,646 | 50.2% | 5,254 | 9.9% | 0 | 0.0% |
| Midostaurin | 1,841 | 635 | 34.5% | 614 | 33.4% | 463 | 25.1% | 98 | 5.3% | 31 | 1.7% |
| Naldemedine | 13,921 | 4,556 | 32.7% | 3,218 | 23.1% | 4,234 | 30.4% | 1,273 | 9.1% | 640 | 4.6% |
| Niraparib | 6,415 | 1,767 | 27.5% | 1,846 | 28.8% | 2,089 | 32.6% | 540 | 8.4% | 173 | 2.7% |
| Ocrelizumab | 43,156 | 40,407 | 93.6% | 578 | 1.3% | 1,344 | 3.1% | 557 | 1.3% | 270 | 0.6% |
| Plecanatide | 66,616 | 20,358 | 30.6% | 17,581 | 26.4% | 19,885 | 29.9% | 5,845 | 8.8% | 2,947 | 4.4% |
| Ribociclib | 4,213 | 813 | 19.3% | 943 | 22.4% | 1,610 | 38.2% | 551 | 13.1% | 296 | 7.0% |
| Safinamide | 2,319 | 385 | 16.6% | 410 | 17.7% | 613 | 26.4% | 389 | 16.8% | 522 | 22.5% |
| Sarilumab | 8,534 | 3,018 | 35.4% | 1,588 | 18.6% | 2,682 | 31.4% | 809 | 9.5% | 437 | 5.1% |
| Telotristat Ethyl | 1,061 | 258 | 24.3% | 266 | 25.1% | 353 | 33.3% | 115 | 10.8% | 69 | 6.5% |
| Valbenazine | 26,601 | 4,624 | 17.4% | 5,366 | 20.2% | 9,018 | 33.9% | 3,790 | 14.2% | 3,803 | 14.3% |

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 3b. Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Distribution of Cumulative Treatment Episode Duration, Days | | | | | | | | |
|---|--------------------------|---------|-----|--------|-----|---------|-------|--------------------|
| | Total Number of Patients | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Abaloparatide | 23,148 | 1 | 60 | 159 | 370 | 1,470 | 237.6 | 215.7 |
| Avelumab | 2,803 | 1 | 3 | 7 | 17 | 450 | 14.1 | 21.5 |
| Betrixaban | 21 | 7 | 28 | 30 | 35 | 330 | 57.7 | 75.4 |
| Brigatinib | 502 | 1 | 59 | 121 | 289 | 1,809 | 234.6 | 296.1 |
| Brodalumab | 841 | 1 | 91 | 198 | 450 | 1,670 | 327.9 | 328.5 |
| Cerliponase Alfa | 18 | 2 | 11 | 16 | 52 | 126 | 36.7 | 40.1 |
| Deflazacort | 1,129 | 1 | 120 | 281 | 473 | 1,867 | 393.2 | 406.7 |
| Delafloxacin | 2,996 | 1 | 10 | 14 | 20 | 1,140 | 20.2 | 39.0 |
| Deutetrabenazine | 16,357 | 1 | 60 | 191 | 510 | 1,855 | 345.4 | 372.6 |
| Dupilumab | 83,061 | 1 | 75 | 207 | 458 | 1,928 | 322.3 | 333.8 |
| Durvalumab | 26,005 | 1 | 4 | 9 | 18 | 1,074 | 13.1 | 29.2 |
| Edaravone | 2,163 | 1 | 28 | 105 | 252 | 1,688 | 207.7 | 284.9 |
| Etelcalcetide | 53,102 | 1 | 47 | 127 | 251 | 730 | 161.7 | 135.7 |
| Midostaurin | 1,841 | 1 | 28 | 56 | 118 | 1,765 | 118.6 | 189.5 |
| Naldemedine | 13,921 | 1 | 30 | 90 | 216 | 1,630 | 180.1 | 238.7 |
| Niraparib | 6,415 | 1 | 30 | 90 | 186 | 1,838 | 162.3 | 211.9 |
| Ocrelizumab | 43,156 | 1 | 2 | 3 | 6 | 1,728 | 24.3 | 107.8 |
| Plecanatide | 66,616 | 1 | 30 | 90 | 210 | 1,912 | 179.3 | 241.0 |
| Ribociclib | 4,213 | 1 | 56 | 126 | 308 | 1,801 | 237.1 | 285.6 |
| Safinamide | 2,319 | 1 | 60 | 227 | 661 | 1,806 | 425.6 | 457.8 |
| Sarilumab | 8,534 | 1 | 2 | 84 | 224 | 1,757 | 178.3 | 256.5 |
| Telotristat Ethyl | 1,061 | 2 | 41 | 100 | 241 | 1,848 | 216.5 | 291.4 |
| Valbenazine | 26,601 | 1 | 60 | 154 | 427 | 1,848 | 319.1 | 375.3 |

Table 3c. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Sex

| | Number of Patients by Cumulative Treatment Episode Duration | | | | | | | | | | |
|-------------------------|---|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|
| | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | | |
| | Total Number of Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients |
| Abaloparatide | 23,148 | 4,520 | 100.0% | 4,426 | 100.0% | 8,376 | 100.0% | 5,377 | 100.0% | 449 | 100.0% |
| Female | 22,565 | 4,369 | 96.7% | 4,317 | 97.5% | 8,178 | 97.6% | 5,268 | 98.0% | 433 | 96.4% |
| Male | 583 | 151 | 3.3% | 109 | 2.5% | 198 | 2.4% | 109 | 2.0% | 16 | 3.6% |
| Avelumab | 2,803 | 2,475 | 100.0% | 298 | 100.0% | ***** | ***** | ***** | ***** | 0 | NaN |
| Female | 739 | 662 | 26.7% | ***** | ***** | ***** | ***** | ***** | ***** | 0 | NaN |
| Male | 2,064 | 1,813 | 73.3% | ***** | ***** | ***** | ***** | ***** | ***** | 0 | NaN |
| Betrixaban | 21 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN |
| Female | ***** | ***** | ***** | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN |
| Male | ***** | ***** | ***** | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN |
| Brigatinib | 502 | 93 | 100.0% | 124 | 100.0% | 193 | 100.0% | 56 | 100.0% | 36 | 100.0% |
| Female | 292 | 48 | 51.6% | 71 | 57.3% | 121 | 62.7% | 32 | 57.1% | 20 | 55.6% |
| Male | 210 | 45 | 48.4% | 53 | 42.7% | 72 | 37.3% | 24 | 42.9% | 16 | 44.4% |
| Brodalumab | 841 | 61 | 100.0% | 148 | 100.0% | 366 | 100.0% | 160 | 100.0% | 106 | 100.0% |
| Female | 397 | 37 | 60.7% | 74 | 50.0% | 165 | 45.1% | 70 | 43.8% | 51 | 48.1% |
| Male | 444 | 24 | 39.3% | 74 | 50.0% | 201 | 54.9% | 90 | 56.3% | 55 | 51.9% |
| Cerliponase Alfa | 18 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN |
| Female | ***** | ***** | ***** | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN |
| Male | ***** | ***** | ***** | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN |
| Deflazacort | 1,129 | 97 | 100.0% | 131 | 100.0% | 474 | 100.0% | 275 | 100.0% | 152 | 100.0% |
| Female | ***** | 0 | 0.0% | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** |
| Male | ***** | 97 | 100.0% | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** |
| Delafloxacin | 2,996 | 2,680 | 100.0% | 258 | 100.0% | ***** | ***** | ***** | ***** | ***** | ***** |
| Female | 1,374 | 1,239 | 46.2% | 105 | 40.7% | ***** | ***** | ***** | ***** | ***** | ***** |
| Male | 1,622 | 1,441 | 53.8% | 153 | 59.3% | ***** | ***** | ***** | ***** | ***** | ***** |

Table 3c. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Sex

| | Number of Patients by Cumulative Treatment Episode Duration | | | | | | | | | | |
|-------------------------|---|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|
| | 1-30 Days | | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
| | Total Number of Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients |
| Deutetrabenazine | 16,357 | 2,495 | 100.0% | 2,996 | 100.0% | 5,410 | 100.0% | 2,838 | 100.0% | 2,618 | 100.0% |
| Female | 10,101 | 1,577 | 63.2% | 1,877 | 62.7% | 3,338 | 61.7% | 1,724 | 60.7% | 1,585 | 60.5% |
| Male | 6,256 | 918 | 36.8% | 1,119 | 37.3% | 2,072 | 38.3% | 1,114 | 39.3% | 1,033 | 39.5% |
| Dupilumab | 83,061 | 10,733 | 100.0% | 12,961 | 100.0% | 32,885 | 100.0% | 16,331 | 100.0% | 10,151 | 100.0% |
| Female | 45,942 | 6,074 | 56.6% | 7,320 | 56.5% | 18,183 | 55.3% | 8,968 | 54.9% | 5,397 | 53.2% |
| Male | 37,119 | 4,659 | 43.4% | 5,641 | 43.5% | 14,702 | 44.7% | 7,363 | 45.1% | 4,754 | 46.8% |
| Durvalumab | 26,005 | 25,525 | 100.0% | 308 | 100.0% | 134 | 100.0% | ***** | ***** | ***** | ***** |
| Female | 12,431 | 12,235 | 47.9% | 132 | 42.9% | 47 | 35.1% | ***** | ***** | ***** | ***** |
| Male | 13,574 | 13,290 | 52.1% | 176 | 57.1% | 87 | 64.9% | ***** | ***** | ***** | ***** |
| Edaravone | 2,163 | 574 | 100.0% | 430 | 100.0% | 792 | 100.0% | 233 | 100.0% | 134 | 100.0% |
| Female | 977 | 249 | 43.4% | 193 | 44.9% | 368 | 46.5% | 111 | 47.6% | 56 | 41.8% |
| Male | 1,186 | 325 | 56.6% | 237 | 55.1% | 424 | 53.5% | 122 | 52.4% | 78 | 58.2% |
| Etelcalcetide | 53,102 | 9,409 | 100.0% | 11,793 | 100.0% | 26,646 | 100.0% | 5,254 | 100.0% | 0 | NaN |
| Female | 24,800 | 4,532 | 48.2% | 5,578 | 47.3% | 12,321 | 46.2% | 2,369 | 45.1% | 0 | NaN |
| Male | 28,302 | 4,877 | 51.8% | 6,215 | 52.7% | 14,325 | 53.8% | 2,885 | 54.9% | 0 | NaN |
| Midostaurin | 1,841 | 635 | 100.0% | 614 | 100.0% | 463 | 100.0% | 98 | 100.0% | 31 | 100.0% |
| Female | 948 | 316 | 49.8% | 330 | 53.7% | 231 | 49.9% | ***** | ***** | ***** | ***** |
| Male | 893 | 319 | 50.2% | 284 | 46.3% | 232 | 50.1% | ***** | ***** | ***** | ***** |
| Naldemedine | 13,921 | 4,556 | 100.0% | 3,218 | 100.0% | 4,234 | 100.0% | 1,273 | 100.0% | 640 | 100.0% |
| Female | 9,168 | 3,003 | 65.9% | 2,122 | 65.9% | 2,795 | 66.0% | 832 | 65.4% | 416 | 65.0% |
| Male | 4,753 | 1,553 | 34.1% | 1,096 | 34.1% | 1,439 | 34.0% | 441 | 34.6% | 224 | 35.0% |
| Niraparib | 6,415 | 1,767 | 100.0% | 1,846 | 100.0% | 2,089 | 100.0% | 540 | 100.0% | 173 | 100.0% |
| Female | 6,382 | 1,756 | 99.4% | 1,829 | 99.1% | ***** | ***** | ***** | ***** | ***** | ***** |
| Male | 33 | 11 | 0.6% | 17 | 0.9% | ***** | ***** | ***** | ***** | ***** | ***** |

Table 3c. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Sex

| | Number of Patients by Cumulative Treatment Episode Duration | | | | | | | | | | |
|--------------------------|---|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|
| | 1-30 Days | | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
| | Total Number of Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients |
| Ocrelizumab | 43,156 | 40,407 | 100.0% | 578 | 100.0% | 1,344 | 100.0% | 557 | 100.0% | 270 | 100.0% |
| Female | 29,326 | 27,434 | 67.9% | 399 | 69.0% | 917 | 68.2% | 385 | 69.1% | 191 | 70.7% |
| Male | 13,830 | 12,973 | 32.1% | 179 | 31.0% | 427 | 31.8% | 172 | 30.9% | 79 | 29.3% |
| Plecanatide | 66,616 | 20,358 | 100.0% | 17,581 | 100.0% | 19,885 | 100.0% | 5,845 | 100.0% | 2,947 | 100.0% |
| Female | 51,852 | 15,680 | 77.0% | 13,758 | 78.3% | 15,628 | 78.6% | 4,505 | 77.1% | 2,281 | 77.4% |
| Male | 14,764 | 4,678 | 23.0% | 3,823 | 21.7% | 4,257 | 21.4% | 1,340 | 22.9% | 666 | 22.6% |
| Ribociclib | 4,213 | 813 | 100.0% | 943 | 100.0% | 1,610 | 100.0% | 551 | 100.0% | 296 | 100.0% |
| Female | 4,135 | 796 | 97.9% | 924 | 98.0% | 1,584 | 98.4% | ***** | ***** | ***** | ***** |
| Male | 78 | 17 | 2.1% | 19 | 2.0% | 26 | 1.6% | ***** | ***** | ***** | ***** |
| Safinamide | 2,319 | 385 | 100.0% | 410 | 100.0% | 613 | 100.0% | 389 | 100.0% | 522 | 100.0% |
| Female | 968 | 147 | 38.2% | 183 | 44.6% | 231 | 37.7% | 181 | 46.5% | 226 | 43.3% |
| Male | 1,351 | 238 | 61.8% | 227 | 55.4% | 382 | 62.3% | 208 | 53.5% | 296 | 56.7% |
| Sarilumab | 8,534 | 3,018 | 100.0% | 1,588 | 100.0% | 2,682 | 100.0% | 809 | 100.0% | 437 | 100.0% |
| Female | 6,345 | 1,691 | 56.0% | 1,338 | 84.3% | 2,272 | 84.7% | 675 | 83.4% | 369 | 84.4% |
| Male | 2,189 | 1,327 | 44.0% | 250 | 15.7% | 410 | 15.3% | 134 | 16.6% | 68 | 15.6% |
| Telotristat Ethyl | 1,061 | 258 | 100.0% | 266 | 100.0% | 353 | 100.0% | 115 | 100.0% | 69 | 100.0% |
| Female | 610 | 157 | 60.9% | 150 | 56.4% | 193 | 54.7% | 73 | 63.5% | 37 | 53.6% |
| Male | 451 | 101 | 39.1% | 116 | 43.6% | 160 | 45.3% | 42 | 36.5% | 32 | 46.4% |
| Valbenazine | 26,601 | 4,624 | 100.0% | 5,366 | 100.0% | 9,018 | 100.0% | 3,790 | 100.0% | 3,803 | 100.0% |
| Female | 15,837 | 2,824 | 61.1% | 3,165 | 59.0% | 5,327 | 59.1% | 2,273 | 60.0% | 2,248 | 59.1% |
| Male | 10,764 | 1,800 | 38.9% | 2,201 | 41.0% | 3,691 | 40.9% | 1,517 | 40.0% | 1,555 | 40.9% |

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 3d. Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Sex

| Distribution of Cumulative Treatment Episode Duration, Days | | | | | | | | |
|---|--------------------------|----------|------------|------------|------------|--------------|--------------|--------------------|
| | Total Number of Patients | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Abaloparatide | 23,148 | 1 | 60 | 159 | 370 | 1,470 | 237.6 | 215.7 |
| Female | 22,565 | 1 | 60 | 161 | 373 | 1,470 | 238.1 | 215.6 |
| Male | 583 | 1 | 30 | 120 | 351 | 1,260 | 218.8 | 218.9 |
| Avelumab | 2,803 | 1 | 3 | 7 | 17 | 450 | 14.1 | 21.5 |
| Female | 739 | 1 | 3 | 7 | 14 | 252 | 13.0 | 18.9 |
| Male | 2,064 | 1 | 4 | 7 | 18 | 450 | 14.5 | 22.4 |
| Betrixaban | 21 | 7 | 28 | 30 | 35 | 330 | 57.7 | 75.4 |
| Female | ***** | 14 | 17 | 30 | 35 | 182 | 45.5 | 49.8 |
| Male | ***** | 7 | 29 | 30 | 90 | 330 | 71.0 | 97.6 |
| Brigatinib | 502 | 1 | 59 | 121 | 289 | 1,809 | 234.6 | 296.1 |
| Female | 292 | 4 | 60 | 139 | 290 | 1,539 | 234.0 | 285.7 |
| Male | 210 | 1 | 45 | 119 | 277 | 1,809 | 235.5 | 310.7 |
| Brodalumab | 841 | 1 | 91 | 198 | 450 | 1,670 | 327.9 | 328.5 |
| Female | 397 | 1 | 84 | 196 | 446 | 1,670 | 327.6 | 343.9 |
| Male | 444 | 1 | 98 | 210 | 462 | 1,533 | 328.2 | 314.4 |
| Cerliponase Alfa | 18 | 2 | 11 | 16 | 52 | 126 | 36.7 | 40.1 |
| Female | ***** | 2 | 10 | 16 | 52 | 95 | 31.6 | 32.5 |
| Male | ***** | 6 | 12 | 18 | 76 | 126 | 43.0 | 49.8 |
| Deflazacort | 1,129 | 1 | 120 | 281 | 473 | 1,867 | 393.2 | 406.7 |
| Female | ***** | 49 | 180 | 275 | 703 | 1,867 | 544.4 | 598.7 |
| Male | ***** | 1 | 120 | 281 | 472 | 1,837 | 391.9 | 404.7 |
| Delafloxacin | 2,996 | 1 | 10 | 14 | 20 | 1,140 | 20.2 | 39.0 |
| Female | 1,374 | 1 | 10 | 14 | 20 | 790 | 19.5 | 34.6 |
| Male | 1,622 | 1 | 10 | 14 | 20 | 1,140 | 20.9 | 42.4 |

Table 3d. Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Sex

| Distribution of Cumulative Treatment Episode Duration, Days | | | | | | | | |
|---|--------------------------|----------|-----------|------------|------------|--------------|--------------|--------------------|
| | Total Number of Patients | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Deutetrabenazine | 16,357 | 1 | 60 | 191 | 510 | 1,855 | 345.4 | 372.6 |
| Female | 10,101 | 1 | 60 | 182 | 497 | 1,855 | 340.4 | 370.8 |
| Male | 6,256 | 1 | 66 | 201 | 529 | 1,808 | 353.5 | 375.4 |
| Dupilumab | 83,061 | 1 | 75 | 207 | 458 | 1,928 | 322.3 | 333.8 |
| Female | 45,942 | 1 | 71 | 199 | 448 | 1,897 | 315.9 | 327.7 |
| Male | 37,119 | 1 | 80 | 210 | 469 | 1,928 | 330.2 | 341.0 |
| Durvalumab | 26,005 | 1 | 4 | 9 | 18 | 1,074 | 13.1 | 29.2 |
| Female | 12,431 | 1 | 4 | 9 | 18 | 1,074 | 12.7 | 26.8 |
| Male | 13,574 | 1 | 4 | 8 | 18 | 989 | 13.4 | 31.3 |
| Edaravone | 2,163 | 1 | 28 | 105 | 252 | 1,688 | 207.7 | 284.9 |
| Female | 977 | 1 | 30 | 108 | 258 | 1,688 | 207.6 | 277.8 |
| Male | 1,186 | 1 | 28 | 104 | 252 | 1,654 | 207.8 | 290.7 |
| Etelcalcetide | 53,102 | 1 | 47 | 127 | 251 | 730 | 161.7 | 135.7 |
| Female | 24,800 | 1 | 45 | 123 | 248 | 684 | 159.2 | 135.0 |
| Male | 28,302 | 1 | 49 | 129 | 254 | 730 | 163.9 | 136.2 |
| Midostaurin | 1,841 | 1 | 28 | 56 | 118 | 1,765 | 118.6 | 189.5 |
| Female | 948 | 1 | 28 | 56 | 123 | 1,765 | 124.5 | 208.8 |
| Male | 893 | 1 | 28 | 56 | 112 | 1,677 | 112.5 | 166.5 |
| Naldemedine | 13,921 | 1 | 30 | 90 | 216 | 1,630 | 180.1 | 238.7 |
| Female | 9,168 | 1 | 30 | 90 | 217 | 1,630 | 179.7 | 238.2 |
| Male | 4,753 | 1 | 30 | 90 | 216 | 1,512 | 180.9 | 239.6 |
| Niraparib | 6,415 | 1 | 30 | 90 | 186 | 1,838 | 162.3 | 211.9 |
| Female | 6,382 | 1 | 30 | 90 | 186 | 1,838 | 162.5 | 212.1 |
| Male | 33 | 3 | 30 | 56 | 60 | 870 | 107.7 | 172.1 |

Table 3d. Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Sex

| Distribution of Cumulative Treatment Episode Duration, Days | | | | | | | | |
|---|--------------------------|----------|-----------|------------|------------|--------------|--------------|--------------------|
| | Total Number of Patients | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Ocrelizumab | 43,156 | 1 | 2 | 3 | 6 | 1,728 | 24.3 | 107.8 |
| Female | 29,326 | 1 | 2 | 3 | 6 | 1,669 | 24.5 | 108.3 |
| Male | 13,830 | 1 | 2 | 3 | 6 | 1,728 | 23.8 | 106.8 |
| Plecanatide | 66,616 | 1 | 30 | 90 | 210 | 1,912 | 179.3 | 241.0 |
| Female | 51,852 | 1 | 30 | 90 | 210 | 1,912 | 179.0 | 239.7 |
| Male | 14,764 | 1 | 30 | 90 | 210 | 1,894 | 180.4 | 245.4 |
| Ribociclib | 4,213 | 1 | 56 | 126 | 308 | 1,801 | 237.1 | 285.6 |
| Female | 4,135 | 1 | 56 | 126 | 308 | 1,801 | 236.9 | 284.2 |
| Male | 78 | 2 | 56 | 110 | 252 | 1,774 | 251.1 | 355.9 |
| Safinamide | 2,319 | 1 | 60 | 227 | 661 | 1,806 | 425.6 | 457.8 |
| Female | 968 | 1 | 60 | 243 | 697 | 1,798 | 446.0 | 474.2 |
| Male | 1,351 | 1 | 60 | 210 | 630 | 1,806 | 410.9 | 445.3 |
| Sarilumab | 8,534 | 1 | 2 | 84 | 224 | 1,757 | 178.3 | 256.5 |
| Female | 6,345 | 1 | 28 | 112 | 252 | 1,757 | 201.3 | 263.1 |
| Male | 2,189 | 1 | 1 | 1 | 112 | 1,565 | 111.7 | 223.3 |
| Telotristat Ethyl | 1,061 | 2 | 41 | 100 | 241 | 1,848 | 216.5 | 291.4 |
| Female | 610 | 2 | 28 | 84 | 224 | 1,820 | 210.3 | 281.4 |
| Male | 451 | 3 | 56 | 112 | 252 | 1,848 | 224.9 | 304.5 |
| Valbenazine | 26,601 | 1 | 60 | 154 | 427 | 1,848 | 319.1 | 375.3 |
| Female | 15,837 | 1 | 60 | 150 | 427 | 1,848 | 317.3 | 373.6 |
| Male | 10,764 | 1 | 60 | 158 | 424 | 1,841 | 321.8 | 377.8 |

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 3e. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| | Number of Patients by Cumulative Treatment Episode Duration | | | | | | | | | | |
|----------------------|---|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|
| | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | | |
| | Total Number of Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients |
| Abaloparatide | 23,148 | 4,520 | 100.0% | 4,426 | 100.0% | 8,376 | 100.0% | 5,377 | 100.0% | 449 | 100.0% |
| 0-17 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | ***** | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | 146 | ***** | 0.8% | ***** | ***** | ***** | ***** | 29 | 0.5% | ***** | ***** |
| 41-64 years | 6,307 | 1,050 | 23.2% | 1,253 | 28.3% | 2,509 | 30.0% | 1,315 | 24.5% | ***** | ***** |
| ≥ 65 years | 16,681 | 3,430 | 75.9% | 3,149 | 71.1% | 5,803 | 69.3% | 4,033 | 75.0% | 266 | 59.2% |
| Avelumab | 2,803 | 2,475 | 100.0% | 298 | 100.0% | ***** | ***** | ***** | ***** | 0 | NaN |
| 0-17 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | NaN |
| 18-24 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | NaN |
| 25-40 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | NaN |
| 41-64 years | 293 | 269 | 10.9% | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | NaN |
| ≥ 65 years | 2,492 | 2,188 | 88.4% | ***** | ***** | ***** | ***** | ***** | ***** | 0 | NaN |
| Betrixaban | 21 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN |
| 0-17 years | 0 | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | NaN | 0 | NaN |
| 18-24 years | 0 | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | NaN | 0 | NaN |
| 25-40 years | 0 | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | NaN | 0 | NaN |
| 41-64 years | ***** | ***** | ***** | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN |
| ≥ 65 years | ***** | ***** | ***** | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN |
| Brigatinib | 502 | 93 | 100.0% | 124 | 100.0% | 193 | 100.0% | 56 | 100.0% | 36 | 100.0% |
| 0-17 years | ***** | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | ***** | 0 | 0.0% | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** |
| 41-64 years | 229 | ***** | ***** | ***** | 44.4% | 97 | 50.3% | ***** | ***** | 18 | 50.0% |
| ≥ 65 years | 228 | 51 | 54.8% | 60 | 48.4% | 75 | 38.9% | ***** | ***** | ***** | ***** |

Table 3e. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| | Number of Patients by Cumulative Treatment Episode Duration | | | | | | | | | | | |
|-------------------------|---|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|---------------|---------------|
| | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | | | |
| | Total Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | | |
| Brodalumab | 841 | | 61 | 100.0% | 148 | 100.0% | 366 | 100.0% | 160 | 100.0% | 106 | 100.0% |
| 0-17 years | 0 | | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | 18 | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** |
| 25-40 years | 140 | 15 | 24.6% | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** |
| 41-64 years | 466 | 30 | 49.2% | 72 | 48.6% | 221 | 60.4% | 94 | 58.8% | 49 | 46.2% | |
| ≥ 65 years | 217 | ***** | ***** | ***** | ***** | 75 | 20.5% | 48 | 30.0% | 44 | 41.5% | |
| Cerliponase Alfa | 18 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN | |
| 0-17 years | 18 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN | |
| 18-24 years | 0 | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | NaN | 0 | NaN | |
| 25-40 years | 0 | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | NaN | 0 | NaN | |
| 41-64 years | 0 | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | NaN | 0 | NaN | |
| ≥ 65 years | 0 | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | NaN | 0 | NaN | |
| Deflazacort | 1,129 | 97 | 100.0% | 131 | 100.0% | 474 | 100.0% | 275 | 100.0% | 152 | 100.0% | |
| 0-17 years | 868 | 66 | 68.0% | 104 | 79.4% | 375 | 79.1% | 221 | 80.4% | 102 | 67.1% | |
| 18-24 years | 179 | ***** | ***** | ***** | ***** | 70 | 14.8% | 38 | 13.8% | 26 | 17.1% | |
| 25-40 years | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | |
| 41-64 years | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | |
| ≥ 65 years | ***** | 0 | 0.0% | 0 | 0.0% | ***** | ***** | 0 | 0.0% | ***** | ***** | |
| Delafloxacin | 2,996 | 2,680 | 100.0% | 258 | 100.0% | ***** | 100.0% | ***** | ***** | ***** | ***** | |
| 0-17 years | 15 | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | |
| 18-24 years | 41 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | |
| 25-40 years | 268 | 246 | 9.2% | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | |
| 41-64 years | 1,342 | 1,183 | 44.1% | 141 | 54.7% | ***** | ***** | ***** | ***** | ***** | ***** | |
| ≥ 65 years | 1,330 | 1,201 | 44.8% | 98 | 38.0% | 28 | 54.9% | ***** | ***** | ***** | ***** | |

Table 3e. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| | Number of Patients by Cumulative Treatment Episode Duration | | | | | | | | | | |
|-------------------------|---|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|
| | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | | |
| | Total Number of Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients |
| Deutetrabenazine | 16,357 | 2,495 | 100.0% | 2,996 | 100.0% | 5,410 | 100.0% | 2,838 | 100.0% | 2,618 | 100.0% |
| 0-17 years | 24 | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% |
| 18-24 years | 160 | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | 17 | 0.6% |
| 25-40 years | 1,500 | 248 | 9.9% | 286 | 9.5% | 502 | 9.3% | 242 | 8.5% | 222 | 8.5% |
| 41-64 years | 8,412 | 1,262 | 50.6% | 1,575 | 52.6% | 2,855 | 52.8% | 1,420 | 50.0% | 1,300 | 49.7% |
| ≥ 65 years | 6,261 | 950 | 38.1% | 1,092 | 36.4% | 1,997 | 36.9% | 1,143 | 40.3% | 1,079 | 41.2% |
| Dupilumab | 83,061 | 10,733 | 100.0% | 12,961 | 100.0% | 32,885 | 100.0% | 16,331 | 100.0% | 10,151 | 100.0% |
| 0-17 years | 7,038 | 828 | 7.7% | 1,089 | 8.4% | 2,982 | 9.1% | 1,498 | 9.2% | 641 | 6.3% |
| 18-24 years | 7,843 | 1,030 | 9.6% | 1,264 | 9.8% | 3,341 | 10.2% | 1,470 | 9.0% | 738 | 7.3% |
| 25-40 years | 16,043 | 2,017 | 18.8% | 2,646 | 20.4% | 6,776 | 20.6% | 2,989 | 18.3% | 1,615 | 15.9% |
| 41-64 years | 32,163 | 3,569 | 33.3% | 4,667 | 36.0% | 12,665 | 38.5% | 6,782 | 41.5% | 4,480 | 44.1% |
| ≥ 65 years | 19,974 | 3,289 | 30.6% | 3,295 | 25.4% | 7,121 | 21.7% | 3,592 | 22.0% | 2,677 | 26.4% |
| Durvalumab | 26,005 | 25,525 | 100.0% | 308 | 100.0% | 134 | 100.0% | ***** | ***** | ***** | ***** |
| 0-17 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 41-64 years | 4,635 | 4,520 | 17.7% | 66 | 21.4% | 43 | 32.1% | ***** | ***** | ***** | ***** |
| ≥ 65 years | 21,303 | 20,938 | 82.0% | 242 | 78.6% | 91 | 67.9% | ***** | ***** | ***** | ***** |
| Edaravone | 2,163 | 574 | 100.0% | 430 | 100.0% | 792 | 100.0% | 233 | 100.0% | 134 | 100.0% |
| 0-17 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | ***** | ***** | ***** | 14 | 3.3% | 25 | 3.2% | ***** | ***** | ***** | ***** |
| 41-64 years | 829 | 268 | 46.7% | 166 | 38.6% | 256 | 32.3% | ***** | ***** | ***** | ***** |
| ≥ 65 years | 1,249 | 279 | 48.6% | 250 | 58.1% | 511 | 64.5% | 144 | 61.8% | 65 | 48.5% |

Table 3e. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| | Number of Patients by Cumulative Treatment Episode Duration | | | | | | | | | | |
|----------------------|---|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|
| | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | | |
| | Total Number of Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients |
| Etelcalcetide | 53,102 | 9,409 | 100.0% | 11,793 | 100.0% | 26,646 | 100.0% | 5,254 | 100.0% | 0 | NaN |
| 0-17 years | 17 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | NaN |
| 18-24 years | 455 | ***** | ***** | ***** | ***** | ***** | ***** | 35 | 0.7% | 0 | NaN |
| 25-40 years | 5,735 | 958 | 10.2% | 1,261 | 10.7% | 2,923 | 11.0% | 593 | 11.3% | 0 | NaN |
| 41-64 years | 26,938 | 4,567 | 48.5% | 5,744 | 48.7% | 13,674 | 51.3% | 2,953 | 56.2% | 0 | NaN |
| ≥ 65 years | 19,957 | 3,780 | 40.2% | 4,667 | 39.6% | 9,837 | 36.9% | 1,673 | 31.8% | 0 | NaN |
| Midostaurin | 1,841 | 635 | 100.0% | 614 | 100.0% | 463 | 100.0% | 98 | 100.0% | 31 | 100.0% |
| 0-17 years | 18 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | 45 | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% |
| 25-40 years | 178 | 57 | 9.0% | 64 | 10.4% | 42 | 9.1% | ***** | ***** | ***** | ***** |
| 41-64 years | 739 | 215 | 33.9% | 267 | 43.5% | 216 | 46.7% | ***** | ***** | ***** | ***** |
| ≥ 65 years | 861 | 340 | 53.5% | 259 | 42.2% | 191 | 41.3% | 54 | 55.1% | 17 | 54.8% |
| Naldemedine | 13,921 | 4,556 | 100.0% | 3,218 | 100.0% | 4,234 | 100.0% | 1,273 | 100.0% | 640 | 100.0% |
| 0-17 years | ***** | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | ***** | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | ***** | ***** |
| 25-40 years | 957 | 320 | 7.0% | 231 | 7.2% | 299 | 7.1% | ***** | ***** | ***** | ***** |
| 41-64 years | 7,235 | 2,198 | 48.2% | 1,697 | 52.7% | 2,268 | 53.6% | 719 | 56.5% | 353 | 55.2% |
| ≥ 65 years | 5,677 | 2,012 | 44.2% | 1,275 | 39.6% | 1,657 | 39.1% | ***** | ***** | ***** | ***** |
| Niraparib | 6,415 | 1,767 | 100.0% | 1,846 | 100.0% | 2,089 | 100.0% | 540 | 100.0% | 173 | 100.0% |
| 0-17 years | ***** | 0 | 0.0% | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | ***** | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** |
| 41-64 years | 1,887 | 360 | 20.4% | 556 | 30.1% | 682 | 32.6% | ***** | ***** | ***** | ***** |
| ≥ 65 years | 4,454 | 1,394 | 78.9% | 1,267 | 68.6% | 1,379 | 66.0% | 320 | 59.3% | 94 | 54.3% |

Table 3e. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| | Number of Patients by Cumulative Treatment Episode Duration | | | | | | | | | | |
|--------------------|---|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|
| | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | | |
| | Total Number of Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients |
| Ocrelizumab | 43,156 | 40,407 | 100.0% | 578 | 100.0% | 1,344 | 100.0% | 557 | 100.0% | 270 | 100.0% |
| 0-17 years | 55 | 55 | 0.1% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | 784 | 746 | 1.8% | ***** | ***** | 20 | 1.5% | ***** | ***** | 0 | 0.0% |
| 25-40 years | 10,500 | 9,855 | 24.4% | ***** | ***** | 305 | 22.7% | ***** | ***** | 53 | 19.6% |
| 41-64 years | 24,374 | 22,645 | 56.0% | 351 | 60.7% | 844 | 62.8% | 361 | 64.8% | 173 | 64.1% |
| ≥ 65 years | 7,443 | 7,106 | 17.6% | 54 | 9.3% | 175 | 13.0% | 64 | 11.5% | 44 | 16.3% |
| Plecanatide | 66,616 | 20,358 | 100.0% | 17,581 | 100.0% | 19,885 | 100.0% | 5,845 | 100.0% | 2,947 | 100.0% |
| 0-17 years | 135 | 49 | 0.2% | 27 | 0.2% | 46 | 0.2% | ***** | ***** | ***** | ***** |
| 18-24 years | 2,505 | 932 | 4.6% | 680 | 3.9% | 672 | 3.4% | ***** | ***** | ***** | ***** |
| 25-40 years | 8,810 | 2,928 | 14.4% | 2,497 | 14.2% | 2,477 | 12.5% | 598 | 10.2% | 310 | 10.5% |
| 41-64 years | 27,632 | 7,665 | 37.7% | 7,417 | 42.2% | 8,744 | 44.0% | 2,544 | 43.5% | 1,262 | 42.8% |
| ≥ 65 years | 27,534 | 8,784 | 43.1% | 6,960 | 39.6% | 7,946 | 40.0% | 2,537 | 43.4% | 1,307 | 44.4% |
| Ribociclib | 4,213 | 813 | 100.0% | 943 | 100.0% | 1,610 | 100.0% | 551 | 100.0% | 296 | 100.0% |
| 0-17 years | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% |
| 18-24 years | ***** | ***** | ***** | 0 | 0.0% | ***** | ***** | ***** | ***** | 0 | 0.0% |
| 25-40 years | 166 | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** |
| 41-64 years | 1,358 | 235 | 28.9% | 305 | 32.3% | 559 | 34.7% | ***** | ***** | ***** | ***** |
| ≥ 65 years | 2,675 | 540 | 66.4% | 598 | 63.4% | 979 | 60.8% | 343 | 62.3% | 215 | 72.6% |
| Safinamide | 2,319 | 385 | 100.0% | 410 | 100.0% | 613 | 100.0% | 389 | 100.0% | 522 | 100.0% |
| 0-17 years | 0 | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | 0 | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | ***** | ***** |
| 41-64 years | ***** | ***** | ***** | ***** | ***** | 111 | 18.1% | 61 | 15.7% | ***** | ***** |
| ≥ 65 years | 1,956 | 329 | 85.5% | 337 | 82.2% | 502 | 81.9% | 328 | 84.3% | 460 | 88.1% |

Table 3e. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| | Number of Patients by Cumulative Treatment Episode Duration | | | | | | | | | | |
|--------------------------|---|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|
| | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | | |
| | Total Number of Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients |
| Sarilumab | 8,534 | 3,018 | 100.0% | 1,588 | 100.0% | 2,682 | 100.0% | 809 | 100.0% | 437 | 100.0% |
| 0-17 years | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | ***** | ***** | ***** | ***** | ***** | 25 | 0.9% | ***** | ***** | ***** | ***** |
| 25-40 years | 671 | 157 | 5.2% | 150 | 9.4% | 251 | 9.4% | ***** | ***** | ***** | ***** |
| 41-64 years | 4,468 | 1,056 | 35.0% | 993 | 62.5% | 1,646 | 61.4% | 512 | 63.3% | 261 | 59.7% |
| ≥ 65 years | 3,322 | 1,784 | 59.1% | 426 | 26.8% | 760 | 28.3% | 217 | 26.8% | 135 | 30.9% |
| Telotristat Ethyl | 1,061 | 258 | 100.0% | 266 | 100.0% | 353 | 100.0% | 115 | 100.0% | 69 | 100.0% |
| 0-17 years | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | ***** | ***** | 0 | 0.0% |
| 18-24 years | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | ***** | ***** | ***** | ***** | ***** | 11 | 3.1% | 0 | 0.0% | ***** | ***** |
| 41-64 years | 376 | 85 | 32.9% | ***** | ***** | 126 | 35.7% | ***** | ***** | ***** | ***** |
| ≥ 65 years | 651 | 164 | 63.6% | 168 | 63.2% | 216 | 61.2% | 61 | 53.0% | 42 | 60.9% |
| Valbenazine | 26,601 | 4,624 | 100.0% | 5,366 | 100.0% | 9,018 | 100.0% | 3,790 | 100.0% | 3,803 | 100.0% |
| 0-17 years | 25 | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% |
| 18-24 years | 292 | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | 19 | 0.5% |
| 25-40 years | 2,528 | 509 | 11.0% | 569 | 10.6% | 883 | 9.8% | 311 | 8.2% | 256 | 6.7% |
| 41-64 years | 14,581 | 2,478 | 53.6% | 2,939 | 54.8% | 5,017 | 55.6% | 2,012 | 53.1% | 2,135 | 56.1% |
| ≥ 65 years | 9,175 | 1,558 | 33.7% | 1,775 | 33.1% | 3,006 | 33.3% | 1,443 | 38.1% | 1,393 | 36.6% |

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 3f. Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| Distribution of Cumulative Treatment Episode Duration, Days | | | | | | | | |
|---|--------------------------|----------|-----------|------------|------------|--------------|--------------|--------------------|
| | Total Number of Patients | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Abaloparatide | 23,148 | 1 | 60 | 159 | 370 | 1,470 | 237.6 | 215.7 |
| 0-17 years | ***** | 18 | 18 | 24 | 30 | 30 | 24.0 | 8.5 |
| 18-24 years | ***** | 30 | 30 | 90 | 195 | 300 | 116.3 | 92.3 |
| 25-40 years | 146 | 1 | 39 | 150 | 360 | 800 | 217.5 | 207.5 |
| 41-64 years | 6,307 | 1 | 60 | 168 | 360 | 1,470 | 238.7 | 220.7 |
| ≥ 65 years | 16,681 | 1 | 60 | 155 | 386 | 1,440 | 237.4 | 213.9 |
| Avelumab | 2,803 | 1 | 3 | 7 | 17 | 450 | 14.1 | 21.5 |
| 0-17 years | ***** | 2 | 2 | 2 | 2 | 2 | 2.0 | NaN |
| 18-24 years | ***** | 1 | 2 | 8 | 14 | 14 | 7.5 | 7.0 |
| 25-40 years | ***** | 1 | 4 | 6 | 11 | 20 | 6.8 | 5.5 |
| 41-64 years | 293 | 1 | 3 | 6 | 14 | 169 | 11.8 | 16.8 |
| ≥ 65 years | 2,492 | 1 | 4 | 7 | 18 | 450 | 14.4 | 22.1 |
| Betrixaban | 21 | 7 | 28 | 30 | 35 | 330 | 57.7 | 75.4 |
| 0-17 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 18-24 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 25-40 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 41-64 years | ***** | 17 | 30 | 30 | 35 | 120 | 45.7 | 34.8 |
| ≥ 65 years | ***** | 7 | 14 | 30 | 61 | 330 | 66.7 | 96.2 |
| Brigatinib | 502 | 1 | 59 | 121 | 289 | 1,809 | 234.6 | 296.1 |
| 0-17 years | ***** | 1 | 38 | 143 | 264 | 318 | 151.0 | 141.0 |
| 18-24 years | ***** | 60 | 60 | 60 | 60 | 60 | 60.0 | 0.0 |
| 25-40 years | ***** | 10 | 68 | 135 | 318 | 1,410 | 224.5 | 259.1 |
| 41-64 years | 229 | 1 | 60 | 148 | 299 | 1,809 | 244.0 | 301.1 |
| ≥ 65 years | 228 | 6 | 43 | 108 | 270 | 1,539 | 229.9 | 300.8 |

Table 3f. Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| Distribution of Cumulative Treatment Episode Duration, Days | | | | | | | | |
|---|--------------------------|----------|------------|------------|------------|--------------|--------------|--------------------|
| | Total Number of Patients | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Brodalumab | 841 | 1 | 91 | 198 | 450 | 1,670 | 327.9 | 328.5 |
| 0-17 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 18-24 years | 18 | 28 | 58 | 131 | 194 | 910 | 191.2 | 233.9 |
| 25-40 years | 140 | 1 | 70 | 151 | 321 | 1,386 | 257.3 | 293.0 |
| 41-64 years | 466 | 1 | 98 | 210 | 434 | 1,549 | 318.3 | 311.8 |
| ≥ 65 years | 217 | 14 | 98 | 280 | 646 | 1,670 | 405.5 | 373.8 |
| Cerliponase Alfa | 18 | 2 | 11 | 16 | 52 | 126 | 36.7 | 40.1 |
| 0-17 years | 18 | 2 | 11 | 16 | 52 | 126 | 36.7 | 40.1 |
| 18-24 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 25-40 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 41-64 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| ≥ 65 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| Deflazacort | 1,129 | 1 | 120 | 281 | 473 | 1,867 | 393.2 | 406.7 |
| 0-17 years | 868 | 1 | 121 | 280 | 466 | 1,837 | 378.8 | 383.4 |
| 18-24 years | 179 | 6 | 90 | 270 | 468 | 1,810 | 380.0 | 405.6 |
| 25-40 years | ***** | 9 | 147 | 373 | 958 | 1,867 | 594.3 | 586.8 |
| 41-64 years | ***** | 30 | 90 | 180 | 240 | 465 | 201.0 | 168.2 |
| ≥ 65 years | ***** | 264 | 264 | 788 | 1,311 | 1,311 | 787.5 | 740.3 |
| Delafloxacin | 2,996 | 1 | 10 | 14 | 20 | 1,140 | 20.2 | 39.0 |
| 0-17 years | 15 | 5 | 10 | 14 | 28 | 54 | 18.4 | 14.0 |
| 18-24 years | 41 | 5 | 10 | 14 | 17 | 180 | 20.0 | 27.3 |
| 25-40 years | 268 | 2 | 10 | 14 | 20 | 398 | 20.0 | 30.6 |
| 41-64 years | 1,342 | 1 | 10 | 14 | 20 | 790 | 20.1 | 34.9 |
| ≥ 65 years | 1,330 | 1 | 10 | 13 | 17 | 1,140 | 20.4 | 44.7 |

Table 3f. Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| Distribution of Cumulative Treatment Episode Duration, Days | | | | | | | | |
|---|--------------------------|----------|-----------|------------|------------|--------------|--------------|--------------------|
| | Total Number of Patients | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Deutetrabenazine | 16,357 | 1 | 60 | 191 | 510 | 1,855 | 345.4 | 372.6 |
| 0-17 years | 24 | 12 | 30 | 86 | 252 | 417 | 146.8 | 129.7 |
| 18-24 years | 160 | 4 | 60 | 178 | 423 | 1,472 | 282.2 | 295.3 |
| 25-40 years | 1,500 | 1 | 60 | 180 | 480 | 1,840 | 328.8 | 372.5 |
| 41-64 years | 8,412 | 1 | 60 | 183 | 492 | 1,855 | 340.5 | 371.2 |
| ≥ 65 years | 6,261 | 1 | 60 | 210 | 541 | 1,801 | 358.3 | 376.2 |
| Dupilumab | 83,061 | 1 | 75 | 207 | 458 | 1,928 | 322.3 | 333.8 |
| 0-17 years | 7,038 | 1 | 84 | 210 | 434 | 1,779 | 296.0 | 280.6 |
| 18-24 years | 7,843 | 1 | 70 | 188 | 406 | 1,810 | 291.9 | 301.3 |
| 25-40 years | 16,043 | 1 | 76 | 190 | 416 | 1,897 | 301.3 | 319.1 |
| 41-64 years | 32,163 | 1 | 86 | 231 | 495 | 1,928 | 347.5 | 345.8 |
| ≥ 65 years | 19,974 | 1 | 57 | 182 | 462 | 1,897 | 319.7 | 351.7 |
| Durvalumab | 26,005 | 1 | 4 | 9 | 18 | 1,074 | 13.1 | 29.2 |
| 0-17 years | ***** | 1 | 1 | 1 | 1 | 1 | 1.0 | NaN |
| 18-24 years | ***** | 1 | 1 | 1 | 2 | 3 | 1.4 | 0.7 |
| 25-40 years | ***** | 1 | 1 | 2 | 5 | 26 | 4.8 | 6.0 |
| 41-64 years | 4,635 | 1 | 3 | 8 | 17 | 840 | 13.7 | 30.7 |
| ≥ 65 years | 21,303 | 1 | 4 | 9 | 18 | 1,074 | 13.0 | 29.0 |
| Edaravone | 2,163 | 1 | 28 | 105 | 252 | 1,688 | 207.7 | 284.9 |
| 0-17 years | ***** | 28 | 28 | 28 | 28 | 28 | 28.0 | NaN |
| 18-24 years | ***** | 1 | 1 | 14 | 23 | 23 | 12.7 | 11.1 |
| 25-40 years | ***** | 1 | 24 | 125 | 330 | 1,569 | 294.1 | 400.1 |
| 41-64 years | 829 | 1 | 23 | 82 | 240 | 1,663 | 200.7 | 296.8 |
| ≥ 65 years | 1,249 | 1 | 42 | 116 | 258 | 1,688 | 207.3 | 267.0 |

Table 3f. Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| Distribution of Cumulative Treatment Episode Duration, Days | | | | | | | | |
|---|--------------------------|----------|-----------|------------|------------|--------------|--------------|--------------------|
| | Total Number of Patients | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Etelcalcetide | 53,102 | 1 | 47 | 127 | 251 | 730 | 161.7 | 135.7 |
| 0-17 years | 17 | 1 | 10 | 43 | 174 | 321 | 91.6 | 99.1 |
| 18-24 years | 455 | 1 | 36 | 101 | 215 | 581 | 141.9 | 131.4 |
| 25-40 years | 5,735 | 1 | 50 | 131 | 259 | 730 | 166.6 | 138.9 |
| 41-64 years | 26,938 | 1 | 51 | 133 | 260 | 691 | 167.7 | 138.1 |
| ≥ 65 years | 19,957 | 1 | 43 | 116 | 236 | 694 | 152.6 | 130.9 |
| Midostaurin | 1,841 | 1 | 28 | 56 | 118 | 1,765 | 118.6 | 189.5 |
| 0-17 years | 18 | 9 | 30 | 70 | 140 | 302 | 104.6 | 97.4 |
| 18-24 years | 45 | 4 | 28 | 56 | 84 | 638 | 86.8 | 129.2 |
| 25-40 years | 178 | 1 | 28 | 56 | 140 | 1,128 | 119.4 | 171.3 |
| 41-64 years | 739 | 1 | 28 | 58 | 126 | 1,712 | 117.5 | 173.1 |
| ≥ 65 years | 861 | 1 | 28 | 56 | 112 | 1,765 | 121.4 | 209.7 |
| Naldemedine | 13,921 | 1 | 30 | 90 | 216 | 1,630 | 180.1 | 238.7 |
| 0-17 years | ***** | 30 | 30 | 30 | 75 | 120 | 52.5 | 34.9 |
| 18-24 years | ***** | 2 | 30 | 60 | 90 | 993 | 106.0 | 169.3 |
| 25-40 years | 957 | 1 | 30 | 90 | 202 | 1,519 | 157.0 | 198.0 |
| 41-64 years | 7,235 | 1 | 30 | 90 | 240 | 1,630 | 188.7 | 244.4 |
| ≥ 65 years | 5,677 | 1 | 30 | 82 | 210 | 1,546 | 173.9 | 237.6 |
| Niraparib | 6,415 | 1 | 30 | 90 | 186 | 1,838 | 162.3 | 211.9 |
| 0-17 years | ***** | 56 | 56 | 56 | 56 | 56 | 56.0 | NaN |
| 18-24 years | ***** | 28 | 28 | 90 | 180 | 180 | 99.3 | 76.4 |
| 25-40 years | ***** | 10 | 56 | 103 | 256 | 840 | 178.6 | 183.2 |
| 41-64 years | 1,887 | 1 | 60 | 110 | 240 | 1,728 | 195.8 | 237.5 |
| ≥ 65 years | 4,454 | 1 | 30 | 77 | 180 | 1,838 | 147.9 | 199.0 |

Table 3f. Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| Distribution of Cumulative Treatment Episode Duration, Days | | | | | | | | | | |
|---|--------------------------|----------|-----------|------------|------------|--------------|--------------|--------------------|--|--|
| | Total Number of Patients | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation | | |
| Ocrelizumab | 43,156 | 1 | 2 | 3 | 6 | 1,728 | 24.3 | 107.8 | | |
| 0-17 years | 55 | 1 | 2 | 3 | 4 | 15 | 3.2 | 2.4 | | |
| 18-24 years | 784 | 1 | 2 | 3 | 5 | 611 | 12.1 | 51.7 | | |
| 25-40 years | 10,500 | 1 | 2 | 3 | 6 | 1,633 | 22.0 | 99.2 | | |
| 41-64 years | 24,374 | 1 | 2 | 3 | 6 | 1,669 | 26.9 | 114.8 | | |
| ≥ 65 years | 7,443 | 1 | 2 | 4 | 7 | 1,728 | 20.4 | 100.2 | | |
| Plecanatide | 66,616 | 1 | 30 | 90 | 210 | 1,912 | 179.3 | 241.0 | | |
| 0-17 years | 135 | 3 | 30 | 90 | 180 | 1,413 | 146.3 | 191.7 | | |
| 18-24 years | 2,505 | 1 | 30 | 60 | 150 | 1,447 | 139.6 | 189.5 | | |
| 25-40 years | 8,810 | 1 | 30 | 88 | 180 | 1,864 | 154.3 | 215.9 | | |
| 41-64 years | 27,632 | 1 | 30 | 90 | 224 | 1,912 | 187.0 | 246.2 | | |
| ≥ 65 years | 27,534 | 1 | 30 | 90 | 210 | 1,894 | 183.4 | 246.9 | | |
| Ribociclib | 4,213 | 1 | 56 | 126 | 308 | 1,801 | 237.1 | 285.6 | | |
| 0-17 years | ***** | 14 | 21 | 84 | 224 | 644 | 159.1 | 187.6 | | |
| 18-24 years | ***** | 28 | 28 | 109 | 401 | 401 | 179.3 | 196.2 | | |
| 25-40 years | 166 | 2 | 53 | 133 | 262 | 1,527 | 206.8 | 237.8 | | |
| 41-64 years | 1,358 | 1 | 56 | 132 | 301 | 1,727 | 226.0 | 265.0 | | |
| ≥ 65 years | 2,675 | 1 | 56 | 114 | 328 | 1,801 | 245.0 | 298.4 | | |
| Safinamide | 2,319 | 1 | 60 | 227 | 661 | 1,806 | 425.6 | 457.8 | | |
| 0-17 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN | | |
| 18-24 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN | | |
| 25-40 years | ***** | 30 | 45 | 79 | 1,022 | 1,230 | 443.8 | 544.8 | | |
| 41-64 years | ***** | 5 | 60 | 210 | 543 | 1,806 | 369.2 | 410.2 | | |
| ≥ 65 years | 1,956 | 1 | 60 | 240 | 690 | 1,806 | 435.8 | 465.1 | | |

Table 3f. Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| Distribution of Cumulative Treatment Episode Duration, Days | | | | | | | | |
|---|--------------------------|----------|-----------|------------|------------|--------------|--------------|--------------------|
| | Total Number of Patients | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Sarilumab | 8,534 | 1 | 2 | 84 | 224 | 1,757 | 178.3 | 256.5 |
| 0-17 years | ***** | 1 | 4 | 31 | 66 | 75 | 34.5 | 36.7 |
| 18-24 years | ***** | 1 | 28 | 84 | 196 | 890 | 157.7 | 172.5 |
| 25-40 years | 671 | 1 | 53 | 112 | 252 | 1,540 | 208.4 | 265.8 |
| 41-64 years | 4,468 | 1 | 43 | 112 | 266 | 1,757 | 209.9 | 265.2 |
| ≥ 65 years | 3,322 | 1 | 1 | 28 | 140 | 1,614 | 130.4 | 236.1 |
| Telotristat Ethyl | 1,061 | 2 | 41 | 100 | 241 | 1,848 | 216.5 | 291.4 |
| 0-17 years | ***** | 672 | 672 | 672 | 672 | 672 | 672.0 | NaN |
| 18-24 years | ***** | 28 | 28 | 42 | 56 | 56 | 42.0 | 19.8 |
| 25-40 years | ***** | 28 | 30 | 84 | 241 | 1,848 | 234.0 | 376.7 |
| 41-64 years | 376 | 3 | 49 | 112 | 270 | 1,820 | 228.2 | 295.3 |
| ≥ 65 years | 651 | 2 | 30 | 84 | 224 | 1,540 | 208.8 | 284.7 |
| Valbenazine | 26,601 | 1 | 60 | 154 | 427 | 1,848 | 319.1 | 375.3 |
| 0-17 years | 25 | 4 | 48 | 60 | 147 | 450 | 113.8 | 106.8 |
| 18-24 years | 292 | 4 | 31 | 90 | 262 | 1,669 | 205.9 | 283.2 |
| 25-40 years | 2,528 | 1 | 56 | 124 | 330 | 1,774 | 266.4 | 333.7 |
| 41-64 years | 14,581 | 1 | 60 | 157 | 425 | 1,841 | 321.0 | 376.7 |
| ≥ 65 years | 9,175 | 1 | 60 | 168 | 466 | 1,848 | 334.9 | 384.8 |

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 4a. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| | Number of Treatment Episodes by Duration | | | | | | | | | | |
|-------------------|--|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
| | Total Number of Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes |
| Abaloparatide | 71,072 | 39,656 | 55.8% | 18,831 | 26.5% | 10,713 | 15.1% | 1,670 | 2.3% | 202 | 0.3% |
| Avelumab | 36,616 | 36,593 | 99.9% | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| Betrixaban | 30 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| Brigatinib | 1,211 | 578 | 47.7% | 336 | 27.7% | 248 | 20.5% | 33 | 2.7% | 16 | 1.3% |
| Brodalumab | 3,358 | 1,688 | 50.3% | 931 | 27.7% | 637 | 19.0% | 77 | 2.3% | 25 | 0.7% |
| Cerliponase Alfa | 532 | ***** | ***** | 0 | 0.0% | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| Deflazacort | 3,619 | 1,772 | 49.0% | 847 | 23.4% | 724 | 20.0% | 186 | 5.1% | 90 | 2.5% |
| Delafloxacin | 4,097 | 3,942 | 96.2% | 133 | 3.2% | ***** | 0.5% | ***** | ***** | ***** | ***** |
| Deutetrabenazine | 46,882 | 22,902 | 48.9% | 11,286 | 24.1% | 9,028 | 19.3% | 2,294 | 4.9% | 1,372 | 2.9% |
| Dupilumab | 312,719 | 169,125 | 54.1% | 75,374 | 24.1% | 55,838 | 17.9% | 8,965 | 2.9% | 3,417 | 1.1% |
| Durvalumab | 285,274 | 284,982 | 99.9% | 155 | 0.1% | 108 | 0.0% | ***** | ***** | ***** | ***** |
| Edaravone | 28,577 | 26,945 | 94.3% | 720 | 2.5% | 735 | 2.6% | 137 | 0.5% | 40 | 0.1% |
| Etelcalcetide | 8,510,448 | 8,510,437 | 100.0% | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| Midostaurin | 4,736 | 3,495 | 73.8% | 831 | 17.5% | 372 | 7.9% | 26 | 0.5% | 12 | 0.3% |
| Naldemedine | 39,747 | 26,041 | 65.5% | 8,869 | 22.3% | 4,181 | 10.5% | 510 | 1.3% | 146 | 0.4% |
| Niraparib | 15,712 | 9,490 | 60.4% | 4,014 | 25.5% | 1,942 | 12.4% | 218 | 1.4% | 48 | 0.3% |
| Ocrelizumab | 165,673 | 160,923 | 97.1% | 1,397 | 0.8% | 3,169 | 1.9% | 159 | 0.1% | 25 | 0.0% |
| Plecanatide | 159,824 | 91,944 | 57.5% | 44,204 | 27.7% | 20,079 | 12.6% | 2,754 | 1.7% | 843 | 0.5% |
| Ribociclib | 14,484 | 8,572 | 59.2% | 3,468 | 23.9% | 2,116 | 14.6% | 263 | 1.8% | 65 | 0.4% |
| Safinamide | 7,891 | 3,432 | 43.5% | 2,294 | 29.1% | 1,608 | 20.4% | 347 | 4.4% | 210 | 2.7% |
| Sarilumab | 21,098 | 11,873 | 56.3% | 5,294 | 25.1% | 3,449 | 16.3% | 361 | 1.7% | 121 | 0.6% |
| Telotristat Ethyl | 3,774 | 2,322 | 61.5% | 906 | 24.0% | 502 | 13.3% | 32 | 0.8% | 12 | 0.3% |
| Valbenazine | 74,593 | 34,189 | 45.8% | 19,916 | 26.7% | 15,775 | 21.1% | 3,138 | 4.2% | 1,575 | 2.1% |

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 4b. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Distribution of Treatment Episode Durations, Days | | | | | | | | |
|---|--------------------------|---------|----|--------|-----|---------|-------|--------------------|
| | Total Number of Episodes | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Abaloparatide | 71,072 | 1 | 30 | 30 | 90 | 1,470 | 77.4 | 103.1 |
| Avelumab | 36,616 | 1 | 1 | 1 | 1 | 308 | 1.1 | 3.0 |
| Betrixaban | 30 | 3 | 14 | 30 | 42 | 330 | 40.4 | 57.8 |
| Brigatinib | 1,211 | 1 | 30 | 45 | 90 | 1,809 | 97.3 | 156.1 |
| Brodalumab | 3,358 | 1 | 28 | 30 | 84 | 1,670 | 82.1 | 123.5 |
| Cerliponase Alfa | 532 | 1 | 1 | 1 | 1 | 98 | 1.2 | 4.4 |
| Deflazacort | 3,619 | 1 | 30 | 34 | 120 | 1,837 | 122.7 | 215.9 |
| Delafloxacin | 4,097 | 1 | 10 | 10 | 14 | 870 | 14.8 | 21.0 |
| Deutetrabenazine | 46,882 | 1 | 30 | 39 | 120 | 1,802 | 120.5 | 205.0 |
| Dupilumab | 312,719 | 1 | 28 | 28 | 84 | 1,897 | 85.6 | 142.7 |
| Durvalumab | 285,274 | 1 | 1 | 1 | 1 | 1,074 | 1.2 | 7.7 |
| Edaravone | 28,577 | 1 | 3 | 5 | 10 | 1,613 | 15.7 | 60.2 |
| Etelcalcetide | 8,510,448 | 1 | 1 | 1 | 1 | 117 | 1.0 | 0.1 |
| Midostaurin | 4,736 | 1 | 21 | 28 | 42 | 1,593 | 46.1 | 83.4 |
| Naldemedine | 39,747 | 1 | 30 | 30 | 60 | 1,630 | 63.1 | 92.0 |
| Niraparib | 15,712 | 1 | 30 | 30 | 60 | 1,648 | 66.2 | 92.3 |
| Ocrelizumab | 165,673 | 1 | 1 | 1 | 1 | 1,616 | 6.3 | 35.4 |
| Plecanatide | 159,824 | 1 | 30 | 30 | 90 | 1,912 | 74.7 | 107.3 |
| Ribociclib | 14,484 | 1 | 28 | 28 | 56 | 1,635 | 69.0 | 105.7 |
| Safinamide | 7,891 | 1 | 30 | 60 | 120 | 1,798 | 125.1 | 199.2 |
| Sarilumab | 21,098 | 1 | 28 | 28 | 84 | 1,757 | 72.1 | 112.7 |
| Telotristat Ethyl | 3,774 | 2 | 28 | 28 | 56 | 1,725 | 60.9 | 83.3 |
| Valbenazine | 74,593 | 1 | 30 | 60 | 120 | 1,841 | 113.8 | 179.4 |

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Sex

| | Number of Treatment Episodes by Duration | | | | | | | | | | |
|-------------------------|--|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|
| | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | | |
| | Total Number of Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes |
| Abaloparatide | 71,072 | 39,656 | 100.0% | 18,831 | 100.0% | 10,713 | 100.0% | 1,670 | 100.0% | 202 | 100.0% |
| Female | 69,356 | 38,660 | 97.5% | 18,380 | 97.6% | 10,491 | 97.9% | ***** | ***** | ***** | ***** |
| Male | 1,716 | 996 | 2.5% | 451 | 2.4% | 222 | 2.1% | ***** | ***** | ***** | ***** |
| Avelumab | 36,616 | 36,593 | 100.0% | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN |
| Female | 8,721 | 8,713 | 23.8% | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN |
| Male | 27,895 | 27,880 | 76.2% | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN |
| Betrixaban | 30 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN |
| Female | 19 | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | NaN | 0 | NaN |
| Male | 11 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN |
| Brigatinib | 1,211 | 578 | 100.0% | 336 | 100.0% | 248 | 100.0% | 33 | 100.0% | 16 | 100.0% |
| Female | 746 | 349 | 60.4% | 207 | 61.6% | 162 | 65.3% | ***** | ***** | ***** | ***** |
| Male | 465 | 229 | 39.6% | 129 | 38.4% | 86 | 34.7% | ***** | ***** | ***** | ***** |
| Brodalumab | 3,358 | 1,688 | 100.0% | 931 | 100.0% | 637 | 100.0% | 77 | 100.0% | 25 | 100.0% |
| Female | 1,586 | 813 | 48.2% | 415 | 44.6% | 311 | 48.8% | 35 | 45.5% | 12 | 48.0% |
| Male | 1,772 | 875 | 51.8% | 516 | 55.4% | 326 | 51.2% | 42 | 54.5% | 13 | 52.0% |
| Cerliponase Alfa | 532 | ***** | ***** | 0 | NaN | ***** | ***** | 0 | NaN | 0 | NaN |
| Female | ***** | ***** | ***** | 0 | NaN | 0 | 0.0% | 0 | NaN | 0 | NaN |
| Male | ***** | ***** | ***** | 0 | NaN | ***** | ***** | 0 | NaN | 0 | NaN |
| Deflazacort | 3,619 | 1,772 | 100.0% | 847 | 100.0% | 724 | 100.0% | 186 | 100.0% | 90 | 100.0% |
| Female | 29 | 16 | 0.9% | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** |
| Male | 3,590 | 1,756 | 99.1% | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** |
| Delafloxacin | 4,097 | 3,942 | 100.0% | 133 | 100.0% | ***** | ***** | ***** | ***** | ***** | ***** |
| Female | 1,873 | 1,801 | 45.7% | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| Male | 2,224 | 2,141 | 54.3% | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** |

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Sex

| | Number of Treatment Episodes by Duration | | | | | | | | | | |
|-------------------------|--|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|
| | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | | |
| | Total Number of Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes |
| Deutetrabenazine | 46,882 | 22,902 | 100.0% | 11,286 | 100.0% | 9,028 | 100.0% | 2,294 | 100.0% | 1,372 | 100.0% |
| Female | 28,878 | 14,102 | 61.6% | 6,992 | 62.0% | 5,569 | 61.7% | 1,390 | 60.6% | 825 | 60.1% |
| Male | 18,004 | 8,800 | 38.4% | 4,294 | 38.0% | 3,459 | 38.3% | 904 | 39.4% | 547 | 39.9% |
| Dupilumab | 312,719 | 169,125 | 100.0% | 75,374 | 100.0% | 55,838 | 100.0% | 8,965 | 100.0% | 3,417 | 100.0% |
| Female | 172,105 | 93,679 | 55.4% | 41,324 | 54.8% | 30,513 | 54.6% | 4,806 | 53.6% | 1,783 | 52.2% |
| Male | 140,614 | 75,446 | 44.6% | 34,050 | 45.2% | 25,325 | 45.4% | 4,159 | 46.4% | 1,634 | 47.8% |
| Durvalumab | 285,274 | 284,982 | 100.0% | 155 | 100.0% | 108 | 100.0% | ***** | ***** | ***** | ***** |
| Female | 137,746 | 137,644 | 48.3% | 54 | 34.8% | 35 | 32.4% | ***** | ***** | ***** | ***** |
| Male | 147,528 | 147,338 | 51.7% | 101 | 65.2% | 73 | 67.6% | ***** | ***** | ***** | ***** |
| Edaravone | 28,577 | 26,945 | 100.0% | 720 | 100.0% | 735 | 100.0% | 137 | 100.0% | 40 | 100.0% |
| Female | 12,590 | 11,887 | 44.1% | 311 | 43.2% | 303 | 41.2% | 68 | 49.6% | 21 | 52.5% |
| Male | 15,987 | 15,058 | 55.9% | 409 | 56.8% | 432 | 58.8% | 69 | 50.4% | 19 | 47.5% |
| Etelcalcetide | 8,510,448 | 8,510,437 | 100.0% | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN |
| Female | 3,910,778 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN |
| Male | 4,599,670 | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | NaN | 0 | NaN |
| Midostaurin | 4,736 | 3,495 | 100.0% | 831 | 100.0% | 372 | 100.0% | 26 | 100.0% | 12 | 100.0% |
| Female | 2,468 | 1,822 | 52.1% | 418 | 50.3% | 206 | 55.4% | ***** | ***** | ***** | ***** |
| Male | 2,268 | 1,673 | 47.9% | 413 | 49.7% | 166 | 44.6% | ***** | ***** | ***** | ***** |
| Naldemedine | 39,747 | 26,041 | 100.0% | 8,869 | 100.0% | 4,181 | 100.0% | 510 | 100.0% | 146 | 100.0% |
| Female | 26,315 | 17,281 | 66.4% | 5,867 | 66.2% | 2,745 | 65.7% | 328 | 64.3% | 94 | 64.4% |
| Male | 13,432 | 8,760 | 33.6% | 3,002 | 33.8% | 1,436 | 34.3% | 182 | 35.7% | 52 | 35.6% |
| Niraparib | 15,712 | 9,490 | 100.0% | 4,014 | 100.0% | 1,942 | 100.0% | 218 | 100.0% | 48 | 100.0% |
| Female | 15,658 | 9,457 | 99.7% | 3,997 | 99.6% | ***** | ***** | 218 | 100.0% | ***** | ***** |
| Male | 54 | 33 | 0.3% | 17 | 0.4% | ***** | ***** | 0 | 0.0% | ***** | ***** |

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Sex

| | Number of Treatment Episodes by Duration | | | | | | | | | | |
|--------------------------|--|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|
| | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | | |
| | Total Number of Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes |
| Ocrelizumab | 165,673 | 160,923 | 100.0% | 1,397 | 100.0% | 3,169 | 100.0% | 159 | 100.0% | 25 | 100.0% |
| Female | 111,881 | 108,619 | 67.5% | 937 | 67.1% | 2,192 | 69.2% | 119 | 74.8% | 14 | 56.0% |
| Male | 53,792 | 52,304 | 32.5% | 460 | 32.9% | 977 | 30.8% | 40 | 25.2% | 11 | 44.0% |
| Plecanatide | 159,824 | 91,944 | 100.0% | 44,204 | 100.0% | 20,079 | 100.0% | 2,754 | 100.0% | 843 | 100.0% |
| Female | 125,160 | 72,168 | 78.5% | 34,667 | 78.4% | 15,588 | 77.6% | 2,102 | 76.3% | 635 | 75.3% |
| Male | 34,664 | 19,776 | 21.5% | 9,537 | 21.6% | 4,491 | 22.4% | 652 | 23.7% | 208 | 24.7% |
| Ribociclib | 14,484 | 8,572 | 100.0% | 3,468 | 100.0% | 2,116 | 100.0% | 263 | 100.0% | 65 | 100.0% |
| Female | 14,221 | 8,436 | 98.4% | 3,394 | 97.9% | ***** | ***** | ***** | ***** | ***** | ***** |
| Male | 263 | 136 | 1.6% | 74 | 2.1% | ***** | ***** | ***** | ***** | ***** | ***** |
| Safinamide | 7,891 | 3,432 | 100.0% | 2,294 | 100.0% | 1,608 | 100.0% | 347 | 100.0% | 210 | 100.0% |
| Female | 3,405 | 1,483 | 43.2% | 995 | 43.4% | 678 | 42.2% | 150 | 43.2% | 99 | 47.1% |
| Male | 4,486 | 1,949 | 56.8% | 1,299 | 56.6% | 930 | 57.8% | 197 | 56.8% | 111 | 52.9% |
| Sarilumab | 21,098 | 11,873 | 100.0% | 5,294 | 100.0% | 3,449 | 100.0% | 361 | 100.0% | 121 | 100.0% |
| Female | 16,943 | 9,147 | 77.0% | 4,467 | 84.4% | 2,934 | 85.1% | 296 | 82.0% | 99 | 81.8% |
| Male | 4,155 | 2,726 | 23.0% | 827 | 15.6% | 515 | 14.9% | 65 | 18.0% | 22 | 18.2% |
| Telotristat Ethyl | 3,774 | 2,322 | 100.0% | 906 | 100.0% | 502 | 100.0% | 32 | 100.0% | 12 | 100.0% |
| Female | 2,182 | 1,371 | 59.0% | 516 | 57.0% | 266 | 53.0% | ***** | ***** | ***** | ***** |
| Male | 1,592 | 951 | 41.0% | 390 | 43.0% | 236 | 47.0% | ***** | ***** | ***** | ***** |
| Valbenazine | 74,593 | 34,189 | 100.0% | 19,916 | 100.0% | 15,775 | 100.0% | 3,138 | 100.0% | 1,575 | 100.0% |
| Female | 44,672 | 20,495 | 59.9% | 12,034 | 60.4% | 9,402 | 59.6% | 1,825 | 58.2% | 916 | 58.2% |
| Male | 29,921 | 13,694 | 40.1% | 7,882 | 39.6% | 6,373 | 40.4% | 1,313 | 41.8% | 659 | 41.8% |

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Sex

| Distribution of Treatment Episode Durations, Days | | | | | | | | |
|---|--------------------------|----------|-----------|-----------|------------|--------------|--------------|--------------------|
| | Total Number of Episodes | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Abaloparatide | 71,072 | 1 | 30 | 30 | 90 | 1,470 | 77.4 | 103.1 |
| Female | 69,356 | 1 | 30 | 30 | 90 | 1,470 | 77.5 | 103.2 |
| Male | 1,716 | 1 | 30 | 30 | 89 | 1,260 | 74.4 | 102.6 |
| Avelumab | 36,616 | 1 | 1 | 1 | 1 | 308 | 1.1 | 3.0 |
| Female | 8,721 | 1 | 1 | 1 | 1 | 140 | 1.1 | 2.6 |
| Male | 27,895 | 1 | 1 | 1 | 1 | 308 | 1.1 | 3.1 |
| Betrixaban | 30 | 3 | 14 | 30 | 42 | 330 | 40.4 | 57.8 |
| Female | 19 | 3 | 14 | 28 | 35 | 60 | 26.4 | 14.0 |
| Male | 11 | 7 | 29 | 30 | 60 | 330 | 64.5 | 91.1 |
| Brigatinib | 1,211 | 1 | 30 | 45 | 90 | 1,809 | 97.3 | 156.1 |
| Female | 746 | 4 | 30 | 52 | 102 | 1,334 | 91.6 | 125.9 |
| Male | 465 | 1 | 30 | 37 | 90 | 1,809 | 106.4 | 194.8 |
| Brodalumab | 3,358 | 1 | 28 | 30 | 84 | 1,670 | 82.1 | 123.5 |
| Female | 1,586 | 1 | 28 | 30 | 84 | 1,670 | 82.0 | 125.9 |
| Male | 1,772 | 1 | 28 | 38 | 84 | 1,386 | 82.2 | 121.4 |
| Cerliponase Alfa | 532 | 1 | 1 | 1 | 1 | 98 | 1.2 | 4.4 |
| Female | 312 | 1 | 1 | 1 | 1 | 2 | 1.0 | 0.1 |
| Male | 220 | 1 | 1 | 1 | 1 | 98 | 1.6 | 6.8 |
| Deflazacort | 3,619 | 1 | 30 | 34 | 120 | 1,837 | 122.7 | 215.9 |
| Female | 29 | 19 | 30 | 30 | 90 | 1,227 | 187.7 | 328.8 |
| Male | 3,590 | 1 | 30 | 34 | 120 | 1,837 | 122.2 | 214.8 |
| Delafloxacin | 4,097 | 1 | 10 | 10 | 14 | 870 | 14.8 | 21.0 |
| Female | 1,873 | 1 | 10 | 10 | 14 | 180 | 14.3 | 13.6 |
| Male | 2,224 | 1 | 10 | 10 | 14 | 870 | 15.2 | 25.6 |

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Sex

| Distribution of Treatment Episode Durations, Days | | | | | | | | |
|---|--------------------------|----------|-----------|-----------|------------|--------------|--------------|--------------------|
| | Total Number of Episodes | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Deutetrabenazine | 46,882 | 1 | 30 | 39 | 120 | 1,802 | 120.5 | 205.0 |
| Female | 28,878 | 1 | 30 | 39 | 116 | 1,802 | 119.1 | 202.8 |
| Male | 18,004 | 1 | 30 | 38 | 120 | 1,779 | 122.8 | 208.6 |
| Dupilumab | 312,719 | 1 | 28 | 28 | 84 | 1,897 | 85.6 | 142.7 |
| Female | 172,105 | 1 | 28 | 28 | 84 | 1,891 | 84.3 | 139.7 |
| Male | 140,614 | 1 | 28 | 28 | 84 | 1,897 | 87.2 | 146.3 |
| Durvalumab | 285,274 | 1 | 1 | 1 | 1 | 1,074 | 1.2 | 7.7 |
| Female | 137,746 | 1 | 1 | 1 | 1 | 1,074 | 1.1 | 7.2 |
| Male | 147,528 | 1 | 1 | 1 | 1 | 989 | 1.2 | 8.1 |
| Edaravone | 28,577 | 1 | 3 | 5 | 10 | 1,613 | 15.7 | 60.2 |
| Female | 12,590 | 1 | 3 | 5 | 10 | 1,568 | 16.1 | 63.9 |
| Male | 15,987 | 1 | 2 | 5 | 10 | 1,613 | 15.4 | 57.1 |
| Etelcalcetide | 8,510,448 | 1 | 1 | 1 | 1 | 117 | 1.0 | 0.1 |
| Female | 3,910,778 | 1 | 1 | 1 | 1 | 117 | 1.0 | 0.1 |
| Male | 4,599,670 | 1 | 1 | 1 | 1 | 90 | 1.0 | 0.1 |
| Midostaurin | 4,736 | 1 | 21 | 28 | 42 | 1,593 | 46.1 | 83.4 |
| Female | 2,468 | 1 | 21 | 28 | 42 | 1,569 | 47.8 | 90.7 |
| Male | 2,268 | 1 | 19 | 28 | 42 | 1,593 | 44.3 | 74.6 |
| Naldemedine | 39,747 | 1 | 30 | 30 | 60 | 1,630 | 63.1 | 92.0 |
| Female | 26,315 | 1 | 30 | 30 | 60 | 1,630 | 62.6 | 91.3 |
| Male | 13,432 | 1 | 30 | 30 | 60 | 1,440 | 64.0 | 93.3 |
| Niraparib | 15,712 | 1 | 30 | 30 | 60 | 1,648 | 66.2 | 92.3 |
| Female | 15,658 | 1 | 30 | 30 | 60 | 1,648 | 66.2 | 92.2 |
| Male | 54 | 3 | 30 | 30 | 60 | 840 | 65.8 | 120.5 |

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Sex

| Distribution of Treatment Episode Durations, Days | | | | | | | | |
|---|--------------------------|----------|-----------|-----------|------------|--------------|--------------|--------------------|
| | Total Number of Episodes | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Ocrelizumab | 165,673 | 1 | 1 | 1 | 1 | 1,616 | 6.3 | 35.4 |
| Female | 111,881 | 1 | 1 | 1 | 1 | 1,616 | 6.4 | 35.7 |
| Male | 53,792 | 1 | 1 | 1 | 1 | 1,292 | 6.1 | 34.7 |
| Plecanatide | 159,824 | 1 | 30 | 30 | 90 | 1,912 | 74.7 | 107.3 |
| Female | 125,160 | 1 | 30 | 30 | 90 | 1,912 | 74.2 | 105.9 |
| Male | 34,664 | 1 | 30 | 30 | 90 | 1,864 | 76.8 | 112.1 |
| Ribociclib | 14,484 | 1 | 28 | 28 | 56 | 1,635 | 69.0 | 105.7 |
| Female | 14,221 | 1 | 28 | 28 | 56 | 1,635 | 68.9 | 105.7 |
| Male | 263 | 2 | 28 | 28 | 84 | 904 | 74.5 | 106.7 |
| Safinamide | 7,891 | 1 | 30 | 60 | 120 | 1,798 | 125.1 | 199.2 |
| Female | 3,405 | 1 | 30 | 60 | 120 | 1,798 | 126.8 | 206.4 |
| Male | 4,486 | 1 | 30 | 60 | 120 | 1,724 | 123.8 | 193.6 |
| Sarilumab | 21,098 | 1 | 28 | 28 | 84 | 1,757 | 72.1 | 112.7 |
| Female | 16,943 | 1 | 28 | 28 | 84 | 1,757 | 75.4 | 112.3 |
| Male | 4,155 | 1 | 1 | 28 | 56 | 1,444 | 58.8 | 113.4 |
| Telotristat Ethyl | 3,774 | 2 | 28 | 28 | 56 | 1,725 | 60.9 | 83.3 |
| Female | 2,182 | 2 | 28 | 28 | 56 | 1,176 | 58.8 | 77.0 |
| Male | 1,592 | 2 | 28 | 28 | 56 | 1,725 | 63.7 | 91.3 |
| Valbenazine | 74,593 | 1 | 30 | 60 | 120 | 1,841 | 113.8 | 179.4 |
| Female | 44,672 | 1 | 30 | 60 | 120 | 1,831 | 112.5 | 176.7 |
| Male | 29,921 | 1 | 30 | 60 | 120 | 1,841 | 115.8 | 183.5 |

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| | Number of Treatment Episodes by Duration | | | | | | | | | | |
|----------------------|--|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|
| | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | | |
| | Total Number of Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes |
| Abaloparatide | 71,072 | 39,656 | 100.0% | 18,831 | 100.0% | 10,713 | 100.0% | 1,670 | 100.0% | 202 | 100.0% |
| 0-17 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | ***** | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | 407 | 244 | 0.6% | ***** | ***** | ***** | ***** | 14 | 0.8% | ***** | ***** |
| 41-64 years | 18,846 | 10,592 | 26.7% | 4,853 | 25.8% | 2,842 | 26.5% | 441 | 26.4% | 118 | 58.4% |
| ≥ 65 years | 51,796 | 28,806 | 72.6% | 13,879 | 73.7% | 7,814 | 72.9% | ***** | ***** | ***** | ***** |
| Avelumab | 36,616 | 36,593 | 100.0% | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN |
| 0-17 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | NaN | 0 | NaN |
| 18-24 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | NaN | 0 | NaN |
| 25-40 years | 89 | 89 | 0.2% | 0 | 0.0% | 0 | 0.0% | 0 | NaN | 0 | NaN |
| 41-64 years | 3,258 | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | NaN | 0 | NaN |
| ≥ 65 years | 33,237 | 33,216 | 90.8% | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN |
| Betrixaban | 30 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN |
| 0-17 years | 0 | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | NaN | 0 | NaN |
| 18-24 years | 0 | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | NaN | 0 | NaN |
| 25-40 years | 0 | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | NaN | 0 | NaN |
| 41-64 years | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | NaN | 0 | NaN |
| ≥ 65 years | ***** | ***** | ***** | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN |
| Brigatinib | 1,211 | 578 | 100.0% | 336 | 100.0% | 248 | 100.0% | 33 | 100.0% | 16 | 100.0% |
| 0-17 years | ***** | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | ***** | 0 | 0.0% | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% |
| 41-64 years | 542 | 257 | 44.5% | 142 | 42.3% | 118 | 47.6% | ***** | ***** | ***** | ***** |
| ≥ 65 years | 545 | 256 | 44.3% | 158 | 47.0% | 110 | 44.4% | ***** | ***** | ***** | ***** |

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| | Number of Treatment Episodes by Duration | | | | | | | | | | |
|-------------------------|--|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|
| | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | | |
| | Total Number of Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes |
| Brodalumab | 3,358 | 1,688 | 100.0% | 931 | 100.0% | 637 | 100.0% | 77 | 100.0% | 25 | 100.0% |
| 0-17 years | 0 | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | 55 | 30 | 1.8% | 14 | 1.5% | 11 | 1.7% | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | 537 | 323 | 19.1% | 127 | 13.6% | 76 | 11.9% | ***** | ***** | ***** | ***** |
| 41-64 years | 1,755 | 867 | 51.4% | 472 | 50.7% | 359 | 56.4% | 46 | 59.7% | 11 | 44.0% |
| ≥ 65 years | 1,011 | 468 | 27.7% | 318 | 34.2% | 191 | 30.0% | ***** | ***** | ***** | ***** |
| Cerliponase Alfa | ***** | ***** | ***** | 0 | NaN | ***** | ***** | 0 | NaN | 0 | NaN |
| 0-17 years | ***** | ***** | ***** | 0 | NaN | ***** | ***** | 0 | NaN | 0 | NaN |
| 18-24 years | 0 | 0 | 0.0% | 0 | NaN | 0 | 0.0% | 0 | NaN | 0 | NaN |
| 25-40 years | 0 | 0 | 0.0% | 0 | NaN | 0 | 0.0% | 0 | NaN | 0 | NaN |
| 41-64 years | 0 | 0 | 0.0% | 0 | NaN | 0 | 0.0% | 0 | NaN | 0 | NaN |
| ≥ 65 years | 0 | 0 | 0.0% | 0 | NaN | 0 | 0.0% | 0 | NaN | 0 | NaN |
| Deflazacort | 3,619 | 1,772 | 100.0% | 847 | 100.0% | 724 | 100.0% | 186 | 100.0% | 90 | 100.0% |
| 0-17 years | 2,731 | 1,332 | 75.2% | 645 | 76.2% | 551 | 76.1% | 141 | 75.8% | 62 | 68.9% |
| 18-24 years | 589 | 301 | 17.0% | 131 | 15.5% | 115 | 15.9% | 30 | 16.1% | 12 | 13.3% |
| 25-40 years | 284 | ***** | 7.4% | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** |
| 41-64 years | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% |
| ≥ 65 years | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | ***** | ***** |
| Delafloxacin | 4,097 | 3,942 | 100.0% | 133 | 100.0% | ***** | 100.0% | ***** | ***** | ***** | ***** |
| 0-17 years | 22 | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | 47 | ***** | ***** | 0 | 0.0% | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | 366 | 352 | 8.9% | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| 41-64 years | 1,830 | 1,763 | 44.7% | 59 | 44.4% | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| ≥ 65 years | 1,832 | 1,760 | 44.6% | 61 | 45.9% | ***** | ***** | ***** | ***** | ***** | ***** |

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| | Number of Treatment Episodes by Duration | | | | | | | | | | |
|-------------------------|--|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|
| | 1-30 Days | | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
| | Total Number of Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes |
| Deutetrabenazine | 46,882 | 22,902 | 100.0% | 11,286 | 100.0% | 9,028 | 100.0% | 2,294 | 100.0% | 1,372 | 100.0% |
| 0-17 years | 50 | 27 | 0.1% | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | 410 | 205 | 0.9% | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** |
| 25-40 years | 4,107 | 2,053 | 9.0% | 977 | 8.7% | 751 | 8.3% | ***** | ***** | ***** | ***** |
| 41-64 years | 23,401 | 11,256 | 49.1% | 5,698 | 50.5% | 4,601 | 51.0% | 1,140 | 49.7% | 706 | 51.5% |
| ≥ 65 years | 18,914 | 9,361 | 40.9% | 4,498 | 39.9% | 3,587 | 39.7% | 927 | 40.4% | 541 | 39.4% |
| Dupilumab | 312,719 | 169,125 | 100.0% | 75,374 | 100.0% | 55,838 | 100.0% | 8,965 | 100.0% | 3,417 | 100.0% |
| 0-17 years | 27,811 | 16,028 | 9.5% | 6,666 | 8.8% | 4,254 | 7.6% | 646 | 7.2% | 217 | 6.4% |
| 18-24 years | 32,069 | 18,872 | 11.2% | 7,562 | 10.0% | 4,826 | 8.6% | 593 | 6.6% | 216 | 6.3% |
| 25-40 years | 60,878 | 34,027 | 20.1% | 14,752 | 19.6% | 10,108 | 18.1% | 1,445 | 16.1% | 546 | 16.0% |
| 41-64 years | 123,372 | 65,407 | 38.7% | 29,513 | 39.2% | 22,921 | 41.0% | 3,930 | 43.8% | 1,601 | 46.9% |
| ≥ 65 years | 68,589 | 34,791 | 20.6% | 16,881 | 22.4% | 13,729 | 24.6% | 2,351 | 26.2% | 837 | 24.5% |
| Durvalumab | 285,274 | 284,982 | 100.0% | 155 | 100.0% | 108 | 100.0% | ***** | ***** | ***** | 100.0% |
| 0-17 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 41-64 years | 49,384 | 49,309 | 17.3% | 38 | 24.5% | 32 | 29.6% | ***** | ***** | ***** | ***** |
| ≥ 65 years | 235,622 | 235,405 | 82.6% | 117 | 75.5% | 76 | 70.4% | ***** | ***** | ***** | ***** |
| Edaravone | 28,577 | 26,945 | 100.0% | 720 | 100.0% | 735 | 100.0% | 137 | 100.0% | 40 | 100.0% |
| 0-17 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | 920 | 816 | 3.0% | 48 | 6.7% | ***** | ***** | ***** | ***** | ***** | ***** |
| 41-64 years | 10,754 | 10,138 | 37.6% | 270 | 37.5% | ***** | ***** | ***** | ***** | ***** | ***** |
| ≥ 65 years | 16,889 | 15,977 | 59.3% | 402 | 55.8% | 405 | 55.1% | 81 | 59.1% | 24 | 60.0% |

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| | Number of Treatment Episodes by Duration | | | | | | | | | | |
|----------------------|--|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|
| | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | | |
| | Total Number of Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes |
| Etelcalcetide | 8,510,448 | 8,510,437 | 100.0% | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN |
| 0-17 years | 1,534 | 1,534 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | NaN | 0 | NaN |
| 18-24 years | 63,750 | 63,750 | 0.7% | 0 | 0.0% | 0 | 0.0% | 0 | NaN | 0 | NaN |
| 25-40 years | 942,069 | 942,065 | 11.1% | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN |
| 41-64 years | 4,475,392 | 4,475,386 | 52.6% | ***** | ***** | 0 | 0.0% | 0 | NaN | 0 | NaN |
| ≥ 65 years | 3,027,703 | 3,027,702 | 35.6% | ***** | ***** | 0 | 0.0% | 0 | NaN | 0 | NaN |
| Midostaurin | 4,736 | 3,495 | 100.0% | 831 | 100.0% | 372 | 100.0% | 26 | 100.0% | 12 | 100.0% |
| 0-17 years | 40 | 31 | 0.9% | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | 103 | 83 | 2.4% | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% |
| 25-40 years | 415 | 293 | 8.4% | 80 | 9.6% | ***** | ***** | ***** | ***** | ***** | ***** |
| 41-64 years | 1,991 | 1,467 | 42.0% | 363 | 43.7% | 148 | 39.8% | ***** | ***** | ***** | ***** |
| ≥ 65 years | 2,187 | 1,621 | 46.4% | 368 | 44.3% | 180 | 48.4% | ***** | ***** | ***** | ***** |
| Naldemedine | 39,747 | 26,041 | 100.0% | 8,869 | 100.0% | 4,181 | 100.0% | 510 | 100.0% | 146 | 100.0% |
| 0-17 years | 11 | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | 82 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | ***** | ***** |
| 25-40 years | 2,496 | 1,639 | 6.3% | 579 | 6.5% | ***** | ***** | ***** | ***** | ***** | ***** |
| 41-64 years | 20,532 | 13,142 | 50.5% | 4,662 | 52.6% | 2,324 | 55.6% | 311 | 61.0% | 93 | 63.7% |
| ≥ 65 years | 16,626 | 11,193 | 43.0% | 3,608 | 40.7% | 1,606 | 38.4% | ***** | ***** | ***** | ***** |
| Niraparib | 15,712 | 9,490 | 100.0% | 4,014 | 100.0% | 1,942 | 100.0% | 218 | 100.0% | 48 | 100.0% |
| 0-17 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | 220 | 136 | 1.4% | 57 | 1.4% | 27 | 1.4% | 0 | 0.0% | 0 | 0.0% |
| 41-64 years | 5,079 | 2,945 | 31.0% | 1,343 | 33.5% | 664 | 34.2% | 101 | 46.3% | 26 | 54.2% |
| ≥ 65 years | 10,401 | 6,397 | 67.4% | 2,614 | 65.1% | 1,251 | 64.4% | 117 | 53.7% | 22 | 45.8% |

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| | Number of Treatment Episodes by Duration | | | | | | | | | | |
|--------------------|--|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|
| | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | | |
| | Total Number of Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes |
| Ocrelizumab | 165,673 | 160,923 | 100.0% | 1,397 | 100.0% | 3,169 | 100.0% | 159 | 100.0% | 25 | 100.0% |
| 0-17 years | 163 | 163 | 0.1% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | 2,406 | 2,358 | 1.5% | 23 | 1.6% | 25 | 0.8% | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | 37,619 | 36,581 | 22.7% | 299 | 21.4% | 700 | 22.1% | ***** | ***** | ***** | ***** |
| 41-64 years | 92,936 | 89,881 | 55.9% | 912 | 65.3% | 2,028 | 64.0% | ***** | ***** | ***** | ***** |
| ≥ 65 years | 32,549 | 31,940 | 19.8% | 163 | 11.7% | 416 | 13.1% | ***** | ***** | ***** | ***** |
| Plecanatide | 159,824 | 91,944 | 100.0% | 44,204 | 100.0% | 20,079 | 100.0% | 2,754 | 100.0% | 843 | 100.0% |
| 0-17 years | 336 | 226 | 0.2% | 72 | 0.2% | 33 | 0.2% | ***** | ***** | ***** | ***** |
| 18-24 years | 5,188 | 3,261 | 3.5% | 1,297 | 2.9% | 538 | 2.7% | ***** | ***** | ***** | ***** |
| 25-40 years | 20,072 | 12,302 | 13.4% | 5,263 | 11.9% | 2,141 | 10.7% | 280 | 10.2% | 86 | 10.2% |
| 41-64 years | 68,340 | 38,630 | 42.0% | 19,452 | 44.0% | 8,715 | 43.4% | 1,168 | 42.4% | 375 | 44.5% |
| ≥ 65 years | 65,888 | 37,525 | 40.8% | 18,120 | 41.0% | 8,652 | 43.1% | 1,233 | 44.8% | 358 | 42.5% |
| Ribociclib | 14,484 | 8,572 | 100.0% | 3,468 | 100.0% | 2,116 | 100.0% | 263 | 100.0% | 65 | 100.0% |
| 0-17 years | 36 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | 13 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | 503 | 289 | 3.4% | 136 | 3.9% | ***** | ***** | ***** | ***** | ***** | ***** |
| 41-64 years | 4,312 | 2,526 | 29.5% | 1,052 | 30.3% | 630 | 29.8% | ***** | ***** | ***** | ***** |
| ≥ 65 years | 9,620 | 5,727 | 66.8% | 2,268 | 65.4% | 1,412 | 66.7% | 178 | 67.7% | 35 | 53.8% |
| Safinamide | 7,891 | 3,432 | 100.0% | 2,294 | 100.0% | 1,608 | 100.0% | 347 | 100.0% | 210 | 100.0% |
| 0-17 years | 0 | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | 0 | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | 31 | 14 | 0.4% | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** |
| 41-64 years | 1,114 | 495 | 14.4% | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** |
| ≥ 65 years | 6,746 | 2,923 | 85.2% | 1,959 | 85.4% | 1,381 | 85.9% | 298 | 85.9% | 185 | 88.1% |

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| | Number of Treatment Episodes by Duration | | | | | | | | | | |
|--------------------------|--|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|
| | Total Number of Episodes | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
| | | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes |
| Sarilumab | 21,098 | 11,873 | 100.0% | 5,294 | 100.0% | 3,449 | 100.0% | 361 | 100.0% | 121 | 100.0% |
| 0-17 years | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | ***** | ***** | ***** | ***** | ***** | 18 | 0.5% | ***** | ***** | ***** | ***** |
| 25-40 years | 1,980 | 1,131 | 9.5% | 510 | 9.6% | 304 | 8.8% | ***** | ***** | ***** | ***** |
| 41-64 years | 12,350 | 6,676 | 56.2% | 3,304 | 62.4% | 2,069 | 60.0% | 219 | 60.7% | 82 | 67.8% |
| ≥ 65 years | 6,604 | 3,955 | 33.3% | 1,450 | 27.4% | 1,058 | 30.7% | 113 | 31.3% | 28 | 23.1% |
| Telotristat Ethyl | 3,774 | 2,322 | 100.0% | 906 | 100.0% | 502 | 100.0% | 32 | 100.0% | 12 | 100.0% |
| 0-17 years | ***** | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | ***** | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | 142 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | ***** | ***** |
| 41-64 years | 1,358 | 828 | 35.7% | 326 | 36.0% | 184 | 36.7% | ***** | ***** | ***** | ***** |
| ≥ 65 years | 2,263 | 1,392 | 59.9% | 542 | 59.8% | 306 | 61.0% | ***** | ***** | ***** | ***** |
| Valbenazine | 74,593 | 34,189 | 100.0% | 19,916 | 100.0% | 15,775 | 100.0% | 3,138 | 100.0% | 1,575 | 100.0% |
| 0-17 years | 38 | 20 | 0.1% | 12 | 0.1% | ***** | ***** | ***** | ***** | 0 | 0.0% |
| 18-24 years | 672 | 364 | 1.1% | 183 | 0.9% | ***** | ***** | ***** | ***** | ***** | ***** |
| 25-40 years | 6,149 | 2,873 | 8.4% | 1,633 | 8.2% | 1,300 | 8.2% | ***** | ***** | ***** | ***** |
| 41-64 years | 41,050 | 18,833 | 55.1% | 10,964 | 55.1% | 8,655 | 54.9% | 1,695 | 54.0% | 903 | 57.3% |
| ≥ 65 years | 26,684 | 12,099 | 35.4% | 7,124 | 35.8% | 5,717 | 36.2% | 1,200 | 38.2% | 544 | 34.5% |

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| Distribution of Treatment Episode Durations, Days | | | | | | | | |
|---|--------------------------|----------|-----------|-----------|-----------|--------------|-------------|--------------------|
| | Total Number of Episodes | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Abaloparatide | 71,072 | 1 | 30 | 30 | 90 | 1,470 | 77.4 | 103.1 |
| 0-17 years | ***** | 18 | 18 | 24 | 30 | 30 | 24.0 | 8.5 |
| 18-24 years | ***** | 11 | 30 | 30 | 60 | 300 | 66.5 | 68.6 |
| 25-40 years | 407 | 1 | 30 | 30 | 67 | 800 | 78.0 | 115.5 |
| 41-64 years | 18,846 | 1 | 30 | 30 | 90 | 1,470 | 79.9 | 117.3 |
| ≥ 65 years | 51,796 | 1 | 30 | 30 | 90 | 1,440 | 76.5 | 97.4 |
| Avelumab | 36,616 | 1 | 1 | 1 | 1 | 308 | 1.1 | 3.0 |
| 0-17 years | ***** | 1 | 1 | 1 | 1 | 1 | 1.0 | 0.0 |
| 18-24 years | ***** | 1 | 1 | 1 | 1 | 1 | 1.0 | 0.0 |
| 25-40 years | 89 | 1 | 1 | 1 | 1 | 1 | 1.0 | 0.0 |
| 41-64 years | 3,258 | 1 | 1 | 1 | 1 | 56 | 1.1 | 1.6 |
| ≥ 65 years | 33,237 | 1 | 1 | 1 | 1 | 308 | 1.1 | 3.1 |
| Betrixaban | 30 | 3 | 14 | 30 | 42 | 330 | 40.4 | 57.8 |
| 0-17 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 18-24 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 25-40 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 41-64 years | ***** | 17 | 30 | 30 | 60 | 90 | 41.1 | 22.0 |
| ≥ 65 years | ***** | 3 | 14 | 28 | 36 | 330 | 40.0 | 69.7 |
| Brigatinib | 1,211 | 1 | 30 | 45 | 90 | 1,809 | 97.3 | 156.1 |
| 0-17 years | ***** | 1 | 14 | 30 | 99 | 318 | 75.5 | 110.0 |
| 18-24 years | ***** | 60 | 60 | 60 | 60 | 60 | 60.0 | 0.0 |
| 25-40 years | ***** | 6 | 30 | 30 | 90 | 518 | 76.8 | 90.3 |
| 41-64 years | 542 | 1 | 30 | 46 | 113 | 1,809 | 103.1 | 177.5 |
| ≥ 65 years | 545 | 4 | 30 | 48 | 90 | 1,414 | 96.2 | 144.5 |

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| Distribution of Treatment Episode Durations, Days | | | | | | | | |
|---|--------------------------|----------|-----------|-----------|------------|--------------|--------------|--------------------|
| | Total Number of Episodes | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Brodalumab | 3,358 | 1 | 28 | 30 | 84 | 1,670 | 82.1 | 123.5 |
| 0-17 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 18-24 years | 55 | 1 | 28 | 28 | 56 | 251 | 62.6 | 63.3 |
| 25-40 years | 537 | 1 | 28 | 28 | 56 | 1,386 | 67.1 | 108.7 |
| 41-64 years | 1,755 | 1 | 28 | 35 | 84 | 1,466 | 84.5 | 125.4 |
| ≥ 65 years | 1,011 | 1 | 28 | 56 | 84 | 1,670 | 87.0 | 129.3 |
| Cerliponase Alfa | 532 | 1 | 1 | 1 | 1 | 98 | 1.2 | 4.4 |
| 0-17 years | 532 | 1 | 1 | 1 | 1 | 98 | 1.2 | 4.4 |
| 18-24 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 25-40 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 41-64 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| ≥ 65 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| Deflazacort | 3,619 | 1 | 30 | 34 | 120 | 1,837 | 122.7 | 215.9 |
| 0-17 years | 2,731 | 1 | 30 | 34 | 120 | 1,837 | 120.4 | 211.9 |
| 18-24 years | 589 | 1 | 30 | 30 | 120 | 1,750 | 115.5 | 187.8 |
| 25-40 years | 284 | 4 | 30 | 52 | 120 | 1,814 | 157.0 | 288.3 |
| 41-64 years | ***** | 30 | 30 | 120 | 240 | 465 | 167.5 | 166.1 |
| ≥ 65 years | ***** | 24 | 30 | 30 | 60 | 1,227 | 175.0 | 395.1 |
| Delafloxacin | 4,097 | 1 | 10 | 10 | 14 | 870 | 14.8 | 21.0 |
| 0-17 years | 22 | 4 | 10 | 12 | 14 | 40 | 12.5 | 6.9 |
| 18-24 years | 47 | 5 | 10 | 14 | 14 | 180 | 17.5 | 25.0 |
| 25-40 years | 366 | 1 | 10 | 10 | 14 | 120 | 14.6 | 12.2 |
| 41-64 years | 1,830 | 1 | 10 | 10 | 14 | 150 | 14.8 | 13.0 |
| ≥ 65 years | 1,832 | 1 | 10 | 10 | 14 | 870 | 14.8 | 27.8 |

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| Distribution of Treatment Episode Durations, Days | | | | | | | | |
|---|--------------------------|----------|-----------|-----------|------------|--------------|--------------|--------------------|
| | Total Number of Episodes | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Deutetrabenazine | 46,882 | 1 | 30 | 39 | 120 | 1,802 | 120.5 | 205.0 |
| 0-17 years | 50 | 7 | 30 | 30 | 74 | 316 | 70.5 | 71.1 |
| 18-24 years | 410 | 2 | 30 | 32 | 102 | 1,313 | 110.1 | 173.8 |
| 25-40 years | 4,107 | 1 | 30 | 31 | 111 | 1,802 | 120.1 | 206.2 |
| 41-64 years | 23,401 | 1 | 30 | 42 | 120 | 1,779 | 122.4 | 206.7 |
| ≥ 65 years | 18,914 | 1 | 30 | 35 | 112 | 1,731 | 118.6 | 203.6 |
| Dupilumab | 312,719 | 1 | 28 | 28 | 84 | 1,897 | 85.6 | 142.7 |
| 0-17 years | 27,811 | 1 | 28 | 28 | 70 | 1,717 | 74.9 | 123.9 |
| 18-24 years | 32,069 | 1 | 28 | 28 | 69 | 1,790 | 71.4 | 118.8 |
| 25-40 years | 60,878 | 1 | 28 | 28 | 84 | 1,817 | 79.4 | 135.1 |
| 41-64 years | 123,372 | 1 | 28 | 28 | 84 | 1,885 | 90.6 | 151.5 |
| ≥ 65 years | 68,589 | 1 | 28 | 30 | 85 | 1,897 | 93.1 | 149.3 |
| Durvalumab | 285,274 | 1 | 1 | 1 | 1 | 1,074 | 1.2 | 7.7 |
| 0-17 years | ***** | 1 | 1 | 1 | 1 | 1 | 1.0 | NaN |
| 18-24 years | ***** | 1 | 1 | 1 | 2 | 3 | 1.4 | 0.7 |
| 25-40 years | ***** | 1 | 1 | 1 | 1 | 14 | 1.1 | 0.8 |
| 41-64 years | 49,384 | 1 | 1 | 1 | 1 | 840 | 1.3 | 8.2 |
| ≥ 65 years | 235,622 | 1 | 1 | 1 | 1 | 1,074 | 1.2 | 7.6 |
| Edaravone | 28,577 | 1 | 3 | 5 | 10 | 1,613 | 15.7 | 60.2 |
| 0-17 years | ***** | 28 | 28 | 28 | 28 | 28 | 28.0 | NaN |
| 18-24 years | ***** | 1 | 1 | 1 | 3 | 14 | 2.9 | 3.7 |
| 25-40 years | 920 | 1 | 3 | 5 | 14 | 840 | 25.9 | 74.0 |
| 41-64 years | 10,754 | 1 | 1 | 5 | 10 | 1,568 | 15.5 | 60.0 |
| ≥ 65 years | 16,889 | 1 | 4 | 5 | 6 | 1,613 | 15.3 | 59.5 |

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| Distribution of Treatment Episode Durations, Days | | | | | | | | | |
|---|--------------------------|----------|-----------|-----------|-----------|--------------|-------------|--------------------|--|
| | Total Number of Episodes | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation | |
| Etelcalcetide | 8,510,448 | 1 | 1 | 1 | 1 | 117 | 1.0 | 0.1 | |
| 0-17 years | 1,534 | 1 | 1 | 1 | 1 | 3 | 1.0 | 0.1 | |
| 18-24 years | 63,750 | 1 | 1 | 1 | 1 | 3 | 1.0 | 0.1 | |
| 25-40 years | 942,069 | 1 | 1 | 1 | 1 | 117 | 1.0 | 0.2 | |
| 41-64 years | 4,475,392 | 1 | 1 | 1 | 1 | 90 | 1.0 | 0.1 | |
| ≥ 65 years | 3,027,703 | 1 | 1 | 1 | 1 | 58 | 1.0 | 0.1 | |
| Midostaurin | 4,736 | 1 | 21 | 28 | 42 | 1,593 | 46.1 | 83.4 | |
| 0-17 years | 40 | 7 | 27 | 28 | 30 | 265 | 47.1 | 55.8 | |
| 18-24 years | 103 | 2 | 14 | 28 | 28 | 638 | 37.9 | 70.4 | |
| 25-40 years | 415 | 1 | 21 | 28 | 56 | 1,109 | 51.2 | 92.3 | |
| 41-64 years | 1,991 | 1 | 21 | 28 | 42 | 1,036 | 43.6 | 66.2 | |
| ≥ 65 years | 2,187 | 1 | 15 | 28 | 42 | 1,593 | 47.8 | 95.7 | |
| Naldemedine | 39,747 | 1 | 30 | 30 | 60 | 1,630 | 63.1 | 92.0 | |
| 0-17 years | 11 | 30 | 30 | 30 | 30 | 90 | 38.2 | 19.4 | |
| 18-24 years | 82 | 2 | 30 | 30 | 60 | 757 | 56.9 | 92.6 | |
| 25-40 years | 2,496 | 1 | 30 | 30 | 60 | 1,128 | 60.2 | 81.3 | |
| 41-64 years | 20,532 | 1 | 30 | 30 | 60 | 1,630 | 66.5 | 98.6 | |
| ≥ 65 years | 16,626 | 1 | 30 | 30 | 60 | 1,516 | 59.4 | 84.6 | |
| Niraparib | 15,712 | 1 | 30 | 30 | 60 | 1,648 | 66.2 | 92.3 | |
| 0-17 years | ***** | 28 | 28 | 28 | 28 | 28 | 28.0 | 0.0 | |
| 18-24 years | ***** | 28 | 30 | 30 | 30 | 30 | 29.8 | 0.6 | |
| 25-40 years | 220 | 6 | 30 | 30 | 60 | 330 | 56.8 | 57.3 | |
| 41-64 years | 5,079 | 1 | 30 | 30 | 60 | 1,577 | 72.7 | 108.6 | |
| ≥ 65 years | 10,401 | 1 | 30 | 30 | 60 | 1,648 | 63.3 | 83.7 | |

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| Distribution of Treatment Episode Durations, Days | | | | | | | | | |
|---|--------------------------|----------|-----------|-----------|------------|--------------|--------------|--------------------|--|
| | Total Number of Episodes | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation | |
| Ocrelizumab | 165,673 | 1 | 1 | 1 | 1 | 1,616 | 6.3 | 35.4 | |
| 0-17 years | 163 | 1 | 1 | 1 | 1 | 15 | 1.1 | 1.1 | |
| 18-24 years | 2,406 | 1 | 1 | 1 | 1 | 360 | 4.0 | 21.0 | |
| 25-40 years | 37,619 | 1 | 1 | 1 | 1 | 1,178 | 6.1 | 33.7 | |
| 41-64 years | 92,936 | 1 | 1 | 1 | 1 | 1,616 | 7.1 | 38.1 | |
| ≥ 65 years | 32,549 | 1 | 1 | 1 | 1 | 1,040 | 4.7 | 29.7 | |
| Plecanatide | 159,824 | 1 | 30 | 30 | 90 | 1,912 | 74.7 | 107.3 | |
| 0-17 years | 336 | 3 | 30 | 30 | 60 | 897 | 58.8 | 79.4 | |
| 18-24 years | 5,188 | 1 | 30 | 30 | 78 | 1,423 | 67.4 | 99.3 | |
| 25-40 years | 20,072 | 1 | 30 | 30 | 89 | 1,792 | 67.7 | 97.2 | |
| 41-64 years | 68,340 | 1 | 30 | 30 | 90 | 1,912 | 75.6 | 109.3 | |
| ≥ 65 years | 65,888 | 1 | 30 | 30 | 90 | 1,864 | 76.6 | 108.8 | |
| Ribociclib | 14,484 | 1 | 28 | 28 | 56 | 1,635 | 69.0 | 105.7 | |
| 0-17 years | 36 | 14 | 28 | 28 | 56 | 196 | 48.6 | 40.0 | |
| 18-24 years | 13 | 4 | 21 | 21 | 56 | 149 | 41.4 | 43.0 | |
| 25-40 years | 503 | 1 | 28 | 28 | 56 | 1,079 | 68.2 | 100.7 | |
| 41-64 years | 4,312 | 1 | 28 | 28 | 62 | 1,635 | 71.2 | 119.0 | |
| ≥ 65 years | 9,620 | 1 | 28 | 28 | 56 | 1,387 | 68.1 | 99.6 | |
| Safinamide | 7,891 | 1 | 30 | 60 | 120 | 1,798 | 125.1 | 199.2 | |
| 0-17 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN | |
| 18-24 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN | |
| 25-40 years | 31 | 14 | 30 | 53 | 90 | 854 | 114.5 | 185.5 | |
| 41-64 years | 1,114 | 1 | 30 | 60 | 120 | 1,724 | 117.6 | 187.0 | |
| ≥ 65 years | 6,746 | 1 | 30 | 60 | 120 | 1,798 | 126.3 | 201.2 | |

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| Distribution of Treatment Episode Durations, Days | | | | | | | | |
|---|--------------------------|----------|-----------|-----------|------------|--------------|--------------|--------------------|
| | Total Number of Episodes | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Sarilumab | 21,098 | 1 | 28 | 28 | 84 | 1,757 | 72.1 | 112.7 |
| 0-17 years | ***** | 1 | 1 | 1 | 28 | 56 | 13.8 | 21.7 |
| 18-24 years | ***** | 1 | 28 | 28 | 56 | 890 | 70.6 | 111.9 |
| 25-40 years | 1,980 | 1 | 28 | 28 | 84 | 1,540 | 70.6 | 107.5 |
| 41-64 years | 12,350 | 1 | 28 | 28 | 84 | 1,757 | 75.9 | 116.0 |
| ≥ 65 years | 6,604 | 1 | 21 | 28 | 84 | 1,575 | 65.6 | 107.7 |
| Telotristat Ethyl | 3,774 | 2 | 28 | 28 | 56 | 1,725 | 60.9 | 83.3 |
| 0-17 years | ***** | 28 | 28 | 28 | 84 | 280 | 74.7 | 82.8 |
| 18-24 years | ***** | 28 | 28 | 42 | 56 | 56 | 42.0 | 19.8 |
| 25-40 years | 142 | 13 | 28 | 28 | 56 | 1,008 | 51.1 | 90.0 |
| 41-64 years | 1,358 | 3 | 28 | 28 | 56 | 1,725 | 63.2 | 96.6 |
| ≥ 65 years | 2,263 | 2 | 28 | 28 | 56 | 1,176 | 60.1 | 73.8 |
| Valbenazine | 74,593 | 1 | 30 | 60 | 120 | 1,841 | 113.8 | 179.4 |
| 0-17 years | 38 | 4 | 30 | 30 | 60 | 450 | 74.9 | 93.4 |
| 18-24 years | 672 | 1 | 30 | 30 | 90 | 1,334 | 89.5 | 149.6 |
| 25-40 years | 6,149 | 1 | 30 | 55 | 118 | 1,757 | 109.5 | 176.5 |
| 41-64 years | 41,050 | 1 | 30 | 60 | 120 | 1,831 | 114.0 | 180.1 |
| ≥ 65 years | 26,684 | 1 | 30 | 60 | 120 | 1,841 | 115.1 | 179.8 |

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 5a. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| | Total Number of Patients | Number of Patients by First Treatment Episode Duration | | | | | | | | | |
|-------------------|--------------------------|--|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
| | | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients |
| Abaloparatide | 23,148 | 11,801 | 51.0% | 6,013 | 26.0% | 4,154 | 17.9% | 996 | 4.3% | 184 | 0.8% |
| Avelumab | 2,803 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| Betrixaban | 21 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| Brigatinib | 502 | 225 | 44.8% | 138 | 27.5% | 113 | 22.5% | ***** | ***** | ***** | ***** |
| Brodalumab | 841 | 387 | 46.0% | 212 | 25.2% | 190 | 22.6% | 35 | 4.2% | 17 | 2.0% |
| Cerliponase Alfa | 18 | ***** | ***** | 0 | 0.0% | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| Deflazacort | 1,129 | 432 | 38.3% | 253 | 22.4% | 289 | 25.6% | 109 | 9.7% | 46 | 4.1% |
| Delafloxacin | 2,996 | 2,897 | 96.7% | 85 | 2.8% | ***** | ***** | ***** | ***** | ***** | ***** |
| Deutetrabenazine | 16,357 | 7,284 | 44.5% | 3,719 | 22.7% | 3,481 | 21.3% | 1,098 | 6.7% | 775 | 4.7% |
| Dupilumab | 83,061 | 42,922 | 51.7% | 17,287 | 20.8% | 17,050 | 20.5% | 3,837 | 4.6% | 1,965 | 2.4% |
| Durvalumab | 26,005 | 25,879 | 99.5% | 49 | 0.2% | 51 | 0.2% | ***** | 0.1% | ***** | ***** |
| Edaravone | 2,163 | 1,808 | 83.6% | 148 | 6.8% | 156 | 7.2% | 38 | 1.8% | 13 | 0.6% |
| Etelcalcetide | 53,102 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| Midostaurin | 1,841 | 1,374 | 74.6% | 323 | 17.5% | 133 | 7.2% | ***** | ***** | ***** | ***** |
| Naldemedine | 13,921 | 9,503 | 68.3% | 2,724 | 19.6% | 1,400 | 10.1% | 219 | 1.6% | 75 | 0.5% |
| Niraparib | 6,415 | 4,028 | 62.8% | 1,608 | 25.1% | 669 | 10.4% | 90 | 1.4% | 20 | 0.3% |
| Ocrelizumab | 43,156 | 41,799 | 96.9% | 425 | 1.0% | 885 | 2.1% | ***** | ***** | ***** | ***** |
| Plecanatide | 66,616 | 38,272 | 57.5% | 18,076 | 27.1% | 8,480 | 12.7% | 1,344 | 2.0% | 444 | 0.7% |
| Ribociclib | 4,213 | 2,398 | 56.9% | 1,014 | 24.1% | 674 | 16.0% | 90 | 2.1% | 37 | 0.9% |
| Safinamide | 2,319 | 1,080 | 46.6% | 611 | 26.3% | 437 | 18.8% | 114 | 4.9% | 77 | 3.3% |
| Sarilumab | 8,534 | 4,907 | 57.5% | 1,864 | 21.8% | 1,492 | 17.5% | 198 | 2.3% | 73 | 0.9% |
| Telotristat Ethyl | 1,061 | 585 | 55.1% | 274 | 25.8% | 187 | 17.6% | ***** | ***** | ***** | ***** |
| Valbenazine | 26,601 | 11,713 | 44.0% | 6,817 | 25.6% | 5,905 | 22.2% | 1,372 | 5.2% | 794 | 3.0% |

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 5b. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Distribution of First Treatment Episode Duration, Days | | | | | | | | |
|--|--------------------------|---------|----|--------|-----|---------|-------|--------------------|
| | Total Number of Patients | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Abaloparatide | 23,148 | 1 | 30 | 30 | 90 | 1,470 | 97.9 | 138.4 |
| Avelumab | 2,803 | 1 | 1 | 1 | 1 | 112 | 1.3 | 4.2 |
| Betrixaban | 21 | 7 | 17 | 30 | 30 | 330 | 43.8 | 67.9 |
| Brigatinib | 502 | 1 | 30 | 49 | 119 | 1,809 | 109.4 | 187.9 |
| Brodalumab | 841 | 1 | 15 | 42 | 107 | 1,670 | 106.2 | 183.8 |
| Cerliponase Alfa | 18 | 1 | 1 | 1 | 1 | 98 | 6.4 | 22.9 |
| Deflazacort | 1,129 | 1 | 30 | 60 | 201 | 1,837 | 173.4 | 273.0 |
| Delafloxacin | 2,996 | 1 | 10 | 10 | 14 | 870 | 14.3 | 22.4 |
| Deutetrabenazine | 16,357 | 1 | 30 | 58 | 150 | 1,779 | 151.6 | 247.4 |
| Dupilumab | 83,061 | 1 | 14 | 28 | 102 | 1,897 | 107.7 | 194.6 |
| Durvalumab | 26,005 | 1 | 1 | 1 | 1 | 1,074 | 2.3 | 23.3 |
| Edaravone | 2,163 | 1 | 5 | 14 | 28 | 1,613 | 42.1 | 116.2 |
| Etelcalcetide | 53,102 | 1 | 1 | 1 | 1 | 117 | 1.0 | 0.8 |
| Midostaurin | 1,841 | 1 | 14 | 28 | 35 | 1,109 | 41.6 | 64.4 |
| Naldemedine | 13,921 | 1 | 30 | 30 | 60 | 1,630 | 64.9 | 104.1 |
| Niraparib | 6,415 | 1 | 30 | 30 | 60 | 1,577 | 62.8 | 91.4 |
| Ocrelizumab | 43,156 | 1 | 1 | 1 | 1 | 1,292 | 6.9 | 36.0 |
| Plecanatide | 66,616 | 1 | 30 | 30 | 90 | 1,912 | 78.1 | 116.4 |
| Ribociclib | 4,213 | 1 | 28 | 28 | 84 | 1,635 | 78.4 | 129.2 |
| Safinamide | 2,319 | 1 | 30 | 60 | 120 | 1,798 | 132.5 | 224.1 |
| Sarilumab | 8,534 | 1 | 2 | 28 | 84 | 1,757 | 75.4 | 134.0 |
| Telotristat Ethyl | 1,061 | 2 | 28 | 28 | 84 | 1,725 | 69.0 | 98.0 |
| Valbenazine | 26,601 | 1 | 30 | 60 | 120 | 1,841 | 128.3 | 206.0 |

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Sex

| | Number of Patients by First Treatment Episode Duration | | | | | | | | | | |
|-------------------------|--|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|
| | Total Number of Patients | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
| | | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients |
| Abaloparatide | 23,148 | 11,801 | 100.0% | 6,013 | 100.0% | 4,154 | 100.0% | 996 | 100.0% | 184 | 100.0% |
| Female | 22,565 | 11,478 | 97.3% | 5,875 | 97.7% | 4,066 | 97.9% | ***** | ***** | ***** | ***** |
| Male | 583 | 323 | 2.7% | 138 | 2.3% | 88 | 2.1% | ***** | ***** | ***** | ***** |
| Avelumab | 2,803 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN |
| Female | 739 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN |
| Male | 2,064 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN |
| Betrixaban | 21 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN |
| Female | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | NaN | 0 | NaN |
| Male | ***** | ***** | ***** | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN |
| Brigatinib | 502 | 225 | 100.0% | 138 | 100.0% | 113 | 100.0% | ***** | ***** | ***** | ***** |
| Female | 292 | 130 | 57.8% | 75 | 54.3% | 73 | 64.6% | ***** | ***** | ***** | ***** |
| Male | 210 | 95 | 42.2% | 63 | 45.7% | 40 | 35.4% | ***** | ***** | ***** | ***** |
| Brodalumab | 841 | 387 | 100.0% | 212 | 100.0% | 190 | 100.0% | ***** | ***** | ***** | ***** |
| Female | 397 | 189 | 48.8% | 105 | 49.5% | 84 | 44.2% | ***** | ***** | ***** | ***** |
| Male | 444 | 198 | 51.2% | 107 | 50.5% | 106 | 55.8% | ***** | ***** | ***** | ***** |
| Cerliponase Alfa | 18 | ***** | ***** | 0 | NaN | ***** | ***** | 0 | NaN | 0 | NaN |
| Female | ***** | ***** | ***** | 0 | NaN | 0 | 0.0% | 0 | NaN | 0 | NaN |
| Male | ***** | ***** | ***** | 0 | NaN | ***** | ***** | 0 | NaN | 0 | NaN |
| Deflazacort | 1,129 | 432 | 100.0% | 253 | 100.0% | 289 | 100.0% | 109 | 100.0% | 46 | 100.0% |
| Female | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | ***** | ***** | ***** | ***** |
| Male | ***** | ***** | ***** | ***** | ***** | 289 | 100.0% | ***** | ***** | ***** | ***** |
| Delafloxacin | 2,996 | 2,897 | 100.0% | 85 | 100.0% | ***** | ***** | ***** | ***** | ***** | ***** |
| Female | 1,374 | 1,330 | 45.9% | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| Male | 1,622 | 1,567 | 54.1% | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** |

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Sex

| | Number of Patients by First Treatment Episode Duration | | | | | | | | | | |
|-------------------------|--|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
| | Total Number of Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients |
| Deutetrabenazine | 16,357 | 7,284 | 100.0% | 3,719 | 100.0% | 3,481 | 100.0% | 1,098 | 100.0% | 775 | 100.0% |
| Female | 10,101 | 4,535 | 62.3% | 2,337 | 62.8% | 2,100 | 60.3% | 667 | 60.7% | 462 | 59.6% |
| Male | 6,256 | 2,749 | 37.7% | 1,382 | 37.2% | 1,381 | 39.7% | 431 | 39.3% | 313 | 40.4% |
| Dupilumab | 83,061 | 42,922 | 100.0% | 17,287 | 100.0% | 17,050 | 100.0% | 3,837 | 100.0% | 1,965 | 100.0% |
| Female | 45,942 | 24,074 | 56.1% | 9,451 | 54.7% | 9,355 | 54.9% | 2,057 | 53.6% | 1,005 | 51.1% |
| Male | 37,119 | 18,848 | 43.9% | 7,836 | 45.3% | 7,695 | 45.1% | 1,780 | 46.4% | 960 | 48.9% |
| Durvalumab | 26,005 | 25,879 | 100.0% | 49 | 100.0% | 51 | 100.0% | ***** | ***** | ***** | ***** |
| Female | 12,431 | 12,382 | 47.8% | 21 | 42.9% | 16 | 31.4% | ***** | ***** | ***** | ***** |
| Male | 13,574 | 13,497 | 52.2% | 28 | 57.1% | 35 | 68.6% | ***** | ***** | ***** | ***** |
| Edaravone | 2,163 | 1,808 | 100.0% | 148 | 100.0% | 156 | 100.0% | 38 | 100.0% | ***** | ***** |
| Female | 977 | 821 | 45.4% | 66 | 44.6% | 65 | 41.7% | ***** | ***** | ***** | ***** |
| Male | 1,186 | 987 | 54.6% | 82 | 55.4% | 91 | 58.3% | ***** | ***** | ***** | ***** |
| Etelcalcetide | 53,102 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN |
| Female | 24,800 | ***** | ***** | 0 | 0.0% | ***** | ***** | 0 | NaN | 0 | NaN |
| Male | 28,302 | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | NaN | 0 | NaN |
| Midostaurin | 1,841 | 1,374 | 100.0% | 323 | 100.0% | 133 | 100.0% | ***** | ***** | ***** | ***** |
| Female | 948 | 716 | 52.1% | 158 | 48.9% | ***** | ***** | ***** | ***** | ***** | ***** |
| Male | 893 | 658 | 47.9% | 165 | 51.1% | ***** | ***** | ***** | ***** | ***** | ***** |
| Naldemedine | 13,921 | 9,503 | 100.0% | 2,724 | 100.0% | 1,400 | 100.0% | 219 | 100.0% | 75 | 100.0% |
| Female | 9,168 | 6,262 | 65.9% | 1,803 | 66.2% | 921 | 65.8% | 136 | 62.1% | 46 | 61.3% |
| Male | 4,753 | 3,241 | 34.1% | 921 | 33.8% | 479 | 34.2% | 83 | 37.9% | 29 | 38.7% |
| Niraparib | 6,415 | 4,028 | 100.0% | 1,608 | 100.0% | 669 | 100.0% | 90 | 100.0% | 20 | 100.0% |
| Female | 6,382 | 4,009 | 99.5% | ***** | ***** | ***** | ***** | 90 | 100.0% | 20 | 100.0% |
| Male | 33 | 19 | 0.5% | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Sex

| | Total Number of Patients | Number of Patients by First Treatment Episode Duration | | | | | | | | | |
|--------------------------|--------------------------|--|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
| | | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients |
| Ocrelizumab | 43,156 | 41,799 | 100.0% | 425 | 100.0% | 885 | 100.0% | ***** | ***** | ***** | ***** |
| Female | 29,326 | 28,405 | 68.0% | 288 | 67.8% | 601 | 67.9% | ***** | ***** | ***** | ***** |
| Male | 13,830 | 13,394 | 32.0% | 137 | 32.2% | 284 | 32.1% | ***** | ***** | ***** | ***** |
| Plecanatide | 66,616 | 38,272 | 100.0% | 18,076 | 100.0% | 8,480 | 100.0% | 1,344 | 100.0% | 444 | 100.0% |
| Female | 51,852 | 29,689 | 77.6% | 14,147 | 78.3% | 6,641 | 78.3% | 1,033 | 76.9% | 342 | 77.0% |
| Male | 14,764 | 8,583 | 22.4% | 3,929 | 21.7% | 1,839 | 21.7% | 311 | 23.1% | 102 | 23.0% |
| Ribociclib | 4,213 | 2,398 | 100.0% | 1,014 | 100.0% | 674 | 100.0% | 90 | 100.0% | 37 | 100.0% |
| Female | 4,135 | 2,360 | 98.4% | 991 | 97.7% | ***** | ***** | ***** | ***** | 37 | 100.0% |
| Male | 78 | 38 | 1.6% | 23 | 2.3% | ***** | ***** | ***** | ***** | 0 | 0.0% |
| Safinamide | 2,319 | 1,080 | 100.0% | 611 | 100.0% | 437 | 100.0% | 114 | 100.0% | 77 | 100.0% |
| Female | 968 | 441 | 40.8% | 266 | 43.5% | 180 | 41.2% | 48 | 42.1% | 33 | 42.9% |
| Male | 1,351 | 639 | 59.2% | 345 | 56.5% | 257 | 58.8% | 66 | 57.9% | 44 | 57.1% |
| Sarilumab | 8,534 | 4,907 | 100.0% | 1,864 | 100.0% | 1,492 | 100.0% | 198 | 100.0% | 73 | 100.0% |
| Female | 6,345 | 3,298 | 67.2% | 1,564 | 83.9% | 1,261 | 84.5% | 165 | 83.3% | 57 | 78.1% |
| Male | 2,189 | 1,609 | 32.8% | 300 | 16.1% | 231 | 15.5% | 33 | 16.7% | 16 | 21.9% |
| Telotristat Ethyl | 1,061 | 585 | 100.0% | 274 | 100.0% | 187 | 100.0% | ***** | ***** | ***** | ***** |
| Female | 610 | 347 | 59.3% | 153 | 55.8% | 100 | 53.5% | ***** | ***** | ***** | ***** |
| Male | 451 | 238 | 40.7% | 121 | 44.2% | 87 | 46.5% | ***** | ***** | ***** | ***** |
| Valbenazine | 26,601 | 11,713 | 100.0% | 6,817 | 100.0% | 5,905 | 100.0% | 1,372 | 100.0% | 794 | 100.0% |
| Female | 15,837 | 7,034 | 60.1% | 4,054 | 59.5% | 3,494 | 59.2% | 793 | 57.8% | 462 | 58.2% |
| Male | 10,764 | 4,679 | 39.9% | 2,763 | 40.5% | 2,411 | 40.8% | 579 | 42.2% | 332 | 41.8% |

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.
Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Sex

| | Distribution of First Treatment Episode Duration, Days | | | | | | | Standard Deviation |
|-------------------------|--|----------|-----------|-----------|------------|--------------|--------------|--------------------|
| | Total Number of Patients | Minimum | Q1 | Median | Q3 | Maximum | Mean | |
| Abaloparatide | 23,148 | 1 | 30 | 30 | 90 | 1,470 | 97.9 | 138.4 |
| Female | 22,565 | 1 | 30 | 30 | 90 | 1,470 | 98.0 | 138.3 |
| Male | 583 | 1 | 30 | 30 | 90 | 1,260 | 94.9 | 143.4 |
| Avelumab | 2,803 | 1 | 1 | 1 | 1 | 112 | 1.3 | 4.2 |
| Female | 739 | 1 | 1 | 1 | 1 | 112 | 1.5 | 5.7 |
| Male | 2,064 | 1 | 1 | 1 | 1 | 112 | 1.2 | 3.6 |
| Betrixaban | 21 | 7 | 17 | 30 | 30 | 330 | 43.8 | 67.9 |
| Female | ***** | 14 | 14 | 28 | 30 | 35 | 24.5 | 8.0 |
| Male | ***** | 7 | 29 | 30 | 60 | 330 | 65.0 | 96.1 |
| Brigatinib | 502 | 1 | 30 | 49 | 119 | 1,809 | 109.4 | 187.9 |
| Female | 292 | 4 | 30 | 52 | 120 | 1,334 | 103.3 | 154.5 |
| Male | 210 | 1 | 30 | 45 | 90 | 1,809 | 117.7 | 226.4 |
| Brodalumab | 841 | 1 | 15 | 42 | 107 | 1,670 | 106.2 | 183.8 |
| Female | 397 | 1 | 14 | 42 | 98 | 1,670 | 96.9 | 183.7 |
| Male | 444 | 1 | 21 | 42 | 116 | 1,386 | 114.5 | 183.7 |
| Cerliponase Alfa | 18 | 1 | 1 | 1 | 1 | 98 | 6.4 | 22.9 |
| Female | ***** | 1 | 1 | 1 | 1 | 1 | 1.0 | 0.0 |
| Male | ***** | 1 | 1 | 1 | 1 | 98 | 13.1 | 34.3 |
| Deflazacort | 1,129 | 1 | 30 | 60 | 201 | 1,837 | 173.4 | 273.0 |
| Female | ***** | 28 | 30 | 45 | 90 | 750 | 184.1 | 287.1 |
| Male | ***** | 1 | 30 | 60 | 204 | 1,837 | 173.3 | 273.0 |
| Delafloxacin | 2,996 | 1 | 10 | 10 | 14 | 870 | 14.3 | 22.4 |
| Female | 1,374 | 1 | 10 | 10 | 14 | 180 | 13.5 | 11.7 |
| Male | 1,622 | 1 | 10 | 10 | 14 | 870 | 14.9 | 28.4 |

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Sex

| | Distribution of First Treatment Episode Duration, Days | | | | | | | Standard Deviation |
|-------------------------|--|----------|-----------|-----------|------------|--------------|--------------|--------------------|
| | Total Number of Patients | Minimum | Q1 | Median | Q3 | Maximum | Mean | |
| Deutetrabenazine | 16,357 | 1 | 30 | 58 | 150 | 1,779 | 151.6 | 247.4 |
| Female | 10,101 | 1 | 30 | 56 | 146 | 1,732 | 148.0 | 242.8 |
| Male | 6,256 | 1 | 30 | 58 | 150 | 1,779 | 157.3 | 254.6 |
| Dupilumab | 83,061 | 1 | 14 | 28 | 102 | 1,897 | 107.7 | 194.6 |
| Female | 45,942 | 1 | 14 | 28 | 98 | 1,891 | 104.5 | 188.3 |
| Male | 37,119 | 1 | 14 | 30 | 112 | 1,897 | 111.7 | 202.1 |
| Durvalumab | 26,005 | 1 | 1 | 1 | 1 | 1,074 | 2.3 | 23.3 |
| Female | 12,431 | 1 | 1 | 1 | 1 | 1,074 | 2.0 | 22.1 |
| Male | 13,574 | 1 | 1 | 1 | 1 | 989 | 2.4 | 24.3 |
| Edaravone | 2,163 | 1 | 5 | 14 | 28 | 1,613 | 42.1 | 116.2 |
| Female | 977 | 1 | 5 | 14 | 28 | 1,568 | 42.4 | 115.3 |
| Male | 1,186 | 1 | 5 | 14 | 28 | 1,613 | 41.8 | 117.0 |
| Etelcalcetide | 53,102 | 1 | 1 | 1 | 1 | 117 | 1.0 | 0.8 |
| Female | 24,800 | 1 | 1 | 1 | 1 | 117 | 1.0 | 0.8 |
| Male | 28,302 | 1 | 1 | 1 | 1 | 90 | 1.0 | 0.8 |
| Midostaurin | 1,841 | 1 | 14 | 28 | 35 | 1,109 | 41.6 | 64.4 |
| Female | 948 | 1 | 14 | 28 | 30 | 1,109 | 41.5 | 68.0 |
| Male | 893 | 1 | 14 | 28 | 42 | 1,036 | 41.7 | 60.5 |
| Naldemedine | 13,921 | 1 | 30 | 30 | 60 | 1,630 | 64.9 | 104.1 |
| Female | 9,168 | 1 | 30 | 30 | 60 | 1,630 | 64.1 | 101.9 |
| Male | 4,753 | 1 | 30 | 30 | 60 | 1,386 | 66.5 | 108.2 |
| Niraparib | 6,415 | 1 | 30 | 30 | 60 | 1,577 | 62.8 | 91.4 |
| Female | 6,382 | 1 | 30 | 30 | 60 | 1,577 | 62.8 | 91.5 |
| Male | 33 | 3 | 30 | 30 | 58 | 300 | 54.2 | 65.2 |

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Sex

| | Distribution of First Treatment Episode Duration, Days | | | | | | | Standard Deviation |
|--------------------------|--|----------|-----------|-----------|------------|--------------|--------------|--------------------|
| | Total Number of Patients | Minimum | Q1 | Median | Q3 | Maximum | Mean | |
| Ocrelizumab | 43,156 | 1 | 1 | 1 | 1 | 1,292 | 6.9 | 36.0 |
| Female | 29,326 | 1 | 1 | 1 | 1 | 1,292 | 6.9 | 35.8 |
| Male | 13,830 | 1 | 1 | 1 | 1 | 1,040 | 6.9 | 36.5 |
| Plecanatide | 66,616 | 1 | 30 | 30 | 90 | 1,912 | 78.1 | 116.4 |
| Female | 51,852 | 1 | 30 | 30 | 90 | 1,912 | 78.1 | 116.3 |
| Male | 14,764 | 1 | 30 | 30 | 90 | 1,567 | 78.1 | 116.8 |
| Ribociclib | 4,213 | 1 | 28 | 28 | 84 | 1,635 | 78.4 | 129.2 |
| Female | 4,135 | 1 | 28 | 28 | 84 | 1,635 | 78.5 | 129.7 |
| Male | 78 | 2 | 28 | 42 | 84 | 672 | 73.2 | 95.0 |
| Safinamide | 2,319 | 1 | 30 | 60 | 120 | 1,798 | 132.5 | 224.1 |
| Female | 968 | 1 | 30 | 60 | 120 | 1,798 | 134.8 | 232.3 |
| Male | 1,351 | 1 | 30 | 56 | 120 | 1,724 | 130.9 | 218.1 |
| Sarilumab | 8,534 | 1 | 2 | 28 | 84 | 1,757 | 75.4 | 134.0 |
| Female | 6,345 | 1 | 28 | 28 | 84 | 1,757 | 84.1 | 135.5 |
| Male | 2,189 | 1 | 1 | 1 | 56 | 1,444 | 50.3 | 126.2 |
| Telotristat Ethyl | 1,061 | 2 | 28 | 28 | 84 | 1,725 | 69.0 | 98.0 |
| Female | 610 | 2 | 28 | 28 | 84 | 1,176 | 65.7 | 86.4 |
| Male | 451 | 3 | 28 | 28 | 84 | 1,725 | 73.6 | 111.8 |
| Valbenazine | 26,601 | 1 | 30 | 60 | 120 | 1,841 | 128.3 | 206.0 |
| Female | 15,837 | 1 | 30 | 60 | 120 | 1,831 | 126.4 | 202.3 |
| Male | 10,764 | 1 | 30 | 60 | 120 | 1,841 | 131.0 | 211.3 |

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| | Number of Patients by First Treatment Episode Duration | | | | | | | | | | |
|----------------------|--|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|
| | 1-30 Days | | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
| | Total Number of Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients |
| Abaloparatide | 23,148 | 11,801 | 100.0% | 6,013 | 100.0% | 4,154 | 100.0% | 996 | 100.0% | 184 | 100.0% |
| 0-17 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | ***** | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | 146 | 73 | 0.6% | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** |
| 41-64 years | 6,307 | 2,946 | 25.0% | 1,652 | 27.5% | 1,297 | 31.2% | 301 | 30.2% | 111 | 60.3% |
| ≥ 65 years | 16,681 | 8,773 | 74.3% | 4,328 | 72.0% | 2,825 | 68.0% | ***** | ***** | ***** | ***** |
| Avelumab | 2,803 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN |
| 0-17 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | NaN | 0 | NaN |
| 18-24 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | NaN | 0 | NaN |
| 25-40 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | NaN | 0 | NaN |
| 41-64 years | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | NaN | 0 | NaN |
| ≥ 65 years | ***** | ***** | ***** | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN |
| Betrixaban | 21 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN |
| 0-17 years | 0 | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | NaN | 0 | NaN |
| 18-24 years | 0 | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | NaN | 0 | NaN |
| 25-40 years | 0 | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | NaN | 0 | NaN |
| 41-64 years | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | NaN | 0 | NaN |
| ≥ 65 years | ***** | ***** | ***** | 0 | 0.0% | ***** | ***** | 0 | NaN | 0 | NaN |
| Brigatinib | 502 | 225 | 100.0% | 138 | 100.0% | 113 | 100.0% | ***** | ***** | ***** | ***** |
| 0-17 years | ***** | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | ***** | 0 | 0.0% | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% |
| 41-64 years | 229 | 102 | 45.3% | 57 | 41.3% | 57 | 50.4% | ***** | ***** | ***** | ***** |
| ≥ 65 years | 228 | 102 | 45.3% | 69 | 50.0% | ***** | ***** | ***** | ***** | ***** | ***** |

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| | Number of Patients by First Treatment Episode Duration | | | | | | | | | | |
|-------------------------|--|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|
| | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | | |
| | Total Number of Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients |
| Brodalumab | 841 | 387 | 100.0% | 212 | 100.0% | 190 | 100.0% | 35 | 100.0% | 17 | 100.0% |
| 0-17 years | 0 | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | 18 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | 140 | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** |
| 41-64 years | 466 | 210 | 54.3% | 106 | 50.0% | 117 | 61.6% | ***** | ***** | ***** | ***** |
| ≥ 65 years | 217 | 99 | 25.6% | 64 | 30.2% | 42 | 22.1% | ***** | ***** | ***** | ***** |
| Cerliponase Alfa | 18 | ***** | ***** | 0 | NaN | ***** | ***** | 0 | NaN | 0 | NaN |
| 0-17 years | 18 | ***** | ***** | 0 | NaN | ***** | ***** | 0 | NaN | 0 | NaN |
| 18-24 years | 0 | 0 | 0.0% | 0 | NaN | 0 | 0.0% | 0 | NaN | 0 | NaN |
| 25-40 years | 0 | 0 | 0.0% | 0 | NaN | 0 | 0.0% | 0 | NaN | 0 | NaN |
| 41-64 years | 0 | 0 | 0.0% | 0 | NaN | 0 | 0.0% | 0 | NaN | 0 | NaN |
| ≥ 65 years | 0 | 0 | 0.0% | 0 | NaN | 0 | 0.0% | 0 | NaN | 0 | NaN |
| Deflazacort | 1,129 | 432 | 100.0% | 253 | 100.0% | 289 | 100.0% | 109 | 100.0% | 46 | 100.0% |
| 0-17 years | 868 | 322 | 74.5% | 192 | 75.9% | 234 | 81.0% | 85 | 78.0% | 35 | 76.1% |
| 18-24 years | 179 | 77 | 17.8% | 41 | 16.2% | 41 | 14.2% | ***** | ***** | ***** | ***** |
| 25-40 years | ***** | ***** | 6.7% | ***** | ***** | ***** | 4.5% | ***** | ***** | ***** | ***** |
| 41-64 years | ***** | ***** | ***** | ***** | ***** | ***** | 0.3% | ***** | ***** | 0 | 0.0% |
| ≥ 65 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Delafloxacin | 2,996 | 2,897 | 100.0% | 85 | 100.0% | ***** | ***** | ***** | ***** | ***** | ***** |
| 0-17 years | 15 | 14 | 0.5% | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | 41 | 40 | 1.4% | 0 | 0.0% | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | 268 | 258 | 8.9% | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| 41-64 years | 1,342 | 1,304 | 45.0% | 33 | 38.8% | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| ≥ 65 years | 1,330 | 1,281 | 44.2% | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** |

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| | Number of Patients by First Treatment Episode Duration | | | | | | | | | | |
|-------------------------|--|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|
| | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | | |
| | Total Number of Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients |
| Deutetrabenazine | 16,357 | 7,284 | 100.0% | 3,719 | 100.0% | 3,481 | 100.0% | 1,098 | 100.0% | 775 | 100.0% |
| 0-17 years | 24 | 14 | 0.2% | ***** | ***** | ***** | 0.2% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | 160 | 75 | 1.0% | ***** | ***** | ***** | 0.9% | ***** | ***** | ***** | ***** |
| 25-40 years | 1,500 | 693 | 9.5% | 342 | 9.2% | 306 | 8.8% | ***** | ***** | ***** | ***** |
| 41-64 years | 8,412 | 3,714 | 51.0% | 1,924 | 51.7% | 1,811 | 52.0% | 566 | 51.5% | 397 | 51.2% |
| ≥ 65 years | 6,261 | 2,788 | 38.3% | 1,410 | 37.9% | 1,326 | 38.1% | 430 | 39.2% | 307 | 39.6% |
| Dupilumab | 83,061 | 42,922 | 100.0% | 17,287 | 100.0% | 17,050 | 100.0% | 3,837 | 100.0% | 1,965 | 100.0% |
| 0-17 years | 7,038 | 3,723 | 8.7% | 1,528 | 8.8% | 1,329 | 7.8% | 315 | 8.2% | 143 | 7.3% |
| 18-24 years | 7,843 | 4,363 | 10.2% | 1,638 | 9.5% | 1,428 | 8.4% | 276 | 7.2% | 138 | 7.0% |
| 25-40 years | 16,043 | 8,361 | 19.5% | 3,435 | 19.9% | 3,236 | 19.0% | 655 | 17.1% | 356 | 18.1% |
| 41-64 years | 32,163 | 15,996 | 37.3% | 6,540 | 37.8% | 6,978 | 40.9% | 1,696 | 44.2% | 953 | 48.5% |
| ≥ 65 years | 19,974 | 10,479 | 24.4% | 4,146 | 24.0% | 4,079 | 23.9% | 895 | 23.3% | 375 | 19.1% |
| Durvalumab | 26,005 | 25,879 | 100.0% | 49 | 100.0% | 51 | 100.0% | ***** | ***** | ***** | ***** |
| 0-17 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 41-64 years | 4,635 | 4,598 | 17.8% | 16 | 32.7% | ***** | ***** | ***** | ***** | ***** | ***** |
| ≥ 65 years | 21,303 | 21,214 | 82.0% | 33 | 67.3% | ***** | ***** | ***** | ***** | ***** | ***** |
| Edaravone | 2,163 | 1,808 | 100.0% | 148 | 100.0% | 156 | 100.0% | 38 | 100.0% | 13 | 100.0% |
| 0-17 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** |
| 41-64 years | 829 | 707 | 39.1% | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** |
| ≥ 65 years | 1,249 | 1,031 | 57.0% | 92 | 62.2% | 97 | 62.2% | ***** | ***** | ***** | ***** |

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| | Number of Patients by First Treatment Episode Duration | | | | | | | | | | |
|----------------------|--|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|
| | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | | |
| | Total Number of Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients |
| Etelcalcetide | 53,102 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN |
| 0-17 years | 17 | 17 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | NaN | 0 | NaN |
| 18-24 years | 455 | 455 | 0.9% | 0 | 0.0% | 0 | 0.0% | 0 | NaN | 0 | NaN |
| 25-40 years | 5,735 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN |
| 41-64 years | 26,938 | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | NaN | 0 | NaN |
| ≥ 65 years | 19,957 | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | NaN | 0 | NaN |
| Midostaurin | 1,841 | 1,374 | 100.0% | 323 | 100.0% | 133 | 100.0% | ***** | ***** | ***** | ***** |
| 0-17 years | 18 | ***** | ***** | 0 | 0.0% | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | 45 | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% |
| 25-40 years | 178 | 122 | 8.9% | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** |
| 41-64 years | 739 | 532 | 38.7% | 142 | 44.0% | 63 | 47.4% | ***** | ***** | ***** | ***** |
| ≥ 65 years | 861 | 668 | 48.6% | 144 | 44.6% | ***** | ***** | ***** | ***** | 0 | 0.0% |
| Naldemedine | 13,921 | 9,503 | 100.0% | 2,724 | 100.0% | 1,400 | 100.0% | 219 | 100.0% | 75 | 100.0% |
| 0-17 years | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | ***** | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | 957 | 640 | 6.7% | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** |
| 41-64 years | 7,235 | 4,741 | 49.9% | 1,497 | 55.0% | 799 | 57.1% | 148 | 67.6% | 50 | 66.7% |
| ≥ 65 years | 5,677 | 4,082 | 43.0% | 1,005 | 36.9% | 507 | 36.2% | ***** | ***** | ***** | ***** |
| Niraparib | 6,415 | 4,028 | 100.0% | 1,608 | 100.0% | 669 | 100.0% | 90 | 100.0% | 20 | 100.0% |
| 0-17 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | ***** | ***** | ***** | 17 | 1.1% | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| 41-64 years | 1,887 | 1,080 | 26.8% | 496 | 30.8% | ***** | ***** | ***** | ***** | ***** | ***** |
| ≥ 65 years | 4,454 | 2,901 | 72.0% | 1,095 | 68.1% | 415 | 62.0% | ***** | ***** | ***** | ***** |

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| | Number of Patients by First Treatment Episode Duration | | | | | | | | | | |
|--------------------|--|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|
| | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | | |
| | Total Number of Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients |
| Ocrelizumab | 43,156 | 41,799 | 100.0% | 425 | 100.0% | 885 | 100.0% | ***** | ***** | ***** | ***** |
| 0-17 years | 55 | 55 | 0.1% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | 784 | 768 | 1.8% | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | 10,500 | 10,178 | 24.3% | 99 | 23.3% | 214 | 24.2% | ***** | ***** | ***** | ***** |
| 41-64 years | 24,374 | 23,525 | 56.3% | 276 | 64.9% | 539 | 60.9% | ***** | ***** | ***** | ***** |
| ≥ 65 years | 7,443 | 7,273 | 17.4% | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** |
| Plecanatide | 66,616 | 38,272 | 100.0% | 18,076 | 100.0% | 8,480 | 100.0% | 1,344 | 100.0% | 444 | 100.0% |
| 0-17 years | 135 | 92 | 0.2% | 24 | 0.1% | 18 | 0.2% | ***** | ***** | ***** | ***** |
| 18-24 years | 2,505 | 1,574 | 4.1% | 609 | 3.4% | 273 | 3.2% | ***** | ***** | ***** | ***** |
| 25-40 years | 8,810 | 5,367 | 14.0% | 2,292 | 12.7% | 955 | 11.3% | 146 | 10.9% | 50 | 11.3% |
| 41-64 years | 27,632 | 15,278 | 39.9% | 7,816 | 43.2% | 3,745 | 44.2% | 594 | 44.2% | 199 | 44.8% |
| ≥ 65 years | 27,534 | 15,961 | 41.7% | 7,335 | 40.6% | 3,489 | 41.1% | 568 | 42.3% | 181 | 40.8% |
| Ribociclib | 4,213 | 2,398 | 100.0% | 1,014 | 100.0% | 674 | 100.0% | 90 | 100.0% | 37 | 100.0% |
| 0-17 years | ***** | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | 166 | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** |
| 41-64 years | 1,358 | 749 | 31.2% | 326 | 32.1% | 228 | 33.8% | ***** | ***** | ***** | ***** |
| ≥ 65 years | 2,675 | 1,551 | 64.7% | 646 | 63.7% | 415 | 61.6% | 48 | 53.3% | 15 | 40.5% |
| Safinamide | 2,319 | 1,080 | 100.0% | 611 | 100.0% | 437 | 100.0% | 114 | 100.0% | 77 | 100.0% |
| 0-17 years | 0 | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | 0 | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | ***** | ***** | 0.4% | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| 41-64 years | ***** | ***** | 15.4% | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** |
| ≥ 65 years | 1,956 | 910 | 84.3% | 512 | 83.8% | 366 | 83.8% | ***** | ***** | ***** | ***** |

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| | Number of Patients by First Treatment Episode Duration | | | | | | | | | | |
|--------------------------|--|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|
| | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | | |
| | Total Number of Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients | Number of Patients | Percent of Total Patients |
| Sarilumab | 8,534 | 4,907 | 100.0% | 1,864 | 100.0% | 1,492 | 100.0% | 198 | 100.0% | 73 | 100.0% |
| 0-17 years | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** |
| 25-40 years | 671 | 363 | 7.4% | 162 | 8.7% | ***** | ***** | ***** | ***** | ***** | ***** |
| 41-64 years | 4,468 | 2,216 | 45.2% | 1,167 | 62.6% | 910 | 61.0% | 127 | 64.1% | 48 | 65.8% |
| ≥ 65 years | 3,322 | 2,282 | 46.5% | 523 | 28.1% | 447 | 30.0% | ***** | ***** | ***** | ***** |
| Telotristat Ethyl | 1,061 | 585 | 100.0% | 274 | 100.0% | 187 | 100.0% | ***** | ***** | ***** | ***** |
| 0-17 years | ***** | 0 | 0.0% | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | ***** | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| 41-64 years | 376 | 195 | 33.3% | 102 | 37.2% | ***** | ***** | ***** | ***** | ***** | ***** |
| ≥ 65 years | 651 | 370 | 63.2% | 161 | 58.8% | 113 | 60.4% | ***** | ***** | ***** | ***** |
| Valbenazine | 26,601 | 11,713 | 100.0% | 6,817 | 100.0% | 5,905 | 100.0% | 1,372 | 100.0% | 794 | 100.0% |
| 0-17 years | 25 | 13 | 0.1% | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% |
| 18-24 years | 292 | 162 | 1.4% | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** |
| 25-40 years | 2,528 | 1,154 | 9.9% | 643 | 9.4% | 552 | 9.3% | ***** | ***** | ***** | ***** |
| 41-64 years | 14,581 | 6,377 | 54.4% | 3,756 | 55.1% | 3,247 | 55.0% | 738 | 53.8% | 463 | 58.3% |
| ≥ 65 years | 9,175 | 4,007 | 34.2% | 2,336 | 34.3% | 2,056 | 34.8% | 517 | 37.7% | 259 | 32.6% |

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| Distribution of First Treatment Episode Duration, Days | | | | | | | | |
|--|--------------------------|----------|-----------|-----------|------------|--------------|--------------|--------------------|
| | Total Number of Patients | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Abaloparatide | 23,148 | 1 | 30 | 30 | 90 | 1,470 | 97.9 | 138.4 |
| 0-17 years | ***** | 18 | 18 | 24 | 30 | 30 | 24.0 | 8.5 |
| 18-24 years | ***** | 30 | 30 | 30 | 123 | 300 | 85.4 | 86.0 |
| 25-40 years | 146 | 1 | 30 | 32 | 120 | 800 | 116.9 | 165.3 |
| 41-64 years | 6,307 | 1 | 30 | 58 | 120 | 1,470 | 113.2 | 168.1 |
| ≥ 65 years | 16,681 | 1 | 30 | 30 | 90 | 1,440 | 92.0 | 124.6 |
| Avelumab | 2,803 | 1 | 1 | 1 | 1 | 112 | 1.3 | 4.2 |
| 0-17 years | ***** | 1 | 1 | 1 | 1 | 1 | 1.0 | NaN |
| 18-24 years | ***** | 1 | 1 | 1 | 1 | 1 | 1.0 | 0.0 |
| 25-40 years | ***** | 1 | 1 | 1 | 1 | 1 | 1.0 | 0.0 |
| 41-64 years | 293 | 1 | 1 | 1 | 1 | 51 | 1.3 | 3.3 |
| ≥ 65 years | 2,492 | 1 | 1 | 1 | 1 | 112 | 1.3 | 4.3 |
| Betrixaban | 21 | 7 | 17 | 30 | 30 | 330 | 43.8 | 67.9 |
| 0-17 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 18-24 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 25-40 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 41-64 years | ***** | 17 | 30 | 30 | 35 | 90 | 39.0 | 22.3 |
| ≥ 65 years | ***** | 7 | 14 | 28 | 30 | 330 | 47.4 | 89.4 |
| Brigatinib | 502 | 1 | 30 | 49 | 119 | 1,809 | 109.4 | 187.9 |
| 0-17 years | ***** | 1 | 16 | 34 | 178 | 318 | 96.5 | 148.5 |
| 18-24 years | ***** | 60 | 60 | 60 | 60 | 60 | 60.0 | 0.0 |
| 25-40 years | ***** | 7 | 30 | 37 | 103 | 518 | 99.8 | 124.8 |
| 41-64 years | 229 | 1 | 30 | 52 | 120 | 1,809 | 121.4 | 228.9 |
| ≥ 65 years | 228 | 6 | 30 | 49 | 92 | 1,200 | 99.5 | 148.8 |

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| Distribution of First Treatment Episode Duration, Days | | | | | | | | |
|--|--------------------------|----------|-----------|-----------|------------|--------------|--------------|--------------------|
| | Total Number of Patients | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Brodalumab | 841 | 1 | 15 | 42 | 107 | 1,670 | 106.2 | 183.8 |
| 0-17 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 18-24 years | 18 | 14 | 28 | 35 | 119 | 232 | 69.4 | 73.9 |
| 25-40 years | 140 | 1 | 15 | 35 | 84 | 1,386 | 95.0 | 172.3 |
| 41-64 years | 466 | 1 | 14 | 42 | 118 | 1,466 | 112.5 | 186.2 |
| ≥ 65 years | 217 | 7 | 17 | 42 | 86 | 1,670 | 102.8 | 191.9 |
| Cerliponase Alfa | 18 | 1 | 1 | 1 | 1 | 98 | 6.4 | 22.9 |
| 0-17 years | 18 | 1 | 1 | 1 | 1 | 98 | 6.4 | 22.9 |
| 18-24 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 25-40 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 41-64 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| ≥ 65 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| Deflazacort | 1,129 | 1 | 30 | 60 | 201 | 1,837 | 173.4 | 273.0 |
| 0-17 years | 868 | 1 | 30 | 60 | 210 | 1,837 | 177.1 | 275.9 |
| 18-24 years | 179 | 6 | 30 | 60 | 180 | 1,488 | 138.7 | 203.6 |
| 25-40 years | ***** | 9 | 30 | 60 | 207 | 1,814 | 217.6 | 370.0 |
| 41-64 years | ***** | 30 | 30 | 90 | 240 | 465 | 171.0 | 185.4 |
| ≥ 65 years | ***** | 28 | 28 | 29 | 30 | 30 | 29.0 | 1.4 |
| Delafloxacin | 2,996 | 1 | 10 | 10 | 14 | 870 | 14.3 | 22.4 |
| 0-17 years | 15 | 5 | 10 | 14 | 14 | 40 | 13.3 | 7.9 |
| 18-24 years | 41 | 5 | 10 | 14 | 14 | 180 | 18.2 | 26.7 |
| 25-40 years | 268 | 1 | 10 | 10 | 14 | 120 | 14.3 | 12.9 |
| 41-64 years | 1,342 | 1 | 10 | 10 | 14 | 150 | 13.9 | 10.9 |
| ≥ 65 years | 1,330 | 1 | 10 | 10 | 14 | 870 | 14.5 | 30.8 |

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| Distribution of First Treatment Episode Duration, Days | | | | | | | | |
|--|--------------------------|----------|-----------|-----------|------------|--------------|--------------|--------------------|
| | Total Number of Patients | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Deutetrabenazine | 16,357 | 1 | 30 | 58 | 150 | 1,779 | 151.6 | 247.4 |
| 0-17 years | 24 | 12 | 29 | 30 | 120 | 316 | 82.0 | 86.4 |
| 18-24 years | 160 | 4 | 30 | 44 | 120 | 1,298 | 127.0 | 191.6 |
| 25-40 years | 1,500 | 1 | 30 | 50 | 129 | 1,669 | 143.8 | 240.7 |
| 41-64 years | 8,412 | 1 | 30 | 58 | 150 | 1,779 | 152.3 | 247.0 |
| ≥ 65 years | 6,261 | 1 | 30 | 56 | 150 | 1,717 | 153.4 | 251.2 |
| Dupilumab | 83,061 | 1 | 14 | 28 | 102 | 1,897 | 107.7 | 194.6 |
| 0-17 years | 7,038 | 1 | 14 | 28 | 98 | 1,717 | 100.6 | 179.9 |
| 18-24 years | 7,843 | 1 | 14 | 28 | 84 | 1,713 | 91.4 | 174.4 |
| 25-40 years | 16,043 | 1 | 14 | 28 | 98 | 1,817 | 104.6 | 194.5 |
| 41-64 years | 32,163 | 1 | 14 | 35 | 121 | 1,885 | 119.3 | 210.9 |
| ≥ 65 years | 19,974 | 1 | 14 | 28 | 98 | 1,897 | 100.5 | 178.2 |
| Durvalumab | 26,005 | 1 | 1 | 1 | 1 | 1,074 | 2.3 | 23.3 |
| 0-17 years | ***** | 1 | 1 | 1 | 1 | 1 | 1.0 | NaN |
| 18-24 years | ***** | 1 | 1 | 1 | 2 | 3 | 1.4 | 0.7 |
| 25-40 years | ***** | 1 | 1 | 1 | 1 | 14 | 1.3 | 1.7 |
| 41-64 years | 4,635 | 1 | 1 | 1 | 1 | 840 | 2.8 | 23.6 |
| ≥ 65 years | 21,303 | 1 | 1 | 1 | 1 | 1,074 | 2.1 | 23.2 |
| Edaravone | 2,163 | 1 | 5 | 14 | 28 | 1,613 | 42.1 | 116.2 |
| 0-17 years | ***** | 28 | 28 | 28 | 28 | 28 | 28.0 | NaN |
| 18-24 years | ***** | 1 | 1 | 3 | 14 | 14 | 6.0 | 7.0 |
| 25-40 years | ***** | 1 | 3 | 14 | 28 | 840 | 53.6 | 147.8 |
| 41-64 years | 829 | 1 | 1 | 10 | 15 | 1,568 | 37.4 | 108.1 |
| ≥ 65 years | 1,249 | 1 | 5 | 14 | 28 | 1,613 | 44.6 | 119.2 |

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| Distribution of First Treatment Episode Duration, Days | | | | | | | | | |
|--|--------------------------|----------|-----------|-----------|-----------|--------------|-------------|--------------------|--|
| | Total Number of Patients | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation | |
| Etelcalcetide | 53,102 | 1 | 1 | 1 | 1 | 117 | 1.0 | 0.8 | |
| 0-17 years | 17 | 1 | 1 | 1 | 1 | 1 | 1.0 | 0.0 | |
| 18-24 years | 455 | 1 | 1 | 1 | 1 | 2 | 1.0 | 0.1 | |
| 25-40 years | 5,735 | 1 | 1 | 1 | 1 | 117 | 1.1 | 1.8 | |
| 41-64 years | 26,938 | 1 | 1 | 1 | 1 | 90 | 1.0 | 0.7 | |
| ≥ 65 years | 19,957 | 1 | 1 | 1 | 1 | 58 | 1.0 | 0.4 | |
| Midostaurin | 1,841 | 1 | 14 | 28 | 35 | 1,109 | 41.6 | 64.4 | |
| 0-17 years | 18 | 9 | 22 | 28 | 30 | 265 | 48.6 | 63.2 | |
| 18-24 years | 45 | 2 | 14 | 21 | 28 | 638 | 42.1 | 95.6 | |
| 25-40 years | 178 | 1 | 21 | 28 | 50 | 1,109 | 60.5 | 124.4 | |
| 41-64 years | 739 | 1 | 14 | 28 | 43 | 1,036 | 42.1 | 58.7 | |
| ≥ 65 years | 861 | 1 | 14 | 28 | 28 | 476 | 37.1 | 45.8 | |
| Naldemedine | 13,921 | 1 | 30 | 30 | 60 | 1,630 | 64.9 | 104.1 | |
| 0-17 years | ***** | 30 | 30 | 30 | 45 | 90 | 41.3 | 22.3 | |
| 18-24 years | ***** | 2 | 30 | 30 | 30 | 346 | 46.9 | 57.3 | |
| 25-40 years | 957 | 1 | 30 | 30 | 60 | 1,128 | 59.6 | 81.4 | |
| 41-64 years | 7,235 | 1 | 30 | 30 | 60 | 1,630 | 70.9 | 115.9 | |
| ≥ 65 years | 5,677 | 1 | 30 | 30 | 60 | 1,473 | 58.4 | 90.5 | |
| Niraparib | 6,415 | 1 | 30 | 30 | 60 | 1,577 | 62.8 | 91.4 | |
| 0-17 years | ***** | 28 | 28 | 28 | 28 | 28 | 28.0 | NaN | |
| 18-24 years | ***** | 28 | 28 | 30 | 30 | 30 | 29.3 | 1.2 | |
| 25-40 years | ***** | 10 | 30 | 30 | 60 | 330 | 58.2 | 63.6 | |
| 41-64 years | 1,887 | 1 | 30 | 30 | 60 | 1,577 | 79.2 | 126.4 | |
| ≥ 65 years | 4,454 | 1 | 30 | 30 | 60 | 1,156 | 55.9 | 71.1 | |

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| Distribution of First Treatment Episode Duration, Days | | | | | | | | |
|--|--------------------------|----------|-----------|-----------|------------|--------------|--------------|--------------------|
| | Total Number of Patients | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Ocrelizumab | 43,156 | 1 | 1 | 1 | 1 | 1,292 | 6.9 | 36.0 |
| 0-17 years | 55 | 1 | 1 | 1 | 1 | 15 | 1.3 | 1.9 |
| 18-24 years | 784 | 1 | 1 | 1 | 1 | 360 | 4.2 | 21.1 |
| 25-40 years | 10,500 | 1 | 1 | 1 | 1 | 888 | 6.7 | 33.8 |
| 41-64 years | 24,374 | 1 | 1 | 1 | 1 | 1,292 | 7.5 | 38.6 |
| ≥ 65 years | 7,443 | 1 | 1 | 1 | 1 | 1,040 | 5.5 | 31.5 |
| Plecanatide | 66,616 | 1 | 30 | 30 | 90 | 1,912 | 78.1 | 116.4 |
| 0-17 years | 135 | 3 | 30 | 30 | 60 | 450 | 60.5 | 70.5 |
| 18-24 years | 2,505 | 1 | 30 | 30 | 90 | 1,423 | 69.9 | 105.7 |
| 25-40 years | 8,810 | 1 | 30 | 30 | 90 | 1,734 | 70.7 | 105.1 |
| 41-64 years | 27,632 | 1 | 30 | 30 | 90 | 1,912 | 81.3 | 122.2 |
| ≥ 65 years | 27,534 | 1 | 30 | 30 | 90 | 1,848 | 78.1 | 115.0 |
| Ribociclib | 4,213 | 1 | 28 | 28 | 84 | 1,635 | 78.4 | 129.2 |
| 0-17 years | ***** | 14 | 21 | 28 | 51 | 196 | 46.0 | 51.5 |
| 18-24 years | ***** | 14 | 14 | 21 | 56 | 56 | 30.3 | 22.5 |
| 25-40 years | 166 | 2 | 28 | 28 | 84 | 1,079 | 94.8 | 149.5 |
| 41-64 years | 1,358 | 1 | 28 | 28 | 84 | 1,635 | 87.8 | 159.5 |
| ≥ 65 years | 2,675 | 1 | 28 | 28 | 66 | 1,177 | 72.8 | 109.0 |
| Safinamide | 2,319 | 1 | 30 | 60 | 120 | 1,798 | 132.5 | 224.1 |
| 0-17 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 18-24 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 25-40 years | ***** | 30 | 30 | 34 | 79 | 180 | 61.9 | 53.4 |
| 41-64 years | ***** | 5 | 30 | 60 | 108 | 1,724 | 118.1 | 194.1 |
| ≥ 65 years | 1,956 | 1 | 30 | 60 | 120 | 1,798 | 135.4 | 229.4 |

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| | Distribution of First Treatment Episode Duration, Days | | | | | | | Standard Deviation |
|--------------------------|--|----------|-----------|-----------|------------|--------------|--------------|--------------------|
| | Total Number of Patients | Minimum | Q1 | Median | Q3 | Maximum | Mean | |
| Sarilumab | 8,534 | 1 | 2 | 28 | 84 | 1,757 | 75.4 | 134.0 |
| 0-17 years | ***** | 1 | 1 | 15 | 42 | 56 | 21.5 | 26.3 |
| 18-24 years | ***** | 1 | 28 | 28 | 84 | 890 | 94.0 | 152.1 |
| 25-40 years | 671 | 1 | 28 | 28 | 84 | 1,540 | 84.1 | 141.8 |
| 41-64 years | 4,468 | 1 | 28 | 36 | 84 | 1,757 | 89.8 | 145.4 |
| ≥ 65 years | 3,322 | 1 | 1 | 28 | 56 | 1,575 | 54.0 | 111.3 |
| Telotristat Ethyl | 1,061 | 2 | 28 | 28 | 84 | 1,725 | 69.0 | 98.0 |
| 0-17 years | ***** | 84 | 84 | 84 | 84 | 84 | 84.0 | NaN |
| 18-24 years | ***** | 28 | 28 | 42 | 56 | 56 | 42.0 | 19.8 |
| 25-40 years | ***** | 28 | 28 | 28 | 56 | 140 | 46.5 | 30.1 |
| 41-64 years | 376 | 3 | 28 | 28 | 84 | 1,725 | 75.3 | 117.1 |
| ≥ 65 years | 651 | 2 | 28 | 28 | 84 | 1,176 | 66.6 | 87.5 |
| Valbenazine | 26,601 | 1 | 30 | 60 | 120 | 1,841 | 128.3 | 206.0 |
| 0-17 years | 25 | 4 | 30 | 30 | 90 | 450 | 90.0 | 111.1 |
| 18-24 years | 292 | 4 | 30 | 30 | 64 | 1,334 | 87.3 | 157.1 |
| 25-40 years | 2,528 | 1 | 30 | 54 | 120 | 1,757 | 119.5 | 198.4 |
| 41-64 years | 14,581 | 1 | 30 | 60 | 120 | 1,831 | 129.8 | 208.8 |
| ≥ 65 years | 9,175 | 1 | 30 | 60 | 120 | 1,841 | 129.6 | 205.0 |

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 6a. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| | Number of Treatment Episodes by Duration (Excluding First Treatment Episode) | | | | | | | | | | |
|--------------------------|--|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|-------|
| | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | | |
| Total Number of Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | |
| Abaloparatide | 47,924 | 27,855 | 58.1% | 12,818 | 26.7% | 6,559 | 13.7% | 674 | 1.4% | 18 | 0.0% |
| Avelumab | 33,813 | 33,797 | 100.0% | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| Betrixaban | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Brigatinib | 709 | 353 | 49.8% | 198 | 27.9% | 135 | 19.0% | ***** | ***** | ***** | ***** |
| Brodalumab | 2,517 | 1,301 | 51.7% | 719 | 28.6% | 447 | 17.8% | ***** | ***** | ***** | ***** |
| Cerliponase Alfa | 514 | 514 | 100.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Deflazacort | 2,490 | 1,340 | 53.8% | 594 | 23.9% | 435 | 17.5% | 77 | 3.1% | 44 | 1.8% |
| Delafloxacin | 1,101 | 1,045 | 94.9% | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| Deutetrabenazine | 30,525 | 15,618 | 51.2% | 7,567 | 24.8% | 5,547 | 18.2% | 1,196 | 3.9% | 597 | 2.0% |
| Dupilumab | 229,658 | 126,203 | 55.0% | 58,087 | 25.3% | 38,788 | 16.9% | 5,128 | 2.2% | 1,452 | 0.6% |
| Durvalumab | 259,269 | 259,103 | 99.9% | 106 | 0.0% | ***** | ***** | ***** | ***** | 0 | 0.0% |
| Edaravone | 26,414 | 25,137 | 95.2% | 572 | 2.2% | 579 | 2.2% | 99 | 0.4% | 27 | 0.1% |
| Etelcalcetide | 8,457,346 | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Midostaurin | 2,895 | 2,121 | 73.3% | 508 | 17.5% | 239 | 8.3% | ***** | ***** | ***** | ***** |
| Naldemedine | 25,826 | 16,538 | 64.0% | 6,145 | 23.8% | 2,781 | 10.8% | 291 | 1.1% | 71 | 0.3% |
| Niraparib | 9,297 | 5,462 | 58.8% | 2,406 | 25.9% | 1,273 | 13.7% | 128 | 1.4% | 28 | 0.3% |
| Ocrelizumab | 122,517 | 119,124 | 97.2% | 972 | 0.8% | 2,284 | 1.9% | 118 | 0.1% | 19 | 0.0% |
| Plecanatide | 93,208 | 53,672 | 57.6% | 26,128 | 28.0% | 11,599 | 12.4% | 1,410 | 1.5% | 399 | 0.4% |
| Ribociclib | 10,271 | 6,174 | 60.1% | 2,454 | 23.9% | 1,442 | 14.0% | 173 | 1.7% | 28 | 0.3% |
| Safinamide | 5,572 | 2,352 | 42.2% | 1,683 | 30.2% | 1,171 | 21.0% | 233 | 4.2% | 133 | 2.4% |
| Sarilumab | 12,564 | 6,966 | 55.4% | 3,430 | 27.3% | 1,957 | 15.6% | 163 | 1.3% | 48 | 0.4% |
| Telotristat Ethyl | 2,713 | 1,737 | 64.0% | 632 | 23.3% | 315 | 11.6% | ***** | ***** | ***** | ***** |
| Valbenazine | 47,992 | 22,476 | 46.8% | 13,099 | 27.3% | 9,870 | 20.6% | 1,766 | 3.7% | 781 | 1.6% |

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 6b. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

Distribution of Treatment Episode Durations Excluding First Treatment Episode, Days

| | Total Number of Episodes | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
|-------------------|--------------------------|---------|----|--------|-----|---------|-------|--------------------|
| Abaloparatide | 47,924 | 1 | 30 | 30 | 65 | 1,081 | 67.5 | 78.9 |
| Avelumab | 33,813 | 1 | 1 | 1 | 1 | 308 | 1.1 | 2.8 |
| Betrixaban | ***** | 3 | 14 | 42 | 42 | 60 | 32.3 | 21.4 |
| Brigatinib | 709 | 4 | 30 | 36 | 90 | 1,414 | 88.7 | 128.4 |
| Brodalumab | 2,517 | 1 | 28 | 28 | 84 | 1,225 | 74.1 | 93.9 |
| Cerliponase Alfa | 514 | 1 | 1 | 1 | 1 | 28 | 1.1 | 1.2 |
| Deflazacort | 2,490 | 1 | 30 | 30 | 90 | 1,802 | 99.7 | 179.7 |
| Delafloxacin | 1,101 | 1 | 10 | 10 | 14 | 180 | 16.3 | 16.7 |
| Deutetrabenazine | 30,525 | 1 | 30 | 30 | 90 | 1,802 | 103.9 | 176.0 |
| Dupilumab | 229,658 | 1 | 28 | 28 | 84 | 1,858 | 77.6 | 117.5 |
| Durvalumab | 259,269 | 1 | 1 | 1 | 1 | 588 | 1.1 | 3.3 |
| Edaravone | 26,414 | 1 | 3 | 5 | 7 | 1,288 | 13.6 | 52.5 |
| Etelcalcetide | 8,457,346 | 1 | 1 | 1 | 1 | 82 | 1.0 | 0.1 |
| Midostaurin | 2,895 | 1 | 21 | 28 | 42 | 1,593 | 49.0 | 93.4 |
| Naldemedine | 25,826 | 1 | 30 | 30 | 60 | 1,516 | 62.1 | 84.8 |
| Niraparib | 9,297 | 1 | 30 | 30 | 60 | 1,648 | 68.7 | 92.8 |
| Ocrelizumab | 122,517 | 1 | 1 | 1 | 1 | 1,616 | 6.1 | 35.1 |
| Plecanatide | 93,208 | 1 | 30 | 30 | 90 | 1,864 | 72.3 | 100.2 |
| Ribociclib | 10,271 | 1 | 28 | 28 | 56 | 1,415 | 65.1 | 94.1 |
| Safinamide | 5,572 | 1 | 30 | 60 | 120 | 1,686 | 122.0 | 187.8 |
| Sarilumab | 12,564 | 1 | 28 | 28 | 84 | 1,485 | 69.9 | 95.5 |
| Telotristat Ethyl | 2,713 | 2 | 28 | 28 | 56 | 1,008 | 57.7 | 76.6 |
| Valbenazine | 47,992 | 1 | 30 | 60 | 108 | 1,781 | 105.8 | 162.3 |

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Sex

| | Number of Treatment Episodes by Duration (Excluding First Treatment Episode) | | | | | | | | | | |
|-------------------------|--|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|
| | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | | |
| | Total Number of Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes |
| Abaloparatide | 47,924 | 27,855 | 100.0% | 12,818 | 100.0% | 6,559 | 100.0% | 674 | 100.0% | 18 | 100.0% |
| Female | 46,791 | 27,182 | 97.6% | 12,505 | 97.6% | 6,425 | 98.0% | 661 | 98.1% | 18 | 100.0% |
| Male | 1,133 | 673 | 2.4% | 313 | 2.4% | 134 | 2.0% | 13 | 1.9% | 0 | 0.0% |
| Avelumab | 33,813 | 33,797 | 100.0% | ***** | ***** | ***** | 100.0% | 0 | NaN | 0 | NaN |
| Female | 7,982 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN |
| Male | 25,831 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN |
| Betrixaban | ***** | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN | 0 | NaN |
| Female | ***** | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN | 0 | NaN |
| Male | ***** | 0 | 0.0% | ***** | ***** | 0 | NaN | 0 | NaN | 0 | NaN |
| Brigatinib | 709 | 353 | 100.0% | 198 | 100.0% | 135 | 100.0% | ***** | ***** | ***** | ***** |
| Female | 454 | 219 | 62.0% | 132 | 66.7% | ***** | ***** | ***** | ***** | ***** | ***** |
| Male | 255 | 134 | 38.0% | 66 | 33.3% | ***** | ***** | ***** | ***** | ***** | ***** |
| Brodalumab | 2,517 | 1,301 | 100.0% | 719 | 100.0% | 447 | 100.0% | ***** | ***** | ***** | ***** |
| Female | 1,189 | 624 | 48.0% | 310 | 43.1% | 227 | 50.8% | ***** | ***** | ***** | ***** |
| Male | 1,328 | 677 | 52.0% | 409 | 56.9% | 220 | 49.2% | ***** | ***** | ***** | ***** |
| Cerliponase Alfa | 514 | 514 | 100.0% | 0 | NaN | 0 | NaN | 0 | NaN | 0 | NaN |
| Female | 302 | 302 | 58.8% | 0 | NaN | 0 | NaN | 0 | NaN | 0 | NaN |
| Male | 212 | 212 | 41.2% | 0 | NaN | 0 | NaN | 0 | NaN | 0 | NaN |
| Deflazacort | 2,490 | 1,340 | 100.0% | 594 | 100.0% | 435 | 100.0% | 77 | 100.0% | 44 | 100.0% |
| Female | 19 | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** |
| Male | 2,471 | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** |
| Delafloxacin | 1,101 | 1,045 | 100.0% | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN |
| Female | 499 | 471 | 45.1% | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN |
| Male | 602 | 574 | 54.9% | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN |

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Sex

| | Number of Treatment Episodes by Duration (Excluding First Treatment Episode) | | | | | | | | | | |
|-------------------------|--|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|
| | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | | |
| | Total Number of Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes |
| Deutetrabenazine | 30,525 | 15,618 | 100.0% | 7,567 | 100.0% | 5,547 | 100.0% | 1,196 | 100.0% | 597 | 100.0% |
| Female | 18,777 | 9,567 | 61.3% | 4,655 | 61.5% | 3,469 | 62.5% | 723 | 60.5% | 363 | 60.8% |
| Male | 11,748 | 6,051 | 38.7% | 2,912 | 38.5% | 2,078 | 37.5% | 473 | 39.5% | 234 | 39.2% |
| Dupilumab | 229,658 | 126,203 | 100.0% | 58,087 | 100.0% | 38,788 | 100.0% | 5,128 | 100.0% | 1,452 | 100.0% |
| Female | 126,163 | 69,605 | 55.2% | 31,873 | 54.9% | 21,158 | 54.5% | 2,749 | 53.6% | 778 | 53.6% |
| Male | 103,495 | 56,598 | 44.8% | 26,214 | 45.1% | 17,630 | 45.5% | 2,379 | 46.4% | 674 | 46.4% |
| Durvalumab | 259,269 | 259,103 | 100.0% | 106 | 100.0% | ***** | ***** | ***** | ***** | 0 | NaN |
| Female | 125,315 | 125,262 | 48.3% | 33 | 31.1% | ***** | ***** | ***** | ***** | 0 | NaN |
| Male | 133,954 | 133,841 | 51.7% | 73 | 68.9% | ***** | ***** | ***** | ***** | 0 | NaN |
| Edaravone | 26,414 | 25,137 | 100.0% | 572 | 100.0% | 579 | 100.0% | 99 | 100.0% | 27 | 100.0% |
| Female | 11,613 | 11,066 | 44.0% | 245 | 42.8% | 238 | 41.1% | 49 | 49.5% | 15 | 55.6% |
| Male | 14,801 | 14,071 | 56.0% | 327 | 57.2% | 341 | 58.9% | 50 | 50.5% | 12 | 44.4% |
| Etelcalcetide | 8,457,346 | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN | 0 | NaN |
| Female | 3,885,978 | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN | 0 | NaN |
| Male | 4,571,368 | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN | 0 | NaN |
| Midostaurin | 2,895 | 2,121 | 100.0% | 508 | 100.0% | 239 | 100.0% | ***** | ***** | ***** | ***** |
| Female | 1,520 | 1,106 | 52.1% | 260 | 51.2% | 138 | 57.7% | ***** | ***** | ***** | ***** |
| Male | 1,375 | 1,015 | 47.9% | 248 | 48.8% | 101 | 42.3% | ***** | ***** | ***** | ***** |
| Naldemedine | 25,826 | 16,538 | 100.0% | 6,145 | 100.0% | 2,781 | 100.0% | 291 | 100.0% | 71 | 100.0% |
| Female | 17,147 | 11,019 | 66.6% | 4,064 | 66.1% | 1,824 | 65.6% | 192 | 66.0% | 48 | 67.6% |
| Male | 8,679 | 5,519 | 33.4% | 2,081 | 33.9% | 957 | 34.4% | 99 | 34.0% | 23 | 32.4% |
| Niraparib | 9,297 | 5,462 | 100.0% | 2,406 | 100.0% | 1,273 | 100.0% | 128 | 100.0% | 28 | 100.0% |
| Female | 9,276 | 5,448 | 99.7% | ***** | ***** | ***** | ***** | 128 | 100.0% | ***** | ***** |
| Male | 21 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | ***** | ***** |

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Sex

| | Total Number of Episodes | Number of Treatment Episodes by Duration (Excluding First Treatment Episode) | | | | | | | | | |
|--------------------------|--------------------------|--|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|
| | | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
| | | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes |
| Ocrelizumab | 122,517 | 119,124 | 100.0% | 972 | 100.0% | 2,284 | 100.0% | 118 | 100.0% | 19 | 100.0% |
| Female | 82,555 | 80,214 | 67.3% | 649 | 66.8% | 1,591 | 69.7% | ***** | ***** | ***** | ***** |
| Male | 39,962 | 38,910 | 32.7% | 323 | 33.2% | 693 | 30.3% | ***** | ***** | ***** | ***** |
| Plecanatide | 93,208 | 53,672 | 100.0% | 26,128 | 100.0% | 11,599 | 100.0% | 1,410 | 100.0% | 399 | 100.0% |
| Female | 73,308 | 42,479 | 79.1% | 20,520 | 78.5% | 8,947 | 77.1% | 1,069 | 75.8% | 293 | 73.4% |
| Male | 19,900 | 11,193 | 20.9% | 5,608 | 21.5% | 2,652 | 22.9% | 341 | 24.2% | 106 | 26.6% |
| Ribociclib | 10,271 | 6,174 | 100.0% | 2,454 | 100.0% | 1,442 | 100.0% | 173 | 100.0% | 28 | 100.0% |
| Female | 10,086 | 6,076 | 98.4% | 2,403 | 97.9% | ***** | ***** | ***** | ***** | ***** | ***** |
| Male | 185 | 98 | 1.6% | 51 | 2.1% | ***** | ***** | ***** | ***** | ***** | ***** |
| Safinamide | 5,572 | 2,352 | 100.0% | 1,683 | 100.0% | 1,171 | 100.0% | 233 | 100.0% | 133 | 100.0% |
| Female | 2,437 | 1,042 | 44.3% | 729 | 43.3% | 498 | 42.5% | 102 | 43.8% | 66 | 49.6% |
| Male | 3,135 | 1,310 | 55.7% | 954 | 56.7% | 673 | 57.5% | 131 | 56.2% | 67 | 50.4% |
| Sarilumab | 12,564 | 6,966 | 100.0% | 3,430 | 100.0% | 1,957 | 100.0% | 163 | 100.0% | 48 | 100.0% |
| Female | 10,598 | 5,849 | 84.0% | 2,903 | 84.6% | 1,673 | 85.5% | ***** | ***** | ***** | ***** |
| Male | 1,966 | 1,117 | 16.0% | 527 | 15.4% | 284 | 14.5% | ***** | ***** | ***** | ***** |
| Telotristat Ethyl | 2,713 | 1,737 | 100.0% | 632 | 100.0% | 315 | 100.0% | ***** | ***** | ***** | ***** |
| Female | 1,572 | 1,024 | 59.0% | 363 | 57.4% | 166 | 52.7% | ***** | ***** | ***** | ***** |
| Male | 1,141 | 713 | 41.0% | 269 | 42.6% | 149 | 47.3% | ***** | ***** | ***** | ***** |
| Valbenazine | 47,992 | 22,476 | 100.0% | 13,099 | 100.0% | 9,870 | 100.0% | 1,766 | 100.0% | 781 | 100.0% |
| Female | 28,835 | 13,461 | 59.9% | 7,980 | 60.9% | 5,908 | 59.9% | 1,032 | 58.4% | 454 | 58.1% |
| Male | 19,157 | 9,015 | 40.1% | 5,119 | 39.1% | 3,962 | 40.1% | 734 | 41.6% | 327 | 41.9% |

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Sex

Distribution of Treatment Episode Durations Excluding First Treatment Episode, Days

| | Total Number of Episodes | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
|-------------------------|--------------------------|----------|-----------|-----------|-----------|--------------|-------------|--------------------|
| Abaloparatide | 47,924 | 1 | 30 | 30 | 65 | 1,081 | 67.5 | 78.9 |
| Female | 46,791 | 1 | 30 | 30 | 66 | 1,081 | 67.5 | 79.1 |
| Male | 1,133 | 1 | 30 | 30 | 60 | 660 | 63.8 | 71.1 |
| Avelumab | 33,813 | 1 | 1 | 1 | 1 | 308 | 1.1 | 2.8 |
| Female | 7,982 | 1 | 1 | 1 | 1 | 140 | 1.1 | 2.1 |
| Male | 25,831 | 1 | 1 | 1 | 1 | 308 | 1.1 | 3.0 |
| Betrixaban | ***** | 3 | 14 | 42 | 42 | 60 | 32.3 | 21.4 |
| Female | ***** | 3 | 14 | 28 | 42 | 60 | 28.9 | 20.1 |
| Male | ***** | 60 | 60 | 60 | 60 | 60 | 60.0 | NaN |
| Brigatinib | 709 | 4 | 30 | 36 | 90 | 1,414 | 88.7 | 128.4 |
| Female | 454 | 4 | 30 | 53 | 90 | 768 | 84.0 | 102.8 |
| Male | 255 | 6 | 30 | 30 | 90 | 1,414 | 97.0 | 164.2 |
| Brodalumab | 2,517 | 1 | 28 | 28 | 84 | 1,225 | 74.1 | 93.9 |
| Female | 1,189 | 1 | 28 | 28 | 84 | 940 | 77.0 | 98.9 |
| Male | 1,328 | 1 | 28 | 28 | 84 | 1,225 | 71.5 | 89.0 |
| Cerliponase Alfa | 514 | 1 | 1 | 1 | 1 | 28 | 1.1 | 1.2 |
| Female | 302 | 1 | 1 | 1 | 1 | 2 | 1.0 | 0.1 |
| Male | 212 | 1 | 1 | 1 | 1 | 28 | 1.1 | 1.9 |
| Deflazacort | 2,490 | 1 | 30 | 30 | 90 | 1,802 | 99.7 | 179.7 |
| Female | 19 | 19 | 30 | 30 | 150 | 1,227 | 189.6 | 356.3 |
| Male | 2,471 | 1 | 30 | 30 | 90 | 1,802 | 99.0 | 177.6 |
| Delafloxacin | 1,101 | 1 | 10 | 10 | 14 | 180 | 16.3 | 16.7 |
| Female | 499 | 1 | 10 | 14 | 14 | 150 | 16.5 | 17.7 |
| Male | 602 | 1 | 10 | 10 | 14 | 180 | 16.1 | 15.9 |

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Sex

Distribution of Treatment Episode Durations Excluding First Treatment Episode, Days

| | Total Number of Episodes | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
|-------------------------|---------------------------------|----------------|-----------|---------------|-----------|----------------|--------------|---------------------------|
| Deutetrabenazine | 30,525 | 1 | 30 | 30 | 90 | 1,802 | 103.9 | 176.0 |
| Female | 18,777 | 1 | 30 | 30 | 90 | 1,802 | 103.5 | 175.6 |
| Male | 11,748 | 1 | 30 | 30 | 90 | 1,769 | 104.5 | 176.5 |
| Dupilumab | 229,658 | 1 | 28 | 28 | 84 | 1,858 | 77.6 | 117.5 |
| Female | 126,163 | 1 | 28 | 28 | 84 | 1,858 | 77.0 | 116.2 |
| Male | 103,495 | 1 | 28 | 28 | 84 | 1,798 | 78.3 | 118.9 |
| Durvalumab | 259,269 | 1 | 1 | 1 | 1 | 588 | 1.1 | 3.3 |
| Female | 125,315 | 1 | 1 | 1 | 1 | 464 | 1.1 | 2.9 |
| Male | 133,954 | 1 | 1 | 1 | 1 | 588 | 1.1 | 3.6 |
| Edaravone | 26,414 | 1 | 3 | 5 | 7 | 1,288 | 13.6 | 52.5 |
| Female | 11,613 | 1 | 3 | 5 | 9 | 1,288 | 13.9 | 57.0 |
| Male | 14,801 | 1 | 2 | 5 | 6 | 1,107 | 13.3 | 48.7 |
| Etelcalcetide | 8,457,346 | 1 | 1 | 1 | 1 | 82 | 1.0 | 0.1 |
| Female | 3,885,978 | 1 | 1 | 1 | 1 | 82 | 1.0 | 0.1 |
| Male | 4,571,368 | 1 | 1 | 1 | 1 | 56 | 1.0 | 0.1 |
| Midostaurin | 2,895 | 1 | 21 | 28 | 42 | 1,593 | 49.0 | 93.4 |
| Female | 1,520 | 1 | 21 | 28 | 49 | 1,569 | 51.7 | 102.2 |
| Male | 1,375 | 1 | 21 | 28 | 35 | 1,593 | 45.9 | 82.5 |
| Naldemedine | 25,826 | 1 | 30 | 30 | 60 | 1,516 | 62.1 | 84.8 |
| Female | 17,147 | 1 | 30 | 30 | 60 | 1,516 | 61.8 | 85.1 |
| Male | 8,679 | 1 | 30 | 30 | 60 | 1,440 | 62.6 | 84.1 |
| Niraparib | 9,297 | 1 | 30 | 30 | 60 | 1,648 | 68.7 | 92.8 |
| Female | 9,276 | 1 | 30 | 30 | 60 | 1,648 | 68.6 | 92.5 |
| Male | 21 | 15 | 30 | 30 | 60 | 840 | 84.1 | 176.3 |

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Sex

Distribution of Treatment Episode Durations Excluding First Treatment Episode, Days

| | Total Number of Episodes | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
|--------------------------|---------------------------------|----------------|-----------|---------------|------------|----------------|--------------|---------------------------|
| Ocrelizumab | 122,517 | 1 | 1 | 1 | 1 | 1,616 | 6.1 | 35.1 |
| Female | 82,555 | 1 | 1 | 1 | 1 | 1,616 | 6.3 | 35.6 |
| Male | 39,962 | 1 | 1 | 1 | 1 | 1,292 | 5.8 | 34.1 |
| Plecanatide | 93,208 | 1 | 30 | 30 | 90 | 1,864 | 72.3 | 100.2 |
| Female | 73,308 | 1 | 30 | 30 | 90 | 1,847 | 71.3 | 97.8 |
| Male | 19,900 | 1 | 30 | 30 | 90 | 1,864 | 75.9 | 108.5 |
| Ribociclib | 10,271 | 1 | 28 | 28 | 56 | 1,415 | 65.1 | 94.1 |
| Female | 10,086 | 1 | 28 | 28 | 56 | 1,415 | 64.9 | 93.7 |
| Male | 185 | 3 | 28 | 28 | 84 | 904 | 75.0 | 111.5 |
| Safinamide | 5,572 | 1 | 30 | 60 | 120 | 1,686 | 122.0 | 187.8 |
| Female | 2,437 | 1 | 30 | 60 | 120 | 1,554 | 123.6 | 195.2 |
| Male | 3,135 | 1 | 30 | 60 | 120 | 1,686 | 120.7 | 182.0 |
| Sarilumab | 12,564 | 1 | 28 | 28 | 84 | 1,485 | 69.9 | 95.5 |
| Female | 10,598 | 1 | 28 | 28 | 84 | 1,485 | 70.2 | 95.4 |
| Male | 1,966 | 1 | 28 | 28 | 84 | 1,160 | 68.3 | 96.2 |
| Telotristat Ethyl | 2,713 | 2 | 28 | 28 | 56 | 1,008 | 57.7 | 76.6 |
| Female | 1,572 | 3 | 28 | 28 | 56 | 896 | 56.1 | 72.9 |
| Male | 1,141 | 2 | 28 | 28 | 56 | 1,008 | 59.8 | 81.5 |
| Valbenazine | 47,992 | 1 | 30 | 60 | 108 | 1,781 | 105.8 | 162.3 |
| Female | 28,835 | 1 | 30 | 60 | 103 | 1,781 | 104.8 | 160.3 |
| Male | 19,157 | 1 | 30 | 58 | 113 | 1,697 | 107.2 | 165.2 |

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.
Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| | Number of Treatment Episodes by Duration (Excluding First Treatment Episode) | | | | | | | | | | |
|----------------------|--|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|
| | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | | |
| | Total Number of Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes |
| Abaloparatide | 47,924 | 27,855 | 100.0% | 12,818 | 100.0% | 6,559 | 100.0% | 674 | 100.0% | 18 | 100.0% |
| 0-17 years | 0 | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | ***** | ***** | ***** | ***** | ***** | 25 | 0.4% | ***** | ***** | 0 | 0.0% |
| 41-64 years | 12,539 | 7,646 | 27.4% | 3,201 | 25.0% | 1,545 | 23.6% | ***** | ***** | ***** | ***** |
| ≥ 65 years | 35,115 | 20,033 | 71.9% | 9,551 | 74.5% | 4,989 | 76.1% | ***** | ***** | ***** | ***** |
| Avelumab | 33,813 | 33,797 | 100.0% | ***** | ***** | ***** | 100.0% | 0 | NaN | 0 | NaN |
| 0-17 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | NaN | 0 | NaN |
| 18-24 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | NaN | 0 | NaN |
| 25-40 years | 76 | 76 | 0.2% | 0 | 0.0% | 0 | 0.0% | 0 | NaN | 0 | NaN |
| 41-64 years | 2,965 | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | NaN | 0 | NaN |
| ≥ 65 years | 30,745 | 30,730 | 90.9% | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN |
| Betrixaban | ***** | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN | 0 | NaN |
| 0-17 years | 0 | 0 | 0.0% | 0 | 0.0% | 0 | NaN | 0 | NaN | 0 | NaN |
| 18-24 years | 0 | 0 | 0.0% | 0 | 0.0% | 0 | NaN | 0 | NaN | 0 | NaN |
| 25-40 years | 0 | 0 | 0.0% | 0 | 0.0% | 0 | NaN | 0 | NaN | 0 | NaN |
| 41-64 years | ***** | 0 | 0.0% | ***** | ***** | 0 | NaN | 0 | NaN | 0 | NaN |
| ≥ 65 years | ***** | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN | 0 | NaN |
| Brigatinib | 709 | 353 | 100.0% | 198 | 100.0% | 135 | 100.0% | ***** | ***** | ***** | ***** |
| 0-17 years | ***** | ***** | ***** | 0 | 0.0% | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | 0 | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | ***** | ***** | ***** | 24 | 12.1% | ***** | ***** | ***** | ***** | 0 | 0.0% |
| 41-64 years | 313 | 155 | 43.9% | 85 | 42.9% | 61 | 45.2% | ***** | ***** | ***** | ***** |
| ≥ 65 years | 317 | 154 | 43.6% | 89 | 44.9% | 64 | 47.4% | ***** | ***** | ***** | ***** |

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| | Number of Treatment Episodes by Duration (Excluding First Treatment Episode) | | | | | | | | | | |
|-------------------------|--|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|
| | 1-30 Days | | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
| | Total Number of Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes |
| Brodalumab | 2,517 | 1,301 | 100.0% | 719 | 100.0% | 447 | 100.0% | ***** | ***** | ***** | ***** |
| 0-17 years | 0 | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | 37 | 21 | 1.6% | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | 397 | 254 | 19.5% | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** |
| 41-64 years | 1,289 | 657 | 50.5% | 366 | 50.9% | 242 | 54.1% | ***** | ***** | ***** | ***** |
| ≥ 65 years | 794 | 369 | 28.4% | 254 | 35.3% | 149 | 33.3% | ***** | ***** | ***** | ***** |
| Cerliponase Alfa | 514 | 514 | 100.0% | 0 | NaN | 0 | NaN | 0 | NaN | 0 | NaN |
| 0-17 years | 514 | 514 | 100.0% | 0 | NaN | 0 | NaN | 0 | NaN | 0 | NaN |
| 18-24 years | 0 | 0 | 0.0% | 0 | NaN | 0 | NaN | 0 | NaN | 0 | NaN |
| 25-40 years | 0 | 0 | 0.0% | 0 | NaN | 0 | NaN | 0 | NaN | 0 | NaN |
| 41-64 years | 0 | 0 | 0.0% | 0 | NaN | 0 | NaN | 0 | NaN | 0 | NaN |
| ≥ 65 years | 0 | 0 | 0.0% | 0 | NaN | 0 | NaN | 0 | NaN | 0 | NaN |
| Deflazacort | 2,490 | 1,340 | 100.0% | 594 | 100.0% | 435 | 100.0% | 77 | 100.0% | 44 | 100.0% |
| 0-17 years | 1,863 | 1,010 | 75.4% | 453 | 76.3% | 317 | 72.9% | 56 | 72.7% | 27 | 61.4% |
| 18-24 years | 410 | 224 | 16.7% | 90 | 15.2% | 74 | 17.0% | ***** | ***** | ***** | ***** |
| 25-40 years | ***** | ***** | 7.7% | ***** | 8.1% | ***** | ***** | ***** | ***** | ***** | ***** |
| 41-64 years | ***** | 0 | 0.0% | 0 | 0.0% | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| ≥ 65 years | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | ***** | ***** |
| Delafloxacin | 1,101 | 1,045 | 100.0% | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN |
| 0-17 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | NaN | 0 | NaN |
| 18-24 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | NaN | 0 | NaN |
| 25-40 years | 98 | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | NaN | 0 | NaN |
| 41-64 years | 488 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN |
| ≥ 65 years | 502 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN |

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| | Number of Treatment Episodes by Duration (Excluding First Treatment Episode) | | | | | | | | | | |
|-------------------------|--|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|
| | 1-30 Days | | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
| | Total Number of Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes |
| Deutetrabenazine | 30,525 | 15,618 | 100.0% | 7,567 | 100.0% | 5,547 | 100.0% | 1,196 | 100.0% | 597 | 100.0% |
| 0-17 years | 26 | 13 | 0.1% | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | 250 | 130 | 0.8% | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** |
| 25-40 years | 2,607 | 1,360 | 8.7% | 635 | 8.4% | 445 | 8.0% | ***** | ***** | ***** | ***** |
| 41-64 years | 14,989 | 7,542 | 48.3% | 3,774 | 49.9% | 2,790 | 50.3% | 574 | 48.0% | 309 | 51.8% |
| ≥ 65 years | 12,653 | 6,573 | 42.1% | 3,088 | 40.8% | 2,261 | 40.8% | 497 | 41.6% | 234 | 39.2% |
| Dupilumab | 229,658 | 126,203 | 100.0% | 58,087 | 100.0% | 38,788 | 100.0% | 5,128 | 100.0% | 1,452 | 100.0% |
| 0-17 years | 20,773 | 12,305 | 9.8% | 5,138 | 8.8% | 2,925 | 7.5% | 331 | 6.5% | 74 | 5.1% |
| 18-24 years | 24,226 | 14,509 | 11.5% | 5,924 | 10.2% | 3,398 | 8.8% | 317 | 6.2% | 78 | 5.4% |
| 25-40 years | 44,835 | 25,666 | 20.3% | 11,317 | 19.5% | 6,872 | 17.7% | 790 | 15.4% | 190 | 13.1% |
| 41-64 years | 91,209 | 49,411 | 39.2% | 22,973 | 39.5% | 15,943 | 41.1% | 2,234 | 43.6% | 648 | 44.6% |
| ≥ 65 years | 48,615 | 24,312 | 19.3% | 12,735 | 21.9% | 9,650 | 24.9% | 1,456 | 28.4% | 462 | 31.8% |
| Durvalumab | 259,269 | 259,103 | 100.0% | 106 | 100.0% | ***** | ***** | ***** | ***** | 0 | NaN |
| 0-17 years | 0 | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | NaN |
| 18-24 years | 0 | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | NaN |
| 25-40 years | 201 | 201 | 0.1% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | NaN |
| 41-64 years | 44,749 | 44,711 | 17.3% | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | NaN |
| ≥ 65 years | 214,319 | 214,191 | 82.7% | ***** | ***** | ***** | ***** | ***** | ***** | 0 | NaN |
| Edaravone | 26,414 | 25,137 | 100.0% | 572 | 100.0% | 579 | 100.0% | 99 | 100.0% | 27 | 100.0% |
| 0-17 years | 0 | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | ***** | ***** | ***** | 40 | 7.0% | 43 | 7.4% | ***** | ***** | 0 | 0.0% |
| 41-64 years | 9,925 | 9,431 | 37.5% | 222 | 38.8% | 228 | 39.4% | ***** | ***** | ***** | ***** |
| ≥ 65 years | 15,640 | 14,946 | 59.5% | 310 | 54.2% | 308 | 53.2% | ***** | ***** | ***** | ***** |

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| | Number of Treatment Episodes by Duration (Excluding First Treatment Episode) | | | | | | | | | | |
|----------------------|--|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|
| | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | | |
| | Total Number of Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes |
| Etelcalcetide | 8,457,346 | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN | 0 | NaN |
| 0-17 years | 1,517 | 1,517 | 0.0% | 0 | 0.0% | 0 | NaN | 0 | NaN | 0 | NaN |
| 18-24 years | 63,295 | 63,295 | 0.7% | 0 | 0.0% | 0 | NaN | 0 | NaN | 0 | NaN |
| 25-40 years | 936,334 | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN | 0 | NaN |
| 41-64 years | 4,448,454 | ***** | ***** | ***** | ***** | 0 | NaN | 0 | NaN | 0 | NaN |
| ≥ 65 years | 3,007,746 | 3,007,746 | 35.6% | 0 | 0.0% | 0 | NaN | 0 | NaN | 0 | NaN |
| Midostaurin | 2,895 | 2,121 | 100.0% | 508 | 100.0% | 239 | 100.0% | ***** | ***** | ***** | ***** |
| 0-17 years | 22 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | 58 | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | 237 | 171 | 8.1% | 49 | 9.6% | ***** | ***** | ***** | ***** | 0 | 0.0% |
| 41-64 years | 1,252 | 935 | 44.1% | 221 | 43.5% | 85 | 35.6% | ***** | ***** | ***** | ***** |
| ≥ 65 years | 1,326 | 953 | 44.9% | 224 | 44.1% | 134 | 56.1% | ***** | ***** | ***** | ***** |
| Naldemedine | 25,826 | 16,538 | 100.0% | 6,145 | 100.0% | 2,781 | 100.0% | 291 | 100.0% | 71 | 100.0% |
| 0-17 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | ***** | ***** | ***** | 11 | 0.2% | ***** | ***** | 0 | 0.0% | ***** | ***** |
| 25-40 years | 1,539 | 999 | 6.0% | 366 | 6.0% | ***** | ***** | ***** | ***** | ***** | ***** |
| 41-64 years | 13,297 | 8,401 | 50.8% | 3,165 | 51.5% | 1,525 | 54.8% | 163 | 56.0% | 43 | 60.6% |
| ≥ 65 years | 10,949 | 7,111 | 43.0% | 2,603 | 42.4% | 1,099 | 39.5% | ***** | ***** | ***** | ***** |
| Niraparib | 9,297 | 5,462 | 100.0% | 2,406 | 100.0% | 1,273 | 100.0% | 128 | 100.0% | 28 | 100.0% |
| 0-17 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | ***** | ***** | ***** | 40 | 1.7% | 17 | 1.3% | 0 | 0.0% | 0 | 0.0% |
| 41-64 years | 3,192 | 1,865 | 34.1% | 847 | 35.2% | 420 | 33.0% | 49 | 38.3% | 11 | 39.3% |
| ≥ 65 years | 5,947 | 3,496 | 64.0% | 1,519 | 63.1% | 836 | 65.7% | 79 | 61.7% | 17 | 60.7% |

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| | Number of Treatment Episodes by Duration (Excluding First Treatment Episode) | | | | | | | | | | |
|--------------------|--|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|
| | 1-30 Days | | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | |
| | Total Number of Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes |
| Ocrelizumab | 122,517 | 119,124 | 100.0% | 972 | 100.0% | 2,284 | 100.0% | 118 | 100.0% | 19 | 100.0% |
| 0-17 years | 108 | 108 | 0.1% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | 1,622 | 1,590 | 1.3% | 16 | 1.6% | 16 | 0.7% | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | 27,119 | 26,403 | 22.2% | 200 | 20.6% | 486 | 21.3% | ***** | ***** | ***** | ***** |
| 41-64 years | 68,562 | 66,356 | 55.7% | 636 | 65.4% | 1,489 | 65.2% | ***** | ***** | ***** | ***** |
| ≥ 65 years | 25,106 | 24,667 | 20.7% | 120 | 12.3% | 293 | 12.8% | ***** | ***** | ***** | ***** |
| Plecanatide | 93,208 | 53,672 | 100.0% | 26,128 | 100.0% | 11,599 | 100.0% | 1,410 | 100.0% | 399 | 100.0% |
| 0-17 years | 201 | 134 | 0.2% | 48 | 0.2% | ***** | ***** | ***** | ***** | ***** | ***** |
| 18-24 years | 2,683 | 1,687 | 3.1% | 688 | 2.6% | ***** | ***** | ***** | ***** | ***** | ***** |
| 25-40 years | 11,262 | 6,935 | 12.9% | 2,971 | 11.4% | 1,186 | 10.2% | 134 | 9.5% | 36 | 9.0% |
| 41-64 years | 40,708 | 23,352 | 43.5% | 11,636 | 44.5% | 4,970 | 42.8% | 574 | 40.7% | 176 | 44.1% |
| ≥ 65 years | 38,354 | 21,564 | 40.2% | 10,785 | 41.3% | 5,163 | 44.5% | 665 | 47.2% | 177 | 44.4% |
| Ribociclib | 10,271 | 6,174 | 100.0% | 2,454 | 100.0% | 1,442 | 100.0% | 173 | 100.0% | 28 | 100.0% |
| 0-17 years | ***** | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | ***** | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | 337 | 200 | 3.2% | ***** | ***** | ***** | ***** | ***** | ***** | 0 | 0.0% |
| 41-64 years | 2,954 | 1,777 | 28.8% | 726 | 29.6% | 402 | 27.9% | ***** | ***** | ***** | ***** |
| ≥ 65 years | 6,945 | 4,176 | 67.6% | 1,622 | 66.1% | 997 | 69.1% | ***** | ***** | ***** | ***** |
| Safinamide | 5,572 | 2,352 | 100.0% | 1,683 | 100.0% | 1,171 | 100.0% | 233 | 100.0% | 133 | 100.0% |
| 0-17 years | 0 | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | 0 | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | 23 | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** |
| 41-64 years | 759 | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** |
| ≥ 65 years | 4,790 | 2,013 | 85.6% | 1,447 | 86.0% | 1,015 | 86.7% | 200 | 85.8% | 115 | 86.5% |

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| | Number of Treatment Episodes by Duration (Excluding First Treatment Episode) | | | | | | | | | | |
|--------------------------|--|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|--------------------|---------------------------|
| | 1-30 Days | | 31-90 Days | | 91-365 Days | | 366-730 Days | | 731+ Days | | |
| | Total Number of Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes |
| Sarilumab | 12,564 | 6,966 | 100.0% | 3,430 | 100.0% | 1,957 | 100.0% | 163 | 100.0% | 48 | 100.0% |
| 0-17 years | **** | **** | **** | **** | **** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | **** | **** | **** | **** | **** | **** | **** | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | 1,309 | 768 | 11.0% | 348 | 10.1% | **** | **** | **** | **** | **** | **** |
| 41-64 years | 7,882 | 4,460 | 64.0% | 2,137 | 62.3% | 1,159 | 59.2% | 92 | 56.4% | 34 | 70.8% |
| ≥ 65 years | 3,282 | 1,673 | 24.0% | 927 | 27.0% | 611 | 31.2% | **** | **** | **** | **** |
| Telotristat Ethyl | 2,713 | 1,737 | 100.0% | 632 | 100.0% | 315 | 100.0% | **** | **** | **** | **** |
| 0-17 years | **** | **** | **** | **** | **** | **** | **** | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | 0 | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 25-40 years | **** | **** | **** | **** | **** | **** | **** | 0 | 0.0% | **** | **** |
| 41-64 years | 982 | 633 | 36.4% | 224 | 35.4% | **** | **** | **** | **** | **** | **** |
| ≥ 65 years | 1,612 | 1,022 | 58.8% | 381 | 60.3% | 193 | 61.3% | **** | **** | **** | **** |
| Valbenazine | 47,992 | 22,476 | 100.0% | 13,099 | 100.0% | 9,870 | 100.0% | 1,766 | 100.0% | 781 | 100.0% |
| 0-17 years | 13 | **** | **** | **** | **** | **** | **** | 0 | 0.0% | 0 | 0.0% |
| 18-24 years | 380 | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** |
| 25-40 years | 3,621 | 1,719 | 7.6% | 990 | 7.6% | 748 | 7.6% | **** | **** | **** | **** |
| 41-64 years | 26,469 | 12,456 | 55.4% | 7,208 | 55.0% | 5,408 | 54.8% | 957 | 54.2% | 440 | 56.3% |
| ≥ 65 years | 17,509 | 8,092 | 36.0% | 4,788 | 36.6% | 3,661 | 37.1% | 683 | 38.7% | 285 | 36.5% |

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

Distribution of Treatment Episode Durations Excluding First Treatment Episode, Days

| | Total Number of Episodes | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
|----------------------|--------------------------|----------|-----------|-----------|-----------|--------------|-------------|--------------------|
| Abaloparatide | 47,924 | 1 | 30 | 30 | 65 | 1,081 | 67.5 | 78.9 |
| 0-17 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 18-24 years | ***** | 11 | 30 | 30 | 60 | 60 | 41.2 | 18.8 |
| 25-40 years | ***** | 1 | 30 | 30 | 60 | 550 | 56.3 | 65.4 |
| 41-64 years | 12,539 | 1 | 30 | 30 | 60 | 1,081 | 63.1 | 75.0 |
| ≥ 65 years | 35,115 | 1 | 30 | 30 | 84 | 834 | 69.1 | 80.3 |
| Avelumab | 33,813 | 1 | 1 | 1 | 1 | 308 | 1.1 | 2.8 |
| 0-17 years | ***** | 1 | 1 | 1 | 1 | 1 | 1.0 | NaN |
| 18-24 years | ***** | 1 | 1 | 1 | 1 | 1 | 1.0 | 0.0 |
| 25-40 years | 76 | 1 | 1 | 1 | 1 | 1 | 1.0 | 0.0 |
| 41-64 years | 2,965 | 1 | 1 | 1 | 1 | 56 | 1.0 | 1.3 |
| ≥ 65 years | 30,745 | 1 | 1 | 1 | 1 | 308 | 1.1 | 2.9 |
| Betrixaban | ***** | 3 | 14 | 42 | 42 | 60 | 32.3 | 21.4 |
| 0-17 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 18-24 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 25-40 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 41-64 years | ***** | 60 | 60 | 60 | 60 | 60 | 60.0 | NaN |
| ≥ 65 years | ***** | 3 | 14 | 28 | 42 | 60 | 28.9 | 20.1 |
| Brigatinib | 709 | 4 | 30 | 36 | 90 | 1,414 | 88.7 | 128.4 |
| 0-17 years | ***** | 8 | 14 | 25 | 95 | 160 | 54.5 | 70.9 |
| 18-24 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 25-40 years | ***** | 6 | 30 | 30 | 86 | 390 | 64.8 | 63.5 |
| 41-64 years | 313 | 6 | 30 | 36 | 90 | 1,052 | 89.7 | 126.1 |
| ≥ 65 years | 317 | 4 | 30 | 46 | 90 | 1,414 | 93.8 | 141.6 |

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| Distribution of Treatment Episode Durations Excluding First Treatment Episode, Days | | | | | | | | |
|---|--------------------------|----------|-----------|-----------|-----------|--------------|-------------|--------------------|
| | Total Number of Episodes | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Brodalumab | 2,517 | 1 | 28 | 28 | 84 | 1,225 | 74.1 | 93.9 |
| 0-17 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 18-24 years | 37 | 1 | 28 | 28 | 56 | 251 | 59.2 | 58.3 |
| 25-40 years | 397 | 4 | 28 | 28 | 56 | 784 | 57.2 | 72.1 |
| 41-64 years | 1,289 | 1 | 28 | 28 | 84 | 940 | 74.4 | 92.2 |
| ≥ 65 years | 794 | 1 | 28 | 56 | 84 | 1,225 | 82.7 | 105.7 |
| Cerliponase Alfa | 514 | 1 | 1 | 1 | 1 | 28 | 1.1 | 1.2 |
| 0-17 years | 514 | 1 | 1 | 1 | 1 | 28 | 1.1 | 1.2 |
| 18-24 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 25-40 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 41-64 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| ≥ 65 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| Deflazacort | 2,490 | 1 | 30 | 30 | 90 | 1,802 | 99.7 | 179.7 |
| 0-17 years | 1,863 | 1 | 30 | 30 | 90 | 1,794 | 94.0 | 167.9 |
| 18-24 years | 410 | 1 | 30 | 30 | 90 | 1,750 | 105.3 | 179.7 |
| 25-40 years | ***** | 4 | 30 | 34 | 119 | 1,802 | 135.2 | 250.1 |
| 41-64 years | ***** | 150 | 150 | 150 | 150 | 150 | 150.0 | NaN |
| ≥ 65 years | ***** | 24 | 30 | 56 | 90 | 1,227 | 216.7 | 446.1 |
| Delafloxacin | 1,101 | 1 | 10 | 10 | 14 | 180 | 16.3 | 16.7 |
| 0-17 years | ***** | 4 | 10 | 10 | 14 | 14 | 10.9 | 3.6 |
| 18-24 years | ***** | 7 | 10 | 14 | 14 | 15 | 12.3 | 3.1 |
| 25-40 years | 98 | 1 | 10 | 14 | 18 | 60 | 15.4 | 10.0 |
| 41-64 years | 488 | 1 | 10 | 14 | 14 | 150 | 17.1 | 17.2 |
| ≥ 65 years | 502 | 1 | 10 | 10 | 14 | 180 | 15.8 | 17.5 |

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| Distribution of Treatment Episode Durations Excluding First Treatment Episode, Days | | | | | | | | |
|---|--------------------------|----------|-----------|-----------|-----------|--------------|--------------|--------------------|
| | Total Number of Episodes | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Deutetrabenazine | 30,525 | 1 | 30 | 30 | 90 | 1,802 | 103.9 | 176.0 |
| 0-17 years | 26 | 7 | 30 | 37 | 60 | 240 | 59.9 | 52.9 |
| 18-24 years | 250 | 2 | 30 | 30 | 90 | 1,313 | 99.3 | 160.8 |
| 25-40 years | 2,607 | 1 | 30 | 30 | 90 | 1,802 | 106.4 | 182.1 |
| 41-64 years | 14,989 | 1 | 30 | 30 | 90 | 1,769 | 105.6 | 177.9 |
| ≥ 65 years | 12,653 | 1 | 30 | 30 | 90 | 1,731 | 101.4 | 172.7 |
| Dupilumab | 229,658 | 1 | 28 | 28 | 84 | 1,858 | 77.6 | 117.5 |
| 0-17 years | 20,773 | 1 | 28 | 28 | 56 | 1,603 | 66.2 | 96.3 |
| 18-24 years | 24,226 | 1 | 28 | 28 | 56 | 1,790 | 64.9 | 93.0 |
| 25-40 years | 44,835 | 1 | 28 | 28 | 77 | 1,798 | 70.4 | 104.7 |
| 41-64 years | 91,209 | 1 | 28 | 28 | 84 | 1,858 | 80.5 | 122.3 |
| ≥ 65 years | 48,615 | 1 | 28 | 30 | 84 | 1,782 | 90.1 | 135.6 |
| Durvalumab | 259,269 | 1 | 1 | 1 | 1 | 588 | 1.1 | 3.3 |
| 0-17 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 18-24 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 25-40 years | 201 | 1 | 1 | 1 | 1 | 1 | 1.0 | 0.0 |
| 41-64 years | 44,749 | 1 | 1 | 1 | 1 | 350 | 1.1 | 4.1 |
| ≥ 65 years | 214,319 | 1 | 1 | 1 | 1 | 588 | 1.1 | 3.1 |
| Edaravone | 26,414 | 1 | 3 | 5 | 7 | 1,288 | 13.6 | 52.5 |
| 0-17 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 18-24 years | ***** | 1 | 1 | 1 | 3 | 5 | 2.0 | 1.7 |
| 25-40 years | ***** | 1 | 3 | 5 | 10 | 714 | 23.2 | 61.9 |
| 41-64 years | 9,925 | 1 | 1 | 5 | 10 | 1,288 | 13.6 | 53.7 |
| ≥ 65 years | 15,640 | 1 | 4 | 5 | 5 | 1,211 | 13.0 | 51.1 |

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

Distribution of Treatment Episode Durations Excluding First Treatment Episode, Days

| | Total Number of Episodes | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
|----------------------|--------------------------|----------|-----------|-----------|-----------|--------------|-------------|--------------------|
| Etelcalcetide | 8,457,346 | 1 | 1 | 1 | 1 | 82 | 1.0 | 0.1 |
| 0-17 years | 1,517 | 1 | 1 | 1 | 1 | 3 | 1.0 | 0.1 |
| 18-24 years | 63,295 | 1 | 1 | 1 | 1 | 3 | 1.0 | 0.1 |
| 25-40 years | 936,334 | 1 | 1 | 1 | 1 | 63 | 1.0 | 0.2 |
| 41-64 years | 4,448,454 | 1 | 1 | 1 | 1 | 82 | 1.0 | 0.1 |
| ≥ 65 years | 3,007,746 | 1 | 1 | 1 | 1 | 6 | 1.0 | 0.1 |
| Midostaurin | 2,895 | 1 | 21 | 28 | 42 | 1,593 | 49.0 | 93.4 |
| 0-17 years | 22 | 7 | 28 | 28 | 53 | 218 | 45.8 | 50.4 |
| 18-24 years | 58 | 12 | 14 | 28 | 28 | 268 | 34.7 | 42.3 |
| 25-40 years | 237 | 3 | 28 | 28 | 56 | 616 | 44.2 | 56.7 |
| 41-64 years | 1,252 | 1 | 21 | 28 | 33 | 1,000 | 44.5 | 70.2 |
| ≥ 65 years | 1,326 | 1 | 21 | 28 | 56 | 1,593 | 54.8 | 116.7 |
| Naldemedine | 25,826 | 1 | 30 | 30 | 60 | 1,516 | 62.1 | 84.8 |
| 0-17 years | ***** | 30 | 30 | 30 | 30 | 30 | 30.0 | 0.0 |
| 18-24 years | ***** | 4 | 30 | 30 | 60 | 757 | 68.4 | 121.2 |
| 25-40 years | 1,539 | 1 | 30 | 30 | 60 | 1,075 | 60.5 | 81.3 |
| 41-64 years | 13,297 | 1 | 30 | 30 | 60 | 1,455 | 64.1 | 87.7 |
| ≥ 65 years | 10,949 | 1 | 30 | 30 | 60 | 1,516 | 59.9 | 81.4 |
| Niraparib | 9,297 | 1 | 30 | 30 | 60 | 1,648 | 68.7 | 92.8 |
| 0-17 years | ***** | 28 | 28 | 28 | 28 | 28 | 28.0 | NaN |
| 18-24 years | ***** | 30 | 30 | 30 | 30 | 30 | 30.0 | 0.0 |
| 25-40 years | ***** | 6 | 30 | 30 | 60 | 330 | 56.2 | 54.3 |
| 41-64 years | 3,192 | 1 | 30 | 30 | 60 | 1,345 | 68.9 | 96.3 |
| ≥ 65 years | 5,947 | 1 | 30 | 30 | 60 | 1,648 | 68.9 | 91.7 |

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| Distribution of Treatment Episode Durations Excluding First Treatment Episode, Days | | | | | | | | |
|---|--------------------------|----------|-----------|-----------|------------|--------------|--------------|--------------------|
| | Total Number of Episodes | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Ocrelizumab | 122,517 | 1 | 1 | 1 | 1 | 1,616 | 6.1 | 35.1 |
| 0-17 years | 108 | 1 | 1 | 1 | 1 | 1 | 1.0 | 0.0 |
| 18-24 years | 1,622 | 1 | 1 | 1 | 1 | 360 | 3.8 | 20.9 |
| 25-40 years | 27,119 | 1 | 1 | 1 | 1 | 1,178 | 5.9 | 33.6 |
| 41-64 years | 68,562 | 1 | 1 | 1 | 1 | 1,616 | 6.9 | 37.9 |
| ≥ 65 years | 25,106 | 1 | 1 | 1 | 1 | 876 | 4.4 | 29.2 |
| Plecanatide | 93,208 | 1 | 30 | 30 | 90 | 1,864 | 72.3 | 100.2 |
| 0-17 years | 201 | 7 | 30 | 30 | 60 | 897 | 57.6 | 85.0 |
| 18-24 years | 2,683 | 1 | 30 | 30 | 63 | 1,340 | 65.1 | 93.0 |
| 25-40 years | 11,262 | 1 | 30 | 30 | 73 | 1,792 | 65.4 | 90.4 |
| 41-64 years | 40,708 | 1 | 30 | 30 | 90 | 1,847 | 71.7 | 99.5 |
| ≥ 65 years | 38,354 | 1 | 30 | 30 | 90 | 1,864 | 75.6 | 104.1 |
| Ribociclib | 10,271 | 1 | 28 | 28 | 56 | 1,415 | 65.1 | 94.1 |
| 0-17 years | ***** | 15 | 28 | 28 | 56 | 140 | 49.8 | 35.0 |
| 18-24 years | ***** | 4 | 21 | 21 | 56 | 149 | 44.7 | 47.9 |
| 25-40 years | 337 | 1 | 28 | 28 | 56 | 392 | 55.2 | 60.4 |
| 41-64 years | 2,954 | 1 | 28 | 28 | 56 | 1,415 | 63.5 | 93.9 |
| ≥ 65 years | 6,945 | 1 | 28 | 28 | 56 | 1,387 | 66.3 | 95.7 |
| Safinamide | 5,572 | 1 | 30 | 60 | 120 | 1,686 | 122.0 | 187.8 |
| 0-17 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 18-24 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 25-40 years | 23 | 14 | 30 | 60 | 90 | 854 | 132.8 | 211.3 |
| 41-64 years | 759 | 1 | 30 | 60 | 120 | 1,585 | 117.4 | 183.7 |
| ≥ 65 years | 4,790 | 1 | 30 | 60 | 120 | 1,686 | 122.6 | 188.4 |

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| Distribution of Treatment Episode Durations Excluding First Treatment Episode, Days | | | | | | | | |
|---|--------------------------|----------|-----------|-----------|------------|--------------|--------------|--------------------|
| | Total Number of Episodes | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Sarilumab | 12,564 | 1 | 28 | 28 | 84 | 1,485 | 69.9 | 95.5 |
| 0-17 years | ***** | 1 | 1 | 1 | 1 | 47 | 8.7 | 18.8 |
| 18-24 years | ***** | 27 | 28 | 28 | 56 | 336 | 51.7 | 57.0 |
| 25-40 years | 1,309 | 1 | 28 | 28 | 57 | 1,253 | 63.7 | 84.0 |
| 41-64 years | 7,882 | 1 | 28 | 28 | 83 | 1,485 | 68.0 | 94.5 |
| ≥ 65 years | 3,282 | 1 | 28 | 30 | 84 | 1,474 | 77.3 | 102.5 |
| Telotristat Ethyl | 2,713 | 2 | 28 | 28 | 56 | 1,008 | 57.7 | 76.6 |
| 0-17 years | ***** | 28 | 28 | 28 | 84 | 280 | 73.5 | 88.5 |
| 18-24 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 25-40 years | ***** | 13 | 28 | 28 | 56 | 1,008 | 52.4 | 100.7 |
| 41-64 years | 982 | 3 | 28 | 28 | 56 | 980 | 58.6 | 87.1 |
| ≥ 65 years | 1,612 | 2 | 28 | 28 | 56 | 756 | 57.4 | 67.4 |
| Valbenazine | 47,992 | 1 | 30 | 60 | 108 | 1,781 | 105.8 | 162.3 |
| 0-17 years | 13 | 5 | 30 | 30 | 60 | 120 | 45.8 | 28.2 |
| 18-24 years | 380 | 1 | 30 | 30 | 90 | 1,054 | 91.1 | 143.8 |
| 25-40 years | 3,621 | 1 | 30 | 56 | 95 | 1,656 | 102.5 | 159.0 |
| 41-64 years | 26,469 | 1 | 30 | 59 | 103 | 1,781 | 105.3 | 161.5 |
| ≥ 65 years | 17,509 | 1 | 30 | 60 | 120 | 1,709 | 107.5 | 164.6 |

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 7a. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| Distribution of Treatment Episode Gap Durations, Days | | | | | | | | |
|---|-------------------------|---------|-----|--------|-----|---------|-------|-----------------------|
| | Total Number of Gaps | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Abaloparatide | 47,924 | 1 | 3 | 8 | 19 | 1,481 | 19.4 | 47.2 |
| Avelumab | 33,813 | 1 | 13 | 13 | 13 | 839 | 15.4 | 16.7 |
| Betrixaban | 9 | 1 | 1 | 2 | 4 | 10 | 3.6 | 3.3 |
| Brigatinib | 709 | 1 | 3 | 6 | 15 | 1,192 | 24.7 | 90.6 |
| Brodalumab | 2,517 | 1 | 4 | 7 | 17 | 609 | 17.4 | 40.1 |
| Cerliponase Alfa | 514 | 1 | 13 | 13 | 13 | 266 | 14.0 | 12.5 |
| Deflazacort | 2,490 | 1 | 3 | 6 | 17 | 1,487 | 22.1 | 65.4 |
| Delafloxacin | 1,101 | 1 | 6 | 23 | 75 | 1,025 | 71.0 | 121.7 |
| Deutetrabenazine | 30,525 | 1 | 3 | 6 | 18 | 1,510 | 23.8 | 71.5 |
| Dupilumab | 229,658 | 1 | 3 | 7 | 18 | 1,776 | 22.2 | 62.2 |
| Durvalumab | 259,269 | 1 | 13 | 13 | 13 | 985 | 16.3 | 11.5 |
| Edaravone | 26,414 | 1 | 2 | 14 | 17 | 572 | 12.0 | 14.9 |
| Etelcalcetide | 8,457,346 | 1 | 1 | 1 | 2 | 1,548 | 1.9 | 9.9 |
| Midostaurin | 2,895 | 1 | 5 | 13 | 28 | 1,272 | 27.3 | 58.2 |
| Naldemedine | 25,826 | 1 | 4 | 12 | 32 | 1,561 | 35.9 | 81.5 |
| Niraparib | 9,297 | 1 | 3 | 8 | 24 | 1,271 | 26.1 | 67.4 |
| Ocrelizumab | 122,517 | 1 | 165 | 181 | 188 | 1,572 | 161.9 | 100.2 |
| Plecanatide | 93,208 | 1 | 4 | 11 | 35 | 1,667 | 42.0 | 101.4 |
| Ribociclib | 10,271 | 1 | 3 | 7 | 15 | 1,449 | 17.3 | 46.5 |
| Safinamide | 5,572 | 1 | 3 | 6 | 19 | 1,362 | 24.3 | 74.6 |
| Sarilumab | 12,564 | 1 | 3 | 8 | 19 | 1,385 | 20.9 | 54.0 |
| Telotristat Ethyl | 2,713 | 1 | 4 | 8 | 19 | 1,278 | 23.6 | 69.3 |
| Valbenazine | 47,992 | 1 | 3 | 7 | 18 | 1,704 | 26.0 | 86.0 |

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Sex

| Distribution of Treatment Episode Gap Durations, Days | | | | | | | | |
|---|-------------------------|----------|-----------|-----------|-----------|--------------|-------------|-----------------------|
| | Total Number of Gaps | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Abaloparatide | 47,924 | 1 | 3 | 8 | 19 | 1,481 | 19.4 | 47.2 |
| Female | 46,791 | 1 | 3 | 8 | 19 | 1,481 | 19.5 | 47.3 |
| Male | 1,133 | 1 | 4 | 8 | 18 | 1,159 | 18.2 | 44.0 |
| Avelumab | 33,813 | 1 | 13 | 13 | 13 | 839 | 15.4 | 16.7 |
| Female | 7,982 | 1 | 13 | 13 | 13 | 700 | 15.5 | 19.7 |
| Male | 25,831 | 1 | 13 | 13 | 13 | 839 | 15.3 | 15.6 |
| Betrixaban | 9 | 1 | 1 | 2 | 4 | 10 | 3.6 | 3.3 |
| Female | 8 | 1 | 1 | 2 | 4 | 8 | 2.8 | 2.4 |
| Male | 1 | 10 | 10 | 10 | 10 | 10 | 10.0 | NaN |
| Brigatinib | 709 | 1 | 3 | 6 | 15 | 1,192 | 24.7 | 90.6 |
| Female | 454 | 1 | 3 | 6 | 15 | 1,192 | 21.8 | 82.1 |
| Male | 255 | 1 | 3 | 6 | 15 | 1,127 | 29.8 | 104.0 |
| Brodalumab | 2,517 | 1 | 4 | 7 | 17 | 609 | 17.4 | 40.1 |
| Female | 1,189 | 1 | 4 | 7 | 16 | 535 | 15.7 | 30.0 |
| Male | 1,328 | 1 | 3 | 7 | 17 | 609 | 18.9 | 47.2 |
| Cerliponase Alfa | 514 | 1 | 13 | 13 | 13 | 266 | 14.0 | 12.5 |
| Female | 302 | 4 | 13 | 13 | 13 | 266 | 14.2 | 15.7 |
| Male | 212 | 1 | 13 | 13 | 13 | 69 | 13.7 | 5.2 |
| Deflazacort | 2,490 | 1 | 3 | 6 | 17 | 1,487 | 22.1 | 65.4 |
| Female | 19 | 1 | 3 | 13 | 56 | 232 | 41.9 | 69.4 |
| Male | 2,471 | 1 | 3 | 6 | 17 | 1,487 | 22.0 | 65.3 |
| Delafloxacin | 1,101 | 1 | 6 | 23 | 75 | 1,025 | 71.0 | 121.7 |
| Female | 499 | 1 | 7 | 27 | 81 | 1,025 | 70.2 | 111.5 |
| Male | 602 | 1 | 5 | 20 | 73 | 852 | 71.6 | 129.7 |

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Sex

| Distribution of Treatment Episode Gap Durations, Days | | | | | | | | |
|---|-------------------------|----------|-----------|-----------|-----------|--------------|-------------|-----------------------|
| | Total Number of Gaps | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Deutetrabenazine | 30,525 | 1 | 3 | 6 | 18 | 1,510 | 23.8 | 71.5 |
| Female | 18,777 | 1 | 3 | 6 | 17 | 1,510 | 24.0 | 73.2 |
| Male | 11,748 | 1 | 3 | 6 | 18 | 1,429 | 23.7 | 68.9 |
| Dupilumab | 229,658 | 1 | 3 | 7 | 18 | 1,776 | 22.2 | 62.2 |
| Female | 126,163 | 1 | 3 | 8 | 19 | 1,776 | 22.0 | 61.3 |
| Male | 103,495 | 1 | 3 | 7 | 18 | 1,664 | 22.5 | 63.4 |
| Durvalumab | 259,269 | 1 | 13 | 13 | 13 | 985 | 16.3 | 11.5 |
| Female | 125,315 | 1 | 13 | 13 | 14 | 944 | 16.4 | 11.7 |
| Male | 133,954 | 1 | 13 | 13 | 13 | 985 | 16.2 | 11.4 |
| Edaravone | 26,414 | 1 | 2 | 14 | 17 | 572 | 12.0 | 14.9 |
| Female | 11,613 | 1 | 2 | 14 | 17 | 482 | 11.8 | 14.6 |
| Male | 14,801 | 1 | 2 | 13 | 17 | 572 | 12.1 | 15.1 |
| Etelcalcetide | 8,457,346 | 1 | 1 | 1 | 2 | 1,548 | 1.9 | 9.9 |
| Female | 3,885,978 | 1 | 1 | 1 | 2 | 1,383 | 2.0 | 10.1 |
| Male | 4,571,368 | 1 | 1 | 1 | 2 | 1,548 | 1.9 | 9.7 |
| Midostaurin | 2,895 | 1 | 5 | 13 | 28 | 1,272 | 27.3 | 58.2 |
| Female | 1,520 | 1 | 5 | 13 | 29 | 1,272 | 30.0 | 66.7 |
| Male | 1,375 | 1 | 5 | 12 | 26 | 761 | 24.2 | 46.8 |
| Naldemedine | 25,826 | 1 | 4 | 12 | 32 | 1,561 | 35.9 | 81.5 |
| Female | 17,147 | 1 | 4 | 12 | 32 | 1,561 | 35.6 | 81.2 |
| Male | 8,679 | 1 | 4 | 12 | 33 | 1,498 | 36.5 | 81.9 |
| Niraparib | 9,297 | 1 | 3 | 8 | 24 | 1,271 | 26.1 | 67.4 |
| Female | 9,276 | 1 | 3 | 8 | 24 | 1,271 | 26.1 | 67.4 |
| Male | 21 | 2 | 5 | 8 | 16 | 153 | 17.8 | 32.7 |

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Sex

| Distribution of Treatment Episode Gap Durations, Days | | | | | | | | |
|---|-------------------------|----------|------------|------------|------------|--------------|--------------|-----------------------|
| | Total Number of Gaps | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Ocrelizumab | 122,517 | 1 | 165 | 181 | 188 | 1,572 | 161.9 | 100.2 |
| Female | 82,555 | 1 | 163 | 181 | 188 | 1,572 | 161.3 | 100.9 |
| Male | 39,962 | 1 | 167 | 181 | 188 | 1,518 | 163.0 | 98.7 |
| Plecanatide | 93,208 | 1 | 4 | 11 | 35 | 1,667 | 42.0 | 101.4 |
| Female | 73,308 | 1 | 4 | 11 | 35 | 1,641 | 41.8 | 100.7 |
| Male | 19,900 | 1 | 4 | 11 | 35 | 1,667 | 42.5 | 104.1 |
| Ribociclib | 10,271 | 1 | 3 | 7 | 15 | 1,449 | 17.3 | 46.5 |
| Female | 10,086 | 1 | 3 | 7 | 15 | 1,449 | 17.2 | 45.3 |
| Male | 185 | 1 | 2 | 6 | 14 | 1,011 | 24.7 | 89.6 |
| Ssatinamide | 5,572 | 1 | 3 | 6 | 19 | 1,362 | 24.3 | 74.6 |
| Female | 2,437 | 1 | 3 | 6 | 19 | 1,308 | 24.4 | 72.9 |
| Male | 3,135 | 1 | 3 | 6 | 19 | 1,362 | 24.3 | 75.9 |
| Sarilumab | 12,564 | 1 | 3 | 8 | 19 | 1,385 | 20.9 | 54.0 |
| Female | 10,598 | 1 | 3 | 8 | 20 | 1,385 | 21.3 | 54.5 |
| Male | 1,966 | 1 | 3 | 7 | 15 | 1,056 | 18.8 | 51.0 |
| Telotristat Ethyl | 2,713 | 1 | 4 | 8 | 19 | 1,278 | 23.6 | 69.3 |
| Female | 1,572 | 1 | 4 | 8 | 19 | 1,278 | 22.9 | 68.9 |
| Male | 1,141 | 1 | 4 | 8 | 20 | 857 | 24.6 | 69.8 |
| Valbenazine | 47,992 | 1 | 3 | 7 | 18 | 1,704 | 26.0 | 86.0 |
| Female | 28,835 | 1 | 3 | 7 | 18 | 1,704 | 26.0 | 87.2 |
| Male | 19,157 | 1 | 3 | 7 | 18 | 1,574 | 26.1 | 84.2 |

Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| Distribution of Treatment Episode Gap Durations, Days | | | | | | | | |
|---|-------------------------|----------|-----------|-----------|-----------|--------------|-------------|-----------------------|
| | Total Number of Gaps | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Abaloparatide | 47,924 | 1 | 3 | 8 | 19 | 1,481 | 19.4 | 47.2 |
| 0-17 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 18-24 years | 9 | 1 | 2 | 5 | 13 | 23 | 8.7 | 8.1 |
| 25-40 years | 261 | 1 | 3 | 7 | 19 | 1,481 | 24.0 | 95.7 |
| 41-64 years | 12,539 | 1 | 3 | 8 | 19 | 1,397 | 20.4 | 48.9 |
| ≥ 65 years | 35,115 | 1 | 3 | 8 | 19 | 1,234 | 19.1 | 46.0 |
| Avelumab | 33,813 | 1 | 13 | 13 | 13 | 839 | 15.4 | 16.7 |
| 0-17 years | 1 | 21 | 21 | 21 | 21 | 21 | 21.0 | NaN |
| 18-24 years | 26 | 12 | 13 | 13 | 13 | 27 | 13.8 | 3.0 |
| 25-40 years | 76 | 11 | 13 | 13 | 27 | 76 | 19.2 | 10.3 |
| 41-64 years | 2,965 | 1 | 13 | 13 | 13 | 195 | 15.3 | 9.1 |
| ≥ 65 years | 30,745 | 1 | 13 | 13 | 13 | 839 | 15.4 | 17.2 |
| Betrixaban | 9 | 1 | 1 | 2 | 4 | 10 | 3.6 | 3.3 |
| 0-17 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 18-24 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 25-40 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 41-64 years | 1 | 10 | 10 | 10 | 10 | 10 | 10.0 | NaN |
| ≥ 65 years | 8 | 1 | 1 | 2 | 4 | 8 | 2.8 | 2.4 |
| Brigatinib | 709 | 1 | 3 | 6 | 15 | 1,192 | 24.7 | 90.6 |
| 0-17 years | 4 | 12 | 17 | 31 | 48 | 56 | 32.3 | 19.7 |
| 18-24 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 25-40 years | 75 | 1 | 4 | 9 | 16 | 74 | 13.2 | 13.9 |
| 41-64 years | 313 | 1 | 3 | 6 | 14 | 1,127 | 23.2 | 83.6 |
| ≥ 65 years | 317 | 1 | 2 | 5 | 16 | 1,192 | 28.8 | 106.8 |

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| Distribution of Treatment Episode Gap Durations, Days | | | | | | | | |
|---|-------------------------|----------|-----------|-----------|-----------|--------------|-------------|-----------------------|
| | Total Number of Gaps | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Brodalumab | 2,517 | 1 | 4 | 7 | 17 | 609 | 17.4 | 40.1 |
| 0-17 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 18-24 years | 37 | 1 | 6 | 9 | 17 | 242 | 19.9 | 40.0 |
| 25-40 years | 397 | 1 | 4 | 8 | 17 | 535 | 17.4 | 40.2 |
| 41-64 years | 1,289 | 1 | 3 | 7 | 17 | 546 | 16.4 | 32.6 |
| ≥ 65 years | 794 | 1 | 3 | 7 | 16 | 609 | 18.8 | 49.8 |
| Cerliponase Alfa | 514 | 1 | 13 | 13 | 13 | 266 | 14.0 | 12.5 |
| 0-17 years | 514 | 1 | 13 | 13 | 13 | 266 | 14.0 | 12.5 |
| 18-24 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 25-40 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 41-64 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| ≥ 65 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| Deflazacort | 2,490 | 1 | 3 | 6 | 17 | 1,487 | 22.1 | 65.4 |
| 0-17 years | 1,863 | 1 | 3 | 6 | 17 | 1,487 | 21.7 | 63.4 |
| 18-24 years | 410 | 1 | 3 | 7 | 16 | 798 | 23.9 | 72.8 |
| 25-40 years | 209 | 1 | 2 | 5 | 15 | 755 | 21.4 | 67.4 |
| 41-64 years | 1 | 17 | 17 | 17 | 17 | 17 | 17.0 | NaN |
| ≥ 65 years | 7 | 1 | 6 | 13 | 66 | 218 | 52.3 | 77.6 |
| Delafloxacin | 1,101 | 1 | 6 | 23 | 75 | 1,025 | 71.0 | 121.7 |
| 0-17 years | 7 | 10 | 14 | 22 | 55 | 76 | 31.7 | 24.3 |
| 18-24 years | 6 | 1 | 22 | 45 | 63 | 145 | 53.5 | 51.0 |
| 25-40 years | 98 | 1 | 12 | 34 | 108 | 478 | 77.2 | 100.0 |
| 41-64 years | 488 | 1 | 6 | 22 | 70 | 1,025 | 75.0 | 139.2 |
| ≥ 65 years | 502 | 1 | 5 | 22 | 76 | 684 | 66.6 | 107.9 |

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| Distribution of Treatment Episode Gap Durations, Days | | | | | | | | |
|---|-------------------------|----------|-----------|-----------|-----------|--------------|-------------|-----------------------|
| | Total Number of Gaps | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Deutetrabenazine | 30,525 | 1 | 3 | 6 | 18 | 1,510 | 23.8 | 71.5 |
| 0-17 years | 26 | 1 | 2 | 3 | 17 | 166 | 24.1 | 42.9 |
| 18-24 years | 250 | 1 | 3 | 8 | 23 | 872 | 30.9 | 87.6 |
| 25-40 years | 2,607 | 1 | 3 | 6 | 17 | 979 | 22.8 | 66.0 |
| 41-64 years | 14,989 | 1 | 3 | 7 | 19 | 1,429 | 25.1 | 74.8 |
| ≥ 65 years | 12,653 | 1 | 3 | 6 | 17 | 1,510 | 22.4 | 68.3 |
| Dupilumab | 229,658 | 1 | 3 | 7 | 18 | 1,776 | 22.2 | 62.2 |
| 0-17 years | 20,773 | 1 | 4 | 9 | 22 | 964 | 21.7 | 47.6 |
| 18-24 years | 24,226 | 1 | 4 | 9 | 21 | 1,304 | 25.7 | 68.3 |
| 25-40 years | 44,835 | 1 | 3 | 8 | 20 | 1,776 | 23.7 | 68.3 |
| 41-64 years | 91,209 | 1 | 3 | 7 | 17 | 1,686 | 20.9 | 60.1 |
| ≥ 65 years | 48,615 | 1 | 3 | 7 | 17 | 1,612 | 21.7 | 62.6 |
| Durvalumab | 259,269 | 1 | 13 | 13 | 13 | 985 | 16.3 | 11.5 |
| 0-17 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 18-24 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 25-40 years | 201 | 1 | 13 | 13 | 27 | 223 | 20.5 | 17.0 |
| 41-64 years | 44,749 | 1 | 13 | 13 | 14 | 801 | 16.7 | 12.9 |
| ≥ 65 years | 214,319 | 1 | 13 | 13 | 13 | 985 | 16.2 | 11.2 |
| Edaravone | 26,414 | 1 | 2 | 14 | 17 | 572 | 12.0 | 14.9 |
| 0-17 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 18-24 years | 10 | 1 | 1 | 2 | 17 | 23 | 7.3 | 8.9 |
| 25-40 years | 839 | 1 | 2 | 14 | 18 | 572 | 14.2 | 28.0 |
| 41-64 years | 9,925 | 1 | 2 | 16 | 20 | 423 | 14.6 | 15.3 |
| ≥ 65 years | 15,640 | 1 | 2 | 9 | 16 | 482 | 10.2 | 13.3 |

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| Distribution of Treatment Episode Gap Durations, Days | | | | | | | | |
|---|-------------------------|----------|----------|-----------|-----------|--------------|-------------|-----------------------|
| | Total Number of Gaps | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Etelcalcetide | 8,457,346 | 1 | 1 | 1 | 2 | 1,548 | 1.9 | 9.9 |
| 0-17 years | 1,517 | 1 | 1 | 1 | 2 | 279 | 2.2 | 9.1 |
| 18-24 years | 63,295 | 1 | 1 | 1 | 2 | 774 | 2.1 | 11.1 |
| 25-40 years | 936,334 | 1 | 1 | 1 | 2 | 1,190 | 2.0 | 11.0 |
| 41-64 years | 4,448,454 | 1 | 1 | 1 | 2 | 1,548 | 1.9 | 10.0 |
| ≥ 65 years | 3,007,746 | 1 | 1 | 1 | 2 | 1,429 | 1.9 | 9.4 |
| Midostaurin | 2,895 | 1 | 5 | 13 | 28 | 1,272 | 27.3 | 58.2 |
| 0-17 years | 22 | 1 | 3 | 7 | 19 | 128 | 18.3 | 28.3 |
| 18-24 years | 58 | 1 | 10 | 20 | 35 | 135 | 27.7 | 26.4 |
| 25-40 years | 237 | 1 | 4 | 12 | 30 | 1,272 | 29.2 | 87.3 |
| 41-64 years | 1,252 | 1 | 5 | 13 | 29 | 761 | 28.2 | 55.5 |
| ≥ 65 years | 1,326 | 1 | 5 | 12 | 26 | 871 | 26.2 | 55.5 |
| Naldemedine | 25,826 | 1 | 4 | 12 | 32 | 1,561 | 35.9 | 81.5 |
| 0-17 years | 3 | 19 | 19 | 22 | 48 | 48 | 29.7 | 15.9 |
| 18-24 years | 38 | 1 | 12 | 26 | 83 | 393 | 62.8 | 87.5 |
| 25-40 years | 1,539 | 1 | 4 | 12 | 33 | 1,024 | 36.3 | 82.0 |
| 41-64 years | 13,297 | 1 | 4 | 12 | 32 | 1,498 | 35.5 | 80.2 |
| ≥ 65 years | 10,949 | 1 | 4 | 12 | 32 | 1,561 | 36.1 | 82.8 |
| Niraparib | 9,297 | 1 | 3 | 8 | 24 | 1,271 | 26.1 | 67.4 |
| 0-17 years | 1 | 5 | 5 | 5 | 5 | 5 | 5.0 | NaN |
| 18-24 years | 7 | 1 | 2 | 19 | 36 | 48 | 20.3 | 17.6 |
| 25-40 years | 150 | 1 | 3 | 8 | 19 | 741 | 22.6 | 71.0 |
| 41-64 years | 3,192 | 1 | 3 | 8 | 20 | 1,271 | 20.6 | 55.6 |
| ≥ 65 years | 5,947 | 1 | 3 | 9 | 26 | 1,221 | 29.1 | 72.7 |

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| Distribution of Treatment Episode Gap Durations, Days | | | | | | | | |
|---|-------------------------|----------|------------|------------|------------|--------------|--------------|-----------------------|
| | Total Number of Gaps | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Ocrelizumab | 122,517 | 1 | 165 | 181 | 188 | 1,572 | 161.9 | 100.2 |
| 0-17 years | 108 | 7 | 13 | 178 | 187 | 910 | 130.8 | 116.9 |
| 18-24 years | 1,622 | 1 | 20 | 180 | 188 | 1,364 | 148.5 | 107.2 |
| 25-40 years | 27,119 | 1 | 153 | 181 | 188 | 1,393 | 158.4 | 103.9 |
| 41-64 years | 68,562 | 1 | 165 | 181 | 188 | 1,572 | 163.0 | 101.5 |
| ≥ 65 years | 25,106 | 1 | 167 | 181 | 188 | 1,476 | 163.6 | 91.5 |
| Plecanatide | 93,208 | 1 | 4 | 11 | 35 | 1,667 | 42.0 | 101.4 |
| 0-17 years | 201 | 1 | 3 | 10 | 28 | 929 | 37.7 | 107.7 |
| 18-24 years | 2,683 | 1 | 4 | 10 | 28 | 1,343 | 33.7 | 85.7 |
| 25-40 years | 11,262 | 1 | 4 | 11 | 33 | 1,460 | 40.1 | 97.0 |
| 41-64 years | 40,708 | 1 | 4 | 11 | 35 | 1,665 | 41.1 | 98.9 |
| ≥ 65 years | 38,354 | 1 | 4 | 11 | 36 | 1,667 | 44.0 | 106.2 |
| Ribociclib | 10,271 | 1 | 3 | 7 | 15 | 1,449 | 17.3 | 46.5 |
| 0-17 years | 25 | 1 | 2 | 6 | 12 | 101 | 11.1 | 20.0 |
| 18-24 years | 10 | 1 | 4 | 6 | 8 | 14 | 6.3 | 3.7 |
| 25-40 years | 337 | 1 | 2 | 6 | 14 | 457 | 15.7 | 36.4 |
| 41-64 years | 2,954 | 1 | 3 | 7 | 14 | 748 | 15.8 | 35.7 |
| ≥ 65 years | 6,945 | 1 | 3 | 7 | 15 | 1,449 | 18.0 | 50.8 |
| Safinamide | 5,572 | 1 | 3 | 6 | 19 | 1,362 | 24.3 | 74.6 |
| 0-17 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 18-24 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 25-40 years | 23 | 1 | 2 | 4 | 9 | 52 | 8.4 | 11.7 |
| 41-64 years | 759 | 1 | 3 | 7 | 21 | 1,066 | 23.6 | 67.0 |
| ≥ 65 years | 4,790 | 1 | 3 | 6 | 19 | 1,362 | 24.5 | 75.9 |

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| Distribution of Treatment Episode Gap Durations, Days | | | | | | | | |
|---|-------------------------|----------|----------|----------|-----------|--------------|-------------|-----------------------|
| | Total Number of Gaps | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Sarilumab | 12,564 | 1 | 3 | 8 | 19 | 1,385 | 20.9 | 54.0 |
| 0-17 years | 6 | 13 | 13 | 13 | 14 | 15 | 13.5 | 0.8 |
| 18-24 years | 85 | 1 | 3 | 6 | 14 | 175 | 15.8 | 28.7 |
| 25-40 years | 1,309 | 1 | 4 | 8 | 21 | 1,385 | 27.3 | 83.8 |
| 41-64 years | 7,882 | 1 | 3 | 8 | 19 | 1,137 | 20.3 | 50.4 |
| ≥ 65 years | 3,282 | 1 | 3 | 7 | 19 | 827 | 20.0 | 47.0 |
| Telotristat Ethyl | 2,713 | 1 | 4 | 8 | 19 | 1,278 | 23.6 | 69.3 |
| 0-17 years | 8 | 1 | 2 | 5 | 10 | 12 | 5.9 | 4.4 |
| 18-24 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 25-40 years | 111 | 1 | 3 | 8 | 24 | 665 | 23.8 | 65.4 |
| 41-64 years | 982 | 1 | 4 | 8 | 20 | 1,278 | 23.5 | 67.5 |
| ≥ 65 years | 1,612 | 1 | 4 | 8 | 18 | 1,061 | 23.7 | 70.9 |
| Valbenazine | 47,992 | 1 | 3 | 7 | 18 | 1,704 | 26.0 | 86.0 |
| 0-17 years | 13 | 2 | 4 | 6 | 24 | 131 | 26.4 | 41.4 |
| 18-24 years | 380 | 1 | 3 | 7 | 23 | 1,281 | 28.5 | 93.8 |
| 25-40 years | 3,621 | 1 | 3 | 7 | 19 | 1,704 | 27.4 | 87.0 |
| 41-64 years | 26,469 | 1 | 3 | 7 | 18 | 1,643 | 27.1 | 90.0 |
| ≥ 65 years | 17,509 | 1 | 3 | 6 | 17 | 1,509 | 24.1 | 79.2 |

Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 8a. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| | Distribution of First Treatment Episode Gap Duration, Days | | | | | | | |
|-------------------|--|---------|----|--------|-----|---------|------|--------------------|
| | Total Number of Gaps | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Abaloparatide | 13,406 | 1 | 3 | 9 | 22 | 1,481 | 24.2 | 60.3 |
| Avelumab | 2,518 | 1 | 13 | 13 | 13 | 654 | 15.8 | 19.3 |
| Betrixaban | 4 | 1 | 3 | 6 | 9 | 10 | 5.8 | 4.0 |
| Brigatinib | 234 | 1 | 3 | 6 | 15 | 1,192 | 39.4 | 139.3 |
| Brodalumab | 585 | 1 | 4 | 8 | 20 | 592 | 20.4 | 46.9 |
| Cerliponase Alfa | 18 | 1 | 11 | 13 | 15 | 69 | 16.8 | 14.9 |
| Deflazacort | 649 | 1 | 4 | 9 | 24 | 934 | 30.9 | 70.8 |
| Delafloxacin | 595 | 1 | 5 | 22 | 77 | 861 | 72.3 | 122.4 |
| Deutetrabenazine | 8,783 | 1 | 3 | 8 | 21 | 1,510 | 32.4 | 95.1 |
| Dupilumab | 55,904 | 1 | 3 | 8 | 17 | 1,776 | 25.7 | 79.9 |
| Durvalumab | 23,311 | 1 | 13 | 13 | 20 | 644 | 17.7 | 14.2 |
| Edaravone | 1,782 | 1 | 2 | 12 | 16 | 572 | 13.2 | 26.1 |
| Etelcalcetide | 52,314 | 1 | 1 | 1 | 2 | 1,299 | 3.5 | 23.9 |
| Midostaurin | 1,016 | 1 | 7 | 17 | 33 | 1,272 | 33.5 | 71.1 |
| Naldemedine | 7,317 | 1 | 5 | 14 | 41 | 1,561 | 46.3 | 105.0 |
| Niraparib | 3,397 | 1 | 4 | 13 | 32 | 1,271 | 33.8 | 75.2 |
| Ocrelizumab | 35,722 | 1 | 13 | 15 | 181 | 1,572 | 96.5 | 117.7 |
| Plecanatide | 30,732 | 1 | 4 | 12 | 41 | 1,667 | 52.8 | 127.0 |
| Ribociclib | 2,618 | 1 | 3 | 7 | 18 | 1,449 | 21.5 | 62.9 |
| Safinamide | 1,403 | 1 | 3 | 9 | 26 | 1,308 | 33.8 | 103.9 |
| Sarilumab | 3,571 | 1 | 3 | 8 | 19 | 1,385 | 22.9 | 66.1 |
| Telotristat Ethyl | 605 | 1 | 3 | 8 | 20 | 1,278 | 31.3 | 92.3 |
| Valbenazine | 14,118 | 1 | 3 | 8 | 21 | 1,704 | 36.1 | 115.8 |

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Sex

| Distribution of First Treatment Episode Gap Duration, Days | | | | | | | | |
|--|----------------------|----------|-----------|-----------|-----------|--------------|-------------|--------------------|
| | Total Number of Gaps | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Abaloparatide | 13,406 | 1 | 3 | 9 | 22 | 1,481 | 24.2 | 60.3 |
| Female | 13,100 | 1 | 3 | 9 | 22 | 1,481 | 24.2 | 60.7 |
| Male | 306 | 1 | 4 | 10 | 23 | 374 | 22.5 | 40.3 |
| Avelumab | 2,518 | 1 | 13 | 13 | 13 | 654 | 15.8 | 19.3 |
| Female | 641 | 1 | 13 | 13 | 13 | 654 | 16.6 | 28.6 |
| Male | 1,877 | 1 | 13 | 13 | 13 | 489 | 15.5 | 14.8 |
| Betrixaban | 4 | 1 | 3 | 6 | 9 | 10 | 5.8 | 4.0 |
| Female | 3 | 1 | 1 | 4 | 8 | 8 | 4.3 | 3.5 |
| Male | 1 | 10 | 10 | 10 | 10 | 10 | 10.0 | NaN |
| Brigatinib | 234 | 1 | 3 | 6 | 15 | 1,192 | 39.4 | 139.3 |
| Female | 141 | 1 | 3 | 6 | 15 | 1,192 | 31.6 | 124.3 |
| Male | 93 | 1 | 3 | 7 | 14 | 1,127 | 51.3 | 159.3 |
| Brodalumab | 585 | 1 | 4 | 8 | 20 | 592 | 20.4 | 46.9 |
| Female | 278 | 1 | 3 | 8 | 19 | 535 | 20.1 | 45.5 |
| Male | 307 | 1 | 4 | 8 | 20 | 592 | 20.6 | 48.2 |
| Cerliponase Alfa | 18 | 1 | 11 | 13 | 15 | 69 | 16.8 | 14.9 |
| Female | 10 | 11 | 13 | 13 | 15 | 40 | 15.8 | 8.6 |
| Male | 8 | 1 | 11 | 13 | 14 | 69 | 18.0 | 21.0 |
| Deflazacort | 649 | 1 | 4 | 9 | 24 | 934 | 30.9 | 70.8 |
| Female | 8 | 2 | 5 | 7 | 20 | 232 | 37.1 | 79.1 |
| Male | 641 | 1 | 4 | 9 | 24 | 934 | 30.8 | 70.8 |
| Delafloxacin | 595 | 1 | 5 | 22 | 77 | 861 | 72.3 | 122.4 |
| Female | 264 | 1 | 7 | 28 | 86 | 861 | 73.5 | 115.6 |
| Male | 331 | 1 | 4 | 19 | 75 | 852 | 71.3 | 127.7 |

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Sex

| Distribution of First Treatment Episode Gap Duration, Days | | | | | | | | |
|--|----------------------|----------|-----------|-----------|-----------|--------------|-------------|--------------------|
| | Total Number of Gaps | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Deutetrabenazine | 8,783 | 1 | 3 | 8 | 21 | 1,510 | 32.4 | 95.1 |
| Female | 5,413 | 1 | 3 | 8 | 21 | 1,510 | 33.1 | 97.1 |
| Male | 3,370 | 1 | 3 | 8 | 21 | 1,429 | 31.3 | 91.7 |
| Dupilumab | 55,904 | 1 | 3 | 8 | 17 | 1,776 | 25.7 | 79.9 |
| Female | 30,871 | 1 | 3 | 8 | 17 | 1,776 | 24.9 | 78.1 |
| Male | 25,033 | 1 | 3 | 7 | 17 | 1,664 | 26.6 | 82.1 |
| Durvalumab | 23,311 | 1 | 13 | 13 | 20 | 644 | 17.7 | 14.2 |
| Female | 11,161 | 1 | 13 | 13 | 20 | 587 | 17.7 | 13.5 |
| Male | 12,150 | 1 | 13 | 13 | 20 | 644 | 17.7 | 14.9 |
| Edaravone | 1,782 | 1 | 2 | 12 | 16 | 572 | 13.2 | 26.1 |
| Female | 800 | 1 | 2 | 12 | 16 | 482 | 13.4 | 28.8 |
| Male | 982 | 1 | 2 | 12 | 17 | 572 | 13.0 | 23.6 |
| Etelcalcetide | 52,314 | 1 | 1 | 1 | 2 | 1,299 | 3.5 | 23.9 |
| Female | 24,400 | 1 | 1 | 1 | 2 | 917 | 3.4 | 22.4 |
| Male | 27,914 | 1 | 1 | 1 | 2 | 1,299 | 3.5 | 25.1 |
| Midostaurin | 1,016 | 1 | 7 | 17 | 33 | 1,272 | 33.5 | 71.1 |
| Female | 538 | 1 | 8 | 19 | 36 | 1,272 | 37.2 | 80.5 |
| Male | 478 | 1 | 6 | 15 | 30 | 761 | 29.5 | 58.6 |
| Naldemedine | 7,317 | 1 | 5 | 14 | 41 | 1,561 | 46.3 | 105.0 |
| Female | 4,836 | 1 | 5 | 15 | 41 | 1,561 | 46.3 | 104.3 |
| Male | 2,481 | 1 | 4 | 14 | 40 | 1,498 | 46.3 | 106.5 |
| Niraparib | 3,397 | 1 | 4 | 13 | 32 | 1,271 | 33.8 | 75.2 |
| Female | 3,386 | 1 | 4 | 13 | 32 | 1,271 | 33.9 | 75.3 |
| Male | 11 | 2 | 3 | 6 | 11 | 17 | 7.8 | 5.2 |

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Sex

| Distribution of First Treatment Episode Gap Duration, Days | | | | | | | | |
|--|----------------------|----------|-----------|-----------|------------|--------------|-------------|--------------------|
| | Total Number of Gaps | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Ocrelizumab | 35,722 | 1 | 13 | 15 | 181 | 1,572 | 96.5 | 117.7 |
| Female | 24,247 | 1 | 13 | 15 | 181 | 1,572 | 93.5 | 117.0 |
| Male | 11,475 | 1 | 13 | 19 | 182 | 1,518 | 102.9 | 118.7 |
| Plecanatide | 30,732 | 1 | 4 | 12 | 41 | 1,667 | 52.8 | 127.0 |
| Female | 24,026 | 1 | 4 | 13 | 41 | 1,641 | 52.3 | 125.6 |
| Male | 6,706 | 1 | 4 | 12 | 43 | 1,667 | 54.4 | 132.2 |
| Ribociclib | 2,618 | 1 | 3 | 7 | 18 | 1,449 | 21.5 | 62.9 |
| Female | 2,572 | 1 | 3 | 7 | 18 | 1,449 | 20.9 | 59.2 |
| Male | 46 | 1 | 2 | 6 | 17 | 1,011 | 55.3 | 170.6 |
| Safinamide | 1,403 | 1 | 3 | 9 | 26 | 1,308 | 33.8 | 103.9 |
| Female | 582 | 1 | 3 | 9 | 25 | 1,308 | 36.5 | 115.4 |
| Male | 821 | 1 | 3 | 9 | 26 | 1,212 | 31.9 | 94.9 |
| Sarilumab | 3,571 | 1 | 3 | 8 | 19 | 1,385 | 22.9 | 66.1 |
| Female | 3,016 | 1 | 3 | 8 | 19 | 1,385 | 23.3 | 68.1 |
| Male | 555 | 1 | 3 | 7 | 16 | 697 | 20.2 | 54.2 |
| Telotristat Ethyl | 605 | 1 | 3 | 8 | 20 | 1,278 | 31.3 | 92.3 |
| Female | 346 | 1 | 4 | 8 | 20 | 1,278 | 33.5 | 108.2 |
| Male | 259 | 1 | 3 | 7 | 22 | 598 | 28.5 | 65.1 |
| Valbenazine | 14,118 | 1 | 3 | 8 | 21 | 1,704 | 36.1 | 115.8 |
| Female | 8,383 | 1 | 3 | 8 | 22 | 1,704 | 37.6 | 120.6 |
| Male | 5,735 | 1 | 3 | 8 | 21 | 1,574 | 33.8 | 108.3 |

Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 9. Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022¹

| | Censoring Reason | | | | | | | | | | | | |
|-------------------|--------------------------------------|--------------------|---|--------------------|--------------------------------|--------------------|----------------------------|--------------------|---------------------------------------|--------------------|----------------------------------|--------------------|---------------------------|
| | End of exposure episode ² | | Occurrence of request-defined censoring criteria ³ | | Evidence of death ⁴ | | Disenrollment ⁵ | | End of data partner data ⁶ | | End of query period ⁷ | | |
| | Total Number of Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes | Number of Episodes | Percent of Total Episodes |
| Abaloparatide | 71,072 | 70,579 | 99.3% | 0 | 0.0% | 211 | 0.3% | 5,626 | 7.9% | 4,168 | 5.9% | 0 | 0.0% |
| Avelumab | 36,616 | 36,615 | 100.0% | 0 | 0.0% | ***** | ***** | 83 | 0.2% | 79 | 0.2% | 0 | 0.0% |
| Betrixaban | 30 | 30 | 100.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Brigatinib | 1,211 | 1,151 | 95.0% | 0 | 0.0% | 50 | 4.1% | 161 | 13.3% | 94 | 7.8% | 0 | 0.0% |
| Brodalumab | 3,358 | 3,339 | 99.4% | 0 | 0.0% | ***** | ***** | 305 | 9.1% | 184 | 5.5% | 0 | 0.0% |
| Cerliponase Alfa | 532 | 532 | 100.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Deflazacort | 3,619 | 3,576 | 98.8% | 0 | 0.0% | 15 | 0.4% | 798 | 22.1% | 663 | 18.3% | 0 | 0.0% |
| Delafloxacin | 4,097 | 4,092 | 99.9% | 0 | 0.0% | ***** | ***** | 41 | 1.0% | 24 | 0.6% | 0 | 0.0% |
| Deutetrabenazine | 46,882 | 45,929 | 98.0% | 0 | 0.0% | 794 | 1.7% | 7,397 | 15.8% | 5,686 | 12.1% | 0 | 0.0% |
| Dupilumab | 312,719 | 308,165 | 98.5% | 0 | 0.0% | 571 | 0.2% | 44,023 | 14.1% | 32,684 | 10.5% | 0 | 0.0% |
| Durvalumab | 285,274 | 285,253 | 100.0% | 0 | 0.0% | 25 | 0.0% | 500 | 0.2% | 427 | 0.1% | 0 | 0.0% |
| Edaravone | 28,577 | 28,357 | 99.2% | 0 | 0.0% | 219 | 0.8% | 360 | 1.3% | 306 | 1.1% | 0 | 0.0% |
| Etelcalcetide | 8,510,448 | 8,510,448 | 100.0% | 0 | 0.0% | 257 | 0.0% | 3,654 | 0.0% | 1,479 | 0.0% | 0 | 0.0% |
| Midostaurin | 4,736 | 4,633 | 97.8% | 0 | 0.0% | 110 | 2.3% | 229 | 4.8% | 131 | 2.8% | 0 | 0.0% |
| Naldemedine | 39,747 | 39,464 | 99.3% | 0 | 0.0% | 190 | 0.5% | 2,802 | 7.0% | 1,757 | 4.4% | 0 | 0.0% |
| Niraparib | 15,712 | 15,551 | 99.0% | 0 | 0.0% | 120 | 0.8% | 1,009 | 6.4% | 710 | 4.5% | 0 | 0.0% |
| Ocrelizumab | 165,673 | 165,610 | 100.0% | 0 | 0.0% | 19 | 0.0% | 1,402 | 0.8% | 991 | 0.6% | 0 | 0.0% |
| Plecanatide | 159,824 | 158,531 | 99.2% | 0 | 0.0% | 687 | 0.4% | 15,058 | 9.4% | 10,302 | 6.4% | 0 | 0.0% |
| Ribociclib | 14,484 | 14,283 | 98.6% | 0 | 0.0% | 158 | 1.1% | 1,065 | 7.4% | 778 | 5.4% | 0 | 0.0% |
| Safinamide | 7,891 | 7,767 | 98.4% | 0 | 0.0% | 114 | 1.4% | 682 | 8.6% | 533 | 6.8% | 0 | 0.0% |
| Sarilumab | 21,098 | 20,891 | 99.0% | 0 | 0.0% | 58 | 0.3% | 1,933 | 9.2% | 1,330 | 6.3% | 0 | 0.0% |
| Telotristat Ethyl | 3,774 | 3,718 | 98.5% | 0 | 0.0% | 62 | 1.6% | 117 | 3.1% | 19 | 0.5% | 0 | 0.0% |
| Valbenazine | 74,593 | 73,316 | 98.3% | 0 | 0.0% | 1,105 | 1.5% | 10,686 | 14.3% | 8,136 | 10.9% | 0 | 0.0% |

¹An episode may be censored due to more than one reason if they occur on the same date. Therefore, the sum of the reasons for censoring may be greater than the total number of episodes.

²Represents episodes censored due to end of the exposure episode. In as-treated analyses, exposure episodes are defined using days supplied as recorded in outpatient pharmacy dispensing records, and episodes end after days supplied are exhausted or a pre-determined maximum episode duration is met. In point exposure analyses, exposure episodes end when a pre-determined maximum episode duration is met.

³Represents episodes censored due to occurrence of additional user-defined criteria using drug, procedure, diagnosis, and/or laboratory codes.

⁴Represents episodes censored due to evidence of death. Death data source and completeness varies by Data Partner.

⁵Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

⁶Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

⁷Represents episodes censored due to user-specified study end date.

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| Distribution of First Treatment Episode Gap Duration, Days | | | | | | | | |
|--|----------------------|----------|-----------|-----------|-----------|--------------|-------------|--------------------|
| | Total Number of Gaps | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Abaloparatide | 13,406 | 1 | 3 | 9 | 22 | 1,481 | 24.2 | 60.3 |
| 0-17 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 18-24 years | 4 | 5 | 9 | 15 | 21 | 23 | 14.5 | 7.8 |
| 25-40 years | 77 | 1 | 3 | 11 | 24 | 1,481 | 42.2 | 170.4 |
| 41-64 years | 3,525 | 1 | 3 | 9 | 22 | 963 | 24.9 | 59.9 |
| ≥ 65 years | 9,800 | 1 | 3 | 9 | 22 | 1,117 | 23.8 | 58.8 |
| Avelumab | 2,518 | 1 | 13 | 13 | 13 | 654 | 15.8 | 19.3 |
| 0-17 years | 1 | 21 | 21 | 21 | 21 | 21 | 21.0 | NaN |
| 18-24 years | 3 | 12 | 12 | 16 | 19 | 19 | 15.7 | 3.5 |
| 25-40 years | 10 | 13 | 13 | 14 | 20 | 41 | 17.4 | 8.8 |
| 41-64 years | 261 | 10 | 13 | 13 | 14 | 132 | 15.8 | 9.2 |
| ≥ 65 years | 2,243 | 1 | 13 | 13 | 13 | 654 | 15.8 | 20.2 |
| Betrixaban | 4 | 1 | 3 | 6 | 9 | 10 | 5.8 | 4.0 |
| 0-17 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 18-24 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 25-40 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 41-64 years | 1 | 10 | 10 | 10 | 10 | 10 | 10.0 | NaN |
| ≥ 65 years | 3 | 1 | 1 | 4 | 8 | 8 | 4.3 | 3.5 |
| Brigatinib | 234 | 1 | 3 | 6 | 15 | 1,192 | 39.4 | 139.3 |
| 0-17 years | 2 | 21 | 21 | 31 | 40 | 40 | 30.5 | 13.4 |
| 18-24 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 25-40 years | 18 | 2 | 4 | 9 | 21 | 60 | 16.6 | 17.8 |
| 41-64 years | 108 | 1 | 3 | 5 | 14 | 1,127 | 33.4 | 127.1 |
| ≥ 65 years | 106 | 1 | 3 | 6 | 15 | 1,192 | 49.6 | 162.2 |

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| Distribution of First Treatment Episode Gap Duration, Days | | | | | | | | |
|--|----------------------|----------|-----------|-----------|-----------|------------|-------------|--------------------|
| | Total Number of Gaps | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Brodalumab | 585 | 1 | 4 | 8 | 20 | 592 | 20.4 | 46.9 |
| 0-17 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 18-24 years | 12 | 4 | 7 | 14 | 28 | 53 | 17.8 | 14.6 |
| 25-40 years | 87 | 1 | 4 | 6 | 15 | 535 | 19.6 | 58.9 |
| 41-64 years | 324 | 1 | 3 | 8 | 21 | 364 | 18.7 | 32.0 |
| ≥ 65 years | 162 | 1 | 4 | 9 | 19 | 592 | 24.3 | 63.6 |
| Cerliponase Alfa | 18 | 1 | 11 | 13 | 15 | 69 | 16.8 | 14.9 |
| 0-17 years | 18 | 1 | 11 | 13 | 15 | 69 | 16.8 | 14.9 |
| 18-24 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 25-40 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 41-64 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| ≥ 65 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| Deflazacort | 649 | 1 | 4 | 9 | 24 | 934 | 30.9 | 70.8 |
| 0-17 years | 490 | 1 | 3 | 8 | 22 | 934 | 30.9 | 73.7 |
| 18-24 years | 108 | 1 | 4 | 10 | 32 | 402 | 32.6 | 64.2 |
| 25-40 years | 48 | 1 | 5 | 10 | 22 | 297 | 28.5 | 55.9 |
| 41-64 years | 1 | 17 | 17 | 17 | 17 | 17 | 17.0 | NaN |
| ≥ 65 years | 2 | 6 | 6 | 6 | 6 | 6 | 6.0 | 0.0 |
| Delafloxacin | 595 | 1 | 5 | 22 | 77 | 861 | 72.3 | 122.4 |
| 0-17 years | 4 | 21 | 23 | 40 | 66 | 76 | 44.0 | 26.3 |
| 18-24 years | 4 | 1 | 32 | 63 | 104 | 145 | 68.0 | 59.1 |
| 25-40 years | 56 | 1 | 9 | 30 | 111 | 478 | 77.2 | 107.6 |
| 41-64 years | 275 | 1 | 6 | 25 | 79 | 861 | 77.7 | 135.9 |
| ≥ 65 years | 256 | 1 | 4 | 18 | 64 | 653 | 65.9 | 111.4 |

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| Distribution of First Treatment Episode Gap Duration, Days | | | | | | | | |
|--|----------------------|----------|-----------|-----------|-----------|--------------|-------------|--------------------|
| | Total Number of Gaps | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Deutetrabenazine | 8,783 | 1 | 3 | 8 | 21 | 1,510 | 32.4 | 95.1 |
| 0-17 years | 11 | 1 | 2 | 8 | 92 | 166 | 43.8 | 59.4 |
| 18-24 years | 84 | 1 | 5 | 12 | 27 | 872 | 48.3 | 126.3 |
| 25-40 years | 782 | 1 | 3 | 8 | 20 | 979 | 30.9 | 88.1 |
| 41-64 years | 4,464 | 1 | 3 | 8 | 21 | 1,429 | 32.3 | 94.9 |
| ≥ 65 years | 3,442 | 1 | 3 | 7 | 21 | 1,510 | 32.4 | 96.0 |
| Dupilumab | 55,904 | 1 | 3 | 8 | 17 | 1,776 | 25.7 | 79.9 |
| 0-17 years | 4,989 | 1 | 4 | 9 | 20 | 964 | 24.5 | 60.1 |
| 18-24 years | 5,586 | 1 | 4 | 9 | 21 | 1,277 | 30.7 | 89.1 |
| 25-40 years | 10,856 | 1 | 3 | 8 | 18 | 1,776 | 27.4 | 89.0 |
| 41-64 years | 21,757 | 1 | 3 | 7 | 17 | 1,519 | 24.4 | 77.1 |
| ≥ 65 years | 12,716 | 1 | 3 | 7 | 16 | 1,612 | 24.7 | 78.9 |
| Durvalumab | 23,311 | 1 | 13 | 13 | 20 | 644 | 17.7 | 14.2 |
| 0-17 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 18-24 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 25-40 years | 29 | 3 | 13 | 19 | 27 | 39 | 19.7 | 8.3 |
| 41-64 years | 4,121 | 1 | 13 | 13 | 20 | 587 | 18.3 | 16.7 |
| ≥ 65 years | 19,161 | 1 | 13 | 13 | 20 | 644 | 17.5 | 13.7 |
| Edaravone | 1,782 | 1 | 2 | 12 | 16 | 572 | 13.2 | 26.1 |
| 0-17 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 18-24 years | 1 | 1 | 1 | 1 | 1 | 1 | 1.0 | NaN |
| 25-40 years | 72 | 1 | 3 | 13 | 19 | 572 | 21.8 | 67.5 |
| 41-64 years | 707 | 1 | 3 | 14 | 20 | 385 | 14.7 | 19.6 |
| ≥ 65 years | 1,002 | 1 | 2 | 11 | 14 | 482 | 11.5 | 24.6 |

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| Distribution of First Treatment Episode Gap Duration, Days | | | | | | | | |
|--|----------------------|----------|----------|-----------|-----------|--------------|-------------|--------------------|
| | Total Number of Gaps | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Etelcalcetide | 52,314 | 1 | 1 | 1 | 2 | 1,299 | 3.5 | 23.9 |
| 0-17 years | 14 | 1 | 1 | 1 | 2 | 6 | 1.6 | 1.3 |
| 18-24 years | 445 | 1 | 1 | 1 | 2 | 237 | 2.9 | 12.1 |
| 25-40 years | 5,674 | 1 | 1 | 1 | 2 | 1,060 | 3.7 | 28.5 |
| 41-64 years | 26,569 | 1 | 1 | 1 | 2 | 1,299 | 3.4 | 23.1 |
| ≥ 65 years | 19,612 | 1 | 1 | 1 | 2 | 867 | 3.5 | 23.6 |
| Midostaurin | 1,016 | 1 | 7 | 17 | 33 | 1,272 | 33.5 | 71.1 |
| 0-17 years | 10 | 2 | 3 | 9 | 36 | 43 | 16.7 | 17.2 |
| 18-24 years | 24 | 3 | 14 | 25 | 42 | 61 | 27.0 | 16.9 |
| 25-40 years | 81 | 1 | 5 | 16 | 36 | 1,272 | 43.7 | 142.8 |
| 41-64 years | 443 | 1 | 7 | 18 | 34 | 761 | 34.9 | 59.4 |
| ≥ 65 years | 458 | 1 | 7 | 15 | 31 | 871 | 31.2 | 64.8 |
| Naldemedine | 7,317 | 1 | 5 | 14 | 41 | 1,561 | 46.3 | 105.0 |
| 0-17 years | 3 | 19 | 19 | 22 | 48 | 48 | 29.7 | 15.9 |
| 18-24 years | 15 | 2 | 16 | 39 | 85 | 335 | 67.5 | 88.0 |
| 25-40 years | 478 | 1 | 5 | 13 | 36 | 1,024 | 48.2 | 117.5 |
| 41-64 years | 3,824 | 1 | 5 | 14 | 40 | 1,498 | 44.0 | 98.9 |
| ≥ 65 years | 2,997 | 1 | 5 | 15 | 42 | 1,561 | 48.9 | 110.5 |
| Niraparib | 3,397 | 1 | 4 | 13 | 32 | 1,271 | 33.8 | 75.2 |
| 0-17 years | 1 | 5 | 5 | 5 | 5 | 5 | 5.0 | NaN |
| 18-24 years | 2 | 1 | 1 | 10 | 19 | 19 | 10.0 | 12.7 |
| 25-40 years | 42 | 1 | 3 | 12 | 26 | 404 | 28.2 | 66.6 |
| 41-64 years | 1,106 | 1 | 4 | 12 | 27 | 1,271 | 25.1 | 58.7 |
| ≥ 65 years | 2,246 | 1 | 5 | 15 | 34 | 834 | 38.3 | 81.9 |

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| Distribution of First Treatment Episode Gap Duration, Days | | | | | | | | |
|--|----------------------|----------|-----------|-----------|------------|--------------|-------------|--------------------|
| | Total Number of Gaps | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Ocrelizumab | 35,722 | 1 | 13 | 15 | 181 | 1,572 | 96.5 | 117.7 |
| 0-17 years | 43 | 7 | 13 | 13 | 15 | 214 | 38.4 | 61.7 |
| 18-24 years | 616 | 1 | 13 | 14 | 181 | 1,364 | 82.6 | 112.5 |
| 25-40 years | 8,553 | 1 | 13 | 14 | 181 | 1,393 | 89.9 | 115.2 |
| 41-64 years | 20,050 | 1 | 13 | 16 | 181 | 1,572 | 97.9 | 121.5 |
| ≥ 65 years | 6,460 | 1 | 13 | 21 | 182 | 1,472 | 102.6 | 108.5 |
| Plecanatide | 30,732 | 1 | 4 | 12 | 41 | 1,667 | 52.8 | 127.0 |
| 0-17 years | 60 | 1 | 3 | 11 | 35 | 929 | 59.7 | 152.8 |
| 18-24 years | 978 | 1 | 4 | 11 | 32 | 1,204 | 40.8 | 100.0 |
| 25-40 years | 3,877 | 1 | 4 | 12 | 38 | 1,271 | 47.8 | 112.0 |
| 41-64 years | 13,241 | 1 | 4 | 12 | 41 | 1,665 | 51.1 | 124.4 |
| ≥ 65 years | 12,576 | 1 | 4 | 13 | 44 | 1,667 | 57.0 | 135.5 |
| Ribociclib | 2,618 | 1 | 3 | 7 | 18 | 1,449 | 21.5 | 62.9 |
| 0-17 years | 7 | 1 | 2 | 6 | 9 | 101 | 18.3 | 36.6 |
| 18-24 years | 3 | 4 | 4 | 8 | 14 | 14 | 8.7 | 5.0 |
| 25-40 years | 95 | 1 | 2 | 6 | 15 | 148 | 14.5 | 23.9 |
| 41-64 years | 825 | 1 | 3 | 7 | 17 | 748 | 18.8 | 48.4 |
| ≥ 65 years | 1,688 | 1 | 3 | 8 | 20 | 1,449 | 23.3 | 70.4 |
| Safinamide | 1,403 | 1 | 3 | 9 | 26 | 1,308 | 33.8 | 103.9 |
| 0-17 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 18-24 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 25-40 years | 6 | 1 | 2 | 7 | 29 | 52 | 16.2 | 20.4 |
| 41-64 years | 209 | 1 | 4 | 11 | 30 | 1,066 | 34.8 | 95.7 |
| ≥ 65 years | 1,188 | 1 | 3 | 9 | 25 | 1,308 | 33.7 | 105.5 |

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022, by Age Group

| Distribution of First Treatment Episode Gap Duration, Days | | | | | | | | |
|--|----------------------|----------|----------|----------|-----------|--------------|-------------|--------------------|
| | Total Number of Gaps | Minimum | Q1 | Median | Q3 | Maximum | Mean | Standard Deviation |
| Sarilumab | 3,571 | 1 | 3 | 8 | 19 | 1,385 | 22.9 | 66.1 |
| 0-17 years | 2 | 13 | 13 | 14 | 15 | 15 | 14.0 | 1.4 |
| 18-24 years | 32 | 1 | 3 | 8 | 17 | 175 | 18.6 | 33.8 |
| 25-40 years | 354 | 1 | 4 | 10 | 22 | 1,385 | 29.4 | 99.3 |
| 41-64 years | 2,207 | 1 | 3 | 7 | 18 | 1,137 | 22.5 | 66.0 |
| ≥ 65 years | 976 | 1 | 4 | 8 | 20 | 697 | 21.6 | 50.0 |
| Telotristat Ethyl | 605 | 1 | 3 | 8 | 20 | 1,278 | 31.3 | 92.3 |
| 0-17 years | 1 | 12 | 12 | 12 | 12 | 12 | 12.0 | NaN |
| 18-24 years | 0 | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 25-40 years | 19 | 1 | 7 | 11 | 32 | 62 | 19.6 | 17.9 |
| 41-64 years | 215 | 1 | 4 | 8 | 20 | 1,278 | 29.4 | 97.1 |
| ≥ 65 years | 370 | 1 | 3 | 8 | 20 | 1,061 | 33.1 | 91.8 |
| Valbenazine | 14,118 | 1 | 3 | 8 | 21 | 1,704 | 36.1 | 115.8 |
| 0-17 years | 8 | 2 | 4 | 7 | 73 | 131 | 37.5 | 50.2 |
| 18-24 years | 145 | 1 | 3 | 7 | 20 | 1,281 | 30.3 | 114.5 |
| 25-40 years | 1,231 | 1 | 3 | 9 | 24 | 1,704 | 36.8 | 112.7 |
| 41-64 years | 7,738 | 1 | 3 | 8 | 22 | 1,643 | 38.7 | 123.5 |
| ≥ 65 years | 4,996 | 1 | 3 | 7 | 20 | 1,509 | 32.1 | 103.6 |

Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 10. Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| | Abaloparatide | | Avelumab | | Betrixaban | | Brigatinib | |
|--|---------------|-------------|-------------|-------------|-------------|-------------|-------------|----------|
| | Remaining | Excluded | Remaining | Excluded | Remaining | Excluded | Remaining | Excluded |
| Members meeting enrollment and demographic requirements | | | | | | | | |
| Enrolled at any point during the query period | 300,466,583 | N/A | 300,466,583 | N/A | 300,466,583 | N/A | 300,466,583 | N/A |
| Had required coverage type (medical and/or drug coverage) | 218,088,518 | 82,378,065 | 218,088,518 | 82,378,065 | 218,088,518 | 82,378,065 | 218,088,518 | 5 |
| Enrolled during specified age range | 218,043,398 | 45,120 | 218,043,398 | 45,120 | 218,043,398 | 45,120 | 218,043,398 | 45,120 |
| Had requestable medical charts | 218,043,398 | 0 | 218,043,398 | 0 | 218,043,398 | 0 | 218,043,398 | 0 |
| Met demographic requirements (sex, race, and Hispanic origin) | 217,244,109 | 799,289 | 217,244,109 | 799,289 | 217,244,109 | 799,289 | 217,244,109 | 799,289 |
| Members with a valid index event | | | | | | | | |
| Had any cohort-defining claim during the query period | 25,544 | 217,218,565 | 3,006 | 217,241,103 | 24 | 217,244,085 | 595 | 14 |
| Claim recorded during specified age range | 25,544 | 0 | 3,006 | 0 | 24 | 0 | 595 | 0 |
| Episode defining index claim recorded during the query period | 25,544 | 0 | 3,006 | 0 | 24 | 0 | 595 | 0 |
| Met exposure incidence criteria | 25,544 | 0 | 3,006 | 0 | 24 | 0 | 595 | 0 |
| Members with required pre-index history | | | | | | | | |
| Had sufficient pre-index continuous enrollment | 23,148 | 2,396 | 2,803 | 203 | 21 | ***** | 502 | 93 |
| Met inclusion and exclusion criteria | 23,148 | 0 | 2,803 | 0 | 21 | 0 | 502 | 0 |
| Members with required post-index follow-up | | | | | | | | |
| Had sufficient post-index continuous enrollment | 23,148 | 0 | 2,803 | 0 | 21 | 0 | 502 | 0 |
| Final cohort | | | | | | | | |
| Number of members | 23,148 | N/A | 2,803 | N/A | 21 | N/A | 502 | N/A |
| Number of episodes | 23,148 | N/A | 2,803 | N/A | 21 | N/A | 502 | N/A |

Table 10. Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| | Brodalumab | | Cerliponase Alfa | | Deflazacort | | Delafloxacin | |
|--|-------------|-------------|------------------|-------------|-------------|-------------|--------------|----------|
| | Remaining | Excluded | Remaining | Excluded | Remaining | Excluded | Remaining | Excluded |
| Members meeting enrollment and demographic requirements | | | | | | | | |
| Enrolled at any point during the query period | 300,466,583 | N/A | 300,466,583 | N/A | 300,466,583 | N/A | 300,466,583 | N/A |
| Had required coverage type (medical and/or drug coverage) | 218,088,518 | 82,378,065 | 218,088,518 | 82,378,065 | 218,088,518 | 82,378,065 | 218,088,518 | 5 |
| Enrolled during specified age range | 218,043,398 | 45,120 | 218,043,398 | 45,120 | 218,043,398 | 45,120 | 218,043,398 | 45,120 |
| Had requestable medical charts | 218,043,398 | 0 | 218,043,398 | 0 | 218,043,398 | 0 | 218,043,398 | 0 |
| Met demographic requirements (sex, race, and Hispanic origin) | 217,244,109 | 799,289 | 217,244,109 | 799,289 | 217,244,109 | 799,289 | 217,244,109 | 799,289 |
| Members with a valid index event | | | | | | | | |
| Had any cohort-defining claim during the query period | 968 | 217,243,141 | 22 | 217,244,087 | 1,274 | 217,242,835 | 3,341 | 68 |
| Claim recorded during specified age range | 968 | 0 | 22 | 0 | 1,274 | 0 | 3,341 | 0 |
| Episode defining index claim recorded during the query period | 968 | 0 | 22 | 0 | 1,274 | 0 | 3,341 | 0 |
| Met exposure incidence criteria | 968 | 0 | 22 | 0 | 1,274 | 0 | 3,341 | 0 |
| Members with required pre-index history | | | | | | | | |
| Had sufficient pre-index continuous enrollment | 841 | 127 | 18 | ***** | 1,129 | 145 | 2,996 | 345 |
| Met inclusion and exclusion criteria | 841 | 0 | 18 | 0 | 1,129 | 0 | 2,996 | 0 |
| Members with required post-index follow-up | | | | | | | | |
| Had sufficient post-index continuous enrollment | 841 | 0 | 18 | 0 | 1,129 | 0 | 2,996 | 0 |
| Final cohort | | | | | | | | |
| Number of members | 841 | N/A | 18 | N/A | 1,129 | N/A | 2,996 | N/A |
| Number of episodes | 841 | N/A | 18 | N/A | 1,129 | N/A | 2,996 | N/A |

Table 10. Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| | Deutetrabenazine | | Dupilumab | | Durvalumab | | Edaravone | |
|--|------------------|-------------|-------------|-------------|-------------|-------------|-------------|----------|
| | Remaining | Excluded | Remaining | Excluded | Remaining | Excluded | Remaining | Excluded |
| Members meeting enrollment and demographic requirements | | | | | | | | |
| Enrolled at any point during the query period | 300,466,583 | N/A | 300,466,583 | N/A | 300,466,583 | N/A | 300,466,583 | N/A |
| Had required coverage type (medical and/or drug coverage) | 218,088,518 | 82,378,065 | 218,088,518 | 82,378,065 | 218,088,518 | 82,378,065 | 218,088,518 | 5 |
| Enrolled during specified age range | 218,043,398 | 45,120 | 218,043,398 | 45,120 | 218,043,398 | 45,120 | 218,043,398 | 45,120 |
| Had requestable medical charts | 218,043,398 | 0 | 218,043,398 | 0 | 218,043,398 | 0 | 218,043,398 | 0 |
| Met demographic requirements (sex, race, and Hispanic origin) | 217,244,109 | 799,289 | 217,244,109 | 799,289 | 217,244,109 | 799,289 | 217,244,109 | 799,289 |
| Members with a valid index event | | | | | | | | |
| Had any cohort-defining claim during the query period | 18,591 | 217,225,518 | 97,284 | 217,146,825 | 28,560 | 217,215,549 | 2,558 | 51 |
| Claim recorded during specified age range | 18,591 | 0 | 97,284 | 0 | 28,560 | 0 | 2,558 | 0 |
| Episode defining index claim recorded during the query period | 18,591 | 0 | 97,284 | 0 | 28,560 | 0 | 2,558 | 0 |
| Met exposure incidence criteria | 18,591 | 0 | 97,284 | 0 | 28,560 | 0 | 2,558 | 0 |
| Members with required pre-index history | | | | | | | | |
| Had sufficient pre-index continuous enrollment | 16,357 | 2,234 | 83,061 | 14,223 | 26,005 | 2,555 | 2,163 | 395 |
| Met inclusion and exclusion criteria | 16,357 | 0 | 83,061 | 0 | 26,005 | 0 | 2,163 | 0 |
| Members with required post-index follow-up | | | | | | | | |
| Had sufficient post-index continuous enrollment | 16,357 | 0 | 83,061 | 0 | 26,005 | 0 | 2,163 | 0 |
| Final cohort | | | | | | | | |
| Number of members | 16,357 | N/A | 83,061 | N/A | 26,005 | N/A | 2,163 | N/A |
| Number of episodes | 16,357 | N/A | 83,061 | N/A | 26,005 | N/A | 2,163 | N/A |

Table 10. Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| | Etelcalcetide | | Midostaurin | | Naldemedine | | Niraparib | |
|--|---------------|-------------|-------------|-------------|-------------|-------------|-------------|----------|
| | Remaining | Excluded | Remaining | Excluded | Remaining | Excluded | Remaining | Excluded |
| Members meeting enrollment and demographic requirements | | | | | | | | |
| Enrolled at any point during the query period | 300,466,583 | N/A | 300,466,583 | N/A | 300,466,583 | N/A | 300,466,583 | N/A |
| Had required coverage type (medical and/or drug coverage) | 218,088,518 | 82,378,065 | 218,088,518 | 82,378,065 | 218,088,518 | 82,378,065 | 218,088,518 | 5 |
| Enrolled during specified age range | 218,043,398 | 45,120 | 218,043,398 | 45,120 | 218,043,398 | 45,120 | 218,043,398 | 45,120 |
| Had requestable medical charts | 218,043,398 | 0 | 218,043,398 | 0 | 218,043,398 | 0 | 218,043,398 | 0 |
| Met demographic requirements (sex, race, and Hispanic origin) | 217,244,109 | 799,289 | 217,244,109 | 799,289 | 217,244,109 | 799,289 | 217,244,109 | 799,289 |
| Members with a valid index event | | | | | | | | |
| Had any cohort-defining claim during the query period | 56,269 | 217,187,840 | 2,126 | 217,241,983 | 15,857 | 217,228,252 | 7,072 | 37 |
| Claim recorded during specified age range | 56,269 | 0 | 2,126 | 0 | 15,857 | 0 | 7,072 | 0 |
| Episode defining index claim recorded during the query period | 56,269 | 0 | 2,126 | 0 | 15,857 | 0 | 7,072 | 0 |
| Met exposure incidence criteria | 56,269 | 0 | 2,126 | 0 | 15,857 | 0 | 7,072 | 0 |
| Members with required pre-index history | | | | | | | | |
| Had sufficient pre-index continuous enrollment | 53,102 | 3,167 | 1,841 | 285 | 13,921 | 1,936 | 6,415 | 657 |
| Met inclusion and exclusion criteria | 53,102 | 0 | 1,841 | 0 | 13,921 | 0 | 6,415 | 0 |
| Members with required post-index follow-up | | | | | | | | |
| Had sufficient post-index continuous enrollment | 53,102 | 0 | 1,841 | 0 | 13,921 | 0 | 6,415 | 0 |
| Final cohort | | | | | | | | |
| Number of members | 53,102 | N/A | 1,841 | N/A | 13,921 | N/A | 6,415 | N/A |
| Number of episodes | 53,102 | N/A | 1,841 | N/A | 13,921 | N/A | 6,415 | N/A |

Table 10. Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| | Ocrelizumab | | Plecanatide | | Ribociclib | | Safinamide | |
|--|-------------|-------------|-------------|-------------|-------------|-------------|-------------|------------|
| | Remaining | Excluded | Remaining | Excluded | Remaining | Excluded | Remaining | Excluded |
| Members meeting enrollment and demographic requirements | | | | | | | | |
| Enrolled at any point during the query period | 300,466,583 | N/A | 300,466,583 | N/A | 300,466,583 | N/A | 300,466,583 | N/A |
| Had required coverage type (medical and/or drug coverage) | 218,088,518 | 82,378,065 | 218,088,518 | 82,378,065 | 218,088,518 | 82,378,065 | 218,088,518 | 82,378,065 |
| Enrolled during specified age range | 218,043,398 | 45,120 | 218,043,398 | 45,120 | 218,043,398 | 45,120 | 218,043,398 | 45,120 |
| Had requestable medical charts | 218,043,398 | 0 | 218,043,398 | 0 | 218,043,398 | 0 | 218,043,398 | 0 |
| Met demographic requirements (sex, race, and Hispanic origin) | 217,244,109 | 799,289 | 217,244,109 | 799,289 | 217,244,109 | 799,289 | 217,244,109 | 799,289 |
| Members with a valid index event | | | | | | | | |
| Had any cohort-defining claim during the query period | 48,329 | 217,195,780 | 74,944 | 217,169,165 | 4,849 | 217,239,260 | 2,517 | 92 |
| Claim recorded during specified age range | 48,329 | 0 | 74,944 | 0 | 4,849 | 0 | 2,517 | 0 |
| Episode defining index claim recorded during the query period | 48,329 | 0 | 74,944 | 0 | 4,849 | 0 | 2,517 | 0 |
| Met exposure incidence criteria | 48,329 | 0 | 74,944 | 0 | 4,849 | 0 | 2,517 | 0 |
| Members with required pre-index history | | | | | | | | |
| Had sufficient pre-index continuous enrollment | 43,156 | 5,173 | 66,616 | 8,328 | 4,213 | 636 | 2,319 | 198 |
| Met inclusion and exclusion criteria | 43,156 | 0 | 66,616 | 0 | 4,213 | 0 | 2,319 | 0 |
| Members with required post-index follow-up | | | | | | | | |
| Had sufficient post-index continuous enrollment | 43,156 | 0 | 66,616 | 0 | 4,213 | 0 | 2,319 | 0 |
| Final cohort | | | | | | | | |
| Number of members | 43,156 | N/A | 66,616 | N/A | 4,213 | N/A | 2,319 | N/A |
| Number of episodes | 43,156 | N/A | 66,616 | N/A | 4,213 | N/A | 2,319 | N/A |


Table 10. Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

| | Sarilumab | | Telotristat Ethyl | | Valbenazine | |
|--|-------------|-------------|-------------------|-------------|-------------|-------------|
| | Remaining | Excluded | Remaining | Excluded | Remaining | Excluded |
| Members meeting enrollment and demographic requirements | | | | | | |
| Enrolled at any point during the query period | 300,466,583 | N/A | 300,466,583 | N/A | 300,466,583 | N/A |
| Had required coverage type (medical and/or drug coverage) | 218,088,518 | 82,378,065 | 218,088,518 | 82,378,065 | 218,088,518 | 82,378,065 |
| Enrolled during specified age range | 218,043,398 | 45,120 | 218,043,398 | 45,120 | 218,043,398 | 45,120 |
| Had requestable medical charts | 218,043,398 | 0 | 218,043,398 | 0 | 218,043,398 | 0 |
| Met demographic requirements (sex, race, and Hispanic origin) | 217,244,109 | 799,289 | 217,244,109 | 799,289 | 217,244,109 | 799,289 |
| Members with a valid index event | | | | | | |
| Had any cohort-defining claim during the query period | 9,575 | 217,234,534 | 1,158 | 217,242,951 | 29,741 | 217,214,368 |
| Claim recorded during specified age range | 9,575 | 0 | 1,158 | 0 | 29,741 | 0 |
| Episode defining index claim recorded during the query period | 9,575 | 0 | 1,158 | 0 | 29,741 | 0 |
| Met exposure incidence criteria | 9,575 | 0 | 1,158 | 0 | 29,741 | 0 |
| Members with required pre-index history | | | | | | |
| Had sufficient pre-index continuous enrollment | 8,534 | 1,041 | 1,061 | 97 | 26,601 | 3,140 |
| Met inclusion and exclusion criteria | 8,534 | 0 | 1,061 | 0 | 26,601 | 0 |
| Members with required post-index follow-up | | | | | | |
| Had sufficient post-index continuous enrollment | 8,534 | 0 | 1,061 | 0 | 26,601 | 0 |
| Final cohort | | | | | | |
| Number of members | 8,534 | N/A | 1,061 | N/A | 26,601 | N/A |
| Number of episodes | 8,534 | N/A | 1,061 | N/A | 26,601 | N/A |

***Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.


N/A: Not Applicable

Figure 1a. Patient Entry into Study by Month for Abaloparatide in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022



The FDA approval date for this drug was on April 28, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>

Figure 1b. Patient Entry into Study by Month for Avelumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022



The FDA approval date for this drug was on March 23, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>

Figure 1c. Patient Entry into Study by Month for betrixaban in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*

The FDA approval date for this drug was on June 23, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>

Figure 1d. Patient Entry into Study by Month for Brigatinib in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

******Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*

The FDA approval date for this drug was on April 28, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>

Figure 1e. Patient Entry into Study by Month for Brodalumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*

The FDA approval date for this drug was on February 15, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>

Figure 1f. Patient Entry into Study by Month for Cerliponase Alfa in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*


The FDA approval date for this drug was on April 27, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>

Figure 1g. Patient Entry into Study by Month for Deflazacort in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*


The FDA approval date for this drug was on February 9, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>

Figure 1h. Patient Entry into Study by Month for Delafloxacin in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022




The FDA approval date for this drug was on June 19, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>

Figure 1i. Patient Entry into Study by Month for Deutetrabenazine in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022




The FDA approval date for this drug was on April 3, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>

Figure 1j. Patient Entry into Study by Month for Dupilumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022




The FDA approval date for this drug was on March 28, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>

Figure 1k. Patient Entry into Study by Month for Durvalumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022




The FDA approval date for this drug was on May 1, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>

Figure 1I. Patient Entry into Study by Month for Edaravone in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022




The FDA approval date for this drug was on May 5, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>

Figure 1m. Patient Entry into Study by Month for Etelcalcetide in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022




The FDA approval date for this drug was on February 7, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>

Figure 1n. Patient Entry into Study by Month for Midostaurin in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022




The FDA approval date for this drug was on April 28, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>

Figure 1o. Patient Entry into Study by Month for Naldemedine in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022




The FDA approval date for this drug was on March 23, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>

Figure 1p. Patient Entry into Study by Month for Niraparib in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022




The FDA approval date for this drug was on March 27, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>

Figure 1q. Patient Entry into Study by Month for Ocrelizumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022




The FDA approval date for this drug was on March 28, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>

Figure 1r. Patient Entry into Study by Month for Plecanatide in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022




The FDA approval date for this drug was on January 19, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>

Figure 1s. Patient Entry into Study by Month for Ribociclib in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022




The FDA approval date for this drug was on March 13, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>

Figure 1t. Patient Entry into Study by Month for Safinamide in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022



The FDA approval date for this drug was on March 21, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>

Figure 1u. Patient Entry into Study by Month for Sarilumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022




The FDA approval date for this drug was on May 22, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>

Figure 1v. Patient Entry into Study by Month for Telotristat Ethyl in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*

The FDA approval date for this drug was on February 28, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>

Figure 1w. Patient Entry into Study by Month for Valbenazine in the Sentinel Distributed Database (SDD) from January 1, 2017 to November 30, 2022



The FDA approval date for this drug was on April 11, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>

Appendix A. Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (March 22, 2023)

| Masked DP ID | DP Start Date | DP End Date ¹ |
|--------------|---------------|--------------------------|
| DP01 | 01/01/2005 | 07/31/2022 |
| DP02 | 01/01/2000 | 07/31/2022 |
| DP03 | 01/01/2000 | 12/31/2020 |
| DP04 | 01/01/2008 | 06/30/2022 |
| DP05 | 01/01/2006 | 06/30/2022 |
| DP06 | 01/01/2010 | 06/30/2022 |
| DP07 | 01/01/2000 | 08/31/2022 |
| DP08 | 01/01/2000 | 08/31/2022 |
| DP09 | 01/01/2000 | 05/31/2021 |
| DP10 | 01/01/2004 | 11/30/2022 |
| DP11 | 01/01/2008 | 04/30/2022 |
| DP12 | 01/01/2000 | 05/31/2022 |
| DP13 | 01/01/2007 | 05/31/2022 |
| DP14 | 01/01/2014 | 12/31/2018 |

¹End Date represents the earliest of: (1) query end date, or (2) last day of the most recent month for which all of a Data Partner's data tables (enrollment, dispensing, etc.) have at least 80% of the record count relative to the prior month.

Appendix B. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposures in this Request

| Non-Proprietary Name | Proprietary Name |
|-----------------------------|---------------------------------|
| Abaloparatide | |
| abaloparatide | Tymlos |
| Avelumab | |
| avelumab | Bavencio |
| Betrixaban | |
| betrixaban maleate | Bevyxxa |
| Brigatinib | |
| brigatinib | Alunbrig |
| Brodalumab | |
| brodalumab | Siliq |
| Cerliponase alfa | |
| cerliponase alfa | Brineura |
| Deflazacort | |
| deflazacort | Emflaza |
| Delafloxacin | |
| delafloxacin meglumine | Baxdela |
| Deutetrabenazine | |
| deutetrabenazine | Austedo |
| deutetrabenazine | Austedo 12mg Start Titr(Wk1-4) |
| deutetrabenazine | Austedo TD Titratrn Pk (Wk 1-2) |
| Dupilumab | |
| dupilumab | Dupixent Pen |
| dupilumab | Dupixent Syringe |
| Durvalumab | |
| durvalumab | Imfinzi |
| Edaravone | |
| edaravone | Radicava |
| edaravone | Radicava ORS |
| edaravone | Radicava ORS Starter Kit Susp |
| Etelcalcetide | |
| etelcalcetide hydrochloride | Parsabiv |
| Midostaurin | |
| midostaurin | Rydapt |
| Naldemedine | |
| naldemedine tosylate | Symproic |
| Niraparib | |
| niraparib tosylate | Zejula |

Appendix B. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposures in this Request

| Non-Proprietary Name | Proprietary Name |
|--------------------------------|--------------------------|
| Ocrelizumab | |
| ocrelizumab | Ocrevus |
| Plecanatide | |
| Plecanatide | Trulance |
| plecanatide | Trulance |
| Ribociclib | |
| ribociclib succinate | Kisqali |
| ribociclib succinate/letrozole | Kisqali Femara Co-Pack |
| Safinamide | |
| safinamide mesylate | Xadago |
| Sarilumab | |
| sarilumab | Kevzara |
| Telotristat Ethyl | |
| telotristat etiprate | Xermelo |
| Valbenazine | |
| valbenazine tosylate | Ingrezza |
| valbenazine tosylate | Ingrezza Initiation Pack |

Appendix C. List of Healthcare Common Procedure Coding System, Level II (HCPCS) and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exposures in this Request

| Code | Description | Code Category | Code Type |
|-------------------------|---|---------------|------------|
| Etelcalcetide | | | |
| J0606 | Injection, etelcalcetide, 0.1 mg | Procedure | HCPCS |
| Avelumab | | | |
| J9023 | Injection, avelumab, 10 mg | Procedure | HCPCS |
| Ocrelizumab | | | |
| J2350 | Injection, ocrelizumab, 1 mg | Procedure | HCPCS |
| Cerliponase alfa | | | |
| J0567 | Injection, cerliponase alfa, 1 mg | Procedure | HCPCS |
| Durvalumab | | | |
| J9173 | Injection, durvalumab, 10 mg | Procedure | HCPCS |
| XW03336 | Introduction of Durvalumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 6 | Procedure | ICD-10-PCS |
| XW04336 | Introduction of Durvalumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 6 | Procedure | ICD-10-PCS |
| Edaravone | | | |
| J1301 | Injection, edaravone, 1 mg | Procedure | HCPCS |
| Sarilumab | | | |
| XW033G5 | Introduction of Sarilumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5 | Procedure | ICD-10-PCS |
| XW043G5 | Introduction of Sarilumab into Central Vein, Percutaneous Approach, New Technology Group 5 | Procedure | ICD-10-PCS |
| Delafloxacin | | | |
| C9462 | Injection, delafloxacin, 1 mg | Procedure | HCPCS |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|--------------------------------|---|---------------|-----------|
| Acquired Hypothyroidism | | | |
| 244.0 | Postsurgical hypothyroidism | Diagnosis | ICD-9-CM |
| 244.1 | Other postablative hypothyroidism | Diagnosis | ICD-9-CM |
| 244.2 | Iodine hypothyroidism | Diagnosis | ICD-9-CM |
| 244.3 | Other iatrogenic hypothyroidism | Diagnosis | ICD-9-CM |
| 244.8 | Other specified acquired hypothyroidism | Diagnosis | ICD-9-CM |
| 244.9 | Unspecified hypothyroidism | Diagnosis | ICD-9-CM |
| E00.0 | Congenital iodine-deficiency syndrome, neurological type | Diagnosis | ICD-10-CM |
| E00.1 | Congenital iodine-deficiency syndrome, myxedematous type | Diagnosis | ICD-10-CM |
| E00.2 | Congenital iodine-deficiency syndrome, mixed type | Diagnosis | ICD-10-CM |
| E00.9 | Congenital iodine-deficiency syndrome, unspecified | Diagnosis | ICD-10-CM |
| E01.8 | Other iodine-deficiency related thyroid disorders and allied conditions | Diagnosis | ICD-10-CM |
| E02 | Subclinical iodine-deficiency hypothyroidism | Diagnosis | ICD-10-CM |
| E03.0 | Congenital hypothyroidism with diffuse goiter | Diagnosis | ICD-10-CM |
| E03.1 | Congenital hypothyroidism without goiter | Diagnosis | ICD-10-CM |
| E03.2 | Hypothyroidism due to medicaments and other exogenous substances | Diagnosis | ICD-10-CM |
| E03.3 | Postinfectious hypothyroidism | Diagnosis | ICD-10-CM |
| E03.4 | Atrophy of thyroid (acquired) | Diagnosis | ICD-10-CM |
| E03.8 | Other specified hypothyroidism | Diagnosis | ICD-10-CM |
| E03.9 | Hypothyroidism, unspecified | Diagnosis | ICD-10-CM |
| E89.0 | Postprocedural hypothyroidism | Diagnosis | ICD-10-CM |
| Alcohol Abuse | | | |
| 291.0 | Alcohol withdrawal delirium | Diagnosis | ICD-9-CM |
| 291.1 | Alcohol-induced persisting amnestic disorder | Diagnosis | ICD-9-CM |
| 291.2 | Alcohol-induced persisting dementia | Diagnosis | ICD-9-CM |
| 291.3 | Alcohol-induced psychotic disorder with hallucinations | Diagnosis | ICD-9-CM |
| 291.4 | Idiosyncratic alcohol intoxication | Diagnosis | ICD-9-CM |
| 291.5 | Alcohol-induced psychotic disorder with delusions | Diagnosis | ICD-9-CM |
| 291.8 | Other specified alcohol-induced mental disorders | Diagnosis | ICD-9-CM |
| 291.81 | Alcohol withdrawal | Diagnosis | ICD-9-CM |
| 291.82 | Alcohol induced sleep disorders | Diagnosis | ICD-9-CM |
| 291.89 | Other specified alcohol-induced mental disorders | Diagnosis | ICD-9-CM |
| 291.9 | Unspecified alcohol-induced mental disorders | Diagnosis | ICD-9-CM |
| 303.00 | Acute alcoholic intoxication, unspecified | Diagnosis | ICD-9-CM |
| 303.01 | Acute alcoholic intoxication, continuous | Diagnosis | ICD-9-CM |
| 303.02 | Acute alcoholic intoxication, episodic | Diagnosis | ICD-9-CM |
| 303.90 | Other and unspecified alcohol dependence, unspecified | Diagnosis | ICD-9-CM |
| 303.91 | Other and unspecified alcohol dependence, continuous | Diagnosis | ICD-9-CM |
| 303.92 | Other and unspecified alcohol dependence, episodic | Diagnosis | ICD-9-CM |
| 305.00 | Nondependent alcohol abuse, unspecified | Diagnosis | ICD-9-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| 305.01 | Nondependent alcohol abuse, continuous | Diagnosis | ICD-9-CM |
| 305.02 | Nondependent alcohol abuse, episodic | Diagnosis | ICD-9-CM |
| 357.5 | Alcoholic polyneuropathy | Diagnosis | ICD-9-CM |
| 425.5 | Alcoholic cardiomyopathy | Diagnosis | ICD-9-CM |
| 535.30 | Alcoholic gastritis without mention of hemorrhage | Diagnosis | ICD-9-CM |
| 535.31 | Alcoholic gastritis with hemorrhage | Diagnosis | ICD-9-CM |
| 571.0 | Alcoholic fatty liver | Diagnosis | ICD-9-CM |
| 571.1 | Acute alcoholic hepatitis | Diagnosis | ICD-9-CM |
| 571.2 | Alcoholic cirrhosis of liver | Diagnosis | ICD-9-CM |
| 571.3 | Unspecified alcoholic liver damage | Diagnosis | ICD-9-CM |
| 760.71 | Noxious influences affecting fetus or newborn via placenta or breast milk, alcohol | Diagnosis | ICD-9-CM |
| 94.6 | Alcohol and drug rehabilitation and detoxification | Procedure | ICD-9-CM |
| 94.61 | Alcohol rehabilitation | Procedure | ICD-9-CM |
| 94.62 | Alcohol detoxification | Procedure | ICD-9-CM |
| 94.63 | Alcohol rehabilitation and detoxification | Procedure | ICD-9-CM |
| 94.67 | Combined alcohol and drug rehabilitation | Procedure | ICD-9-CM |
| 94.68 | Combined alcohol and drug detoxification | Procedure | ICD-9-CM |
| 94.69 | Combined alcohol and drug rehabilitation and detoxification | Procedure | ICD-9-CM |
| 980.0 | Toxic effect of ethyl alcohol | Diagnosis | ICD-9-CM |
| E860.0 | Accidental poisoning by alcoholic beverages | Diagnosis | ICD-9-CM |
| F10.10 | Alcohol abuse, uncomplicated | Diagnosis | ICD-10-CM |
| F10.11 | Alcohol abuse, in remission | Diagnosis | ICD-10-CM |
| F10.120 | Alcohol abuse with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F10.121 | Alcohol abuse with intoxication delirium | Diagnosis | ICD-10-CM |
| F10.129 | Alcohol abuse with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F10.130 | Alcohol abuse with withdrawal, uncomplicated | Diagnosis | ICD-10-CM |
| F10.131 | Alcohol abuse with withdrawal delirium | Diagnosis | ICD-10-CM |
| F10.132 | Alcohol abuse with withdrawal with perceptual disturbance | Diagnosis | ICD-10-CM |
| F10.139 | Alcohol abuse with withdrawal, unspecified | Diagnosis | ICD-10-CM |
| F10.14 | Alcohol abuse with alcohol-induced mood disorder | Diagnosis | ICD-10-CM |
| F10.150 | Alcohol abuse with alcohol-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F10.151 | Alcohol abuse with alcohol-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F10.159 | Alcohol abuse with alcohol-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F10.180 | Alcohol abuse with alcohol-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F10.181 | Alcohol abuse with alcohol-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F10.182 | Alcohol abuse with alcohol-induced sleep disorder | Diagnosis | ICD-10-CM |
| F10.188 | Alcohol abuse with other alcohol-induced disorder | Diagnosis | ICD-10-CM |
| F10.19 | Alcohol abuse with unspecified alcohol-induced disorder | Diagnosis | ICD-10-CM |
| F10.20 | Alcohol dependence, uncomplicated | Diagnosis | ICD-10-CM |
| F10.21 | Alcohol dependence, in remission | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| F10.220 | Alcohol dependence with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F10.221 | Alcohol dependence with intoxication delirium | Diagnosis | ICD-10-CM |
| F10.229 | Alcohol dependence with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F10.230 | Alcohol dependence with withdrawal, uncomplicated | Diagnosis | ICD-10-CM |
| F10.231 | Alcohol dependence with withdrawal delirium | Diagnosis | ICD-10-CM |
| F10.232 | Alcohol dependence with withdrawal with perceptual disturbance | Diagnosis | ICD-10-CM |
| F10.239 | Alcohol dependence with withdrawal, unspecified | Diagnosis | ICD-10-CM |
| F10.24 | Alcohol dependence with alcohol-induced mood disorder | Diagnosis | ICD-10-CM |
| F10.250 | Alcohol dependence with alcohol-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F10.251 | Alcohol dependence with alcohol-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F10.259 | Alcohol dependence with alcohol-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F10.26 | Alcohol dependence with alcohol-induced persisting amnestic disorder | Diagnosis | ICD-10-CM |
| F10.27 | Alcohol dependence with alcohol-induced persisting dementia | Diagnosis | ICD-10-CM |
| F10.280 | Alcohol dependence with alcohol-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F10.281 | Alcohol dependence with alcohol-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F10.282 | Alcohol dependence with alcohol-induced sleep disorder | Diagnosis | ICD-10-CM |
| F10.288 | Alcohol dependence with other alcohol-induced disorder | Diagnosis | ICD-10-CM |
| F10.29 | Alcohol dependence with unspecified alcohol-induced disorder | Diagnosis | ICD-10-CM |
| F10.920 | Alcohol use, unspecified with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F10.921 | Alcohol use, unspecified with intoxication delirium | Diagnosis | ICD-10-CM |
| F10.929 | Alcohol use, unspecified with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F10.930 | Alcohol use, unspecified with withdrawal, uncomplicated | Diagnosis | ICD-10-CM |
| F10.931 | Alcohol use, unspecified with withdrawal delirium | Diagnosis | ICD-10-CM |
| F10.932 | Alcohol use, unspecified with withdrawal with perceptual disturbance | Diagnosis | ICD-10-CM |
| F10.939 | Alcohol use, unspecified with withdrawal, unspecified | Diagnosis | ICD-10-CM |
| F10.94 | Alcohol use, unspecified with alcohol-induced mood disorder | Diagnosis | ICD-10-CM |
| F10.950 | Alcohol use, unspecified with alcohol-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F10.951 | Alcohol use, unspecified with alcohol-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F10.959 | Alcohol use, unspecified with alcohol-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F10.96 | Alcohol use, unspecified with alcohol-induced persisting amnestic disorder | Diagnosis | ICD-10-CM |
| F10.97 | Alcohol use, unspecified with alcohol-induced persisting dementia | Diagnosis | ICD-10-CM |
| F10.980 | Alcohol use, unspecified with alcohol-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F10.981 | Alcohol use, unspecified with alcohol-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F10.982 | Alcohol use, unspecified with alcohol-induced sleep disorder | Diagnosis | ICD-10-CM |
| F10.988 | Alcohol use, unspecified with other alcohol-induced disorder | Diagnosis | ICD-10-CM |
| F10.99 | Alcohol use, unspecified with unspecified alcohol-induced disorder | Diagnosis | ICD-10-CM |
| G62.1 | Alcoholic polyneuropathy | Diagnosis | ICD-10-CM |
| I42.6 | Alcoholic cardiomyopathy | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|--------------------|--|---------------|-----------|
| K29.20 | Alcoholic gastritis without bleeding | Diagnosis | ICD-10-CM |
| K29.21 | Alcoholic gastritis with bleeding | Diagnosis | ICD-10-CM |
| K70.0 | Alcoholic fatty liver | Diagnosis | ICD-10-CM |
| K70.10 | Alcoholic hepatitis without ascites | Diagnosis | ICD-10-CM |
| K70.11 | Alcoholic hepatitis with ascites | Diagnosis | ICD-10-CM |
| K70.2 | Alcoholic fibrosis and sclerosis of liver | Diagnosis | ICD-10-CM |
| K70.30 | Alcoholic cirrhosis of liver without ascites | Diagnosis | ICD-10-CM |
| K70.31 | Alcoholic cirrhosis of liver with ascites | Diagnosis | ICD-10-CM |
| K70.40 | Alcoholic hepatic failure without coma | Diagnosis | ICD-10-CM |
| K70.41 | Alcoholic hepatic failure with coma | Diagnosis | ICD-10-CM |
| K70.9 | Alcoholic liver disease, unspecified | Diagnosis | ICD-10-CM |
| R78.0 | Finding of alcohol in blood | Diagnosis | ICD-10-CM |
| V65.42 | Counseling on substance use and abuse | Diagnosis | ICD-9-CM |
| V79.1 | Screening for alcoholism | Diagnosis | ICD-9-CM |
| Z65.8 | Other specified problems related to psychosocial circumstances | Diagnosis | ICD-10-CM |
| Z71.41 | Alcohol abuse counseling and surveillance of alcoholic | Diagnosis | ICD-10-CM |
| Alzheimer's | | | |
| 290.0 | Senile dementia, uncomplicated | Diagnosis | ICD-9-CM |
| 290.10 | Presenile dementia, uncomplicated | Diagnosis | ICD-9-CM |
| 290.11 | Presenile dementia with delirium | Diagnosis | ICD-9-CM |
| 290.12 | Presenile dementia with delusional features | Diagnosis | ICD-9-CM |
| 290.13 | Presenile dementia with depressive features | Diagnosis | ICD-9-CM |
| 290.20 | Senile dementia with delusional features | Diagnosis | ICD-9-CM |
| 290.21 | Senile dementia with depressive features | Diagnosis | ICD-9-CM |
| 290.3 | Senile dementia with delirium | Diagnosis | ICD-9-CM |
| 290.40 | Vascular dementia, uncomplicated | Diagnosis | ICD-9-CM |
| 290.41 | Vascular dementia, with delirium | Diagnosis | ICD-9-CM |
| 290.42 | Vascular dementia, with delusions | Diagnosis | ICD-9-CM |
| 290.43 | Vascular dementia, with depressed mood | Diagnosis | ICD-9-CM |
| 294.0 | Amnestic disorder in conditions classified elsewhere | Diagnosis | ICD-9-CM |
| 294.10 | Dementia in conditions classified elsewhere without behavioral disturbance | Diagnosis | ICD-9-CM |
| 294.11 | Dementia in conditions classified elsewhere with behavioral disturbance | Diagnosis | ICD-9-CM |
| 294.20 | Dementia, unspecified, without behavioral disturbance | Diagnosis | ICD-9-CM |
| 294.21 | Dementia, unspecified, with behavioral disturbance | Diagnosis | ICD-9-CM |
| 294.8 | Other persistent mental disorders due to conditions classified elsewhere | Diagnosis | ICD-9-CM |
| 331.0 | Alzheimer's disease | Diagnosis | ICD-9-CM |
| 331.11 | Pick's disease | Diagnosis | ICD-9-CM |
| 331.19 | Other frontotemporal dementia | Diagnosis | ICD-9-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|------------------------------------|--|---------------|-----------|
| 331.2 | Senile degeneration of brain | Diagnosis | ICD-9-CM |
| 331.7 | Cerebral degeneration in diseases classified elsewhere | Diagnosis | ICD-9-CM |
| 797 | Senility without mention of psychosis | Diagnosis | ICD-9-CM |
| F01.50 | Vascular dementia without behavioral disturbance | Diagnosis | ICD-10-CM |
| F01.51 | Vascular dementia with behavioral disturbance | Diagnosis | ICD-10-CM |
| F02.80 | Dementia in other diseases classified elsewhere without behavioral disturbance | Diagnosis | ICD-10-CM |
| F02.81 | Dementia in other diseases classified elsewhere with behavioral disturbance | Diagnosis | ICD-10-CM |
| F03.90 | Unspecified dementia without behavioral disturbance | Diagnosis | ICD-10-CM |
| F03.91 | Unspecified dementia with behavioral disturbance | Diagnosis | ICD-10-CM |
| F04 | Amnestic disorder due to known physiological condition | Diagnosis | ICD-10-CM |
| F05 | Delirium due to known physiological condition | Diagnosis | ICD-10-CM |
| F06.1 | Catatonic disorder due to known physiological condition | Diagnosis | ICD-10-CM |
| F06.8 | Other specified mental disorders due to known physiological condition | Diagnosis | ICD-10-CM |
| G13.8 | Systemic atrophy primarily affecting central nervous system in other diseases classified | Diagnosis | ICD-10-CM |
| G30.0 | Alzheimer's disease with early onset | Diagnosis | ICD-10-CM |
| G30.1 | Alzheimer's disease with late onset | Diagnosis | ICD-10-CM |
| G30.8 | Other Alzheimer's disease | Diagnosis | ICD-10-CM |
| G30.9 | Alzheimer's disease, unspecified | Diagnosis | ICD-10-CM |
| G31.01 | Pick's disease | Diagnosis | ICD-10-CM |
| G31.09 | Other frontotemporal dementia | Diagnosis | ICD-10-CM |
| G31.1 | Senile degeneration of brain, not elsewhere classified | Diagnosis | ICD-10-CM |
| G31.2 | Degeneration of nervous system due to alcohol | Diagnosis | ICD-10-CM |
| G94 | Other disorders of brain in diseases classified elsewhere | Diagnosis | ICD-10-CM |
| R41.81 | Age-related cognitive decline | Diagnosis | ICD-10-CM |
| R54 | Age-related physical debility | Diagnosis | ICD-10-CM |
| Acute Myocardial Infarction | | | |
| 410.01 | Acute myocardial infarction of anterolateral wall, initial episode of care | Diagnosis | ICD-9-CM |
| 410.11 | Acute myocardial infarction of other anterior wall, initial episode of care | Diagnosis | ICD-9-CM |
| 410.21 | Acute myocardial infarction of inferolateral wall, initial episode of care | Diagnosis | ICD-9-CM |
| 410.31 | Acute myocardial infarction of inferoposterior wall, initial episode of care | Diagnosis | ICD-9-CM |
| 410.41 | Acute myocardial infarction of other inferior wall, initial episode of care | Diagnosis | ICD-9-CM |
| 410.51 | Acute myocardial infarction of other lateral wall, initial episode of care | Diagnosis | ICD-9-CM |
| 410.61 | Acute myocardial infarction, true posterior wall infarction, initial episode of care | Diagnosis | ICD-9-CM |
| 410.71 | Acute myocardial infarction, subendocardial infarction, initial episode of care | Diagnosis | ICD-9-CM |
| 410.81 | Acute myocardial infarction of other specified sites, initial episode of care | Diagnosis | ICD-9-CM |
| 410.91 | Acute myocardial infarction, unspecified site, initial episode of care | Diagnosis | ICD-9-CM |
| I21.01 | ST elevation (STEMI) myocardial infarction involving left main coronary artery | Diagnosis | ICD-10-CM |
| I21.02 | ST elevation (STEMI) myocardial infarction involving left anterior descending coronary | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------------|---|---------------|-----------|
| I21.09 | ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall | Diagnosis | ICD-10-CM |
| I21.11 | ST elevation (STEMI) myocardial infarction involving right coronary artery | Diagnosis | ICD-10-CM |
| I21.19 | ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall | Diagnosis | ICD-10-CM |
| I21.21 | ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery | Diagnosis | ICD-10-CM |
| I21.29 | ST elevation (STEMI) myocardial infarction involving other sites | Diagnosis | ICD-10-CM |
| I21.3 | ST elevation (STEMI) myocardial infarction of unspecified site | Diagnosis | ICD-10-CM |
| I21.4 | Non-ST elevation (NSTEMI) myocardial infarction | Diagnosis | ICD-10-CM |
| I21.9 | Acute myocardial infarction, unspecified | Diagnosis | ICD-10-CM |
| I21.A1 | Myocardial infarction type 2 | Diagnosis | ICD-10-CM |
| I21.A9 | Other myocardial infarction type | Diagnosis | ICD-10-CM |
| I22.0 | Subsequent ST elevation (STEMI) myocardial infarction of anterior wall | Diagnosis | ICD-10-CM |
| I22.1 | Subsequent ST elevation (STEMI) myocardial infarction of inferior wall | Diagnosis | ICD-10-CM |
| I22.2 | Subsequent non-ST elevation (NSTEMI) myocardial infarction | Diagnosis | ICD-10-CM |
| I22.8 | Subsequent ST elevation (STEMI) myocardial infarction of other sites | Diagnosis | ICD-10-CM |
| I22.9 | Subsequent ST elevation (STEMI) myocardial infarction of unspecified site | Diagnosis | ICD-10-CM |
| I23.0 | Hemopericardium as current complication following acute myocardial infarction | Diagnosis | ICD-10-CM |
| I23.1 | Atrial septal defect as current complication following acute myocardial infarction | Diagnosis | ICD-10-CM |
| I23.2 | Ventricular septal defect as current complication following acute myocardial infarction | Diagnosis | ICD-10-CM |
| I23.3 | Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction | Diagnosis | ICD-10-CM |
| I23.4 | Rupture of chordae tendineae as current complication following acute myocardial infarction | Diagnosis | ICD-10-CM |
| I23.5 | Rupture of papillary muscle as current complication following acute myocardial infarction | Diagnosis | ICD-10-CM |
| I23.6 | Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction | Diagnosis | ICD-10-CM |
| I23.7 | Postinfarction angina | Diagnosis | ICD-10-CM |
| I23.8 | Other current complications following acute myocardial infarction | Diagnosis | ICD-10-CM |
| Anemia | | | |
| 280.0 | Iron deficiency anemia secondary to blood loss (chronic) | Diagnosis | ICD-9-CM |
| 280.1 | Iron deficiency anemia secondary to inadequate dietary iron intake | Diagnosis | ICD-9-CM |
| 280.8 | Other specified iron deficiency anemias | Diagnosis | ICD-9-CM |
| 280.9 | Unspecified iron deficiency anemia | Diagnosis | ICD-9-CM |
| 281.0 | Pernicious anemia | Diagnosis | ICD-9-CM |
| 281.1 | Other vitamin B12 deficiency anemia | Diagnosis | ICD-9-CM |
| 281.2 | Folate-deficiency anemia | Diagnosis | ICD-9-CM |
| 281.3 | Other specified megaloblastic anemias not elsewhere classified | Diagnosis | ICD-9-CM |
| 281.4 | Protein-deficiency anemia | Diagnosis | ICD-9-CM |
| 281.8 | Anemia associated with other specified nutritional deficiency | Diagnosis | ICD-9-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| 281.9 | Unspecified deficiency anemia | Diagnosis | ICD-9-CM |
| 282.0 | Hereditary spherocytosis | Diagnosis | ICD-9-CM |
| 282.1 | Hereditary elliptocytosis | Diagnosis | ICD-9-CM |
| 282.2 | Anemias due to disorders of glutathione metabolism | Diagnosis | ICD-9-CM |
| 282.3 | Other hemolytic anemias due to enzyme deficiency | Diagnosis | ICD-9-CM |
| 282.40 | Thalassemia, unspecified | Diagnosis | ICD-9-CM |
| 282.41 | Sickle-cell thalassemia without crisis | Diagnosis | ICD-9-CM |
| 282.42 | Sickle-cell thalassemia with crisis | Diagnosis | ICD-9-CM |
| 282.43 | Alpha thalassemia | Diagnosis | ICD-9-CM |
| 282.44 | Beta thalassemia | Diagnosis | ICD-9-CM |
| 282.45 | Delta-beta thalassemia | Diagnosis | ICD-9-CM |
| 282.46 | Thalassemia minor | Diagnosis | ICD-9-CM |
| 282.47 | Hemoglobin E-beta thalassemia | Diagnosis | ICD-9-CM |
| 282.49 | Other thalassemia | Diagnosis | ICD-9-CM |
| 282.5 | Sickle-cell trait | Diagnosis | ICD-9-CM |
| 282.60 | Sickle-cell disease, unspecified | Diagnosis | ICD-9-CM |
| 282.61 | Hb-SS disease without crisis | Diagnosis | ICD-9-CM |
| 282.62 | Hb-SS disease with crisis | Diagnosis | ICD-9-CM |
| 282.63 | Sickle-cell/Hb-C disease without crisis | Diagnosis | ICD-9-CM |
| 282.64 | Sickle-cell/Hb-C disease with crisis | Diagnosis | ICD-9-CM |
| 282.68 | Other sickle-cell disease without crisis | Diagnosis | ICD-9-CM |
| 282.69 | Other sickle-cell disease with crisis | Diagnosis | ICD-9-CM |
| 282.7 | Other hemoglobinopathies | Diagnosis | ICD-9-CM |
| 282.8 | Other specified hereditary hemolytic anemias | Diagnosis | ICD-9-CM |
| 282.9 | Unspecified hereditary hemolytic anemia | Diagnosis | ICD-9-CM |
| 283.0 | Autoimmune hemolytic anemias | Diagnosis | ICD-9-CM |
| 283.10 | Unspecified non-autoimmune hemolytic anemia | Diagnosis | ICD-9-CM |
| 283.11 | Hemolytic-uremic syndrome | Diagnosis | ICD-9-CM |
| 283.19 | Other non-autoimmune hemolytic anemias | Diagnosis | ICD-9-CM |
| 283.2 | Hemoglobinuria due to hemolysis from external causes | Diagnosis | ICD-9-CM |
| 283.9 | Acquired hemolytic anemia, unspecified | Diagnosis | ICD-9-CM |
| 284.01 | Constitutional red blood cell aplasia | Diagnosis | ICD-9-CM |
| 284.09 | Other constitutional aplastic anemia | Diagnosis | ICD-9-CM |
| 284.11 | Antineoplastic chemotherapy induced pancytopenia | Diagnosis | ICD-9-CM |
| 284.12 | Other drug induced pancytopenia | Diagnosis | ICD-9-CM |
| 284.19 | Other pancytopenia | Diagnosis | ICD-9-CM |
| 284.2 | Myelophthisis | Diagnosis | ICD-9-CM |
| 284.81 | Red cell aplasia (acquired) (adult) (with thymoma) | Diagnosis | ICD-9-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|--------|---|---------------|-----------|
| 284.89 | Other specified aplastic anemias | Diagnosis | ICD-9-CM |
| 284.9 | Unspecified aplastic anemia | Diagnosis | ICD-9-CM |
| 285.0 | Sideroblastic anemia | Diagnosis | ICD-9-CM |
| 285.1 | Acute posthemorrhagic anemia | Diagnosis | ICD-9-CM |
| 285.21 | Anemia in chronic kidney disease | Diagnosis | ICD-9-CM |
| 285.22 | Anemia in neoplastic disease | Diagnosis | ICD-9-CM |
| 285.29 | Anemia of other chronic disease | Diagnosis | ICD-9-CM |
| 285.3 | Antineoplastic chemotherapy induced anemia | Diagnosis | ICD-9-CM |
| 285.8 | Other specified anemias | Diagnosis | ICD-9-CM |
| 285.9 | Unspecified anemia | Diagnosis | ICD-9-CM |
| C94.6 | Myelodysplastic disease, not elsewhere classified | Diagnosis | ICD-10-CM |
| D46.0 | Refractory anemia without ring sideroblasts, so stated | Diagnosis | ICD-10-CM |
| D46.1 | Refractory anemia with ring sideroblasts | Diagnosis | ICD-10-CM |
| D46.20 | Refractory anemia with excess of blasts, unspecified | Diagnosis | ICD-10-CM |
| D46.21 | Refractory anemia with excess of blasts 1 | Diagnosis | ICD-10-CM |
| D46.22 | Refractory anemia with excess of blasts 2 | Diagnosis | ICD-10-CM |
| D46.4 | Refractory anemia, unspecified | Diagnosis | ICD-10-CM |
| D46.9 | Myelodysplastic syndrome, unspecified | Diagnosis | ICD-10-CM |
| D46.A | Refractory cytopenia with multilineage dysplasia | Diagnosis | ICD-10-CM |
| D46.B | Refractory cytopenia with multilineage dysplasia and ring sideroblasts | Diagnosis | ICD-10-CM |
| D46.C | Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality | Diagnosis | ICD-10-CM |
| D46.Z | Other myelodysplastic syndromes | Diagnosis | ICD-10-CM |
| D47.4 | Osteomyelofibrosis | Diagnosis | ICD-10-CM |
| D50.0 | Iron deficiency anemia secondary to blood loss (chronic) | Diagnosis | ICD-10-CM |
| D50.1 | Sideropenic dysphagia | Diagnosis | ICD-10-CM |
| D50.8 | Other iron deficiency anemias | Diagnosis | ICD-10-CM |
| D50.9 | Iron deficiency anemia, unspecified | Diagnosis | ICD-10-CM |
| D51.0 | Vitamin B12 deficiency anemia due to intrinsic factor deficiency | Diagnosis | ICD-10-CM |
| D51.1 | Vitamin B12 deficiency anemia due to selective vitamin B12 malabsorption with proteinuria | Diagnosis | ICD-10-CM |
| D51.2 | Transcobalamin II deficiency | Diagnosis | ICD-10-CM |
| D51.3 | Other dietary vitamin B12 deficiency anemia | Diagnosis | ICD-10-CM |
| D51.8 | Other vitamin B12 deficiency anemias | Diagnosis | ICD-10-CM |
| D51.9 | Vitamin B12 deficiency anemia, unspecified | Diagnosis | ICD-10-CM |
| D52.0 | Dietary folate deficiency anemia | Diagnosis | ICD-10-CM |
| D52.1 | Drug-induced folate deficiency anemia | Diagnosis | ICD-10-CM |
| D52.8 | Other folate deficiency anemias | Diagnosis | ICD-10-CM |
| D52.9 | Folate deficiency anemia, unspecified | Diagnosis | ICD-10-CM |
| D53.0 | Protein deficiency anemia | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|---|---------------|-----------|
| D53.1 | Other megaloblastic anemias, not elsewhere classified | Diagnosis | ICD-10-CM |
| D53.2 | Scorbutic anemia | Diagnosis | ICD-10-CM |
| D53.8 | Other specified nutritional anemias | Diagnosis | ICD-10-CM |
| D53.9 | Nutritional anemia, unspecified | Diagnosis | ICD-10-CM |
| D55.0 | Anemia due to glucose-6-phosphate dehydrogenase [G6PD] deficiency | Diagnosis | ICD-10-CM |
| D55.1 | Anemia due to other disorders of glutathione metabolism | Diagnosis | ICD-10-CM |
| D55.2 | Anemia due to disorders of glycolytic enzymes | Diagnosis | ICD-10-CM |
| D55.21 | Anemia due to pyruvate kinase deficiency | Diagnosis | ICD-10-CM |
| D55.29 | Anemia due to other disorders of glycolytic enzymes | Diagnosis | ICD-10-CM |
| D55.3 | Anemia due to disorders of nucleotide metabolism | Diagnosis | ICD-10-CM |
| D55.8 | Other anemias due to enzyme disorders | Diagnosis | ICD-10-CM |
| D55.9 | Anemia due to enzyme disorder, unspecified | Diagnosis | ICD-10-CM |
| D56.0 | Alpha thalassemia | Diagnosis | ICD-10-CM |
| D56.1 | Beta thalassemia | Diagnosis | ICD-10-CM |
| D56.2 | Delta-beta thalassemia | Diagnosis | ICD-10-CM |
| D56.3 | Thalassemia minor | Diagnosis | ICD-10-CM |
| D56.4 | Hereditary persistence of fetal hemoglobin [HPFH] | Diagnosis | ICD-10-CM |
| D56.5 | Hemoglobin E-beta thalassemia | Diagnosis | ICD-10-CM |
| D56.8 | Other thalassemias | Diagnosis | ICD-10-CM |
| D56.9 | Thalassemia, unspecified | Diagnosis | ICD-10-CM |
| D57.00 | Hb-SS disease with crisis, unspecified | Diagnosis | ICD-10-CM |
| D57.01 | Hb-SS disease with acute chest syndrome | Diagnosis | ICD-10-CM |
| D57.02 | Hb-SS disease with splenic sequestration | Diagnosis | ICD-10-CM |
| D57.03 | Hb-SS disease with cerebral vascular involvement | Diagnosis | ICD-10-CM |
| D57.09 | Hb-SS disease with crisis with other specified complication | Diagnosis | ICD-10-CM |
| D57.1 | Sickle-cell disease without crisis | Diagnosis | ICD-10-CM |
| D57.20 | Sickle-cell/Hb-C disease without crisis | Diagnosis | ICD-10-CM |
| D57.211 | Sickle-cell/Hb-C disease with acute chest syndrome | Diagnosis | ICD-10-CM |
| D57.212 | Sickle-cell/Hb-C disease with splenic sequestration | Diagnosis | ICD-10-CM |
| D57.213 | Sickle-cell/Hb-C disease with cerebral vascular involvement | Diagnosis | ICD-10-CM |
| D57.218 | Sickle-cell/Hb-C disease with crisis with other specified complication | Diagnosis | ICD-10-CM |
| D57.219 | Sickle-cell/Hb-C disease with crisis, unspecified | Diagnosis | ICD-10-CM |
| D57.3 | Sickle-cell trait | Diagnosis | ICD-10-CM |
| D57.40 | Sickle-cell thalassemia without crisis | Diagnosis | ICD-10-CM |
| D57.411 | Sickle-cell thalassemia with acute chest syndrome | Diagnosis | ICD-10-CM |
| D57.412 | Sickle-cell thalassemia with splenic sequestration | Diagnosis | ICD-10-CM |
| D57.413 | Sickle-cell thalassemia, unspecified, with cerebral vascular involvement | Diagnosis | ICD-10-CM |
| D57.418 | Sickle-cell thalassemia, unspecified, with crisis with other specified complication | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|---|---------------|-----------|
| D57.419 | Sickle-cell thalassemia with crisis, unspecified | Diagnosis | ICD-10-CM |
| D57.42 | Sickle-cell thalassemia beta zero without crisis | Diagnosis | ICD-10-CM |
| D57.431 | Sickle-cell thalassemia beta zero with acute chest syndrome | Diagnosis | ICD-10-CM |
| D57.432 | Sickle-cell thalassemia beta zero with splenic sequestration | Diagnosis | ICD-10-CM |
| D57.433 | Sickle-cell thalassemia beta zero with cerebral vascular involvement | Diagnosis | ICD-10-CM |
| D57.438 | Sickle-cell thalassemia beta zero with crisis with other specified complication | Diagnosis | ICD-10-CM |
| D57.439 | Sickle-cell thalassemia beta zero with crisis, unspecified | Diagnosis | ICD-10-CM |
| D57.44 | Sickle-cell thalassemia beta plus without crisis | Diagnosis | ICD-10-CM |
| D57.451 | Sickle-cell thalassemia beta plus with acute chest syndrome | Diagnosis | ICD-10-CM |
| D57.452 | Sickle-cell thalassemia beta plus with splenic sequestration | Diagnosis | ICD-10-CM |
| D57.453 | Sickle-cell thalassemia beta plus with cerebral vascular involvement | Diagnosis | ICD-10-CM |
| D57.458 | Sickle-cell thalassemia beta plus with crisis with other specified complication | Diagnosis | ICD-10-CM |
| D57.459 | Sickle-cell thalassemia beta plus with crisis, unspecified | Diagnosis | ICD-10-CM |
| D57.80 | Other sickle-cell disorders without crisis | Diagnosis | ICD-10-CM |
| D57.811 | Other sickle-cell disorders with acute chest syndrome | Diagnosis | ICD-10-CM |
| D57.812 | Other sickle-cell disorders with splenic sequestration | Diagnosis | ICD-10-CM |
| D57.813 | Other sickle-cell disorders with cerebral vascular involvement | Diagnosis | ICD-10-CM |
| D57.818 | Other sickle-cell disorders with crisis with other specified complication | Diagnosis | ICD-10-CM |
| D57.819 | Other sickle-cell disorders with crisis, unspecified | Diagnosis | ICD-10-CM |
| D58.0 | Hereditary spherocytosis | Diagnosis | ICD-10-CM |
| D58.1 | Hereditary elliptocytosis | Diagnosis | ICD-10-CM |
| D58.2 | Other hemoglobinopathies | Diagnosis | ICD-10-CM |
| D58.8 | Other specified hereditary hemolytic anemias | Diagnosis | ICD-10-CM |
| D58.9 | Hereditary hemolytic anemia, unspecified | Diagnosis | ICD-10-CM |
| D59.0 | Drug-induced autoimmune hemolytic anemia | Diagnosis | ICD-10-CM |
| D59.1 | Other autoimmune hemolytic anemias | Diagnosis | ICD-10-CM |
| D59.10 | Autoimmune hemolytic anemia, unspecified | Diagnosis | ICD-10-CM |
| D59.11 | Warm autoimmune hemolytic anemia | Diagnosis | ICD-10-CM |
| D59.12 | Cold autoimmune hemolytic anemia | Diagnosis | ICD-10-CM |
| D59.13 | Mixed type autoimmune hemolytic anemia | Diagnosis | ICD-10-CM |
| D59.19 | Other autoimmune hemolytic anemia | Diagnosis | ICD-10-CM |
| D59.2 | Drug-induced nonautoimmune hemolytic anemia | Diagnosis | ICD-10-CM |
| D59.3 | Hemolytic-uremic syndrome | Diagnosis | ICD-10-CM |
| D59.4 | Other nonautoimmune hemolytic anemias | Diagnosis | ICD-10-CM |
| D59.5 | Paroxysmal nocturnal hemoglobinuria [Marchiafava-Micheli] | Diagnosis | ICD-10-CM |
| D59.6 | Hemoglobinuria due to hemolysis from other external causes | Diagnosis | ICD-10-CM |
| D59.8 | Other acquired hemolytic anemias | Diagnosis | ICD-10-CM |
| D59.9 | Acquired hemolytic anemia, unspecified | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------------|--|---------------|-----------|
| D60.0 | Chronic acquired pure red cell aplasia | Diagnosis | ICD-10-CM |
| D60.1 | Transient acquired pure red cell aplasia | Diagnosis | ICD-10-CM |
| D60.8 | Other acquired pure red cell aplasias | Diagnosis | ICD-10-CM |
| D60.9 | Acquired pure red cell aplasia, unspecified | Diagnosis | ICD-10-CM |
| D61.01 | Constitutional (pure) red blood cell aplasia | Diagnosis | ICD-10-CM |
| D61.09 | Other constitutional aplastic anemia | Diagnosis | ICD-10-CM |
| D61.1 | Drug-induced aplastic anemia | Diagnosis | ICD-10-CM |
| D61.2 | Aplastic anemia due to other external agents | Diagnosis | ICD-10-CM |
| D61.3 | Idiopathic aplastic anemia | Diagnosis | ICD-10-CM |
| D61.810 | Antineoplastic chemotherapy induced pancytopenia | Diagnosis | ICD-10-CM |
| D61.811 | Other drug-induced pancytopenia | Diagnosis | ICD-10-CM |
| D61.818 | Other pancytopenia | Diagnosis | ICD-10-CM |
| D61.82 | Myelophthisis | Diagnosis | ICD-10-CM |
| D61.89 | Other specified aplastic anemias and other bone marrow failure syndromes | Diagnosis | ICD-10-CM |
| D61.9 | Aplastic anemia, unspecified | Diagnosis | ICD-10-CM |
| D62 | Acute posthemorrhagic anemia | Diagnosis | ICD-10-CM |
| D63.0 | Anemia in neoplastic disease | Diagnosis | ICD-10-CM |
| D63.1 | Anemia in chronic kidney disease | Diagnosis | ICD-10-CM |
| D63.8 | Anemia in other chronic diseases classified elsewhere | Diagnosis | ICD-10-CM |
| D64.0 | Hereditary sideroblastic anemia | Diagnosis | ICD-10-CM |
| D64.1 | Secondary sideroblastic anemia due to disease | Diagnosis | ICD-10-CM |
| D64.2 | Secondary sideroblastic anemia due to drugs and toxins | Diagnosis | ICD-10-CM |
| D64.3 | Other sideroblastic anemias | Diagnosis | ICD-10-CM |
| D64.4 | Congenital dyserythropoietic anemia | Diagnosis | ICD-10-CM |
| D64.81 | Anemia due to antineoplastic chemotherapy | Diagnosis | ICD-10-CM |
| D64.89 | Other specified anemias | Diagnosis | ICD-10-CM |
| D64.9 | Anemia, unspecified | Diagnosis | ICD-10-CM |
| D75.81 | Myelofibrosis | Diagnosis | ICD-10-CM |
| Asthma | | | |
| 493.00 | Extrinsic asthma, unspecified | Diagnosis | ICD-9-CM |
| 493.01 | Extrinsic asthma with status asthmaticus | Diagnosis | ICD-9-CM |
| 493.02 | Extrinsic asthma, with (acute) exacerbation | Diagnosis | ICD-9-CM |
| 493.10 | Intrinsic asthma, unspecified | Diagnosis | ICD-9-CM |
| 493.11 | Intrinsic asthma with status asthmaticus | Diagnosis | ICD-9-CM |
| 493.12 | Intrinsic asthma, with (acute) exacerbation | Diagnosis | ICD-9-CM |
| 493.20 | Chronic obstructive asthma, unspecified | Diagnosis | ICD-9-CM |
| 493.21 | Chronic obstructive asthma with status asthmaticus | Diagnosis | ICD-9-CM |
| 493.22 | Chronic obstructive asthma, with (acute) exacerbation | Diagnosis | ICD-9-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|-------------------------------------|--|---------------|-----------|
| 493.81 | Exercise induced bronchospasm | Diagnosis | ICD-9-CM |
| 493.82 | Cough variant asthma | Diagnosis | ICD-9-CM |
| 493.90 | Asthma, unspecified, unspecified status | Diagnosis | ICD-9-CM |
| 493.91 | Asthma, unspecified with status asthmaticus | Diagnosis | ICD-9-CM |
| 493.92 | Asthma, unspecified, with (acute) exacerbation | Diagnosis | ICD-9-CM |
| J45.20 | Mild intermittent asthma, uncomplicated | Diagnosis | ICD-10-CM |
| J45.21 | Mild intermittent asthma with (acute) exacerbation | Diagnosis | ICD-10-CM |
| J45.22 | Mild intermittent asthma with status asthmaticus | Diagnosis | ICD-10-CM |
| J45.30 | Mild persistent asthma, uncomplicated | Diagnosis | ICD-10-CM |
| J45.31 | Mild persistent asthma with (acute) exacerbation | Diagnosis | ICD-10-CM |
| J45.32 | Mild persistent asthma with status asthmaticus | Diagnosis | ICD-10-CM |
| J45.40 | Moderate persistent asthma, uncomplicated | Diagnosis | ICD-10-CM |
| J45.41 | Moderate persistent asthma with (acute) exacerbation | Diagnosis | ICD-10-CM |
| J45.42 | Moderate persistent asthma with status asthmaticus | Diagnosis | ICD-10-CM |
| J45.50 | Severe persistent asthma, uncomplicated | Diagnosis | ICD-10-CM |
| J45.51 | Severe persistent asthma with (acute) exacerbation | Diagnosis | ICD-10-CM |
| J45.52 | Severe persistent asthma with status asthmaticus | Diagnosis | ICD-10-CM |
| J45.901 | Unspecified asthma with (acute) exacerbation | Diagnosis | ICD-10-CM |
| J45.902 | Unspecified asthma with status asthmaticus | Diagnosis | ICD-10-CM |
| J45.909 | Unspecified asthma, uncomplicated | Diagnosis | ICD-10-CM |
| J45.990 | Exercise induced bronchospasm | Diagnosis | ICD-10-CM |
| J45.991 | Cough variant asthma | Diagnosis | ICD-10-CM |
| J45.998 | Other asthma | Diagnosis | ICD-10-CM |
| J82.83 | Eosinophilic asthma | Diagnosis | ICD-10-CM |
| Atrial Fibrillation | | | |
| 427.31 | Atrial fibrillation | Diagnosis | ICD-9-CM |
| I48.0 | Paroxysmal atrial fibrillation | Diagnosis | ICD-10-CM |
| I48.1 | Persistent atrial fibrillation | Diagnosis | ICD-10-CM |
| I48.11 | Longstanding persistent atrial fibrillation | Diagnosis | ICD-10-CM |
| I48.19 | Other persistent atrial fibrillation | Diagnosis | ICD-10-CM |
| I48.2 | Chronic atrial fibrillation | Diagnosis | ICD-10-CM |
| I48.20 | Chronic atrial fibrillation, unspecified | Diagnosis | ICD-10-CM |
| I48.21 | Permanent atrial fibrillation | Diagnosis | ICD-10-CM |
| I48.3 | Typical atrial flutter | Diagnosis | ICD-10-CM |
| I48.4 | Atypical atrial flutter | Diagnosis | ICD-10-CM |
| I48.91 | Unspecified atrial fibrillation | Diagnosis | ICD-10-CM |
| Benign Prostatic Hyperplasia | | | |
| 600.00 | Hypertrophy (benign) of prostate without urinary obstruction and other lower urinary tract symptoms [LUTS] | Diagnosis | ICD-9-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|----------------------|--|---------------|-----------|
| 600.01 | Hypertrophy (benign) of prostate with urinary obstruction and other lower urinary tract symptoms [LUTS] | Diagnosis | ICD-9-CM |
| 600.10 | Nodular prostate without urinary obstruction | Diagnosis | ICD-9-CM |
| 600.11 | Nodular prostate with urinary obstruction | Diagnosis | ICD-9-CM |
| 600.20 | Benign localized hyperplasia of prostate without urinary obstruction and other lower urinary tract symptoms [LUTS] | Diagnosis | ICD-9-CM |
| 600.21 | Benign localized hyperplasia of prostate with urinary obstruction and other lower urinary tract symptoms [LUTS] | Diagnosis | ICD-9-CM |
| 600.3 | Cyst of prostate | Diagnosis | ICD-9-CM |
| 600.90 | Hyperplasia of prostate, unspecified, without urinary obstruction and other lower urinary tract symptoms [LUTS] | Diagnosis | ICD-9-CM |
| 600.91 | Hyperplasia of prostate, unspecified, with urinary obstruction and other lower urinary tract symptoms [LUTS] | Diagnosis | ICD-9-CM |
| N40.0 | Benign prostatic hyperplasia without lower urinary tract symptoms | Diagnosis | ICD-10-CM |
| N40.1 | Benign prostatic hyperplasia with lower urinary tract symptoms | Diagnosis | ICD-10-CM |
| N40.2 | Nodular prostate without lower urinary tract symptoms | Diagnosis | ICD-10-CM |
| N40.3 | Nodular prostate with lower urinary tract symptoms | Diagnosis | ICD-10-CM |
| N42.83 | Cyst of prostate | Diagnosis | ICD-10-CM |
| Breast Cancer | | | |
| 174.0 | Malignant neoplasm of nipple and areola of female breast | Diagnosis | ICD-9-CM |
| 174.1 | Malignant neoplasm of central portion of female breast | Diagnosis | ICD-9-CM |
| 174.2 | Malignant neoplasm of upper-inner quadrant of female breast | Diagnosis | ICD-9-CM |
| 174.3 | Malignant neoplasm of lower-inner quadrant of female breast | Diagnosis | ICD-9-CM |
| 174.4 | Malignant neoplasm of upper-outer quadrant of female breast | Diagnosis | ICD-9-CM |
| 174.5 | Malignant neoplasm of lower-outer quadrant of female breast | Diagnosis | ICD-9-CM |
| 174.6 | Malignant neoplasm of axillary tail of female breast | Diagnosis | ICD-9-CM |
| 174.8 | Malignant neoplasm of other specified sites of female breast | Diagnosis | ICD-9-CM |
| 174.9 | Malignant neoplasm of breast (female), unspecified site | Diagnosis | ICD-9-CM |
| 175.0 | Malignant neoplasm of nipple and areola of male breast | Diagnosis | ICD-9-CM |
| 175.9 | Malignant neoplasm of other and unspecified sites of male breast | Diagnosis | ICD-9-CM |
| 233.0 | Carcinoma in situ of breast | Diagnosis | ICD-9-CM |
| C50.011 | Malignant neoplasm of nipple and areola, right female breast | Diagnosis | ICD-10-CM |
| C50.012 | Malignant neoplasm of nipple and areola, left female breast | Diagnosis | ICD-10-CM |
| C50.019 | Malignant neoplasm of nipple and areola, unspecified female breast | Diagnosis | ICD-10-CM |
| C50.021 | Malignant neoplasm of nipple and areola, right male breast | Diagnosis | ICD-10-CM |
| C50.022 | Malignant neoplasm of nipple and areola, left male breast | Diagnosis | ICD-10-CM |
| C50.029 | Malignant neoplasm of nipple and areola, unspecified male breast | Diagnosis | ICD-10-CM |
| C50.111 | Malignant neoplasm of central portion of right female breast | Diagnosis | ICD-10-CM |
| C50.112 | Malignant neoplasm of central portion of left female breast | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|---|---------------|-----------|
| C50.119 | Malignant neoplasm of central portion of unspecified female breast | Diagnosis | ICD-10-CM |
| C50.121 | Malignant neoplasm of central portion of right male breast | Diagnosis | ICD-10-CM |
| C50.122 | Malignant neoplasm of central portion of left male breast | Diagnosis | ICD-10-CM |
| C50.129 | Malignant neoplasm of central portion of unspecified male breast | Diagnosis | ICD-10-CM |
| C50.211 | Malignant neoplasm of upper-inner quadrant of right female breast | Diagnosis | ICD-10-CM |
| C50.212 | Malignant neoplasm of upper-inner quadrant of left female breast | Diagnosis | ICD-10-CM |
| C50.219 | Malignant neoplasm of upper-inner quadrant of unspecified female breast | Diagnosis | ICD-10-CM |
| C50.221 | Malignant neoplasm of upper-inner quadrant of right male breast | Diagnosis | ICD-10-CM |
| C50.222 | Malignant neoplasm of upper-inner quadrant of left male breast | Diagnosis | ICD-10-CM |
| C50.229 | Malignant neoplasm of upper-inner quadrant of unspecified male breast | Diagnosis | ICD-10-CM |
| C50.311 | Malignant neoplasm of lower-inner quadrant of right female breast | Diagnosis | ICD-10-CM |
| C50.312 | Malignant neoplasm of lower-inner quadrant of left female breast | Diagnosis | ICD-10-CM |
| C50.319 | Malignant neoplasm of lower-inner quadrant of unspecified female breast | Diagnosis | ICD-10-CM |
| C50.321 | Malignant neoplasm of lower-inner quadrant of right male breast | Diagnosis | ICD-10-CM |
| C50.322 | Malignant neoplasm of lower-inner quadrant of left male breast | Diagnosis | ICD-10-CM |
| C50.329 | Malignant neoplasm of lower-inner quadrant of unspecified male breast | Diagnosis | ICD-10-CM |
| C50.411 | Malignant neoplasm of upper-outer quadrant of right female breast | Diagnosis | ICD-10-CM |
| C50.412 | Malignant neoplasm of upper-outer quadrant of left female breast | Diagnosis | ICD-10-CM |
| C50.419 | Malignant neoplasm of upper-outer quadrant of unspecified female breast | Diagnosis | ICD-10-CM |
| C50.421 | Malignant neoplasm of upper-outer quadrant of right male breast | Diagnosis | ICD-10-CM |
| C50.422 | Malignant neoplasm of upper-outer quadrant of left male breast | Diagnosis | ICD-10-CM |
| C50.429 | Malignant neoplasm of upper-outer quadrant of unspecified male breast | Diagnosis | ICD-10-CM |
| C50.511 | Malignant neoplasm of lower-outer quadrant of right female breast | Diagnosis | ICD-10-CM |
| C50.512 | Malignant neoplasm of lower-outer quadrant of left female breast | Diagnosis | ICD-10-CM |
| C50.519 | Malignant neoplasm of lower-outer quadrant of unspecified female breast | Diagnosis | ICD-10-CM |
| C50.521 | Malignant neoplasm of lower-outer quadrant of right male breast | Diagnosis | ICD-10-CM |
| C50.522 | Malignant neoplasm of lower-outer quadrant of left male breast | Diagnosis | ICD-10-CM |
| C50.529 | Malignant neoplasm of lower-outer quadrant of unspecified male breast | Diagnosis | ICD-10-CM |
| C50.611 | Malignant neoplasm of axillary tail of right female breast | Diagnosis | ICD-10-CM |
| C50.612 | Malignant neoplasm of axillary tail of left female breast | Diagnosis | ICD-10-CM |
| C50.619 | Malignant neoplasm of axillary tail of unspecified female breast | Diagnosis | ICD-10-CM |
| C50.621 | Malignant neoplasm of axillary tail of right male breast | Diagnosis | ICD-10-CM |
| C50.622 | Malignant neoplasm of axillary tail of left male breast | Diagnosis | ICD-10-CM |
| C50.629 | Malignant neoplasm of axillary tail of unspecified male breast | Diagnosis | ICD-10-CM |
| C50.811 | Malignant neoplasm of overlapping sites of right female breast | Diagnosis | ICD-10-CM |
| C50.812 | Malignant neoplasm of overlapping sites of left female breast | Diagnosis | ICD-10-CM |
| C50.819 | Malignant neoplasm of overlapping sites of unspecified female breast | Diagnosis | ICD-10-CM |
| C50.821 | Malignant neoplasm of overlapping sites of right male breast | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|-------------------------------|--|---------------|-----------|
| C50.822 | Malignant neoplasm of overlapping sites of left male breast | Diagnosis | ICD-10-CM |
| C50.829 | Malignant neoplasm of overlapping sites of unspecified male breast | Diagnosis | ICD-10-CM |
| C50.911 | Malignant neoplasm of unspecified site of right female breast | Diagnosis | ICD-10-CM |
| C50.912 | Malignant neoplasm of unspecified site of left female breast | Diagnosis | ICD-10-CM |
| C50.919 | Malignant neoplasm of unspecified site of unspecified female breast | Diagnosis | ICD-10-CM |
| C50.921 | Malignant neoplasm of unspecified site of right male breast | Diagnosis | ICD-10-CM |
| C50.922 | Malignant neoplasm of unspecified site of left male breast | Diagnosis | ICD-10-CM |
| C50.929 | Malignant neoplasm of unspecified site of unspecified male breast | Diagnosis | ICD-10-CM |
| D05.00 | Lobular carcinoma in situ of unspecified breast | Diagnosis | ICD-10-CM |
| D05.01 | Lobular carcinoma in situ of right breast | Diagnosis | ICD-10-CM |
| D05.02 | Lobular carcinoma in situ of left breast | Diagnosis | ICD-10-CM |
| D05.10 | Intraductal carcinoma in situ of unspecified breast | Diagnosis | ICD-10-CM |
| D05.11 | Intraductal carcinoma in situ of right breast | Diagnosis | ICD-10-CM |
| D05.12 | Intraductal carcinoma in situ of left breast | Diagnosis | ICD-10-CM |
| D05.80 | Other specified type of carcinoma in situ of unspecified breast | Diagnosis | ICD-10-CM |
| D05.81 | Other specified type of carcinoma in situ of right breast | Diagnosis | ICD-10-CM |
| D05.82 | Other specified type of carcinoma in situ of left breast | Diagnosis | ICD-10-CM |
| D05.90 | Unspecified type of carcinoma in situ of unspecified breast | Diagnosis | ICD-10-CM |
| D05.91 | Unspecified type of carcinoma in situ of right breast | Diagnosis | ICD-10-CM |
| D05.92 | Unspecified type of carcinoma in situ of left breast | Diagnosis | ICD-10-CM |
| V10.3 | Personal history of malignant neoplasm of breast | Diagnosis | ICD-9-CM |
| Z17.0 | Estrogen receptor positive status [ER+] | Diagnosis | ICD-10-CM |
| Z17.1 | Estrogen receptor negative status [ER-] | Diagnosis | ICD-10-CM |
| Z19.1 | Hormone sensitive malignancy status | Diagnosis | ICD-10-CM |
| Z19.2 | Hormone resistant malignancy status | Diagnosis | ICD-10-CM |
| Z85.3 | Personal history of malignant neoplasm of breast | Diagnosis | ICD-10-CM |
| Z86.000 | Personal history of in-situ neoplasm of breast | Diagnosis | ICD-10-CM |
| Cardiac Arrest | | | |
| V12.53 | Personal history of sudden cardiac arrest | Diagnosis | ICD-9-CM |
| Z86.74 | Personal history of sudden cardiac arrest | Diagnosis | ICD-10-CM |
| Chronic Kidney Disease | | | |
| 016.00 | Tuberculosis of kidney, confirmation unspecified | Diagnosis | ICD-9-CM |
| 016.01 | Tuberculosis of kidney, bacteriological or histological examination not done | Diagnosis | ICD-9-CM |
| 016.02 | Tuberculosis of kidney, bacteriological or histological examination unknown (at present) | Diagnosis | ICD-9-CM |
| 016.03 | Tuberculosis of kidney, tubercle bacilli found (in sputum) by microscopy | Diagnosis | ICD-9-CM |
| 016.04 | Tuberculosis of kidney, tubercle bacilli not found (in sputum) by microscopy, but found by bacterial culture | Diagnosis | ICD-9-CM |
| 016.05 | Tuberculosis of kidney, tubercle bacilli not found by bacteriological examination, but tuberculosis confirmed histologically | Diagnosis | ICD-9-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|--------|---|---------------|-----------|
| 016.06 | Tuberculosis of kidney, tubercle bacilli not found by bacteriological or histological examination, but tuberculosis confirmed by other methods [inoculation of animals] | Diagnosis | ICD-9-CM |
| 095.4 | Syphilis of kidney | Diagnosis | ICD-9-CM |
| 189.0 | Malignant neoplasm of kidney, except pelvis | Diagnosis | ICD-9-CM |
| 189.9 | Malignant neoplasm of urinary organ, site unspecified | Diagnosis | ICD-9-CM |
| 223.0 | Benign neoplasm of kidney, except pelvis | Diagnosis | ICD-9-CM |
| 236.91 | Neoplasm of uncertain behavior of kidney and ureter | Diagnosis | ICD-9-CM |
| 249.40 | Secondary diabetes mellitus with renal manifestations, not stated as uncontrolled, or unspecified | Diagnosis | ICD-9-CM |
| 249.41 | Secondary diabetes mellitus with renal manifestations, uncontrolled | Diagnosis | ICD-9-CM |
| 250.40 | Diabetes with renal manifestations, type II or unspecified type, not stated as uncontrolled | Diagnosis | ICD-9-CM |
| 250.41 | Diabetes with renal manifestations, type I [juvenile type], not stated as uncontrolled | Diagnosis | ICD-9-CM |
| 250.42 | Diabetes with renal manifestations, type II or unspecified type, uncontrolled | Diagnosis | ICD-9-CM |
| 250.43 | Diabetes with renal manifestations, type I [juvenile type], uncontrolled | Diagnosis | ICD-9-CM |
| 271.4 | Renal glycosuria | Diagnosis | ICD-9-CM |
| 274.10 | Gouty nephropathy, unspecified | Diagnosis | ICD-9-CM |
| 283.11 | Hemolytic-uremic syndrome | Diagnosis | ICD-9-CM |
| 403.01 | Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage V or end stage renal disease | Diagnosis | ICD-9-CM |
| 403.11 | Hypertensive chronic kidney disease, benign, with chronic kidney disease stage V or end stage renal disease | Diagnosis | ICD-9-CM |
| 403.91 | Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage V or end stage renal disease | Diagnosis | ICD-9-CM |
| 404.02 | Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage V or end stage renal disease | Diagnosis | ICD-9-CM |
| 404.03 | Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease | Diagnosis | ICD-9-CM |
| 404.12 | Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage V or end stage renal disease | Diagnosis | ICD-9-CM |
| 404.13 | Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease | Diagnosis | ICD-9-CM |
| 404.92 | Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage V or end stage renal disease | Diagnosis | ICD-9-CM |
| 404.93 | Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease | Diagnosis | ICD-9-CM |
| 440.1 | Atherosclerosis of renal artery | Diagnosis | ICD-9-CM |
| 442.1 | Aneurysm of renal artery | Diagnosis | ICD-9-CM |
| 572.4 | Hepatorenal syndrome | Diagnosis | ICD-9-CM |
| 580.0 | Acute glomerulonephritis with lesion of proliferative glomerulonephritis | Diagnosis | ICD-9-CM |
| 580.4 | Acute glomerulonephritis with lesion of rapidly progressive glomerulonephritis | Diagnosis | ICD-9-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| 580.81 | Acute glomerulonephritis with other specified pathological lesion in kidney in disease classified elsewhere | Diagnosis | ICD-9-CM |
| 580.89 | Other acute glomerulonephritis with other specified pathological lesion in kidney | Diagnosis | ICD-9-CM |
| 580.9 | Acute glomerulonephritis with unspecified pathological lesion in kidney | Diagnosis | ICD-9-CM |
| 581.0 | Nephrotic syndrome with lesion of proliferative glomerulonephritis | Diagnosis | ICD-9-CM |
| 581.1 | Nephrotic syndrome with lesion of membranous glomerulonephritis | Diagnosis | ICD-9-CM |
| 581.2 | Nephrotic syndrome with lesion of membranoproliferative glomerulonephritis | Diagnosis | ICD-9-CM |
| 581.3 | Nephrotic syndrome with lesion of minimal change glomerulonephritis | Diagnosis | ICD-9-CM |
| 581.81 | Nephrotic syndrome with other specified pathological lesion in kidney in diseases classified elsewhere | Diagnosis | ICD-9-CM |
| 581.89 | Other nephrotic syndrome with specified pathological lesion in kidney | Diagnosis | ICD-9-CM |
| 581.9 | Nephrotic syndrome with unspecified pathological lesion in kidney | Diagnosis | ICD-9-CM |
| 582.0 | Chronic glomerulonephritis with lesion of proliferative glomerulonephritis | Diagnosis | ICD-9-CM |
| 582.1 | Chronic glomerulonephritis with lesion of membranous glomerulonephritis | Diagnosis | ICD-9-CM |
| 582.2 | Chronic glomerulonephritis with lesion of membranoproliferative glomerulonephritis | Diagnosis | ICD-9-CM |
| 582.4 | Chronic glomerulonephritis with lesion of rapidly progressive glomerulonephritis | Diagnosis | ICD-9-CM |
| 582.81 | Chronic glomerulonephritis with other specified pathological lesion in kidney in diseases classified elsewhere | Diagnosis | ICD-9-CM |
| 582.89 | Other chronic glomerulonephritis with specified pathological lesion in kidney | Diagnosis | ICD-9-CM |
| 582.9 | Chronic glomerulonephritis with unspecified pathological lesion in kidney | Diagnosis | ICD-9-CM |
| 583.0 | Nephritis and nephropathy, not specified as acute or chronic, with lesion of proliferative glomerulonephritis | Diagnosis | ICD-9-CM |
| 583.1 | Nephritis and nephropathy, not specified as acute or chronic, with lesion of membranous glomerulonephritis | Diagnosis | ICD-9-CM |
| 583.2 | Nephritis and nephropathy, not specified as acute or chronic, with lesion of membranoproliferative glomerulonephritis | Diagnosis | ICD-9-CM |
| 583.4 | Nephritis and nephropathy, not specified as acute or chronic, with lesion of rapidly progressive glomerulonephritis | Diagnosis | ICD-9-CM |
| 583.6 | Nephritis and nephropathy, not specified as acute or chronic, with lesion of renal cortical necrosis | Diagnosis | ICD-9-CM |
| 583.7 | Nephritis and nephropathy, not specified as acute or chronic, with lesion of renal medullary necrosis | Diagnosis | ICD-9-CM |
| 583.81 | Nephritis and nephropathy, not specified as acute or chronic, with other specified pathological lesion in kidney, in diseases classified elsewhere | Diagnosis | ICD-9-CM |
| 583.89 | Other nephritis and nephropathy, not specified as acute or chronic, with specified pathological lesion in kidney | Diagnosis | ICD-9-CM |
| 583.9 | Nephritis and nephropathy, not specified as acute or chronic, with unspecified pathological lesion in kidney | Diagnosis | ICD-9-CM |
| 584.5 | Acute kidney failure with lesion of tubular necrosis | Diagnosis | ICD-9-CM |
| 584.6 | Acute kidney failure with lesion of renal cortical necrosis | Diagnosis | ICD-9-CM |
| 584.7 | Acute kidney failure with lesion of medullary [papillary] necrosis | Diagnosis | ICD-9-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|--------|---|---------------|-----------|
| 584.8 | Acute kidney failure with other specified pathological lesion in kidney | Diagnosis | ICD-9-CM |
| 584.9 | Acute kidney failure, unspecified | Diagnosis | ICD-9-CM |
| 585.1 | Chronic kidney disease, Stage I | Diagnosis | ICD-9-CM |
| 585.2 | Chronic kidney disease, Stage II (mild) | Diagnosis | ICD-9-CM |
| 585.3 | Chronic kidney disease, Stage III (moderate) | Diagnosis | ICD-9-CM |
| 585.4 | Chronic kidney disease, Stage IV (severe) | Diagnosis | ICD-9-CM |
| 585.5 | Chronic kidney disease, Stage V | Diagnosis | ICD-9-CM |
| 585.6 | End stage renal disease | Diagnosis | ICD-9-CM |
| 585.9 | Chronic kidney disease, unspecified | Diagnosis | ICD-9-CM |
| 586 | Unspecified renal failure | Diagnosis | ICD-9-CM |
| 587 | Unspecified renal sclerosis | Diagnosis | ICD-9-CM |
| 588.0 | Renal osteodystrophy | Diagnosis | ICD-9-CM |
| 588.1 | Nephrogenic diabetes insipidus | Diagnosis | ICD-9-CM |
| 588.81 | Secondary hyperparathyroidism (of renal origin) | Diagnosis | ICD-9-CM |
| 588.89 | Other specified disorders resulting from impaired renal function | Diagnosis | ICD-9-CM |
| 588.9 | Unspecified disorder resulting from impaired renal function | Diagnosis | ICD-9-CM |
| 591 | Hydronephrosis | Diagnosis | ICD-9-CM |
| 753.12 | Congenital polycystic kidney, unspecified type | Diagnosis | ICD-9-CM |
| 753.13 | Congenital polycystic kidney, autosomal dominant | Diagnosis | ICD-9-CM |
| 753.14 | Congenital polycystic kidney, autosomal recessive | Diagnosis | ICD-9-CM |
| 753.15 | Congenital renal dysplasia | Diagnosis | ICD-9-CM |
| 753.16 | Congenital medullary cystic kidney | Diagnosis | ICD-9-CM |
| 753.17 | Congenital medullary sponge kidney | Diagnosis | ICD-9-CM |
| 753.19 | Other specified congenital cystic kidney disease | Diagnosis | ICD-9-CM |
| 753.20 | Unspecified obstructive defect of renal pelvis and ureter | Diagnosis | ICD-9-CM |
| 753.21 | Congenital obstruction of ureteropelvic junction | Diagnosis | ICD-9-CM |
| 753.22 | Congenital obstruction of ureterovesical junction | Diagnosis | ICD-9-CM |
| 753.23 | Congenital ureterocele | Diagnosis | ICD-9-CM |
| 753.29 | Other obstructive defect of renal pelvis and ureter | Diagnosis | ICD-9-CM |
| 794.4 | Nonspecific abnormal results of kidney function study | Diagnosis | ICD-9-CM |
| A18.11 | Tuberculosis of kidney and ureter | Diagnosis | ICD-10-CM |
| A52.75 | Syphilis of kidney and ureter | Diagnosis | ICD-10-CM |
| B52.0 | Plasmodium malariae malaria with nephropathy | Diagnosis | ICD-10-CM |
| C64.1 | Malignant neoplasm of right kidney, except renal pelvis | Diagnosis | ICD-10-CM |
| C64.2 | Malignant neoplasm of left kidney, except renal pelvis | Diagnosis | ICD-10-CM |
| C64.9 | Malignant neoplasm of unspecified kidney, except renal pelvis | Diagnosis | ICD-10-CM |
| C68.9 | Malignant neoplasm of urinary organ, unspecified | Diagnosis | ICD-10-CM |
| D30.00 | Benign neoplasm of unspecified kidney | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|--------|---|---------------|-----------|
| D30.01 | Benign neoplasm of right kidney | Diagnosis | ICD-10-CM |
| D30.02 | Benign neoplasm of left kidney | Diagnosis | ICD-10-CM |
| D41.00 | Neoplasm of uncertain behavior of unspecified kidney | Diagnosis | ICD-10-CM |
| D41.01 | Neoplasm of uncertain behavior of right kidney | Diagnosis | ICD-10-CM |
| D41.02 | Neoplasm of uncertain behavior of left kidney | Diagnosis | ICD-10-CM |
| D41.10 | Neoplasm of uncertain behavior of unspecified renal pelvis | Diagnosis | ICD-10-CM |
| D41.11 | Neoplasm of uncertain behavior of right renal pelvis | Diagnosis | ICD-10-CM |
| D41.12 | Neoplasm of uncertain behavior of left renal pelvis | Diagnosis | ICD-10-CM |
| D41.20 | Neoplasm of uncertain behavior of unspecified ureter | Diagnosis | ICD-10-CM |
| D41.21 | Neoplasm of uncertain behavior of right ureter | Diagnosis | ICD-10-CM |
| D41.22 | Neoplasm of uncertain behavior of left ureter | Diagnosis | ICD-10-CM |
| D59.3 | Hemolytic-uremic syndrome | Diagnosis | ICD-10-CM |
| E08.21 | Diabetes mellitus due to underlying condition with diabetic nephropathy | Diagnosis | ICD-10-CM |
| E08.22 | Diabetes mellitus due to underlying condition with diabetic chronic kidney disease | Diagnosis | ICD-10-CM |
| E08.29 | Diabetes mellitus due to underlying condition with other diabetic kidney complication | Diagnosis | ICD-10-CM |
| E09.21 | Drug or chemical induced diabetes mellitus with diabetic nephropathy | Diagnosis | ICD-10-CM |
| E09.22 | Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease | Diagnosis | ICD-10-CM |
| E10.21 | Type 1 diabetes mellitus with diabetic nephropathy | Diagnosis | ICD-10-CM |
| E10.22 | Type 1 diabetes mellitus with diabetic chronic kidney disease | Diagnosis | ICD-10-CM |
| E10.29 | Type 1 diabetes mellitus with other diabetic kidney complication | Diagnosis | ICD-10-CM |
| E11.21 | Type 2 diabetes mellitus with diabetic nephropathy | Diagnosis | ICD-10-CM |
| E11.22 | Type 2 diabetes mellitus with diabetic chronic kidney disease | Diagnosis | ICD-10-CM |
| E11.29 | Type 2 diabetes mellitus with other diabetic kidney complication | Diagnosis | ICD-10-CM |
| E13.21 | Other specified diabetes mellitus with diabetic nephropathy | Diagnosis | ICD-10-CM |
| E13.22 | Other specified diabetes mellitus with diabetic chronic kidney disease | Diagnosis | ICD-10-CM |
| E13.29 | Other specified diabetes mellitus with other diabetic kidney complication | Diagnosis | ICD-10-CM |
| E74.8 | Other specified disorders of carbohydrate metabolism | Diagnosis | ICD-10-CM |
| I12.0 | Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal | Diagnosis | ICD-10-CM |
| I12.9 | Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease | Diagnosis | ICD-10-CM |
| I13.0 | Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease | Diagnosis | ICD-10-CM |
| I13.10 | Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease | Diagnosis | ICD-10-CM |
| I13.11 | Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease | Diagnosis | ICD-10-CM |
| I13.2 | Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease | Diagnosis | ICD-10-CM |
| I70.1 | Atherosclerosis of renal artery | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| I72.2 | Aneurysm of renal artery | Diagnosis | ICD-10-CM |
| K76.7 | Hepatorenal syndrome | Diagnosis | ICD-10-CM |
| M10.30 | Gout due to renal impairment, unspecified site | Diagnosis | ICD-10-CM |
| M10.311 | Gout due to renal impairment, right shoulder | Diagnosis | ICD-10-CM |
| M10.312 | Gout due to renal impairment, left shoulder | Diagnosis | ICD-10-CM |
| M10.319 | Gout due to renal impairment, unspecified shoulder | Diagnosis | ICD-10-CM |
| M10.321 | Gout due to renal impairment, right elbow | Diagnosis | ICD-10-CM |
| M10.322 | Gout due to renal impairment, left elbow | Diagnosis | ICD-10-CM |
| M10.329 | Gout due to renal impairment, unspecified elbow | Diagnosis | ICD-10-CM |
| M10.331 | Gout due to renal impairment, right wrist | Diagnosis | ICD-10-CM |
| M10.332 | Gout due to renal impairment, left wrist | Diagnosis | ICD-10-CM |
| M10.339 | Gout due to renal impairment, unspecified wrist | Diagnosis | ICD-10-CM |
| M10.341 | Gout due to renal impairment, right hand | Diagnosis | ICD-10-CM |
| M10.342 | Gout due to renal impairment, left hand | Diagnosis | ICD-10-CM |
| M10.349 | Gout due to renal impairment, unspecified hand | Diagnosis | ICD-10-CM |
| M10.351 | Gout due to renal impairment, right hip | Diagnosis | ICD-10-CM |
| M10.352 | Gout due to renal impairment, left hip | Diagnosis | ICD-10-CM |
| M10.359 | Gout due to renal impairment, unspecified hip | Diagnosis | ICD-10-CM |
| M10.361 | Gout due to renal impairment, right knee | Diagnosis | ICD-10-CM |
| M10.362 | Gout due to renal impairment, left knee | Diagnosis | ICD-10-CM |
| M10.369 | Gout due to renal impairment, unspecified knee | Diagnosis | ICD-10-CM |
| M10.371 | Gout due to renal impairment, right ankle and foot | Diagnosis | ICD-10-CM |
| M10.372 | Gout due to renal impairment, left ankle and foot | Diagnosis | ICD-10-CM |
| M10.379 | Gout due to renal impairment, unspecified ankle and foot | Diagnosis | ICD-10-CM |
| M10.38 | Gout due to renal impairment, vertebrae | Diagnosis | ICD-10-CM |
| M10.39 | Gout due to renal impairment, multiple sites | Diagnosis | ICD-10-CM |
| M32.14 | Glomerular disease in systemic lupus erythematosus | Diagnosis | ICD-10-CM |
| M32.15 | Tubulo-interstitial nephropathy in systemic lupus erythematosus | Diagnosis | ICD-10-CM |
| M35.04 | Sicca syndrome with tubulo-interstitial nephropathy | Diagnosis | ICD-10-CM |
| M35.0A | Sjogren syndrome with glomerular disease | Diagnosis | ICD-10-CM |
| N00.0 | Acute nephritic syndrome with minor glomerular abnormality | Diagnosis | ICD-10-CM |
| N00.1 | Acute nephritic syndrome with focal and segmental glomerular lesions | Diagnosis | ICD-10-CM |
| N00.2 | Acute nephritic syndrome with diffuse membranous glomerulonephritis | Diagnosis | ICD-10-CM |
| N00.3 | Acute nephritic syndrome with diffuse mesangial proliferative glomerulonephritis | Diagnosis | ICD-10-CM |
| N00.4 | Acute nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis | Diagnosis | ICD-10-CM |
| N00.5 | Acute nephritic syndrome with diffuse mesangiocapillary glomerulonephritis | Diagnosis | ICD-10-CM |
| N00.6 | Acute nephritic syndrome with dense deposit disease | Diagnosis | ICD-10-CM |
| N00.7 | Acute nephritic syndrome with diffuse crescentic glomerulonephritis | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|-------|--|---------------|-----------|
| N00.8 | Acute nephritic syndrome with other morphologic changes | Diagnosis | ICD-10-CM |
| N00.9 | Acute nephritic syndrome with unspecified morphologic changes | Diagnosis | ICD-10-CM |
| N00.A | Acute nephritic syndrome with C3 glomerulonephritis | Diagnosis | ICD-10-CM |
| N01.0 | Rapidly progressive nephritic syndrome with minor glomerular abnormality | Diagnosis | ICD-10-CM |
| N01.1 | Rapidly progressive nephritic syndrome with focal and segmental glomerular lesions | Diagnosis | ICD-10-CM |
| N01.2 | Rapidly progressive nephritic syndrome with diffuse membranous glomerulonephritis | Diagnosis | ICD-10-CM |
| N01.3 | Rapidly progressive nephritic syndrome with diffuse mesangial proliferative glomerulonephritis | Diagnosis | ICD-10-CM |
| N01.4 | Rapidly progressive nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis | Diagnosis | ICD-10-CM |
| N01.5 | Rapidly progressive nephritic syndrome with diffuse mesangiocapillary glomerulonephritis | Diagnosis | ICD-10-CM |
| N01.6 | Rapidly progressive nephritic syndrome with dense deposit disease | Diagnosis | ICD-10-CM |
| N01.7 | Rapidly progressive nephritic syndrome with diffuse crescentic glomerulonephritis | Diagnosis | ICD-10-CM |
| N01.8 | Rapidly progressive nephritic syndrome with other morphologic changes | Diagnosis | ICD-10-CM |
| N01.9 | Rapidly progressive nephritic syndrome with unspecified morphologic changes | Diagnosis | ICD-10-CM |
| N01.A | Rapidly progressive nephritic syndrome with C3 glomerulonephritis | Diagnosis | ICD-10-CM |
| N02.0 | Recurrent and persistent hematuria with minor glomerular abnormality | Diagnosis | ICD-10-CM |
| N02.1 | Recurrent and persistent hematuria with focal and segmental glomerular lesions | Diagnosis | ICD-10-CM |
| N02.2 | Recurrent and persistent hematuria with diffuse membranous glomerulonephritis | Diagnosis | ICD-10-CM |
| N02.3 | Recurrent and persistent hematuria with diffuse mesangial proliferative glomerulonephritis | Diagnosis | ICD-10-CM |
| N02.4 | Recurrent and persistent hematuria with diffuse endocapillary proliferative glomerulonephritis | Diagnosis | ICD-10-CM |
| N02.5 | Recurrent and persistent hematuria with diffuse mesangiocapillary glomerulonephritis | Diagnosis | ICD-10-CM |
| N02.6 | Recurrent and persistent hematuria with dense deposit disease | Diagnosis | ICD-10-CM |
| N02.7 | Recurrent and persistent hematuria with diffuse crescentic glomerulonephritis | Diagnosis | ICD-10-CM |
| N02.8 | Recurrent and persistent hematuria with other morphologic changes | Diagnosis | ICD-10-CM |
| N02.9 | Recurrent and persistent hematuria with unspecified morphologic changes | Diagnosis | ICD-10-CM |
| N02.A | Recurrent and persistent hematuria with C3 glomerulonephritis | Diagnosis | ICD-10-CM |
| N03.0 | Chronic nephritic syndrome with minor glomerular abnormality | Diagnosis | ICD-10-CM |
| N03.1 | Chronic nephritic syndrome with focal and segmental glomerular lesions | Diagnosis | ICD-10-CM |
| N03.2 | Chronic nephritic syndrome with diffuse membranous glomerulonephritis | Diagnosis | ICD-10-CM |
| N03.3 | Chronic nephritic syndrome with diffuse mesangial proliferative glomerulonephritis | Diagnosis | ICD-10-CM |
| N03.4 | Chronic nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis | Diagnosis | ICD-10-CM |
| N03.5 | Chronic nephritic syndrome with diffuse mesangiocapillary glomerulonephritis | Diagnosis | ICD-10-CM |
| N03.6 | Chronic nephritic syndrome with dense deposit disease | Diagnosis | ICD-10-CM |
| N03.7 | Chronic nephritic syndrome with diffuse crescentic glomerulonephritis | Diagnosis | ICD-10-CM |
| N03.8 | Chronic nephritic syndrome with other morphologic changes | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|-------|--|---------------|-----------|
| N03.9 | Chronic nephritic syndrome with unspecified morphologic changes | Diagnosis | ICD-10-CM |
| N03.A | Chronic nephritic syndrome with C3 glomerulonephritis | Diagnosis | ICD-10-CM |
| N04.0 | Nephrotic syndrome with minor glomerular abnormality | Diagnosis | ICD-10-CM |
| N04.1 | Nephrotic syndrome with focal and segmental glomerular lesions | Diagnosis | ICD-10-CM |
| N04.2 | Nephrotic syndrome with diffuse membranous glomerulonephritis | Diagnosis | ICD-10-CM |
| N04.3 | Nephrotic syndrome with diffuse mesangial proliferative glomerulonephritis | Diagnosis | ICD-10-CM |
| N04.4 | Nephrotic syndrome with diffuse endocapillary proliferative glomerulonephritis | Diagnosis | ICD-10-CM |
| N04.5 | Nephrotic syndrome with diffuse mesangiocapillary glomerulonephritis | Diagnosis | ICD-10-CM |
| N04.6 | Nephrotic syndrome with dense deposit disease | Diagnosis | ICD-10-CM |
| N04.7 | Nephrotic syndrome with diffuse crescentic glomerulonephritis | Diagnosis | ICD-10-CM |
| N04.8 | Nephrotic syndrome with other morphologic changes | Diagnosis | ICD-10-CM |
| N04.9 | Nephrotic syndrome with unspecified morphologic changes | Diagnosis | ICD-10-CM |
| N04.A | Nephrotic syndrome with C3 glomerulonephritis | Diagnosis | ICD-10-CM |
| N05.0 | Unspecified nephritic syndrome with minor glomerular abnormality | Diagnosis | ICD-10-CM |
| N05.1 | Unspecified nephritic syndrome with focal and segmental glomerular lesions | Diagnosis | ICD-10-CM |
| N05.2 | Unspecified nephritic syndrome with diffuse membranous glomerulonephritis | Diagnosis | ICD-10-CM |
| N05.3 | Unspecified nephritic syndrome with diffuse mesangial proliferative glomerulonephritis | Diagnosis | ICD-10-CM |
| N05.4 | Unspecified nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis | Diagnosis | ICD-10-CM |
| N05.5 | Unspecified nephritic syndrome with diffuse mesangiocapillary glomerulonephritis | Diagnosis | ICD-10-CM |
| N05.6 | Unspecified nephritic syndrome with dense deposit disease | Diagnosis | ICD-10-CM |
| N05.7 | Unspecified nephritic syndrome with diffuse crescentic glomerulonephritis | Diagnosis | ICD-10-CM |
| N05.8 | Unspecified nephritic syndrome with other morphologic changes | Diagnosis | ICD-10-CM |
| N05.9 | Unspecified nephritic syndrome with unspecified morphologic changes | Diagnosis | ICD-10-CM |
| N05.A | Unspecified nephritic syndrome with C3 glomerulonephritis | Diagnosis | ICD-10-CM |
| N06.0 | Isolated proteinuria with minor glomerular abnormality | Diagnosis | ICD-10-CM |
| N06.1 | Isolated proteinuria with focal and segmental glomerular lesions | Diagnosis | ICD-10-CM |
| N06.2 | Isolated proteinuria with diffuse membranous glomerulonephritis | Diagnosis | ICD-10-CM |
| N06.3 | Isolated proteinuria with diffuse mesangial proliferative glomerulonephritis | Diagnosis | ICD-10-CM |
| N06.4 | Isolated proteinuria with diffuse endocapillary proliferative glomerulonephritis | Diagnosis | ICD-10-CM |
| N06.5 | Isolated proteinuria with diffuse mesangiocapillary glomerulonephritis | Diagnosis | ICD-10-CM |
| N06.6 | Isolated proteinuria with dense deposit disease | Diagnosis | ICD-10-CM |
| N06.7 | Isolated proteinuria with diffuse crescentic glomerulonephritis | Diagnosis | ICD-10-CM |
| N06.8 | Isolated proteinuria with other morphologic lesion | Diagnosis | ICD-10-CM |
| N06.9 | Isolated proteinuria with unspecified morphologic lesion | Diagnosis | ICD-10-CM |
| N06.A | Isolated proteinuria with C3 glomerulonephritis | Diagnosis | ICD-10-CM |
| N07.0 | Hereditary nephropathy, not elsewhere classified with minor glomerular abnormality | Diagnosis | ICD-10-CM |
| N07.1 | Hereditary nephropathy, not elsewhere classified with focal and segmental glomerular lesions | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| N07.2 | Hereditary nephropathy, not elsewhere classified with diffuse membranous glomerulonephritis | Diagnosis | ICD-10-CM |
| N07.3 | Hereditary nephropathy, not elsewhere classified with diffuse mesangial proliferative glomerulonephritis | Diagnosis | ICD-10-CM |
| N07.4 | Hereditary nephropathy, not elsewhere classified with diffuse endocapillary proliferative glomerulonephritis | Diagnosis | ICD-10-CM |
| N07.5 | Hereditary nephropathy, not elsewhere classified with diffuse mesangiocapillary glomerulonephritis | Diagnosis | ICD-10-CM |
| N07.6 | Hereditary nephropathy, not elsewhere classified with dense deposit disease | Diagnosis | ICD-10-CM |
| N07.7 | Hereditary nephropathy, not elsewhere classified with diffuse crescentic glomerulonephritis | Diagnosis | ICD-10-CM |
| N07.8 | Hereditary nephropathy, not elsewhere classified with other morphologic lesions | Diagnosis | ICD-10-CM |
| N07.9 | Hereditary nephropathy, not elsewhere classified with unspecified morphologic lesions | Diagnosis | ICD-10-CM |
| N07.A | Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritis | Diagnosis | ICD-10-CM |
| N08 | Glomerular disorders in diseases classified elsewhere | Diagnosis | ICD-10-CM |
| N13.1 | Hydronephrosis with ureteral stricture, not elsewhere classified | Diagnosis | ICD-10-CM |
| N13.2 | Hydronephrosis with renal and ureteral calculous obstruction | Diagnosis | ICD-10-CM |
| N13.30 | Unspecified hydronephrosis | Diagnosis | ICD-10-CM |
| N13.39 | Other hydronephrosis | Diagnosis | ICD-10-CM |
| N14.0 | Analgesic nephropathy | Diagnosis | ICD-10-CM |
| N14.1 | Nephropathy induced by other drugs, medicaments and biological substances | Diagnosis | ICD-10-CM |
| N14.2 | Nephropathy induced by unspecified drug, medicament or biological substance | Diagnosis | ICD-10-CM |
| N14.3 | Nephropathy induced by heavy metals | Diagnosis | ICD-10-CM |
| N14.4 | Toxic nephropathy, not elsewhere classified | Diagnosis | ICD-10-CM |
| N15.0 | Balkan nephropathy | Diagnosis | ICD-10-CM |
| N15.8 | Other specified renal tubulo-interstitial diseases | Diagnosis | ICD-10-CM |
| N15.9 | Renal tubulo-interstitial disease, unspecified | Diagnosis | ICD-10-CM |
| N16 | Renal tubulo-interstitial disorders in diseases classified elsewhere | Diagnosis | ICD-10-CM |
| N17.0 | Acute kidney failure with tubular necrosis | Diagnosis | ICD-10-CM |
| N17.1 | Acute kidney failure with acute cortical necrosis | Diagnosis | ICD-10-CM |
| N17.2 | Acute kidney failure with medullary necrosis | Diagnosis | ICD-10-CM |
| N17.8 | Other acute kidney failure | Diagnosis | ICD-10-CM |
| N17.9 | Acute kidney failure, unspecified | Diagnosis | ICD-10-CM |
| N18.1 | Chronic kidney disease, stage 1 | Diagnosis | ICD-10-CM |
| N18.2 | Chronic kidney disease, stage 2 (mild) | Diagnosis | ICD-10-CM |
| N18.3 | Chronic kidney disease, stage 3 (moderate) | Diagnosis | ICD-10-CM |
| N18.30 | Chronic kidney disease, stage 3 unspecified | Diagnosis | ICD-10-CM |
| N18.31 | Chronic kidney disease, stage 3a | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| N18.32 | Chronic kidney disease, stage 3b | Diagnosis | ICD-10-CM |
| N18.4 | Chronic kidney disease, stage 4 (severe) | Diagnosis | ICD-10-CM |
| N18.5 | Chronic kidney disease, stage 5 | Diagnosis | ICD-10-CM |
| N18.6 | End stage renal disease | Diagnosis | ICD-10-CM |
| N18.9 | Chronic kidney disease, unspecified | Diagnosis | ICD-10-CM |
| N19 | Unspecified kidney failure | Diagnosis | ICD-10-CM |
| N25.0 | Renal osteodystrophy | Diagnosis | ICD-10-CM |
| N25.1 | Nephrogenic diabetes insipidus | Diagnosis | ICD-10-CM |
| N25.81 | Secondary hyperparathyroidism of renal origin | Diagnosis | ICD-10-CM |
| N25.89 | Other disorders resulting from impaired renal tubular function | Diagnosis | ICD-10-CM |
| N25.9 | Disorder resulting from impaired renal tubular function, unspecified | Diagnosis | ICD-10-CM |
| N26.1 | Atrophy of kidney (terminal) | Diagnosis | ICD-10-CM |
| N26.9 | Renal sclerosis, unspecified | Diagnosis | ICD-10-CM |
| N99.0 | Postprocedural (acute) (chronic) kidney failure | Diagnosis | ICD-10-CM |
| Q61.02 | Congenital multiple renal cysts | Diagnosis | ICD-10-CM |
| Q61.11 | Cystic dilatation of collecting ducts | Diagnosis | ICD-10-CM |
| Q61.19 | Other polycystic kidney, infantile type | Diagnosis | ICD-10-CM |
| Q61.2 | Polycystic kidney, adult type | Diagnosis | ICD-10-CM |
| Q61.3 | Polycystic kidney, unspecified | Diagnosis | ICD-10-CM |
| Q61.4 | Renal dysplasia | Diagnosis | ICD-10-CM |
| Q61.5 | Medullary cystic kidney | Diagnosis | ICD-10-CM |
| Q61.8 | Other cystic kidney diseases | Diagnosis | ICD-10-CM |
| Q62.0 | Congenital hydronephrosis | Diagnosis | ICD-10-CM |
| Q62.10 | Congenital occlusion of ureter, unspecified | Diagnosis | ICD-10-CM |
| Q62.11 | Congenital occlusion of ureteropelvic junction | Diagnosis | ICD-10-CM |
| Q62.12 | Congenital occlusion of ureterovesical orifice | Diagnosis | ICD-10-CM |
| Q62.2 | Congenital megaureter | Diagnosis | ICD-10-CM |
| Q62.31 | Congenital ureterocele, orthotopic | Diagnosis | ICD-10-CM |
| Q62.32 | Cecoureterocele | Diagnosis | ICD-10-CM |
| Q62.39 | Other obstructive defects of renal pelvis and ureter | Diagnosis | ICD-10-CM |
| R94.4 | Abnormal results of kidney function studies | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|--------------------------|---|---------------|-----------|
| Colorectal Cancer | | | |
| 153.0 | Malignant neoplasm of hepatic flexure | Diagnosis | ICD-9-CM |
| 153.1 | Malignant neoplasm of transverse colon | Diagnosis | ICD-9-CM |
| 153.2 | Malignant neoplasm of descending colon | Diagnosis | ICD-9-CM |
| 153.3 | Malignant neoplasm of sigmoid colon | Diagnosis | ICD-9-CM |
| 153.4 | Malignant neoplasm of cecum | Diagnosis | ICD-9-CM |
| 153.5 | Malignant neoplasm of appendix | Diagnosis | ICD-9-CM |
| 153.6 | Malignant neoplasm of ascending colon | Diagnosis | ICD-9-CM |
| 153.7 | Malignant neoplasm of splenic flexure | Diagnosis | ICD-9-CM |
| 153.8 | Malignant neoplasm of other specified sites of large intestine | Diagnosis | ICD-9-CM |
| 153.9 | Malignant neoplasm of colon, unspecified site | Diagnosis | ICD-9-CM |
| 154.0 | Malignant neoplasm of rectosigmoid junction | Diagnosis | ICD-9-CM |
| 154.1 | Malignant neoplasm of rectum | Diagnosis | ICD-9-CM |
| 230.3 | Carcinoma in situ of colon | Diagnosis | ICD-9-CM |
| 230.4 | Carcinoma in situ of rectum | Diagnosis | ICD-9-CM |
| C18.0 | Malignant neoplasm of cecum | Diagnosis | ICD-10-CM |
| C18.1 | Malignant neoplasm of appendix | Diagnosis | ICD-10-CM |
| C18.2 | Malignant neoplasm of ascending colon | Diagnosis | ICD-10-CM |
| C18.3 | Malignant neoplasm of hepatic flexure | Diagnosis | ICD-10-CM |
| C18.4 | Malignant neoplasm of transverse colon | Diagnosis | ICD-10-CM |
| C18.5 | Malignant neoplasm of splenic flexure | Diagnosis | ICD-10-CM |
| C18.6 | Malignant neoplasm of descending colon | Diagnosis | ICD-10-CM |
| C18.7 | Malignant neoplasm of sigmoid colon | Diagnosis | ICD-10-CM |
| C18.8 | Malignant neoplasm of overlapping sites of colon | Diagnosis | ICD-10-CM |
| C18.9 | Malignant neoplasm of colon, unspecified | Diagnosis | ICD-10-CM |
| C19 | Malignant neoplasm of rectosigmoid junction | Diagnosis | ICD-10-CM |
| C20 | Malignant neoplasm of rectum | Diagnosis | ICD-10-CM |
| C49.A4 | Gastrointestinal stromal tumor of large intestine | Diagnosis | ICD-10-CM |
| C49.A5 | Gastrointestinal stromal tumor of rectum | Diagnosis | ICD-10-CM |
| D01.0 | Carcinoma in situ of colon | Diagnosis | ICD-10-CM |
| D01.1 | Carcinoma in situ of rectosigmoid junction | Diagnosis | ICD-10-CM |
| D01.2 | Carcinoma in situ of rectum | Diagnosis | ICD-10-CM |
| V10.05 | Personal history of malignant neoplasm of large intestine | Diagnosis | ICD-9-CM |
| V10.06 | Personal history of malignant neoplasm of rectum, rectosigmoid junction, and anus | Diagnosis | ICD-9-CM |
| Z85.030 | Personal history of malignant carcinoid tumor of large intestine | Diagnosis | ICD-10-CM |
| Z85.038 | Personal history of other malignant neoplasm of large intestine | Diagnosis | ICD-10-CM |
| Z85.040 | Personal history of malignant carcinoid tumor of rectum | Diagnosis | ICD-10-CM |
| Z85.048 | Personal history of other malignant neoplasm of rectum, rectosigmoid junction, and anus | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|--|--|---------------|-----------|
| Chronic Obstructive Pulmonary Disease | | | |
| 490 | Bronchitis, not specified as acute or chronic | Diagnosis | ICD-9-CM |
| 491.0 | Simple chronic bronchitis | Diagnosis | ICD-9-CM |
| 491.1 | Mucopurulent chronic bronchitis | Diagnosis | ICD-9-CM |
| 491.20 | Obstructive chronic bronchitis, without exacerbation | Diagnosis | ICD-9-CM |
| 491.21 | Obstructive chronic bronchitis, with (acute) exacerbation | Diagnosis | ICD-9-CM |
| 491.22 | Obstructive chronic bronchitis with acute bronchitis | Diagnosis | ICD-9-CM |
| 491.8 | Other chronic bronchitis | Diagnosis | ICD-9-CM |
| 491.9 | Unspecified chronic bronchitis | Diagnosis | ICD-9-CM |
| 492.0 | Emphysematous bleb | Diagnosis | ICD-9-CM |
| 492.8 | Other emphysema | Diagnosis | ICD-9-CM |
| 494.0 | Bronchiectasis without acute exacerbation | Diagnosis | ICD-9-CM |
| 494.1 | Bronchiectasis with acute exacerbation | Diagnosis | ICD-9-CM |
| 496 | Chronic airway obstruction, not elsewhere classified | Diagnosis | ICD-9-CM |
| J40 | Bronchitis, not specified as acute or chronic | Diagnosis | ICD-10-CM |
| J41.0 | Simple chronic bronchitis | Diagnosis | ICD-10-CM |
| J41.1 | Mucopurulent chronic bronchitis | Diagnosis | ICD-10-CM |
| J41.8 | Mixed simple and mucopurulent chronic bronchitis | Diagnosis | ICD-10-CM |
| J42 | Unspecified chronic bronchitis | Diagnosis | ICD-10-CM |
| J43.0 | Unilateral pulmonary emphysema [MacLeod's syndrome] | Diagnosis | ICD-10-CM |
| J43.1 | Panlobular emphysema | Diagnosis | ICD-10-CM |
| J43.2 | Centrilobular emphysema | Diagnosis | ICD-10-CM |
| J43.8 | Other emphysema | Diagnosis | ICD-10-CM |
| J43.9 | Emphysema, unspecified | Diagnosis | ICD-10-CM |
| J44.0 | Chronic obstructive pulmonary disease with acute lower respiratory infection | Diagnosis | ICD-10-CM |
| J44.1 | Chronic obstructive pulmonary disease with (acute) exacerbation | Diagnosis | ICD-10-CM |
| J44.9 | Chronic obstructive pulmonary disease, unspecified | Diagnosis | ICD-10-CM |
| J47.0 | Bronchiectasis with acute lower respiratory infection | Diagnosis | ICD-10-CM |
| J47.1 | Bronchiectasis with (acute) exacerbation | Diagnosis | ICD-10-CM |
| J47.9 | Bronchiectasis, uncomplicated | Diagnosis | ICD-10-CM |
| J98.2 | Interstitial emphysema | Diagnosis | ICD-10-CM |
| J98.3 | Compensatory emphysema | Diagnosis | ICD-10-CM |
| Coronary Angioplasty Bypass | | | |
| V45.81 | Postprocedural aortocoronary bypass status | Diagnosis | ICD-9-CM |
| V45.82 | Postprocedural percutaneous transluminal coronary angioplasty status | Diagnosis | ICD-9-CM |
| Z95.1 | Presence of aortocoronary bypass graft | Diagnosis | ICD-10-CM |
| Z95.5 | Presence of coronary angioplasty implant and graft | Diagnosis | ICD-10-CM |
| Z98.61 | Coronary angioplasty status | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|-------------------|---|---------------|-----------|
| Depression | | | |
| 296.20 | Major depressive disorder, single episode, unspecified | Diagnosis | ICD-9-CM |
| 296.21 | Major depressive disorder, single episode, mild | Diagnosis | ICD-9-CM |
| 296.22 | Major depressive disorder, single episode, moderate | Diagnosis | ICD-9-CM |
| 296.23 | Major depressive disorder, single episode, severe, without mention of psychotic behavior | Diagnosis | ICD-9-CM |
| 296.24 | Major depressive disorder, single episode, severe, specified as with psychotic behavior | Diagnosis | ICD-9-CM |
| 296.25 | Major depressive disorder, single episode, in partial or unspecified remission | Diagnosis | ICD-9-CM |
| 296.26 | Major depressive disorder, single episode in full remission | Diagnosis | ICD-9-CM |
| 296.30 | Major depressive disorder, recurrent episode, unspecified | Diagnosis | ICD-9-CM |
| 296.31 | Major depressive disorder, recurrent episode, mild | Diagnosis | ICD-9-CM |
| 296.32 | Major depressive disorder, recurrent episode, moderate | Diagnosis | ICD-9-CM |
| 296.33 | Major depressive disorder, recurrent episode, severe, without mention of psychotic behavior | Diagnosis | ICD-9-CM |
| 296.34 | Major depressive disorder, recurrent episode, severe, specified as with psychotic behavior | Diagnosis | ICD-9-CM |
| 296.35 | Major depressive disorder, recurrent episode, in partial or unspecified remission | Diagnosis | ICD-9-CM |
| 296.36 | Major depressive disorder, recurrent episode, in full remission | Diagnosis | ICD-9-CM |
| 296.51 | Bipolar I disorder, most recent episode (or current) depressed, mild | Diagnosis | ICD-9-CM |
| 296.52 | Bipolar I disorder, most recent episode (or current) depressed, moderate | Diagnosis | ICD-9-CM |
| 296.53 | Bipolar I disorder, most recent episode (or current) depressed, severe, without mention of psychotic behavior | Diagnosis | ICD-9-CM |
| 296.54 | Bipolar I disorder, most recent episode (or current) depressed, severe, specified as with psychotic behavior | Diagnosis | ICD-9-CM |
| 296.55 | Bipolar I disorder, most recent episode (or current) depressed, in partial or unspecified remission | Diagnosis | ICD-9-CM |
| 296.56 | Bipolar I disorder, most recent episode (or current) depressed, in full remission | Diagnosis | ICD-9-CM |
| 296.60 | Bipolar I disorder, most recent episode (or current) mixed, unspecified | Diagnosis | ICD-9-CM |
| 296.61 | Bipolar I disorder, most recent episode (or current) mixed, mild | Diagnosis | ICD-9-CM |
| 296.62 | Bipolar I disorder, most recent episode (or current) mixed, moderate | Diagnosis | ICD-9-CM |
| 296.63 | Bipolar I disorder, most recent episode (or current) mixed, severe, without mention of psychotic behavior | Diagnosis | ICD-9-CM |
| 296.64 | Bipolar I disorder, most recent episode (or current) mixed, severe, specified as with psychotic behavior | Diagnosis | ICD-9-CM |
| 296.65 | Bipolar I disorder, most recent episode (or current) mixed, in partial or unspecified remission | Diagnosis | ICD-9-CM |
| 296.66 | Bipolar I disorder, most recent episode (or current) mixed, in full remission | Diagnosis | ICD-9-CM |
| 296.89 | Other and unspecified bipolar disorders | Diagnosis | ICD-9-CM |
| 298.0 | Depressive type psychosis | Diagnosis | ICD-9-CM |
| 300.4 | Dysthymic disorder | Diagnosis | ICD-9-CM |
| 309.1 | Prolonged depressive reaction as adjustment reaction | Diagnosis | ICD-9-CM |
| 311 | Depressive disorder, not elsewhere classified | Diagnosis | ICD-9-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|--------|---|---------------|-----------|
| F06.31 | Mood disorder due to known physiological condition with depressive features | Diagnosis | ICD-10-CM |
| F06.32 | Mood disorder due to known physiological condition with major depressive-like episode | Diagnosis | ICD-10-CM |
| F31.0 | Bipolar disorder, current episode hypomanic | Diagnosis | ICD-10-CM |
| F31.10 | Bipolar disorder, current episode manic without psychotic features, unspecified | Diagnosis | ICD-10-CM |
| F31.11 | Bipolar disorder, current episode manic without psychotic features, mild | Diagnosis | ICD-10-CM |
| F31.12 | Bipolar disorder, current episode manic without psychotic features, moderate | Diagnosis | ICD-10-CM |
| F31.13 | Bipolar disorder, current episode manic without psychotic features, severe | Diagnosis | ICD-10-CM |
| F31.2 | Bipolar disorder, current episode manic severe with psychotic features | Diagnosis | ICD-10-CM |
| F31.30 | Bipolar disorder, current episode depressed, mild or moderate severity, unspecified | Diagnosis | ICD-10-CM |
| F31.31 | Bipolar disorder, current episode depressed, mild | Diagnosis | ICD-10-CM |
| F31.32 | Bipolar disorder, current episode depressed, moderate | Diagnosis | ICD-10-CM |
| F31.4 | Bipolar disorder, current episode depressed, severe, without psychotic features | Diagnosis | ICD-10-CM |
| F31.5 | Bipolar disorder, current episode depressed, severe, with psychotic features | Diagnosis | ICD-10-CM |
| F31.60 | Bipolar disorder, current episode mixed, unspecified | Diagnosis | ICD-10-CM |
| F31.61 | Bipolar disorder, current episode mixed, mild | Diagnosis | ICD-10-CM |
| F31.62 | Bipolar disorder, current episode mixed, moderate | Diagnosis | ICD-10-CM |
| F31.63 | Bipolar disorder, current episode mixed, severe, without psychotic features | Diagnosis | ICD-10-CM |
| F31.64 | Bipolar disorder, current episode mixed, severe, with psychotic features | Diagnosis | ICD-10-CM |
| F31.71 | Bipolar disorder, in partial remission, most recent episode hypomanic | Diagnosis | ICD-10-CM |
| F31.73 | Bipolar disorder, in partial remission, most recent episode manic | Diagnosis | ICD-10-CM |
| F31.75 | Bipolar disorder, in partial remission, most recent episode depressed | Diagnosis | ICD-10-CM |
| F31.76 | Bipolar disorder, in full remission, most recent episode depressed | Diagnosis | ICD-10-CM |
| F31.77 | Bipolar disorder, in partial remission, most recent episode mixed | Diagnosis | ICD-10-CM |
| F31.78 | Bipolar disorder, in full remission, most recent episode mixed | Diagnosis | ICD-10-CM |
| F31.81 | Bipolar II disorder | Diagnosis | ICD-10-CM |
| F31.89 | Other bipolar disorder | Diagnosis | ICD-10-CM |
| F31.9 | Bipolar disorder, unspecified | Diagnosis | ICD-10-CM |
| F32.0 | Major depressive disorder, single episode, mild | Diagnosis | ICD-10-CM |
| F32.1 | Major depressive disorder, single episode, moderate | Diagnosis | ICD-10-CM |
| F32.2 | Major depressive disorder, single episode, severe without psychotic features | Diagnosis | ICD-10-CM |
| F32.3 | Major depressive disorder, single episode, severe with psychotic features | Diagnosis | ICD-10-CM |
| F32.4 | Major depressive disorder, single episode, in partial remission | Diagnosis | ICD-10-CM |
| F32.5 | Major depressive disorder, single episode, in full remission | Diagnosis | ICD-10-CM |
| F32.8 | Other depressive episodes | Diagnosis | ICD-10-CM |
| F32.89 | Other specified depressive episodes | Diagnosis | ICD-10-CM |
| F32.9 | Major depressive disorder, single episode, unspecified | Diagnosis | ICD-10-CM |
| F32.A | Depression, unspecified | Diagnosis | ICD-10-CM |
| F33.0 | Major depressive disorder, recurrent, mild | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|-----------------|---|---------------|-----------|
| F33.1 | Major depressive disorder, recurrent, moderate | Diagnosis | ICD-10-CM |
| F33.2 | Major depressive disorder, recurrent severe without psychotic features | Diagnosis | ICD-10-CM |
| F33.3 | Major depressive disorder, recurrent, severe with psychotic symptoms | Diagnosis | ICD-10-CM |
| F33.40 | Major depressive disorder, recurrent, in remission, unspecified | Diagnosis | ICD-10-CM |
| F33.41 | Major depressive disorder, recurrent, in partial remission | Diagnosis | ICD-10-CM |
| F33.42 | Major depressive disorder, recurrent, in full remission | Diagnosis | ICD-10-CM |
| F33.8 | Other recurrent depressive disorders | Diagnosis | ICD-10-CM |
| F33.9 | Major depressive disorder, recurrent, unspecified | Diagnosis | ICD-10-CM |
| F34.0 | Cyclothymic disorder | Diagnosis | ICD-10-CM |
| F34.1 | Dysthymic disorder | Diagnosis | ICD-10-CM |
| F43.21 | Adjustment disorder with depressed mood | Diagnosis | ICD-10-CM |
| F43.23 | Adjustment disorder with mixed anxiety and depressed mood | Diagnosis | ICD-10-CM |
| Diabetes | | | |
| 249.00 | Secondary diabetes mellitus without mention of complication, not stated as uncontrolled, | Diagnosis | ICD-9-CM |
| 249.01 | Secondary diabetes mellitus without mention of complication, uncontrolled | Diagnosis | ICD-9-CM |
| 249.10 | Secondary diabetes mellitus with ketoacidosis, not stated as uncontrolled, or unspecified | Diagnosis | ICD-9-CM |
| 249.11 | Secondary diabetes mellitus with ketoacidosis, uncontrolled | Diagnosis | ICD-9-CM |
| 249.20 | Secondary diabetes mellitus with hyperosmolarity, not stated as uncontrolled, or | Diagnosis | ICD-9-CM |
| 249.21 | Secondary diabetes mellitus with hyperosmolarity, uncontrolled | Diagnosis | ICD-9-CM |
| 249.30 | Secondary diabetes mellitus with other coma, not stated as uncontrolled, or unspecified | Diagnosis | ICD-9-CM |
| 249.31 | Secondary diabetes mellitus with other coma, uncontrolled | Diagnosis | ICD-9-CM |
| 249.40 | Secondary diabetes mellitus with renal manifestations, not stated as uncontrolled, or unspecified | Diagnosis | ICD-9-CM |
| 249.41 | Secondary diabetes mellitus with renal manifestations, uncontrolled | Diagnosis | ICD-9-CM |
| 249.50 | Secondary diabetes mellitus with ophthalmic manifestations, not stated as uncontrolled, or unspecified | Diagnosis | ICD-9-CM |
| 249.51 | Secondary diabetes mellitus with ophthalmic manifestations, uncontrolled | Diagnosis | ICD-9-CM |
| 249.60 | Secondary diabetes mellitus with neurological manifestations, not stated as uncontrolled, or unspecified | Diagnosis | ICD-9-CM |
| 249.61 | Secondary diabetes mellitus with neurological manifestations, uncontrolled | Diagnosis | ICD-9-CM |
| 249.70 | Secondary diabetes mellitus with peripheral circulatory disorders, not stated as uncontrolled, or unspecified | Diagnosis | ICD-9-CM |
| 249.71 | Secondary diabetes mellitus with peripheral circulatory disorders, uncontrolled | Diagnosis | ICD-9-CM |
| 249.80 | Secondary diabetes mellitus with other specified manifestations, not stated as uncontrolled, or unspecified | Diagnosis | ICD-9-CM |
| 249.81 | Secondary diabetes mellitus with other specified manifestations, uncontrolled | Diagnosis | ICD-9-CM |
| 249.90 | Secondary diabetes mellitus with unspecified complication, not stated as uncontrolled, or unspecified | Diagnosis | ICD-9-CM |
| 249.91 | Secondary diabetes mellitus with unspecified complication, uncontrolled | Diagnosis | ICD-9-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| 250.00 | Diabetes mellitus without mention of complication, type II or unspecified type, not stated as uncontrolled | Diagnosis | ICD-9-CM |
| 250.01 | Diabetes mellitus without mention of complication, type I [juvenile type], not stated as uncontrolled | Diagnosis | ICD-9-CM |
| 250.02 | Diabetes mellitus without mention of complication, type II or unspecified type, uncontrolled | Diagnosis | ICD-9-CM |
| 250.03 | Diabetes mellitus without mention of complication, type I [juvenile type], uncontrolled | Diagnosis | ICD-9-CM |
| 250.10 | Diabetes with ketoacidosis, type II or unspecified type, not stated as uncontrolled | Diagnosis | ICD-9-CM |
| 250.11 | Diabetes with ketoacidosis, type I [juvenile type], not stated as uncontrolled | Diagnosis | ICD-9-CM |
| 250.12 | Diabetes with ketoacidosis, type II or unspecified type, uncontrolled | Diagnosis | ICD-9-CM |
| 250.13 | Diabetes with ketoacidosis, type I [juvenile type], uncontrolled | Diagnosis | ICD-9-CM |
| 250.20 | Diabetes with hyperosmolarity, type II or unspecified type, not stated as uncontrolled | Diagnosis | ICD-9-CM |
| 250.21 | Diabetes with hyperosmolarity, type I [juvenile type], not stated as uncontrolled | Diagnosis | ICD-9-CM |
| 250.22 | Diabetes with hyperosmolarity, type II or unspecified type, uncontrolled | Diagnosis | ICD-9-CM |
| 250.23 | Diabetes with hyperosmolarity, type I [juvenile type], uncontrolled | Diagnosis | ICD-9-CM |
| 250.30 | Diabetes with other coma, type II or unspecified type, not stated as uncontrolled | Diagnosis | ICD-9-CM |
| 250.31 | Diabetes with other coma, type I [juvenile type], not stated as uncontrolled | Diagnosis | ICD-9-CM |
| 250.32 | Diabetes with other coma, type II or unspecified type, uncontrolled | Diagnosis | ICD-9-CM |
| 250.33 | Diabetes with other coma, type I [juvenile type], uncontrolled | Diagnosis | ICD-9-CM |
| 250.40 | Diabetes with renal manifestations, type II or unspecified type, not stated as uncontrolled | Diagnosis | ICD-9-CM |
| 250.41 | Diabetes with renal manifestations, type I [juvenile type], not stated as uncontrolled | Diagnosis | ICD-9-CM |
| 250.42 | Diabetes with renal manifestations, type II or unspecified type, uncontrolled | Diagnosis | ICD-9-CM |
| 250.43 | Diabetes with renal manifestations, type I [juvenile type], uncontrolled | Diagnosis | ICD-9-CM |
| 250.50 | Diabetes with ophthalmic manifestations, type II or unspecified type, not stated as uncontrolled | Diagnosis | ICD-9-CM |
| 250.51 | Diabetes with ophthalmic manifestations, type I [juvenile type], not stated as uncontrolled | Diagnosis | ICD-9-CM |
| 250.52 | Diabetes with ophthalmic manifestations, type II or unspecified type, uncontrolled | Diagnosis | ICD-9-CM |
| 250.53 | Diabetes with ophthalmic manifestations, type I [juvenile type], uncontrolled | Diagnosis | ICD-9-CM |
| 250.60 | Diabetes with neurological manifestations, type II or unspecified type, not stated as uncontrolled | Diagnosis | ICD-9-CM |
| 250.61 | Diabetes with neurological manifestations, type I [juvenile type], not stated as uncontrolled | Diagnosis | ICD-9-CM |
| 250.62 | Diabetes with neurological manifestations, type II or unspecified type, uncontrolled | Diagnosis | ICD-9-CM |
| 250.63 | Diabetes with neurological manifestations, type I [juvenile type], uncontrolled | Diagnosis | ICD-9-CM |
| 250.70 | Diabetes with peripheral circulatory disorders, type II or unspecified type, not stated as uncontrolled | Diagnosis | ICD-9-CM |
| 250.71 | Diabetes with peripheral circulatory disorders, type I [juvenile type], not stated as uncontrolled | Diagnosis | ICD-9-CM |
| 250.72 | Diabetes with peripheral circulatory disorders, type II or unspecified type, uncontrolled | Diagnosis | ICD-9-CM |
| 250.73 | Diabetes with peripheral circulatory disorders, type I [juvenile type], uncontrolled | Diagnosis | ICD-9-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| 250.80 | Diabetes with other specified manifestations, type II or unspecified type, not stated as uncontrolled | Diagnosis | ICD-9-CM |
| 250.81 | Diabetes with other specified manifestations, type I [juvenile type], not stated as uncontrolled | Diagnosis | ICD-9-CM |
| 250.82 | Diabetes with other specified manifestations, type II or unspecified type, uncontrolled | Diagnosis | ICD-9-CM |
| 250.83 | Diabetes with other specified manifestations, type I [juvenile type], uncontrolled | Diagnosis | ICD-9-CM |
| 250.90 | Diabetes with unspecified complication, type II or unspecified type, not stated as uncontrolled | Diagnosis | ICD-9-CM |
| 250.91 | Diabetes with unspecified complication, type I [juvenile type], not stated as uncontrolled | Diagnosis | ICD-9-CM |
| 250.92 | Diabetes with unspecified complication, type II or unspecified type, uncontrolled | Diagnosis | ICD-9-CM |
| 250.93 | Diabetes with unspecified complication, type I [juvenile type], uncontrolled | Diagnosis | ICD-9-CM |
| 357.2 | Polyneuropathy in diabetes | Diagnosis | ICD-9-CM |
| 362.01 | Background diabetic retinopathy | Diagnosis | ICD-9-CM |
| 362.02 | Proliferative diabetic retinopathy | Diagnosis | ICD-9-CM |
| 362.03 | Nonproliferative diabetic retinopathy NOS | Diagnosis | ICD-9-CM |
| 362.04 | Mild nonproliferative diabetic retinopathy | Diagnosis | ICD-9-CM |
| 362.05 | Moderate nonproliferative diabetic retinopathy | Diagnosis | ICD-9-CM |
| 362.06 | Severe nonproliferative diabetic retinopathy | Diagnosis | ICD-9-CM |
| 366.41 | Diabetic cataract | Diagnosis | ICD-9-CM |
| E08.00 | Diabetes mellitus due to underlying condition with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC) | Diagnosis | ICD-10-CM |
| E08.01 | Diabetes mellitus due to underlying condition with hyperosmolarity with coma | Diagnosis | ICD-10-CM |
| E08.10 | Diabetes mellitus due to underlying condition with ketoacidosis without coma | Diagnosis | ICD-10-CM |
| E08.11 | Diabetes mellitus due to underlying condition with ketoacidosis with coma | Diagnosis | ICD-10-CM |
| E08.21 | Diabetes mellitus due to underlying condition with diabetic nephropathy | Diagnosis | ICD-10-CM |
| E08.22 | Diabetes mellitus due to underlying condition with diabetic chronic kidney disease | Diagnosis | ICD-10-CM |
| E08.29 | Diabetes mellitus due to underlying condition with other diabetic kidney complication | Diagnosis | ICD-10-CM |
| E08.311 | Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema | Diagnosis | ICD-10-CM |
| E08.319 | Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema | Diagnosis | ICD-10-CM |
| E08.321 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema | Diagnosis | ICD-10-CM |
| E08.3211 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye | Diagnosis | ICD-10-CM |
| E08.3212 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye | Diagnosis | ICD-10-CM |
| E08.3213 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral | Diagnosis | ICD-10-CM |
| E08.3219 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| E08.329 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic | Diagnosis | ICD-10-CM |
| E08.3291 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right eye | Diagnosis | ICD-10-CM |
| E08.3292 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left eye | Diagnosis | ICD-10-CM |
| E08.3293 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, bilateral | Diagnosis | ICD-10-CM |
| E08.3299 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye | Diagnosis | ICD-10-CM |
| E08.331 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema | Diagnosis | ICD-10-CM |
| E08.3311 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye | Diagnosis | ICD-10-CM |
| E08.3312 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye | Diagnosis | ICD-10-CM |
| E08.3313 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral | Diagnosis | ICD-10-CM |
| E08.3319 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye | Diagnosis | ICD-10-CM |
| E08.339 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema | Diagnosis | ICD-10-CM |
| E08.3391 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, right eye | Diagnosis | ICD-10-CM |
| E08.3392 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, left eye | Diagnosis | ICD-10-CM |
| E08.3393 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, bilateral | Diagnosis | ICD-10-CM |
| E08.3399 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye | Diagnosis | ICD-10-CM |
| E08.341 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema | Diagnosis | ICD-10-CM |
| E08.3411 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye | Diagnosis | ICD-10-CM |
| E08.3412 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye | Diagnosis | ICD-10-CM |
| E08.3413 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral | Diagnosis | ICD-10-CM |
| E08.3419 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye | Diagnosis | ICD-10-CM |
| E08.349 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema | Diagnosis | ICD-10-CM |
| E08.3491 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, right eye | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| E08.3492 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, left eye | Diagnosis | ICD-10-CM |
| E08.3493 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, bilateral | Diagnosis | ICD-10-CM |
| E08.3499 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye | Diagnosis | ICD-10-CM |
| E08.351 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema | Diagnosis | ICD-10-CM |
| E08.3511 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye | Diagnosis | ICD-10-CM |
| E08.3512 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye | Diagnosis | ICD-10-CM |
| E08.3513 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral | Diagnosis | ICD-10-CM |
| E08.3519 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, unspecified eye | Diagnosis | ICD-10-CM |
| E08.3521 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye | Diagnosis | ICD-10-CM |
| E08.3522 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye | Diagnosis | ICD-10-CM |
| E08.3523 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral | Diagnosis | ICD-10-CM |
| E08.3529 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye | Diagnosis | ICD-10-CM |
| E08.3531 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye | Diagnosis | ICD-10-CM |
| E08.3532 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye | Diagnosis | ICD-10-CM |
| E08.3533 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral | Diagnosis | ICD-10-CM |
| E08.3539 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye | Diagnosis | ICD-10-CM |
| E08.3541 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye | Diagnosis | ICD-10-CM |
| E08.3542 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye | Diagnosis | ICD-10-CM |
| E08.3543 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral | Diagnosis | ICD-10-CM |
| E08.3549 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye | Diagnosis | ICD-10-CM |
| E08.3551 | Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, right eye | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| E08.3552 | Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, left eye | Diagnosis | ICD-10-CM |
| E08.3553 | Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, bilateral | Diagnosis | ICD-10-CM |
| E08.3559 | Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, unspecified eye | Diagnosis | ICD-10-CM |
| E08.359 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema | Diagnosis | ICD-10-CM |
| E08.3591 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, right eye | Diagnosis | ICD-10-CM |
| E08.3592 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, left eye | Diagnosis | ICD-10-CM |
| E08.3593 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, bilateral | Diagnosis | ICD-10-CM |
| E08.3599 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, unspecified eye | Diagnosis | ICD-10-CM |
| E08.36 | Diabetes mellitus due to underlying condition with diabetic cataract | Diagnosis | ICD-10-CM |
| E08.37X1 | Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, right eye | Diagnosis | ICD-10-CM |
| E08.37X2 | Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, left eye | Diagnosis | ICD-10-CM |
| E08.37X3 | Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, bilateral | Diagnosis | ICD-10-CM |
| E08.37X9 | Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, unspecified eye | Diagnosis | ICD-10-CM |
| E08.39 | Diabetes mellitus due to underlying condition with other diabetic ophthalmic complication | Diagnosis | ICD-10-CM |
| E08.40 | Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified | Diagnosis | ICD-10-CM |
| E08.41 | Diabetes mellitus due to underlying condition with diabetic mononeuropathy | Diagnosis | ICD-10-CM |
| E08.42 | Diabetes mellitus due to underlying condition with diabetic polyneuropathy | Diagnosis | ICD-10-CM |
| E08.43 | Diabetes mellitus due to underlying condition with diabetic autonomic (poly)neuropathy | Diagnosis | ICD-10-CM |
| E08.44 | Diabetes mellitus due to underlying condition with diabetic amyotrophy | Diagnosis | ICD-10-CM |
| E08.49 | Diabetes mellitus due to underlying condition with other diabetic neurological complication | Diagnosis | ICD-10-CM |
| E08.51 | Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy without gangrene | Diagnosis | ICD-10-CM |
| E08.52 | Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy with gangrene | Diagnosis | ICD-10-CM |
| E08.59 | Diabetes mellitus due to underlying condition with other circulatory complications | Diagnosis | ICD-10-CM |
| E08.610 | Diabetes mellitus due to underlying condition with diabetic neuropathic arthropathy | Diagnosis | ICD-10-CM |
| E08.618 | Diabetes mellitus due to underlying condition with other diabetic arthropathy | Diagnosis | ICD-10-CM |
| E08.620 | Diabetes mellitus due to underlying condition with diabetic dermatitis | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| E08.621 | Diabetes mellitus due to underlying condition with foot ulcer | Diagnosis | ICD-10-CM |
| E08.622 | Diabetes mellitus due to underlying condition with other skin ulcer | Diagnosis | ICD-10-CM |
| E08.628 | Diabetes mellitus due to underlying condition with other skin complications | Diagnosis | ICD-10-CM |
| E08.630 | Diabetes mellitus due to underlying condition with periodontal disease | Diagnosis | ICD-10-CM |
| E08.638 | Diabetes mellitus due to underlying condition with other oral complications | Diagnosis | ICD-10-CM |
| E08.641 | Diabetes mellitus due to underlying condition with hypoglycemia with coma | Diagnosis | ICD-10-CM |
| E08.649 | Diabetes mellitus due to underlying condition with hypoglycemia without coma | Diagnosis | ICD-10-CM |
| E08.65 | Diabetes mellitus due to underlying condition with hyperglycemia | Diagnosis | ICD-10-CM |
| E08.69 | Diabetes mellitus due to underlying condition with other specified complication | Diagnosis | ICD-10-CM |
| E08.8 | Diabetes mellitus due to underlying condition with unspecified complications | Diagnosis | ICD-10-CM |
| E08.9 | Diabetes mellitus due to underlying condition without complications | Diagnosis | ICD-10-CM |
| E09.00 | Drug or chemical induced diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC) | Diagnosis | ICD-10-CM |
| E09.01 | Drug or chemical induced diabetes mellitus with hyperosmolarity with coma | Diagnosis | ICD-10-CM |
| E09.10 | Drug or chemical induced diabetes mellitus with ketoacidosis without coma | Diagnosis | ICD-10-CM |
| E09.11 | Drug or chemical induced diabetes mellitus with ketoacidosis with coma | Diagnosis | ICD-10-CM |
| E09.21 | Drug or chemical induced diabetes mellitus with diabetic nephropathy | Diagnosis | ICD-10-CM |
| E09.22 | Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease | Diagnosis | ICD-10-CM |
| E09.29 | Drug or chemical induced diabetes mellitus with other diabetic kidney complication | Diagnosis | ICD-10-CM |
| E09.311 | Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edema | Diagnosis | ICD-10-CM |
| E09.319 | Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy without macular edema | Diagnosis | ICD-10-CM |
| E09.321 | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema | Diagnosis | ICD-10-CM |
| E09.3211 | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye | Diagnosis | ICD-10-CM |
| E09.3212 | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye | Diagnosis | ICD-10-CM |
| E09.3213 | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral | Diagnosis | ICD-10-CM |
| E09.3219 | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye | Diagnosis | ICD-10-CM |
| E09.329 | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema | Diagnosis | ICD-10-CM |
| E09.3291 | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye | Diagnosis | ICD-10-CM |
| E09.3292 | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| E09.3293 | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral | Diagnosis | ICD-10-CM |
| E09.3299 | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye | Diagnosis | ICD-10-CM |
| E09.331 | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema | Diagnosis | ICD-10-CM |
| E09.3311 | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye | Diagnosis | ICD-10-CM |
| E09.3312 | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye | Diagnosis | ICD-10-CM |
| E09.3313 | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral | Diagnosis | ICD-10-CM |
| E09.3319 | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye | Diagnosis | ICD-10-CM |
| E09.339 | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema | Diagnosis | ICD-10-CM |
| E09.3391 | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye | Diagnosis | ICD-10-CM |
| E09.3392 | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye | Diagnosis | ICD-10-CM |
| E09.3393 | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral | Diagnosis | ICD-10-CM |
| E09.3399 | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye | Diagnosis | ICD-10-CM |
| E09.341 | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema | Diagnosis | ICD-10-CM |
| E09.3411 | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye | Diagnosis | ICD-10-CM |
| E09.3412 | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye | Diagnosis | ICD-10-CM |
| E09.3413 | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral | Diagnosis | ICD-10-CM |
| E09.3419 | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye | Diagnosis | ICD-10-CM |
| E09.349 | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema | Diagnosis | ICD-10-CM |
| E09.3491 | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye | Diagnosis | ICD-10-CM |
| E09.3492 | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye | Diagnosis | ICD-10-CM |
| E09.3493 | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| E09.3499 | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye | Diagnosis | ICD-10-CM |
| E09.351 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema | Diagnosis | ICD-10-CM |
| E09.3511 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye | Diagnosis | ICD-10-CM |
| E09.3512 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye | Diagnosis | ICD-10-CM |
| E09.3513 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral | Diagnosis | ICD-10-CM |
| E09.3519 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye | Diagnosis | ICD-10-CM |
| E09.3521 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye | Diagnosis | ICD-10-CM |
| E09.3522 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye | Diagnosis | ICD-10-CM |
| E09.3523 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral | Diagnosis | ICD-10-CM |
| E09.3529 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye | Diagnosis | ICD-10-CM |
| E09.3531 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye | Diagnosis | ICD-10-CM |
| E09.3532 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye | Diagnosis | ICD-10-CM |
| E09.3533 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral | Diagnosis | ICD-10-CM |
| E09.3539 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye | Diagnosis | ICD-10-CM |
| E09.3541 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye | Diagnosis | ICD-10-CM |
| E09.3542 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye | Diagnosis | ICD-10-CM |
| E09.3543 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral | Diagnosis | ICD-10-CM |
| E09.3549 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye | Diagnosis | ICD-10-CM |
| E09.3551 | Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, right eye | Diagnosis | ICD-10-CM |
| E09.3552 | Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, left eye | Diagnosis | ICD-10-CM |
| E09.3553 | Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, bilateral | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| E09.3559 | Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye | Diagnosis | ICD-10-CM |
| E09.359 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema | Diagnosis | ICD-10-CM |
| E09.3591 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye | Diagnosis | ICD-10-CM |
| E09.3592 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye | Diagnosis | ICD-10-CM |
| E09.3593 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral | Diagnosis | ICD-10-CM |
| E09.3599 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye | Diagnosis | ICD-10-CM |
| E09.36 | Drug or chemical induced diabetes mellitus with diabetic cataract | Diagnosis | ICD-10-CM |
| E09.37X1 | Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, right eye | Diagnosis | ICD-10-CM |
| E09.37X2 | Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, left eye | Diagnosis | ICD-10-CM |
| E09.37X3 | Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral | Diagnosis | ICD-10-CM |
| E09.37X9 | Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye | Diagnosis | ICD-10-CM |
| E09.39 | Drug or chemical induced diabetes mellitus with other diabetic ophthalmic complication | Diagnosis | ICD-10-CM |
| E09.40 | Drug or chemical induced diabetes mellitus with neurological complications with diabetic neuropathy, unspecified | Diagnosis | ICD-10-CM |
| E09.41 | Drug or chemical induced diabetes mellitus with neurological complications with diabetic mononeuropathy | Diagnosis | ICD-10-CM |
| E09.42 | Drug or chemical induced diabetes mellitus with neurological complications with diabetic polyneuropathy | Diagnosis | ICD-10-CM |
| E09.43 | Drug or chemical induced diabetes mellitus with neurological complications with diabetic autonomic (poly)neuropathy | Diagnosis | ICD-10-CM |
| E09.44 | Drug or chemical induced diabetes mellitus with neurological complications with diabetic amyotrophy | Diagnosis | ICD-10-CM |
| E09.49 | Drug or chemical induced diabetes mellitus with neurological complications with other diabetic neurological complication | Diagnosis | ICD-10-CM |
| E09.51 | Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy without gangrene | Diagnosis | ICD-10-CM |
| E09.52 | Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy with gangrene | Diagnosis | ICD-10-CM |
| E09.59 | Drug or chemical induced diabetes mellitus with other circulatory complications | Diagnosis | ICD-10-CM |
| E09.610 | Drug or chemical induced diabetes mellitus with diabetic neuropathic arthropathy | Diagnosis | ICD-10-CM |
| E09.618 | Drug or chemical induced diabetes mellitus with other diabetic arthropathy | Diagnosis | ICD-10-CM |
| E09.620 | Drug or chemical induced diabetes mellitus with diabetic dermatitis | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| E09.621 | Drug or chemical induced diabetes mellitus with foot ulcer | Diagnosis | ICD-10-CM |
| E09.622 | Drug or chemical induced diabetes mellitus with other skin ulcer | Diagnosis | ICD-10-CM |
| E09.628 | Drug or chemical induced diabetes mellitus with other skin complications | Diagnosis | ICD-10-CM |
| E09.630 | Drug or chemical induced diabetes mellitus with periodontal disease | Diagnosis | ICD-10-CM |
| E09.638 | Drug or chemical induced diabetes mellitus with other oral complications | Diagnosis | ICD-10-CM |
| E09.641 | Drug or chemical induced diabetes mellitus with hypoglycemia with coma | Diagnosis | ICD-10-CM |
| E09.649 | Drug or chemical induced diabetes mellitus with hypoglycemia without coma | Diagnosis | ICD-10-CM |
| E09.65 | Drug or chemical induced diabetes mellitus with hyperglycemia | Diagnosis | ICD-10-CM |
| E09.69 | Drug or chemical induced diabetes mellitus with other specified complication | Diagnosis | ICD-10-CM |
| E09.8 | Drug or chemical induced diabetes mellitus with unspecified complications | Diagnosis | ICD-10-CM |
| E09.9 | Drug or chemical induced diabetes mellitus without complications | Diagnosis | ICD-10-CM |
| E10.10 | Type 1 diabetes mellitus with ketoacidosis without coma | Diagnosis | ICD-10-CM |
| E10.11 | Type 1 diabetes mellitus with ketoacidosis with coma | Diagnosis | ICD-10-CM |
| E10.21 | Type 1 diabetes mellitus with diabetic nephropathy | Diagnosis | ICD-10-CM |
| E10.22 | Type 1 diabetes mellitus with diabetic chronic kidney disease | Diagnosis | ICD-10-CM |
| E10.29 | Type 1 diabetes mellitus with other diabetic kidney complication | Diagnosis | ICD-10-CM |
| E10.311 | Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema | Diagnosis | ICD-10-CM |
| E10.319 | Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema | Diagnosis | ICD-10-CM |
| E10.321 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema | Diagnosis | ICD-10-CM |
| E10.3211 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye | Diagnosis | ICD-10-CM |
| E10.3212 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye | Diagnosis | ICD-10-CM |
| E10.3213 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral | Diagnosis | ICD-10-CM |
| E10.3219 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye | Diagnosis | ICD-10-CM |
| E10.329 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema | Diagnosis | ICD-10-CM |
| E10.3291 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye | Diagnosis | ICD-10-CM |
| E10.3292 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye | Diagnosis | ICD-10-CM |
| E10.3293 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral | Diagnosis | ICD-10-CM |
| E10.3299 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye | Diagnosis | ICD-10-CM |
| E10.331 | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| E10.3311 | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye | Diagnosis | ICD-10-CM |
| E10.3312 | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye | Diagnosis | ICD-10-CM |
| E10.3313 | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral | Diagnosis | ICD-10-CM |
| E10.3319 | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye | Diagnosis | ICD-10-CM |
| E10.339 | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema | Diagnosis | ICD-10-CM |
| E10.3391 | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye | Diagnosis | ICD-10-CM |
| E10.3392 | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye | Diagnosis | ICD-10-CM |
| E10.3393 | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral | Diagnosis | ICD-10-CM |
| E10.3399 | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye | Diagnosis | ICD-10-CM |
| E10.341 | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema | Diagnosis | ICD-10-CM |
| E10.3411 | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye | Diagnosis | ICD-10-CM |
| E10.3412 | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye | Diagnosis | ICD-10-CM |
| E10.3413 | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral | Diagnosis | ICD-10-CM |
| E10.3419 | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye | Diagnosis | ICD-10-CM |
| E10.349 | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema | Diagnosis | ICD-10-CM |
| E10.3491 | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye | Diagnosis | ICD-10-CM |
| E10.3492 | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye | Diagnosis | ICD-10-CM |
| E10.3493 | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral | Diagnosis | ICD-10-CM |
| E10.3499 | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye | Diagnosis | ICD-10-CM |
| E10.351 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema | Diagnosis | ICD-10-CM |
| E10.3511 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye | Diagnosis | ICD-10-CM |
| E10.3512 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| E10.3513 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral | Diagnosis | ICD-10-CM |
| E10.3519 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye | Diagnosis | ICD-10-CM |
| E10.3521 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye | Diagnosis | ICD-10-CM |
| E10.3522 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye | Diagnosis | ICD-10-CM |
| E10.3523 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral | Diagnosis | ICD-10-CM |
| E10.3529 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye | Diagnosis | ICD-10-CM |
| E10.3531 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye | Diagnosis | ICD-10-CM |
| E10.3532 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye | Diagnosis | ICD-10-CM |
| E10.3533 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral | Diagnosis | ICD-10-CM |
| E10.3539 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye | Diagnosis | ICD-10-CM |
| E10.3541 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye | Diagnosis | ICD-10-CM |
| E10.3542 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye | Diagnosis | ICD-10-CM |
| E10.3543 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral | Diagnosis | ICD-10-CM |
| E10.3549 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye | Diagnosis | ICD-10-CM |
| E10.3551 | Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eye | Diagnosis | ICD-10-CM |
| E10.3552 | Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye | Diagnosis | ICD-10-CM |
| E10.3553 | Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral | Diagnosis | ICD-10-CM |
| E10.3559 | Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye | Diagnosis | ICD-10-CM |
| E10.359 | Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema | Diagnosis | ICD-10-CM |
| E10.3591 | Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye | Diagnosis | ICD-10-CM |
| E10.3592 | Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye | Diagnosis | ICD-10-CM |
| E10.3593 | Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| E10.3599 | Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye | Diagnosis | ICD-10-CM |
| E10.36 | Type 1 diabetes mellitus with diabetic cataract | Diagnosis | ICD-10-CM |
| E10.37X1 | Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye | Diagnosis | ICD-10-CM |
| E10.37X2 | Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye | Diagnosis | ICD-10-CM |
| E10.37X3 | Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral | Diagnosis | ICD-10-CM |
| E10.37X9 | Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye | Diagnosis | ICD-10-CM |
| E10.39 | Type 1 diabetes mellitus with other diabetic ophthalmic complication | Diagnosis | ICD-10-CM |
| E10.40 | Type 1 diabetes mellitus with diabetic neuropathy, unspecified | Diagnosis | ICD-10-CM |
| E10.41 | Type 1 diabetes mellitus with diabetic mononeuropathy | Diagnosis | ICD-10-CM |
| E10.42 | Type 1 diabetes mellitus with diabetic polyneuropathy | Diagnosis | ICD-10-CM |
| E10.43 | Type 1 diabetes mellitus with diabetic autonomic (poly)neuropathy | Diagnosis | ICD-10-CM |
| E10.44 | Type 1 diabetes mellitus with diabetic amyotrophy | Diagnosis | ICD-10-CM |
| E10.49 | Type 1 diabetes mellitus with other diabetic neurological complication | Diagnosis | ICD-10-CM |
| E10.51 | Type 1 diabetes mellitus with diabetic peripheral angiopathy without gangrene | Diagnosis | ICD-10-CM |
| E10.52 | Type 1 diabetes mellitus with diabetic peripheral angiopathy with gangrene | Diagnosis | ICD-10-CM |
| E10.59 | Type 1 diabetes mellitus with other circulatory complications | Diagnosis | ICD-10-CM |
| E10.610 | Type 1 diabetes mellitus with diabetic neuropathic arthropathy | Diagnosis | ICD-10-CM |
| E10.618 | Type 1 diabetes mellitus with other diabetic arthropathy | Diagnosis | ICD-10-CM |
| E10.620 | Type 1 diabetes mellitus with diabetic dermatitis | Diagnosis | ICD-10-CM |
| E10.621 | Type 1 diabetes mellitus with foot ulcer | Diagnosis | ICD-10-CM |
| E10.622 | Type 1 diabetes mellitus with other skin ulcer | Diagnosis | ICD-10-CM |
| E10.628 | Type 1 diabetes mellitus with other skin complications | Diagnosis | ICD-10-CM |
| E10.630 | Type 1 diabetes mellitus with periodontal disease | Diagnosis | ICD-10-CM |
| E10.638 | Type 1 diabetes mellitus with other oral complications | Diagnosis | ICD-10-CM |
| E10.641 | Type 1 diabetes mellitus with hypoglycemia with coma | Diagnosis | ICD-10-CM |
| E10.649 | Type 1 diabetes mellitus with hypoglycemia without coma | Diagnosis | ICD-10-CM |
| E10.65 | Type 1 diabetes mellitus with hyperglycemia | Diagnosis | ICD-10-CM |
| E10.69 | Type 1 diabetes mellitus with other specified complication | Diagnosis | ICD-10-CM |
| E10.8 | Type 1 diabetes mellitus with unspecified complications | Diagnosis | ICD-10-CM |
| E10.9 | Type 1 diabetes mellitus without complications | Diagnosis | ICD-10-CM |
| E11.00 | Type 2 diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC) | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| E11.01 | Type 2 diabetes mellitus with hyperosmolarity with coma | Diagnosis | ICD-10-CM |
| E11.10 | Type 2 diabetes mellitus with ketoacidosis without coma | Diagnosis | ICD-10-CM |
| E11.11 | Type 2 diabetes mellitus with ketoacidosis with coma | Diagnosis | ICD-10-CM |
| E11.21 | Type 2 diabetes mellitus with diabetic nephropathy | Diagnosis | ICD-10-CM |
| E11.22 | Type 2 diabetes mellitus with diabetic chronic kidney disease | Diagnosis | ICD-10-CM |
| E11.29 | Type 2 diabetes mellitus with other diabetic kidney complication | Diagnosis | ICD-10-CM |
| E11.311 | Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema | Diagnosis | ICD-10-CM |
| E11.319 | Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema | Diagnosis | ICD-10-CM |
| E11.321 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema | Diagnosis | ICD-10-CM |
| E11.3211 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye | Diagnosis | ICD-10-CM |
| E11.3212 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye | Diagnosis | ICD-10-CM |
| E11.3213 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral | Diagnosis | ICD-10-CM |
| E11.3219 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye | Diagnosis | ICD-10-CM |
| E11.329 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema | Diagnosis | ICD-10-CM |
| E11.3291 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye | Diagnosis | ICD-10-CM |
| E11.3292 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye | Diagnosis | ICD-10-CM |
| E11.3293 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral | Diagnosis | ICD-10-CM |
| E11.3299 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye | Diagnosis | ICD-10-CM |
| E11.331 | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema | Diagnosis | ICD-10-CM |
| E11.3311 | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye | Diagnosis | ICD-10-CM |
| E11.3312 | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye | Diagnosis | ICD-10-CM |
| E11.3313 | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral | Diagnosis | ICD-10-CM |
| E11.3319 | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| E11.339 | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema | Diagnosis | ICD-10-CM |
| E11.3391 | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye | Diagnosis | ICD-10-CM |
| E11.3392 | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye | Diagnosis | ICD-10-CM |
| E11.3393 | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral | Diagnosis | ICD-10-CM |
| E11.3399 | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye | Diagnosis | ICD-10-CM |
| E11.341 | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema | Diagnosis | ICD-10-CM |
| E11.3411 | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye | Diagnosis | ICD-10-CM |
| E11.3412 | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye | Diagnosis | ICD-10-CM |
| E11.3413 | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral | Diagnosis | ICD-10-CM |
| E11.3419 | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye | Diagnosis | ICD-10-CM |
| E11.349 | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema | Diagnosis | ICD-10-CM |
| E11.3491 | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye | Diagnosis | ICD-10-CM |
| E11.3492 | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye | Diagnosis | ICD-10-CM |
| E11.3493 | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral | Diagnosis | ICD-10-CM |
| E11.3499 | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye | Diagnosis | ICD-10-CM |
| E11.351 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema | Diagnosis | ICD-10-CM |
| E11.3511 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye | Diagnosis | ICD-10-CM |
| E11.3512 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye | Diagnosis | ICD-10-CM |
| E11.3513 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral | Diagnosis | ICD-10-CM |
| E11.3519 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye | Diagnosis | ICD-10-CM |
| E11.3521 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| E11.3522 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye | Diagnosis | ICD-10-CM |
| E11.3523 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral | Diagnosis | ICD-10-CM |
| E11.3529 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye | Diagnosis | ICD-10-CM |
| E11.3531 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye | Diagnosis | ICD-10-CM |
| E11.3532 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye | Diagnosis | ICD-10-CM |
| E11.3533 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral | Diagnosis | ICD-10-CM |
| E11.3539 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye | Diagnosis | ICD-10-CM |
| E11.3541 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye | Diagnosis | ICD-10-CM |
| E11.3542 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye | Diagnosis | ICD-10-CM |
| E11.3543 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral | Diagnosis | ICD-10-CM |
| E11.3549 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye | Diagnosis | ICD-10-CM |
| E11.3551 | Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye | Diagnosis | ICD-10-CM |
| E11.3552 | Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye | Diagnosis | ICD-10-CM |
| E11.3553 | Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral | Diagnosis | ICD-10-CM |
| E11.3559 | Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye | Diagnosis | ICD-10-CM |
| E11.359 | Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema | Diagnosis | ICD-10-CM |
| E11.3591 | Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye | Diagnosis | ICD-10-CM |
| E11.3592 | Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye | Diagnosis | ICD-10-CM |
| E11.3593 | Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral | Diagnosis | ICD-10-CM |
| E11.3599 | Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye | Diagnosis | ICD-10-CM |
| E11.36 | Type 2 diabetes mellitus with diabetic cataract | Diagnosis | ICD-10-CM |
| E11.37X1 | Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye | Diagnosis | ICD-10-CM |
| E11.37X2 | Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| E11.37X3 | Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral | Diagnosis | ICD-10-CM |
| E11.37X9 | Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye | Diagnosis | ICD-10-CM |
| E11.39 | Type 2 diabetes mellitus with other diabetic ophthalmic complication | Diagnosis | ICD-10-CM |
| E11.40 | Type 2 diabetes mellitus with diabetic neuropathy, unspecified | Diagnosis | ICD-10-CM |
| E11.41 | Type 2 diabetes mellitus with diabetic mononeuropathy | Diagnosis | ICD-10-CM |
| E11.42 | Type 2 diabetes mellitus with diabetic polyneuropathy | Diagnosis | ICD-10-CM |
| E11.43 | Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy | Diagnosis | ICD-10-CM |
| E11.44 | Type 2 diabetes mellitus with diabetic amyotrophy | Diagnosis | ICD-10-CM |
| E11.49 | Type 2 diabetes mellitus with other diabetic neurological complication | Diagnosis | ICD-10-CM |
| E11.51 | Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene | Diagnosis | ICD-10-CM |
| E11.52 | Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene | Diagnosis | ICD-10-CM |
| E11.59 | Type 2 diabetes mellitus with other circulatory complications | Diagnosis | ICD-10-CM |
| E11.610 | Type 2 diabetes mellitus with diabetic neuropathic arthropathy | Diagnosis | ICD-10-CM |
| E11.618 | Type 2 diabetes mellitus with other diabetic arthropathy | Diagnosis | ICD-10-CM |
| E11.620 | Type 2 diabetes mellitus with diabetic dermatitis | Diagnosis | ICD-10-CM |
| E11.621 | Type 2 diabetes mellitus with foot ulcer | Diagnosis | ICD-10-CM |
| E11.622 | Type 2 diabetes mellitus with other skin ulcer | Diagnosis | ICD-10-CM |
| E11.628 | Type 2 diabetes mellitus with other skin complications | Diagnosis | ICD-10-CM |
| E11.630 | Type 2 diabetes mellitus with periodontal disease | Diagnosis | ICD-10-CM |
| E11.638 | Type 2 diabetes mellitus with other oral complications | Diagnosis | ICD-10-CM |
| E11.641 | Type 2 diabetes mellitus with hypoglycemia with coma | Diagnosis | ICD-10-CM |
| E11.649 | Type 2 diabetes mellitus with hypoglycemia without coma | Diagnosis | ICD-10-CM |
| E11.65 | Type 2 diabetes mellitus with hyperglycemia | Diagnosis | ICD-10-CM |
| E11.69 | Type 2 diabetes mellitus with other specified complication | Diagnosis | ICD-10-CM |
| E11.8 | Type 2 diabetes mellitus with unspecified complications | Diagnosis | ICD-10-CM |
| E11.9 | Type 2 diabetes mellitus without complications | Diagnosis | ICD-10-CM |
| E13.00 | Other specified diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC) | Diagnosis | ICD-10-CM |
| E13.01 | Other specified diabetes mellitus with hyperosmolarity with coma | Diagnosis | ICD-10-CM |
| E13.10 | Other specified diabetes mellitus with ketoacidosis without coma | Diagnosis | ICD-10-CM |
| E13.11 | Other specified diabetes mellitus with ketoacidosis with coma | Diagnosis | ICD-10-CM |
| E13.21 | Other specified diabetes mellitus with diabetic nephropathy | Diagnosis | ICD-10-CM |
| E13.22 | Other specified diabetes mellitus with diabetic chronic kidney disease | Diagnosis | ICD-10-CM |
| E13.29 | Other specified diabetes mellitus with other diabetic kidney complication | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| E13.311 | Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema | Diagnosis | ICD-10-CM |
| E13.319 | Other specified diabetes mellitus with unspecified diabetic retinopathy without macular edema | Diagnosis | ICD-10-CM |
| E13.321 | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema | Diagnosis | ICD-10-CM |
| E13.3211 | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye | Diagnosis | ICD-10-CM |
| E13.3212 | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye | Diagnosis | ICD-10-CM |
| E13.3213 | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral | Diagnosis | ICD-10-CM |
| E13.3219 | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye | Diagnosis | ICD-10-CM |
| E13.329 | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema | Diagnosis | ICD-10-CM |
| E13.3291 | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye | Diagnosis | ICD-10-CM |
| E13.3292 | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye | Diagnosis | ICD-10-CM |
| E13.3293 | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral | Diagnosis | ICD-10-CM |
| E13.3299 | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye | Diagnosis | ICD-10-CM |
| E13.331 | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema | Diagnosis | ICD-10-CM |
| E13.3311 | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye | Diagnosis | ICD-10-CM |
| E13.3312 | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye | Diagnosis | ICD-10-CM |
| E13.3313 | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral | Diagnosis | ICD-10-CM |
| E13.3319 | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye | Diagnosis | ICD-10-CM |
| E13.339 | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema | Diagnosis | ICD-10-CM |
| E13.3391 | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye | Diagnosis | ICD-10-CM |
| E13.3392 | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye | Diagnosis | ICD-10-CM |
| E13.3393 | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| E13.3399 | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye | Diagnosis | ICD-10-CM |
| E13.341 | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema | Diagnosis | ICD-10-CM |
| E13.3411 | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye | Diagnosis | ICD-10-CM |
| E13.3412 | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye | Diagnosis | ICD-10-CM |
| E13.3413 | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral | Diagnosis | ICD-10-CM |
| E13.3419 | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye | Diagnosis | ICD-10-CM |
| E13.349 | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema | Diagnosis | ICD-10-CM |
| E13.3491 | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye | Diagnosis | ICD-10-CM |
| E13.3492 | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye | Diagnosis | ICD-10-CM |
| E13.3493 | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral | Diagnosis | ICD-10-CM |
| E13.3499 | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye | Diagnosis | ICD-10-CM |
| E13.351 | Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema | Diagnosis | ICD-10-CM |
| E13.3511 | Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye | Diagnosis | ICD-10-CM |
| E13.3512 | Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye | Diagnosis | ICD-10-CM |
| E13.3513 | Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral | Diagnosis | ICD-10-CM |
| E13.3519 | Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye | Diagnosis | ICD-10-CM |
| E13.3521 | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye | Diagnosis | ICD-10-CM |
| E13.3522 | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye | Diagnosis | ICD-10-CM |
| E13.3523 | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral | Diagnosis | ICD-10-CM |
| E13.3529 | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye | Diagnosis | ICD-10-CM |
| E13.3531 | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| E13.3532 | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye | Diagnosis | ICD-10-CM |
| E13.3533 | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral | Diagnosis | ICD-10-CM |
| E13.3539 | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye | Diagnosis | ICD-10-CM |
| E13.3541 | Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye | Diagnosis | ICD-10-CM |
| E13.3542 | Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye | Diagnosis | ICD-10-CM |
| E13.3543 | Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral | Diagnosis | ICD-10-CM |
| E13.3549 | Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye | Diagnosis | ICD-10-CM |
| E13.3551 | Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right eye | Diagnosis | ICD-10-CM |
| E13.3552 | Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left eye | Diagnosis | ICD-10-CM |
| E13.3553 | Other specified diabetes mellitus with stable proliferative diabetic retinopathy, bilateral | Diagnosis | ICD-10-CM |
| E13.3559 | Other specified diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye | Diagnosis | ICD-10-CM |
| E13.359 | Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema | Diagnosis | ICD-10-CM |
| E13.3591 | Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye | Diagnosis | ICD-10-CM |
| E13.3592 | Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye | Diagnosis | ICD-10-CM |
| E13.3593 | Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral | Diagnosis | ICD-10-CM |
| E13.3599 | Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye | Diagnosis | ICD-10-CM |
| E13.36 | Other specified diabetes mellitus with diabetic cataract | Diagnosis | ICD-10-CM |
| E13.39 | Other specified diabetes mellitus with other diabetic ophthalmic complication | Diagnosis | ICD-10-CM |
| E13.40 | Other specified diabetes mellitus with diabetic neuropathy, unspecified | Diagnosis | ICD-10-CM |
| E13.41 | Other specified diabetes mellitus with diabetic mononeuropathy | Diagnosis | ICD-10-CM |
| E13.42 | Other specified diabetes mellitus with diabetic polyneuropathy | Diagnosis | ICD-10-CM |
| E13.43 | Other specified diabetes mellitus with diabetic autonomic (poly)neuropathy | Diagnosis | ICD-10-CM |
| E13.44 | Other specified diabetes mellitus with diabetic amyotrophy | Diagnosis | ICD-10-CM |
| E13.49 | Other specified diabetes mellitus with other diabetic neurological complication | Diagnosis | ICD-10-CM |
| E13.51 | Other specified diabetes mellitus with diabetic peripheral angiopathy without gangrene | Diagnosis | ICD-10-CM |
| E13.52 | Other specified diabetes mellitus with diabetic peripheral angiopathy with gangrene | Diagnosis | ICD-10-CM |
| E13.59 | Other specified diabetes mellitus with other circulatory complications | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|-------------------|---|---------------|-----------|
| E13.610 | Other specified diabetes mellitus with diabetic neuropathic arthropathy | Diagnosis | ICD-10-CM |
| E13.618 | Other specified diabetes mellitus with other diabetic arthropathy | Diagnosis | ICD-10-CM |
| E13.620 | Other specified diabetes mellitus with diabetic dermatitis | Diagnosis | ICD-10-CM |
| E13.621 | Other specified diabetes mellitus with foot ulcer | Diagnosis | ICD-10-CM |
| E13.622 | Other specified diabetes mellitus with other skin ulcer | Diagnosis | ICD-10-CM |
| E13.628 | Other specified diabetes mellitus with other skin complications | Diagnosis | ICD-10-CM |
| E13.630 | Other specified diabetes mellitus with periodontal disease | Diagnosis | ICD-10-CM |
| E13.638 | Other specified diabetes mellitus with other oral complications | Diagnosis | ICD-10-CM |
| E13.641 | Other specified diabetes mellitus with hypoglycemia with coma | Diagnosis | ICD-10-CM |
| E13.649 | Other specified diabetes mellitus with hypoglycemia without coma | Diagnosis | ICD-10-CM |
| E13.65 | Other specified diabetes mellitus with hyperglycemia | Diagnosis | ICD-10-CM |
| E13.69 | Other specified diabetes mellitus with other specified complication | Diagnosis | ICD-10-CM |
| E13.8 | Other specified diabetes mellitus with unspecified complications | Diagnosis | ICD-10-CM |
| E13.9 | Other specified diabetes mellitus without complications | Diagnosis | ICD-10-CM |
| Drug Abuse | | | |
| 292.0 | Drug withdrawal | Diagnosis | ICD-9-CM |
| 292.11 | Drug-induced psychotic disorder with delusions | Diagnosis | ICD-9-CM |
| 292.12 | Drug-induced psychotic disorder with hallucinations | Diagnosis | ICD-9-CM |
| 292.2 | Pathological drug intoxication | Diagnosis | ICD-9-CM |
| 292.81 | Drug-induced delirium | Diagnosis | ICD-9-CM |
| 292.82 | Drug-induced persisting dementia | Diagnosis | ICD-9-CM |
| 292.83 | Drug-induced persisting amnestic disorder | Diagnosis | ICD-9-CM |
| 292.84 | Drug-induced mood disorder | Diagnosis | ICD-9-CM |
| 292.85 | Drug induced sleep disorders | Diagnosis | ICD-9-CM |
| 292.89 | Other specified drug-induced mental disorder | Diagnosis | ICD-9-CM |
| 292.9 | Unspecified drug-induced mental disorder | Diagnosis | ICD-9-CM |
| 304.00 | Opioid type dependence, unspecified | Diagnosis | ICD-9-CM |
| 304.01 | Opioid type dependence, continuous | Diagnosis | ICD-9-CM |
| 304.02 | Opioid type dependence, episodic | Diagnosis | ICD-9-CM |
| 304.10 | Sedative, hypnotic or anxiolytic dependence, unspecified | Diagnosis | ICD-9-CM |
| 304.11 | Sedative, hypnotic or anxiolytic dependence, continuous | Diagnosis | ICD-9-CM |
| 304.12 | Sedative, hypnotic or anxiolytic dependence, episodic | Diagnosis | ICD-9-CM |
| 304.2 | Cocaine dependence | Diagnosis | ICD-9-CM |
| 304.20 | Cocaine dependence, unspecified | Diagnosis | ICD-9-CM |
| 304.21 | Cocaine dependence, continuous | Diagnosis | ICD-9-CM |
| 304.22 | Cocaine dependence, episodic | Diagnosis | ICD-9-CM |
| 304.3 | Cannabis dependence | Diagnosis | ICD-9-CM |
| 304.30 | Cannabis dependence, unspecified | Diagnosis | ICD-9-CM |
| 304.31 | Cannabis dependence, continuous | Diagnosis | ICD-9-CM |
| 304.32 | Cannabis dependence, episodic | Diagnosis | ICD-9-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| 304.4 | Amphetamine and other psychostimulant dependence | Diagnosis | ICD-9-CM |
| 304.40 | Amphetamine and other psychostimulant dependence, unspecified | Diagnosis | ICD-9-CM |
| 304.41 | Amphetamine and other psychostimulant dependence, continuous | Diagnosis | ICD-9-CM |
| 304.42 | Amphetamine and other psychostimulant dependence, episodic | Diagnosis | ICD-9-CM |
| 304.5 | Hallucinogen dependence | Diagnosis | ICD-9-CM |
| 304.50 | Hallucinogen dependence, unspecified | Diagnosis | ICD-9-CM |
| 304.51 | Hallucinogen dependence, continuous | Diagnosis | ICD-9-CM |
| 304.52 | Hallucinogen dependence, episodic | Diagnosis | ICD-9-CM |
| 304.6 | Other specified drug dependence | Diagnosis | ICD-9-CM |
| 304.60 | Other specified drug dependence, unspecified | Diagnosis | ICD-9-CM |
| 304.61 | Other specified drug dependence, continuous | Diagnosis | ICD-9-CM |
| 304.62 | Other specified drug dependence, episodic | Diagnosis | ICD-9-CM |
| 304.7 | Combinations of opioid type drug with any other drug dependence | Diagnosis | ICD-9-CM |
| 304.70 | Combinations of opioid type drug with any other drug dependence, unspecified | Diagnosis | ICD-9-CM |
| 304.71 | Combinations of opioid type drug with any other drug dependence, continuous | Diagnosis | ICD-9-CM |
| 304.72 | Combinations of opioid type drug with any other drug dependence, episodic | Diagnosis | ICD-9-CM |
| 304.8 | Combinations of drug dependence excluding opioid type drug | Diagnosis | ICD-9-CM |
| 304.80 | Combinations of drug dependence excluding opioid type drug, unspecified | Diagnosis | ICD-9-CM |
| 304.81 | Combinations of drug dependence excluding opioid type drug, continuous | Diagnosis | ICD-9-CM |
| 304.82 | Combinations of drug dependence excluding opioid type drug, episodic | Diagnosis | ICD-9-CM |
| 304.9 | Unspecified drug dependence | Diagnosis | ICD-9-CM |
| 304.90 | Unspecified drug dependence, unspecified | Diagnosis | ICD-9-CM |
| 304.91 | Unspecified drug dependence, continuous | Diagnosis | ICD-9-CM |
| 304.92 | Unspecified drug dependence, episodic | Diagnosis | ICD-9-CM |
| 305.2 | Nondependent cannabis abuse | Diagnosis | ICD-9-CM |
| 305.20 | Nondependent cannabis abuse, unspecified | Diagnosis | ICD-9-CM |
| 305.21 | Nondependent cannabis abuse, continuous | Diagnosis | ICD-9-CM |
| 305.22 | Nondependent cannabis abuse, episodic | Diagnosis | ICD-9-CM |
| 305.3 | Nondependent hallucinogen abuse | Diagnosis | ICD-9-CM |
| 305.30 | Nondependent hallucinogen abuse, unspecified | Diagnosis | ICD-9-CM |
| 305.31 | Nondependent hallucinogen abuse, continuous | Diagnosis | ICD-9-CM |
| 305.32 | Nondependent hallucinogen abuse, episodic | Diagnosis | ICD-9-CM |
| 305.4 | Nondependent sedative, hypnotic or anxiolytic abuse | Diagnosis | ICD-9-CM |
| 305.40 | Nondependent sedative, hypnotic or anxiolytic abuse, unspecified | Diagnosis | ICD-9-CM |
| 305.41 | Nondependent sedative hypnotic or anxiolytic abuse, continuous | Diagnosis | ICD-9-CM |
| 305.42 | Nondependent sedative, hypnotic or anxiolytic abuse, episodic | Diagnosis | ICD-9-CM |
| 305.5 | Nondependent opioid abuse | Diagnosis | ICD-9-CM |
| 305.50 | Nondependent opioid abuse, unspecified | Diagnosis | ICD-9-CM |
| 305.51 | Nondependent opioid abuse, continuous | Diagnosis | ICD-9-CM |
| 305.52 | Nondependent opioid abuse, episodic | Diagnosis | ICD-9-CM |
| 305.6 | Nondependent cocaine abuse | Diagnosis | ICD-9-CM |
| 305.60 | Nondependent cocaine abuse, unspecified | Diagnosis | ICD-9-CM |
| 305.61 | Nondependent cocaine abuse, continuous | Diagnosis | ICD-9-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| 305.62 | Nondependent cocaine abuse, episodic | Diagnosis | ICD-9-CM |
| 305.7 | Nondependent amphetamine or related acting sympathomimetic abuse | Diagnosis | ICD-9-CM |
| 305.70 | Nondependent amphetamine or related acting sympathomimetic abuse, unspecified | Diagnosis | ICD-9-CM |
| 305.71 | Nondependent amphetamine or related acting sympathomimetic abuse, continuous | Diagnosis | ICD-9-CM |
| 305.72 | Nondependent amphetamine or related acting sympathomimetic abuse, episodic | Diagnosis | ICD-9-CM |
| 305.8 | Nondependent antidepressant type abuse | Diagnosis | ICD-9-CM |
| 305.80 | Nondependent antidepressant type abuse, unspecified | Diagnosis | ICD-9-CM |
| 305.81 | Nondependent antidepressant type abuse, continuous | Diagnosis | ICD-9-CM |
| 305.82 | Nondependent antidepressant type abuse, episodic | Diagnosis | ICD-9-CM |
| 305.9 | Other, mixed, or unspecified nondependent drug abuse | Diagnosis | ICD-9-CM |
| 305.90 | Other, mixed, or unspecified nondependent drug abuse, unspecified | Diagnosis | ICD-9-CM |
| 305.91 | Other, mixed, or unspecified nondependent drug abuse, continuous | Diagnosis | ICD-9-CM |
| 305.92 | Other, mixed, or unspecified nondependent drug abuse, episodic | Diagnosis | ICD-9-CM |
| 648.3 | Maternal drug dependence complicating pregnancy, childbirth, or the puerperium | Diagnosis | ICD-9-CM |
| 648.30 | Maternal drug dependence complicating pregnancy, childbirth, or the puerperium, unspecified as to episode of care | Diagnosis | ICD-9-CM |
| 648.31 | Maternal drug dependence, with delivery | Diagnosis | ICD-9-CM |
| 648.32 | Maternal drug dependence, with delivery, with current postpartum complication | Diagnosis | ICD-9-CM |
| 648.33 | Maternal drug dependence, antepartum | Diagnosis | ICD-9-CM |
| 648.34 | Maternal drug dependence complicating pregnancy, childbirth, or the puerperium, postpartum condition or complication | Diagnosis | ICD-9-CM |
| 655.5 | Suspected damage to fetus from drugs, affecting management of mother | Diagnosis | ICD-9-CM |
| 655.50 | Suspected damage to fetus from drugs, affecting management of mother, unspecified as to episode of care | Diagnosis | ICD-9-CM |
| 655.51 | Suspected damage to fetus from drugs, affecting management of mother, delivered | Diagnosis | ICD-9-CM |
| 655.53 | Suspected damage to fetus from drugs, affecting management of mother, antepartum | Diagnosis | ICD-9-CM |
| 760.72 | Noxious influences affecting fetus or newborn via placenta or breast milk, narcotics | Diagnosis | ICD-9-CM |
| 760.73 | Noxious influences affecting fetus or newborn via placenta or breast milk, hallucinogenic agents | Diagnosis | ICD-9-CM |
| 760.75 | Noxious influences affecting fetus or newborn via placenta or breast milk, cocaine | Diagnosis | ICD-9-CM |
| 779.5 | Drug withdrawal syndrome in newborn | Diagnosis | ICD-9-CM |
| 94.6 | Alcohol and drug rehabilitation and detoxification | Procedure | ICD-9-CM |
| 94.64 | Drug rehabilitation | Procedure | ICD-9-CM |
| 94.65 | Drug detoxification | Procedure | ICD-9-CM |
| 94.66 | Drug rehabilitation and detoxification | Procedure | ICD-9-CM |
| 94.67 | Combined alcohol and drug rehabilitation | Procedure | ICD-9-CM |
| 94.68 | Combined alcohol and drug detoxification | Procedure | ICD-9-CM |
| 94.69 | Combined alcohol and drug rehabilitation and detoxification | Procedure | ICD-9-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|---|---------------|-----------|
| 965.0 | Poisoning by opiates and related narcotics | Diagnosis | ICD-9-CM |
| 965.00 | Poisoning by opium (alkaloids), unspecified | Diagnosis | ICD-9-CM |
| 965.01 | Poisoning by heroin | Diagnosis | ICD-9-CM |
| 965.02 | Poisoning by methadone | Diagnosis | ICD-9-CM |
| 965.09 | Poisoning by opiates and related narcotics, other | Diagnosis | ICD-9-CM |
| E850.0 | Accidental poisoning by heroin | Diagnosis | ICD-9-CM |
| E850.1 | Accidental poisoning by methadone | Diagnosis | ICD-9-CM |
| E850.2 | Accidental poisoning by other opiates and related narcotics | Diagnosis | ICD-9-CM |
| E854.1 | Accidental poisoning by psychodysleptics (hallucinogens) | Diagnosis | ICD-9-CM |
| E935.0 | Heroin causing adverse effect in therapeutic use | Diagnosis | ICD-9-CM |
| E935.1 | Methadone causing adverse effect in therapeutic use | Diagnosis | ICD-9-CM |
| F11.10 | Opioid abuse, uncomplicated | Diagnosis | ICD-10-CM |
| F11.11 | Opioid abuse, in remission | Diagnosis | ICD-10-CM |
| F11.120 | Opioid abuse with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F11.121 | Opioid abuse with intoxication delirium | Diagnosis | ICD-10-CM |
| F11.122 | Opioid abuse with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F11.129 | Opioid abuse with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F11.13 | Opioid abuse with withdrawal | Diagnosis | ICD-10-CM |
| F11.14 | Opioid abuse with opioid-induced mood disorder | Diagnosis | ICD-10-CM |
| F11.150 | Opioid abuse with opioid-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F11.151 | Opioid abuse with opioid-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F11.159 | Opioid abuse with opioid-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F11.181 | Opioid abuse with opioid-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F11.182 | Opioid abuse with opioid-induced sleep disorder | Diagnosis | ICD-10-CM |
| F11.188 | Opioid abuse with other opioid-induced disorder | Diagnosis | ICD-10-CM |
| F11.19 | Opioid abuse with unspecified opioid-induced disorder | Diagnosis | ICD-10-CM |
| F11.20 | Opioid dependence, uncomplicated | Diagnosis | ICD-10-CM |
| F11.220 | Opioid dependence with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F11.221 | Opioid dependence with intoxication delirium | Diagnosis | ICD-10-CM |
| F11.222 | Opioid dependence with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F11.229 | Opioid dependence with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F11.23 | Opioid dependence with withdrawal | Diagnosis | ICD-10-CM |
| F11.24 | Opioid dependence with opioid-induced mood disorder | Diagnosis | ICD-10-CM |
| F11.250 | Opioid dependence with opioid-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| F11.251 | Opioid dependence with opioid-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F11.259 | Opioid dependence with opioid-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F11.281 | Opioid dependence with opioid-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F11.282 | Opioid dependence with opioid-induced sleep disorder | Diagnosis | ICD-10-CM |
| F11.288 | Opioid dependence with other opioid-induced disorder | Diagnosis | ICD-10-CM |
| F11.29 | Opioid dependence with unspecified opioid-induced disorder | Diagnosis | ICD-10-CM |
| F11.90 | Opioid use, unspecified, uncomplicated | Diagnosis | ICD-10-CM |
| F11.920 | Opioid use, unspecified with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F11.921 | Opioid use, unspecified with intoxication delirium | Diagnosis | ICD-10-CM |
| F11.922 | Opioid use, unspecified with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F11.929 | Opioid use, unspecified with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F11.93 | Opioid use, unspecified with withdrawal | Diagnosis | ICD-10-CM |
| F11.94 | Opioid use, unspecified with opioid-induced mood disorder | Diagnosis | ICD-10-CM |
| F11.950 | Opioid use, unspecified with opioid-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F11.951 | Opioid use, unspecified with opioid-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F11.959 | Opioid use, unspecified with opioid-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F11.981 | Opioid use, unspecified with opioid-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F11.982 | Opioid use, unspecified with opioid-induced sleep disorder | Diagnosis | ICD-10-CM |
| F11.988 | Opioid use, unspecified with other opioid-induced disorder | Diagnosis | ICD-10-CM |
| F11.99 | Opioid use, unspecified with unspecified opioid-induced disorder | Diagnosis | ICD-10-CM |
| F12.10 | Cannabis abuse, uncomplicated | Diagnosis | ICD-10-CM |
| F12.11 | Cannabis abuse, in remission | Diagnosis | ICD-10-CM |
| F12.120 | Cannabis abuse with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F12.121 | Cannabis abuse with intoxication delirium | Diagnosis | ICD-10-CM |
| F12.122 | Cannabis abuse with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F12.129 | Cannabis abuse with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F12.13 | Cannabis abuse with withdrawal | Diagnosis | ICD-10-CM |
| F12.150 | Cannabis abuse with psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F12.151 | Cannabis abuse with psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F12.159 | Cannabis abuse with psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F12.180 | Cannabis abuse with cannabis-induced anxiety disorder | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|---|---------------|-----------|
| F12.188 | Cannabis abuse with other cannabis-induced disorder | Diagnosis | ICD-10-CM |
| F12.19 | Cannabis abuse with unspecified cannabis-induced disorder | Diagnosis | ICD-10-CM |
| F12.20 | Cannabis dependence, uncomplicated | Diagnosis | ICD-10-CM |
| F12.220 | Cannabis dependence with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F12.221 | Cannabis dependence with intoxication delirium | Diagnosis | ICD-10-CM |
| F12.222 | Cannabis dependence with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F12.229 | Cannabis dependence with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F12.250 | Cannabis dependence with psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F12.251 | Cannabis dependence with psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F12.259 | Cannabis dependence with psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F12.280 | Cannabis dependence with cannabis-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F12.288 | Cannabis dependence with other cannabis-induced disorder | Diagnosis | ICD-10-CM |
| F12.29 | Cannabis dependence with unspecified cannabis-induced disorder | Diagnosis | ICD-10-CM |
| F12.90 | Cannabis use, unspecified, uncomplicated | Diagnosis | ICD-10-CM |
| F12.920 | Cannabis use, unspecified with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F12.921 | Cannabis use, unspecified with intoxication delirium | Diagnosis | ICD-10-CM |
| F12.922 | Cannabis use, unspecified with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F12.929 | Cannabis use, unspecified with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F12.950 | Cannabis use, unspecified with psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F12.951 | Cannabis use, unspecified with psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F12.959 | Cannabis use, unspecified with psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F12.980 | Cannabis use, unspecified with anxiety disorder | Diagnosis | ICD-10-CM |
| F12.988 | Cannabis use, unspecified with other cannabis-induced disorder | Diagnosis | ICD-10-CM |
| F12.99 | Cannabis use, unspecified with unspecified cannabis-induced disorder | Diagnosis | ICD-10-CM |
| F13.10 | Sedative, hypnotic or anxiolytic abuse, uncomplicated | Diagnosis | ICD-10-CM |
| F13.11 | Sedative, hypnotic or anxiolytic abuse, in remission | Diagnosis | ICD-10-CM |
| F13.120 | Sedative, hypnotic or anxiolytic abuse with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F13.121 | Sedative, hypnotic or anxiolytic abuse with intoxication delirium | Diagnosis | ICD-10-CM |
| F13.129 | Sedative, hypnotic or anxiolytic abuse with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F13.130 | Sedative, hypnotic or anxiolytic abuse with withdrawal, uncomplicated | Diagnosis | ICD-10-CM |
| F13.131 | Sedative, hypnotic or anxiolytic abuse with withdrawal delirium | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| F13.132 | Sedative, hypnotic or anxiolytic abuse with withdrawal with perceptual disturbance | Diagnosis | ICD-10-CM |
| F13.139 | Sedative, hypnotic or anxiolytic abuse with withdrawal, unspecified | Diagnosis | ICD-10-CM |
| F13.14 | Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced mood disorder | Diagnosis | ICD-10-CM |
| F13.150 | Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F13.151 | Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F13.159 | Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F13.180 | Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F13.181 | Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F13.182 | Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sleep disorder | Diagnosis | ICD-10-CM |
| F13.188 | Sedative, hypnotic or anxiolytic abuse with other sedative, hypnotic or anxiolytic-induced disorder | Diagnosis | ICD-10-CM |
| F13.19 | Sedative, hypnotic or anxiolytic abuse with unspecified sedative, hypnotic or anxiolytic-induced disorder | Diagnosis | ICD-10-CM |
| F13.20 | Sedative, hypnotic or anxiolytic dependence, uncomplicated | Diagnosis | ICD-10-CM |
| F13.220 | Sedative, hypnotic or anxiolytic dependence with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F13.221 | Sedative, hypnotic or anxiolytic dependence with intoxication delirium | Diagnosis | ICD-10-CM |
| F13.229 | Sedative, hypnotic or anxiolytic dependence with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F13.230 | Sedative, hypnotic or anxiolytic dependence with withdrawal, uncomplicated | Diagnosis | ICD-10-CM |
| F13.231 | Sedative, hypnotic or anxiolytic dependence with withdrawal delirium | Diagnosis | ICD-10-CM |
| F13.232 | Sedative, hypnotic or anxiolytic dependence with withdrawal with perceptual disturbance | Diagnosis | ICD-10-CM |
| F13.239 | Sedative, hypnotic or anxiolytic dependence with withdrawal, unspecified | Diagnosis | ICD-10-CM |
| F13.24 | Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced mood disorder | Diagnosis | ICD-10-CM |
| F13.250 | Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F13.251 | Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F13.259 | Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F13.26 | Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting amnesic disorder | Diagnosis | ICD-10-CM |
| F13.27 | Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting dementia | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| F13.280 | Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F13.281 | Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F13.282 | Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sleep disorder | Diagnosis | ICD-10-CM |
| F13.288 | Sedative, hypnotic or anxiolytic dependence with other sedative, hypnotic or anxiolytic-induced disorder | Diagnosis | ICD-10-CM |
| F13.29 | Sedative, hypnotic or anxiolytic dependence with unspecified sedative, hypnotic or anxiolytic-induced disorder | Diagnosis | ICD-10-CM |
| F13.90 | Sedative, hypnotic, or anxiolytic use, unspecified, uncomplicated | Diagnosis | ICD-10-CM |
| F13.920 | Sedative, hypnotic or anxiolytic use, unspecified with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F13.921 | Sedative, hypnotic or anxiolytic use, unspecified with intoxication delirium | Diagnosis | ICD-10-CM |
| F13.929 | Sedative, hypnotic or anxiolytic use, unspecified with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F13.930 | Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, uncomplicated | Diagnosis | ICD-10-CM |
| F13.931 | Sedative, hypnotic or anxiolytic use, unspecified with withdrawal delirium | Diagnosis | ICD-10-CM |
| F13.932 | Sedative, hypnotic or anxiolytic use, unspecified with withdrawal with perceptual disturbances | Diagnosis | ICD-10-CM |
| F13.939 | Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, unspecified | Diagnosis | ICD-10-CM |
| F13.94 | Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced mood disorder | Diagnosis | ICD-10-CM |
| F13.950 | Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F13.951 | Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F13.959 | Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F13.96 | Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting amnesic disorder | Diagnosis | ICD-10-CM |
| F13.97 | Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting dementia | Diagnosis | ICD-10-CM |
| F13.980 | Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F13.981 | Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F13.982 | Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sleep disorder | Diagnosis | ICD-10-CM |
| F13.988 | Sedative, hypnotic or anxiolytic use, unspecified with other sedative, hypnotic or anxiolytic-induced disorder | Diagnosis | ICD-10-CM |
| F13.99 | Sedative, hypnotic or anxiolytic use, unspecified with unspecified sedative, hypnotic or anxiolytic-induced disorder | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|-------------|--|----------------------|------------------|
| F14.10 | Cocaine abuse, uncomplicated | Diagnosis | ICD-10-CM |
| F14.11 | Cocaine abuse, in remission | Diagnosis | ICD-10-CM |
| F14.120 | Cocaine abuse with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F14.121 | Cocaine abuse with intoxication with delirium | Diagnosis | ICD-10-CM |
| F14.122 | Cocaine abuse with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F14.129 | Cocaine abuse with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F14.13 | Cocaine abuse, unspecified with withdrawal | Diagnosis | ICD-10-CM |
| F14.14 | Cocaine abuse with cocaine-induced mood disorder | Diagnosis | ICD-10-CM |
| F14.150 | Cocaine abuse with cocaine-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F14.151 | Cocaine abuse with cocaine-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F14.159 | Cocaine abuse with cocaine-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F14.180 | Cocaine abuse with cocaine-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F14.181 | Cocaine abuse with cocaine-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F14.182 | Cocaine abuse with cocaine-induced sleep disorder | Diagnosis | ICD-10-CM |
| F14.188 | Cocaine abuse with other cocaine-induced disorder | Diagnosis | ICD-10-CM |
| F14.19 | Cocaine abuse with unspecified cocaine-induced disorder | Diagnosis | ICD-10-CM |
| F14.20 | Cocaine dependence, uncomplicated | Diagnosis | ICD-10-CM |
| F14.220 | Cocaine dependence with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F14.221 | Cocaine dependence with intoxication delirium | Diagnosis | ICD-10-CM |
| F14.222 | Cocaine dependence with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F14.229 | Cocaine dependence with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F14.23 | Cocaine dependence with withdrawal | Diagnosis | ICD-10-CM |
| F14.24 | Cocaine dependence with cocaine-induced mood disorder | Diagnosis | ICD-10-CM |
| F14.250 | Cocaine dependence with cocaine-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F14.251 | Cocaine dependence with cocaine-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F14.259 | Cocaine dependence with cocaine-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F14.280 | Cocaine dependence with cocaine-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F14.281 | Cocaine dependence with cocaine-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F14.282 | Cocaine dependence with cocaine-induced sleep disorder | Diagnosis | ICD-10-CM |
| F14.288 | Cocaine dependence with other cocaine-induced disorder | Diagnosis | ICD-10-CM |
| F14.29 | Cocaine dependence with unspecified cocaine-induced disorder | Diagnosis | ICD-10-CM |
| F14.90 | Cocaine use, unspecified, uncomplicated | Diagnosis | ICD-10-CM |
| F14.920 | Cocaine use, unspecified with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F14.921 | Cocaine use, unspecified with intoxication delirium | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|-------------|--|----------------------|------------------|
| F14.922 | Cocaine use, unspecified with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F14.929 | Cocaine use, unspecified with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F14.93 | Cocaine use, unspecified with withdrawal | Diagnosis | ICD-10-CM |
| F14.94 | Cocaine use, unspecified with cocaine-induced mood disorder | Diagnosis | ICD-10-CM |
| F14.950 | Cocaine use, unspecified with cocaine-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F14.951 | Cocaine use, unspecified with cocaine-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F14.959 | Cocaine use, unspecified with cocaine-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F14.980 | Cocaine use, unspecified with cocaine-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F14.981 | Cocaine use, unspecified with cocaine-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F14.982 | Cocaine use, unspecified with cocaine-induced sleep disorder | Diagnosis | ICD-10-CM |
| F14.988 | Cocaine use, unspecified with other cocaine-induced disorder | Diagnosis | ICD-10-CM |
| F14.99 | Cocaine use, unspecified with unspecified cocaine-induced disorder | Diagnosis | ICD-10-CM |
| F15.10 | Other stimulant abuse, uncomplicated | Diagnosis | ICD-10-CM |
| F15.11 | Other stimulant abuse, in remission | Diagnosis | ICD-10-CM |
| F15.120 | Other stimulant abuse with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F15.121 | Other stimulant abuse with intoxication delirium | Diagnosis | ICD-10-CM |
| F15.122 | Other stimulant abuse with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F15.129 | Other stimulant abuse with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F15.13 | Other stimulant abuse with withdrawal | Diagnosis | ICD-10-CM |
| F15.14 | Other stimulant abuse with stimulant-induced mood disorder | Diagnosis | ICD-10-CM |
| F15.150 | Other stimulant abuse with stimulant-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F15.151 | Other stimulant abuse with stimulant-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F15.159 | Other stimulant abuse with stimulant-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F15.180 | Other stimulant abuse with stimulant-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F15.181 | Other stimulant abuse with stimulant-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F15.182 | Other stimulant abuse with stimulant-induced sleep disorder | Diagnosis | ICD-10-CM |
| F15.188 | Other stimulant abuse with other stimulant-induced disorder | Diagnosis | ICD-10-CM |
| F15.19 | Other stimulant abuse with unspecified stimulant-induced disorder | Diagnosis | ICD-10-CM |
| F15.20 | Other stimulant dependence, uncomplicated | Diagnosis | ICD-10-CM |
| F15.220 | Other stimulant dependence with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F15.221 | Other stimulant dependence with intoxication delirium | Diagnosis | ICD-10-CM |
| F15.222 | Other stimulant dependence with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F15.229 | Other stimulant dependence with intoxication, unspecified | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| F15.23 | Other stimulant dependence with withdrawal | Diagnosis | ICD-10-CM |
| F15.24 | Other stimulant dependence with stimulant-induced mood disorder | Diagnosis | ICD-10-CM |
| F15.250 | Other stimulant dependence with stimulant-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F15.251 | Other stimulant dependence with stimulant-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F15.259 | Other stimulant dependence with stimulant-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F15.280 | Other stimulant dependence with stimulant-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F15.281 | Other stimulant dependence with stimulant-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F15.282 | Other stimulant dependence with stimulant-induced sleep disorder | Diagnosis | ICD-10-CM |
| F15.288 | Other stimulant dependence with other stimulant-induced disorder | Diagnosis | ICD-10-CM |
| F15.29 | Other stimulant dependence with unspecified stimulant-induced disorder | Diagnosis | ICD-10-CM |
| F15.90 | Other stimulant use, unspecified, uncomplicated | Diagnosis | ICD-10-CM |
| F15.920 | Other stimulant use, unspecified with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F15.921 | Other stimulant use, unspecified with intoxication delirium | Diagnosis | ICD-10-CM |
| F15.922 | Other stimulant use, unspecified with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F15.929 | Other stimulant use, unspecified with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F15.93 | Other stimulant use, unspecified with withdrawal | Diagnosis | ICD-10-CM |
| F15.94 | Other stimulant use, unspecified with stimulant-induced mood disorder | Diagnosis | ICD-10-CM |
| F15.950 | Other stimulant use, unspecified with stimulant-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F15.951 | Other stimulant use, unspecified with stimulant-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F15.959 | Other stimulant use, unspecified with stimulant-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F15.980 | Other stimulant use, unspecified with stimulant-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F15.981 | Other stimulant use, unspecified with stimulant-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F15.982 | Other stimulant use, unspecified with stimulant-induced sleep disorder | Diagnosis | ICD-10-CM |
| F15.988 | Other stimulant use, unspecified with other stimulant-induced disorder | Diagnosis | ICD-10-CM |
| F15.99 | Other stimulant use, unspecified with unspecified stimulant-induced disorder | Diagnosis | ICD-10-CM |
| F16.10 | Hallucinogen abuse, uncomplicated | Diagnosis | ICD-10-CM |
| F16.11 | Hallucinogen abuse, in remission | Diagnosis | ICD-10-CM |
| F16.120 | Hallucinogen abuse with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F16.121 | Hallucinogen abuse with intoxication with delirium | Diagnosis | ICD-10-CM |
| F16.122 | Hallucinogen abuse with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F16.129 | Hallucinogen abuse with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F16.14 | Hallucinogen abuse with hallucinogen-induced mood disorder | Diagnosis | ICD-10-CM |
| F16.150 | Hallucinogen abuse with hallucinogen-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| F16.151 | Hallucinogen abuse with hallucinogen-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F16.159 | Hallucinogen abuse with hallucinogen-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F16.180 | Hallucinogen abuse with hallucinogen-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F16.183 | Hallucinogen abuse with hallucinogen persisting perception disorder (flashbacks) | Diagnosis | ICD-10-CM |
| F16.188 | Hallucinogen abuse with other hallucinogen-induced disorder | Diagnosis | ICD-10-CM |
| F16.19 | Hallucinogen abuse with unspecified hallucinogen-induced disorder | Diagnosis | ICD-10-CM |
| F16.20 | Hallucinogen dependence, uncomplicated | Diagnosis | ICD-10-CM |
| F16.220 | Hallucinogen dependence with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F16.221 | Hallucinogen dependence with intoxication with delirium | Diagnosis | ICD-10-CM |
| F16.229 | Hallucinogen dependence with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F16.24 | Hallucinogen dependence with hallucinogen-induced mood disorder | Diagnosis | ICD-10-CM |
| F16.250 | Hallucinogen dependence with hallucinogen-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F16.251 | Hallucinogen dependence with hallucinogen-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F16.259 | Hallucinogen dependence with hallucinogen-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F16.280 | Hallucinogen dependence with hallucinogen-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F16.283 | Hallucinogen dependence with hallucinogen persisting perception disorder (flashbacks) | Diagnosis | ICD-10-CM |
| F16.288 | Hallucinogen dependence with other hallucinogen-induced disorder | Diagnosis | ICD-10-CM |
| F16.29 | Hallucinogen dependence with unspecified hallucinogen-induced disorder | Diagnosis | ICD-10-CM |
| F16.90 | Hallucinogen use, unspecified, uncomplicated | Diagnosis | ICD-10-CM |
| F16.920 | Hallucinogen use, unspecified with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F16.921 | Hallucinogen use, unspecified with intoxication with delirium | Diagnosis | ICD-10-CM |
| F16.929 | Hallucinogen use, unspecified with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F16.94 | Hallucinogen use, unspecified with hallucinogen-induced mood disorder | Diagnosis | ICD-10-CM |
| F16.950 | Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F16.951 | Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F16.959 | Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F16.980 | Hallucinogen use, unspecified with hallucinogen-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F16.983 | Hallucinogen use, unspecified with hallucinogen persisting perception disorder (flashbacks) | Diagnosis | ICD-10-CM |
| F16.988 | Hallucinogen use, unspecified with other hallucinogen-induced disorder | Diagnosis | ICD-10-CM |
| F16.99 | Hallucinogen use, unspecified with unspecified hallucinogen-induced disorder | Diagnosis | ICD-10-CM |
| F18.10 | Inhalant abuse, uncomplicated | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| F18.11 | Inhalant abuse, in remission | Diagnosis | ICD-10-CM |
| F18.120 | Inhalant abuse with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F18.121 | Inhalant abuse with intoxication delirium | Diagnosis | ICD-10-CM |
| F18.129 | Inhalant abuse with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F18.14 | Inhalant abuse with inhalant-induced mood disorder | Diagnosis | ICD-10-CM |
| F18.150 | Inhalant abuse with inhalant-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F18.151 | Inhalant abuse with inhalant-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F18.159 | Inhalant abuse with inhalant-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F18.17 | Inhalant abuse with inhalant-induced dementia | Diagnosis | ICD-10-CM |
| F18.180 | Inhalant abuse with inhalant-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F18.188 | Inhalant abuse with other inhalant-induced disorder | Diagnosis | ICD-10-CM |
| F18.19 | Inhalant abuse with unspecified inhalant-induced disorder | Diagnosis | ICD-10-CM |
| F18.20 | Inhalant dependence, uncomplicated | Diagnosis | ICD-10-CM |
| F18.220 | Inhalant dependence with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F18.221 | Inhalant dependence with intoxication delirium | Diagnosis | ICD-10-CM |
| F18.229 | Inhalant dependence with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F18.24 | Inhalant dependence with inhalant-induced mood disorder | Diagnosis | ICD-10-CM |
| F18.250 | Inhalant dependence with inhalant-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F18.251 | Inhalant dependence with inhalant-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F18.259 | Inhalant dependence with inhalant-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F18.27 | Inhalant dependence with inhalant-induced dementia | Diagnosis | ICD-10-CM |
| F18.280 | Inhalant dependence with inhalant-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F18.288 | Inhalant dependence with other inhalant-induced disorder | Diagnosis | ICD-10-CM |
| F18.29 | Inhalant dependence with unspecified inhalant-induced disorder | Diagnosis | ICD-10-CM |
| F18.90 | Inhalant use, unspecified, uncomplicated | Diagnosis | ICD-10-CM |
| F18.920 | Inhalant use, unspecified with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F18.921 | Inhalant use, unspecified with intoxication with delirium | Diagnosis | ICD-10-CM |
| F18.929 | Inhalant use, unspecified with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F18.94 | Inhalant use, unspecified with inhalant-induced mood disorder | Diagnosis | ICD-10-CM |
| F18.950 | Inhalant use, unspecified with inhalant-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F18.951 | Inhalant use, unspecified with inhalant-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F18.959 | Inhalant use, unspecified with inhalant-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F18.97 | Inhalant use, unspecified with inhalant-induced persisting dementia | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|---|---------------|-----------|
| F18.980 | Inhalant use, unspecified with inhalant-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F18.988 | Inhalant use, unspecified with other inhalant-induced disorder | Diagnosis | ICD-10-CM |
| F18.99 | Inhalant use, unspecified with unspecified inhalant-induced disorder | Diagnosis | ICD-10-CM |
| F19.10 | Other psychoactive substance abuse, uncomplicated | Diagnosis | ICD-10-CM |
| F19.11 | Other psychoactive substance abuse, in remission | Diagnosis | ICD-10-CM |
| F19.120 | Other psychoactive substance abuse with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F19.121 | Other psychoactive substance abuse with intoxication delirium | Diagnosis | ICD-10-CM |
| F19.122 | Other psychoactive substance abuse with intoxication with perceptual disturbances | Diagnosis | ICD-10-CM |
| F19.129 | Other psychoactive substance abuse with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F19.130 | Other psychoactive substance abuse with withdrawal, uncomplicated | Diagnosis | ICD-10-CM |
| F19.131 | Other psychoactive substance abuse with withdrawal delirium | Diagnosis | ICD-10-CM |
| F19.132 | Other psychoactive substance abuse with withdrawal with perceptual disturbance | Diagnosis | ICD-10-CM |
| F19.139 | Other psychoactive substance abuse with withdrawal, unspecified | Diagnosis | ICD-10-CM |
| F19.14 | Other psychoactive substance abuse with psychoactive substance-induced mood disorder | Diagnosis | ICD-10-CM |
| F19.150 | Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F19.151 | Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F19.159 | Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F19.16 | Other psychoactive substance abuse with psychoactive substance-induced persisting amnesic disorder | Diagnosis | ICD-10-CM |
| F19.17 | Other psychoactive substance abuse with psychoactive substance-induced persisting dementia | Diagnosis | ICD-10-CM |
| F19.180 | Other psychoactive substance abuse with psychoactive substance-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F19.181 | Other psychoactive substance abuse with psychoactive substance-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F19.182 | Other psychoactive substance abuse with psychoactive substance-induced sleep disorder | Diagnosis | ICD-10-CM |
| F19.188 | Other psychoactive substance abuse with other psychoactive substance-induced disorder | Diagnosis | ICD-10-CM |
| F19.19 | Other psychoactive substance abuse with unspecified psychoactive substance-induced disorder | Diagnosis | ICD-10-CM |
| F19.20 | Other psychoactive substance dependence, uncomplicated | Diagnosis | ICD-10-CM |
| F19.21 | Other psychoactive substance dependence, in remission | Diagnosis | ICD-10-CM |
| F19.220 | Other psychoactive substance dependence with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F19.221 | Other psychoactive substance dependence with intoxication delirium | Diagnosis | ICD-10-CM |
| F19.222 | Other psychoactive substance dependence with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| F19.229 | Other psychoactive substance dependence with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F19.230 | Other psychoactive substance dependence with withdrawal, uncomplicated | Diagnosis | ICD-10-CM |
| F19.231 | Other psychoactive substance dependence with withdrawal delirium | Diagnosis | ICD-10-CM |
| F19.232 | Other psychoactive substance dependence with withdrawal with perceptual disturbance | Diagnosis | ICD-10-CM |
| F19.239 | Other psychoactive substance dependence with withdrawal, unspecified | Diagnosis | ICD-10-CM |
| F19.24 | Other psychoactive substance dependence with psychoactive substance-induced mood disorder | Diagnosis | ICD-10-CM |
| F19.250 | Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F19.251 | Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F19.259 | Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F19.26 | Other psychoactive substance dependence with psychoactive substance-induced persisting amnesic disorder | Diagnosis | ICD-10-CM |
| F19.27 | Other psychoactive substance dependence with psychoactive substance-induced persisting dementia | Diagnosis | ICD-10-CM |
| F19.280 | Other psychoactive substance dependence with psychoactive substance-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F19.281 | Other psychoactive substance dependence with psychoactive substance-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F19.282 | Other psychoactive substance dependence with psychoactive substance-induced sleep disorder | Diagnosis | ICD-10-CM |
| F19.288 | Other psychoactive substance dependence with other psychoactive substance-induced disorder | Diagnosis | ICD-10-CM |
| F19.29 | Other psychoactive substance dependence with unspecified psychoactive substance-induced disorder | Diagnosis | ICD-10-CM |
| F19.90 | Other psychoactive substance use, unspecified, uncomplicated | Diagnosis | ICD-10-CM |
| F19.920 | Other psychoactive substance use, unspecified with intoxication, uncomplicated | Diagnosis | ICD-10-CM |
| F19.921 | Other psychoactive substance use, unspecified with intoxication with delirium | Diagnosis | ICD-10-CM |
| F19.922 | Other psychoactive substance use, unspecified with intoxication with perceptual disturbance | Diagnosis | ICD-10-CM |
| F19.929 | Other psychoactive substance use, unspecified with intoxication, unspecified | Diagnosis | ICD-10-CM |
| F19.930 | Other psychoactive substance use, unspecified with withdrawal, uncomplicated | Diagnosis | ICD-10-CM |
| F19.931 | Other psychoactive substance use, unspecified with withdrawal delirium | Diagnosis | ICD-10-CM |
| F19.932 | Other psychoactive substance use, unspecified with withdrawal with perceptual disturbance | Diagnosis | ICD-10-CM |
| F19.939 | Other psychoactive substance use, unspecified with withdrawal, unspecified | Diagnosis | ICD-10-CM |
| F19.94 | Other psychoactive substance use, unspecified with psychoactive substance-induced mood disorder | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|--|---------------|------------|
| F19.950 | Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with delusions | Diagnosis | ICD-10-CM |
| F19.951 | Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with hallucinations | Diagnosis | ICD-10-CM |
| F19.959 | Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder, unspecified | Diagnosis | ICD-10-CM |
| F19.96 | Other psychoactive substance use, unspecified with psychoactive substance-induced persisting amnestic disorder | Diagnosis | ICD-10-CM |
| F19.97 | Other psychoactive substance use, unspecified with psychoactive substance-induced persisting dementia | Diagnosis | ICD-10-CM |
| F19.980 | Other psychoactive substance use, unspecified with psychoactive substance-induced anxiety disorder | Diagnosis | ICD-10-CM |
| F19.981 | Other psychoactive substance use, unspecified with psychoactive substance-induced sexual dysfunction | Diagnosis | ICD-10-CM |
| F19.982 | Other psychoactive substance use, unspecified with psychoactive substance-induced sleep disorder | Diagnosis | ICD-10-CM |
| F19.988 | Other psychoactive substance use, unspecified with other psychoactive substance-induced disorder | Diagnosis | ICD-10-CM |
| F19.99 | Other psychoactive substance use, unspecified with unspecified psychoactive substance-induced disorder | Diagnosis | ICD-10-CM |
| HZ2ZZZZ | Detoxification Services for Substance Abuse Treatment | Procedure | ICD-10-PCS |
| HZ30ZZZ | Individual Counseling for Substance Abuse Treatment, Cognitive | Procedure | ICD-10-PCS |
| HZ31ZZZ | Individual Counseling for Substance Abuse Treatment, Behavioral | Procedure | ICD-10-PCS |
| HZ32ZZZ | Individual Counseling for Substance Abuse Treatment, Cognitive-Behavioral | Procedure | ICD-10-PCS |
| HZ33ZZZ | Individual Counseling for Substance Abuse Treatment, 12-Step | Procedure | ICD-10-PCS |
| HZ34ZZZ | Individual Counseling for Substance Abuse Treatment, Interpersonal | Procedure | ICD-10-PCS |
| HZ35ZZZ | Individual Counseling for Substance Abuse Treatment, Vocational | Procedure | ICD-10-PCS |
| HZ36ZZZ | Individual Counseling for Substance Abuse Treatment, Psychoeducation | Procedure | ICD-10-PCS |
| HZ37ZZZ | Individual Counseling for Substance Abuse Treatment, Motivational Enhancement | Procedure | ICD-10-PCS |
| HZ38ZZZ | Individual Counseling for Substance Abuse Treatment, Confrontational | Procedure | ICD-10-PCS |
| HZ39ZZZ | Individual Counseling for Substance Abuse Treatment, Continuing Care | Procedure | ICD-10-PCS |
| HZ3BZZZ | Individual Counseling for Substance Abuse Treatment, Spiritual | Procedure | ICD-10-PCS |
| HZ40ZZZ | Group Counseling for Substance Abuse Treatment, Cognitive | Procedure | ICD-10-PCS |
| HZ41ZZZ | Group Counseling for Substance Abuse Treatment, Behavioral | Procedure | ICD-10-PCS |
| HZ42ZZZ | Group Counseling for Substance Abuse Treatment, Cognitive-Behavioral | Procedure | ICD-10-PCS |
| HZ43ZZZ | Group Counseling for Substance Abuse Treatment, 12-Step | Procedure | ICD-10-PCS |
| HZ44ZZZ | Group Counseling for Substance Abuse Treatment, Interpersonal | Procedure | ICD-10-PCS |
| HZ45ZZZ | Group Counseling for Substance Abuse Treatment, Vocational | Procedure | ICD-10-PCS |
| HZ46ZZZ | Group Counseling for Substance Abuse Treatment, Psychoeducation | Procedure | ICD-10-PCS |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|----------|---|---------------|------------|
| HZ47ZZZ | Group Counseling for Substance Abuse Treatment, Motivational Enhancement | Procedure | ICD-10-PCS |
| HZ48ZZZ | Group Counseling for Substance Abuse Treatment, Confrontational | Procedure | ICD-10-PCS |
| HZ49ZZZ | Group Counseling for Substance Abuse Treatment, Continuing Care | Procedure | ICD-10-PCS |
| HZ4BZZZ | Group Counseling for Substance Abuse Treatment, Spiritual | Procedure | ICD-10-PCS |
| HZ50ZZZ | Individual Psychotherapy for Substance Abuse Treatment, Cognitive | Procedure | ICD-10-PCS |
| HZ51ZZZ | Individual Psychotherapy for Substance Abuse Treatment, Behavioral | Procedure | ICD-10-PCS |
| HZ52ZZZ | Individual Psychotherapy for Substance Abuse Treatment, Cognitive-Behavioral | Procedure | ICD-10-PCS |
| HZ53ZZZ | Individual Psychotherapy for Substance Abuse Treatment, 12-Step | Procedure | ICD-10-PCS |
| HZ54ZZZ | Individual Psychotherapy for Substance Abuse Treatment, Interpersonal | Procedure | ICD-10-PCS |
| HZ55ZZZ | Individual Psychotherapy for Substance Abuse Treatment, Interactive | Procedure | ICD-10-PCS |
| HZ56ZZZ | Individual Psychotherapy for Substance Abuse Treatment, Psychoeducation | Procedure | ICD-10-PCS |
| HZ57ZZZ | Individual Psychotherapy for Substance Abuse Treatment, Motivational Enhancement | Procedure | ICD-10-PCS |
| HZ58ZZZ | Individual Psychotherapy for Substance Abuse Treatment, Confrontational | Procedure | ICD-10-PCS |
| HZ59ZZZ | Individual Psychotherapy for Substance Abuse Treatment, Supportive | Procedure | ICD-10-PCS |
| HZ5BZZZ | Individual Psychotherapy for Substance Abuse Treatment, Psychoanalysis | Procedure | ICD-10-PCS |
| HZ5CZZZ | Individual Psychotherapy for Substance Abuse Treatment, Psychodynamic | Procedure | ICD-10-PCS |
| HZ5DZZZ | Individual Psychotherapy for Substance Abuse Treatment, Psychophysiological | Procedure | ICD-10-PCS |
| HZ63ZZZ | Family Counseling for Substance Abuse Treatment | Procedure | ICD-10-PCS |
| HZ83ZZZ | Medication Management for Substance Abuse Treatment, Antabuse | Procedure | ICD-10-PCS |
| HZ86ZZZ | Medication Management for Substance Abuse Treatment, Clonidine | Procedure | ICD-10-PCS |
| HZ88ZZZ | Medication Management for Substance Abuse Treatment, Psychiatric Medication | Procedure | ICD-10-PCS |
| HZ89ZZZ | Medication Management for Substance Abuse Treatment, Other Replacement Medication | Procedure | ICD-10-PCS |
| HZ93ZZZ | Pharmacotherapy for Substance Abuse Treatment, Antabuse | Procedure | ICD-10-PCS |
| HZ96ZZZ | Pharmacotherapy for Substance Abuse Treatment, Clonidine | Procedure | ICD-10-PCS |
| HZ98ZZZ | Pharmacotherapy for Substance Abuse Treatment, Psychiatric Medication | Procedure | ICD-10-PCS |
| HZ99ZZZ | Pharmacotherapy for Substance Abuse Treatment, Other Replacement Medication | Procedure | ICD-10-PCS |
| O35.5XX0 | Maternal care for (suspected) damage to fetus by drugs, not applicable or unspecified | Diagnosis | ICD-10-CM |
| O35.5XX1 | Maternal care for (suspected) damage to fetus by drugs, fetus 1 | Diagnosis | ICD-10-CM |
| O35.5XX2 | Maternal care for (suspected) damage to fetus by drugs, fetus 2 | Diagnosis | ICD-10-CM |
| O35.5XX3 | Maternal care for (suspected) damage to fetus by drugs, fetus 3 | Diagnosis | ICD-10-CM |
| O35.5XX4 | Maternal care for (suspected) damage to fetus by drugs, fetus 4 | Diagnosis | ICD-10-CM |
| O35.5XX5 | Maternal care for (suspected) damage to fetus by drugs, fetus 5 | Diagnosis | ICD-10-CM |
| O35.5XX9 | Maternal care for (suspected) damage to fetus by drugs, other fetus | Diagnosis | ICD-10-CM |
| T40.0X1A | Poisoning by opium, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| T40.0X2A | Poisoning by opium, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.0X3A | Poisoning by opium, assault, initial encounter | Diagnosis | ICD-10-CM |
| T40.0X4A | Poisoning by opium, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T40.0X5A | Adverse effect of opium, initial encounter | Diagnosis | ICD-10-CM |
| T40.0X5S | Adverse effect of opium, sequela | Diagnosis | ICD-10-CM |
| T40.1X1A | Poisoning by heroin, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T40.1X2A | Poisoning by heroin, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.1X3A | Poisoning by heroin, assault, initial encounter | Diagnosis | ICD-10-CM |
| T40.1X4A | Poisoning by heroin, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T40.2X1A | Poisoning by other opioids, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T40.2X2A | Poisoning by other opioids, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.2X3A | Poisoning by other opioids, assault, initial encounter | Diagnosis | ICD-10-CM |
| T40.2X4A | Poisoning by other opioids, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T40.3X1A | Poisoning by methadone, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T40.3X2A | Poisoning by methadone, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.3X3A | Poisoning by methadone, assault, initial encounter | Diagnosis | ICD-10-CM |
| T40.3X4A | Poisoning by methadone, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T40.3X5A | Adverse effect of methadone, initial encounter | Diagnosis | ICD-10-CM |
| T40.3X5S | Adverse effect of methadone, sequela | Diagnosis | ICD-10-CM |
| T40.411A | Poisoning by fentanyl or fentanyl analogs, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T40.412A | Poisoning by fentanyl or fentanyl analogs, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.413A | Poisoning by fentanyl or fentanyl analogs, assault, initial encounter | Diagnosis | ICD-10-CM |
| T40.414A | Poisoning by fentanyl or fentanyl analogs, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T40.415A | Adverse effect of fentanyl or fentanyl analogs, initial encounter | Diagnosis | ICD-10-CM |
| T40.421A | Poisoning by tramadol, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T40.422A | Poisoning by tramadol, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.423A | Poisoning by tramadol, assault, initial encounter | Diagnosis | ICD-10-CM |
| T40.424A | Poisoning by tramadol, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T40.425A | Adverse effect of tramadol, initial encounter | Diagnosis | ICD-10-CM |
| T40.491A | Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T40.492A | Poisoning by other synthetic narcotics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.493A | Poisoning by other synthetic narcotics, assault, initial encounter | Diagnosis | ICD-10-CM |
| T40.494A | Poisoning by other synthetic narcotics, undetermined, initial encounter | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------------------------|--|---------------|-----------|
| T40.495A | Adverse effect of other synthetic narcotics, initial encounter | Diagnosis | ICD-10-CM |
| T40.4X1A | Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T40.4X2A | Poisoning by other synthetic narcotics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.4X3A | Poisoning by other synthetic narcotics, assault, initial encounter | Diagnosis | ICD-10-CM |
| T40.4X4A | Poisoning by other synthetic narcotics, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T40.601A | Poisoning by unspecified narcotics, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T40.602A | Poisoning by unspecified narcotics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.603A | Poisoning by unspecified narcotics, assault, initial encounter | Diagnosis | ICD-10-CM |
| T40.604A | Poisoning by unspecified narcotics, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T40.691A | Poisoning by other narcotics, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T40.692A | Poisoning by other narcotics, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T40.693A | Poisoning by other narcotics, assault, initial encounter | Diagnosis | ICD-10-CM |
| T40.694A | Poisoning by other narcotics, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| T40.711A | Poisoning by cannabis, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T40.721A | Poisoning by synthetic cannabinoids, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T40.7X1A | Poisoning by cannabis (derivatives), accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T40.8X1A | Poisoning by lysergide [LSD], accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T40.901A | Poisoning by unspecified psychodysleptics [hallucinogens], accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T40.991A | Poisoning by other psychodysleptics [hallucinogens], accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| V65.42 | Counseling on substance use and abuse | Diagnosis | ICD-9-CM |
| Z71.51 | Drug abuse counseling and surveillance of drug abuser | Diagnosis | ICD-10-CM |
| Endometrial Cancer | | | |
| 182.0 | Malignant neoplasm of corpus uteri, except isthmus | Diagnosis | ICD-9-CM |
| 233.2 | Carcinoma in situ of other and unspecified parts of uterus | Diagnosis | ICD-9-CM |
| C54.0 | Malignant neoplasm of isthmus uteri | Diagnosis | ICD-10-CM |
| C54.1 | Malignant neoplasm of endometrium | Diagnosis | ICD-10-CM |
| C54.2 | Malignant neoplasm of myometrium | Diagnosis | ICD-10-CM |
| C54.3 | Malignant neoplasm of fundus uteri | Diagnosis | ICD-10-CM |
| C54.8 | Malignant neoplasm of overlapping sites of corpus uteri | Diagnosis | ICD-10-CM |
| C54.9 | Malignant neoplasm of corpus uteri, unspecified | Diagnosis | ICD-10-CM |
| D07.0 | Carcinoma in situ of endometrium | Diagnosis | ICD-10-CM |
| V10.42 | Personal history of malignant neoplasm of other parts of uterus | Diagnosis | ICD-9-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|-----------------|--|---------------|-----------|
| Z85.42 | Personal history of malignant neoplasm of other parts of uterus | Diagnosis | ICD-10-CM |
| Glaucoma | | | |
| 365.00 | Unspecified preglaucoma | Diagnosis | ICD-9-CM |
| 365.01 | Borderline glaucoma, open angle with borderline findings, low risk | Diagnosis | ICD-9-CM |
| 365.02 | Borderline glaucoma with anatomical narrow angle | Diagnosis | ICD-9-CM |
| 365.03 | Borderline glaucoma with steroid responders | Diagnosis | ICD-9-CM |
| 365.04 | Borderline glaucoma with ocular hypertension | Diagnosis | ICD-9-CM |
| 365.10 | Unspecified open-angle glaucoma | Diagnosis | ICD-9-CM |
| 365.11 | Primary open-angle glaucoma | Diagnosis | ICD-9-CM |
| 365.12 | Low tension open-angle glaucoma | Diagnosis | ICD-9-CM |
| 365.13 | Pigmentary open-angle glaucoma | Diagnosis | ICD-9-CM |
| 365.15 | Residual stage of open angle glaucoma | Diagnosis | ICD-9-CM |
| 365.20 | Unspecified primary angle-closure glaucoma | Diagnosis | ICD-9-CM |
| 365.21 | Intermittent angle-closure glaucoma | Diagnosis | ICD-9-CM |
| 365.22 | Acute angle-closure glaucoma | Diagnosis | ICD-9-CM |
| 365.23 | Chronic angle-closure glaucoma | Diagnosis | ICD-9-CM |
| 365.24 | Residual stage of angle-closure glaucoma | Diagnosis | ICD-9-CM |
| 365.31 | Corticosteroid-induced glaucoma, glaucomatous stage | Diagnosis | ICD-9-CM |
| 365.32 | Corticosteroid-induced glaucoma, residual stage | Diagnosis | ICD-9-CM |
| 365.41 | Glaucoma associated with chamber angle anomalies | Diagnosis | ICD-9-CM |
| 365.42 | Glaucoma associated with anomalies of iris | Diagnosis | ICD-9-CM |
| 365.43 | Glaucoma associated with other anterior segment anomalies | Diagnosis | ICD-9-CM |
| 365.51 | Phacolytic glaucoma | Diagnosis | ICD-9-CM |
| 365.52 | Pseudoexfoliation glaucoma | Diagnosis | ICD-9-CM |
| 365.59 | Glaucoma associated with other lens disorders | Diagnosis | ICD-9-CM |
| 365.60 | Glaucoma associated with unspecified ocular disorder | Diagnosis | ICD-9-CM |
| 365.61 | Glaucoma associated with pupillary block | Diagnosis | ICD-9-CM |
| 365.62 | Glaucoma associated with ocular inflammations | Diagnosis | ICD-9-CM |
| 365.63 | Glaucoma associated with vascular disorders of eye | Diagnosis | ICD-9-CM |
| 365.64 | Glaucoma associated with tumors or cysts | Diagnosis | ICD-9-CM |
| 365.65 | Glaucoma associated with ocular trauma | Diagnosis | ICD-9-CM |
| 365.81 | Hypersecretion glaucoma | Diagnosis | ICD-9-CM |
| 365.82 | Glaucoma with increased episcleral venous pressure | Diagnosis | ICD-9-CM |
| 365.83 | Aqueous misdirection | Diagnosis | ICD-9-CM |
| 365.89 | Other specified glaucoma | Diagnosis | ICD-9-CM |
| 365.9 | Unspecified glaucoma | Diagnosis | ICD-9-CM |
| 377.14 | Glaucomatous atrophy (cupping) of optic disc | Diagnosis | ICD-9-CM |
| H40.001 | Preglaucoma, unspecified, right eye | Diagnosis | ICD-10-CM |
| H40.002 | Preglaucoma, unspecified, left eye | Diagnosis | ICD-10-CM |
| H40.003 | Preglaucoma, unspecified, bilateral | Diagnosis | ICD-10-CM |
| H40.009 | Preglaucoma, unspecified, unspecified eye | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| H40.011 | Open angle with borderline findings, low risk, right eye | Diagnosis | ICD-10-CM |
| H40.012 | Open angle with borderline findings, low risk, left eye | Diagnosis | ICD-10-CM |
| H40.013 | Open angle with borderline findings, low risk, bilateral | Diagnosis | ICD-10-CM |
| H40.019 | Open angle with borderline findings, low risk, unspecified eye | Diagnosis | ICD-10-CM |
| H40.021 | Open angle with borderline findings, high risk, right eye | Diagnosis | ICD-10-CM |
| H40.022 | Open angle with borderline findings, high risk, left eye | Diagnosis | ICD-10-CM |
| H40.023 | Open angle with borderline findings, high risk, bilateral | Diagnosis | ICD-10-CM |
| H40.029 | Open angle with borderline findings, high risk, unspecified eye | Diagnosis | ICD-10-CM |
| H40.031 | Anatomical narrow angle, right eye | Diagnosis | ICD-10-CM |
| H40.032 | Anatomical narrow angle, left eye | Diagnosis | ICD-10-CM |
| H40.033 | Anatomical narrow angle, bilateral | Diagnosis | ICD-10-CM |
| H40.039 | Anatomical narrow angle, unspecified eye | Diagnosis | ICD-10-CM |
| H40.041 | Steroid responder, right eye | Diagnosis | ICD-10-CM |
| H40.042 | Steroid responder, left eye | Diagnosis | ICD-10-CM |
| H40.043 | Steroid responder, bilateral | Diagnosis | ICD-10-CM |
| H40.049 | Steroid responder, unspecified eye | Diagnosis | ICD-10-CM |
| H40.051 | Ocular hypertension, right eye | Diagnosis | ICD-10-CM |
| H40.052 | Ocular hypertension, left eye | Diagnosis | ICD-10-CM |
| H40.053 | Ocular hypertension, bilateral | Diagnosis | ICD-10-CM |
| H40.059 | Ocular hypertension, unspecified eye | Diagnosis | ICD-10-CM |
| H40.10X0 | Unspecified open-angle glaucoma, stage unspecified | Diagnosis | ICD-10-CM |
| H40.10X1 | Unspecified open-angle glaucoma, mild stage | Diagnosis | ICD-10-CM |
| H40.10X2 | Unspecified open-angle glaucoma, moderate stage | Diagnosis | ICD-10-CM |
| H40.10X3 | Unspecified open-angle glaucoma, severe stage | Diagnosis | ICD-10-CM |
| H40.10X4 | Unspecified open-angle glaucoma, indeterminate stage | Diagnosis | ICD-10-CM |
| H40.1110 | Primary open-angle glaucoma, right eye, stage unspecified | Diagnosis | ICD-10-CM |
| H40.1111 | Primary open-angle glaucoma, right eye, mild stage | Diagnosis | ICD-10-CM |
| H40.1112 | Primary open-angle glaucoma, right eye, moderate stage | Diagnosis | ICD-10-CM |
| H40.1113 | Primary open-angle glaucoma, right eye, severe stage | Diagnosis | ICD-10-CM |
| H40.1114 | Primary open-angle glaucoma, right eye, indeterminate stage | Diagnosis | ICD-10-CM |
| H40.1120 | Primary open-angle glaucoma, left eye, stage unspecified | Diagnosis | ICD-10-CM |
| H40.1121 | Primary open-angle glaucoma, left eye, mild stage | Diagnosis | ICD-10-CM |
| H40.1122 | Primary open-angle glaucoma, left eye, moderate stage | Diagnosis | ICD-10-CM |
| H40.1123 | Primary open-angle glaucoma, left eye, severe stage | Diagnosis | ICD-10-CM |
| H40.1124 | Primary open-angle glaucoma, left eye, indeterminate stage | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| H40.1130 | Primary open-angle glaucoma, bilateral, stage unspecified | Diagnosis | ICD-10-CM |
| H40.1131 | Primary open-angle glaucoma, bilateral, mild stage | Diagnosis | ICD-10-CM |
| H40.1132 | Primary open-angle glaucoma, bilateral, moderate stage | Diagnosis | ICD-10-CM |
| H40.1133 | Primary open-angle glaucoma, bilateral, severe stage | Diagnosis | ICD-10-CM |
| H40.1134 | Primary open-angle glaucoma, bilateral, indeterminate stage | Diagnosis | ICD-10-CM |
| H40.1190 | Primary open-angle glaucoma, unspecified eye, stage unspecified | Diagnosis | ICD-10-CM |
| H40.1191 | Primary open-angle glaucoma, unspecified eye, mild stage | Diagnosis | ICD-10-CM |
| H40.1192 | Primary open-angle glaucoma, unspecified eye, moderate stage | Diagnosis | ICD-10-CM |
| H40.1193 | Primary open-angle glaucoma, unspecified eye, severe stage | Diagnosis | ICD-10-CM |
| H40.1194 | Primary open-angle glaucoma, unspecified eye, indeterminate stage | Diagnosis | ICD-10-CM |
| H40.11X0 | Primary open-angle glaucoma, stage unspecified | Diagnosis | ICD-10-CM |
| H40.11X1 | Primary open-angle glaucoma, mild stage | Diagnosis | ICD-10-CM |
| H40.11X2 | Primary open-angle glaucoma, moderate stage | Diagnosis | ICD-10-CM |
| H40.11X3 | Primary open-angle glaucoma, severe stage | Diagnosis | ICD-10-CM |
| H40.11X4 | Primary open-angle glaucoma, indeterminate stage | Diagnosis | ICD-10-CM |
| H40.1210 | Low-tension glaucoma, right eye, stage unspecified | Diagnosis | ICD-10-CM |
| H40.1211 | Low-tension glaucoma, right eye, mild stage | Diagnosis | ICD-10-CM |
| H40.1212 | Low-tension glaucoma, right eye, moderate stage | Diagnosis | ICD-10-CM |
| H40.1213 | Low-tension glaucoma, right eye, severe stage | Diagnosis | ICD-10-CM |
| H40.1214 | Low-tension glaucoma, right eye, indeterminate stage | Diagnosis | ICD-10-CM |
| H40.1220 | Low-tension glaucoma, left eye, stage unspecified | Diagnosis | ICD-10-CM |
| H40.1221 | Low-tension glaucoma, left eye, mild stage | Diagnosis | ICD-10-CM |
| H40.1222 | Low-tension glaucoma, left eye, moderate stage | Diagnosis | ICD-10-CM |
| H40.1223 | Low-tension glaucoma, left eye, severe stage | Diagnosis | ICD-10-CM |
| H40.1224 | Low-tension glaucoma, left eye, indeterminate stage | Diagnosis | ICD-10-CM |
| H40.1230 | Low-tension glaucoma, bilateral, stage unspecified | Diagnosis | ICD-10-CM |
| H40.1231 | Low-tension glaucoma, bilateral, mild stage | Diagnosis | ICD-10-CM |
| H40.1232 | Low-tension glaucoma, bilateral, moderate stage | Diagnosis | ICD-10-CM |
| H40.1233 | Low-tension glaucoma, bilateral, severe stage | Diagnosis | ICD-10-CM |
| H40.1234 | Low-tension glaucoma, bilateral, indeterminate stage | Diagnosis | ICD-10-CM |
| H40.1290 | Low-tension glaucoma, unspecified eye, stage unspecified | Diagnosis | ICD-10-CM |
| H40.1291 | Low-tension glaucoma, unspecified eye, mild stage | Diagnosis | ICD-10-CM |
| H40.1292 | Low-tension glaucoma, unspecified eye, moderate stage | Diagnosis | ICD-10-CM |
| H40.1293 | Low-tension glaucoma, unspecified eye, severe stage | Diagnosis | ICD-10-CM |
| H40.1294 | Low-tension glaucoma, unspecified eye, indeterminate stage | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| H40.1310 | Pigmentary glaucoma, right eye, stage unspecified | Diagnosis | ICD-10-CM |
| H40.1311 | Pigmentary glaucoma, right eye, mild stage | Diagnosis | ICD-10-CM |
| H40.1312 | Pigmentary glaucoma, right eye, moderate stage | Diagnosis | ICD-10-CM |
| H40.1313 | Pigmentary glaucoma, right eye, severe stage | Diagnosis | ICD-10-CM |
| H40.1314 | Pigmentary glaucoma, right eye, indeterminate stage | Diagnosis | ICD-10-CM |
| H40.1320 | Pigmentary glaucoma, left eye, stage unspecified | Diagnosis | ICD-10-CM |
| H40.1321 | Pigmentary glaucoma, left eye, mild stage | Diagnosis | ICD-10-CM |
| H40.1322 | Pigmentary glaucoma, left eye, moderate stage | Diagnosis | ICD-10-CM |
| H40.1323 | Pigmentary glaucoma, left eye, severe stage | Diagnosis | ICD-10-CM |
| H40.1324 | Pigmentary glaucoma, left eye, indeterminate stage | Diagnosis | ICD-10-CM |
| H40.1330 | Pigmentary glaucoma, bilateral, stage unspecified | Diagnosis | ICD-10-CM |
| H40.1331 | Pigmentary glaucoma, bilateral, mild stage | Diagnosis | ICD-10-CM |
| H40.1332 | Pigmentary glaucoma, bilateral, moderate stage | Diagnosis | ICD-10-CM |
| H40.1333 | Pigmentary glaucoma, bilateral, severe stage | Diagnosis | ICD-10-CM |
| H40.1334 | Pigmentary glaucoma, bilateral, indeterminate stage | Diagnosis | ICD-10-CM |
| H40.1390 | Pigmentary glaucoma, unspecified eye, stage unspecified | Diagnosis | ICD-10-CM |
| H40.1391 | Pigmentary glaucoma, unspecified eye, mild stage | Diagnosis | ICD-10-CM |
| H40.1392 | Pigmentary glaucoma, unspecified eye, moderate stage | Diagnosis | ICD-10-CM |
| H40.1393 | Pigmentary glaucoma, unspecified eye, severe stage | Diagnosis | ICD-10-CM |
| H40.1394 | Pigmentary glaucoma, unspecified eye, indeterminate stage | Diagnosis | ICD-10-CM |
| H40.1410 | Capsular glaucoma with pseudoexfoliation of lens, right eye, stage unspecified | Diagnosis | ICD-10-CM |
| H40.1411 | Capsular glaucoma with pseudoexfoliation of lens, right eye, mild stage | Diagnosis | ICD-10-CM |
| H40.1412 | Capsular glaucoma with pseudoexfoliation of lens, right eye, moderate stage | Diagnosis | ICD-10-CM |
| H40.1413 | Capsular glaucoma with pseudoexfoliation of lens, right eye, severe stage | Diagnosis | ICD-10-CM |
| H40.1414 | Capsular glaucoma with pseudoexfoliation of lens, right eye, indeterminate stage | Diagnosis | ICD-10-CM |
| H40.1420 | Capsular glaucoma with pseudoexfoliation of lens, left eye, stage unspecified | Diagnosis | ICD-10-CM |
| H40.1421 | Capsular glaucoma with pseudoexfoliation of lens, left eye, mild stage | Diagnosis | ICD-10-CM |
| H40.1422 | Capsular glaucoma with pseudoexfoliation of lens, left eye, moderate stage | Diagnosis | ICD-10-CM |
| H40.1423 | Capsular glaucoma with pseudoexfoliation of lens, left eye, severe stage | Diagnosis | ICD-10-CM |
| H40.1424 | Capsular glaucoma with pseudoexfoliation of lens, left eye, indeterminate stage | Diagnosis | ICD-10-CM |
| H40.1430 | Capsular glaucoma with pseudoexfoliation of lens, bilateral, stage unspecified | Diagnosis | ICD-10-CM |
| H40.1431 | Capsular glaucoma with pseudoexfoliation of lens, bilateral, mild stage | Diagnosis | ICD-10-CM |
| H40.1432 | Capsular glaucoma with pseudoexfoliation of lens, bilateral, moderate stage | Diagnosis | ICD-10-CM |
| H40.1433 | Capsular glaucoma with pseudoexfoliation of lens, bilateral, severe stage | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| H40.1434 | Capsular glaucoma with pseudoexfoliation of lens, bilateral, indeterminate stage | Diagnosis | ICD-10-CM |
| H40.1490 | Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, stage unspecified | Diagnosis | ICD-10-CM |
| H40.1491 | Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, mild stage | Diagnosis | ICD-10-CM |
| H40.1492 | Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, moderate stage | Diagnosis | ICD-10-CM |
| H40.1493 | Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, severe stage | Diagnosis | ICD-10-CM |
| H40.1494 | Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, indeterminate stage | Diagnosis | ICD-10-CM |
| H40.151 | Residual stage of open-angle glaucoma, right eye | Diagnosis | ICD-10-CM |
| H40.152 | Residual stage of open-angle glaucoma, left eye | Diagnosis | ICD-10-CM |
| H40.153 | Residual stage of open-angle glaucoma, bilateral | Diagnosis | ICD-10-CM |
| H40.159 | Residual stage of open-angle glaucoma, unspecified eye | Diagnosis | ICD-10-CM |
| H40.20X0 | Unspecified primary angle-closure glaucoma, stage unspecified | Diagnosis | ICD-10-CM |
| H40.20X1 | Unspecified primary angle-closure glaucoma, mild stage | Diagnosis | ICD-10-CM |
| H40.20X2 | Unspecified primary angle-closure glaucoma, moderate stage | Diagnosis | ICD-10-CM |
| H40.20X3 | Unspecified primary angle-closure glaucoma, severe stage | Diagnosis | ICD-10-CM |
| H40.20X4 | Unspecified primary angle-closure glaucoma, indeterminate stage | Diagnosis | ICD-10-CM |
| H40.211 | Acute angle-closure glaucoma, right eye | Diagnosis | ICD-10-CM |
| H40.212 | Acute angle-closure glaucoma, left eye | Diagnosis | ICD-10-CM |
| H40.213 | Acute angle-closure glaucoma, bilateral | Diagnosis | ICD-10-CM |
| H40.219 | Acute angle-closure glaucoma, unspecified eye | Diagnosis | ICD-10-CM |
| H40.2210 | Chronic angle-closure glaucoma, right eye, stage unspecified | Diagnosis | ICD-10-CM |
| H40.2211 | Chronic angle-closure glaucoma, right eye, mild stage | Diagnosis | ICD-10-CM |
| H40.2212 | Chronic angle-closure glaucoma, right eye, moderate stage | Diagnosis | ICD-10-CM |
| H40.2213 | Chronic angle-closure glaucoma, right eye, severe stage | Diagnosis | ICD-10-CM |
| H40.2214 | Chronic angle-closure glaucoma, right eye, indeterminate stage | Diagnosis | ICD-10-CM |
| H40.2220 | Chronic angle-closure glaucoma, left eye, stage unspecified | Diagnosis | ICD-10-CM |
| H40.2221 | Chronic angle-closure glaucoma, left eye, mild stage | Diagnosis | ICD-10-CM |
| H40.2222 | Chronic angle-closure glaucoma, left eye, moderate stage | Diagnosis | ICD-10-CM |
| H40.2223 | Chronic angle-closure glaucoma, left eye, severe stage | Diagnosis | ICD-10-CM |
| H40.2224 | Chronic angle-closure glaucoma, left eye, indeterminate stage | Diagnosis | ICD-10-CM |
| H40.2230 | Chronic angle-closure glaucoma, bilateral, stage unspecified | Diagnosis | ICD-10-CM |
| H40.2231 | Chronic angle-closure glaucoma, bilateral, mild stage | Diagnosis | ICD-10-CM |
| H40.2232 | Chronic angle-closure glaucoma, bilateral, moderate stage | Diagnosis | ICD-10-CM |
| H40.2233 | Chronic angle-closure glaucoma, bilateral, severe stage | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| H40.2234 | Chronic angle-closure glaucoma, bilateral, indeterminate stage | Diagnosis | ICD-10-CM |
| H40.2290 | Chronic angle-closure glaucoma, unspecified eye, stage unspecified | Diagnosis | ICD-10-CM |
| H40.2291 | Chronic angle-closure glaucoma, unspecified eye, mild stage | Diagnosis | ICD-10-CM |
| H40.2292 | Chronic angle-closure glaucoma, unspecified eye, moderate stage | Diagnosis | ICD-10-CM |
| H40.2293 | Chronic angle-closure glaucoma, unspecified eye, severe stage | Diagnosis | ICD-10-CM |
| H40.2294 | Chronic angle-closure glaucoma, unspecified eye, indeterminate stage | Diagnosis | ICD-10-CM |
| H40.231 | Intermittent angle-closure glaucoma, right eye | Diagnosis | ICD-10-CM |
| H40.232 | Intermittent angle-closure glaucoma, left eye | Diagnosis | ICD-10-CM |
| H40.233 | Intermittent angle-closure glaucoma, bilateral | Diagnosis | ICD-10-CM |
| H40.239 | Intermittent angle-closure glaucoma, unspecified eye | Diagnosis | ICD-10-CM |
| H40.241 | Residual stage of angle-closure glaucoma, right eye | Diagnosis | ICD-10-CM |
| H40.242 | Residual stage of angle-closure glaucoma, left eye | Diagnosis | ICD-10-CM |
| H40.243 | Residual stage of angle-closure glaucoma, bilateral | Diagnosis | ICD-10-CM |
| H40.249 | Residual stage of angle-closure glaucoma, unspecified eye | Diagnosis | ICD-10-CM |
| H40.30X0 | Glaucoma secondary to eye trauma, unspecified eye, stage unspecified | Diagnosis | ICD-10-CM |
| H40.30X1 | Glaucoma secondary to eye trauma, unspecified eye, mild stage | Diagnosis | ICD-10-CM |
| H40.30X2 | Glaucoma secondary to eye trauma, unspecified eye, moderate stage | Diagnosis | ICD-10-CM |
| H40.30X3 | Glaucoma secondary to eye trauma, unspecified eye, severe stage | Diagnosis | ICD-10-CM |
| H40.30X4 | Glaucoma secondary to eye trauma, unspecified eye, indeterminate stage | Diagnosis | ICD-10-CM |
| H40.31X0 | Glaucoma secondary to eye trauma, right eye, stage unspecified | Diagnosis | ICD-10-CM |
| H40.31X1 | Glaucoma secondary to eye trauma, right eye, mild stage | Diagnosis | ICD-10-CM |
| H40.31X2 | Glaucoma secondary to eye trauma, right eye, moderate stage | Diagnosis | ICD-10-CM |
| H40.31X3 | Glaucoma secondary to eye trauma, right eye, severe stage | Diagnosis | ICD-10-CM |
| H40.31X4 | Glaucoma secondary to eye trauma, right eye, indeterminate stage | Diagnosis | ICD-10-CM |
| H40.32X0 | Glaucoma secondary to eye trauma, left eye, stage unspecified | Diagnosis | ICD-10-CM |
| H40.32X1 | Glaucoma secondary to eye trauma, left eye, mild stage | Diagnosis | ICD-10-CM |
| H40.32X2 | Glaucoma secondary to eye trauma, left eye, moderate stage | Diagnosis | ICD-10-CM |
| H40.32X3 | Glaucoma secondary to eye trauma, left eye, severe stage | Diagnosis | ICD-10-CM |
| H40.32X4 | Glaucoma secondary to eye trauma, left eye, indeterminate stage | Diagnosis | ICD-10-CM |
| H40.33X0 | Glaucoma secondary to eye trauma, bilateral, stage unspecified | Diagnosis | ICD-10-CM |
| H40.33X1 | Glaucoma secondary to eye trauma, bilateral, mild stage | Diagnosis | ICD-10-CM |
| H40.33X2 | Glaucoma secondary to eye trauma, bilateral, moderate stage | Diagnosis | ICD-10-CM |
| H40.33X3 | Glaucoma secondary to eye trauma, bilateral, severe stage | Diagnosis | ICD-10-CM |
| H40.33X4 | Glaucoma secondary to eye trauma, bilateral, indeterminate stage | Diagnosis | ICD-10-CM |
| H40.40X0 | Glaucoma secondary to eye inflammation, unspecified eye, stage unspecified | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| H40.40X1 | Glaucoma secondary to eye inflammation, unspecified eye, mild stage | Diagnosis | ICD-10-CM |
| H40.40X2 | Glaucoma secondary to eye inflammation, unspecified eye, moderate stage | Diagnosis | ICD-10-CM |
| H40.40X3 | Glaucoma secondary to eye inflammation, unspecified eye, severe stage | Diagnosis | ICD-10-CM |
| H40.40X4 | Glaucoma secondary to eye inflammation, unspecified eye, indeterminate stage | Diagnosis | ICD-10-CM |
| H40.41X0 | Glaucoma secondary to eye inflammation, right eye, stage unspecified | Diagnosis | ICD-10-CM |
| H40.41X1 | Glaucoma secondary to eye inflammation, right eye, mild stage | Diagnosis | ICD-10-CM |
| H40.41X2 | Glaucoma secondary to eye inflammation, right eye, moderate stage | Diagnosis | ICD-10-CM |
| H40.41X3 | Glaucoma secondary to eye inflammation, right eye, severe stage | Diagnosis | ICD-10-CM |
| H40.41X4 | Glaucoma secondary to eye inflammation, right eye, indeterminate stage | Diagnosis | ICD-10-CM |
| H40.42X0 | Glaucoma secondary to eye inflammation, left eye, stage unspecified | Diagnosis | ICD-10-CM |
| H40.42X1 | Glaucoma secondary to eye inflammation, left eye, mild stage | Diagnosis | ICD-10-CM |
| H40.42X2 | Glaucoma secondary to eye inflammation, left eye, moderate stage | Diagnosis | ICD-10-CM |
| H40.42X3 | Glaucoma secondary to eye inflammation, left eye, severe stage | Diagnosis | ICD-10-CM |
| H40.42X4 | Glaucoma secondary to eye inflammation, left eye, indeterminate stage | Diagnosis | ICD-10-CM |
| H40.43X0 | Glaucoma secondary to eye inflammation, bilateral, stage unspecified | Diagnosis | ICD-10-CM |
| H40.43X1 | Glaucoma secondary to eye inflammation, bilateral, mild stage | Diagnosis | ICD-10-CM |
| H40.43X2 | Glaucoma secondary to eye inflammation, bilateral, moderate stage | Diagnosis | ICD-10-CM |
| H40.43X3 | Glaucoma secondary to eye inflammation, bilateral, severe stage | Diagnosis | ICD-10-CM |
| H40.43X4 | Glaucoma secondary to eye inflammation, bilateral, indeterminate stage | Diagnosis | ICD-10-CM |
| H40.50X0 | Glaucoma secondary to other eye disorders, unspecified eye, stage unspecified | Diagnosis | ICD-10-CM |
| H40.50X1 | Glaucoma secondary to other eye disorders, unspecified eye, mild stage | Diagnosis | ICD-10-CM |
| H40.50X2 | Glaucoma secondary to other eye disorders, unspecified eye, moderate stage | Diagnosis | ICD-10-CM |
| H40.50X3 | Glaucoma secondary to other eye disorders, unspecified eye, severe stage | Diagnosis | ICD-10-CM |
| H40.50X4 | Glaucoma secondary to other eye disorders, unspecified eye, indeterminate stage | Diagnosis | ICD-10-CM |
| H40.51X0 | Glaucoma secondary to other eye disorders, right eye, stage unspecified | Diagnosis | ICD-10-CM |
| H40.51X1 | Glaucoma secondary to other eye disorders, right eye, mild stage | Diagnosis | ICD-10-CM |
| H40.51X2 | Glaucoma secondary to other eye disorders, right eye, moderate stage | Diagnosis | ICD-10-CM |
| H40.51X3 | Glaucoma secondary to other eye disorders, right eye, severe stage | Diagnosis | ICD-10-CM |
| H40.51X4 | Glaucoma secondary to other eye disorders, right eye, indeterminate stage | Diagnosis | ICD-10-CM |
| H40.52X0 | Glaucoma secondary to other eye disorders, left eye, stage unspecified | Diagnosis | ICD-10-CM |
| H40.52X1 | Glaucoma secondary to other eye disorders, left eye, mild stage | Diagnosis | ICD-10-CM |
| H40.52X2 | Glaucoma secondary to other eye disorders, left eye, moderate stage | Diagnosis | ICD-10-CM |
| H40.52X3 | Glaucoma secondary to other eye disorders, left eye, severe stage | Diagnosis | ICD-10-CM |
| H40.52X4 | Glaucoma secondary to other eye disorders, left eye, indeterminate stage | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| H40.53X0 | Glaucoma secondary to other eye disorders, bilateral, stage unspecified | Diagnosis | ICD-10-CM |
| H40.53X1 | Glaucoma secondary to other eye disorders, bilateral, mild stage | Diagnosis | ICD-10-CM |
| H40.53X2 | Glaucoma secondary to other eye disorders, bilateral, moderate stage | Diagnosis | ICD-10-CM |
| H40.53X3 | Glaucoma secondary to other eye disorders, bilateral, severe stage | Diagnosis | ICD-10-CM |
| H40.53X4 | Glaucoma secondary to other eye disorders, bilateral, indeterminate stage | Diagnosis | ICD-10-CM |
| H40.60X0 | Glaucoma secondary to drugs, unspecified eye, stage unspecified | Diagnosis | ICD-10-CM |
| H40.60X1 | Glaucoma secondary to drugs, unspecified eye, mild stage | Diagnosis | ICD-10-CM |
| H40.60X2 | Glaucoma secondary to drugs, unspecified eye, moderate stage | Diagnosis | ICD-10-CM |
| H40.60X3 | Glaucoma secondary to drugs, unspecified eye, severe stage | Diagnosis | ICD-10-CM |
| H40.60X4 | Glaucoma secondary to drugs, unspecified eye, indeterminate stage | Diagnosis | ICD-10-CM |
| H40.61X0 | Glaucoma secondary to drugs, right eye, stage unspecified | Diagnosis | ICD-10-CM |
| H40.61X1 | Glaucoma secondary to drugs, right eye, mild stage | Diagnosis | ICD-10-CM |
| H40.61X2 | Glaucoma secondary to drugs, right eye, moderate stage | Diagnosis | ICD-10-CM |
| H40.61X3 | Glaucoma secondary to drugs, right eye, severe stage | Diagnosis | ICD-10-CM |
| H40.61X4 | Glaucoma secondary to drugs, right eye, indeterminate stage | Diagnosis | ICD-10-CM |
| H40.62X0 | Glaucoma secondary to drugs, left eye, stage unspecified | Diagnosis | ICD-10-CM |
| H40.62X1 | Glaucoma secondary to drugs, left eye, mild stage | Diagnosis | ICD-10-CM |
| H40.62X2 | Glaucoma secondary to drugs, left eye, moderate stage | Diagnosis | ICD-10-CM |
| H40.62X3 | Glaucoma secondary to drugs, left eye, severe stage | Diagnosis | ICD-10-CM |
| H40.62X4 | Glaucoma secondary to drugs, left eye, indeterminate stage | Diagnosis | ICD-10-CM |
| H40.63X0 | Glaucoma secondary to drugs, bilateral, stage unspecified | Diagnosis | ICD-10-CM |
| H40.63X1 | Glaucoma secondary to drugs, bilateral, mild stage | Diagnosis | ICD-10-CM |
| H40.63X2 | Glaucoma secondary to drugs, bilateral, moderate stage | Diagnosis | ICD-10-CM |
| H40.63X3 | Glaucoma secondary to drugs, bilateral, severe stage | Diagnosis | ICD-10-CM |
| H40.63X4 | Glaucoma secondary to drugs, bilateral, indeterminate stage | Diagnosis | ICD-10-CM |
| H40.811 | Glaucoma with increased episcleral venous pressure, right eye | Diagnosis | ICD-10-CM |
| H40.812 | Glaucoma with increased episcleral venous pressure, left eye | Diagnosis | ICD-10-CM |
| H40.813 | Glaucoma with increased episcleral venous pressure, bilateral | Diagnosis | ICD-10-CM |
| H40.819 | Glaucoma with increased episcleral venous pressure, unspecified eye | Diagnosis | ICD-10-CM |
| H40.821 | Hypersecretion glaucoma, right eye | Diagnosis | ICD-10-CM |
| H40.822 | Hypersecretion glaucoma, left eye | Diagnosis | ICD-10-CM |
| H40.823 | Hypersecretion glaucoma, bilateral | Diagnosis | ICD-10-CM |
| H40.829 | Hypersecretion glaucoma, unspecified eye | Diagnosis | ICD-10-CM |
| H40.831 | Aqueous misdirection, right eye | Diagnosis | ICD-10-CM |
| H40.832 | Aqueous misdirection, left eye | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|----------------------|---|---------------|-----------|
| H40.833 | Aqueous misdirection, bilateral | Diagnosis | ICD-10-CM |
| H40.839 | Aqueous misdirection, unspecified eye | Diagnosis | ICD-10-CM |
| H40.89 | Other specified glaucoma | Diagnosis | ICD-10-CM |
| H40.9 | Unspecified glaucoma | Diagnosis | ICD-10-CM |
| H42 | Glaucoma in diseases classified elsewhere | Diagnosis | ICD-10-CM |
| H44.511 | Absolute glaucoma, right eye | Diagnosis | ICD-10-CM |
| H44.512 | Absolute glaucoma, left eye | Diagnosis | ICD-10-CM |
| H44.513 | Absolute glaucoma, bilateral | Diagnosis | ICD-10-CM |
| H44.519 | Absolute glaucoma, unspecified eye | Diagnosis | ICD-10-CM |
| H47.231 | Glaucomatous optic atrophy, right eye | Diagnosis | ICD-10-CM |
| H47.232 | Glaucomatous optic atrophy, left eye | Diagnosis | ICD-10-CM |
| H47.233 | Glaucomatous optic atrophy, bilateral | Diagnosis | ICD-10-CM |
| H47.239 | Glaucomatous optic atrophy, unspecified eye | Diagnosis | ICD-10-CM |
| Q15.0 | Congenital glaucoma | Diagnosis | ICD-10-CM |
| Heart Failure | | | |
| 398.91 | Rheumatic heart failure (congestive) | Diagnosis | ICD-9-CM |
| 402.01 | Malignant hypertensive heart disease with heart failure | Diagnosis | ICD-9-CM |
| 402.11 | Benign hypertensive heart disease with heart failure | Diagnosis | ICD-9-CM |
| 402.91 | Hypertensive heart disease, unspecified, with heart failure | Diagnosis | ICD-9-CM |
| 404.01 | Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified | Diagnosis | ICD-9-CM |
| 404.03 | Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease | Diagnosis | ICD-9-CM |
| 404.11 | Hypertensive heart and chronic kidney disease, benign, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified | Diagnosis | ICD-9-CM |
| 404.13 | Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease | Diagnosis | ICD-9-CM |
| 404.91 | Hypertensive heart and chronic kidney disease, unspecified, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified | Diagnosis | ICD-9-CM |
| 404.93 | Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease | Diagnosis | ICD-9-CM |
| 428.0 | Congestive heart failure, unspecified | Diagnosis | ICD-9-CM |
| 428.1 | Left heart failure | Diagnosis | ICD-9-CM |
| 428.20 | Unspecified systolic heart failure | Diagnosis | ICD-9-CM |
| 428.21 | Acute systolic heart failure | Diagnosis | ICD-9-CM |
| 428.22 | Chronic systolic heart failure | Diagnosis | ICD-9-CM |
| 428.23 | Acute on chronic systolic heart failure | Diagnosis | ICD-9-CM |
| 428.30 | Unspecified diastolic heart failure | Diagnosis | ICD-9-CM |
| 428.31 | Acute diastolic heart failure | Diagnosis | ICD-9-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| 428.32 | Chronic diastolic heart failure | Diagnosis | ICD-9-CM |
| 428.33 | Acute on chronic diastolic heart failure | Diagnosis | ICD-9-CM |
| 428.40 | Unspecified combined systolic and diastolic heart failure | Diagnosis | ICD-9-CM |
| 428.41 | Acute combined systolic and diastolic heart failure | Diagnosis | ICD-9-CM |
| 428.42 | Chronic combined systolic and diastolic heart failure | Diagnosis | ICD-9-CM |
| 428.43 | Acute on chronic combined systolic and diastolic heart failure | Diagnosis | ICD-9-CM |
| 428.9 | Unspecified heart failure | Diagnosis | ICD-9-CM |
| I09.81 | Rheumatic heart failure | Diagnosis | ICD-10-CM |
| I11.0 | Hypertensive heart disease with heart failure | Diagnosis | ICD-10-CM |
| I13.0 | Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease | Diagnosis | ICD-10-CM |
| I13.2 | Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease | Diagnosis | ICD-10-CM |
| I42.0 | Dilated cardiomyopathy | Diagnosis | ICD-10-CM |
| I42.5 | Other restrictive cardiomyopathy | Diagnosis | ICD-10-CM |
| I42.6 | Alcoholic cardiomyopathy | Diagnosis | ICD-10-CM |
| I42.7 | Cardiomyopathy due to drug and external agent | Diagnosis | ICD-10-CM |
| I42.8 | Other cardiomyopathies | Diagnosis | ICD-10-CM |
| I43 | Cardiomyopathy in diseases classified elsewhere | Diagnosis | ICD-10-CM |
| I50.1 | Left ventricular failure, unspecified | Diagnosis | ICD-10-CM |
| I50.20 | Unspecified systolic (congestive) heart failure | Diagnosis | ICD-10-CM |
| I50.21 | Acute systolic (congestive) heart failure | Diagnosis | ICD-10-CM |
| I50.22 | Chronic systolic (congestive) heart failure | Diagnosis | ICD-10-CM |
| I50.23 | Acute on chronic systolic (congestive) heart failure | Diagnosis | ICD-10-CM |
| I50.30 | Unspecified diastolic (congestive) heart failure | Diagnosis | ICD-10-CM |
| I50.31 | Acute diastolic (congestive) heart failure | Diagnosis | ICD-10-CM |
| I50.32 | Chronic diastolic (congestive) heart failure | Diagnosis | ICD-10-CM |
| I50.33 | Acute on chronic diastolic (congestive) heart failure | Diagnosis | ICD-10-CM |
| I50.40 | Unspecified combined systolic (congestive) and diastolic (congestive) heart failure | Diagnosis | ICD-10-CM |
| I50.41 | Acute combined systolic (congestive) and diastolic (congestive) heart failure | Diagnosis | ICD-10-CM |
| I50.42 | Chronic combined systolic (congestive) and diastolic (congestive) heart failure | Diagnosis | ICD-10-CM |
| I50.43 | Acute on chronic combined systolic (congestive) and diastolic (congestive) heart failure | Diagnosis | ICD-10-CM |
| I50.810 | Right heart failure, unspecified | Diagnosis | ICD-10-CM |
| I50.811 | Acute right heart failure | Diagnosis | ICD-10-CM |
| I50.812 | Chronic right heart failure | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|-----------------------|--|---------------|-----------|
| I50.813 | Acute on chronic right heart failure | Diagnosis | ICD-10-CM |
| I50.814 | Right heart failure due to left heart failure | Diagnosis | ICD-10-CM |
| I50.82 | Biventricular heart failure | Diagnosis | ICD-10-CM |
| I50.83 | High output heart failure | Diagnosis | ICD-10-CM |
| I50.84 | End stage heart failure | Diagnosis | ICD-10-CM |
| I50.89 | Other heart failure | Diagnosis | ICD-10-CM |
| I50.9 | Heart failure, unspecified | Diagnosis | ICD-10-CM |
| P29.0 | Neonatal cardiac failure | Diagnosis | ICD-10-CM |
| Hyperlipidemia | | | |
| 272.0 | Pure hypercholesterolemia | Diagnosis | ICD-9-CM |
| 272.1 | Pure hyperglyceridemia | Diagnosis | ICD-9-CM |
| 272.2 | Mixed hyperlipidemia | Diagnosis | ICD-9-CM |
| 272.3 | Hyperchylomicronemia | Diagnosis | ICD-9-CM |
| 272.4 | Other and unspecified hyperlipidemia | Diagnosis | ICD-9-CM |
| E78.0 | Pure hypercholesterolemia | Diagnosis | ICD-10-CM |
| E78.00 | Pure hypercholesterolemia, unspecified | Diagnosis | ICD-10-CM |
| E78.01 | Familial hypercholesterolemia | Diagnosis | ICD-10-CM |
| E78.1 | Pure hyperglyceridemia | Diagnosis | ICD-10-CM |
| E78.2 | Mixed hyperlipidemia | Diagnosis | ICD-10-CM |
| E78.3 | Hyperchylomicronemia | Diagnosis | ICD-10-CM |
| E78.4 | Other hyperlipidemia | Diagnosis | ICD-10-CM |
| E78.41 | Elevated Lipoprotein(a) | Diagnosis | ICD-10-CM |
| E78.49 | Other hyperlipidemia | Diagnosis | ICD-10-CM |
| E78.5 | Hyperlipidemia, unspecified | Diagnosis | ICD-10-CM |
| Hypertension | | | |
| 362.11 | Hypertensive retinopathy | Diagnosis | ICD-9-CM |
| 401.0 | Essential hypertension, malignant | Diagnosis | ICD-9-CM |
| 401.1 | Essential hypertension, benign | Diagnosis | ICD-9-CM |
| 401.9 | Unspecified essential hypertension | Diagnosis | ICD-9-CM |
| 402.00 | Malignant hypertensive heart disease without heart failure | Diagnosis | ICD-9-CM |
| 402.01 | Malignant hypertensive heart disease with heart failure | Diagnosis | ICD-9-CM |
| 402.10 | Benign hypertensive heart disease without heart failure | Diagnosis | ICD-9-CM |
| 402.11 | Benign hypertensive heart disease with heart failure | Diagnosis | ICD-9-CM |
| 402.90 | Unspecified hypertensive heart disease without heart failure | Diagnosis | ICD-9-CM |
| 402.91 | Hypertensive heart disease, unspecified, with heart failure | Diagnosis | ICD-9-CM |
| 403.00 | Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage I through stage IV, or unspecified | Diagnosis | ICD-9-CM |
| 403.01 | Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage V or end stage renal disease | Diagnosis | ICD-9-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| 403.10 | Hypertensive chronic kidney disease, benign, with chronic kidney disease stage I through stage IV, or unspecified | Diagnosis | ICD-9-CM |
| 403.11 | Hypertensive chronic kidney disease, benign, with chronic kidney disease stage V or end stage renal disease | Diagnosis | ICD-9-CM |
| 403.90 | Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage I through stage IV, or unspecified | Diagnosis | ICD-9-CM |
| 403.91 | Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage V or end stage renal disease | Diagnosis | ICD-9-CM |
| 404.00 | Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified | Diagnosis | ICD-9-CM |
| 404.01 | Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified | Diagnosis | ICD-9-CM |
| 404.02 | Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage V or end stage renal disease | Diagnosis | ICD-9-CM |
| 404.03 | Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease | Diagnosis | ICD-9-CM |
| 404.10 | Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified | Diagnosis | ICD-9-CM |
| 404.11 | Hypertensive heart and chronic kidney disease, benign, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified | Diagnosis | ICD-9-CM |
| 404.12 | Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage V or end stage renal disease | Diagnosis | ICD-9-CM |
| 404.13 | Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease | Diagnosis | ICD-9-CM |
| 404.90 | Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified | Diagnosis | ICD-9-CM |
| 404.91 | Hypertensive heart and chronic kidney disease, unspecified, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified | Diagnosis | ICD-9-CM |
| 404.92 | Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage V or end stage renal disease | Diagnosis | ICD-9-CM |
| 404.93 | Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease | Diagnosis | ICD-9-CM |
| 405.01 | Secondary renovascular hypertension, malignant | Diagnosis | ICD-9-CM |
| 405.09 | Other secondary hypertension, malignant | Diagnosis | ICD-9-CM |
| 405.11 | Secondary renovascular hypertension, benign | Diagnosis | ICD-9-CM |
| 405.19 | Other secondary hypertension, benign | Diagnosis | ICD-9-CM |
| 405.91 | Secondary renovascular hypertension, unspecified | Diagnosis | ICD-9-CM |
| 405.99 | Other secondary hypertension, unspecified | Diagnosis | ICD-9-CM |
| 437.2 | Hypertensive encephalopathy | Diagnosis | ICD-9-CM |
| H35.031 | Hypertensive retinopathy, right eye | Diagnosis | ICD-10-CM |
| H35.032 | Hypertensive retinopathy, left eye | Diagnosis | ICD-10-CM |
| H35.033 | Hypertensive retinopathy, bilateral | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|-------------------------------|---|---------------|-----------|
| H35.039 | Hypertensive retinopathy, unspecified eye | Diagnosis | ICD-10-CM |
| I10 | Essential (primary) hypertension | Diagnosis | ICD-10-CM |
| I11.0 | Hypertensive heart disease with heart failure | Diagnosis | ICD-10-CM |
| I11.9 | Hypertensive heart disease without heart failure | Diagnosis | ICD-10-CM |
| I12.0 | Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease | Diagnosis | ICD-10-CM |
| I12.9 | Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease | Diagnosis | ICD-10-CM |
| I13.0 | Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease | Diagnosis | ICD-10-CM |
| I13.10 | Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease | Diagnosis | ICD-10-CM |
| I13.11 | Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease | Diagnosis | ICD-10-CM |
| I13.2 | Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease | Diagnosis | ICD-10-CM |
| I15.0 | Renovascular hypertension | Diagnosis | ICD-10-CM |
| I15.1 | Hypertension secondary to other renal disorders | Diagnosis | ICD-10-CM |
| I15.2 | Hypertension secondary to endocrine disorders | Diagnosis | ICD-10-CM |
| I15.8 | Other secondary hypertension | Diagnosis | ICD-10-CM |
| I15.9 | Secondary hypertension, unspecified | Diagnosis | ICD-10-CM |
| I67.4 | Hypertensive encephalopathy | Diagnosis | ICD-10-CM |
| N26.2 | Page kidney | Diagnosis | ICD-10-CM |
| Ischemic Heart Disease | | | |
| 410.00 | Acute myocardial infarction of anterolateral wall, episode of care unspecified | Diagnosis | ICD-9-CM |
| 410.01 | Acute myocardial infarction of anterolateral wall, initial episode of care | Diagnosis | ICD-9-CM |
| 410.02 | Acute myocardial infarction of anterolateral wall, subsequent episode of care | Diagnosis | ICD-9-CM |
| 410.10 | Acute myocardial infarction of other anterior wall, episode of care unspecified | Diagnosis | ICD-9-CM |
| 410.11 | Acute myocardial infarction of other anterior wall, initial episode of care | Diagnosis | ICD-9-CM |
| 410.12 | Acute myocardial infarction of other anterior wall, subsequent episode of care | Diagnosis | ICD-9-CM |
| 410.20 | Acute myocardial infarction of inferolateral wall, episode of care unspecified | Diagnosis | ICD-9-CM |
| 410.21 | Acute myocardial infarction of inferolateral wall, initial episode of care | Diagnosis | ICD-9-CM |
| 410.22 | Acute myocardial infarction of inferolateral wall, subsequent episode of care | Diagnosis | ICD-9-CM |
| 410.30 | Acute myocardial infarction of inferoposterior wall, episode of care unspecified | Diagnosis | ICD-9-CM |
| 410.31 | Acute myocardial infarction of inferoposterior wall, initial episode of care | Diagnosis | ICD-9-CM |
| 410.32 | Acute myocardial infarction of inferoposterior wall, subsequent episode of care | Diagnosis | ICD-9-CM |
| 410.40 | Acute myocardial infarction of other inferior wall, episode of care unspecified | Diagnosis | ICD-9-CM |
| 410.41 | Acute myocardial infarction of other inferior wall, initial episode of care | Diagnosis | ICD-9-CM |
| 410.42 | Acute myocardial infarction of other inferior wall, subsequent episode of care | Diagnosis | ICD-9-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| 410.50 | Acute myocardial infarction of other lateral wall, episode of care unspecified | Diagnosis | ICD-9-CM |
| 410.51 | Acute myocardial infarction of other lateral wall, initial episode of care | Diagnosis | ICD-9-CM |
| 410.52 | Acute myocardial infarction of other lateral wall, subsequent episode of care | Diagnosis | ICD-9-CM |
| 410.60 | Acute myocardial infarction, true posterior wall infarction, episode of care unspecified | Diagnosis | ICD-9-CM |
| 410.61 | Acute myocardial infarction, true posterior wall infarction, initial episode of care | Diagnosis | ICD-9-CM |
| 410.62 | Acute myocardial infarction, true posterior wall infarction, subsequent episode of care | Diagnosis | ICD-9-CM |
| 410.70 | Acute myocardial infarction, subendocardial infarction, episode of care unspecified | Diagnosis | ICD-9-CM |
| 410.71 | Acute myocardial infarction, subendocardial infarction, initial episode of care | Diagnosis | ICD-9-CM |
| 410.72 | Acute myocardial infarction, subendocardial infarction, subsequent episode of care | Diagnosis | ICD-9-CM |
| 410.80 | Acute myocardial infarction of other specified sites, episode of care unspecified | Diagnosis | ICD-9-CM |
| 410.81 | Acute myocardial infarction of other specified sites, initial episode of care | Diagnosis | ICD-9-CM |
| 410.82 | Acute myocardial infarction of other specified sites, subsequent episode of care | Diagnosis | ICD-9-CM |
| 410.90 | Acute myocardial infarction, unspecified site, episode of care unspecified | Diagnosis | ICD-9-CM |
| 410.91 | Acute myocardial infarction, unspecified site, initial episode of care | Diagnosis | ICD-9-CM |
| 410.92 | Acute myocardial infarction, unspecified site, subsequent episode of care | Diagnosis | ICD-9-CM |
| 411.0 | Postmyocardial infarction syndrome | Diagnosis | ICD-9-CM |
| 411.1 | Intermediate coronary syndrome | Diagnosis | ICD-9-CM |
| 411.81 | Acute coronary occlusion without myocardial infarction | Diagnosis | ICD-9-CM |
| 411.89 | Other acute and subacute form of ischemic heart disease | Diagnosis | ICD-9-CM |
| 412 | Old myocardial infarction | Diagnosis | ICD-9-CM |
| 413.0 | Angina decubitus | Diagnosis | ICD-9-CM |
| 413.1 | Prinzmetal angina | Diagnosis | ICD-9-CM |
| 413.9 | Other and unspecified angina pectoris | Diagnosis | ICD-9-CM |
| 414.00 | Coronary atherosclerosis of unspecified type of vessel, native or graft | Diagnosis | ICD-9-CM |
| 414.01 | Coronary atherosclerosis of native coronary artery | Diagnosis | ICD-9-CM |
| 414.02 | Coronary atherosclerosis of autologous vein bypass graft | Diagnosis | ICD-9-CM |
| 414.03 | Coronary atherosclerosis of nonautologous biological bypass graft | Diagnosis | ICD-9-CM |
| 414.04 | Coronary atherosclerosis of artery bypass graft | Diagnosis | ICD-9-CM |
| 414.05 | Coronary atherosclerosis of unspecified type of bypass graft | Diagnosis | ICD-9-CM |
| 414.06 | Coronary atherosclerosis, of native coronary artery of transplanted heart | Diagnosis | ICD-9-CM |
| 414.07 | Coronary atherosclerosis, of bypass graft (artery) (vein) of transplanted heart | Diagnosis | ICD-9-CM |
| 414.12 | Dissection of coronary artery | Diagnosis | ICD-9-CM |
| 414.2 | Chronic total occlusion of coronary artery | Diagnosis | ICD-9-CM |
| 414.3 | Coronary atherosclerosis due to lipid rich plaque | Diagnosis | ICD-9-CM |
| 414.4 | Coronary atherosclerosis due to calcified coronary lesion | Diagnosis | ICD-9-CM |
| 414.8 | Other specified forms of chronic ischemic heart disease | Diagnosis | ICD-9-CM |
| 414.9 | Unspecified chronic ischemic heart disease | Diagnosis | ICD-9-CM |
| I20.0 | Unstable angina | Diagnosis | ICD-10-CM |
| I20.1 | Angina pectoris with documented spasm | Diagnosis | ICD-10-CM |
| I20.8 | Other forms of angina pectoris | Diagnosis | ICD-10-CM |
| I20.9 | Angina pectoris, unspecified | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|---|---------------|-----------|
| I21.01 | ST elevation (STEMI) myocardial infarction involving left main coronary artery | Diagnosis | ICD-10-CM |
| I21.02 | ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery | Diagnosis | ICD-10-CM |
| I21.09 | ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall | Diagnosis | ICD-10-CM |
| I21.11 | ST elevation (STEMI) myocardial infarction involving right coronary artery | Diagnosis | ICD-10-CM |
| I21.19 | ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall | Diagnosis | ICD-10-CM |
| I21.21 | ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery | Diagnosis | ICD-10-CM |
| I21.29 | ST elevation (STEMI) myocardial infarction involving other sites | Diagnosis | ICD-10-CM |
| I21.3 | ST elevation (STEMI) myocardial infarction of unspecified site | Diagnosis | ICD-10-CM |
| I21.4 | Non-ST elevation (NSTEMI) myocardial infarction | Diagnosis | ICD-10-CM |
| I21.A1 | Myocardial infarction type 2 | Diagnosis | ICD-10-CM |
| I21.A9 | Other myocardial infarction type | Diagnosis | ICD-10-CM |
| I22.0 | Subsequent ST elevation (STEMI) myocardial infarction of anterior wall | Diagnosis | ICD-10-CM |
| I22.1 | Subsequent ST elevation (STEMI) myocardial infarction of inferior wall | Diagnosis | ICD-10-CM |
| I22.2 | Subsequent non-ST elevation (NSTEMI) myocardial infarction | Diagnosis | ICD-10-CM |
| I22.8 | Subsequent ST elevation (STEMI) myocardial infarction of other sites | Diagnosis | ICD-10-CM |
| I22.9 | Subsequent ST elevation (STEMI) myocardial infarction of unspecified site | Diagnosis | ICD-10-CM |
| I23.0 | Hemopericardium as current complication following acute myocardial infarction | Diagnosis | ICD-10-CM |
| I23.1 | Atrial septal defect as current complication following acute myocardial infarction | Diagnosis | ICD-10-CM |
| I23.2 | Ventricular septal defect as current complication following acute myocardial infarction | Diagnosis | ICD-10-CM |
| I23.3 | Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction | Diagnosis | ICD-10-CM |
| I23.4 | Rupture of chordae tendineae as current complication following acute myocardial infarction | Diagnosis | ICD-10-CM |
| I23.5 | Rupture of papillary muscle as current complication following acute myocardial infarction | Diagnosis | ICD-10-CM |
| I23.6 | Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction | Diagnosis | ICD-10-CM |
| I23.7 | Postinfarction angina | Diagnosis | ICD-10-CM |
| I23.8 | Other current complications following acute myocardial infarction | Diagnosis | ICD-10-CM |
| I24.0 | Acute coronary thrombosis not resulting in myocardial infarction | Diagnosis | ICD-10-CM |
| I24.1 | Dressler's syndrome | Diagnosis | ICD-10-CM |
| I24.8 | Other forms of acute ischemic heart disease | Diagnosis | ICD-10-CM |
| I24.9 | Acute ischemic heart disease, unspecified | Diagnosis | ICD-10-CM |
| I25.10 | Atherosclerotic heart disease of native coronary artery without angina pectoris | Diagnosis | ICD-10-CM |
| I25.110 | Atherosclerotic heart disease of native coronary artery with unstable angina pectoris | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| I25.111 | Atherosclerotic heart disease of native coronary artery with angina pectoris with documented spasm | Diagnosis | ICD-10-CM |
| I25.118 | Atherosclerotic heart disease of native coronary artery with other forms of angina pectoris | Diagnosis | ICD-10-CM |
| I25.119 | Atherosclerotic heart disease of native coronary artery with unspecified angina pectoris | Diagnosis | ICD-10-CM |
| I25.2 | Old myocardial infarction | Diagnosis | ICD-10-CM |
| I25.3 | Aneurysm of heart | Diagnosis | ICD-10-CM |
| I25.41 | Coronary artery aneurysm | Diagnosis | ICD-10-CM |
| I25.42 | Coronary artery dissection | Diagnosis | ICD-10-CM |
| I25.5 | Ischemic cardiomyopathy | Diagnosis | ICD-10-CM |
| I25.6 | Silent myocardial ischemia | Diagnosis | ICD-10-CM |
| I25.700 | Atherosclerosis of coronary artery bypass graft(s), unspecified, with unstable angina pectoris | Diagnosis | ICD-10-CM |
| I25.701 | Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris with documented spasm | Diagnosis | ICD-10-CM |
| I25.708 | Atherosclerosis of coronary artery bypass graft(s), unspecified, with other forms of angina pectoris | Diagnosis | ICD-10-CM |
| I25.709 | Atherosclerosis of coronary artery bypass graft(s), unspecified, with unspecified angina pectoris | Diagnosis | ICD-10-CM |
| I25.710 | Atherosclerosis of autologous vein coronary artery bypass graft(s) with unstable angina pectoris | Diagnosis | ICD-10-CM |
| I25.711 | Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris with documented spasm | Diagnosis | ICD-10-CM |
| I25.718 | Atherosclerosis of autologous vein coronary artery bypass graft(s) with other forms of angina pectoris | Diagnosis | ICD-10-CM |
| I25.719 | Atherosclerosis of autologous vein coronary artery bypass graft(s) with unspecified angina pectoris | Diagnosis | ICD-10-CM |
| I25.720 | Atherosclerosis of autologous artery coronary artery bypass graft(s) with unstable angina pectoris | Diagnosis | ICD-10-CM |
| I25.721 | Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris with documented spasm | Diagnosis | ICD-10-CM |
| I25.728 | Atherosclerosis of autologous artery coronary artery bypass graft(s) with other forms of angina pectoris | Diagnosis | ICD-10-CM |
| I25.729 | Atherosclerosis of autologous artery coronary artery bypass graft(s) with unspecified angina pectoris | Diagnosis | ICD-10-CM |
| I25.730 | Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unstable angina pectoris | Diagnosis | ICD-10-CM |
| I25.731 | Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina pectoris with documented spasm | Diagnosis | ICD-10-CM |
| I25.738 | Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with other forms of angina pectoris | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|--------------------|---|---------------|-----------|
| I25.739 | Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unspecified angina pectoris | Diagnosis | ICD-10-CM |
| I25.750 | Atherosclerosis of native coronary artery of transplanted heart with unstable angina | Diagnosis | ICD-10-CM |
| I25.751 | Atherosclerosis of native coronary artery of transplanted heart with angina pectoris with documented spasm | Diagnosis | ICD-10-CM |
| I25.758 | Atherosclerosis of native coronary artery of transplanted heart with other forms of angina pectoris | Diagnosis | ICD-10-CM |
| I25.759 | Atherosclerosis of native coronary artery of transplanted heart with unspecified angina pectoris | Diagnosis | ICD-10-CM |
| I25.760 | Atherosclerosis of bypass graft of coronary artery of transplanted heart with unstable angina | Diagnosis | ICD-10-CM |
| I25.761 | Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris with documented spasm | Diagnosis | ICD-10-CM |
| I25.768 | Atherosclerosis of bypass graft of coronary artery of transplanted heart with other forms of angina pectoris | Diagnosis | ICD-10-CM |
| I25.769 | Atherosclerosis of bypass graft of coronary artery of transplanted heart with unspecified angina pectoris | Diagnosis | ICD-10-CM |
| I25.790 | Atherosclerosis of other coronary artery bypass graft(s) with unstable angina pectoris | Diagnosis | ICD-10-CM |
| I25.791 | Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris with documented spasm | Diagnosis | ICD-10-CM |
| I25.798 | Atherosclerosis of other coronary artery bypass graft(s) with other forms of angina pectoris | Diagnosis | ICD-10-CM |
| I25.799 | Atherosclerosis of other coronary artery bypass graft(s) with unspecified angina pectoris | Diagnosis | ICD-10-CM |
| I25.810 | Atherosclerosis of coronary artery bypass graft(s) without angina pectoris | Diagnosis | ICD-10-CM |
| I25.811 | Atherosclerosis of native coronary artery of transplanted heart without angina pectoris | Diagnosis | ICD-10-CM |
| I25.812 | Atherosclerosis of bypass graft of coronary artery of transplanted heart without angina pectoris | Diagnosis | ICD-10-CM |
| I25.82 | Chronic total occlusion of coronary artery | Diagnosis | ICD-10-CM |
| I25.83 | Coronary atherosclerosis due to lipid rich plaque | Diagnosis | ICD-10-CM |
| I25.84 | Coronary atherosclerosis due to calcified coronary lesion | Diagnosis | ICD-10-CM |
| I25.89 | Other forms of chronic ischemic heart disease | Diagnosis | ICD-10-CM |
| I25.9 | Chronic ischemic heart disease, unspecified | Diagnosis | ICD-10-CM |
| Lung Cancer | | | |
| 162.2 | Malignant neoplasm of main bronchus | Diagnosis | ICD-9-CM |
| 162.3 | Malignant neoplasm of upper lobe, bronchus, or lung | Diagnosis | ICD-9-CM |
| 162.4 | Malignant neoplasm of middle lobe, bronchus, or lung | Diagnosis | ICD-9-CM |
| 162.5 | Malignant neoplasm of lower lobe, bronchus, or lung | Diagnosis | ICD-9-CM |
| 162.8 | Malignant neoplasm of other parts of bronchus or lung | Diagnosis | ICD-9-CM |
| 162.9 | Malignant neoplasm of bronchus and lung, unspecified site | Diagnosis | ICD-9-CM |
| 231.2 | Carcinoma in situ of bronchus and lung | Diagnosis | ICD-9-CM |
| C34.00 | Malignant neoplasm of unspecified main bronchus | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|----------------|---|---------------|------------|
| C34.01 | Malignant neoplasm of right main bronchus | Diagnosis | ICD-10-CM |
| C34.02 | Malignant neoplasm of left main bronchus | Diagnosis | ICD-10-CM |
| C34.10 | Malignant neoplasm of upper lobe, unspecified bronchus or lung | Diagnosis | ICD-10-CM |
| C34.11 | Malignant neoplasm of upper lobe, right bronchus or lung | Diagnosis | ICD-10-CM |
| C34.12 | Malignant neoplasm of upper lobe, left bronchus or lung | Diagnosis | ICD-10-CM |
| C34.2 | Malignant neoplasm of middle lobe, bronchus or lung | Diagnosis | ICD-10-CM |
| C34.30 | Malignant neoplasm of lower lobe, unspecified bronchus or lung | Diagnosis | ICD-10-CM |
| C34.31 | Malignant neoplasm of lower lobe, right bronchus or lung | Diagnosis | ICD-10-CM |
| C34.32 | Malignant neoplasm of lower lobe, left bronchus or lung | Diagnosis | ICD-10-CM |
| C34.80 | Malignant neoplasm of overlapping sites of unspecified bronchus and lung | Diagnosis | ICD-10-CM |
| C34.81 | Malignant neoplasm of overlapping sites of right bronchus and lung | Diagnosis | ICD-10-CM |
| C34.82 | Malignant neoplasm of overlapping sites of left bronchus and lung | Diagnosis | ICD-10-CM |
| C34.90 | Malignant neoplasm of unspecified part of unspecified bronchus or lung | Diagnosis | ICD-10-CM |
| C34.91 | Malignant neoplasm of unspecified part of right bronchus or lung | Diagnosis | ICD-10-CM |
| C34.92 | Malignant neoplasm of unspecified part of left bronchus or lung | Diagnosis | ICD-10-CM |
| D02.20 | Carcinoma in situ of unspecified bronchus and lung | Diagnosis | ICD-10-CM |
| D02.21 | Carcinoma in situ of right bronchus and lung | Diagnosis | ICD-10-CM |
| D02.22 | Carcinoma in situ of left bronchus and lung | Diagnosis | ICD-10-CM |
| V10.11 | Personal history of malignant neoplasm of bronchus and lung | Diagnosis | ICD-9-CM |
| Z85.110 | Personal history of malignant carcinoid tumor of bronchus and lung | Diagnosis | ICD-10-CM |
| Z85.118 | Personal history of other malignant neoplasm of bronchus and lung | Diagnosis | ICD-10-CM |
| Obesity | | | |
| 0D16079 | Bypass Stomach to Duodenum with Autologous Tissue Substitute, Open Approach | Procedure | ICD-10-PCS |
| 0D1607A | Bypass Stomach to Jejunum with Autologous Tissue Substitute, Open Approach | Procedure | ICD-10-PCS |
| 0D1607B | Bypass Stomach to Ileum with Autologous Tissue Substitute, Open Approach | Procedure | ICD-10-PCS |
| 0D1607L | Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Open Approach | Procedure | ICD-10-PCS |
| 0D160J9 | Bypass Stomach to Duodenum with Synthetic Substitute, Open Approach | Procedure | ICD-10-PCS |
| 0D160JA | Bypass Stomach to Jejunum with Synthetic Substitute, Open Approach | Procedure | ICD-10-PCS |
| 0D160JB | Bypass Stomach to Ileum with Synthetic Substitute, Open Approach | Procedure | ICD-10-PCS |
| 0D160JL | Bypass Stomach to Transverse Colon with Synthetic Substitute, Open Approach | Procedure | ICD-10-PCS |
| 0D160K9 | Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Open Approach | Procedure | ICD-10-PCS |
| 0D160KA | Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Open Approach | Procedure | ICD-10-PCS |
| 0D160KB | Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Open Approach | Procedure | ICD-10-PCS |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|--|---------------|------------|
| 0D160KL | Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Open Approach | Procedure | ICD-10-PCS |
| 0D160Z9 | Bypass Stomach to Duodenum, Open Approach | Procedure | ICD-10-PCS |
| 0D160ZA | Bypass Stomach to Jejunum, Open Approach | Procedure | ICD-10-PCS |
| 0D160ZB | Bypass Stomach to Ileum, Open Approach | Procedure | ICD-10-PCS |
| 0D160ZL | Bypass Stomach to Transverse Colon, Open Approach | Procedure | ICD-10-PCS |
| 0D16479 | Bypass Stomach to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach | Procedure | ICD-10-PCS |
| 0D1647A | Bypass Stomach to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach | Procedure | ICD-10-PCS |
| 0D1647B | Bypass Stomach to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach | Procedure | ICD-10-PCS |
| 0D1647L | Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Percutaneous Endoscopic Approach | Procedure | ICD-10-PCS |
| 0D164J9 | Bypass Stomach to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach | Procedure | ICD-10-PCS |
| 0D164JA | Bypass Stomach to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach | Procedure | ICD-10-PCS |
| 0D164JB | Bypass Stomach to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach | Procedure | ICD-10-PCS |
| 0D164JL | Bypass Stomach to Transverse Colon with Synthetic Substitute, Percutaneous Endoscopic Approach | Procedure | ICD-10-PCS |
| 0D164K9 | Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach | Procedure | ICD-10-PCS |
| 0D164KA | Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach | Procedure | ICD-10-PCS |
| 0D164KB | Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach | Procedure | ICD-10-PCS |
| 0D164KL | Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach | Procedure | ICD-10-PCS |
| 0D164Z9 | Bypass Stomach to Duodenum, Percutaneous Endoscopic Approach | Procedure | ICD-10-PCS |
| 0D164ZA | Bypass Stomach to Jejunum, Percutaneous Endoscopic Approach | Procedure | ICD-10-PCS |
| 0D164ZB | Bypass Stomach to Ileum, Percutaneous Endoscopic Approach | Procedure | ICD-10-PCS |
| 0D164ZL | Bypass Stomach to Transverse Colon, Percutaneous Endoscopic Approach | Procedure | ICD-10-PCS |
| 0D16879 | Bypass Stomach to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic | Procedure | ICD-10-PCS |
| 0D1687A | Bypass Stomach to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic | Procedure | ICD-10-PCS |
| 0D1687B | Bypass Stomach to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic | Procedure | ICD-10-PCS |
| 0D1687L | Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic | Procedure | ICD-10-PCS |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|---|---------------|------------|
| 0D168J9 | Bypass Stomach to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic | Procedure | ICD-10-PCS |
| 0D168JA | Bypass Stomach to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic | Procedure | ICD-10-PCS |
| 0D168JB | Bypass Stomach to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic | Procedure | ICD-10-PCS |
| 0D168JL | Bypass Stomach to Transverse Colon with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic | Procedure | ICD-10-PCS |
| 0D168K9 | Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic | Procedure | ICD-10-PCS |
| 0D168KA | Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic | Procedure | ICD-10-PCS |
| 0D168KB | Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic | Procedure | ICD-10-PCS |
| 0D168KL | Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic | Procedure | ICD-10-PCS |
| 0D168Z9 | Bypass Stomach to Duodenum, Via Natural or Artificial Opening Endoscopic | Procedure | ICD-10-PCS |
| 0D168ZA | Bypass Stomach to Jejunum, Via Natural or Artificial Opening Endoscopic | Procedure | ICD-10-PCS |
| 0D168ZB | Bypass Stomach to Ileum, Via Natural or Artificial Opening Endoscopic | Procedure | ICD-10-PCS |
| 0D168ZL | Bypass Stomach to Transverse Colon, Via Natural or Artificial Opening Endoscopic | Procedure | ICD-10-PCS |
| 0D19079 | Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Open Approach | Procedure | ICD-10-PCS |
| 0D1907A | Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Open Approach | Procedure | ICD-10-PCS |
| 0D1907B | Bypass Duodenum to Ileum with Autologous Tissue Substitute, Open Approach | Procedure | ICD-10-PCS |
| 0D190J9 | Bypass Duodenum to Duodenum with Synthetic Substitute, Open Approach | Procedure | ICD-10-PCS |
| 0D190JA | Bypass Duodenum to Jejunum with Synthetic Substitute, Open Approach | Procedure | ICD-10-PCS |
| 0D190JB | Bypass Duodenum to Ileum with Synthetic Substitute, Open Approach | Procedure | ICD-10-PCS |
| 0D190K9 | Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Open Approach | Procedure | ICD-10-PCS |
| 0D190KA | Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Open Approach | Procedure | ICD-10-PCS |
| 0D190KB | Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Open Approach | Procedure | ICD-10-PCS |
| 0D190Z9 | Bypass Duodenum to Duodenum, Open Approach | Procedure | ICD-10-PCS |
| 0D190ZA | Bypass Duodenum to Jejunum, Open Approach | Procedure | ICD-10-PCS |
| 0D190ZB | Bypass Duodenum to Ileum, Open Approach | Procedure | ICD-10-PCS |
| 0D19479 | Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach | Procedure | ICD-10-PCS |
| 0D1947A | Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach | Procedure | ICD-10-PCS |
| 0D1947B | Bypass Duodenum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach | Procedure | ICD-10-PCS |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|--|---------------|------------|
| 0D194J9 | Bypass Duodenum to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach | Procedure | ICD-10-PCS |
| 0D194JA | Bypass Duodenum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach | Procedure | ICD-10-PCS |
| 0D194JB | Bypass Duodenum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach | Procedure | ICD-10-PCS |
| 0D194K9 | Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach | Procedure | ICD-10-PCS |
| 0D194KA | Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach | Procedure | ICD-10-PCS |
| 0D194KB | Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach | Procedure | ICD-10-PCS |
| 0D194Z9 | Bypass Duodenum to Duodenum, Percutaneous Endoscopic Approach | Procedure | ICD-10-PCS |
| 0D194ZA | Bypass Duodenum to Jejunum, Percutaneous Endoscopic Approach | Procedure | ICD-10-PCS |
| 0D194ZB | Bypass Duodenum to Ileum, Percutaneous Endoscopic Approach | Procedure | ICD-10-PCS |
| 0D19879 | Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic | Procedure | ICD-10-PCS |
| 0D1987A | Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic | Procedure | ICD-10-PCS |
| 0D1987B | Bypass Duodenum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic | Procedure | ICD-10-PCS |
| 0D198J9 | Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic | Procedure | ICD-10-PCS |
| 0D198JA | Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic | Procedure | ICD-10-PCS |
| 0D198JB | Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic | Procedure | ICD-10-PCS |
| 0D198K9 | Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic | Procedure | ICD-10-PCS |
| 0D198KA | Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic | Procedure | ICD-10-PCS |
| 0D198KB | Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic | Procedure | ICD-10-PCS |
| 0D198Z9 | Bypass Duodenum to Duodenum, Via Natural or Artificial Opening Endoscopic | Procedure | ICD-10-PCS |
| 0D198ZA | Bypass Duodenum to Jejunum, Via Natural or Artificial Opening Endoscopic | Procedure | ICD-10-PCS |
| 0D198ZB | Bypass Duodenum to Ileum, Via Natural or Artificial Opening Endoscopic | Procedure | ICD-10-PCS |
| 0D1A07A | Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Open Approach | Procedure | ICD-10-PCS |
| 0D1A07B | Bypass Jejunum to Ileum with Autologous Tissue Substitute, Open Approach | Procedure | ICD-10-PCS |
| 0D1A0JA | Bypass Jejunum to Jejunum with Synthetic Substitute, Open Approach | Procedure | ICD-10-PCS |
| 0D1A0JB | Bypass Jejunum to Ileum with Synthetic Substitute, Open Approach | Procedure | ICD-10-PCS |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|--|---------------|------------|
| 0D1A0KA | Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Open Approach | Procedure | ICD-10-PCS |
| 0D1A0KB | Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Open Approach | Procedure | ICD-10-PCS |
| 0D1A0ZA | Bypass Jejunum to Jejunum, Open Approach | Procedure | ICD-10-PCS |
| 0D1A0ZB | Bypass Jejunum to Ileum, Open Approach | Procedure | ICD-10-PCS |
| 0D1A47A | Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach | Procedure | ICD-10-PCS |
| 0D1A47B | Bypass Jejunum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach | Procedure | ICD-10-PCS |
| 0D1A4JA | Bypass Jejunum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach | Procedure | ICD-10-PCS |
| 0D1A4JB | Bypass Jejunum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach | Procedure | ICD-10-PCS |
| 0D1A4KA | Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach | Procedure | ICD-10-PCS |
| 0D1A4KB | Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach | Procedure | ICD-10-PCS |
| 0D1A4ZA | Bypass Jejunum to Jejunum, Percutaneous Endoscopic Approach | Procedure | ICD-10-PCS |
| 0D1A4ZB | Bypass Jejunum to Ileum, Percutaneous Endoscopic Approach | Procedure | ICD-10-PCS |
| 0D1A87A | Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic | Procedure | ICD-10-PCS |
| 0D1A87B | Bypass Jejunum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic | Procedure | ICD-10-PCS |
| 0D1A8JA | Bypass Jejunum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic | Procedure | ICD-10-PCS |
| 0D1A8JB | Bypass Jejunum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic | Procedure | ICD-10-PCS |
| 0D1A8KA | Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic | Procedure | ICD-10-PCS |
| 0D1A8KB | Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic | Procedure | ICD-10-PCS |
| 0D1A8ZA | Bypass Jejunum to Jejunum, Via Natural or Artificial Opening Endoscopic | Procedure | ICD-10-PCS |
| 0D1A8ZB | Bypass Jejunum to Ileum, Via Natural or Artificial Opening Endoscopic | Procedure | ICD-10-PCS |
| 0D1A8ZH | Bypass Jejunum to Cecum, Via Natural or Artificial Opening Endoscopic | Procedure | ICD-10-PCS |
| 0D1B07B | Bypass Ileum to Ileum with Autologous Tissue Substitute, Open Approach | Procedure | ICD-10-PCS |
| 0D1B0JB | Bypass Ileum to Ileum with Synthetic Substitute, Open Approach | Procedure | ICD-10-PCS |
| 0D1B0KB | Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Open Approach | Procedure | ICD-10-PCS |
| 0D1B0ZB | Bypass Ileum to Ileum, Open Approach | Procedure | ICD-10-PCS |
| 0D1B47B | Bypass Ileum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach | Procedure | ICD-10-PCS |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|--|---------------|------------|
| 0D1B4JB | Bypass Ileum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach | Procedure | ICD-10-PCS |
| 0D1B4KB | Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach | Procedure | ICD-10-PCS |
| 0D1B4ZB | Bypass Ileum to Ileum, Percutaneous Endoscopic Approach | Procedure | ICD-10-PCS |
| 0D1B87B | Bypass Ileum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic | Procedure | ICD-10-PCS |
| 0D1B8JB | Bypass Ileum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic | Procedure | ICD-10-PCS |
| 0D1B8KB | Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic | Procedure | ICD-10-PCS |
| 0D1B8ZB | Bypass Ileum to Ileum, Via Natural or Artificial Opening Endoscopic | Procedure | ICD-10-PCS |
| 0D1B8ZH | Bypass Ileum to Cecum, Via Natural or Artificial Opening Endoscopic | Procedure | ICD-10-PCS |
| 0DB60Z3 | Excision of Stomach, Open Approach, Vertical | Procedure | ICD-10-PCS |
| 0DB60ZZ | Excision of Stomach, Open Approach | Procedure | ICD-10-PCS |
| 0DB63Z3 | Excision of Stomach, Percutaneous Approach, Vertical | Procedure | ICD-10-PCS |
| 0DB63ZZ | Excision of Stomach, Percutaneous Approach | Procedure | ICD-10-PCS |
| 0DB67Z3 | Excision of Stomach, Via Natural or Artificial Opening, Vertical | Procedure | ICD-10-PCS |
| 0DB67ZZ | Excision of Stomach, Via Natural or Artificial Opening | Procedure | ICD-10-PCS |
| 0DB68Z3 | Excision of Stomach, Via Natural or Artificial Opening Endoscopic, Vertical | Procedure | ICD-10-PCS |
| 0DB80ZZ | Excision of Small Intestine, Open Approach | Procedure | ICD-10-PCS |
| 0DB90ZZ | Excision of Duodenum, Open Approach | Procedure | ICD-10-PCS |
| 0DBB0ZZ | Excision of Ileum, Open Approach | Procedure | ICD-10-PCS |
| 0DQ64ZZ | Repair Stomach, Percutaneous Endoscopic Approach | Procedure | ICD-10-PCS |
| 0DV64CZ | Restriction of Stomach with Extraluminal Device, Percutaneous Endoscopic Approach | Procedure | ICD-10-PCS |
| 0F190Z3 | Bypass Common Bile Duct to Duodenum, Open Approach | Procedure | ICD-10-PCS |
| 0TRB07Z | Replacement of Bladder with Autologous Tissue Substitute, Open Approach | Procedure | ICD-10-PCS |
| 278.0 | Overweight and obesity | Diagnosis | ICD-9-CM |
| 278.00 | Obesity, unspecified | Diagnosis | ICD-9-CM |
| 278.01 | Morbid obesity | Diagnosis | ICD-9-CM |
| 278.03 | Obesity hypoventilation syndrome | Diagnosis | ICD-9-CM |
| 43644 | Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (roux limb 150 cm or less) | Procedure | CPT-4 |
| 43645 | Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and small intestine reconstruction to limit absorption | Procedure | CPT-4 |
| 43770 | Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable gastric restrictive device (eg, gastric band and subcutaneous port components) | Procedure | CPT-4 |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| 43842 | Gastric restrictive procedure, without gastric bypass, for morbid obesity; vertical-banded gastroplasty | Procedure | CPT-4 |
| 43843 | Gastric restrictive procedure, without gastric bypass, for morbid obesity; other than vertical-banded gastroplasty | Procedure | CPT-4 |
| 43845 | Gastric restrictive procedure with partial gastrectomy, pylorus-preserving duodenoileostomy and ileoileostomy (50 to 100 cm common channel) to limit absorption (biliopancreatic diversion with duodenal switch) | Procedure | CPT-4 |
| 43846 | Gastric restrictive procedure, with gastric bypass for morbid obesity; with short limb (150 cm or less) Roux-en-Y gastroenterostomy | Procedure | CPT-4 |
| 43847 | Gastric restrictive procedure, with gastric bypass for morbid obesity; with small intestine reconstruction to limit absorption | Procedure | CPT-4 |
| E66.01 | Morbid (severe) obesity due to excess calories | Diagnosis | ICD-10-CM |
| E66.09 | Other obesity due to excess calories | Diagnosis | ICD-10-CM |
| E66.1 | Drug-induced obesity | Diagnosis | ICD-10-CM |
| E66.2 | Morbid (severe) obesity with alveolar hypoventilation | Diagnosis | ICD-10-CM |
| E66.8 | Other obesity | Diagnosis | ICD-10-CM |
| E66.9 | Obesity, unspecified | Diagnosis | ICD-10-CM |
| K95.01 | Infection due to gastric band procedure | Diagnosis | ICD-10-CM |
| K95.09 | Other complications of gastric band procedure | Diagnosis | ICD-10-CM |
| K95.81 | Infection due to other bariatric procedure | Diagnosis | ICD-10-CM |
| K95.89 | Other complications of other bariatric procedure | Diagnosis | ICD-10-CM |
| O99.210 | Obesity complicating pregnancy, unspecified trimester | Diagnosis | ICD-10-CM |
| O99.211 | Obesity complicating pregnancy, first trimester | Diagnosis | ICD-10-CM |
| O99.212 | Obesity complicating pregnancy, second trimester | Diagnosis | ICD-10-CM |
| O99.213 | Obesity complicating pregnancy, third trimester | Diagnosis | ICD-10-CM |
| O99.214 | Obesity complicating childbirth | Diagnosis | ICD-10-CM |
| O99.215 | Obesity complicating the puerperium | Diagnosis | ICD-10-CM |
| O99.840 | Bariatric surgery status complicating pregnancy, unspecified trimester | Diagnosis | ICD-10-CM |
| O99.841 | Bariatric surgery status complicating pregnancy, first trimester | Diagnosis | ICD-10-CM |
| O99.842 | Bariatric surgery status complicating pregnancy, second trimester | Diagnosis | ICD-10-CM |
| O99.843 | Bariatric surgery status complicating pregnancy, third trimester | Diagnosis | ICD-10-CM |
| O99.844 | Bariatric surgery status complicating childbirth | Diagnosis | ICD-10-CM |
| O99.845 | Bariatric surgery status complicating the puerperium | Diagnosis | ICD-10-CM |
| V85.3 | Body Mass Index between 30-39, adult | Diagnosis | ICD-9-CM |
| V85.30 | Body Mass Index 30.0-30.9, adult | Diagnosis | ICD-9-CM |
| V85.31 | Body Mass Index 31.0-31.9, adult | Diagnosis | ICD-9-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------------------|---|---------------|-----------|
| V85.32 | Body Mass Index 32.0-32.9, adult | Diagnosis | ICD-9-CM |
| V85.33 | Body Mass Index 33.0-33.9, adult | Diagnosis | ICD-9-CM |
| V85.34 | Body Mass Index 34.0-34.9, adult | Diagnosis | ICD-9-CM |
| V85.35 | Body Mass Index 35.0-35.9, adult | Diagnosis | ICD-9-CM |
| V85.36 | Body Mass Index 36.0-36.9, adult | Diagnosis | ICD-9-CM |
| V85.37 | Body Mass Index 37.0-37.9, adult | Diagnosis | ICD-9-CM |
| V85.38 | Body Mass Index 38.0-38.9, adult | Diagnosis | ICD-9-CM |
| V85.39 | Body Mass Index 39.0-39.9, adult | Diagnosis | ICD-9-CM |
| V85.4 | Body Mass Index 40 and over, adult | Diagnosis | ICD-9-CM |
| V85.41 | Body Mass Index 40.0-44.9, adult | Diagnosis | ICD-9-CM |
| V85.42 | Body Mass Index 45.0-49.9, adult | Diagnosis | ICD-9-CM |
| V85.43 | Body Mass Index 50.0-59.9, adult | Diagnosis | ICD-9-CM |
| V85.44 | Body Mass Index 60.0-69.9, adult | Diagnosis | ICD-9-CM |
| V85.45 | Body Mass Index 70 and over, adult | Diagnosis | ICD-9-CM |
| Z68.30 | Body mass index (BMI) 30.0-30.9, adult | Diagnosis | ICD-10-CM |
| Z68.31 | Body mass index (BMI) 31.0-31.9, adult | Diagnosis | ICD-10-CM |
| Z68.32 | Body mass index (BMI) 32.0-32.9, adult | Diagnosis | ICD-10-CM |
| Z68.33 | Body mass index (BMI) 33.0-33.9, adult | Diagnosis | ICD-10-CM |
| Z68.34 | Body mass index (BMI) 34.0-34.9, adult | Diagnosis | ICD-10-CM |
| Z68.35 | Body mass index (BMI) 35.0-35.9, adult | Diagnosis | ICD-10-CM |
| Z68.36 | Body mass index (BMI) 36.0-36.9, adult | Diagnosis | ICD-10-CM |
| Z68.37 | Body mass index (BMI) 37.0-37.9, adult | Diagnosis | ICD-10-CM |
| Z68.38 | Body mass index (BMI) 38.0-38.9, adult | Diagnosis | ICD-10-CM |
| Z68.39 | Body mass index (BMI) 39.0-39.9, adult | Diagnosis | ICD-10-CM |
| Z68.41 | Body mass index (BMI) 40.0-44.9, adult | Diagnosis | ICD-10-CM |
| Z68.42 | Body mass index (BMI) 45.0-49.9, adult | Diagnosis | ICD-10-CM |
| Z68.43 | Body mass index (BMI) 50-59.9, adult | Diagnosis | ICD-10-CM |
| Z68.44 | Body mass index (BMI) 60.0-69.9, adult | Diagnosis | ICD-10-CM |
| Z68.45 | Body mass index (BMI) 70 or greater, adult | Diagnosis | ICD-10-CM |
| Osteoporosis | | | |
| 733.00 | Unspecified osteoporosis | Diagnosis | ICD-9-CM |
| 733.01 | Senile osteoporosis | Diagnosis | ICD-9-CM |
| 733.02 | Idiopathic osteoporosis | Diagnosis | ICD-9-CM |
| 733.03 | Disuse osteoporosis | Diagnosis | ICD-9-CM |
| 733.09 | Other osteoporosis | Diagnosis | ICD-9-CM |
| M80.00XA | Age-related osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|----------|---|---------------|-----------|
| M80.011A | Age-related osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture | Diagnosis | ICD-10-CM |
| M80.012A | Age-related osteoporosis with current pathological fracture, left shoulder, initial encounter for fracture | Diagnosis | ICD-10-CM |
| M80.019A | Age-related osteoporosis with current pathological fracture, unspecified shoulder, initial encounter for fracture | Diagnosis | ICD-10-CM |
| M80.021A | Age-related osteoporosis with current pathological fracture, right humerus, initial encounter for fracture | Diagnosis | ICD-10-CM |
| M80.022A | Age-related osteoporosis with current pathological fracture, left humerus, initial encounter for fracture | Diagnosis | ICD-10-CM |
| M80.029A | Age-related osteoporosis with current pathological fracture, unspecified humerus, initial encounter for fracture | Diagnosis | ICD-10-CM |
| M80.031A | Age-related osteoporosis with current pathological fracture, right forearm, initial encounter for fracture | Diagnosis | ICD-10-CM |
| M80.032A | Age-related osteoporosis with current pathological fracture, left forearm, initial encounter for fracture | Diagnosis | ICD-10-CM |
| M80.039A | Age-related osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture | Diagnosis | ICD-10-CM |
| M80.041A | Age-related osteoporosis with current pathological fracture, right hand, initial encounter for fracture | Diagnosis | ICD-10-CM |
| M80.042A | Age-related osteoporosis with current pathological fracture, left hand, initial encounter for fracture | Diagnosis | ICD-10-CM |
| M80.049A | Age-related osteoporosis with current pathological fracture, unspecified hand, initial encounter for fracture | Diagnosis | ICD-10-CM |
| M80.051A | Age-related osteoporosis with current pathological fracture, right femur, initial encounter for fracture | Diagnosis | ICD-10-CM |
| M80.052A | Age-related osteoporosis with current pathological fracture, left femur, initial encounter for fracture | Diagnosis | ICD-10-CM |
| M80.059A | Age-related osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture | Diagnosis | ICD-10-CM |
| M80.061A | Age-related osteoporosis with current pathological fracture, right lower leg, initial encounter for fracture | Diagnosis | ICD-10-CM |
| M80.062A | Age-related osteoporosis with current pathological fracture, left lower leg, initial encounter for fracture | Diagnosis | ICD-10-CM |
| M80.069A | Age-related osteoporosis with current pathological fracture, unspecified lower leg, initial encounter for fracture | Diagnosis | ICD-10-CM |
| M80.071A | Age-related osteoporosis with current pathological fracture, right ankle and foot, initial encounter for fracture | Diagnosis | ICD-10-CM |
| M80.072A | Age-related osteoporosis with current pathological fracture, left ankle and foot, initial encounter for fracture | Diagnosis | ICD-10-CM |
| M80.079A | Age-related osteoporosis with current pathological fracture, unspecified ankle and foot, initial encounter for fracture | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|----------|--|---------------|-----------|
| M80.08XA | Age-related osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture | Diagnosis | ICD-10-CM |
| M80.0AXA | Age-related osteoporosis with current pathological fracture, other site, initial encounter for fracture | Diagnosis | ICD-10-CM |
| M80.80XA | Other osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture | Diagnosis | ICD-10-CM |
| M80.811A | Other osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture | Diagnosis | ICD-10-CM |
| M80.812A | Other osteoporosis with current pathological fracture, left shoulder, initial encounter for fracture | Diagnosis | ICD-10-CM |
| M80.819A | Other osteoporosis with current pathological fracture, unspecified shoulder, initial encounter for fracture | Diagnosis | ICD-10-CM |
| M80.821A | Other osteoporosis with current pathological fracture, right humerus, initial encounter for fracture | Diagnosis | ICD-10-CM |
| M80.822A | Other osteoporosis with current pathological fracture, left humerus, initial encounter for fracture | Diagnosis | ICD-10-CM |
| M80.829A | Other osteoporosis with current pathological fracture, unspecified humerus, initial encounter for fracture | Diagnosis | ICD-10-CM |
| M80.831A | Other osteoporosis with current pathological fracture, right forearm, initial encounter for fracture | Diagnosis | ICD-10-CM |
| M80.832A | Other osteoporosis with current pathological fracture, left forearm, initial encounter for fracture | Diagnosis | ICD-10-CM |
| M80.839A | Other osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture | Diagnosis | ICD-10-CM |
| M80.841A | Other osteoporosis with current pathological fracture, right hand, initial encounter for fracture | Diagnosis | ICD-10-CM |
| M80.842A | Other osteoporosis with current pathological fracture, left hand, initial encounter for fracture | Diagnosis | ICD-10-CM |
| M80.849A | Other osteoporosis with current pathological fracture, unspecified hand, initial encounter for fracture | Diagnosis | ICD-10-CM |
| M80.851A | Other osteoporosis with current pathological fracture, right femur, initial encounter for fracture | Diagnosis | ICD-10-CM |
| M80.852A | Other osteoporosis with current pathological fracture, left femur, initial encounter for fracture | Diagnosis | ICD-10-CM |
| M80.859A | Other osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture | Diagnosis | ICD-10-CM |
| M80.861A | Other osteoporosis with current pathological fracture, right lower leg, initial encounter for fracture | Diagnosis | ICD-10-CM |
| M80.862A | Other osteoporosis with current pathological fracture, left lower leg, initial encounter for fracture | Diagnosis | ICD-10-CM |
| M80.869A | Other osteoporosis with current pathological fracture, unspecified lower leg, initial encounter for fracture | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|-----------------------------|---|---------------|-----------|
| M80.871A | Other osteoporosis with current pathological fracture, right ankle and foot, initial encounter for fracture | Diagnosis | ICD-10-CM |
| M80.872A | Other osteoporosis with current pathological fracture, left ankle and foot, initial encounter for fracture | Diagnosis | ICD-10-CM |
| M80.879A | Other osteoporosis with current pathological fracture, unspecified ankle and foot, initial encounter for fracture | Diagnosis | ICD-10-CM |
| M80.88XA | Other osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture | Diagnosis | ICD-10-CM |
| M80.8AXA | Other osteoporosis with current pathological fracture, other site, initial encounter for fracture | Diagnosis | ICD-10-CM |
| M81.0 | Age-related osteoporosis without current pathological fracture | Diagnosis | ICD-10-CM |
| M81.6 | Localized osteoporosis [Lequesne] | Diagnosis | ICD-10-CM |
| M81.8 | Other osteoporosis without current pathological fracture | Diagnosis | ICD-10-CM |
| Overweight | | | |
| E66.3 | Overweight | Diagnosis | ICD-10-CM |
| Z68.25 | Body mass index (BMI) 25.0-25.9, adult | Diagnosis | ICD-10-CM |
| Z68.26 | Body mass index (BMI) 26.0-26.9, adult | Diagnosis | ICD-10-CM |
| Z68.27 | Body mass index (BMI) 27.0-27.9, adult | Diagnosis | ICD-10-CM |
| Z68.28 | Body mass index (BMI) 28.0-28.9, adult | Diagnosis | ICD-10-CM |
| Z68.29 | Body mass index (BMI) 29.0-29.9, adult | Diagnosis | ICD-10-CM |
| Prostate | | | |
| 185 | Malignant neoplasm of prostate | Diagnosis | ICD-9-CM |
| 233.4 | Carcinoma in situ of prostate | Diagnosis | ICD-9-CM |
| C61 | Malignant neoplasm of prostate | Diagnosis | ICD-10-CM |
| D07.5 | Carcinoma in situ of prostate | Diagnosis | ICD-10-CM |
| V10.46 | Personal history of malignant neoplasm of prostate | Diagnosis | ICD-9-CM |
| Z85.46 | Personal history of malignant neoplasm of prostate | Diagnosis | ICD-10-CM |
| Rheumatoid Arthritis | | | |
| 714.0 | Rheumatoid arthritis | Diagnosis | ICD-9-CM |
| 714.1 | Felty's syndrome | Diagnosis | ICD-9-CM |
| 714.2 | Other rheumatoid arthritis with visceral or systemic involvement | Diagnosis | ICD-9-CM |
| 714.30 | Polyarticular juvenile rheumatoid arthritis, chronic or unspecified | Diagnosis | ICD-9-CM |
| 714.31 | Polyarticular juvenile rheumatoid arthritis, acute | Diagnosis | ICD-9-CM |
| 714.32 | Pauciarticular juvenile rheumatoid arthritis | Diagnosis | ICD-9-CM |
| 714.33 | Monoarticular juvenile rheumatoid arthritis | Diagnosis | ICD-9-CM |
| 715.00 | Generalized osteoarthritis, unspecified site | Diagnosis | ICD-9-CM |
| 715.04 | Generalized osteoarthritis, involving hand | Diagnosis | ICD-9-CM |
| 715.09 | Generalized osteoarthritis, involving multiple sites | Diagnosis | ICD-9-CM |
| 715.10 | Primary localized osteoarthritis, unspecified site | Diagnosis | ICD-9-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|--------|---|---------------|-----------|
| 715.11 | Primary localized osteoarthritis, shoulder region | Diagnosis | ICD-9-CM |
| 715.12 | Primary localized osteoarthritis, upper arm | Diagnosis | ICD-9-CM |
| 715.13 | Primary localized osteoarthritis, forearm | Diagnosis | ICD-9-CM |
| 715.14 | Primary localized osteoarthritis, hand | Diagnosis | ICD-9-CM |
| 715.15 | Primary localized osteoarthritis, pelvic region and thigh | Diagnosis | ICD-9-CM |
| 715.16 | Primary localized osteoarthritis, lower leg | Diagnosis | ICD-9-CM |
| 715.17 | Primary localized osteoarthritis, ankle and foot | Diagnosis | ICD-9-CM |
| 715.18 | Primary localized osteoarthritis, other specified sites | Diagnosis | ICD-9-CM |
| 715.20 | Secondary localized osteoarthritis, unspecified site | Diagnosis | ICD-9-CM |
| 715.21 | Secondary localized osteoarthritis, shoulder region | Diagnosis | ICD-9-CM |
| 715.22 | Secondary localized osteoarthritis, upper arm | Diagnosis | ICD-9-CM |
| 715.23 | Secondary localized osteoarthritis, forearm | Diagnosis | ICD-9-CM |
| 715.24 | Secondary localized osteoarthritis, involving hand | Diagnosis | ICD-9-CM |
| 715.25 | Secondary localized osteoarthritis, pelvic region and thigh | Diagnosis | ICD-9-CM |
| 715.26 | Secondary localized osteoarthritis, lower leg | Diagnosis | ICD-9-CM |
| 715.27 | Secondary localized osteoarthritis, ankle and foot | Diagnosis | ICD-9-CM |
| 715.28 | Secondary localized osteoarthritis, other specified site | Diagnosis | ICD-9-CM |
| 715.30 | Localized osteoarthritis not specified whether primary or secondary, unspecified site | Diagnosis | ICD-9-CM |
| 715.31 | Localized osteoarthritis not specified whether primary or secondary, shoulder region | Diagnosis | ICD-9-CM |
| 715.32 | Localized osteoarthritis not specified whether primary or secondary, upper arm | Diagnosis | ICD-9-CM |
| 715.33 | Localized osteoarthritis not specified whether primary or secondary, forearm | Diagnosis | ICD-9-CM |
| 715.34 | Localized osteoarthritis not specified whether primary or secondary, hand | Diagnosis | ICD-9-CM |
| 715.35 | Localized osteoarthritis not specified whether primary or secondary, pelvic region and thigh | Diagnosis | ICD-9-CM |
| 715.36 | Localized osteoarthritis not specified whether primary or secondary, lower leg | Diagnosis | ICD-9-CM |
| 715.37 | Localized osteoarthritis not specified whether primary or secondary, ankle and foot | Diagnosis | ICD-9-CM |
| 715.38 | Localized osteoarthritis not specified whether primary or secondary, other specified sites | Diagnosis | ICD-9-CM |
| 715.80 | Osteoarthritis involving more than one site, but not specified as generalized, unspecified site | Diagnosis | ICD-9-CM |
| 715.89 | Osteoarthritis involving multiple sites, but not specified as generalized | Diagnosis | ICD-9-CM |
| 715.90 | Osteoarthritis, unspecified whether generalized or localized, unspecified site | Diagnosis | ICD-9-CM |
| 715.91 | Osteoarthritis, unspecified whether generalized or localized, shoulder region | Diagnosis | ICD-9-CM |
| 715.92 | Osteoarthritis, unspecified whether generalized or localized, upper arm | Diagnosis | ICD-9-CM |
| 715.93 | Osteoarthritis, unspecified whether generalized or localized, forearm | Diagnosis | ICD-9-CM |
| 715.94 | Osteoarthritis, unspecified whether generalized or localized, hand | Diagnosis | ICD-9-CM |
| 715.95 | Osteoarthritis, unspecified whether generalized or localized, pelvic region and thigh | Diagnosis | ICD-9-CM |
| 715.96 | Osteoarthritis, unspecified whether generalized or localized, lower leg | Diagnosis | ICD-9-CM |
| 715.97 | Osteoarthritis, unspecified whether generalized or localized, ankle and foot | Diagnosis | ICD-9-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|---|---------------|-----------|
| 715.98 | Osteoarthritis, unspecified whether generalized or localized, other specified sites | Diagnosis | ICD-9-CM |
| 720.0 | Ankylosing spondylitis | Diagnosis | ICD-9-CM |
| 721.0 | Cervical spondylosis without myelopathy | Diagnosis | ICD-9-CM |
| 721.1 | Cervical spondylosis with myelopathy | Diagnosis | ICD-9-CM |
| 721.2 | Thoracic spondylosis without myelopathy | Diagnosis | ICD-9-CM |
| 721.3 | Lumbosacral spondylosis without myelopathy | Diagnosis | ICD-9-CM |
| 721.90 | Spondylosis of unspecified site without mention of myelopathy | Diagnosis | ICD-9-CM |
| 721.91 | Spondylosis of unspecified site with myelopathy | Diagnosis | ICD-9-CM |
| L40.50 | Arthropathic psoriasis, unspecified | Diagnosis | ICD-10-CM |
| L40.51 | Distal interphalangeal psoriatic arthropathy | Diagnosis | ICD-10-CM |
| L40.54 | Psoriatic juvenile arthropathy | Diagnosis | ICD-10-CM |
| L40.59 | Other psoriatic arthropathy | Diagnosis | ICD-10-CM |
| M05.00 | Felty's syndrome, unspecified site | Diagnosis | ICD-10-CM |
| M05.011 | Felty's syndrome, right shoulder | Diagnosis | ICD-10-CM |
| M05.012 | Felty's syndrome, left shoulder | Diagnosis | ICD-10-CM |
| M05.019 | Felty's syndrome, unspecified shoulder | Diagnosis | ICD-10-CM |
| M05.021 | Felty's syndrome, right elbow | Diagnosis | ICD-10-CM |
| M05.022 | Felty's syndrome, left elbow | Diagnosis | ICD-10-CM |
| M05.029 | Felty's syndrome, unspecified elbow | Diagnosis | ICD-10-CM |
| M05.031 | Felty's syndrome, right wrist | Diagnosis | ICD-10-CM |
| M05.032 | Felty's syndrome, left wrist | Diagnosis | ICD-10-CM |
| M05.039 | Felty's syndrome, unspecified wrist | Diagnosis | ICD-10-CM |
| M05.041 | Felty's syndrome, right hand | Diagnosis | ICD-10-CM |
| M05.042 | Felty's syndrome, left hand | Diagnosis | ICD-10-CM |
| M05.049 | Felty's syndrome, unspecified hand | Diagnosis | ICD-10-CM |
| M05.051 | Felty's syndrome, right hip | Diagnosis | ICD-10-CM |
| M05.052 | Felty's syndrome, left hip | Diagnosis | ICD-10-CM |
| M05.059 | Felty's syndrome, unspecified hip | Diagnosis | ICD-10-CM |
| M05.061 | Felty's syndrome, right knee | Diagnosis | ICD-10-CM |
| M05.062 | Felty's syndrome, left knee | Diagnosis | ICD-10-CM |
| M05.069 | Felty's syndrome, unspecified knee | Diagnosis | ICD-10-CM |
| M05.071 | Felty's syndrome, right ankle and foot | Diagnosis | ICD-10-CM |
| M05.072 | Felty's syndrome, left ankle and foot | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|-------------|---|----------------------|------------------|
| M05.079 | Felty's syndrome, unspecified ankle and foot | Diagnosis | ICD-10-CM |
| M05.09 | Felty's syndrome, multiple sites | Diagnosis | ICD-10-CM |
| M05.10 | Rheumatoid lung disease with rheumatoid arthritis of unspecified site | Diagnosis | ICD-10-CM |
| M05.111 | Rheumatoid lung disease with rheumatoid arthritis of right shoulder | Diagnosis | ICD-10-CM |
| M05.112 | Rheumatoid lung disease with rheumatoid arthritis of left shoulder | Diagnosis | ICD-10-CM |
| M05.119 | Rheumatoid lung disease with rheumatoid arthritis of unspecified shoulder | Diagnosis | ICD-10-CM |
| M05.121 | Rheumatoid lung disease with rheumatoid arthritis of right elbow | Diagnosis | ICD-10-CM |
| M05.122 | Rheumatoid lung disease with rheumatoid arthritis of left elbow | Diagnosis | ICD-10-CM |
| M05.129 | Rheumatoid lung disease with rheumatoid arthritis of unspecified elbow | Diagnosis | ICD-10-CM |
| M05.131 | Rheumatoid lung disease with rheumatoid arthritis of right wrist | Diagnosis | ICD-10-CM |
| M05.132 | Rheumatoid lung disease with rheumatoid arthritis of left wrist | Diagnosis | ICD-10-CM |
| M05.139 | Rheumatoid lung disease with rheumatoid arthritis of unspecified wrist | Diagnosis | ICD-10-CM |
| M05.141 | Rheumatoid lung disease with rheumatoid arthritis of right hand | Diagnosis | ICD-10-CM |
| M05.142 | Rheumatoid lung disease with rheumatoid arthritis of left hand | Diagnosis | ICD-10-CM |
| M05.149 | Rheumatoid lung disease with rheumatoid arthritis of unspecified hand | Diagnosis | ICD-10-CM |
| M05.151 | Rheumatoid lung disease with rheumatoid arthritis of right hip | Diagnosis | ICD-10-CM |
| M05.152 | Rheumatoid lung disease with rheumatoid arthritis of left hip | Diagnosis | ICD-10-CM |
| M05.159 | Rheumatoid lung disease with rheumatoid arthritis of unspecified hip | Diagnosis | ICD-10-CM |
| M05.161 | Rheumatoid lung disease with rheumatoid arthritis of right knee | Diagnosis | ICD-10-CM |
| M05.162 | Rheumatoid lung disease with rheumatoid arthritis of left knee | Diagnosis | ICD-10-CM |
| M05.169 | Rheumatoid lung disease with rheumatoid arthritis of unspecified knee | Diagnosis | ICD-10-CM |
| M05.171 | Rheumatoid lung disease with rheumatoid arthritis of right ankle and foot | Diagnosis | ICD-10-CM |
| M05.172 | Rheumatoid lung disease with rheumatoid arthritis of left ankle and foot | Diagnosis | ICD-10-CM |
| M05.179 | Rheumatoid lung disease with rheumatoid arthritis of unspecified ankle and foot | Diagnosis | ICD-10-CM |
| M05.19 | Rheumatoid lung disease with rheumatoid arthritis of multiple sites | Diagnosis | ICD-10-CM |
| M05.20 | Rheumatoid vasculitis with rheumatoid arthritis of unspecified site | Diagnosis | ICD-10-CM |
| M05.211 | Rheumatoid vasculitis with rheumatoid arthritis of right shoulder | Diagnosis | ICD-10-CM |
| M05.212 | Rheumatoid vasculitis with rheumatoid arthritis of left shoulder | Diagnosis | ICD-10-CM |
| M05.219 | Rheumatoid vasculitis with rheumatoid arthritis of unspecified shoulder | Diagnosis | ICD-10-CM |
| M05.221 | Rheumatoid vasculitis with rheumatoid arthritis of right elbow | Diagnosis | ICD-10-CM |
| M05.222 | Rheumatoid vasculitis with rheumatoid arthritis of left elbow | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|---|---------------|-----------|
| M05.229 | Rheumatoid vasculitis with rheumatoid arthritis of unspecified elbow | Diagnosis | ICD-10-CM |
| M05.231 | Rheumatoid vasculitis with rheumatoid arthritis of right wrist | Diagnosis | ICD-10-CM |
| M05.232 | Rheumatoid vasculitis with rheumatoid arthritis of left wrist | Diagnosis | ICD-10-CM |
| M05.239 | Rheumatoid vasculitis with rheumatoid arthritis of unspecified wrist | Diagnosis | ICD-10-CM |
| M05.241 | Rheumatoid vasculitis with rheumatoid arthritis of right hand | Diagnosis | ICD-10-CM |
| M05.242 | Rheumatoid vasculitis with rheumatoid arthritis of left hand | Diagnosis | ICD-10-CM |
| M05.249 | Rheumatoid vasculitis with rheumatoid arthritis of unspecified hand | Diagnosis | ICD-10-CM |
| M05.251 | Rheumatoid vasculitis with rheumatoid arthritis of right hip | Diagnosis | ICD-10-CM |
| M05.252 | Rheumatoid vasculitis with rheumatoid arthritis of left hip | Diagnosis | ICD-10-CM |
| M05.259 | Rheumatoid vasculitis with rheumatoid arthritis of unspecified hip | Diagnosis | ICD-10-CM |
| M05.261 | Rheumatoid vasculitis with rheumatoid arthritis of right knee | Diagnosis | ICD-10-CM |
| M05.262 | Rheumatoid vasculitis with rheumatoid arthritis of left knee | Diagnosis | ICD-10-CM |
| M05.269 | Rheumatoid vasculitis with rheumatoid arthritis of unspecified knee | Diagnosis | ICD-10-CM |
| M05.271 | Rheumatoid vasculitis with rheumatoid arthritis of right ankle and foot | Diagnosis | ICD-10-CM |
| M05.272 | Rheumatoid vasculitis with rheumatoid arthritis of left ankle and foot | Diagnosis | ICD-10-CM |
| M05.279 | Rheumatoid vasculitis with rheumatoid arthritis of unspecified ankle and foot | Diagnosis | ICD-10-CM |
| M05.29 | Rheumatoid vasculitis with rheumatoid arthritis of multiple sites | Diagnosis | ICD-10-CM |
| M05.30 | Rheumatoid heart disease with rheumatoid arthritis of unspecified site | Diagnosis | ICD-10-CM |
| M05.311 | Rheumatoid heart disease with rheumatoid arthritis of right shoulder | Diagnosis | ICD-10-CM |
| M05.312 | Rheumatoid heart disease with rheumatoid arthritis of left shoulder | Diagnosis | ICD-10-CM |
| M05.319 | Rheumatoid heart disease with rheumatoid arthritis of unspecified shoulder | Diagnosis | ICD-10-CM |
| M05.321 | Rheumatoid heart disease with rheumatoid arthritis of right elbow | Diagnosis | ICD-10-CM |
| M05.322 | Rheumatoid heart disease with rheumatoid arthritis of left elbow | Diagnosis | ICD-10-CM |
| M05.329 | Rheumatoid heart disease with rheumatoid arthritis of unspecified elbow | Diagnosis | ICD-10-CM |
| M05.331 | Rheumatoid heart disease with rheumatoid arthritis of right wrist | Diagnosis | ICD-10-CM |
| M05.332 | Rheumatoid heart disease with rheumatoid arthritis of left wrist | Diagnosis | ICD-10-CM |
| M05.339 | Rheumatoid heart disease with rheumatoid arthritis of unspecified wrist | Diagnosis | ICD-10-CM |
| M05.341 | Rheumatoid heart disease with rheumatoid arthritis of right hand | Diagnosis | ICD-10-CM |
| M05.342 | Rheumatoid heart disease with rheumatoid arthritis of left hand | Diagnosis | ICD-10-CM |
| M05.349 | Rheumatoid heart disease with rheumatoid arthritis of unspecified hand | Diagnosis | ICD-10-CM |
| M05.351 | Rheumatoid heart disease with rheumatoid arthritis of right hip | Diagnosis | ICD-10-CM |
| M05.352 | Rheumatoid heart disease with rheumatoid arthritis of left hip | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| M05.359 | Rheumatoid heart disease with rheumatoid arthritis of unspecified hip | Diagnosis | ICD-10-CM |
| M05.361 | Rheumatoid heart disease with rheumatoid arthritis of right knee | Diagnosis | ICD-10-CM |
| M05.362 | Rheumatoid heart disease with rheumatoid arthritis of left knee | Diagnosis | ICD-10-CM |
| M05.369 | Rheumatoid heart disease with rheumatoid arthritis of unspecified knee | Diagnosis | ICD-10-CM |
| M05.371 | Rheumatoid heart disease with rheumatoid arthritis of right ankle and foot | Diagnosis | ICD-10-CM |
| M05.372 | Rheumatoid heart disease with rheumatoid arthritis of left ankle and foot | Diagnosis | ICD-10-CM |
| M05.379 | Rheumatoid heart disease with rheumatoid arthritis of unspecified ankle and foot | Diagnosis | ICD-10-CM |
| M05.39 | Rheumatoid heart disease with rheumatoid arthritis of multiple sites | Diagnosis | ICD-10-CM |
| M05.40 | Rheumatoid myopathy with rheumatoid arthritis of unspecified site | Diagnosis | ICD-10-CM |
| M05.411 | Rheumatoid myopathy with rheumatoid arthritis of right shoulder | Diagnosis | ICD-10-CM |
| M05.412 | Rheumatoid myopathy with rheumatoid arthritis of left shoulder | Diagnosis | ICD-10-CM |
| M05.419 | Rheumatoid myopathy with rheumatoid arthritis of unspecified shoulder | Diagnosis | ICD-10-CM |
| M05.421 | Rheumatoid myopathy with rheumatoid arthritis of right elbow | Diagnosis | ICD-10-CM |
| M05.422 | Rheumatoid myopathy with rheumatoid arthritis of left elbow | Diagnosis | ICD-10-CM |
| M05.429 | Rheumatoid myopathy with rheumatoid arthritis of unspecified elbow | Diagnosis | ICD-10-CM |
| M05.431 | Rheumatoid myopathy with rheumatoid arthritis of right wrist | Diagnosis | ICD-10-CM |
| M05.432 | Rheumatoid myopathy with rheumatoid arthritis of left wrist | Diagnosis | ICD-10-CM |
| M05.439 | Rheumatoid myopathy with rheumatoid arthritis of unspecified wrist | Diagnosis | ICD-10-CM |
| M05.441 | Rheumatoid myopathy with rheumatoid arthritis of right hand | Diagnosis | ICD-10-CM |
| M05.442 | Rheumatoid myopathy with rheumatoid arthritis of left hand | Diagnosis | ICD-10-CM |
| M05.449 | Rheumatoid myopathy with rheumatoid arthritis of unspecified hand | Diagnosis | ICD-10-CM |
| M05.451 | Rheumatoid myopathy with rheumatoid arthritis of right hip | Diagnosis | ICD-10-CM |
| M05.452 | Rheumatoid myopathy with rheumatoid arthritis of left hip | Diagnosis | ICD-10-CM |
| M05.459 | Rheumatoid myopathy with rheumatoid arthritis of unspecified hip | Diagnosis | ICD-10-CM |
| M05.461 | Rheumatoid myopathy with rheumatoid arthritis of right knee | Diagnosis | ICD-10-CM |
| M05.462 | Rheumatoid myopathy with rheumatoid arthritis of left knee | Diagnosis | ICD-10-CM |
| M05.469 | Rheumatoid myopathy with rheumatoid arthritis of unspecified knee | Diagnosis | ICD-10-CM |
| M05.471 | Rheumatoid myopathy with rheumatoid arthritis of right ankle and foot | Diagnosis | ICD-10-CM |
| M05.472 | Rheumatoid myopathy with rheumatoid arthritis of left ankle and foot | Diagnosis | ICD-10-CM |
| M05.479 | Rheumatoid myopathy with rheumatoid arthritis of unspecified ankle and foot | Diagnosis | ICD-10-CM |
| M05.49 | Rheumatoid myopathy with rheumatoid arthritis of multiple sites | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|-------------|---|----------------------|------------------|
| M05.50 | Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified site | Diagnosis | ICD-10-CM |
| M05.511 | Rheumatoid polyneuropathy with rheumatoid arthritis of right shoulder | Diagnosis | ICD-10-CM |
| M05.512 | Rheumatoid polyneuropathy with rheumatoid arthritis of left shoulder | Diagnosis | ICD-10-CM |
| M05.519 | Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified shoulder | Diagnosis | ICD-10-CM |
| M05.521 | Rheumatoid polyneuropathy with rheumatoid arthritis of right elbow | Diagnosis | ICD-10-CM |
| M05.522 | Rheumatoid polyneuropathy with rheumatoid arthritis of left elbow | Diagnosis | ICD-10-CM |
| M05.529 | Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified elbow | Diagnosis | ICD-10-CM |
| M05.531 | Rheumatoid polyneuropathy with rheumatoid arthritis of right wrist | Diagnosis | ICD-10-CM |
| M05.532 | Rheumatoid polyneuropathy with rheumatoid arthritis of left wrist | Diagnosis | ICD-10-CM |
| M05.539 | Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified wrist | Diagnosis | ICD-10-CM |
| M05.541 | Rheumatoid polyneuropathy with rheumatoid arthritis of right hand | Diagnosis | ICD-10-CM |
| M05.542 | Rheumatoid polyneuropathy with rheumatoid arthritis of left hand | Diagnosis | ICD-10-CM |
| M05.549 | Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hand | Diagnosis | ICD-10-CM |
| M05.551 | Rheumatoid polyneuropathy with rheumatoid arthritis of right hip | Diagnosis | ICD-10-CM |
| M05.552 | Rheumatoid polyneuropathy with rheumatoid arthritis of left hip | Diagnosis | ICD-10-CM |
| M05.559 | Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hip | Diagnosis | ICD-10-CM |
| M05.561 | Rheumatoid polyneuropathy with rheumatoid arthritis of right knee | Diagnosis | ICD-10-CM |
| M05.562 | Rheumatoid polyneuropathy with rheumatoid arthritis of left knee | Diagnosis | ICD-10-CM |
| M05.569 | Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified knee | Diagnosis | ICD-10-CM |
| M05.571 | Rheumatoid polyneuropathy with rheumatoid arthritis of right ankle and foot | Diagnosis | ICD-10-CM |
| M05.572 | Rheumatoid polyneuropathy with rheumatoid arthritis of left ankle and foot | Diagnosis | ICD-10-CM |
| M05.579 | Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified ankle and foot | Diagnosis | ICD-10-CM |
| M05.59 | Rheumatoid polyneuropathy with rheumatoid arthritis of multiple sites | Diagnosis | ICD-10-CM |
| M05.60 | Rheumatoid arthritis of unspecified site with involvement of other organs and systems | Diagnosis | ICD-10-CM |
| M05.611 | Rheumatoid arthritis of right shoulder with involvement of other organs and systems | Diagnosis | ICD-10-CM |
| M05.612 | Rheumatoid arthritis of left shoulder with involvement of other organs and systems | Diagnosis | ICD-10-CM |
| M05.619 | Rheumatoid arthritis of unspecified shoulder with involvement of other organs and systems | Diagnosis | ICD-10-CM |
| M05.621 | Rheumatoid arthritis of right elbow with involvement of other organs and systems | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| M05.622 | Rheumatoid arthritis of left elbow with involvement of other organs and systems | Diagnosis | ICD-10-CM |
| M05.629 | Rheumatoid arthritis of unspecified elbow with involvement of other organs and systems | Diagnosis | ICD-10-CM |
| M05.631 | Rheumatoid arthritis of right wrist with involvement of other organs and systems | Diagnosis | ICD-10-CM |
| M05.632 | Rheumatoid arthritis of left wrist with involvement of other organs and systems | Diagnosis | ICD-10-CM |
| M05.639 | Rheumatoid arthritis of unspecified wrist with involvement of other organs and systems | Diagnosis | ICD-10-CM |
| M05.641 | Rheumatoid arthritis of right hand with involvement of other organs and systems | Diagnosis | ICD-10-CM |
| M05.642 | Rheumatoid arthritis of left hand with involvement of other organs and systems | Diagnosis | ICD-10-CM |
| M05.649 | Rheumatoid arthritis of unspecified hand with involvement of other organs and systems | Diagnosis | ICD-10-CM |
| M05.651 | Rheumatoid arthritis of right hip with involvement of other organs and systems | Diagnosis | ICD-10-CM |
| M05.652 | Rheumatoid arthritis of left hip with involvement of other organs and systems | Diagnosis | ICD-10-CM |
| M05.659 | Rheumatoid arthritis of unspecified hip with involvement of other organs and systems | Diagnosis | ICD-10-CM |
| M05.661 | Rheumatoid arthritis of right knee with involvement of other organs and systems | Diagnosis | ICD-10-CM |
| M05.662 | Rheumatoid arthritis of left knee with involvement of other organs and systems | Diagnosis | ICD-10-CM |
| M05.669 | Rheumatoid arthritis of unspecified knee with involvement of other organs and systems | Diagnosis | ICD-10-CM |
| M05.671 | Rheumatoid arthritis of right ankle and foot with involvement of other organs and systems | Diagnosis | ICD-10-CM |
| M05.672 | Rheumatoid arthritis of left ankle and foot with involvement of other organs and systems | Diagnosis | ICD-10-CM |
| M05.679 | Rheumatoid arthritis of unspecified ankle and foot with involvement of other organs and systems | Diagnosis | ICD-10-CM |
| M05.69 | Rheumatoid arthritis of multiple sites with involvement of other organs and systems | Diagnosis | ICD-10-CM |
| M05.70 | Rheumatoid arthritis with rheumatoid factor of unspecified site without organ or systems involvement | Diagnosis | ICD-10-CM |
| M05.711 | Rheumatoid arthritis with rheumatoid factor of right shoulder without organ or systems involvement | Diagnosis | ICD-10-CM |
| M05.712 | Rheumatoid arthritis with rheumatoid factor of left shoulder without organ or systems involvement | Diagnosis | ICD-10-CM |
| M05.719 | Rheumatoid arthritis with rheumatoid factor of unspecified shoulder without organ or systems involvement | Diagnosis | ICD-10-CM |
| M05.721 | Rheumatoid arthritis with rheumatoid factor of right elbow without organ or systems involvement | Diagnosis | ICD-10-CM |
| M05.722 | Rheumatoid arthritis with rheumatoid factor of left elbow without organ or systems involvement | Diagnosis | ICD-10-CM |
| M05.729 | Rheumatoid arthritis with rheumatoid factor of unspecified elbow without organ or systems involvement | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| M05.731 | Rheumatoid arthritis with rheumatoid factor of right wrist without organ or systems involvement | Diagnosis | ICD-10-CM |
| M05.732 | Rheumatoid arthritis with rheumatoid factor of left wrist without organ or systems involvement | Diagnosis | ICD-10-CM |
| M05.739 | Rheumatoid arthritis with rheumatoid factor of unspecified wrist without organ or systems involvement | Diagnosis | ICD-10-CM |
| M05.741 | Rheumatoid arthritis with rheumatoid factor of right hand without organ or systems involvement | Diagnosis | ICD-10-CM |
| M05.742 | Rheumatoid arthritis with rheumatoid factor of left hand without organ or systems involvement | Diagnosis | ICD-10-CM |
| M05.749 | Rheumatoid arthritis with rheumatoid factor of unspecified hand without organ or systems involvement | Diagnosis | ICD-10-CM |
| M05.751 | Rheumatoid arthritis with rheumatoid factor of right hip without organ or systems involvement | Diagnosis | ICD-10-CM |
| M05.752 | Rheumatoid arthritis with rheumatoid factor of left hip without organ or systems involvement | Diagnosis | ICD-10-CM |
| M05.759 | Rheumatoid arthritis with rheumatoid factor of unspecified hip without organ or systems involvement | Diagnosis | ICD-10-CM |
| M05.761 | Rheumatoid arthritis with rheumatoid factor of right knee without organ or systems involvement | Diagnosis | ICD-10-CM |
| M05.762 | Rheumatoid arthritis with rheumatoid factor of left knee without organ or systems involvement | Diagnosis | ICD-10-CM |
| M05.769 | Rheumatoid arthritis with rheumatoid factor of unspecified knee without organ or systems involvement | Diagnosis | ICD-10-CM |
| M05.771 | Rheumatoid arthritis with rheumatoid factor of right ankle and foot without organ or systems involvement | Diagnosis | ICD-10-CM |
| M05.772 | Rheumatoid arthritis with rheumatoid factor of left ankle and foot without organ or systems involvement | Diagnosis | ICD-10-CM |
| M05.779 | Rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot without organ or systems involvement | Diagnosis | ICD-10-CM |
| M05.79 | Rheumatoid arthritis with rheumatoid factor of multiple sites without organ or systems involvement | Diagnosis | ICD-10-CM |
| M05.7A | Rheumatoid arthritis with rheumatoid factor of other specified site without organ or systems involvement | Diagnosis | ICD-10-CM |
| M05.80 | Other rheumatoid arthritis with rheumatoid factor of unspecified site | Diagnosis | ICD-10-CM |
| M05.811 | Other rheumatoid arthritis with rheumatoid factor of right shoulder | Diagnosis | ICD-10-CM |
| M05.812 | Other rheumatoid arthritis with rheumatoid factor of left shoulder | Diagnosis | ICD-10-CM |
| M05.819 | Other rheumatoid arthritis with rheumatoid factor of unspecified shoulder | Diagnosis | ICD-10-CM |
| M05.821 | Other rheumatoid arthritis with rheumatoid factor of right elbow | Diagnosis | ICD-10-CM |
| M05.822 | Other rheumatoid arthritis with rheumatoid factor of left elbow | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|---|---------------|-----------|
| M05.829 | Other rheumatoid arthritis with rheumatoid factor of unspecified elbow | Diagnosis | ICD-10-CM |
| M05.831 | Other rheumatoid arthritis with rheumatoid factor of right wrist | Diagnosis | ICD-10-CM |
| M05.832 | Other rheumatoid arthritis with rheumatoid factor of left wrist | Diagnosis | ICD-10-CM |
| M05.839 | Other rheumatoid arthritis with rheumatoid factor of unspecified wrist | Diagnosis | ICD-10-CM |
| M05.841 | Other rheumatoid arthritis with rheumatoid factor of right hand | Diagnosis | ICD-10-CM |
| M05.842 | Other rheumatoid arthritis with rheumatoid factor of left hand | Diagnosis | ICD-10-CM |
| M05.849 | Other rheumatoid arthritis with rheumatoid factor of unspecified hand | Diagnosis | ICD-10-CM |
| M05.851 | Other rheumatoid arthritis with rheumatoid factor of right hip | Diagnosis | ICD-10-CM |
| M05.852 | Other rheumatoid arthritis with rheumatoid factor of left hip | Diagnosis | ICD-10-CM |
| M05.859 | Other rheumatoid arthritis with rheumatoid factor of unspecified hip | Diagnosis | ICD-10-CM |
| M05.861 | Other rheumatoid arthritis with rheumatoid factor of right knee | Diagnosis | ICD-10-CM |
| M05.862 | Other rheumatoid arthritis with rheumatoid factor of left knee | Diagnosis | ICD-10-CM |
| M05.869 | Other rheumatoid arthritis with rheumatoid factor of unspecified knee | Diagnosis | ICD-10-CM |
| M05.871 | Other rheumatoid arthritis with rheumatoid factor of right ankle and foot | Diagnosis | ICD-10-CM |
| M05.872 | Other rheumatoid arthritis with rheumatoid factor of left ankle and foot | Diagnosis | ICD-10-CM |
| M05.879 | Other rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot | Diagnosis | ICD-10-CM |
| M05.89 | Other rheumatoid arthritis with rheumatoid factor of multiple sites | Diagnosis | ICD-10-CM |
| M05.8A | Other rheumatoid arthritis with rheumatoid factor of other specified site | Diagnosis | ICD-10-CM |
| M05.9 | Rheumatoid arthritis with rheumatoid factor, unspecified | Diagnosis | ICD-10-CM |
| M06.00 | Rheumatoid arthritis without rheumatoid factor, unspecified site | Diagnosis | ICD-10-CM |
| M06.011 | Rheumatoid arthritis without rheumatoid factor, right shoulder | Diagnosis | ICD-10-CM |
| M06.012 | Rheumatoid arthritis without rheumatoid factor, left shoulder | Diagnosis | ICD-10-CM |
| M06.019 | Rheumatoid arthritis without rheumatoid factor, unspecified shoulder | Diagnosis | ICD-10-CM |
| M06.021 | Rheumatoid arthritis without rheumatoid factor, right elbow | Diagnosis | ICD-10-CM |
| M06.022 | Rheumatoid arthritis without rheumatoid factor, left elbow | Diagnosis | ICD-10-CM |
| M06.029 | Rheumatoid arthritis without rheumatoid factor, unspecified elbow | Diagnosis | ICD-10-CM |
| M06.031 | Rheumatoid arthritis without rheumatoid factor, right wrist | Diagnosis | ICD-10-CM |
| M06.032 | Rheumatoid arthritis without rheumatoid factor, left wrist | Diagnosis | ICD-10-CM |
| M06.039 | Rheumatoid arthritis without rheumatoid factor, unspecified wrist | Diagnosis | ICD-10-CM |
| M06.041 | Rheumatoid arthritis without rheumatoid factor, right hand | Diagnosis | ICD-10-CM |
| M06.042 | Rheumatoid arthritis without rheumatoid factor, left hand | Diagnosis | ICD-10-CM |
| M06.049 | Rheumatoid arthritis without rheumatoid factor, unspecified hand | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| M06.051 | Rheumatoid arthritis without rheumatoid factor, right hip | Diagnosis | ICD-10-CM |
| M06.052 | Rheumatoid arthritis without rheumatoid factor, left hip | Diagnosis | ICD-10-CM |
| M06.059 | Rheumatoid arthritis without rheumatoid factor, unspecified hip | Diagnosis | ICD-10-CM |
| M06.061 | Rheumatoid arthritis without rheumatoid factor, right knee | Diagnosis | ICD-10-CM |
| M06.062 | Rheumatoid arthritis without rheumatoid factor, left knee | Diagnosis | ICD-10-CM |
| M06.069 | Rheumatoid arthritis without rheumatoid factor, unspecified knee | Diagnosis | ICD-10-CM |
| M06.071 | Rheumatoid arthritis without rheumatoid factor, right ankle and foot | Diagnosis | ICD-10-CM |
| M06.072 | Rheumatoid arthritis without rheumatoid factor, left ankle and foot | Diagnosis | ICD-10-CM |
| M06.079 | Rheumatoid arthritis without rheumatoid factor, unspecified ankle and foot | Diagnosis | ICD-10-CM |
| M06.08 | Rheumatoid arthritis without rheumatoid factor, vertebrae | Diagnosis | ICD-10-CM |
| M06.09 | Rheumatoid arthritis without rheumatoid factor, multiple sites | Diagnosis | ICD-10-CM |
| M06.0A | Rheumatoid arthritis without rheumatoid factor, other specified site | Diagnosis | ICD-10-CM |
| M06.1 | Adult-onset Still's disease | Diagnosis | ICD-10-CM |
| M06.20 | Rheumatoid bursitis, unspecified site | Diagnosis | ICD-10-CM |
| M06.211 | Rheumatoid bursitis, right shoulder | Diagnosis | ICD-10-CM |
| M06.212 | Rheumatoid bursitis, left shoulder | Diagnosis | ICD-10-CM |
| M06.219 | Rheumatoid bursitis, unspecified shoulder | Diagnosis | ICD-10-CM |
| M06.221 | Rheumatoid bursitis, right elbow | Diagnosis | ICD-10-CM |
| M06.222 | Rheumatoid bursitis, left elbow | Diagnosis | ICD-10-CM |
| M06.229 | Rheumatoid bursitis, unspecified elbow | Diagnosis | ICD-10-CM |
| M06.231 | Rheumatoid bursitis, right wrist | Diagnosis | ICD-10-CM |
| M06.232 | Rheumatoid bursitis, left wrist | Diagnosis | ICD-10-CM |
| M06.239 | Rheumatoid bursitis, unspecified wrist | Diagnosis | ICD-10-CM |
| M06.241 | Rheumatoid bursitis, right hand | Diagnosis | ICD-10-CM |
| M06.242 | Rheumatoid bursitis, left hand | Diagnosis | ICD-10-CM |
| M06.249 | Rheumatoid bursitis, unspecified hand | Diagnosis | ICD-10-CM |
| M06.251 | Rheumatoid bursitis, right hip | Diagnosis | ICD-10-CM |
| M06.252 | Rheumatoid bursitis, left hip | Diagnosis | ICD-10-CM |
| M06.259 | Rheumatoid bursitis, unspecified hip | Diagnosis | ICD-10-CM |
| M06.261 | Rheumatoid bursitis, right knee | Diagnosis | ICD-10-CM |
| M06.262 | Rheumatoid bursitis, left knee | Diagnosis | ICD-10-CM |
| M06.269 | Rheumatoid bursitis, unspecified knee | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| M06.271 | Rheumatoid bursitis, right ankle and foot | Diagnosis | ICD-10-CM |
| M06.272 | Rheumatoid bursitis, left ankle and foot | Diagnosis | ICD-10-CM |
| M06.279 | Rheumatoid bursitis, unspecified ankle and foot | Diagnosis | ICD-10-CM |
| M06.28 | Rheumatoid bursitis, vertebrae | Diagnosis | ICD-10-CM |
| M06.29 | Rheumatoid bursitis, multiple sites | Diagnosis | ICD-10-CM |
| M06.30 | Rheumatoid nodule, unspecified site | Diagnosis | ICD-10-CM |
| M06.311 | Rheumatoid nodule, right shoulder | Diagnosis | ICD-10-CM |
| M06.312 | Rheumatoid nodule, left shoulder | Diagnosis | ICD-10-CM |
| M06.319 | Rheumatoid nodule, unspecified shoulder | Diagnosis | ICD-10-CM |
| M06.321 | Rheumatoid nodule, right elbow | Diagnosis | ICD-10-CM |
| M06.322 | Rheumatoid nodule, left elbow | Diagnosis | ICD-10-CM |
| M06.329 | Rheumatoid nodule, unspecified elbow | Diagnosis | ICD-10-CM |
| M06.331 | Rheumatoid nodule, right wrist | Diagnosis | ICD-10-CM |
| M06.332 | Rheumatoid nodule, left wrist | Diagnosis | ICD-10-CM |
| M06.339 | Rheumatoid nodule, unspecified wrist | Diagnosis | ICD-10-CM |
| M06.341 | Rheumatoid nodule, right hand | Diagnosis | ICD-10-CM |
| M06.342 | Rheumatoid nodule, left hand | Diagnosis | ICD-10-CM |
| M06.349 | Rheumatoid nodule, unspecified hand | Diagnosis | ICD-10-CM |
| M06.351 | Rheumatoid nodule, right hip | Diagnosis | ICD-10-CM |
| M06.352 | Rheumatoid nodule, left hip | Diagnosis | ICD-10-CM |
| M06.359 | Rheumatoid nodule, unspecified hip | Diagnosis | ICD-10-CM |
| M06.361 | Rheumatoid nodule, right knee | Diagnosis | ICD-10-CM |
| M06.362 | Rheumatoid nodule, left knee | Diagnosis | ICD-10-CM |
| M06.369 | Rheumatoid nodule, unspecified knee | Diagnosis | ICD-10-CM |
| M06.371 | Rheumatoid nodule, right ankle and foot | Diagnosis | ICD-10-CM |
| M06.372 | Rheumatoid nodule, left ankle and foot | Diagnosis | ICD-10-CM |
| M06.379 | Rheumatoid nodule, unspecified ankle and foot | Diagnosis | ICD-10-CM |
| M06.38 | Rheumatoid nodule, vertebrae | Diagnosis | ICD-10-CM |
| M06.39 | Rheumatoid nodule, multiple sites | Diagnosis | ICD-10-CM |
| M06.80 | Other specified rheumatoid arthritis, unspecified site | Diagnosis | ICD-10-CM |
| M06.811 | Other specified rheumatoid arthritis, right shoulder | Diagnosis | ICD-10-CM |
| M06.812 | Other specified rheumatoid arthritis, left shoulder | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| M06.819 | Other specified rheumatoid arthritis, unspecified shoulder | Diagnosis | ICD-10-CM |
| M06.821 | Other specified rheumatoid arthritis, right elbow | Diagnosis | ICD-10-CM |
| M06.822 | Other specified rheumatoid arthritis, left elbow | Diagnosis | ICD-10-CM |
| M06.829 | Other specified rheumatoid arthritis, unspecified elbow | Diagnosis | ICD-10-CM |
| M06.831 | Other specified rheumatoid arthritis, right wrist | Diagnosis | ICD-10-CM |
| M06.832 | Other specified rheumatoid arthritis, left wrist | Diagnosis | ICD-10-CM |
| M06.839 | Other specified rheumatoid arthritis, unspecified wrist | Diagnosis | ICD-10-CM |
| M06.841 | Other specified rheumatoid arthritis, right hand | Diagnosis | ICD-10-CM |
| M06.842 | Other specified rheumatoid arthritis, left hand | Diagnosis | ICD-10-CM |
| M06.849 | Other specified rheumatoid arthritis, unspecified hand | Diagnosis | ICD-10-CM |
| M06.851 | Other specified rheumatoid arthritis, right hip | Diagnosis | ICD-10-CM |
| M06.852 | Other specified rheumatoid arthritis, left hip | Diagnosis | ICD-10-CM |
| M06.859 | Other specified rheumatoid arthritis, unspecified hip | Diagnosis | ICD-10-CM |
| M06.861 | Other specified rheumatoid arthritis, right knee | Diagnosis | ICD-10-CM |
| M06.862 | Other specified rheumatoid arthritis, left knee | Diagnosis | ICD-10-CM |
| M06.869 | Other specified rheumatoid arthritis, unspecified knee | Diagnosis | ICD-10-CM |
| M06.871 | Other specified rheumatoid arthritis, right ankle and foot | Diagnosis | ICD-10-CM |
| M06.872 | Other specified rheumatoid arthritis, left ankle and foot | Diagnosis | ICD-10-CM |
| M06.879 | Other specified rheumatoid arthritis, unspecified ankle and foot | Diagnosis | ICD-10-CM |
| M06.88 | Other specified rheumatoid arthritis, vertebrae | Diagnosis | ICD-10-CM |
| M06.89 | Other specified rheumatoid arthritis, multiple sites | Diagnosis | ICD-10-CM |
| M06.8A | Other specified rheumatoid arthritis, other specified site | Diagnosis | ICD-10-CM |
| M06.9 | Rheumatoid arthritis, unspecified | Diagnosis | ICD-10-CM |
| M08.00 | Unspecified juvenile rheumatoid arthritis of unspecified site | Diagnosis | ICD-10-CM |
| M08.011 | Unspecified juvenile rheumatoid arthritis, right shoulder | Diagnosis | ICD-10-CM |
| M08.012 | Unspecified juvenile rheumatoid arthritis, left shoulder | Diagnosis | ICD-10-CM |
| M08.019 | Unspecified juvenile rheumatoid arthritis, unspecified shoulder | Diagnosis | ICD-10-CM |
| M08.021 | Unspecified juvenile rheumatoid arthritis, right elbow | Diagnosis | ICD-10-CM |
| M08.022 | Unspecified juvenile rheumatoid arthritis, left elbow | Diagnosis | ICD-10-CM |
| M08.029 | Unspecified juvenile rheumatoid arthritis, unspecified elbow | Diagnosis | ICD-10-CM |
| M08.031 | Unspecified juvenile rheumatoid arthritis, right wrist | Diagnosis | ICD-10-CM |
| M08.032 | Unspecified juvenile rheumatoid arthritis, left wrist | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|---|---------------|-----------|
| M08.039 | Unspecified juvenile rheumatoid arthritis, unspecified wrist | Diagnosis | ICD-10-CM |
| M08.041 | Unspecified juvenile rheumatoid arthritis, right hand | Diagnosis | ICD-10-CM |
| M08.042 | Unspecified juvenile rheumatoid arthritis, left hand | Diagnosis | ICD-10-CM |
| M08.049 | Unspecified juvenile rheumatoid arthritis, unspecified hand | Diagnosis | ICD-10-CM |
| M08.051 | Unspecified juvenile rheumatoid arthritis, right hip | Diagnosis | ICD-10-CM |
| M08.052 | Unspecified juvenile rheumatoid arthritis, left hip | Diagnosis | ICD-10-CM |
| M08.059 | Unspecified juvenile rheumatoid arthritis, unspecified hip | Diagnosis | ICD-10-CM |
| M08.061 | Unspecified juvenile rheumatoid arthritis, right knee | Diagnosis | ICD-10-CM |
| M08.062 | Unspecified juvenile rheumatoid arthritis, left knee | Diagnosis | ICD-10-CM |
| M08.069 | Unspecified juvenile rheumatoid arthritis, unspecified knee | Diagnosis | ICD-10-CM |
| M08.071 | Unspecified juvenile rheumatoid arthritis, right ankle and foot | Diagnosis | ICD-10-CM |
| M08.072 | Unspecified juvenile rheumatoid arthritis, left ankle and foot | Diagnosis | ICD-10-CM |
| M08.079 | Unspecified juvenile rheumatoid arthritis, unspecified ankle and foot | Diagnosis | ICD-10-CM |
| M08.08 | Unspecified juvenile rheumatoid arthritis, vertebrae | Diagnosis | ICD-10-CM |
| M08.09 | Unspecified juvenile rheumatoid arthritis, multiple sites | Diagnosis | ICD-10-CM |
| M08.0A | Unspecified juvenile rheumatoid arthritis, other specified site | Diagnosis | ICD-10-CM |
| M08.1 | Juvenile ankylosing spondylitis | Diagnosis | ICD-10-CM |
| M08.20 | Juvenile rheumatoid arthritis with systemic onset, unspecified site | Diagnosis | ICD-10-CM |
| M08.211 | Juvenile rheumatoid arthritis with systemic onset, right shoulder | Diagnosis | ICD-10-CM |
| M08.212 | Juvenile rheumatoid arthritis with systemic onset, left shoulder | Diagnosis | ICD-10-CM |
| M08.219 | Juvenile rheumatoid arthritis with systemic onset, unspecified shoulder | Diagnosis | ICD-10-CM |
| M08.221 | Juvenile rheumatoid arthritis with systemic onset, right elbow | Diagnosis | ICD-10-CM |
| M08.222 | Juvenile rheumatoid arthritis with systemic onset, left elbow | Diagnosis | ICD-10-CM |
| M08.229 | Juvenile rheumatoid arthritis with systemic onset, unspecified elbow | Diagnosis | ICD-10-CM |
| M08.231 | Juvenile rheumatoid arthritis with systemic onset, right wrist | Diagnosis | ICD-10-CM |
| M08.232 | Juvenile rheumatoid arthritis with systemic onset, left wrist | Diagnosis | ICD-10-CM |
| M08.239 | Juvenile rheumatoid arthritis with systemic onset, unspecified wrist | Diagnosis | ICD-10-CM |
| M08.241 | Juvenile rheumatoid arthritis with systemic onset, right hand | Diagnosis | ICD-10-CM |
| M08.242 | Juvenile rheumatoid arthritis with systemic onset, left hand | Diagnosis | ICD-10-CM |
| M08.249 | Juvenile rheumatoid arthritis with systemic onset, unspecified hand | Diagnosis | ICD-10-CM |
| M08.251 | Juvenile rheumatoid arthritis with systemic onset, right hip | Diagnosis | ICD-10-CM |
| M08.252 | Juvenile rheumatoid arthritis with systemic onset, left hip | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|---|---------------|-----------|
| M08.259 | Juvenile rheumatoid arthritis with systemic onset, unspecified hip | Diagnosis | ICD-10-CM |
| M08.261 | Juvenile rheumatoid arthritis with systemic onset, right knee | Diagnosis | ICD-10-CM |
| M08.262 | Juvenile rheumatoid arthritis with systemic onset, left knee | Diagnosis | ICD-10-CM |
| M08.269 | Juvenile rheumatoid arthritis with systemic onset, unspecified knee | Diagnosis | ICD-10-CM |
| M08.271 | Juvenile rheumatoid arthritis with systemic onset, right ankle and foot | Diagnosis | ICD-10-CM |
| M08.272 | Juvenile rheumatoid arthritis with systemic onset, left ankle and foot | Diagnosis | ICD-10-CM |
| M08.279 | Juvenile rheumatoid arthritis with systemic onset, unspecified ankle and foot | Diagnosis | ICD-10-CM |
| M08.28 | Juvenile rheumatoid arthritis with systemic onset, vertebrae | Diagnosis | ICD-10-CM |
| M08.29 | Juvenile rheumatoid arthritis with systemic onset, multiple sites | Diagnosis | ICD-10-CM |
| M08.2A | Juvenile rheumatoid arthritis with systemic onset, other specified site | Diagnosis | ICD-10-CM |
| M08.3 | Juvenile rheumatoid polyarthritis (seronegative) | Diagnosis | ICD-10-CM |
| M08.40 | Pauciarticular juvenile rheumatoid arthritis, unspecified site | Diagnosis | ICD-10-CM |
| M08.411 | Pauciarticular juvenile rheumatoid arthritis, right shoulder | Diagnosis | ICD-10-CM |
| M08.412 | Pauciarticular juvenile rheumatoid arthritis, left shoulder | Diagnosis | ICD-10-CM |
| M08.419 | Pauciarticular juvenile rheumatoid arthritis, unspecified shoulder | Diagnosis | ICD-10-CM |
| M08.421 | Pauciarticular juvenile rheumatoid arthritis, right elbow | Diagnosis | ICD-10-CM |
| M08.422 | Pauciarticular juvenile rheumatoid arthritis, left elbow | Diagnosis | ICD-10-CM |
| M08.429 | Pauciarticular juvenile rheumatoid arthritis, unspecified elbow | Diagnosis | ICD-10-CM |
| M08.431 | Pauciarticular juvenile rheumatoid arthritis, right wrist | Diagnosis | ICD-10-CM |
| M08.432 | Pauciarticular juvenile rheumatoid arthritis, left wrist | Diagnosis | ICD-10-CM |
| M08.439 | Pauciarticular juvenile rheumatoid arthritis, unspecified wrist | Diagnosis | ICD-10-CM |
| M08.441 | Pauciarticular juvenile rheumatoid arthritis, right hand | Diagnosis | ICD-10-CM |
| M08.442 | Pauciarticular juvenile rheumatoid arthritis, left hand | Diagnosis | ICD-10-CM |
| M08.449 | Pauciarticular juvenile rheumatoid arthritis, unspecified hand | Diagnosis | ICD-10-CM |
| M08.451 | Pauciarticular juvenile rheumatoid arthritis, right hip | Diagnosis | ICD-10-CM |
| M08.452 | Pauciarticular juvenile rheumatoid arthritis, left hip | Diagnosis | ICD-10-CM |
| M08.459 | Pauciarticular juvenile rheumatoid arthritis, unspecified hip | Diagnosis | ICD-10-CM |
| M08.461 | Pauciarticular juvenile rheumatoid arthritis, right knee | Diagnosis | ICD-10-CM |
| M08.462 | Pauciarticular juvenile rheumatoid arthritis, left knee | Diagnosis | ICD-10-CM |
| M08.469 | Pauciarticular juvenile rheumatoid arthritis, unspecified knee | Diagnosis | ICD-10-CM |
| M08.471 | Pauciarticular juvenile rheumatoid arthritis, right ankle and foot | Diagnosis | ICD-10-CM |
| M08.472 | Pauciarticular juvenile rheumatoid arthritis, left ankle and foot | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| M08.479 | Pauciarticular juvenile rheumatoid arthritis, unspecified ankle and foot | Diagnosis | ICD-10-CM |
| M08.48 | Pauciarticular juvenile rheumatoid arthritis, vertebrae | Diagnosis | ICD-10-CM |
| M08.4A | Pauciarticular juvenile rheumatoid arthritis, other specified site | Diagnosis | ICD-10-CM |
| M08.80 | Other juvenile arthritis, unspecified site | Diagnosis | ICD-10-CM |
| M08.811 | Other juvenile arthritis, right shoulder | Diagnosis | ICD-10-CM |
| M08.812 | Other juvenile arthritis, left shoulder | Diagnosis | ICD-10-CM |
| M08.819 | Other juvenile arthritis, unspecified shoulder | Diagnosis | ICD-10-CM |
| M08.821 | Other juvenile arthritis, right elbow | Diagnosis | ICD-10-CM |
| M08.822 | Other juvenile arthritis, left elbow | Diagnosis | ICD-10-CM |
| M08.829 | Other juvenile arthritis, unspecified elbow | Diagnosis | ICD-10-CM |
| M08.831 | Other juvenile arthritis, right wrist | Diagnosis | ICD-10-CM |
| M08.832 | Other juvenile arthritis, left wrist | Diagnosis | ICD-10-CM |
| M08.839 | Other juvenile arthritis, unspecified wrist | Diagnosis | ICD-10-CM |
| M08.841 | Other juvenile arthritis, right hand | Diagnosis | ICD-10-CM |
| M08.842 | Other juvenile arthritis, left hand | Diagnosis | ICD-10-CM |
| M08.849 | Other juvenile arthritis, unspecified hand | Diagnosis | ICD-10-CM |
| M08.851 | Other juvenile arthritis, right hip | Diagnosis | ICD-10-CM |
| M08.852 | Other juvenile arthritis, left hip | Diagnosis | ICD-10-CM |
| M08.859 | Other juvenile arthritis, unspecified hip | Diagnosis | ICD-10-CM |
| M08.861 | Other juvenile arthritis, right knee | Diagnosis | ICD-10-CM |
| M08.862 | Other juvenile arthritis, left knee | Diagnosis | ICD-10-CM |
| M08.869 | Other juvenile arthritis, unspecified knee | Diagnosis | ICD-10-CM |
| M08.871 | Other juvenile arthritis, right ankle and foot | Diagnosis | ICD-10-CM |
| M08.872 | Other juvenile arthritis, left ankle and foot | Diagnosis | ICD-10-CM |
| M08.879 | Other juvenile arthritis, unspecified ankle and foot | Diagnosis | ICD-10-CM |
| M08.88 | Other juvenile arthritis, other specified site | Diagnosis | ICD-10-CM |
| M08.89 | Other juvenile arthritis, multiple sites | Diagnosis | ICD-10-CM |
| M08.90 | Juvenile arthritis, unspecified, unspecified site | Diagnosis | ICD-10-CM |
| M08.911 | Juvenile arthritis, unspecified, right shoulder | Diagnosis | ICD-10-CM |
| M08.912 | Juvenile arthritis, unspecified, left shoulder | Diagnosis | ICD-10-CM |
| M08.919 | Juvenile arthritis, unspecified, unspecified shoulder | Diagnosis | ICD-10-CM |
| M08.921 | Juvenile arthritis, unspecified, right elbow | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|---|---------------|-----------|
| M08.922 | Juvenile arthritis, unspecified, left elbow | Diagnosis | ICD-10-CM |
| M08.929 | Juvenile arthritis, unspecified, unspecified elbow | Diagnosis | ICD-10-CM |
| M08.931 | Juvenile arthritis, unspecified, right wrist | Diagnosis | ICD-10-CM |
| M08.932 | Juvenile arthritis, unspecified, left wrist | Diagnosis | ICD-10-CM |
| M08.939 | Juvenile arthritis, unspecified, unspecified wrist | Diagnosis | ICD-10-CM |
| M08.941 | Juvenile arthritis, unspecified, right hand | Diagnosis | ICD-10-CM |
| M08.942 | Juvenile arthritis, unspecified, left hand | Diagnosis | ICD-10-CM |
| M08.949 | Juvenile arthritis, unspecified, unspecified hand | Diagnosis | ICD-10-CM |
| M08.951 | Juvenile arthritis, unspecified, right hip | Diagnosis | ICD-10-CM |
| M08.952 | Juvenile arthritis, unspecified, left hip | Diagnosis | ICD-10-CM |
| M08.959 | Juvenile arthritis, unspecified, unspecified hip | Diagnosis | ICD-10-CM |
| M08.961 | Juvenile arthritis, unspecified, right knee | Diagnosis | ICD-10-CM |
| M08.962 | Juvenile arthritis, unspecified, left knee | Diagnosis | ICD-10-CM |
| M08.969 | Juvenile arthritis, unspecified, unspecified knee | Diagnosis | ICD-10-CM |
| M08.971 | Juvenile arthritis, unspecified, right ankle and foot | Diagnosis | ICD-10-CM |
| M08.972 | Juvenile arthritis, unspecified, left ankle and foot | Diagnosis | ICD-10-CM |
| M08.979 | Juvenile arthritis, unspecified, unspecified ankle and foot | Diagnosis | ICD-10-CM |
| M08.98 | Juvenile arthritis, unspecified, vertebrae | Diagnosis | ICD-10-CM |
| M08.99 | Juvenile arthritis, unspecified, multiple sites | Diagnosis | ICD-10-CM |
| M08.9A | Juvenile arthritis, unspecified, other specified site | Diagnosis | ICD-10-CM |
| M15.0 | Primary generalized (osteo)arthritis | Diagnosis | ICD-10-CM |
| M15.1 | Heberden's nodes (with arthropathy) | Diagnosis | ICD-10-CM |
| M15.2 | Bouchard's nodes (with arthropathy) | Diagnosis | ICD-10-CM |
| M15.3 | Secondary multiple arthritis | Diagnosis | ICD-10-CM |
| M15.4 | Erosive (osteo)arthritis | Diagnosis | ICD-10-CM |
| M15.8 | Other polyosteoarthritis | Diagnosis | ICD-10-CM |
| M15.9 | Polyosteoarthritis, unspecified | Diagnosis | ICD-10-CM |
| M16.0 | Bilateral primary osteoarthritis of hip | Diagnosis | ICD-10-CM |
| M16.10 | Unilateral primary osteoarthritis, unspecified hip | Diagnosis | ICD-10-CM |
| M16.11 | Unilateral primary osteoarthritis, right hip | Diagnosis | ICD-10-CM |
| M16.12 | Unilateral primary osteoarthritis, left hip | Diagnosis | ICD-10-CM |
| M16.2 | Bilateral osteoarthritis resulting from hip dysplasia | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|--------|--|---------------|-----------|
| M16.30 | Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip | Diagnosis | ICD-10-CM |
| M16.31 | Unilateral osteoarthritis resulting from hip dysplasia, right hip | Diagnosis | ICD-10-CM |
| M16.32 | Unilateral osteoarthritis resulting from hip dysplasia, left hip | Diagnosis | ICD-10-CM |
| M16.4 | Bilateral post-traumatic osteoarthritis of hip | Diagnosis | ICD-10-CM |
| M16.50 | Unilateral post-traumatic osteoarthritis, unspecified hip | Diagnosis | ICD-10-CM |
| M16.51 | Unilateral post-traumatic osteoarthritis, right hip | Diagnosis | ICD-10-CM |
| M16.52 | Unilateral post-traumatic osteoarthritis, left hip | Diagnosis | ICD-10-CM |
| M16.6 | Other bilateral secondary osteoarthritis of hip | Diagnosis | ICD-10-CM |
| M16.7 | Other unilateral secondary osteoarthritis of hip | Diagnosis | ICD-10-CM |
| M16.9 | Osteoarthritis of hip, unspecified | Diagnosis | ICD-10-CM |
| M17.0 | Bilateral primary osteoarthritis of knee | Diagnosis | ICD-10-CM |
| M17.10 | Unilateral primary osteoarthritis, unspecified knee | Diagnosis | ICD-10-CM |
| M17.11 | Unilateral primary osteoarthritis, right knee | Diagnosis | ICD-10-CM |
| M17.12 | Unilateral primary osteoarthritis, left knee | Diagnosis | ICD-10-CM |
| M17.2 | Bilateral post-traumatic osteoarthritis of knee | Diagnosis | ICD-10-CM |
| M17.30 | Unilateral post-traumatic osteoarthritis, unspecified knee | Diagnosis | ICD-10-CM |
| M17.31 | Unilateral post-traumatic osteoarthritis, right knee | Diagnosis | ICD-10-CM |
| M17.32 | Unilateral post-traumatic osteoarthritis, left knee | Diagnosis | ICD-10-CM |
| M17.4 | Other bilateral secondary osteoarthritis of knee | Diagnosis | ICD-10-CM |
| M17.5 | Other unilateral secondary osteoarthritis of knee | Diagnosis | ICD-10-CM |
| M17.9 | Osteoarthritis of knee, unspecified | Diagnosis | ICD-10-CM |
| M18.0 | Bilateral primary osteoarthritis of first carpometacarpal joints | Diagnosis | ICD-10-CM |
| M18.10 | Unilateral primary osteoarthritis of first carpometacarpal joint, unspecified hand | Diagnosis | ICD-10-CM |
| M18.11 | Unilateral primary osteoarthritis of first carpometacarpal joint, right hand | Diagnosis | ICD-10-CM |
| M18.12 | Unilateral primary osteoarthritis of first carpometacarpal joint, left hand | Diagnosis | ICD-10-CM |
| M18.2 | Bilateral post-traumatic osteoarthritis of first carpometacarpal joints | Diagnosis | ICD-10-CM |
| M18.30 | Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecified hand | Diagnosis | ICD-10-CM |
| M18.31 | Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right hand | Diagnosis | ICD-10-CM |
| M18.32 | Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, left hand | Diagnosis | ICD-10-CM |
| M18.4 | Other bilateral secondary osteoarthritis of first carpometacarpal joints | Diagnosis | ICD-10-CM |
| M18.50 | Other unilateral secondary osteoarthritis of first carpometacarpal joint, unspecified hand | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| M18.51 | Other unilateral secondary osteoarthritis of first carpometacarpal joint, right hand | Diagnosis | ICD-10-CM |
| M18.52 | Other unilateral secondary osteoarthritis of first carpometacarpal joint, left hand | Diagnosis | ICD-10-CM |
| M18.9 | Osteoarthritis of first carpometacarpal joint, unspecified | Diagnosis | ICD-10-CM |
| M19.011 | Primary osteoarthritis, right shoulder | Diagnosis | ICD-10-CM |
| M19.012 | Primary osteoarthritis, left shoulder | Diagnosis | ICD-10-CM |
| M19.019 | Primary osteoarthritis, unspecified shoulder | Diagnosis | ICD-10-CM |
| M19.021 | Primary osteoarthritis, right elbow | Diagnosis | ICD-10-CM |
| M19.022 | Primary osteoarthritis, left elbow | Diagnosis | ICD-10-CM |
| M19.029 | Primary osteoarthritis, unspecified elbow | Diagnosis | ICD-10-CM |
| M19.031 | Primary osteoarthritis, right wrist | Diagnosis | ICD-10-CM |
| M19.032 | Primary osteoarthritis, left wrist | Diagnosis | ICD-10-CM |
| M19.039 | Primary osteoarthritis, unspecified wrist | Diagnosis | ICD-10-CM |
| M19.041 | Primary osteoarthritis, right hand | Diagnosis | ICD-10-CM |
| M19.042 | Primary osteoarthritis, left hand | Diagnosis | ICD-10-CM |
| M19.049 | Primary osteoarthritis, unspecified hand | Diagnosis | ICD-10-CM |
| M19.071 | Primary osteoarthritis, right ankle and foot | Diagnosis | ICD-10-CM |
| M19.072 | Primary osteoarthritis, left ankle and foot | Diagnosis | ICD-10-CM |
| M19.079 | Primary osteoarthritis, unspecified ankle and foot | Diagnosis | ICD-10-CM |
| M19.09 | Primary osteoarthritis, other specified site | Diagnosis | ICD-10-CM |
| M19.111 | Post-traumatic osteoarthritis, right shoulder | Diagnosis | ICD-10-CM |
| M19.112 | Post-traumatic osteoarthritis, left shoulder | Diagnosis | ICD-10-CM |
| M19.119 | Post-traumatic osteoarthritis, unspecified shoulder | Diagnosis | ICD-10-CM |
| M19.121 | Post-traumatic osteoarthritis, right elbow | Diagnosis | ICD-10-CM |
| M19.122 | Post-traumatic osteoarthritis, left elbow | Diagnosis | ICD-10-CM |
| M19.129 | Post-traumatic osteoarthritis, unspecified elbow | Diagnosis | ICD-10-CM |
| M19.131 | Post-traumatic osteoarthritis, right wrist | Diagnosis | ICD-10-CM |
| M19.132 | Post-traumatic osteoarthritis, left wrist | Diagnosis | ICD-10-CM |
| M19.139 | Post-traumatic osteoarthritis, unspecified wrist | Diagnosis | ICD-10-CM |
| M19.141 | Post-traumatic osteoarthritis, right hand | Diagnosis | ICD-10-CM |
| M19.142 | Post-traumatic osteoarthritis, left hand | Diagnosis | ICD-10-CM |
| M19.149 | Post-traumatic osteoarthritis, unspecified hand | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|---|---------------|-----------|
| M19.171 | Post-traumatic osteoarthritis, right ankle and foot | Diagnosis | ICD-10-CM |
| M19.172 | Post-traumatic osteoarthritis, left ankle and foot | Diagnosis | ICD-10-CM |
| M19.179 | Post-traumatic osteoarthritis, unspecified ankle and foot | Diagnosis | ICD-10-CM |
| M19.19 | Post-traumatic osteoarthritis, other specified site | Diagnosis | ICD-10-CM |
| M19.211 | Secondary osteoarthritis, right shoulder | Diagnosis | ICD-10-CM |
| M19.212 | Secondary osteoarthritis, left shoulder | Diagnosis | ICD-10-CM |
| M19.219 | Secondary osteoarthritis, unspecified shoulder | Diagnosis | ICD-10-CM |
| M19.221 | Secondary osteoarthritis, right elbow | Diagnosis | ICD-10-CM |
| M19.222 | Secondary osteoarthritis, left elbow | Diagnosis | ICD-10-CM |
| M19.229 | Secondary osteoarthritis, unspecified elbow | Diagnosis | ICD-10-CM |
| M19.231 | Secondary osteoarthritis, right wrist | Diagnosis | ICD-10-CM |
| M19.232 | Secondary osteoarthritis, left wrist | Diagnosis | ICD-10-CM |
| M19.239 | Secondary osteoarthritis, unspecified wrist | Diagnosis | ICD-10-CM |
| M19.241 | Secondary osteoarthritis, right hand | Diagnosis | ICD-10-CM |
| M19.242 | Secondary osteoarthritis, left hand | Diagnosis | ICD-10-CM |
| M19.249 | Secondary osteoarthritis, unspecified hand | Diagnosis | ICD-10-CM |
| M19.271 | Secondary osteoarthritis, right ankle and foot | Diagnosis | ICD-10-CM |
| M19.272 | Secondary osteoarthritis, left ankle and foot | Diagnosis | ICD-10-CM |
| M19.279 | Secondary osteoarthritis, unspecified ankle and foot | Diagnosis | ICD-10-CM |
| M19.29 | Secondary osteoarthritis, other specified site | Diagnosis | ICD-10-CM |
| M19.90 | Unspecified osteoarthritis, unspecified site | Diagnosis | ICD-10-CM |
| M19.91 | Primary osteoarthritis, unspecified site | Diagnosis | ICD-10-CM |
| M19.92 | Post-traumatic osteoarthritis, unspecified site | Diagnosis | ICD-10-CM |
| M19.93 | Secondary osteoarthritis, unspecified site | Diagnosis | ICD-10-CM |
| M45.0 | Ankylosing spondylitis of multiple sites in spine | Diagnosis | ICD-10-CM |
| M45.1 | Ankylosing spondylitis of occipito-atlanto-axial region | Diagnosis | ICD-10-CM |
| M45.2 | Ankylosing spondylitis of cervical region | Diagnosis | ICD-10-CM |
| M45.3 | Ankylosing spondylitis of cervicothoracic region | Diagnosis | ICD-10-CM |
| M45.4 | Ankylosing spondylitis of thoracic region | Diagnosis | ICD-10-CM |
| M45.5 | Ankylosing spondylitis of thoracolumbar region | Diagnosis | ICD-10-CM |
| M45.6 | Ankylosing spondylitis lumbar region | Diagnosis | ICD-10-CM |
| M45.7 | Ankylosing spondylitis of lumbosacral region | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|-------------|--|----------------------|------------------|
| M45.8 | Ankylosing spondylitis sacral and sacrococcygeal region | Diagnosis | ICD-10-CM |
| M45.9 | Ankylosing spondylitis of unspecified sites in spine | Diagnosis | ICD-10-CM |
| M45.A0 | Non-radiographic axial spondyloarthritis of unspecified sites in spine | Diagnosis | ICD-10-CM |
| M45.A1 | Non-radiographic axial spondyloarthritis of occipito-atlanto-axial region | Diagnosis | ICD-10-CM |
| M45.A2 | Non-radiographic axial spondyloarthritis of cervical region | Diagnosis | ICD-10-CM |
| M45.A3 | Non-radiographic axial spondyloarthritis of cervicothoracic region | Diagnosis | ICD-10-CM |
| M45.A4 | Non-radiographic axial spondyloarthritis of thoracic region | Diagnosis | ICD-10-CM |
| M45.A5 | Non-radiographic axial spondyloarthritis of thoracolumbar region | Diagnosis | ICD-10-CM |
| M45.A6 | Non-radiographic axial spondyloarthritis of lumbar region | Diagnosis | ICD-10-CM |
| M45.A7 | Non-radiographic axial spondyloarthritis of lumbosacral region | Diagnosis | ICD-10-CM |
| M45.A8 | Non-radiographic axial spondyloarthritis of sacral and sacrococcygeal region | Diagnosis | ICD-10-CM |
| M45.AB | Non-radiographic axial spondyloarthritis of multiple sites in spine | Diagnosis | ICD-10-CM |
| M46.80 | Other specified inflammatory spondylopathies, site unspecified | Diagnosis | ICD-10-CM |
| M46.81 | Other specified inflammatory spondylopathies, occipito-atlanto-axial region | Diagnosis | ICD-10-CM |
| M46.82 | Other specified inflammatory spondylopathies, cervical region | Diagnosis | ICD-10-CM |
| M46.83 | Other specified inflammatory spondylopathies, cervicothoracic region | Diagnosis | ICD-10-CM |
| M46.84 | Other specified inflammatory spondylopathies, thoracic region | Diagnosis | ICD-10-CM |
| M46.85 | Other specified inflammatory spondylopathies, thoracolumbar region | Diagnosis | ICD-10-CM |
| M46.86 | Other specified inflammatory spondylopathies, lumbar region | Diagnosis | ICD-10-CM |
| M46.87 | Other specified inflammatory spondylopathies, lumbosacral region | Diagnosis | ICD-10-CM |
| M46.88 | Other specified inflammatory spondylopathies, sacral and sacrococcygeal region | Diagnosis | ICD-10-CM |
| M46.89 | Other specified inflammatory spondylopathies, multiple sites in spine | Diagnosis | ICD-10-CM |
| M46.90 | Unspecified inflammatory spondylopathy, site unspecified | Diagnosis | ICD-10-CM |
| M46.91 | Unspecified inflammatory spondylopathy, occipito-atlanto-axial region | Diagnosis | ICD-10-CM |
| M46.92 | Unspecified inflammatory spondylopathy, cervical region | Diagnosis | ICD-10-CM |
| M46.93 | Unspecified inflammatory spondylopathy, cervicothoracic region | Diagnosis | ICD-10-CM |
| M46.94 | Unspecified inflammatory spondylopathy, thoracic region | Diagnosis | ICD-10-CM |
| M46.95 | Unspecified inflammatory spondylopathy, thoracolumbar region | Diagnosis | ICD-10-CM |
| M46.96 | Unspecified inflammatory spondylopathy, lumbar region | Diagnosis | ICD-10-CM |
| M46.97 | Unspecified inflammatory spondylopathy, lumbosacral region | Diagnosis | ICD-10-CM |
| M46.98 | Unspecified inflammatory spondylopathy, sacral and sacrococcygeal region | Diagnosis | ICD-10-CM |
| M46.99 | Unspecified inflammatory spondylopathy, multiple sites in spine | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|-------------|--|----------------------|------------------|
| M47.011 | Anterior spinal artery compression syndromes, occipito-atlanto-axial region | Diagnosis | ICD-10-CM |
| M47.012 | Anterior spinal artery compression syndromes, cervical region | Diagnosis | ICD-10-CM |
| M47.013 | Anterior spinal artery compression syndromes, cervicothoracic region | Diagnosis | ICD-10-CM |
| M47.014 | Anterior spinal artery compression syndromes, thoracic region | Diagnosis | ICD-10-CM |
| M47.015 | Anterior spinal artery compression syndromes, thoracolumbar region | Diagnosis | ICD-10-CM |
| M47.016 | Anterior spinal artery compression syndromes, lumbar region | Diagnosis | ICD-10-CM |
| M47.019 | Anterior spinal artery compression syndromes, site unspecified | Diagnosis | ICD-10-CM |
| M47.021 | Vertebral artery compression syndromes, occipito-atlanto-axial region | Diagnosis | ICD-10-CM |
| M47.022 | Vertebral artery compression syndromes, cervical region | Diagnosis | ICD-10-CM |
| M47.029 | Vertebral artery compression syndromes, site unspecified | Diagnosis | ICD-10-CM |
| M47.10 | Other spondylosis with myelopathy, site unspecified | Diagnosis | ICD-10-CM |
| M47.11 | Other spondylosis with myelopathy, occipito-atlanto-axial region | Diagnosis | ICD-10-CM |
| M47.12 | Other spondylosis with myelopathy, cervical region | Diagnosis | ICD-10-CM |
| M47.13 | Other spondylosis with myelopathy, cervicothoracic region | Diagnosis | ICD-10-CM |
| M47.14 | Other spondylosis with myelopathy, thoracic region | Diagnosis | ICD-10-CM |
| M47.15 | Other spondylosis with myelopathy, thoracolumbar region | Diagnosis | ICD-10-CM |
| M47.16 | Other spondylosis with myelopathy, lumbar region | Diagnosis | ICD-10-CM |
| M47.20 | Other spondylosis with radiculopathy, site unspecified | Diagnosis | ICD-10-CM |
| M47.21 | Other spondylosis with radiculopathy, occipito-atlanto-axial region | Diagnosis | ICD-10-CM |
| M47.22 | Other spondylosis with radiculopathy, cervical region | Diagnosis | ICD-10-CM |
| M47.23 | Other spondylosis with radiculopathy, cervicothoracic region | Diagnosis | ICD-10-CM |
| M47.24 | Other spondylosis with radiculopathy, thoracic region | Diagnosis | ICD-10-CM |
| M47.25 | Other spondylosis with radiculopathy, thoracolumbar region | Diagnosis | ICD-10-CM |
| M47.26 | Other spondylosis with radiculopathy, lumbar region | Diagnosis | ICD-10-CM |
| M47.27 | Other spondylosis with radiculopathy, lumbosacral region | Diagnosis | ICD-10-CM |
| M47.28 | Other spondylosis with radiculopathy, sacral and sacrococcygeal region | Diagnosis | ICD-10-CM |
| M47.811 | Spondylosis without myelopathy or radiculopathy, occipito-atlanto-axial region | Diagnosis | ICD-10-CM |
| M47.812 | Spondylosis without myelopathy or radiculopathy, cervical region | Diagnosis | ICD-10-CM |
| M47.813 | Spondylosis without myelopathy or radiculopathy, cervicothoracic region | Diagnosis | ICD-10-CM |
| M47.814 | Spondylosis without myelopathy or radiculopathy, thoracic region | Diagnosis | ICD-10-CM |
| M47.815 | Spondylosis without myelopathy or radiculopathy, thoracolumbar region | Diagnosis | ICD-10-CM |
| M47.816 | Spondylosis without myelopathy or radiculopathy, lumbar region | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| M47.817 | Spondylosis without myelopathy or radiculopathy, lumbosacral region | Diagnosis | ICD-10-CM |
| M47.818 | Spondylosis without myelopathy or radiculopathy, sacral and sacrococcygeal region | Diagnosis | ICD-10-CM |
| M47.819 | Spondylosis without myelopathy or radiculopathy, site unspecified | Diagnosis | ICD-10-CM |
| M47.891 | Other spondylosis, occipito-atlanto-axial region | Diagnosis | ICD-10-CM |
| M47.892 | Other spondylosis, cervical region | Diagnosis | ICD-10-CM |
| M47.893 | Other spondylosis, cervicothoracic region | Diagnosis | ICD-10-CM |
| M47.894 | Other spondylosis, thoracic region | Diagnosis | ICD-10-CM |
| M47.895 | Other spondylosis, thoracolumbar region | Diagnosis | ICD-10-CM |
| M47.896 | Other spondylosis, lumbar region | Diagnosis | ICD-10-CM |
| M47.897 | Other spondylosis, lumbosacral region | Diagnosis | ICD-10-CM |
| M47.898 | Other spondylosis, sacral and sacrococcygeal region | Diagnosis | ICD-10-CM |
| M47.899 | Other spondylosis, site unspecified | Diagnosis | ICD-10-CM |
| M47.9 | Spondylosis, unspecified | Diagnosis | ICD-10-CM |
| M48.8X1 | Other specified spondylopathies, occipito-atlanto-axial region | Diagnosis | ICD-10-CM |
| M48.8X2 | Other specified spondylopathies, cervical region | Diagnosis | ICD-10-CM |
| M48.8X3 | Other specified spondylopathies, cervicothoracic region | Diagnosis | ICD-10-CM |
| M48.8X4 | Other specified spondylopathies, thoracic region | Diagnosis | ICD-10-CM |
| M48.8X5 | Other specified spondylopathies, thoracolumbar region | Diagnosis | ICD-10-CM |
| M48.8X6 | Other specified spondylopathies, lumbar region | Diagnosis | ICD-10-CM |
| M48.8X7 | Other specified spondylopathies, lumbosacral region | Diagnosis | ICD-10-CM |
| M48.8X8 | Other specified spondylopathies, sacral and sacrococcygeal region | Diagnosis | ICD-10-CM |
| M48.8X9 | Other specified spondylopathies, site unspecified | Diagnosis | ICD-10-CM |
| Smoking | | | |
| 1034F | Current tobacco smoker (CAD, CAP, COPD, PV) (DM) | Procedure | CPT-2 |
| 4001F | Tobacco use cessation intervention, pharmacologic therapy (COPD, CAD, CAP, PV, Asthma) (DM) (PV) | Procedure | CPT-2 |
| 4004F | Patient screened for tobacco use and received tobacco cessation intervention (counseling, pharmacotherapy, or both), if identified as a tobacco user (PV, CAD) | Procedure | CPT-2 |
| 99406 | Smoking and tobacco use cessation counseling visit; intermediate, greater than 3 minutes up to 10 minutes | Procedure | CPT-4 |
| 99407 | Smoking and tobacco use cessation counseling visit; intensive, greater than 10 minutes | Procedure | CPT-4 |
| F17.200 | Nicotine dependence, unspecified, uncomplicated | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|---|---------------|-----------|
| F17.201 | Nicotine dependence, unspecified, in remission | Diagnosis | ICD-10-CM |
| F17.203 | Nicotine dependence unspecified, with withdrawal | Diagnosis | ICD-10-CM |
| F17.208 | Nicotine dependence, unspecified, with other nicotine-induced disorders | Diagnosis | ICD-10-CM |
| F17.209 | Nicotine dependence, unspecified, with unspecified nicotine-induced disorders | Diagnosis | ICD-10-CM |
| F17.210 | Nicotine dependence, cigarettes, uncomplicated | Diagnosis | ICD-10-CM |
| F17.211 | Nicotine dependence, cigarettes, in remission | Diagnosis | ICD-10-CM |
| F17.213 | Nicotine dependence, cigarettes, with withdrawal | Diagnosis | ICD-10-CM |
| F17.218 | Nicotine dependence, cigarettes, with other nicotine-induced disorders | Diagnosis | ICD-10-CM |
| F17.219 | Nicotine dependence, cigarettes, with unspecified nicotine-induced disorders | Diagnosis | ICD-10-CM |
| F17.223 | Nicotine dependence, chewing tobacco, with withdrawal | Diagnosis | ICD-10-CM |
| F17.228 | Nicotine dependence, chewing tobacco, with other nicotine-induced disorders | Diagnosis | ICD-10-CM |
| F17.229 | Nicotine dependence, chewing tobacco, with unspecified nicotine-induced disorders | Diagnosis | ICD-10-CM |
| F17.290 | Nicotine dependence, other tobacco product, uncomplicated | Diagnosis | ICD-10-CM |
| F17.291 | Nicotine dependence, other tobacco product, in remission | Diagnosis | ICD-10-CM |
| F17.293 | Nicotine dependence, other tobacco product, with withdrawal | Diagnosis | ICD-10-CM |
| F17.298 | Nicotine dependence, other tobacco product, with other nicotine-induced disorders | Diagnosis | ICD-10-CM |
| F17.299 | Nicotine dependence, other tobacco product, with unspecified nicotine-induced disorders | Diagnosis | ICD-10-CM |
| G0436 | Smoking and tobacco cessation counseling visit for the asymptomatic patient; intermediate, greater than 3 minutes, up to 10 minutes | Procedure | HCPCS |
| G0437 | Smoking and tobacco cessation counseling visit for the asymptomatic patient; intensive, greater than 10 minutes | Procedure | HCPCS |
| G9016 | Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [demo project code only] | Procedure | HCPCS |
| G9276 | Documentation that patient is a current tobacco user | Procedure | HCPCS |
| G9458 | Patient documented as tobacco user and received tobacco cessation intervention (must include at least one of the following: advice given to quit smoking or tobacco use, counseling on the benefits of quitting smoking or tobacco use, assistance with or referral to external smoking or tobacco cessation support programs, or current enrollment in smoking or tobacco use cessation program) if identified as a tobacco user | Procedure | HCPCS |
| O99.330 | Smoking (tobacco) complicating pregnancy, unspecified trimester | Diagnosis | ICD-10-CM |
| O99.331 | Smoking (tobacco) complicating pregnancy, first trimester | Diagnosis | ICD-10-CM |
| O99.332 | Smoking (tobacco) complicating pregnancy, second trimester | Diagnosis | ICD-10-CM |
| O99.333 | Smoking (tobacco) complicating pregnancy, third trimester | Diagnosis | ICD-10-CM |
| O99.334 | Smoking (tobacco) complicating childbirth | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|----------------------------------|--|---------------|-----------|
| O99.335 | Smoking (tobacco) complicating the puerperium | Diagnosis | ICD-10-CM |
| S4995 | Smoking cessation gum | Procedure | HCPCS |
| S9075 | Smoking cessation treatment | Procedure | HCPCS |
| S9453 | Smoking cessation classes, nonphysician provider, per session | Procedure | HCPCS |
| T65.221A | Toxic effect of tobacco cigarettes, accidental (unintentional), initial encounter | Diagnosis | ICD-10-CM |
| T65.222A | Toxic effect of tobacco cigarettes, intentional self-harm, initial encounter | Diagnosis | ICD-10-CM |
| T65.223A | Toxic effect of tobacco cigarettes, assault, initial encounter | Diagnosis | ICD-10-CM |
| T65.224A | Toxic effect of tobacco cigarettes, undetermined, initial encounter | Diagnosis | ICD-10-CM |
| Z71.6 | Tobacco abuse counseling | Diagnosis | ICD-10-CM |
| Z87.891 | Personal history of nicotine dependence | Diagnosis | ICD-10-CM |
| Transient Ischemic Attack | | | |
| 430 | Subarachnoid hemorrhage | Diagnosis | ICD-9-CM |
| 431 | Intracerebral hemorrhage | Diagnosis | ICD-9-CM |
| 433.01 | Occlusion and stenosis of basilar artery with cerebral infarction | Diagnosis | ICD-9-CM |
| 433.11 | Occlusion and stenosis of carotid artery with cerebral infarction | Diagnosis | ICD-9-CM |
| 433.21 | Occlusion and stenosis of vertebral artery with cerebral infarction | Diagnosis | ICD-9-CM |
| 433.31 | Occlusion and stenosis of multiple and bilateral precerebral arteries with cerebral infarction | Diagnosis | ICD-9-CM |
| 433.81 | Occlusion and stenosis of other specified precerebral artery with cerebral infarction | Diagnosis | ICD-9-CM |
| 433.91 | Occlusion and stenosis of unspecified precerebral artery with cerebral infarction | Diagnosis | ICD-9-CM |
| 434.00 | Cerebral thrombosis without mention of cerebral infarction | Diagnosis | ICD-9-CM |
| 434.01 | Cerebral thrombosis with cerebral infarction | Diagnosis | ICD-9-CM |
| 434.10 | Cerebral embolism without mention of cerebral infarction | Diagnosis | ICD-9-CM |
| 434.11 | Cerebral embolism with cerebral infarction | Diagnosis | ICD-9-CM |
| 434.90 | Unspecified cerebral artery occlusion without mention of cerebral infarction | Diagnosis | ICD-9-CM |
| 434.91 | Unspecified cerebral artery occlusion with cerebral infarction | Diagnosis | ICD-9-CM |
| 435.0 | Basilar artery syndrome | Diagnosis | ICD-9-CM |
| 435.1 | Vertebral artery syndrome | Diagnosis | ICD-9-CM |
| 435.3 | Vertebrobasilar artery syndrome | Diagnosis | ICD-9-CM |
| 435.8 | Other specified transient cerebral ischemias | Diagnosis | ICD-9-CM |
| 435.9 | Unspecified transient cerebral ischemia | Diagnosis | ICD-9-CM |
| 436 | Acute, but ill-defined, cerebrovascular disease | Diagnosis | ICD-9-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|--------|---|---------------|-----------|
| 997.02 | Iatrogenic cerebrovascular infarction or hemorrhage | Diagnosis | ICD-9-CM |
| G45.0 | Vertebro-basilar artery syndrome | Diagnosis | ICD-10-CM |
| G45.1 | Carotid artery syndrome (hemispheric) | Diagnosis | ICD-10-CM |
| G45.2 | Multiple and bilateral precerebral artery syndromes | Diagnosis | ICD-10-CM |
| G45.3 | Amaurosis fugax | Diagnosis | ICD-10-CM |
| G45.8 | Other transient cerebral ischemic attacks and related syndromes | Diagnosis | ICD-10-CM |
| G45.9 | Transient cerebral ischemic attack, unspecified | Diagnosis | ICD-10-CM |
| G46.0 | Middle cerebral artery syndrome | Diagnosis | ICD-10-CM |
| G46.1 | Anterior cerebral artery syndrome | Diagnosis | ICD-10-CM |
| G46.2 | Posterior cerebral artery syndrome | Diagnosis | ICD-10-CM |
| G46.3 | Brain stem stroke syndrome | Diagnosis | ICD-10-CM |
| G46.4 | Cerebellar stroke syndrome | Diagnosis | ICD-10-CM |
| G46.5 | Pure motor lacunar syndrome | Diagnosis | ICD-10-CM |
| G46.6 | Pure sensory lacunar syndrome | Diagnosis | ICD-10-CM |
| G46.7 | Other lacunar syndromes | Diagnosis | ICD-10-CM |
| G46.8 | Other vascular syndromes of brain in cerebrovascular diseases | Diagnosis | ICD-10-CM |
| G97.31 | Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating a nervous system procedure | Diagnosis | ICD-10-CM |
| G97.32 | Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating other procedure | Diagnosis | ICD-10-CM |
| I60.00 | Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and bifurcation | Diagnosis | ICD-10-CM |
| I60.01 | Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcation | Diagnosis | ICD-10-CM |
| I60.02 | Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcation | Diagnosis | ICD-10-CM |
| I60.10 | Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral artery | Diagnosis | ICD-10-CM |
| I60.11 | Nontraumatic subarachnoid hemorrhage from right middle cerebral artery | Diagnosis | ICD-10-CM |
| I60.12 | Nontraumatic subarachnoid hemorrhage from left middle cerebral artery | Diagnosis | ICD-10-CM |
| I60.2 | Nontraumatic subarachnoid hemorrhage from anterior communicating artery | Diagnosis | ICD-10-CM |
| I60.20 | Nontraumatic subarachnoid hemorrhage from unspecified anterior communicating artery | Diagnosis | ICD-10-CM |
| I60.21 | Nontraumatic subarachnoid hemorrhage from right anterior communicating artery | Diagnosis | ICD-10-CM |
| I60.22 | Nontraumatic subarachnoid hemorrhage from left anterior communicating artery | Diagnosis | ICD-10-CM |
| I60.30 | Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating artery | Diagnosis | ICD-10-CM |
| I60.31 | Nontraumatic subarachnoid hemorrhage from right posterior communicating artery | Diagnosis | ICD-10-CM |
| I60.32 | Nontraumatic subarachnoid hemorrhage from left posterior communicating artery | Diagnosis | ICD-10-CM |
| I60.4 | Nontraumatic subarachnoid hemorrhage from basilar artery | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|---|---------------|-----------|
| I60.50 | Nontraumatic subarachnoid hemorrhage from unspecified vertebral artery | Diagnosis | ICD-10-CM |
| I60.51 | Nontraumatic subarachnoid hemorrhage from right vertebral artery | Diagnosis | ICD-10-CM |
| I60.52 | Nontraumatic subarachnoid hemorrhage from left vertebral artery | Diagnosis | ICD-10-CM |
| I60.6 | Nontraumatic subarachnoid hemorrhage from other intracranial arteries | Diagnosis | ICD-10-CM |
| I60.7 | Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery | Diagnosis | ICD-10-CM |
| I60.8 | Other nontraumatic subarachnoid hemorrhage | Diagnosis | ICD-10-CM |
| I60.9 | Nontraumatic subarachnoid hemorrhage, unspecified | Diagnosis | ICD-10-CM |
| I61.0 | Nontraumatic intracerebral hemorrhage in hemisphere, subcortical | Diagnosis | ICD-10-CM |
| I61.1 | Nontraumatic intracerebral hemorrhage in hemisphere, cortical | Diagnosis | ICD-10-CM |
| I61.2 | Nontraumatic intracerebral hemorrhage in hemisphere, unspecified | Diagnosis | ICD-10-CM |
| I61.3 | Nontraumatic intracerebral hemorrhage in brain stem | Diagnosis | ICD-10-CM |
| I61.4 | Nontraumatic intracerebral hemorrhage in cerebellum | Diagnosis | ICD-10-CM |
| I61.5 | Nontraumatic intracerebral hemorrhage, intraventricular | Diagnosis | ICD-10-CM |
| I61.6 | Nontraumatic intracerebral hemorrhage, multiple localized | Diagnosis | ICD-10-CM |
| I61.8 | Other nontraumatic intracerebral hemorrhage | Diagnosis | ICD-10-CM |
| I61.9 | Nontraumatic intracerebral hemorrhage, unspecified | Diagnosis | ICD-10-CM |
| I62.00 | Nontraumatic subdural hemorrhage, unspecified | Diagnosis | ICD-10-CM |
| I62.01 | Nontraumatic acute subdural hemorrhage | Diagnosis | ICD-10-CM |
| I62.02 | Nontraumatic subacute subdural hemorrhage | Diagnosis | ICD-10-CM |
| I62.9 | Nontraumatic intracranial hemorrhage, unspecified | Diagnosis | ICD-10-CM |
| I63.00 | Cerebral infarction due to thrombosis of unspecified precerebral artery | Diagnosis | ICD-10-CM |
| I63.011 | Cerebral infarction due to thrombosis of right vertebral artery | Diagnosis | ICD-10-CM |
| I63.012 | Cerebral infarction due to thrombosis of left vertebral artery | Diagnosis | ICD-10-CM |
| I63.013 | Cerebral infarction due to thrombosis of bilateral vertebral arteries | Diagnosis | ICD-10-CM |
| I63.019 | Cerebral infarction due to thrombosis of unspecified vertebral artery | Diagnosis | ICD-10-CM |
| I63.02 | Cerebral infarction due to thrombosis of basilar artery | Diagnosis | ICD-10-CM |
| I63.031 | Cerebral infarction due to thrombosis of right carotid artery | Diagnosis | ICD-10-CM |
| I63.032 | Cerebral infarction due to thrombosis of left carotid artery | Diagnosis | ICD-10-CM |
| I63.033 | Cerebral infarction due to thrombosis of bilateral carotid arteries | Diagnosis | ICD-10-CM |
| I63.039 | Cerebral infarction due to thrombosis of unspecified carotid artery | Diagnosis | ICD-10-CM |
| I63.09 | Cerebral infarction due to thrombosis of other precerebral artery | Diagnosis | ICD-10-CM |
| I63.10 | Cerebral infarction due to embolism of unspecified precerebral artery | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| I63.111 | Cerebral infarction due to embolism of right vertebral artery | Diagnosis | ICD-10-CM |
| I63.112 | Cerebral infarction due to embolism of left vertebral artery | Diagnosis | ICD-10-CM |
| I63.113 | Cerebral infarction due to embolism of bilateral vertebral arteries | Diagnosis | ICD-10-CM |
| I63.119 | Cerebral infarction due to embolism of unspecified vertebral artery | Diagnosis | ICD-10-CM |
| I63.12 | Cerebral infarction due to embolism of basilar artery | Diagnosis | ICD-10-CM |
| I63.131 | Cerebral infarction due to embolism of right carotid artery | Diagnosis | ICD-10-CM |
| I63.132 | Cerebral infarction due to embolism of left carotid artery | Diagnosis | ICD-10-CM |
| I63.133 | Cerebral infarction due to embolism of bilateral carotid arteries | Diagnosis | ICD-10-CM |
| I63.139 | Cerebral infarction due to embolism of unspecified carotid artery | Diagnosis | ICD-10-CM |
| I63.19 | Cerebral infarction due to embolism of other precerebral artery | Diagnosis | ICD-10-CM |
| I63.20 | Cerebral infarction due to unspecified occlusion or stenosis of unspecified precerebral arteries | Diagnosis | ICD-10-CM |
| I63.211 | Cerebral infarction due to unspecified occlusion or stenosis of right vertebral artery | Diagnosis | ICD-10-CM |
| I63.212 | Cerebral infarction due to unspecified occlusion or stenosis of left vertebral artery | Diagnosis | ICD-10-CM |
| I63.213 | Cerebral infarction due to unspecified occlusion or stenosis of bilateral vertebral arteries | Diagnosis | ICD-10-CM |
| I63.219 | Cerebral infarction due to unspecified occlusion or stenosis of unspecified vertebral arteries | Diagnosis | ICD-10-CM |
| I63.22 | Cerebral infarction due to unspecified occlusion or stenosis of basilar artery | Diagnosis | ICD-10-CM |
| I63.231 | Cerebral infarction due to unspecified occlusion or stenosis of right carotid arteries | Diagnosis | ICD-10-CM |
| I63.232 | Cerebral infarction due to unspecified occlusion or stenosis of left carotid arteries | Diagnosis | ICD-10-CM |
| I63.233 | Cerebral infarction due to unspecified occlusion or stenosis of bilateral carotid arteries | Diagnosis | ICD-10-CM |
| I63.239 | Cerebral infarction due to unspecified occlusion or stenosis of unspecified carotid arteries | Diagnosis | ICD-10-CM |
| I63.29 | Cerebral infarction due to unspecified occlusion or stenosis of other precerebral arteries | Diagnosis | ICD-10-CM |
| I63.30 | Cerebral infarction due to thrombosis of unspecified cerebral artery | Diagnosis | ICD-10-CM |
| I63.311 | Cerebral infarction due to thrombosis of right middle cerebral artery | Diagnosis | ICD-10-CM |
| I63.312 | Cerebral infarction due to thrombosis of left middle cerebral artery | Diagnosis | ICD-10-CM |
| I63.313 | Cerebral infarction due to thrombosis of bilateral middle cerebral arteries | Diagnosis | ICD-10-CM |
| I63.319 | Cerebral infarction due to thrombosis of unspecified middle cerebral artery | Diagnosis | ICD-10-CM |
| I63.321 | Cerebral infarction due to thrombosis of right anterior cerebral artery | Diagnosis | ICD-10-CM |
| I63.322 | Cerebral infarction due to thrombosis of left anterior cerebral artery | Diagnosis | ICD-10-CM |
| I63.323 | Cerebral infarction due to thrombosis of bilateral anterior cerebral arteries | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|--|---------------|-----------|
| I63.329 | Cerebral infarction due to thrombosis of unspecified anterior cerebral artery | Diagnosis | ICD-10-CM |
| I63.331 | Cerebral infarction due to thrombosis of right posterior cerebral artery | Diagnosis | ICD-10-CM |
| I63.332 | Cerebral infarction due to thrombosis of left posterior cerebral artery | Diagnosis | ICD-10-CM |
| I63.333 | Cerebral infarction to thrombosis of bilateral posterior cerebral arteries | Diagnosis | ICD-10-CM |
| I63.339 | Cerebral infarction due to thrombosis of unspecified posterior cerebral artery | Diagnosis | ICD-10-CM |
| I63.341 | Cerebral infarction due to thrombosis of right cerebellar artery | Diagnosis | ICD-10-CM |
| I63.342 | Cerebral infarction due to thrombosis of left cerebellar artery | Diagnosis | ICD-10-CM |
| I63.343 | Cerebral infarction to thrombosis of bilateral cerebellar arteries | Diagnosis | ICD-10-CM |
| I63.349 | Cerebral infarction due to thrombosis of unspecified cerebellar artery | Diagnosis | ICD-10-CM |
| I63.39 | Cerebral infarction due to thrombosis of other cerebral artery | Diagnosis | ICD-10-CM |
| I63.40 | Cerebral infarction due to embolism of unspecified cerebral artery | Diagnosis | ICD-10-CM |
| I63.411 | Cerebral infarction due to embolism of right middle cerebral artery | Diagnosis | ICD-10-CM |
| I63.412 | Cerebral infarction due to embolism of left middle cerebral artery | Diagnosis | ICD-10-CM |
| I63.413 | Cerebral infarction due to embolism of bilateral middle cerebral arteries | Diagnosis | ICD-10-CM |
| I63.419 | Cerebral infarction due to embolism of unspecified middle cerebral artery | Diagnosis | ICD-10-CM |
| I63.421 | Cerebral infarction due to embolism of right anterior cerebral artery | Diagnosis | ICD-10-CM |
| I63.422 | Cerebral infarction due to embolism of left anterior cerebral artery | Diagnosis | ICD-10-CM |
| I63.423 | Cerebral infarction due to embolism of bilateral anterior cerebral arteries | Diagnosis | ICD-10-CM |
| I63.429 | Cerebral infarction due to embolism of unspecified anterior cerebral artery | Diagnosis | ICD-10-CM |
| I63.431 | Cerebral infarction due to embolism of right posterior cerebral artery | Diagnosis | ICD-10-CM |
| I63.432 | Cerebral infarction due to embolism of left posterior cerebral artery | Diagnosis | ICD-10-CM |
| I63.433 | Cerebral infarction due to embolism of bilateral posterior cerebral arteries | Diagnosis | ICD-10-CM |
| I63.439 | Cerebral infarction due to embolism of unspecified posterior cerebral artery | Diagnosis | ICD-10-CM |
| I63.441 | Cerebral infarction due to embolism of right cerebellar artery | Diagnosis | ICD-10-CM |
| I63.442 | Cerebral infarction due to embolism of left cerebellar artery | Diagnosis | ICD-10-CM |
| I63.443 | Cerebral infarction due to embolism of bilateral cerebellar arteries | Diagnosis | ICD-10-CM |
| I63.449 | Cerebral infarction due to embolism of unspecified cerebellar artery | Diagnosis | ICD-10-CM |
| I63.49 | Cerebral infarction due to embolism of other cerebral artery | Diagnosis | ICD-10-CM |
| I63.50 | Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebral artery | Diagnosis | ICD-10-CM |
| I63.511 | Cerebral infarction due to unspecified occlusion or stenosis of right middle cerebral artery | Diagnosis | ICD-10-CM |
| I63.512 | Cerebral infarction due to unspecified occlusion or stenosis of left middle cerebral artery | Diagnosis | ICD-10-CM |
| I63.513 | Cerebral infarction due to unspecified occlusion or stenosis of bilateral middle cerebral arteries | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|---|---------------|-----------|
| I63.519 | Cerebral infarction due to unspecified occlusion or stenosis of unspecified middle cerebral artery | Diagnosis | ICD-10-CM |
| I63.521 | Cerebral infarction due to unspecified occlusion or stenosis of right anterior cerebral artery | Diagnosis | ICD-10-CM |
| I63.522 | Cerebral infarction due to unspecified occlusion or stenosis of left anterior cerebral artery | Diagnosis | ICD-10-CM |
| I63.523 | Cerebral infarction due to unspecified occlusion or stenosis of bilateral anterior cerebral arteries | Diagnosis | ICD-10-CM |
| I63.529 | Cerebral infarction due to unspecified occlusion or stenosis of unspecified anterior cerebral artery | Diagnosis | ICD-10-CM |
| I63.531 | Cerebral infarction due to unspecified occlusion or stenosis of right posterior cerebral artery | Diagnosis | ICD-10-CM |
| I63.532 | Cerebral infarction due to unspecified occlusion or stenosis of left posterior cerebral artery | Diagnosis | ICD-10-CM |
| I63.533 | Cerebral infarction due to unspecified occlusion or stenosis of bilateral posterior cerebral arteries | Diagnosis | ICD-10-CM |
| I63.539 | Cerebral infarction due to unspecified occlusion or stenosis of unspecified posterior cerebral artery | Diagnosis | ICD-10-CM |
| I63.541 | Cerebral infarction due to unspecified occlusion or stenosis of right cerebellar artery | Diagnosis | ICD-10-CM |
| I63.542 | Cerebral infarction due to unspecified occlusion or stenosis of left cerebellar artery | Diagnosis | ICD-10-CM |
| I63.543 | Cerebral infarction due to unspecified occlusion or stenosis of bilateral cerebellar arteries | Diagnosis | ICD-10-CM |
| I63.549 | Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebellar artery | Diagnosis | ICD-10-CM |
| I63.59 | Cerebral infarction due to unspecified occlusion or stenosis of other cerebral artery | Diagnosis | ICD-10-CM |
| I63.6 | Cerebral infarction due to cerebral venous thrombosis, nonpyogenic | Diagnosis | ICD-10-CM |
| I63.8 | Other cerebral infarction | Diagnosis | ICD-10-CM |
| I63.81 | Other cerebral infarction due to occlusion or stenosis of small artery | Diagnosis | ICD-10-CM |
| I63.89 | Other cerebral infarction | Diagnosis | ICD-10-CM |
| I63.9 | Cerebral infarction, unspecified | Diagnosis | ICD-10-CM |
| I66.01 | Occlusion and stenosis of right middle cerebral artery | Diagnosis | ICD-10-CM |
| I66.02 | Occlusion and stenosis of left middle cerebral artery | Diagnosis | ICD-10-CM |
| I66.03 | Occlusion and stenosis of bilateral middle cerebral arteries | Diagnosis | ICD-10-CM |
| I66.09 | Occlusion and stenosis of unspecified middle cerebral artery | Diagnosis | ICD-10-CM |
| I66.11 | Occlusion and stenosis of right anterior cerebral artery | Diagnosis | ICD-10-CM |
| I66.12 | Occlusion and stenosis of left anterior cerebral artery | Diagnosis | ICD-10-CM |

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

| Code | Description | Code Category | Code Type |
|---------|---|---------------|-----------|
| I66.13 | Occlusion and stenosis of bilateral anterior cerebral arteries | Diagnosis | ICD-10-CM |
| I66.19 | Occlusion and stenosis of unspecified anterior cerebral artery | Diagnosis | ICD-10-CM |
| I66.21 | Occlusion and stenosis of right posterior cerebral artery | Diagnosis | ICD-10-CM |
| I66.22 | Occlusion and stenosis of left posterior cerebral artery | Diagnosis | ICD-10-CM |
| I66.23 | Occlusion and stenosis of bilateral posterior cerebral arteries | Diagnosis | ICD-10-CM |
| I66.29 | Occlusion and stenosis of unspecified posterior cerebral artery | Diagnosis | ICD-10-CM |
| I66.3 | Occlusion and stenosis of cerebellar arteries | Diagnosis | ICD-10-CM |
| I66.8 | Occlusion and stenosis of other cerebral arteries | Diagnosis | ICD-10-CM |
| I66.9 | Occlusion and stenosis of unspecified cerebral artery | Diagnosis | ICD-10-CM |
| I67.841 | Reversible cerebrovascular vasoconstriction syndrome | Diagnosis | ICD-10-CM |
| I67.848 | Other cerebrovascular vasospasm and vasoconstriction | Diagnosis | ICD-10-CM |
| I67.89 | Other cerebrovascular disease | Diagnosis | ICD-10-CM |
| I97.810 | Intraoperative cerebrovascular infarction during cardiac surgery | Diagnosis | ICD-10-CM |
| I97.811 | Intraoperative cerebrovascular infarction during other surgery | Diagnosis | ICD-10-CM |
| I97.820 | Postprocedural cerebrovascular infarction following cardiac surgery | Diagnosis | ICD-10-CM |
| I97.821 | Postprocedural cerebrovascular infarction following other surgery | Diagnosis | ICD-10-CM |

Appendix E. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

| Non-Proprietary Name | Proprietary Name |
|--|------------------------------|
| Obesity | |
| Amino Acids/Multivit-Minerals/Dietary Supplement/Protein Sup | Optifast 70 |
| Benzphetamine HCl | Benzphetamine |
| Benzphetamine HCl | Regimex |
| Diethylpropion HCl | Diethylpropion |
| Diethylpropion HCl | Diethylpropion HCl (bulk) |
| Liraglutide | Saxenda |
| Liraglutide | Victoza 2-Pak |
| Liraglutide | Victoza 3-Pak |
| Lorcaserin HCl | Belviq |
| Lorcaserin HCl | Belviq XR |
| Naltrexone HCl/Bupropion HCl | Contrave |
| Orlistat | Alli |
| Orlistat | Xenical |
| Phendimetrazine Tartrate | Bontril PDM |
| Phendimetrazine Tartrate | Phendimetrazine Tartrate |
| Phentermine HCl | Adipex-P |
| Phentermine HCl | Lomaira |
| Phentermine HCl | Phentermine |
| Phentermine HCl | Phentermine HCl (bulk) |
| Phentermine HCl | Suprenza |
| Phentermine HCl/Topiramate | Qsymia |
| Tea/EGCG/Caffeine/Digestive3 | Resveratrol Diet |
| Smoking | |
| Nicotine | NTS Step 1 |
| Nicotine | Nicoderm CQ |
| Nicotine | Nicotine |
| Nicotine | Nicotrol |
| Nicotine | Nicotrol NS |
| Nicotine Bitartrate | Nicotine Tartrate |
| Nicotine Polacrilex | Nicorelief |
| Nicotine Polacrilex | Nicorette |
| Nicotine Polacrilex | Nicotine (Polacrilex) |
| Nicotine Polacrilex | Nicotine Polacrilex (bulk) |
| Nicotine Polacrilex | Quit 2 |
| Nicotine Polacrilex | Quit 4 |
| Nicotine Polacrilex | Stop Smoking Aid |
| Varenicline Tartrate | Chantix |
| Varenicline Tartrate | Chantix Continuing Month Box |
| Varenicline Tartrate | Chantix Starting Month Box |
| Varenicline Tartrate | Tyrvaya |
| Varenicline Tartrate | Varenicline |

Appendix F. Specifications Defining Parameters for this Request

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool, version 11.0.0, to assess utilization and uptake of the 2017 (part 1) New Molecular Entities (NMEs) to inform FDA in the Sentinel Distributed Database (SDD).

Query period: 01/01/2017 - Most recent available data
Coverage requirement: Medical and Drug Coverage
Pre-index enrollment requirement: 183 days
Post-index requirement: 0 days
Enrollment gap: 45 days
Age groups: 0-17, 18-24, 25-40, 41-64, 65+ years
Stratifications: age group, sex, year-month
Restrictions: Male and Female
Distribution of index-defining codes: No
Envelope macro: Reclassify encounters during inpatient stay as inpatient
Freeze data: No

Exposure

| Scenario | Index Exposure/ Event | Cohort definition | Incident exposure washout period | Exclude evidence of days supply if exposure washout includes dispensing | Treatment episode gap | Treatment episode extension | Care setting | Principal diagnosis position | Create Baseline Table? | Censor treatment episode at evidence of: |
|----------|--------------------------|--|--|---|-----------------------------|-----------------------------------|------------------|------------------------------------|------------------------------|---|
| 1 | Abaloparatide | First valid index date during query period | 0 | N/A | 0 days | 0 days | Any care setting | Any | Yes | Disenrollment; Death; Data Partner End Date; Query End Date |
| 2 | Avelumab | First valid index date during query period | 0 | N/A | 0 days | 0 days | Any care setting | Any | Yes | Disenrollment; Death; Data Partner End Date; Query End Date |
| 3 | Betrixaban | First valid index date during query period | 0 | N/A | 0 days | 0 days | Any care setting | Any | Yes | Disenrollment; Death; Data Partner End Date; Query End Date |

| Appendix F. Specifications Defining Parameters for this Request | | | | | | | | | | |
|---|------------------|--|---|-----|--------|--------|------------------|-----|-----|---|
| The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool, version 11.0.0, to assess utilization and uptake of the 2017 (part 1) New Molecular Entities (NMEs) to inform FDA in the Sentinel Distributed Database (SDD). | | | | | | | | | | |
| 4 | Brigatinib | First valid index date during query period | 0 | N/A | 0 days | 0 days | Any care setting | Any | Yes | Disenrollment; Death; Data Partner End Date; Query End Date |
| 5 | Brodalumab | First valid index date during query period | 0 | N/A | 0 days | 0 days | Any care setting | Any | Yes | Disenrollment; Death; Data Partner End Date; Query End Date |
| 6 | Cerliponase Alfa | First valid index date during query period | 0 | N/A | 0 days | 0 days | Any care setting | Any | Yes | Disenrollment; Death; Data Partner End Date; Query End Date |
| 7 | Deflazacort | First valid index date during query period | 0 | N/A | 0 days | 0 days | Any care setting | Any | Yes | Disenrollment; Death; Data Partner End Date; Query End Date |
| 8 | Delafloxacin | First valid index date during query period | 0 | N/A | 0 days | 0 days | Any care setting | Any | Yes | Disenrollment; Death; Data Partner End Date; Query End Date |
| 9 | Deutetrabenazine | First valid index date during query period | 0 | N/A | 0 days | 0 days | Any care setting | Any | Yes | Disenrollment; Death; Data Partner End Date; Query End Date |
| 10 | Dupilumab | First valid index date during query period | 0 | N/A | 0 days | 0 days | Any care setting | Any | Yes | Disenrollment; Death; Data Partner End Date; Query End Date |

| Appendix F. Specifications Defining Parameters for this Request | | | | | | | | | | |
|---|---------------|--|---|-----|--------|--------|------------------|-----|-----|---|
| The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool, version 11.0.0, to assess utilization and uptake of the 2017 (part 1) New Molecular Entities (NMEs) to inform FDA in the Sentinel Distributed Database (SDD). | | | | | | | | | | |
| 11 | Durvalumab | First valid index date during query period | 0 | N/A | 0 days | 0 days | Any care setting | Any | Yes | Disenrollment; Death; Data Partner End Date; Query End Date |
| 12 | Edaravone | First valid index date during query period | 0 | N/A | 0 days | 0 days | Any care setting | Any | Yes | Disenrollment; Death; Data Partner End Date; Query End Date |
| 13 | Etelcalcetide | First valid index date during query period | 0 | N/A | 0 days | 0 days | Any care setting | Any | Yes | Disenrollment; Death; Data Partner End Date; Query End Date |
| 14 | Midostaurin | First valid index date during query period | 0 | N/A | 0 days | 0 days | Any care setting | Any | Yes | Disenrollment; Death; Data Partner End Date; Query End Date |
| 15 | Naldemedine | First valid index date during query period | 0 | N/A | 0 days | 0 days | Any care setting | Any | Yes | Disenrollment; Death; Data Partner End Date; Query End Date |
| 16 | Niraparib | First valid index date during query period | 0 | N/A | 0 days | 0 days | Any care setting | Any | Yes | Disenrollment; Death; Data Partner End Date; Query End Date |
| 17 | Ocrelizumab | First valid index date during query period | 0 | N/A | 0 days | 0 days | Any care setting | Any | Yes | Disenrollment; Death; Data Partner End Date; Query End Date |

Appendix F. Specifications Defining Parameters for this Request

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool, version 11.0.0, to assess utilization and uptake of the 2017 (part 1) New Molecular Entities (NMEs) to inform FDA in the Sentinel Distributed Database (SDD).

| | | | | | | | | | | |
|----|-------------------|--|---|-----|--------|--------|------------------|-----|-----|---|
| 18 | Plecanatide | First valid index date during query period | 0 | N/A | 0 days | 0 days | Any care setting | Any | Yes | Disenrollment; Death; Data Partner End Date; Query End Date |
| 19 | Ribociclib | First valid index date during query period | 0 | N/A | 0 days | 0 days | Any care setting | Any | Yes | Disenrollment; Death; Data Partner End Date; Query End Date |
| 20 | Safinamide | First valid index date during query period | 0 | N/A | 0 days | 0 days | Any care setting | Any | Yes | Disenrollment; Death; Data Partner End Date; Query End Date |
| 21 | Sarilumab | First valid index date during query period | 0 | N/A | 0 days | 0 days | Any care setting | Any | Yes | Disenrollment; Death; Data Partner End Date; Query End Date |
| 22 | Telotristat ethyl | First valid index date during query period | 0 | N/A | 0 days | 0 days | Any care setting | Any | Yes | Disenrollment; Death; Data Partner End Date; Query End Date |
| 23 | Valbenazine | First valid index date during query period | 0 | N/A | 0 days | 0 days | Any care setting | Any | Yes | Disenrollment; Death; Data Partner End Date; Query End Date |

N/A: Not Applicable

International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology (CPT) codes are provided by Optum360.

National Drug codes (NDC) are checked against First Data Bank's FDB MedKnowledge®.

Appendix G. Specifications Defining Parameters for Baseline Characteristics in this Request

Baseline Characteristics

| Health Characteristics | Care setting/ Principal diagnosis¹ | Evaluation period start | Evaluation period end | Exclude evidence of days supply if health characteristic includes dispensing | Number of instances the health characteristic should be found in evaluation period | supply to attach to dispensing |
|--|--|--|--------------------------------------|---|---|---|
| <i>Chronic Conditions Data Warehouse</i> | | | | | | |
| Acute Myocardial Infarction | IPP, IPS | -183 | -1 | N/A | 1 | N/A |
| Alzheimer's Disease and related conditions | Any | -183 | -1 | N/A | 1 | N/A |
| Atrial Fibrillation | IPP, IPS or | -183 | -1 | N/A | 1 | N/A |
| | AV*, ED*, OA* | -183 | -1 | N/A | 2 | N/A |
| Diabetes | IP*, IS* | -183 | -1 | N/A | 1 | N/A |
| | AV*, ED*, OA* | -183 | -1 | N/A | 2 | N/A |
| Heart Failure | IP*, AV*, ED* | -183 | -1 | N/A | 1 | N/A |
| Hyperlipidemia | IP*, IS* | -183 | -1 | N/A | 1 | N/A |
| | AV*, ED*, OA* | -183 | -1 | N/A | 2 | N/A |
| Hypertension | IP*, IS* | -183 | -1 | N/A | 1 | N/A |
| | AV*, ED*, OA* | -183 | -1 | N/A | 2 | N/A |
| Depression | Any | -183 | -1 | N/A | 1 | N/A |
| Ischemic Heart Disease | Any | -183 | -1 | N/A | 1 | N/A |
| Rheumatoid Arthritis/Osteoarthritis | Any | -183 | -1 | N/A | 2 | N/A |
| Stroke/TIA | IP* | -183 | -1 | N/A | 1 | N/A |
| | AV*, ED*, OA* | -183 | -1 | N/A | 2 | N/A |
| Breast Cancer | IP*, IS* or | -183 | -1 | N/A | 1 | N/A |
| | AV*, ED* OA* | -183 | -1 | N/A | 2 | N/A |
| Colorectal Cancer | IP*, IS* or | -183 | -1 | N/A | 1 | N/A |
| | AV*, ED* OA* | -183 | -1 | N/A | 2 | N/A |
| Prostate Cancer | IP*, IS* or | -183 | -1 | N/A | 1 | N/A |
| | AV*, ED* OA* | -183 | -1 | N/A | 2 | N/A |
| Lung Cancer | IP*, IS* or | -183 | -1 | N/A | 1 | N/A |
| | AV*, ED* OA* | -183 | -1 | N/A | 2 | N/A |
| Endometrial Cancer | IP*, IS* or | -183 | -1 | N/A | 1 | N/A |
| | AV*, ED* OA* | -183 | -1 | N/A | 2 | N/A |
| Acquired Hypothyroidism | IP*, IS*, or | -183 | -1 | N/A | 1 | N/A |
| | AV*, ED* OA* | -183 | -1 | N/A | 2 | N/A |

Appendix G. Specifications Defining Parameters for Baseline Characteristics in this Request

Baseline Characteristics

| Health Characteristics | Care setting/ Principal diagnosis¹ | Evaluation period start | Evaluation period end | Exclude evidence of days supply if health characteristic includes dispensing | Number of instances the health characteristic should be found in evaluation period | supply to attach to dispensing |
|--|--|--|--------------------------------------|---|---|---|
| <i>Chronic Conditions Data Warehouse</i> | | | | | | |
| Anemia | Any | -183 | -1 | N/A | 1 | N/A |
| Asthma | IP*, IS*, or | -183 | -1 | N/A | 1 | N/A |
| | AV*, ED* OA* | -183 | -1 | N/A | 2 | N/A |
| Benign Prostatic Hyperplasia | IP*, IS*, or | -183 | -1 | N/A | 1 | N/A |
| | AV*, ED* OA* | -183 | -1 | N/A | 2 | N/A |
| Chronic Kidney Disease | IP*, IS*, or | -183 | -1 | N/A | 1 | N/A |
| | AV*, ED* OA* | -183 | -1 | N/A | 2 | N/A |
| COPD and Bronchiectasis | IP*, IS*, or | -183 | -1 | N/A | 1 | N/A |
| | AV*, ED* OA* | -183 | -1 | N/A | 2 | N/A |
| Glaucoma | AV*, ED*, OA* | -183 | -1 | N/A | 2 | N/A |
| Osteoporosis | IP*, IS*, or | -183 | -1 | N/A | 1 | N/A |
| | AV*, ED* OA* | -183 | -1 | N/A | 2 | N/A |
| <i>Other</i> | | | | | | |
| Obesity | Any | -183 | -1 | Evaluation period should search for evidence of days supply | 1 | N/A |
| Overweight | Any | -183 | -1 | N/A | 1 | N/A |
| Smoking | Any | -183 | -1 | Evaluation period should search for evidence of days supply | 1 | N/A |
| Alcohol Abuse or Dependence | Any | -183 | -1 | N/A | 1 | N/A |
| Drug Abuse or Dependence | Any | -183 | -1 | N/A | 1 | N/A |
| History of Cardiac Arrest | Any | -183 | -1 | N/A | 1 | N/A |
| History of Coronary Angioplasty or Bypass | Any | -183 | -1 | N/A | 1 | N/A |

*These codes must be within 365 days of the index date, not each other as in version 1.

N/A: Not Applicable

¹Care setting/ Principal Diagnosis

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Appendix G. Specifications Defining Parameters for Baseline Characteristics in this Request

Baseline Characteristics

| Health Characteristics | Care setting/ Principal diagnosis¹ | Evaluation period start | Evaluation period end | Exclude evidence of days supply if health characteristic includes dispensing | Number of instances the health characteristic should be found in evaluation period | supply to attach to dispensing |
|-------------------------------|--|--|----------------------------------|---|---|---|
|-------------------------------|--|--|----------------------------------|---|---|---|

Chronic Conditions Data Warehouse

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.


Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Care setting/PDX parameter.

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Appendix H. Diagram Detailing the Design of this Request



¹ Includes all valid exposure episodes during the query period; only the first valid episode's incidence is assessed using the washout period.

² 23 scenarios defined based on initiation of NMEs approved in 2017 part 1 (one scenario per NME); Cohort entry date = first dispensing date for qualifying NME

³ Baseline characteristics:

Window I: Age, sex, year

Window II: Chronic conditions warehouse (CCW), alcohol abuse or dependence, drug abuse or dependence, history of cardiac arrest, history of coronary angioplasty or bypass, obesity, overweight, and smoking

⁴ Censoring: earliest of death, disenrollment, data partner data end date, query end date